drug	drug_cui	synonyms	variations	additional_umls_atoms	drug_type	source_type	id	hit_drug	hit_type	evidence	evidence_source
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3569575_20201005_0.5			In vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid Vaccines	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3569575_20201005_0.5			intestinal mucosal barrier|epithelial permeability|mucosal immunity|typhoid vaccines|cytokines	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3569575_20201005_0.5	ty21a typhoid vaccine	drug_name	Humans|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Salmonella typhi|Vaccines, Attenuated|Caco-2 Cells|Typhoid Fever|Polysaccharides, Bacterial|Intestinal Mucosa|Antibodies, Bacterial|Salmonella enterica	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3569575_20201005_0.5	ty21a typhoid vaccine	drug_name	We have evaluated in vitro the effects of wild-type S. Typhi, the licensed Ty21a typhoid vaccine and the leading strains CVD 908-htrA and CVD 909 vaccine candidates on intestinal barrier function and immune response.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3751609_20201005_0.5			Genome Sequence of Salmonella enterica Serovar Typhi Oral Vaccine Strain Ty21a	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3751609_20201005_0.5	ty21a typhoid vaccine	drug_name	Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Polysaccharides, Bacterial|Vaccines, Attenuated|Antibodies, Bacterial|Base Sequence	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3155226_20201005_0.5			Effect of live Salmonella Ty21a in Dextran Sulfate Sodium-induced Colitis	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3155226_20201005_0.5			salmonella Ty21a|colitis|rats|inflammatory bowel disease	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3155226_20201005_0.5	ty21a typhoid vaccine	drug_name	Rats|Male|Animals|Dextran Sulfate|Rats, Wistar|Colitis|Inflammatory Bowel Diseases|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Colon|Polysaccharides, Bacterial|Inflammation|Salmonella|Disease Models, Animal|Gastrointestinal Microbiome|Salmonella typhi|Peroxidase	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5776093_20201005_0.5			Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5776093_20201005_0.5			typhoid infection|bactericidal activity|human challenge model|immune responses	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5776093_20201005_0.5	ty21a typhoid vaccine	drug_name	Adult|Humans|Typhoid Fever|Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Antibodies, Bacterial|Salmonella paratyphi A|Polysaccharides, Bacterial|Vaccines, Attenuated|Cross Reactions|Salmonella enterica|Lipopolysaccharides|Vaccination	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID1457647_20201005_0.5	ty21a typhoid vaccine	drug_name	Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a typhoid vaccine strain.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID1457647_20201005_0.5			Chloroquine|Mefloquine|Microbial Sensitivity Tests|Salmonella typhi|Typhoid-Paratyphoid Vaccines	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID11179942_20201005_0.5	ty21a typhoid vaccine	drug_name	Compliance to live oral Ty21a typhoid vaccine, and its effect on viability.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID11179942_20201005_0.5			Administration, Oral|Adult|Aged|Drug Storage|Female|Humans|Immunization Schedule|Male|Middle Aged|Patient Compliance|Patient Education as Topic|Polysaccharides, Bacterial|Surveys and Questionnaires|Travel|Typhoid Fever|Typhoid-Paratyphoid Vaccines	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID11179942_20201005_0.5	ty21a typhoid vaccine	drug_name	BACKGROUND Concerns have been expressed that in travelers the efficacy of the live oral Ty21a typhoid vaccine Vivotif could be lower than reported, maybe due to a lack of compliance.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3634757_20201005_0.5			Impact of Oral Typhoid Vaccination on the Human Gut Microbiota and Correlations with S. Typhi-Specific Immunological Responses	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3634757_20201005_0.5			Administration, Oral|Bacteria|Biodiversity|Feces|Gastrointestinal Tract|Humans|Immunity, Cellular|Immunity, Humoral|Microbiota|Phylogeny|Polysaccharides, Bacterial|RNA, Ribosomal, 16S|Salmonella typhi|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccination	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC3634757_20201005_0.5	ty21a typhoid vaccine	drug_name	The fecal microbiota composition and temporal dynamics were characterized using bacterial 16S rRNA pyrosequencing from individuals who were either immunized with the Ty21a typhoid vaccine (n = 13) or served as unvaccinated controls (n = 4).	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID8854008_20201005_0.5			Reasons for instability of bacterial vaccines.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID8854008_20201005_0.5			Amino Acid Sequence|Bacterial Vaccines|Chemical Phenomena|Chemistry, Physical|Delayed-Action Preparations|Drug Stability|Drug Storage|Freeze Drying|Genetic Vectors|Molecular Sequence Data|Temperature|Toxoids|Vaccines, Attenuated|Vaccines, Conjugate|Vaccines, Inactivated|Vaccines, Synthetic	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID8854008_20201005_0.5	ty21a typhoid vaccine	drug_name	Live attenuated vaccines such as BCG and Ty21a typhoid vaccines lose potency through loss of viability when exposed to adverse conditions.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID1976928_20201005_0.5	ty21a typhoid vaccine	drug_name	Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID1976928_20201005_0.5			Administration, Oral|Adolescent|Age Factors|Bacterial Vaccines|Capsules|Child|Child, Preschool|Chile|Double-Blind Method|Follow-Up Studies|Humans|Immunization Schedule|Incidence|Methylcellulose|Salmonella typhi|Solutions|Travel|Typhoid Fever|Vaccination|Vaccines, Attenuated	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID9772310_20201005_0.5			Patient compliance in the use of Vivotif Berna(R) vaccine, typhoid vaccine, live oral Ty21a.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID9772310_20201005_0.5			Administration, Oral|Adult|Drug Storage|Humans|Patient Compliance|Patient Education as Topic|Polysaccharides, Bacterial|Surveys and Questionnaires|Travel|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccines, Attenuated	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID9772310_20201005_0.5	ty21a typhoid vaccine	drug_name	These include the Salmonella typhi Ty21a typhoid vaccine (Vivotif Berna(R) Vaccine) and Vibrio cholerae CVD103-HgR cholera vaccine (Mutacol Berna(R) Vaccine).	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID26140240_20210211_0.5			Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID26140240_20210211_0.5			BCG, Bacillus Calmette Guerin|BMDC, bone marrow-derived dendritic cell|C5a, complement component 5a|ESL, E-selectin ligands|GM, genital mucosa|IVAG, intravaginal|IVES, intravesical|NMIBC, non-muscle invasive bladder cancer|PBS, phosphate buffered saline|PE, phycoerythrin|PIC, poly (I:C)|SEM, standard error of the mean|Salmonella Ty21a|TLR, toll-like receptor|TUR, transurethral resection|bacterial immunostimulant|bladder cancer|combinatorial therapy|s.c., subcutaneously|therapeutic vaccination	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID26140240_20210211_0.5	ty21a typhoid vaccine	drug_name	Female|Humans|Mice|Animals|Urinary Bladder Neoplasms|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Administration, Intravesical|BCG Vaccine|Typhoid Fever|CD8-Positive T-Lymphocytes|Immunization|Cancer Vaccines|Polysaccharides, Bacterial|Urinary Bladder|Uterine Cervical Neoplasms|Neoplasm Recurrence, Local|Antigens, Neoplasm|Vaccines, Combined|Salmonella	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID30951606_20210311_0.5			Diversity of Salmonella Typhi-responsive CD4 and CD8 T cells before and after Ty21a typhoid vaccination in children and adults.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID30951606_20210311_0.5			 Salmonella Typhi|T-cell response|dimensionality reduction|multifunctionality|pediatric immunology	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID30951606_20210311_0.5			Adolescent|Adult|Aged|CD4-Positive T-Lymphocytes|CD8-Positive T-Lymphocytes|Child|Female|Humans|Male|Middle Aged|Polysaccharides, Bacterial|Salmonella typhi|Typhoid-Paratyphoid Vaccines|Vaccination|Young Adult	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID30951606_20210311_0.5	ty21a typhoid vaccine	drug_name	The oral live attenuated Ty21a typhoid vaccine protects against this severe disease by eliciting robust, multifunctional cell-mediated immunity (CMI), shown to be associated with protection in wild-type S. Typhi challenge studies.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID15908381_20201005_0.5			Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID15908381_20201005_0.5			Adult|Antigens, Bacterial|CD8-Positive T-Lymphocytes|Cell Line|Cytotoxicity, Immunologic|Flow Cytometry|Genes, T-Cell Receptor beta|Humans|Immunization|Immunologic Memory|Interferon-gamma|Polysaccharides, Bacterial|Salmonella typhi|Typhoid-Paratyphoid Vaccines	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID15908381_20201005_0.5	ty21a typhoid vaccine	drug_name	To this end, we determined the TCR beta chain (Vbeta) usage of CD8(+) T cells from three volunteers orally immunized with Ty21a typhoid vaccine by flow cytometry using a panel of monoclonal antibodies.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID2105702_20201005_0.5			The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID2105702_20201005_0.5			Administration, Oral|Adult|Female|Humans|Incidence|Injections|Male|Nepal|Paratyphoid Fever|Salmonella paratyphi A|Salmonella typhi|Travel|Typhoid Fever|Typhoid-Paratyphoid Vaccines	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID2105702_20201005_0.5	ty21a typhoid vaccine	drug_name	Among 22 vaccinated foreigners, S typhi was isolated from 35%, compared with 65% with S paratyphi A. Nine percent of tourists had received the oral Ty21A typhoid vaccine.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID24383914_20201005_0.5			Cross-reactive immune response induced by the Vi capsular polysaccharide typhoid vaccine against Salmonella Paratyphi strains.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID24383914_20201005_0.5			Adult|Antibodies, Bacterial|Cross Reactions|Female|Humans|Male|Middle Aged|O Antigens|Paratyphoid Fever|Polysaccharides, Bacterial|Salmonella paratyphi A|Salmonella paratyphi B|Salmonella paratyphi C|Typhoid-Paratyphoid Vaccines|Vaccination|Young Adult	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID24383914_20201005_0.5	ty21a typhoid vaccine	drug_name	No section There are no vaccines in clinical use against paratyphoid fever, caused by Salmonella Paratyphi A and B or, rarely, C. Oral Salmonella Typhi Ty21a typhoid vaccine elicits a significant cross-reactive immune response against S. Paratyphi A and B, and some reports suggest cross-protective efficacy against the disease.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID31629569_20210211_0.5	ty21a typhoid vaccine	drug_name	Differential functional patterns of memory CD4+ and CD8+ T-cells from volunteers immunized with Ty21a typhoid vaccine observed using a recombinant Escherichia coli system expressing S. Typhi proteins.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID31629569_20210211_0.5			Human|Recombinant E. coli|Salmonella|T-cells|Vaccine	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID31629569_20210211_0.5			Adult|CD4-Positive T-Lymphocytes|CD8-Positive T-Lymphocytes|Escherichia coli|Humans|Middle Aged|Polysaccharides, Bacterial|Salmonella typhi|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccination|Vaccines, Attenuated|Young Adult	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID24426167_20201005_0.5			Physiological and Immunological Regulations in Caenorhabditis elegans Infected with Salmonella enterica serovar Typhi.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID24426167_20201005_0.5			Caenorhabditis elegans|Innate immune response|Pre-exposed host|RNAi|Salmonella enterica serovar Typhi	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID24426167_20201005_0.5	ty21a typhoid vaccine	drug_name	Animals|Humans|Salmonella typhi|Caenorhabditis elegans|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Salmonella paratyphi A|Polysaccharides, Bacterial|Vaccines, Attenuated|Antibodies, Bacterial|Salmonella typhimurium|Cross Reactions|Immunoglobulin G	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID12165550_20201005_0.5	ty21a typhoid vaccine	drug_name	Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID12165550_20201005_0.5			Adult|Antigens, Bacterial|CD8-Positive T-Lymphocytes|Cytotoxicity, Immunologic|Humans|Immunization|In Vitro Techniques|Interferon-gamma|Lymphocyte Activation|Phytohemagglutinins|Salmonella typhi|T-Lymphocyte Subsets|T-Lymphocytes, Cytotoxic|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccines, Attenuated	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID12165550_20201005_0.5	ty21a typhoid vaccine	drug_name	Despite years of research, the identity of the protective immunological mechanisms elicited by immunization with the Ty21a typhoid vaccine remains elusive.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID12165550_20201005_0.5	ty21a typhoid vaccine	drug_name	The present study was designed to characterize effector T cell responses in volunteers immunized with S. typhi strain Ty21a typhoid vaccine.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5626924_20201005_0.5	ty21a typhoid vaccine	drug_name	Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5626924_20201005_0.5			CMI, cell-mediated immune responses|EBV-B, Epstein-Barr virus–transformed lymphoblastoid B cells|IFN, interferon|IL, interleukin|LPMC, lamina propria mononuclear cells|MF, multifunctional|MIP, macrophage inflammatory protein|PBMC, peripheral blood mononuclear cells|S, |T|T|T|T|TI, terminal ileum|TNF, tumor necrosis factor|wt, wild-type	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5626924_20201005_0.5	ty21a typhoid vaccine	drug_name	Adult|Humans|Ty21a typhoid vaccine|Immunity, Mucosal|Typhoid-Paratyphoid Vaccines|Polysaccharides, Bacterial|Salmonella typhi|Typhoid Fever|Immunization|Vaccination|CD8-Positive T-Lymphocytes|Interferon-gamma|Flow Cytometry|Immunity, Cellular|Ileum	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID6174449_20210611_0.5	ty21a typhoid vaccine	drug_name	Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID6174449_20210611_0.5			Animals|Antibodies, Bacterial|Antigens, Bacterial|Epitopes|Galactose|Immunization|Mice|Plasmids|Salmonella typhi|Shigella sonnei|Vaccines	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID28197393_20210211_0.5			Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID28197393_20210211_0.5			BCG|Ty21a vaccine|immunotherapy|non-muscle invasive bladder cancer	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID28197393_20210211_0.5	ty21a typhoid vaccine	drug_name	Humans|Mice|Animals|Urinary Bladder Neoplasms|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Leukocytes, Mononuclear|Neoplasm Recurrence, Local|Administration, Intravesical|BCG Vaccine|Cystectomy|Immunotherapy|Adjuvants, Immunologic|Mycobacterium bovis|Polysaccharides, Bacterial|Disease Progression|Treatment Outcome|Treatment Failure	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5046385_20201005_0.5			Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5046385_20201005_0.5	ty21a typhoid vaccine	drug_name	Humans|Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Polysaccharides, Bacterial|Vaccines, Attenuated|Drug Delivery Systems|Plasmids|Dysentery, Bacillary|Anthrax|Immunization|Antibodies, Bacterial|Salmonella enterica|Vaccination|Gene Transfer Techniques	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5643418_20201005_0.5			Induction of Cell Cycle and NK Cell Responses by Live-Attenuated Oral Vaccines against Typhoid Fever	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5643418_20201005_0.5			typhoid|typhoid vaccines|functional genomics|vaccine immunity|Ty21a|NK cell|cell cycle regulation	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5643418_20201005_0.5	ty21a typhoid vaccine	drug_name	Humans|Typhoid Fever|Leukocytes, Mononuclear|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Salmonella typhi|Vaccines, Attenuated|Polysaccharides, Bacterial|Antibodies, Bacterial|Killer Cells, Natural|Vaccination|Salmonella enterica	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5627300_20201005_0.5			Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5627300_20201005_0.5	ty21a typhoid vaccine	drug_name	Humans|Female|Mice|Animals|Rabbits|Inhalation anthrax|Anthrax|Bacillus anthracis|Biothrax|Anthrax Vaccines|Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Respiratory Tract Infections|Immunization|Vaccination|anthrax toxin|Polysaccharides, Bacterial|Bacterial Toxins|Spores, Bacterial|Exotoxins|Antibodies, Bacterial|Administration, Intranasal|Typhoid Fever|Enzyme-Linked Immunosorbent Assay	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC4607552_20201005_0.5			Immunization with Ty21a live oral typhoid vaccine elicits cross-reactive multifunctional CD8+ T cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A and S. Paratyphi B in humans	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC4607552_20201005_0.5			Ty21a|Cross-reactive CD8 T cells|Multifunctional|Human	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC4607552_20201005_0.5			Adult|CD8-Positive T-Lymphocytes|Cross Reactions|Female|Flow Cytometry|Humans|Male|Middle Aged|Paratyphoid Fever|Polysaccharides, Bacterial|Salmonella paratyphi A|Salmonella paratyphi B|Salmonella typhi|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Young Adult	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC4607552_20201005_0.5	ty21a typhoid vaccine	drug_name	No section Previously we have extensively characterized Salmonella enterica serovar Typhi (S. Typhi)-specific cell-mediated immune responses (CMI) in volunteers orally immunized with the licensed Ty21a typhoid vaccine.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5600385_20201005_0.5			Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5600385_20201005_0.5			Adult|Antigen Presentation|Antigens, Bacterial|Bacterial Proteins|Escherichia coli|Female|Flow Cytometry|Humans|Male|Middle Aged|Polysaccharides, Bacterial|Recombinant Proteins|Salmonella typhi|T-Lymphocytes|Typhoid-Paratyphoid Vaccines|Volunteers|Young Adult	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC5600385_20201005_0.5	ty21a typhoid vaccine	drug_name	Here, cells from individuals immunized with Ty21a typhoid vaccine were collected before and after immunization and used as effectors.	abstract
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID26443352_20201005_0.5			Vaccines against Infections Caused by Salmonella, Shigella, and Pathogenic Escherichia coli.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID26443352_20201005_0.5	ty21a typhoid vaccine	drug_name	Humans|Escherichia coli|Shigella|Salmonella|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Escherichia coli Infections|Vaccines, Attenuated|Dysentery, Bacillary|Salmonella typhi|Salmonella Infections|Bacterial Vaccines|Cholera Vaccines|Polysaccharides, Bacterial|Vaccines, Inactivated	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID27655911_20201005_0.5			Stable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID27655911_20201005_0.5			Combination oral vaccine|Ty21a vector expressing Shigella dysenteriae 1 O-antigen|shigellosis-enteric fever combination vaccine|stable expression of inserted antigenic genes|λ red-mediated recombineering	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID27655911_20201005_0.5	ty21a typhoid vaccine	drug_name	Mice|Animals|O Antigens|Shigella dysenteriae|Serogroup|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Shigella Vaccines|Salmonella typhi|Vaccines, Attenuated|Polysaccharides, Bacterial|Typhoid Fever|Salmonella Vaccines|Dysentery, Bacillary|Shigella sonnei|Salmonella|Antibodies, Bacterial|Chromosomes	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC8053564_20210511_0.5			Age-dependency of terminal ileum tissue resident memory T cell responsiveness profiles to S. Typhi following oral Ty21a immunization in humans	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC8053564_20210511_0.5			Aging|Oral vaccine|Terminal ileum LPMC|Tissue resident memory T cells|Ty21a|Vaccine-induced responses	author_keywords
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMC8053564_20210511_0.5	ty21a typhoid vaccine	drug_name	Aged|Humans|Adult|Middle Aged|Young Adult|Male|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Immunologic Memory|Polysaccharides, Bacterial|Immunization|Vaccination|Salmonella typhi|CD8-Positive T-Lymphocytes|CD4-Positive T-Lymphocytes|T-Lymphocyte Subsets|Ileum|Vaccines|Immunity, Mucosal|IL17A protein, human|Interleukin-17|Mucous Membrane	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID7726905_20201005_0.5			Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers.	title
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID7726905_20201005_0.5			Antimalarials|Cost of Illness|Cost-Benefit Analysis|Drug Costs|Hepatitis A|Hepatitis A Vaccines|Hepatovirus|Hospital Costs|Humans|Incidence|Malaria|Malaria Vaccines|Patient Acceptance of Health Care|Retrospective Studies|Travel|Typhoid Fever|United Kingdom|Viral Hepatitis Vaccines	mesh_terms
Ty21a typhoid vaccine	C0147265		ty-21a typhoid vaccine|ty 21a typhoid vaccine		inn	PubMed	PMID7726905_20201005_0.5	ty 21a typhoid vaccine	drug_name_variant	Similarly, low incidence of typhoid (0.02%) and its high cost gave whole cell killed, polysaccharide Vi, and oral Ty 21a typhoid vaccines cost-benefit ratios of 18.1, 18.0, and 22.0 respectively.	abstract
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID17983899_20201005_0.5			Premature ejaculation: state of the art.	title
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID17983899_20201005_0.5			Adrenergic alpha-Antagonists|Ejaculation|Humans|Male|Prevalence|Serotonin Uptake Inhibitors|Sexual Dysfunction, Physiological|Sexual Dysfunctions, Psychological|Treatment Outcome	mesh_terms
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID17983899_20201005_0.5	paroxetine hemihydrate	drug_name	A meta-analysis of all selective serotonin reuptake inhibitors (SSRIs) and clomipramine studies, which were performed according to current standards of evidence-based medicine, demonstrated a similar efficacy for the daily treatment with the serotonergic antidepressants paroxetine hemihydrate, clomipramine, sertraline, and fluoxetine, with paroxetine hemihydrate exerting the strongest effect on ejaculation.	abstract
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID17352514_20201005_0.5			Premature ejaculation: definition and drug treatment.	title
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID17352514_20201005_0.5			Adrenergic alpha-1 Receptor Antagonists|Adrenergic alpha-Antagonists|Animals|Antidepressive Agents, Tricyclic|Ejaculation|Humans|Male|Serotonin Uptake Inhibitors|Sexual Dysfunction, Physiological	mesh_terms
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID17352514_20201005_0.5	paroxetine hemihydrate	drug_name	A meta-analysis of those studies, conducted in accordance with current standards of evidence-based medicine, demonstrated similar efficacies for daily treatment with the serotonergic antidepressants paroxetine hemihydrate, clomipramine, sertraline and fluoxetine, with paroxetine (hydrochloride) hemihydrate exerting the strongest effect on ejaculation.	abstract
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMC4165923_20201005_0.5			Nonresponders to Daily Paroxetine and Another SSRI in Men With Lifelong Premature Ejaculation: A Pharmacokinetic Dose-Escalation Study for a Rare Phenomenon	title
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMC4165923_20201005_0.5	paroxetine hemihydrate	drug_name	5-HT1A (C-1019G) polymorphism|CYP2D6|Leptin|Lifelong premature ejaculation|Paroxetine hemihydrate	author_keywords
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMC4165923_20201005_0.5			Adolescent|Adult|Aged|Body Mass Index|Cytochrome P-450 CYP2D6|Humans|Leptin|Male|Middle Aged|Mutation|Paroxetine|Polymorphism, Genetic|Premature Ejaculation|Receptor, Serotonin, 5-HT1A|Risk Factors|Serotonin Uptake Inhibitors|Time Factors|Treatment Outcome|Young Adult	mesh_terms
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID29274752_20201005_0.5			Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease.	title
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID29274752_20201005_0.5	paroxetine hydrochloride hemihydrate	drug_umls_atom	(+)-methamphetamine hydrochloride (PubChem CID: 66124)|(−)-Cocaine hydrochloride (PubChem CID: 656832)|haloperidol (PubChem CID: 3559)|paroxetine hydrochloride hemihydrate (PubChem CID: 62878)|reserpine (PubChem CID: 5770)	author_keywords
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID29274752_20201005_0.5			Animals|Central Nervous System Stimulants|Circadian Clocks|Circadian Rhythm|Cocaine|Disease Models, Animal|Female|Huntington Disease|Male|Methamphetamine|Mice, Inbred C57BL|Mice, Inbred CBA|Mice, Transgenic|Motor Activity|Paroxetine|Receptors, Dopamine|Serotonin|Serotonin Uptake Inhibitors|Synaptic Transmission|Vesicular Monoamine Transport Proteins	mesh_terms
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID22607046_20201005_0.5	paroxetine hydrochloride hemihydrate	drug_umls_atom	Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology.	title
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID22607046_20201005_0.5			Adolescent|Adult|Biological Availability|Chemistry, Pharmaceutical|Delayed-Action Preparations|Humans|Hypromellose Derivatives|Male|Methylcellulose|Middle Aged|Paroxetine|Serotonin Uptake Inhibitors|Solubility|Tablets|Tablets, Enteric-Coated	mesh_terms
paroxetine hemihydrate	Z0000023363			paroxetine hydrochloride hemihydrate	inn	PubMed	PMID22607046_20201005_0.5	paroxetine hydrochloride hemihydrate	drug_umls_atom	No section The objective of this study is to develop, in vitro and in vivo evaluation of novel approaches for controlled release of paroxetine hydrochloride hemihydrate (PHH) in comparison to patented formulation PAXIL CR(®) tablets of GlaxoSmithKline (GeomatrixTM technology).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17287673_20201005_0.5	infracyanine	drug_name	[Macular hole surgery with and without infracyanine-green-guided removal of the internal limiting membrane].	title
infracyanine	Z0000013997				inn	PubMed	PMID17287673_20201005_0.5			Atrophy|Cataract|Fluorescent Dyes|Follow-Up Studies|Humans|Indocyanine Green|Injections|Membranes|Osmolar Concentration|Pigment Epithelium of Eye|Postoperative Complications|Reoperation|Retina|Retinal Perforations|Retrospective Studies|Visual Acuity|Vitrectomy|Vitreous Body	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID17287673_20201005_0.5	infracyanine	drug_name	OBJECTIVE To investigate the possibility of an adverse effect of infracyanine-guided internal limiting membrane (ILM) removal on functional results of macular hole surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17287673_20201005_0.5	infracyanine	drug_name	In group 2 (21 patients), the ILM was peeled using infracyanine green (ICG).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17287673_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS In this study, infracyanine-guided removal of the internal limiting membrane did not significantly improve the results of macular hole surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17287673_20201005_0.5	infracyanine	drug_name	No adverse effect of infracyanine on visual function or retinal toxicity was found and late reopening was less frequent.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID24022718_20201005_0.5			Effect of vital dyes on retinal pigmented epithelial cell viability and apoptosis: implications for chromovitrectomy.	title
infracyanine	Z0000013997				inn	PubMed	PMID24022718_20201005_0.5			Apoptosis|Blotting, Western|Cell Line|Cell Survival|Coloring Agents|Humans|Retinal Pigment Epithelium|Time Factors|Vitrectomy|bcl-2-Associated X Protein	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID24022718_20201005_0.5	infracyanine	drug_name	 METHODS ARPE-19 cells were exposed to brilliant blue (BBG), Evans Blue (EB), bromophenol blue (BroB), indocyanine green (ICG), infracyanine green (IfCG), light green (LG), fast green (FG), indigo carmine (IC) and Congo red (CR).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12527826_20201005_0.5			[Study of internal limiting membrane peeling in stage-3 and -4 idiopathic macular hole surgery].	title
infracyanine	Z0000013997				inn	PubMed	PMID12527826_20201005_0.5			Aged|Disease Progression|Female|Humans|Male|Middle Aged|Retinal Perforations|Retrospective Studies	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID12527826_20201005_0.5	infracyanine	drug_name	In addition, in the second group, the ILM of the eyes was systematically peeled after its coloring by indocyanine green (infracyanine) in the latter patients.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID25301478_20201005_0.5			Functional and morphological changes after macular pucker surgery: an optical coherence tomography and microperimetric study.	title
infracyanine	Z0000013997				inn	PubMed	PMID25301478_20201005_0.5			Aged|Female|Follow-Up Studies|Humans|Macula Lutea|Male|Postoperative Period|Prospective Studies|Retinal Perforations|Tomography, Optical Coherence|Treatment Outcome|Visual Field Tests|Visual Fields|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID25301478_20201005_0.5	infracyanine	drug_name	 METHODS Thirty-eight eyes with idiopathic macular pucker that underwent 25-gauge vitrectomy and infracyanine green-assisted internal limiting membrane peeling were prospectively enrolled.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID27089009_20201005_0.5			PERSISTENT PLACOID MACULOPATHY IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.	title
infracyanine	Z0000013997				inn	PubMed	PMID27089009_20201005_0.5			Aged|Fluorescein Angiography|Humans|Macular Pigment|Male|Multimodal Imaging|Retinal Diseases|Tomography, Optical Coherence	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID27089009_20201005_0.5	infracyanine	drug_name	fundus photography, fluorescein angiography, infracyanine green angiography, fundus autofluorescence imaging, spectral domain optical coherence tomography, optical coherence tomography angiography, and split spectrum amplitude decorrelation angiography were performed.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID27089009_20201005_0.5	infracyanine	drug_name	In both eyes, infracyanine green angiography showed hypocyanescence of the lesions, persisting throughout late phases.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID27089009_20201005_0.5	infracyanine	drug_name	In optical coherence tomography angiography, imaging of the choroidal capillary layers revealed hyposignal lesions, topographically corresponding exactly to hypocyanescent lesions on infracyanine green angiography.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID27089009_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS In this patient, a distinct hyposignal on optical coherence tomography angiography, combined with hypocyanescence on infracyanine green angiography, was interpreted as indicating focal hypoperfusion of the choriocapillaris.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12515936_20201214_0.5	infracyanine	drug_name	[Contribution of intravitreal infracyanine green to macular hole and epimacular membrane surgery: preliminary study].	title
infracyanine	Z0000013997				inn	PubMed	PMID12515936_20201214_0.5			Epiretinal Membrane|Humans|Immunohistochemistry|Indocyanine Green|Microscopy, Confocal|Middle Aged|Retinal Perforations|Solutions|Time Factors|Vitrectomy|Vitreous Body	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID12515936_20201214_0.5	infracyanine	drug_name	OBJECTIVE To evaluate the contribution of intravitreal infracyanine green to macular hole and epimacular membrane surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12515936_20201214_0.5	infracyanine	drug_name	 METHODS Twenty-five consecutive patients were operated on for macular hole (seven cases) or epiretinal membrane (18 cases) using intravitreal infracyanine.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12515936_20201214_0.5	infracyanine	drug_name	In most cases, 25mg of infracyanine powder was diluted in 5ml of solvent, then in 5ml of BSS and used within 1 hour.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12515936_20201214_0.5	infracyanine	drug_name	 CONCLUSIONS Intravitreal infracyanine green is very helpful for the removal of internal limiting membrane in macular holes and epiretinal membrane surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID16050416_20201005_0.5			Vitrectomy with peeling of the inner limiting membrane for treating diabetic macular edema.	title
infracyanine	Z0000013997				inn	PubMed	PMID16050416_20201005_0.5			Adult|Aged|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Retinopathy|Epiretinal Membrane|Female|Humans|Macular Edema|Male|Middle Aged|Treatment Outcome|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID16050416_20201005_0.5	infracyanine	drug_name	OBJECTIVE to evaluate the results of pars plana vitrectomy with peeling of the inner limiting membrane (ILM stained with infracyanine green (IfCG) in 26 patients with diabetic macular edema, and to identify which factors are associated with a better postoperative visual outcome.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID29450324_20201005_0.5			Chromovitrectomy.	title
infracyanine	Z0000013997				inn	PubMed	PMID29450324_20201005_0.5	infracyanine	drug_name	brilliant blue|chromovitrectomy|epiretinal membrane|indocyanine green|infracyanine green|internal limiting membrane|lutein- based dyes|triamcinolone acetonide	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMID29450324_20201005_0.5			Benzenesulfonates|Coloring Agents|Epiretinal Membrane|Humans|Indocyanine Green|Intravitreal Injections|Staining and Labeling|Triamcinolone Acetonide|Trypan Blue|Vitrectomy|Vitreoretinal Surgery|Vitreous Body	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID29450324_20201005_0.5	infracyanine	drug_name	The vital dyes indocyanine green, infracyanine green, and brilliant blue stain the internal limiting membrane, trypan blue and triamcinolone acetonide help to visualize the epiretinal and vitreous membranes.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID23804076_20201005_0.5			Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization.	title
infracyanine	Z0000013997				inn	PubMed	PMID23804076_20201005_0.5			Animals|Cell Line|Choroid|Choroidal Neovascularization|Ciliary Body|Disease Models, Animal|Electroporation|Female|Fluorescein Angiography|Gene Expression Regulation|Genetic Therapy|Humans|Neovascularization, Pathologic|Plasmids|Rats|Retinal Pigment Epithelium|Transfection|Vascular Endothelial Growth Factor A|Vascular Endothelial Growth Factor Receptor-1	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID23804076_20201005_0.5	infracyanine	drug_name	FA and infracyanine angiography demonstrated that inhibition of CNV was maintained for up to 6 months after gene transfer of the two shortest sFlt-1 variants.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID15834606_20201005_0.5	infracyanine	drug_name	Toxic effects of indocyanine green, infracyanine green, and trypan blue on the human retinal pigmented epithelium.	title
infracyanine	Z0000013997				inn	PubMed	PMID15834606_20201005_0.5			Cell Proliferation|Cell Survival|Cells, Cultured|Coloring Agents|Humans|Indocyanine Green|Pigment Epithelium of Eye|Trypan Blue	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID15834606_20201005_0.5	infracyanine	drug_name	BACKGROUND Indocyanine green, infracyanine green, and trypan blue are frequently used as aids to visualize structures removed during vitreoretinal surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID15834606_20201005_0.5	infracyanine	drug_name	 METHODS Monolayers of RPE cells were incubated with various concentrations of indocyanine green, infracyanine green (each at 0.005%, 0.05%, and 0.5%) or trypan blue (0.05%, 0.06%, 0.1%, 0.15%, and 0.5%) for 5 min (acute exposure) or 6 days (chronic exposure).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID15834606_20201005_0.5	infracyanine	drug_name	 RESULTS Indocyanine and infracyanine green induced acute and chronic toxicities at a concentration above 0.05%.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID15834606_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS Despite thorough rinsing after application, significant amounts of the not sufficiently water soluble indocyanine and infracyanine green are retained after surgery by the eye.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID16988623_20201005_0.5			[Clinical case of management with intravitreal injection of Ranibizumab (Lucentis) on AMD predominant occult CNV: 6-month follow-up with FA, ICG-A, and OCT].	title
infracyanine	Z0000013997				inn	PubMed	PMID16988623_20201005_0.5			Aged|Angiography|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Choroidal Neovascularization|Female|Fluorescein Angiography|Follow-Up Studies|Humans|Indocyanine Green|Injections|Macular Degeneration|Ranibizumab|Time Factors|Tomography, Optical Coherence|Vitreous Body	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID16988623_20201005_0.5	infracyanine	drug_name	 METHODS The first clinical case of minimally classic CNV is reported here with the results at 6 months, not only with changes in visual acuity but also with complete imaging at each follow-up with fluorescein angiography, infracyanine angiography using the scanning laser ophthalmoscope (SLO) and with OCT examination.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID16988623_20201005_0.5	infracyanine	drug_name	The situation is now stabilized in terms of function and morphology, as shown by the fluorescein and infracyanine SLO angiography and OCT examination.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID21394068_20201005_0.5	infracyanine	drug_name	Comparative in vitro safety analysis of dyes for chromovitrectomy: indocyanine green, brilliant blue green, bromophenol blue, and infracyanine green.	title
infracyanine	Z0000013997				inn	PubMed	PMID21394068_20201005_0.5			Animals|Apoptosis|Bromphenol Blue|Cell Survival|Cells, Cultured|Coloring Agents|Flow Cytometry|Humans|Indocyanine Green|Rats|Retinal Ganglion Cells|Retinal Pigment Epithelium|Rosaniline Dyes|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID21394068_20201005_0.5	infracyanine	drug_name	OBJECTIVE Vital dyes such as infracyanine green (IfCG), brilliant blue green (BBG), and bromophenol blue (BPB) have been used as an alternative to indocyanine green (ICG) during chromovitrectomy.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID21394068_20201005_0.5	infracyanine	drug_name	Infracyanine green, BBG, and BPB were significantly less toxic on the 2 cell lines at exposure times <15 minutes. (	abstract
infracyanine	Z0000013997				inn	PubMed	PMID21394068_20201005_0.5	infracyanine	drug_name	Infracyanine green was least toxic among the three newer dyes studied.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID15767895_20201005_0.5			[Advantages of confocal microscopy in the analysis of epiretinal membranes and internal limiting membranes after macular surgery].	title
infracyanine	Z0000013997				inn	PubMed	PMID15767895_20201005_0.5			Adult|Aged|Aged, 80 and over|Epiretinal Membrane|Female|Humans|Male|Microscopy, Confocal|Middle Aged|Retinal Perforations|Retrospective Studies	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID15767895_20201005_0.5	infracyanine	drug_name	Infracyanine green was used in 45 cases.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12140045_20201005_0.5			Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent.	title
infracyanine	Z0000013997				inn	PubMed	PMID12140045_20201005_0.5			Cell Death|Cell Survival|Cells, Cultured|Coloring Agents|Fluoresceins|Humans|Indocyanine Green|Microscopy, Confocal|Osmolar Concentration|Pigment Epithelium of Eye|Solvents	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID12140045_20201005_0.5	infracyanine	drug_name	OBJECTIVE To investigate whether the toxic effect on cultured retinal pigment epithelial (RPE) cells after application of indocyanine green is related to the osmolarity of the solvent or to toxic effects of the dye and evaluate whether these changes also occur using infracyanine green.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12140045_20201005_0.5	infracyanine	drug_name	In cultures exposed to a 5% glucose solution, no increased cell death was found (P =.94, n = 12), nor when infracyanine green was added (P =.13, n = 12).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12140045_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS The observed toxicity of indocyanine green on RPE cells is probably related to the hypo-osmolarity of the solvent and may be avoided by using infracyanine green dissolved in glucose 5%.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17576712_20201005_0.5	infracyanine	drug_name	Heavy trypan blue staining of epiretinal membranes: an alternative to infracyanine green.	title
infracyanine	Z0000013997				inn	PubMed	PMID17576712_20201005_0.5			Adult|Aged|Aged, 80 and over|Coloring Agents|Epiretinal Membrane|Female|Follow-Up Studies|Glucose|Humans|Indocyanine Green|Male|Middle Aged|Pharmaceutical Vehicles|Prospective Studies|Staining and Labeling|Tomography, Optical Coherence|Treatment Outcome|Trypan Blue|Visual Acuity	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID9801048_20201005_0.5	infracyanine	drug_name	Hypotensive shock as a complication of infracyanine green injection.	title
infracyanine	Z0000013997				inn	PubMed	PMID9801048_20201005_0.5			Aged|Blood Pressure|Coloring Agents|Drug Administration Routes|Drug Therapy, Combination|Female|Fluorescein Angiography|Fundus Oculi|Glucocorticoids|Head-Down Tilt|Histamine Antagonists|Humans|Hypotension|Indocyanine Green|Macular Degeneration|Retinal Detachment|Shock|Vasoconstrictor Agents	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5			Recovery of visual field and acuity after removal of epiretinal and inner limiting membranes.	title
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5			Aged|Coloring Agents|Epiretinal Membrane|Humans|Indocyanine Green|Middle Aged|Prospective Studies|Treatment Outcome|Trypan Blue|Vision Disorders|Visual Acuity|Visual Field Tests|Visual Fields|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5	infracyanine	drug_name	The aim therefore was to ascertain whether central an assessment of the central visual field afforded a closer insight into visual function after removal of epiretinal membranes and Infracyanine-Green- or Trypan-Blue-assisted peeling of the inner limiting membrane.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5	infracyanine	drug_name	 METHODS Fourty-three patients undergoing pars-plana vitrectomy for the removal of epimacular membranes and dye-assisted peeling of the inner limiting membrane using either Infracyanine Green (n = 29; group 1) or Trypan Blue (n = 14; group 2) were monitored prospectively for 12 months.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5	infracyanine	drug_name	Likewise at this juncture, the mean size of the visual-field defect remained unchanged in Trypan-Blue-treated eyes (preoperative: 4.3 (SD 2.1) dB; 12 months: 4.0 (2.1) dB (p = 0.15)), but had increased in Infracyanine-Green-treated ones (from 5.3 (3.7) dB to 8.0 (5.2) dB (p = 0.027)).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS Unlike visual acuity, the central visual field had deteriorated in Infracyanine-Green-treated eyes but not in Trypan-Blue-treated eyes 12 months after surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18055572_20201005_0.5	infracyanine	drug_name	Furthermore, Infracyanine Green may have a chronic and potentially clinically relevant effect on the macula which is not reflected in the visual acuity.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID24022720_20201005_0.5			Biochemical analysis and decomposition products of indocyanine green in relation to solvents, dye concentrations and laser exposure.	title
infracyanine	Z0000013997				inn	PubMed	PMID24022720_20201005_0.5			Acetates|Chemical Precipitation|Chromatography, High Pressure Liquid|Coloring Agents|Drug Combinations|Electrophoresis, Capillary|Hydrogen-Ion Concentration|Indocyanine Green|Lasers|Microscopy, Electron, Scanning|Minerals|Osmolar Concentration|Sodium Chloride	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID24022720_20201005_0.5	infracyanine	drug_name	Anion and iodate analyses of ICG and infracyanine green (IfCG) were performed by capillary zone electrophoresis.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID24371423_20201005_0.5			Chromovitrectomy: update.	title
infracyanine	Z0000013997				inn	PubMed	PMID24371423_20201005_0.5			Chromovitrectomy|Indocyanine green|Internal limiting membrane|Vital dyes|Vitreoretinal surgery	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMID24371423_20201005_0.5	infracyanine	drug_name	The vital dyes, indocyanine green, infracyanine green, and brilliant blue stain the internal limiting membrane, and trypan blue and triamcinolone acetonide help to visualize epiretinal membranes and vitreous, respectively.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12442343_20201005_0.5			[Transpupillary thermotherapy for treatment of choroidal melanomas].	title
infracyanine	Z0000013997				inn	PubMed	PMID12442343_20201005_0.5			Adult|Aged|Aged, 80 and over|Choroid Neoplasms|Female|Follow-Up Studies|Humans|Hyperthermia, Induced|Male|Melanoma|Middle Aged|Prospective Studies|Retinal Diseases|Treatment Outcome	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID12442343_20201005_0.5	infracyanine	drug_name	The injection of infracyanine green (I CG) was randomized.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19477708_20201005_0.5			Dyes in ocular surgery: principles for use in chromovitrectomy.	title
infracyanine	Z0000013997				inn	PubMed	PMID19477708_20201005_0.5			Benzenesulfonates|Coloring Agents|Epiretinal Membrane|Humans|Indocyanine Green|Macular Edema|Retinal Perforations|Rosaniline Dyes|Staining and Labeling|Triamcinolone Acetonide|Trypan Blue|Vitrectomy|Vitreoretinopathy, Proliferative	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID19477708_20201005_0.5	infracyanine	drug_name	The dyes currently used for different steps in chromovitrectomy are: triamcinolone acetonide for vitreous identification; indocyanine green, infracyanine green, and Brilliant blue for internal limiting membrane identification; and Trypan blue for epiretinal membrane identification.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5			Assessment of retinal function before and after idiopathic macular hole surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5			Aged|Basement Membrane|Coloring Agents|Electroretinography|Female|Humans|Indocyanine Green|Male|Middle Aged|Postoperative Period|Preoperative Period|Prospective Studies|Retina|Retinal Perforations|Tomography, Optical Coherence|Triamcinolone Acetonide|Visual Acuity|Visual Field Tests|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5	infracyanine	drug_name	ILM visualization was improved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients by using infracyanine green dye.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5	infracyanine	drug_name	In the infracyanine green group, at 12 months the amplitude of the first harmonic (1F) decreased in both areas.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS Vitrectomy and ILM peeling assisted with either triamcinolone acetonide or infracyanine green staining improves visual acuity and mean macular sensitivity at 12 months in patients affected by idiopathic macular hole.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5	infracyanine	drug_name	However, triamcinolone acetonide staining is associated with an increase of fERG's first harmonic amplitude in the foveal and macular region, whereas in the case of infracyanine green staining it seems to decrease after surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID23664151_20201005_0.5	infracyanine	drug_name	The reduction of the amplitude of fERG's first harmonic suggests that infracyanine green may have a late toxic effect on photoreceptor cells.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18370875_20201005_0.5	infracyanine	drug_name	Morphologic and clinical effects of subretinal injection of indocyanine green and infracyanine green in rabbits.	title
infracyanine	Z0000013997				inn	PubMed	PMID18370875_20201005_0.5			Animals|Coloring Agents|Electroretinography|Follow-Up Studies|Indocyanine Green|Injections|Microscopy, Electron, Transmission|Osmolar Concentration|Pharmaceutical Solutions|Rabbits|Retina	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID18370875_20201005_0.5	infracyanine	drug_name	OBJECTIVE The aim of this study was to determine the effects of subretinal injection of indocyanine green (ICG), infracyanine (IfCG), and balanced salt solution (BSS) in rabbits.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14597040_20201005_0.5	infracyanine	drug_name	Anatomical and visual outcome of macular hole surgery with infracyanine green-assisted peeling of the internal limiting membrane, endodrainage, and silicone oil tamponade.	title
infracyanine	Z0000013997				inn	PubMed	PMID14597040_20201005_0.5			Adult|Aged|Basement Membrane|Coloring Agents|Drainage|Female|Follow-Up Studies|Humans|Indocyanine Green|Male|Middle Aged|Phacoemulsification|Prospective Studies|Retinal Perforations|Silicone Oils|Tomography, Optical Coherence|Treatment Outcome|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID14597040_20201005_0.5	infracyanine	drug_name	OBJECTIVE To evaluate the anatomical and visual outcome in macular hole patients who underwent surgery with infracyanine green-assisted internal limiting membrane peeling.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14597040_20201005_0.5	infracyanine	drug_name	 METHODS After removing the vitreous, in all eyes infracyanine green-assisted removal of the internal limiting membrane was performed.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14597040_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS These findings indicate that infracyanine green-assisted removal of the retinal internal limiting membrane appears to induce a high incidence of anatomical closure, with good visual outcome.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID15183827_20201005_0.5	infracyanine	drug_name	Anatomical and visual outcome of macular hole surgery with infracyanine green-assisted peeling of the internal limiting membrane, endodrainage, and silicone oil tamponade.	title
infracyanine	Z0000013997				inn	PubMed	PMID15183827_20201005_0.5			Basement Membrane|Coloring Agents|Drainage|Humans|Indocyanine Green|Retinal Perforations|Silicone Oils|Visual Acuity	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID15452079_20201005_0.5	infracyanine	drug_name	Safety testing of infracyanine green using retinal pigment epithelium and glial cell cultures.	title
infracyanine	Z0000013997				inn	PubMed	PMID15452079_20201005_0.5			Cell Culture Techniques|Cell Survival|Coloring Agents|Ethidium|Humans|Indocyanine Green|Neuroglia|Pigment Epithelium of Eye|Safety|Trypan Blue	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID15452079_20201005_0.5	infracyanine	drug_name	OBJECTIVE To undertake safety testing of infracyanine green (IFCG) in a cell culture model.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18670454_20201005_0.5			Vital staining with indocyanine green: a review of the clinical and experimental studies relating to safety.	title
infracyanine	Z0000013997				inn	PubMed	PMID18670454_20201005_0.5			Animals|Coloring Agents|Disease Models, Animal|Epiretinal Membrane|Evidence-Based Medicine|Humans|Indocyanine Green|Intraoperative Care|Staining and Labeling|Vision Disorders|Visual Fields	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID18670454_20201005_0.5	infracyanine	drug_name	This review considers the clinical and experimental studies of ICG and a related agent, infracyanine green.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18670454_20201005_0.5	infracyanine	drug_name	A smaller number of studies suggest that infracyanine green produces similar staining to ICG, and may possibly be safer, but there are too few well-designed studies to reach a conclusion.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID25383819_20201005_0.5			Bilateral retinal pigment epithelium tears in acute Vogt-Koyanagi-Harada disease.	title
infracyanine	Z0000013997				inn	PubMed	PMID25383819_20201005_0.5			Humans|Female|Adult|Uveomeningoencephalitic Syndrome|Retinal Pigment Epithelium|Retinal Detachment|Fluorescein Angiography|Tomography, Optical Coherence|Methylprednisolone|Glucocorticoids|Fundus Oculi|Visual Acuity|Fluorescein|Acute Disease	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID25383819_20201005_0.5	infracyanine	drug_name	 METHODS Observational case report of a patient who presented with RPE tears in acute Vogt-Koyanagi-Harada disease, who underwent clinical examination, fluorescein and infracyanine green angiographies, and optical coherence tomography evaluation.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID16376661_20201005_0.5	infracyanine	drug_name	Immunohistochemical analysis of the internal limiting membrane peeled with infracyanine green.	title
infracyanine	Z0000013997				inn	PubMed	PMID16376661_20201005_0.5			Aged|Basement Membrane|Coloring Agents|Diabetic Retinopathy|Epiretinal Membrane|Female|Glial Fibrillary Acidic Protein|Humans|Immunoenzyme Techniques|Indocyanine Green|Macular Edema|Male|Middle Aged|Neuroglia|Retinal Detachment|Retinal Perforations|S100 Proteins|Vimentin|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID16376661_20201005_0.5	infracyanine	drug_name	 METHODS ILM peeled from ten eyes during vitrectomy by infracyanine green (ICG) was studied immunohistochemically using the markers: GFAP, S-100, and vimentin.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14962428_20201005_0.5	infracyanine	drug_name	Histology of the vitreoretinal interface after staining of the internal limiting membrane using glucose 5% diluted indocyanine and infracyanine green.	title
infracyanine	Z0000013997				inn	PubMed	PMID14962428_20201005_0.5			Adult|Basement Membrane|Coloring Agents|Glucose|Humans|Indocyanine Green|Male|Retina|Retinal Perforations|Staining and Labeling|Vitreous Body	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID14962428_20201005_0.5	infracyanine	drug_name	 METHODS Possible adverse effects of two different solutions of 0.05% ICG (Pulsion, Munich, Germany; and Infracyanine, Laboratoire SERB, Paris, France) diluted with glucose 5% were evaluated in four eyes of two donors.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17386297_20201005_0.5	infracyanine	drug_name	Idiopathic macular hole surgery with low-concentration infracyanine green-assisted peeling of the internal limiting membrane.	title
infracyanine	Z0000013997				inn	PubMed	PMID17386297_20201005_0.5			Basement Membrane|Coloring Agents|Epiretinal Membrane|Fluorescein Angiography|Fluorocarbons|Follow-Up Studies|Humans|Indocyanine Green|Retinal Perforations|Staining and Labeling|Tomography, Optical Coherence|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID16755682_20201005_0.5			Clinical evaluation of the use of indocyanine green for peeling the internal limiting membrane in macular hole surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID16755682_20201005_0.5			Aged|Basement Membrane|Coloring Agents|Epiretinal Membrane|Female|Fluorescein Angiography|Follow-Up Studies|Humans|Indocyanine Green|Male|Middle Aged|Retinal Perforations|Retrospective Studies|Tomography, Optical Coherence|Treatment Outcome|Visual Acuity|Visual Fields	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID16755682_20201005_0.5	infracyanine	drug_name	BACKGROUND To evaluate the role of indocyanine green (infracyanine) in macular hole surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID16755682_20201005_0.5	infracyanine	drug_name	 METHODS A retrospective review of 38 consecutive eyes with macular hole, operated on with internal limiting membrane peeling (ILM), using or not using infracyanine (ICG), diluted in glucose 5% and filtered.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID27523490_20201005_0.5			Birdshot Retinochoroidopathy: Prognostic Factors of Long-term Visual Outcome.	title
infracyanine	Z0000013997				inn	PubMed	PMID27523490_20201005_0.5			Adult|Aged|Birdshot Chorioretinopathy|Capillary Permeability|Chorioretinitis|Electrooculography|Eye Diseases|Female|Fluorescein Angiography|Follow-Up Studies|Glucocorticoids|HLA-A Antigens|Humans|Macular Edema|Male|Middle Aged|Prognosis|Retrospective Studies|Tomography, Optical Coherence|Vision Disorders|Visual Acuity|Visual Fields|Vitreous Body	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID27523490_20201005_0.5	infracyanine	drug_name	Preserved electrooculography light peak and Arden ratio (P = .06) and presence of choroidal spots on infracyanine green angiograms (80.0% vs 53.3%, P = .08) seemed associated with the best prognoses.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17056361_20201005_0.5	infracyanine	drug_name	Idiopathic macular hole surgery with low-concentration infracyanine green-assisted peeling of the internal limiting membrane.	title
infracyanine	Z0000013997				inn	PubMed	PMID17056361_20201005_0.5			Aged|Aged, 80 and over|Basement Membrane|Coloring Agents|Epiretinal Membrane|Female|Fluorescein Angiography|Fluorocarbons|Follow-Up Studies|Humans|Indocyanine Green|Male|Middle Aged|Ophthalmoscopy|Prospective Studies|Retinal Perforations|Staining and Labeling|Tomography, Optical Coherence|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID17056361_20201005_0.5	infracyanine	drug_name	OBJECTIVE To evaluate the efficacy of pars plana vitrectomy with infracyanine green (IFCG)-assisted internal limiting membrane peeling for the treatment of idiopathic macular hole.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID27341760_20201005_0.5			[Birdshot retinochoroidopathy: Key messages].	title
infracyanine	Z0000013997				inn	PubMed	PMID27341760_20201005_0.5			Acuité visuelle|Angiogram|Angiographie|Birdshot retinochoroidopathy|Champs visuels|Electro-oculogram|Electroretinogram|Inflammation|Optical coherence tomography|Perimetry|Rétinochoroïdopathie de Birdshot|Tomographie par cohérence optique|Uveitis|Uvéite|Visual acuity|Électro-oculographie|Électrorétinographie	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMID27341760_20201005_0.5			Choroiditis|Electroretinography|Fluorescein Angiography|Fundus Oculi|Humans|Multifocal Choroiditis|Tomography, Optical Coherence|Visual Acuity|Visual Field Tests	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID27341760_20201005_0.5	infracyanine	drug_name	Fluorescein and infracyanine green angiograms can show signs of inflammatory activity and give further diagnostic clues.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19682624_20201005_0.5			The use of vital dyes in ocular surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID19682624_20201005_0.5			Coloring Agents|Eye Diseases|Humans|Intraoperative Care|Ophthalmologic Surgical Procedures|Staining and Labeling	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID19682624_20201005_0.5	infracyanine	drug_name	For chromovitrectomy, the vital dyes indocyanine green, infracyanine green, and brilliant blue stain the internal limiting membrane, and trypan blue and triamcinolone acetonide help visualize epiretinal membranes and vitreous, respectively.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID31326594_20201005_0.5			Fluorescent indocyanine green angiography: Preliminary results in microsurgery monitoring.	title
infracyanine	Z0000013997				inn	PubMed	PMID31326594_20201005_0.5			Fluorescent indocyanine green angiography|Free flap|Head and neck reconstruction|Monitoring|Non invasive|Pedagogical tool	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMID31326594_20201005_0.5			Adult|Aged|Female|Fluorescein Angiography|Free Tissue Flaps|Humans|Indocyanine Green|Male|Microsurgery|Middle Aged|Reproducibility of Results	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID31326594_20201005_0.5	infracyanine	drug_name	Intra-veinous injections of 0.1mg/kg of INFRACYANINE® (concentration 2.5mg/mL) were done intraoperatively.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID20554611_20201005_0.5			Comparative effects of six intraocular vital dyes on retinal pigment epithelial cells.	title
infracyanine	Z0000013997				inn	PubMed	PMID20554611_20201005_0.5			Bromphenol Blue|Cell Membrane Permeability|Cell Survival|Cells, Cultured|Colorimetry|Coloring Agents|Humans|Indocyanine Green|Membrane Potential, Mitochondrial|Microscopy, Phase-Contrast|Retinal Pigment Epithelium|Rosaniline Dyes|Trypan Blue	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID20554611_20201005_0.5	infracyanine	drug_name	OBJECTIVE To evaluate and compare the effects of the following dyes on human pigmented epithelial cells: indocyanine green (ICG), infracyanine green (IfCG), trypan blue (TB), bromophenol blue (BrB), patent blue (PB), and Brilliant Blue G (BBG).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID12770967_20201005_0.5	infracyanine	drug_name	Double vital staining using trypan blue and infracyanine green in macular pucker surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID12770967_20201005_0.5			Aged|Aged, 80 and over|Coloring Agents|Female|Humans|Immunohistochemistry|Indocyanine Green|Macula Lutea|Male|Middle Aged|Retinal Diseases|Staining and Labeling|Trypan Blue|Visual Acuity	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID12770967_20201005_0.5	infracyanine	drug_name	 METHODS In a two step surgery, the epiretinal pucker was removed after staining with trypan blue, whereafter the inner limiting membrane was peeled after staining with infracyanine green.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID20098913_20201005_0.5			[Vital dyes in chromovitrectomy].	title
infracyanine	Z0000013997				inn	PubMed	PMID20098913_20201005_0.5			Coloring Agents|Humans|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID20098913_20201005_0.5	infracyanine	drug_name	Newer generation vital dyes for chromovitrectomy include trypan blue, patent blue, triamcinolone acetonide, infracyanine green, sodium fluorescein, bromophenol blue, fluorometholone acetate and brilliant blue.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID20098913_20201005_0.5	infracyanine	drug_name	The first line agents for internal limiting membrane staining in chromovitrectomy are indocyanine green, infracyanine green, and brilliant blue.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19019339_20201005_0.5			Macular hole surgery with inner limiting membrane peeling, endodrainage, and heavy silicone oil tamponade.	title
infracyanine	Z0000013997				inn	PubMed	PMID19019339_20201005_0.5			Aged|Aged, 80 and over|Basement Membrane|Coloring Agents|Drainage|Female|Humans|Indocyanine Green|Male|Middle Aged|Phacoemulsification|Retinal Perforations|Retrospective Studies|Silicone Oils|Tomography, Optical Coherence|Treatment Outcome|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID19019339_20201005_0.5	infracyanine	drug_name	 METHODS Surgery with infracyanine green-assisted ILM peeling and endodrainage was performed.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17435423_20201005_0.5			Vital dyes for chromovitrectomy.	title
infracyanine	Z0000013997				inn	PubMed	PMID17435423_20201005_0.5			Benzenesulfonates|Bromphenol Blue|Coloring Agents|Epiretinal Membrane|Humans|Indocyanine Green|Retinal Perforations|Rosaniline Dyes|Trypan Blue|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID17435423_20201005_0.5	infracyanine	drug_name	Newer generation vital dyes for chromovitrectomy include trypan blue, patent blue, triamcinolone acetonide, infracyanine green, sodium fluorescein, bromophenol blue, fluorometholone acetate and brilliant blue.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID17435423_20201005_0.5	infracyanine	drug_name	The first line agents for internal limiting membrane staining in chromovitrectomy are indocyanine green, infracyanine green, and brilliant blue.	abstract
infracyanine	Z0000013997				inn	PubMed	PMC2946993_20201005_0.5			A case of acute retinal pigment epithelitis: spectral domain optical coherence tomography time course and physiopathologic hypothesis	title
infracyanine	Z0000013997				inn	PubMed	PMC2946993_20201005_0.5			acute retinal pigment epithelitis|picornavirus|SD-OCT	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMC2946993_20201005_0.5			Male|Humans|Animals|Rats|Adult|Tomography, Optical Coherence|Retinitis|Fluorescein Angiography|Retinal Pigment Epithelium|Macula Lutea|Visual Acuity|Chorioretinitis|Retina|Acute Disease|Retinal Pigments	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMC2946993_20201005_0.5	infracyanine	drug_name	SD-OCT was performed immediately, followed by fluorescein and infracyanine angiography at eight days and then at three weeks.	abstract
infracyanine	Z0000013997				inn	PubMed	PMC7022749_20201005_0.5	infracyanine	drug_name	Infracyanine Green vs. Brilliant Blue G in Inverted Flap Surgery for Large Macular Holes: A Long-Term Swept-Source OCT Analysis	title
infracyanine	Z0000013997				inn	PubMed	PMC7022749_20201005_0.5	infracyanine	drug_name	Infracyanine green|brilliant blue G|inverted flap surgery|large macular hole|swept-source OCT	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMC7022749_20201005_0.5			Aged|Aged, 80 and over|Contrast Media|Female|Humans|Indocyanine Green|Male|Middle Aged|Retina|Retinal Perforations|Rosaniline Dyes|Surgical Flaps|Tomography, Optical Coherence|Treatment Outcome	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMC7022749_20201005_0.5	infracyanine	drug_name	No section Background and Objectives: To compare the long-term toxicity of infracyanine green (IFCG) to brilliant blue G (BBG) in inverted internal limiting membrane flap surgery (I-ILMFS) for large, full-thickness macular holes (FTMHs).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5	infracyanine	drug_name	Infracyanine-assisted internal limiting membrane peeling in macular hole repair: does it make a difference?	title
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5			Aged|Aged, 80 and over|Basement Membrane|Coloring Agents|Female|Humans|Indocyanine Green|Male|Middle Aged|Retinal Perforations|Retrospective Studies|Staining and Labeling|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5	infracyanine	drug_name	OBJECTIVE To investigate whether Infracyanine-assisted internal limiting membrane (ILM) peeling in macular hole repair affects the anatomical and functional outcome and complication rate.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5	infracyanine	drug_name	 METHODS A retrospective analysis of 139 consecutive cases of stage 2 and stage 3 macular hole repairs with or without Infracyanine-assisted ILM peeling.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5	infracyanine	drug_name	 RESULTS There were 67 eyes with Infracyanine staining of the ILM and 72 eyes in the non-ILM-stained group.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS Anatomical and functional results are similar with or without Infracyanine-assisted ILM peeling.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID14749933_20201005_0.5	infracyanine	drug_name	There was no apparent adverse effect of Infracyanine use on visual function, and no apparent retinal toxicity was found.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID16445438_20201005_0.5			An isotonic preparation of 1 mg/ml indocyanine green is not toxic to hyperconfluent ARPE19 cells, even after prolonged exposure.	title
infracyanine	Z0000013997				inn	PubMed	PMID16445438_20201005_0.5			Cell Line|Cell Survival|Coloring Agents|Humans|Indocyanine Green|Isotonic Solutions|Pigment Epithelium of Eye|Retinal Perforations|Tetrazolium Salts|Thiazoles|Time Factors	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID16445438_20201005_0.5	infracyanine	drug_name	OBJECTIVE To investigate the in vitro toxicity of indocyanine green and infracyanine green (ICG) to cultured ARPE19 cells, in particular with respect to the concentration and time dependence of this toxicity.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID26502062_20201005_0.5			The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy.	title
infracyanine	Z0000013997				inn	PubMed	PMID26502062_20201005_0.5			Basement Membrane|Coloring Agents|Epiretinal Membrane|Humans|Intravitreal Injections|Staining and Labeling|Vitrectomy|Vitreoretinal Surgery	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID26502062_20201005_0.5	infracyanine	drug_name	Different vital dyes has been tested for chromovitrectomy including trypan blue, patent blue, triamcinolone acetonide, infracyanine green, sodium fluorescein and brilliant blue.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID22034019_20201005_0.5	infracyanine	drug_name	Low-concentration infracyanine green-assisted internal limiting membrane peeling in idiopathic macular pucker 25-gauge surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID22034019_20201005_0.5			Aged|Basement Membrane|Coloring Agents|Epiretinal Membrane|Female|Follow-Up Studies|Humans|Indocyanine Green|Male|Microsurgery|Prognosis|Retinal Diseases|Retrospective Studies|Tomography, Optical Coherence|Visual Acuity|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID22034019_20201005_0.5	infracyanine	drug_name	OBJECTIVE To investigate the efficacy of 25-gauge infracyanine green-assisted idiopathic macular pucker surgery and to identify prognostic factors.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID22034019_20201005_0.5	infracyanine	drug_name	 METHODS In this retrospective interventional case series, 83 patients with idiopathic macular pucker who underwent 25-gauge surgery with infracyanine green-assisted internal limiting membrane (ILM) peeling were retrospectively reviewed.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID22034019_20201005_0.5	infracyanine	drug_name	 CONCLUSIONS Low-concentration infracyanine green-assisted ILM peeling during minimally invasive surgery is associated with significant visual acuity improvement.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID18988171_20201005_0.5	infracyanine	drug_name	Clinical evaluation of the use of infracyanine green staining for internal limiting membrane peeling in epimacular membrane surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID18988171_20201005_0.5			Aged|Basement Membrane|Coloring Agents|Electroretinography|Epiretinal Membrane|Fluorescein Angiography|Humans|Indocyanine Green|Intraoperative Complications|Postoperative Complications|Recurrence|Retina|Retrospective Studies|Staining and Labeling|Tomography, Optical Coherence|Treatment Outcome|Visual Acuity|Visual Field Tests|Visual Fields	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID18988171_20201005_0.5	infracyanine	drug_name	OBJECTIVE To evaluate the use of infracyanine green (IFCG) staining in idiopathic epiretinal membrane (ERM) surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID32529665_20210511_0.5			Descemet's membrane detachments, ruptures, and separations in ten adult horses: Clinical signs, diagnostics, treatment options, and preliminary results.	title
infracyanine	Z0000013997				inn	PubMed	PMID32529665_20210511_0.5	infracyanine	drug_name	Descemet's membrane detachment|EmunDo(R)|Gundersen inlay flaps|corneal tissue welding|equine ophthalmology|infracyanine green|optical coherence tomography	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMID32529665_20210511_0.5			Animals|Descemet Membrane|Eye Injuries|Female|Horses|Male|Phacoemulsification|Visual Acuity	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID23623768_20201005_0.5			['En face' optical coherence tomography for multiple evanescent white dot syndrome].	title
infracyanine	Z0000013997				inn	PubMed	PMID23623768_20201005_0.5	infracyanine	drug_name	Advanced “en face” visualization mode|Angiographie au vert d’infracyanine|Inflammation|Infracyanine green angiography|Multiple evanescent white dot syndrome|Photoreceptors|Photorécepteurs|Syndrome des taches blanches évanescentes multiples|Tomographie par cohérence optique « en face »|“En face” optical coherence tomography	author_keywords
infracyanine	Z0000013997				inn	PubMed	PMID23623768_20201005_0.5			Choroiditis|Female|Fluorescein Angiography|Humans|Indocyanine Green|Multifocal Choroiditis|Retinal Diseases|Tomography, Optical Coherence|Young Adult	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID23623768_20201005_0.5	infracyanine	drug_name	 METHODS A 21-year-old woman presenting with bilateral MEWDS underwent Cirrus(®) OCT with advanced "en face" reconstructions of the various retinal layers and inner choroid, fluorescein angiography, and infracyanine green angiography (ICGA).	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19823863_20201005_0.5	infracyanine	drug_name	Comparison of macular function and visual fields after membrane blue or infracyanine green staining in vitreoretinal surgery.	title
infracyanine	Z0000013997				inn	PubMed	PMID19823863_20201005_0.5			Aged|Aged, 80 and over|Basement Membrane|Coloring Agents|Epiretinal Membrane|Female|Humans|Indocyanine Green|Macula Lutea|Male|Middle Aged|Prospective Studies|Retinal Perforations|Staining and Labeling|Tomography, Optical Coherence|Trypan Blue|Visual Acuity|Visual Field Tests|Visual Fields|Vitrectomy	mesh_terms
infracyanine	Z0000013997				inn	PubMed	PMID19823863_20201005_0.5	infracyanine	drug_name	BACKGROUND To compare possible toxic effects of membrane blue and infracyanine green used as vital stains in macular surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19823863_20201005_0.5	infracyanine	drug_name	To compare possible toxicities of the two vital stains membrane blue and infracyanine green in vivo, we conducted a prospective, randomized, clinical trial.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19823863_20201005_0.5	infracyanine	drug_name	 METHODS A prospective, randomized clinical trial including 30 eyes of 30 patients with either full-thickness macular hole or idiopathic epiretinal membrane were included and randomized 1:1 to receive either membrane blue or infracyanine green during vitreoretinal surgery.	abstract
infracyanine	Z0000013997				inn	PubMed	PMID19823863_20201005_0.5	infracyanine	drug_name	Eight eyes (53%) of the infracyanine group had a decrease in temporal visual fields of at least 5 degrees .	abstract
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5	urochloa mutica	drug_name	Isoforms of Group 1 Allergens from a Tropical/Subtropical Para Grass (Urochloa mutica) Display Different Levels of IgE Reactivity and Cross-reactivity.	title
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5			Para grass pollen|Uro m 1|beta-expansins|isoallergens|recombinant group-1 allergen	author_keywords
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5			Adolescent|Adult|Allergens|Amino Acid Sequence|Child|Cross Reactions|Female|Humans|Immunoglobulin E|Male|Middle Aged|Plant Proteins|Poaceae|Protein Isoforms	mesh_terms
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5	urochloa mutica	drug_name	This study aimed to investigate the sequence similarity, and immunoreactivity of group 1 allergens from Para grass (Urochloa mutica).	abstract
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID27838316_20201005_0.5	urochloa mutica	drug_name	Kinetic analyses and pyrolytic behavior of Para grass (Urochloa mutica) for its bioenergy potential.	title
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID27838316_20201005_0.5			Bioenergy|Low cost biomass|Pyrolysis|TGA-DSC analyses	author_keywords
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID27838316_20201005_0.5			Biofuels|Biomass|Heating|Kinetics|Models, Theoretical|Poaceae|Thermodynamics|Thermogravimetry	mesh_terms
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID27838316_20201005_0.5	urochloa mutica	drug_name	No section The biomass of Urochloa mutica was subjected to thermal degradation analyses to understand its pyrolytic behavior for bioenergy production.	abstract
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID29549697_20201005_0.5	para grass pollen	drug_umls_atom	Beta-Expansin of Bermuda, Johnson, and Para grass pollens, is a major cross-reactive allergen for Allergic Rhinitis patients in subtropical climate.	title
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID29549697_20201005_0.5			Adolescent|Adult|Allergens|Antibody Specificity|Antigens, Plant|Child|Chromatography, Liquid|Cross Reactions|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunoglobulin E|Male|Middle Aged|Poaceae|Pollen|Rhinitis, Allergic|Tandem Mass Spectrometry|Thailand|Tropical Climate|Young Adult	mesh_terms
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5			Isoforms of Group 1 Allergens from a Tropical/Subtropical Para Grass (Urochloa mutica) Display Different Levels of IgE Reactivity and Cross-reactivity.	title
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5	para grass pollen	drug_umls_atom	Para grass pollen|Uro m 1|beta-expansins|isoallergens|recombinant group-1 allergen	author_keywords
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5			Adolescent|Adult|Allergens|Amino Acid Sequence|Child|Cross Reactions|Female|Humans|Immunoglobulin E|Male|Middle Aged|Plant Proteins|Poaceae|Protein Isoforms	mesh_terms
Urochloa mutica	C0331513			para grass pollen	trade_name	PubMed	PMID30983309_20201005_0.5	para grass pollen	drug_umls_atom	Three isoforms (Uro m 1.01, Uro m 1.02, and Uro m 1.03) were cloned from cDNA of Para grass pollen.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5			Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5			Aphasia|Apraxia of speech|Longitudinal|PET|Tauopathy	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Child, Preschool|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Speech|Carbolines|Apraxias|Positron-Emission Tomography|Aphasia, Primary Progressive|Brain|Amyloid beta-Peptides|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|tau Proteins|Tauopathies|Aphasia|Amyloid|Frontal Lobe|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33462630_20210611_0.5			Indication of retrograde tau spreading along Braak stages and functional connectivity pathways.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33462630_20210611_0.5			Alzheimer's disease|Braak stage|Functional connectivity|Network degeneration hypothesis|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33462630_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Adult|Male|Female|Neurofibrillary Tangles|Alzheimer Disease|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33164934_20210311_0.5			Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33164934_20210311_0.5			AV-1451|dementia|functional magnetic resonance imaging|mild cognitive impairment|positron emission tomography	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33164934_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Aged, 80 and over|Female|Alzheimer Disease|tau Proteins|Hippocampus|Cognitive Dysfunction|Neurofibrillary Tangles|Memory Disorders|Amyloid beta-Peptides|Positron-Emission Tomography|Neuropsychological Tests|Magnetic Resonance Imaging|Memory|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Temporal Lobe|Aging|Disease Progression	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5			Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5			tau imaging|amyloid imaging|Alzheimer’s disease|mild cognitive impairment|biomarkers	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Aged, 80 and over|Male|Humans|Female|Aged|Amyloid beta-Peptides|Tomography, X-Ray Computed|Amyloid|Amyloidogenic Proteins|Amyloidosis|Alzheimer Disease|Positron-Emission Tomography|florbetapir|Ethylene Glycols|tau Proteins|Aniline Compounds|Cognitive Dysfunction|Cognition Disorders|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Peptide Fragments|Brain|Cognition	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7151662_20201005_0.5			Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7151662_20201005_0.5			vision|Alzheimer’s disease|amyloid|tau|mild cognitive impairment	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7151662_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Humans|Male|Aged, 80 and over|Female|Aged|Contrast Sensitivity|Amyloid|Amyloidosis|Amyloidogenic Proteins|Alzheimer Disease|Cognitive Dysfunction|tau Proteins|Amyloid beta-Peptides|Positron-Emission Tomography|Brain|Neuroimaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Magnetic Resonance Imaging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7886030_20210311_0.5			Flortaucipir (tau) PET in LGI1 antibody encephalitis	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7886030_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Adult|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Neuroimaging|Positron-Emission Tomography|Neuropsychological Tests|Brain|Encephalitis|LGI1 protein, human|Intracellular Signaling Peptides and Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7780444_20210211_0.5			Variants in PPP2R2B and IGF2BP3 are associated with higher tau deposition	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7780444_20210211_0.5			Alzheimer's disease|imaging genetics|resilience|resistance|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7780444_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Genome-Wide Association Study|Tomography, X-Ray Computed|MAPT protein, human|tau Proteins|Alzheimer Disease|Positron-Emission Tomography|Amyloid beta-Peptides|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Amyloid|Ethylene Glycols|Fluorodeoxyglucose F18|Brain|Neuropsychological Tests|Aging|Aniline Compounds|Case-Control Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33130455_20210311_0.5			Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β-negative cognitively normal individuals.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33130455_20210311_0.5			Mesial temporal lobe|PART|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33130455_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Aged|Neocortex|Tomography, X-Ray Computed|Amyloid beta-Peptides|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Alzheimer Disease|Cognition|Positron-Emission Tomography|Cognitive Dysfunction|Amyloid|Radiopharmaceuticals|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5			Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5			Correlative Imaging|Molecular Imaging|Neurology|amyloid|dynamic PET|florbetapir|flortaucipir-PET|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Young Adult|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Tomography, X-Ray Computed|Carbolines|tau Proteins|Amyloid|Tauopathies|Alzheimer Disease|Positron-Emission Tomography|Cognitive Dysfunction|florbetapir|Ethylene Glycols|Brain|Hippocampus|Aniline Compounds|Amyloidogenic Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5			Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5			Alzheimer's Disease (AD)|Chronic Traumatic Encephalopathy (CTE)|Positron Emission Tomography (PET)|case report|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Male|Humans|Middle Aged|Chronic Traumatic Encephalopathy|Football|Retirement|Australia|Tomography, X-Ray Computed|Positron-Emission Tomography|Tauopathies|Brain Injury, Chronic|Plaque, Amyloid|tau Proteins|Alzheimer Disease|Brain Concussion|Soccer|Brain|Magnetic Resonance Imaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Amyloid beta-Peptides	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5			Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5			Alzheimer's disease|Biomarkers|CSF|Flortaucipir|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Middle Aged|Male|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Peptide Fragments|Positron-Emission Tomography|Biomarkers|Sensitivity and Specificity|Phosphorylation	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7866464_20210211_0.5			In vivo tau pathology is associated with synaptic loss and altered synaptic function	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7866464_20210211_0.5			Alzheimer|MEG|PET|Synaptic density|Synaptic function|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7866464_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Adult|Tomography, X-Ray Computed|Alzheimer Disease|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Brain|Positron-Emission Tomography|Amyloid beta-Peptides|Cognitive Dysfunction|Amyloid|Neuropsychological Tests|Cohort Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33356820_20210511_0.5			Finding New Communities: A Principle of Neuronal Network Reorganization in Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33356820_20210511_0.5			Alzheimer's disease|Network Reconfiguration|functional connectivity|graph theory|tau pathology	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33356820_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Adult|Alzheimer Disease|Connectome|tau Proteins|Brain|Positron-Emission Tomography|Magnetic Resonance Imaging|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5			Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5			AV1451 PET|Alzheimer's disease|Amyloid-beta|CSF p-tau181|Plasma p-tau181	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Male|Humans|Tomography, X-Ray Computed|Amyloid beta-Peptides|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Biomarkers|Peptide Fragments|Positron-Emission Tomography|Cognition Disorders|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Disease Progression|Plasma|Phosphorylation	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5491530_20201005_0.5			Imaging tau pathology in Parkinsonisms	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5491530_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Tomography, X-Ray Computed|Parkinsonian Disorders|Supranuclear Palsy, Progressive|Tauopathies|tau Proteins|Alzheimer Disease|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Pick Disease of the Brain|Brain|6-((3-fluoro-2-hydroxy)propoxy)-2-(4-methylaminophenyl)quinoline|Aniline Compounds|Frontotemporal Dementia|Quinolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33527648_20210611_0.5			Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33527648_20210611_0.5			Alzheimer's disease|NfL|biomarkers|pathology|preclinical|presenilin-1	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33527648_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Alzheimer Disease|Amyloid beta-Peptides|Intermediate Filaments|Presenilin-1|tau Proteins|Neurofilament Proteins|Cognition|Positron-Emission Tomography|Brain|Biomarkers|Neuropsychological Tests|Magnetic Resonance Imaging|Cross-Sectional Studies|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Thiazoles|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5			Financial Capacity and Regional Cerebral Tau in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5			Alzheimer's disease|amyloid|financial capacity|instrumental activities of daily living|mild cognitive impairment|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Aged, 80 and over|Humans|Male|Female|Aged|Alzheimer Disease|Cross-Sectional Studies|Activities of Daily Living|Tomography, X-Ray Computed|Cognitive Dysfunction|tau Proteins|Amyloid beta-Peptides|Positron-Emission Tomography|Amyloid|Cognition|Neuropsychological Tests|Neuroimaging|Brain|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34057079_20210611_0.5			Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34057079_20210611_0.5			18F-AV-1451|18F-AV-45|Alzheimer's disease|amyloid|connectome|diffusion tensor imaging|magnetic resonance imaging|mild cognitive impairment|positron emission tomography|tau protein	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34057079_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Alzheimer Disease|Connectome|Cognitive Dysfunction|Amyloid beta-Peptides|Amyloid|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Amyloidogenic Proteins|Magnetic Resonance Imaging|Aniline Compounds|Amyloidosis|Cerebral Cortex	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33215319_20210611_0.5			The impact of demographic, clinical, genetic, and imaging variables on tau PET status.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33215319_20210611_0.5			Alzheimer's disease|Abeta|Dementia|MCI|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33215319_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Aged, 80 and over|Female|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Amyloid beta-Peptides|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Entorhinal Cortex|Demography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5			Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5			Thickness|Atrophy|Tau|Amyloid|PET|Positron emission tomography|MRI	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Aged, 80 and over|Aged|Middle Aged|Humans|Female|Amyloid beta-Peptides|Cross-Sectional Studies|Positron-Emission Tomography|Alzheimer Disease|Atrophy|tau Proteins|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Brain|Ethylene Glycols|Radiopharmaceuticals|Magnetic Resonance Imaging|Aniline Compounds|Neuropsychological Tests|Cerebral Cortex	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32808011_20210111_0.5			Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32808011_20210111_0.5			amyloid|neurodegeneration|spatial extent|tau|topography	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32808011_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Alzheimer Disease|Pathology, Molecular|Amyloid beta-Peptides|Cognitive Dysfunction|tau Proteins|Positron-Emission Tomography|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Amyloid|Magnetic Resonance Imaging|Fluorodeoxyglucose F18|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Brain|Benzothiazoles|Neuropsychological Tests|Cognition|Aging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33002767_20210311_0.5			Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33002767_20210311_0.5			CSF|Cognition|Lewy body diseases|Neuropathology|PET imaging|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33002767_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Aged, 80 and over|Autopsy|Lewy Bodies|Lewy Body Disease|tau Proteins|Alzheimer Disease|Amyloid beta-Peptides|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Cognitive Dysfunction|Brain|Radiopharmaceuticals|Amyloid|Cohort Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5790630_20201005_0.5			Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5790630_20201005_0.5			Tau|positron emission tomography|parkinsonism	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5790630_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Tomography, X-Ray Computed|Positron-Emission Tomography|Supranuclear Palsy, Progressive|Parkinsonian Disorders|tau Proteins|Neurofibrillary Tangles|Fluorine Radioisotopes|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Alzheimer Disease|Autoradiography|Brain|Globus Pallidus|Lewy Body Disease	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33353724_20210411_0.5			Imaging of Tau Pathology in Neurodegenerative Diseases: An Update.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33353724_20210411_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Neurodegenerative Diseases|Tomography, X-Ray Computed|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Tauopathies|Radiopharmaceuticals|Autoradiography|Brain|THK5351|Aminopyridines|Quinolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5			Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5			Alzheimer's disease|SRTM|Standardised uptake value|[18F]Florbetapir|[18F]Flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Middle Aged|Male|Female|Aged, 80 and over|Aged|florbetapir|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Tomography, X-Ray Computed|Ethylene Glycols|Positron-Emission Tomography|Carbolines|Aniline Compounds|Alzheimer Disease|tau Proteins|Radiopharmaceuticals|Cognitive Dysfunction|Brain|Neuroimaging|Gray Matter	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7752786_20210111_0.5			11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7752786_20210111_0.5			Amyloid|Brain atrophy|Dementia|Lewy bodies|Synaptic imaging|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7752786_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one|Lewy Body Disease|Carbon-11|Carbon Radioisotopes|Pyridines|Pyrrolidinones|Lewy Bodies|Positron-Emission Tomography|Magnetic Resonance Imaging|Alzheimer Disease|Amyloid|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Aniline Compounds|Gray Matter|Multimodal Imaging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5			Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Aged|Female|Aged, 80 and over|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Amyloid beta-Peptides|Cohort Studies|Tomography, X-Ray Computed|Carbolines|Cognitive Dysfunction|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Neuroimaging|Brain|Aging|Radiopharmaceuticals|Neuropsychological Tests|Magnetic Resonance Imaging|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5			TauIQ - A canonical image based algorithm to quantify tau PET scans.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5			Canonical Images|Flortaucipir|IQ platform|Image Processing|PET|Power in clinical trials|Statistical Analysis|Tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Cross-Sectional Studies|Positron-Emission Tomography|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Alzheimer Disease|Amyloid beta-Peptides|Cognitive Dysfunction|Radiopharmaceuticals|Amyloid|Disease Progression|Algorithms	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33691512_20210311_0.5			Crossed cerebellar diaschisis on 18F-FDG PET: Frequency across neurodegenerative syndromes and association with 11C-PIB and 18F-Flortaucipir.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33691512_20210311_0.5			Alzheimer's|FDG|PET|Tau|diaschisis	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33691512_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Fluorodeoxyglucose F18|Syndrome|Carbon-11|Carbon Radioisotopes|Aniline Compounds|Carbolines|Thiazoles|Positron-Emission Tomography|Amyloid beta-Peptides|Alzheimer Disease|tau Proteins|Radiopharmaceuticals|Cerebellum|Magnetic Resonance Imaging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33749655_20210511_0.5			Synergistic Effect of Serum Homocysteine and Diabetes Mellitus on Brain Alterations.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33749655_20210511_0.5			Brain atrophy|diabetes mellitus|homocysteine|magnetic resonance imaging|positron emission tomography	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33749655_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Aged, 80 and over|Aged|Homocysteine|Brain|Alzheimer Disease|Cognitive Dysfunction|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|tau Proteins|Magnetic Resonance Imaging|Amyloid beta-Peptides|Neuroimaging|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neuropsychological Tests|Amyloid|Thiazoles|Cerebrovascular Disorders|Atrophy|Diabetes Mellitus	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7366127_20201005_0.5			PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7366127_20201005_0.5			corticobasal syndrome|progressive supranuclear palsy|Alzheimer's disease|positron emission tomography|motor symptoms|PSPRS|UPDRS	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7366127_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Middle Aged|Male|Female|Supranuclear Palsy, Progressive|Alzheimer Disease|Syndrome|Motor Disorders|tau Proteins|Biomarkers|Tauopathies|Positron-Emission Tomography|Parkinsonian Disorders|Magnetic Resonance Imaging|Brain|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Diagnostic Tests, Routine|Cohort Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33631469_20210611_0.5			Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33631469_20210611_0.5			Amyloid|Dementia|Lewy bodies|Neuroinflammation|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33631469_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Middle Aged|Male|Female|Lewy Body Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Lewy Bodies|Tomography, X-Ray Computed|Positron-Emission Tomography|Carbolines|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Cognitive Dysfunction|Temporal Lobe|Mental Status and Dementia Tests|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7943867_20210411_0.5			Blood Hemoglobin, in-vivo Alzheimer Pathologies, and Cognitive Impairment: A Cross-Sectional Study	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7943867_20210411_0.5			Alzheimer's disease|anemia|cerebral hypometabolism|cognitive impairment|hemoglobin	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7943867_20210411_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Aged, 80 and over|Male|Female|Aged|Alzheimer Disease|Cross-Sectional Studies|Tomography, X-Ray Computed|Cognitive Dysfunction|Brain|Cognition|Magnetic Resonance Imaging|Positron-Emission Tomography|Neuropsychological Tests|White Matter|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Cerebrovascular Trauma|Hemoglobins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32161362_20210311_0.5			APOEε4 potentiates the relationship between amyloid-β and tau pathologies.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32161362_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Aged, 80 and over|Female|Amyloid beta-Peptides|Alzheimer Disease|Cognitive Dysfunction|tau Proteins|florbetapir|Ethylene Glycols|Amyloid|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Brain|Aging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32388611_20210211_0.5			Correction to: Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32388611_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|tau Proteins|Amyloid beta-Peptides|Cognitive Dysfunction|Positron-Emission Tomography|Radiopharmaceuticals|Brain|Severity of Illness Index	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5			The development and validation of tau PET tracers: current status and future directions	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5			Tau|Positron emission tomography|Neurofibrillary tangles|Alzheimer’s disease|Neurodegeneration|Aging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|tau Proteins|Tauopathies|Neurofibrillary Tangles|Alzheimer Disease|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Radiopharmaceuticals|Supranuclear Palsy, Progressive|Brain|Autoradiography|6-((3-fluoro-2-hydroxy)propoxy)-2-(4-methylaminophenyl)quinoline|Quinolines|THK5351|Aminopyridines|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34060233_20210611_0.5			The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34060233_20210611_0.5			Alzheimer's disease|BIN1|amyloid|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34060233_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Alzheimer Disease|Amyloid beta-Peptides|Polymorphism, Single Nucleotide|Cognitive Dysfunction|tau Proteins|Positron-Emission Tomography|Brain|Radiopharmaceuticals|Biomarkers|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|BIN1 protein, human|Nuclear Proteins|Tumor Suppressor Proteins|Adaptor Proteins, Signal Transducing	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7892378_20210311_0.5			In vivo PET imaging of neuroinflammation in familial frontotemporal dementia	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7892378_20210311_0.5			PET|frontotemporal dementia|genetics	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7892378_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Adult|Frontotemporal Dementia|Tomography, X-Ray Computed|MAPT protein, human|tau Proteins|C9orf72 Protein|Progranulins|Intercellular Signaling Peptides and Proteins|Brain|Mutation|Heterozygote|DNA-Binding Proteins|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32762790_20210511_0.5			Association Between Visual Memory and In Vivo Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32762790_20210511_0.5			ADAD|Alzheimer's disease|Amyloid|Neuropsychological testing|Preclinical|Rey-Osterrieth Complex Figure|Tau|Visual memory	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32762790_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Adult|Humans|Male|Aged, 80 and over|Female|Alzheimer Disease|Amyloid|Presenilin-1|tau Proteins|Memory|Positron-Emission Tomography|Neuropsychological Tests|Amyloid beta-Peptides|Brain|Amyloidogenic Proteins|Magnetic Resonance Imaging|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Heterozygote|Amyloidosis|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32094584_20210611_0.5			Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32094584_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Animals|Humans|Rats|Male|Syndrome|Tauopathies|Chronic Traumatic Encephalopathy|Brain|Brain Injury, Chronic|Blast Injuries|Brain Concussion|Veterans|Neurons|Brain Injuries, Traumatic|Anxiety|Neuroimaging|Neurodegenerative Diseases|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Biomarkers|Afghanistan	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7075450_20201005_0.5			Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7075450_20201005_0.5			MRI|functional connectivity|PET|beta-amyloid|tau|multiband fMRI|preclinical|aging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7075450_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Aged|Humans|Male|Female|Adolescent|Apolipoprotein E4|Tomography, X-Ray Computed|Brain|Cognition|Alzheimer Disease|Amyloid beta-Peptides|tau Proteins|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Magnetic Resonance Imaging|Positron-Emission Tomography|flutemetamol|Cognitive Dysfunction|Memory|Neuropsychological Tests|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Benzothiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5			CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5			amyloid beta|apolipoprotein E|cerebrospinal fluid markers|cognitive impairment|family history of Alzheimer's disease|glucose|positron magnetic imaging|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Female|Adult|Alzheimer Disease|Amyloid beta-Peptides|Risk Factors|Apolipoprotein E4|tau Proteins|Cognitive Dysfunction|Disease Progression|Neuroimaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Brain|Biomarkers|Glucose	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34024836_20210611_0.5			Association of Midlife Depressive Symptoms with Regional Amyloid-β and Tau in the Framingham Heart Study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34024836_20210611_0.5			APOE|Amygdala|PET imaging|amyloid-beta|depression|depressive symptoms|entorhinal|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34024836_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Aged, 80 and over|Aged|Female|Cross-Sectional Studies|Depression|Amyloid beta-Peptides|Apolipoprotein E4|tau Proteins|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Positron-Emission Tomography|Amyloid|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Longitudinal Studies|Entorhinal Cortex|Brain|Thiazoles|Temporal Lobe|Cohort Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6530456_20201005_0.5			Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6530456_20201005_0.5			Tau PET|cognitively normal|mild cognition impairment|Alzheimer's disease	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6530456_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Aged|Aged, 80 and over|Middle Aged|Male|Humans|Female|Alzheimer Disease|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Positron-Emission Tomography|Carbolines|Brain|Neuroimaging|Amyloid beta-Peptides|tau Proteins|Fluorodeoxyglucose F18|Plaque, Amyloid|Cognition|Ethylene Glycols|Amyloid|Magnetic Resonance Imaging|Aniline Compounds|Entorhinal Cortex|Biomarkers|Aged|Middle Aged|Aged, 80 and over|Male|Humans|Female|Alzheimer Disease|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Positron-Emission Tomography|Carbolines|Brain|Neuroimaging|Amyloid beta-Peptides|tau Proteins|Fluorodeoxyglucose F18|Plaque, Amyloid|Cognition|Radiopharmaceuticals|Amyloid|Magnetic Resonance Imaging|Biomarkers	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5834417_20201005_0.5			Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5834417_20201005_0.5			Alzheimer’s disease|PET|Amyloid|Tau|Modelling	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5834417_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Carbolines|tau Proteins|Positron-Emission Tomography|Radiopharmaceuticals|Brain|Aniline Compounds|Amyloid|Metabolic Clearance Rate|Computer Simulation	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5			Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5			Flortaucipir|[|PET|Alzheimer’s|Tau|NFT|PHF|Autopsy|Histelide	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Humans|Male|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Immunohistochemistry|Pilot Projects|Alzheimer Disease|Carbolines|tau Proteins|Cognitive Dysfunction|Amyloid beta-Peptides|Positron-Emission Tomography|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33497190_20210411_0.5			Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33497190_20210411_0.5			4R-tau|CBD-2115|PET|fluorine-18|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33497190_20210411_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Animals|Humans|Mice|Rats|Tauopathies|Fluorine Radioisotopes|Positron-Emission Tomography|tau Proteins|Radiopharmaceuticals|Supranuclear Palsy, Progressive|Brain|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Mice, Transgenic	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5			Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5			AV-1451|Alzheimer's disease|PET|cognition|flortaucipir|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Humans|Male|Female|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neurofibrillary Tangles|tau Proteins|Cognitive Dysfunction|Positron-Emission Tomography|Amyloid beta-Peptides|Cognition|florbetapir|Ethylene Glycols|Amyloid|Neuropsychological Tests|Radiopharmaceuticals|Neuropathology|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5			Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Adult|Male|Female|Tauopathies|tau Proteins|Neurofibrillary Tangles|Brain Injury, Chronic|Chronic Traumatic Encephalopathy|florbetapir|Ethylene Glycols|Alzheimer Disease|Positron-Emission Tomography|Aniline Compounds|Brain Concussion|Brain|Brain Injuries, Traumatic|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Football	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5			Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5			18F-flortaucipir PET|Alzheimer's disease|apolipoprotein E|dose effect|sex	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Middle Aged|Aged, 80 and over|Aged|Apolipoprotein E4|Cognitive Dysfunction|Brain|Alzheimer Disease|tau Proteins|Neuroimaging|Amyloid beta-Peptides|florbetapir|Ethylene Glycols|Data Management|Positron-Emission Tomography|Magnetic Resonance Imaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Aniline Compounds|Radiopharmaceuticals|Amyloid|Neuropsychological Tests	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6688244_20201005_0.5			[18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6688244_20201005_0.5			TBI|CTE|neurodegeneration|PET|PiB|amyloid|AV-1451|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6688244_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Male|Humans|Female|Fluorodeoxyglucose F18|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbon-11|Carbon Radioisotopes|Positron-Emission Tomography|Carbolines|Neuroimaging|Alzheimer Disease|Brain|Amyloid|Magnetic Resonance Imaging|Aniline Compounds|Neuropsychological Tests|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5			Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5			Alzheimer's disease|Biomarker-based diagnosis|PET|Strategic roadmap|[18F]flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neurofibrillary Tangles|tau Proteins|Cognitive Dysfunction|Positron-Emission Tomography|Biomarkers	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5			Direct comparison of the tau PET tracers [18F]flortaucipir and [18F]MK-6240 in human subjects.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5			Alzheimer's disease|Neurology|PET|Research Methods|Tau|[F-18]MK-6240|flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Aged|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|MK-6240|Carbolines|Isoquinolines|tau Proteins|Alzheimer Disease|Cognitive Dysfunction|Brain|Positron-Emission Tomography|Gray Matter|Amyloid|Cognition|Choroid Plexus|Research Subjects|Longitudinal Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33731446_20210511_0.5			Reduced Repetition Suppression in Aging is Driven by Tau-Related Hyperactivity in Medial Temporal Lobe.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33731446_20210511_0.5			Alzheimer's disease|PET|aging|fMRI|repetition suppression|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33731446_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Young Adult|Humans|Male|Aged, 80 and over|Aged|Tomography, X-Ray Computed|Temporal Lobe|Amyloid beta-Peptides|Alzheimer Disease|tau Proteins|Entorhinal Cortex|Aging|Hippocampus|Magnetic Resonance Imaging|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Cognition	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5			Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5			18F-Flortaucipir PET|Alzheimer disease|Dual reference tissues|Logan plot|SRTM|SUVR|Spatially constrained kinetic modeling	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Carbolines|Positron-Emission Tomography|tau Proteins|Radiopharmaceuticals|Brain|Gray Matter|Magnetic Resonance Imaging|Kinetics|Cognition	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5224822_20201005_0.5			[18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5224822_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Female|Tauopathies|Frontotemporal Lobar Degeneration|tau Proteins|Frontotemporal Dementia|Alzheimer Disease|Brain|Mutation|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33475761_20210611_0.5			Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33475761_20210611_0.5			Hyperintensity|Longitudinal|Myelin|Reference region|Tau PET|White matter	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33475761_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|White Matter|Carbolines|Alzheimer Disease|Cognitive Dysfunction|Positron-Emission Tomography|Gray Matter|Magnetic Resonance Imaging|Leukoaraiosis|Neuroimaging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33952655_20210511_0.5			Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33952655_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Alzheimer Disease|Prospective Studies|Cognitive Dysfunction|Magnetic Resonance Imaging|Amyloid beta-Peptides|Positron-Emission Tomography|Brain|tau Proteins|Fluorodeoxyglucose F18|Amyloid|Cognition|Biomarkers|Neuropsychological Tests|Entorhinal Cortex|Aniline Compounds|Aging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7743860_20210111_0.5			Medial Temporal Tau Pathology Is Associated With Verbal Memory	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7743860_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Adult|Female|Longitudinal Studies|Tomography, X-Ray Computed|tau Proteins|Aging|Alzheimer Disease|Entorhinal Cortex|Amyloid beta-Peptides|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Hippocampus|Cognitive Dysfunction|Amyloid|Memory, Episodic|Brain|Cognition|Baltimore	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6186940_20201005_0.5			[18F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6186940_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Frontotemporal Dementia|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Pick Disease of the Brain|DNA Repeat Expansion|Carbolines|Frontotemporal Lobar Degeneration|DNA-Binding Proteins|Alzheimer Disease|tau Proteins|Mutation|Atrophy|Brain|C9orf72 Protein|Pedigree|Neuropsychological Tests|C9orf72 protein, human	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5			Sleep and Tau Pathology in Vietnam War Veterans with Preclinical and Prodromal Alzheimer’s Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5			Amyloid|mild cognitive impairment|positron emission tomography|preclinical AD|sleep|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Male|Humans|Middle Aged|Female|Adult|Veterans|Cross-Sectional Studies|Vietnam|Alzheimer Disease|tau Proteins|florbetapir|Ethylene Glycols|Amyloid beta-Peptides|Neuroimaging|Positron-Emission Tomography|Vietnam Conflict|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Cognitive Dysfunction|Aniline Compounds|Amyloid|Sleep|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5257031_20201005_0.5			Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5257031_20201005_0.5			Alzheimer disease|Tau imaging|Amyloid imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5257031_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Aged|Humans|Female|Adult|Alzheimer Disease|Positron-Emission Tomography|Amyloid beta-Peptides|tau Proteins|Amyloid|Cognitive Dysfunction|Brain|Aniline Compounds|Temporal Lobe|Amyloidosis|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7144772_20201005_0.5			In vivo network models identify sex differences in the spread of tau pathology across the brain	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7144772_20201005_0.5			[|Alzheimer's disease|mild cognitive impairment|network|sex differences|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7144772_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Female|Male|Humans|Adult|Tomography, X-Ray Computed|Brain|Alzheimer Disease|Cognitive Dysfunction|tau Proteins|Sex Characteristics|Amyloid beta-Peptides|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neuropsychological Tests|Tauopathies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5			Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5			Alzheimer's disease|PART|Pittsburgh compound B|atrophy|cortical integrity|flortaucipir|literature review|neurodegeneration|normal aging|positron emission tomography|publication bias|structural magnetic resonance imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Aged, 80 and over|Female|Aged|Amyloid beta-Peptides|Tomography, X-Ray Computed|Positron-Emission Tomography|tau Proteins|Alzheimer Disease|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Magnetic Resonance Imaging|Cognitive Dysfunction|Brain|Amyloid|Neuropsychological Tests|Aging|Cognition|Memory|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5			Tau pathology in cognitively normal older adults	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5			Tau|AV-1451|T807|Flortaucipir|FTP|PET|Cognition|Volume|Longitudinal|Cognitively normal	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Middle Aged|Aged, 80 and over|Male|Humans|Female|Aged|Retrospective Studies|Longitudinal Studies|Tomography, X-Ray Computed|Alzheimer Disease|tau Proteins|Cognition|Cognitive Dysfunction|Positron-Emission Tomography|Amyloid beta-Peptides|Brain|Amyloid|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Ethylene Glycols|Entorhinal Cortex|Aniline Compounds|Amyloidogenic Proteins|Baltimore	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7602678_20210111_0.5			Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7602678_20210111_0.5			Alzheimer's disease|Down syndrome|PET amyloid|TAU	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7602678_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Adult|Humans|Male|Middle Aged|Female|Amyloid beta-Peptides|Down Syndrome|Cohort Studies|Tomography, X-Ray Computed|Alzheimer Disease|Positron-Emission Tomography|Aging|tau Proteins|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Brain|Magnetic Resonance Imaging|Cognitive Dysfunction|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5			18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5			Alzheimer's disease|cerebrospinal fluid biomarkers|cognitive function|cortical thickness|flortaucipir|mild cognitive impairment|positron emission tomography|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Aged, 80 and over|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Carbolines|Cognitive Dysfunction|Amyloid beta-Peptides|tau Proteins|Cognition|Neuroimaging|Positron-Emission Tomography|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Neuropsychological Tests|Brain|Radiopharmaceuticals|Benzothiazoles|Magnetic Resonance Imaging|Longitudinal Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443955_20210611_0.5			Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443955_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Female|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|florbetapir|MAPT protein, human|tau Proteins|Carbolines|Ethylene Glycols|Neurofibrillary Tangles|Aniline Compounds|Amyloid beta-Peptides|Cognitive Dysfunction|Plaque, Amyloid|Positron-Emission Tomography|Amyloid|Radiopharmaceuticals	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5			Evaluation of a visual interpretation method for tau‐PET with 18F‐flortaucipir	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5			Alzheimer's disease|flortaucipir|qualitative assessment|tau positron emission tomography|visual assessment	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Tomography, X-Ray Computed|Carbolines|Alzheimer Disease|tau Proteins|Positron-Emission Tomography|Cognitive Dysfunction|Amyloid beta-Peptides|Amyloid|Brain|Radiopharmaceuticals	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6283453_20201005_0.5			Amyloid- and tau-PET imaging in a familial prion kindred	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6283453_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Positron-Emission Tomography|Amyloid|Alzheimer Disease|Prions|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Plaque, Amyloid|tau Proteins|Amyloidogenic Proteins|Amyloid beta-Peptides|Prion Diseases|Amyloidosis|Brain|Thiazoles|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Magnetic Resonance Imaging|Prion Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5			Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	United States|Humans|Male|Female|Aged|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Prospective Studies|Tomography, X-Ray Computed|Carbolines|Cognitive Dysfunction|Positron-Emission Tomography|tau Proteins|Amyloid beta-Peptides|Neuropsychological Tests|Brain|Mental Status and Dementia Tests	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34091353_20210611_0.5			Sex differences in off-target binding using tau positron emission tomography.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34091353_20210611_0.5			Alzheimer's disease|Off-target binding|PET|Sex differences|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34091353_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Middle Aged|Adult|Sex Characteristics|Cross-Sectional Studies|Tomography, X-Ray Computed|Positron-Emission Tomography|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Alzheimer Disease|Cognitive Dysfunction|Amyloid beta-Peptides|Brain|Skull	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5			Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5			Alzheimer's disease|affective symptoms|amyloid|mild cognitive impairment|neuropsychiatric symptoms|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Alzheimer Disease|Cross-Sectional Studies|Affective Symptoms|Tomography, X-Ray Computed|Cognitive Dysfunction|tau Proteins|Amyloid beta-Peptides|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neuroimaging|Neuropsychological Tests|Amyloid|Atrophy|Amyloidosis|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7714680_20210111_0.5			Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7714680_20210111_0.5			Cognition|Dementia with Lewy bodies|FDG PET|Relative cerebral blood flow|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7714680_20210111_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Lewy Body Disease|Lewy Bodies|Cerebrovascular Circulation|Alzheimer Disease|tau Proteins|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Brain|Cognitive Dysfunction|Amyloid|Neuropsychological Tests	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5671473_20201005_0.5			Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5671473_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Alzheimer Disease|tau Proteins|Positron-Emission Tomography|Radiopharmaceuticals|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Gray Matter|Brain|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33594726_20210311_0.5			Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33594726_20210311_0.5			Alzheimer's disease|cholinesterase inhibitors|positron emission tomography|tau aggregation	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33594726_20210311_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Middle Aged|Male|Female|Alzheimer Disease|Amyloid beta-Peptides|Cholinesterase Inhibitors|Tomography, X-Ray Computed|Positron-Emission Tomography|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Cognitive Dysfunction|Brain|Amyloid|Neuroimaging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32748322_20210211_0.5			Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32748322_20210211_0.5			Alzheimer's disease|Amyloid|Neuroimaging|Population neuroscience|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32748322_20210211_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Aged, 80 and over|Female|Aged|Alzheimer Disease|Longitudinal Studies|Neuroimaging|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Amyloid beta-Peptides|tau Proteins|Positron-Emission Tomography|Amyloid|Brain|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Cognitive Dysfunction|Apolipoprotein E4|Aging|Benzothiazoles|Cohort Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			An updated radiosynthesis of [18F]AV1451 for tau PET imaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			Tau imaging|Brain PET|[|Flortaucipir F18|Fluorine-18 radiochemistry|Automated radiosynthesis	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Positron-Emission Tomography|Radiopharmaceuticals|Carbolines|Fluorine Radioisotopes|tau Proteins|Alzheimer Disease|Radiochemistry|Tauopathies|Chromatography, High Pressure Liquid	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5			Neuroinflammation is highest in areas of disease progression in semantic dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5			MAOB|PBR28 PET|flortaucipir PET|neuroinflammation|semantic variant primary progressive aphasia	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Middle Aged|Female|Frontotemporal Dementia|Aphasia, Primary Progressive|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|tau Proteins|Alzheimer Disease|Positron-Emission Tomography|White Matter|Amyloid|Temporal Lobe|Cerebral Cortex|Atrophy|Disease Progression	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6939035_20201005_0.5			Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep-phenotyping case report	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6939035_20201005_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Down Syndrome|Amyloid beta-Peptides|Alzheimer Disease|Neuroimaging|Cognitive Dysfunction|Magnetic Resonance Imaging|tau Proteins|Positron-Emission Tomography|Amyloid|Neuropsychological Tests|Brain|Cerebral Cortex|Atrophy|Aniline Compounds|Longitudinal Studies|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33731439_20210411_0.5			Neuroinflammation predicts disease progression in progressive supranuclear palsy.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33731439_20210411_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Supranuclear Palsy, Progressive|Tomography, X-Ray Computed|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Magnetic Resonance Imaging|tau Proteins|Positron-Emission Tomography|Gray Matter|Multimodal Imaging|Severity of Illness Index|Biomarkers|Disease Progression	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5			Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5			Atrophy|Flortaucipir|Longitudinal change|Mild cognitive impairment|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5	7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole	drug_name	Humans|Male|Female|Longitudinal Studies|Tomography, X-Ray Computed|Cognitive Dysfunction|Atrophy|Alzheimer Disease|tau Proteins|Brain|Magnetic Resonance Imaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Data Management|Temporal Lobe|Neuropsychological Tests|Neuroimaging|Disease Progression	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7860631_20210211_0.5			Associations of quantitative susceptibility mapping with Alzheimer’s disease clinical and imaging markers	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7860631_20210211_0.5			Alzheimer's disease|Beta amyloid PET|Quantitative susceptibility mapping|Tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7860631_20210211_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Basal Ganglia|Brain|Brain Mapping|Carbolines|Cerebral Cortex|Cognitive Dysfunction|Female|Globus Pallidus|Gray Matter|Humans|Iron|Linear Models|Magnetic Resonance Imaging|Male|Middle Aged|Organ Size|Positron-Emission Tomography|Putamen|Radiopharmaceuticals|Substantia Nigra|Subthalamic Nucleus|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7860631_20210211_0.5	tauvid	drug_synonym	All participants had multi-echo gradient recalled echo imaging, PiB amyloid PET, and Tauvid tau PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5	tauvid	drug_synonym	Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5	tauvid	drug_synonym	PET|[18F]flortaucipir|alzheimer's disease|tau neurofibrillary tangles (NFTs)|tauvid	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5			United States|Adult|Humans|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Positron-Emission Tomography|Radiopharmaceuticals|Brain|Carbolines|Diagnostic Tests, Routine	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5	tauvid	drug_synonym	No section Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5	tauvid	drug_synonym	In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5	tauvid	drug_synonym	The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27802224_20201005_0.5			In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27802224_20201005_0.5	t-807	drug_synonym	18F-AV-1451|18F-FDG|Alzheimer’s disease|Pittsburghcompound B|T-807|amyloid|molecular imaging|multimodal imaging|positron-emission tomography|tau protein	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27802224_20201005_0.5			Alzheimer Disease|Amyloid beta-Peptides|Atrophy|Brain|Carbolines|Cognition Disorders|Corticomedial Nuclear Complex|Executive Function|Female|Fluorodeoxyglucose F18|Humans|Language Disorders|Male|Neuropsychological Tests|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27171905_20210111_0.5			Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27171905_20210111_0.5			Alzheimer's disease|PET|Radioligand|in vitro assay|tangle|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27171905_20210111_0.5			Alzheimer Disease|Aniline Compounds|Autoradiography|Binding Sites|Brain|Carbolines|Diagnosis|Dose-Response Relationship, Drug|Female|Humans|Male|Neurofibrillary Tangles|Positron-Emission Tomography|Quinolines|Radioligand Assay|Radiopharmaceuticals|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27171905_20210111_0.5	t807	drug_name_variant	Although [(18)F]THK-523 and [(18)F]T807 are considered high-affinity selective radioligands for NFTs, uncertainty has existed as to whether PET radioligands for imaging NFTs bind to the same molecular site because in vitro assays for ligands binding to NFTs have been lacking.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27171905_20210111_0.5	t807	drug_name_variant	We labeled THK-523 and T807 with tritium to serve as reference radioligands for in vitro binding assays with AD brain homogenates for newly synthesized ligands.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27171905_20210111_0.5	t807	drug_name_variant	With these radioligands, we identified two distinct binding sites for small molecules, one site with high affinity for THK-523 and the other with high affinity for T807.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5964045_20201005_0.5			Flortaucipir tau PET imaging in semantic variant primary progressive aphasia	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5964045_20201005_0.5			brain atrophy|tau PET|primary progressive aphasia|semantic dementia|temporallobe	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5964045_20201005_0.5			Aged|Aged, 80 and over|Aphasia, Primary Progressive|Brain|Carbolines|Female|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Neuroimaging|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5964045_20201005_0.5	t807	drug_name_variant	We undertook this study to investigate the localisation and magnitude of the presumed tau Positron Emission Tomography (PET) tracer [ F]Flortaucipir (FTP; also known as T807 or AV1451) in patients with svPPA, hypothesising that most patients would not show tracer uptake different from controls.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4249716_20201005_0.5			Chronic traumatic encephalopathy: clinical‐biomarker correlations and current concepts in pathogenesis	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4249716_20201005_0.5			Biomarkers|Brain Injury, Chronic|Humans	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4249716_20201005_0.5	t807	drug_name_variant	New positron emission tomography (PET) ligands (e.g., [  F] T807) that identify brain tauopathy have been successfully deployed for the in vitro and in vivo detection of presumptive tauopathy in the brains of subjects with clinically probable CTE.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4249716_20201005_0.5	t807	drug_name_variant	Newer achievements, such as serum tau and [  F] T807 tauopathy imaging, are also introduced and their significance has been explained.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10339462_20210311_0.5	t807	drug_name_variant	The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10339462_20210311_0.5			Adult|Age Factors|Blood Platelets|Cerebrovascular Disorders|Female|Humans|Integrins|Male|Middle Aged|Polymorphism, Genetic|Receptors, Collagen|Risk Factors	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10339462_20210311_0.5	t807	drug_name_variant	The GPIa T807/A873 allele causes a higher receptor expression, enhancing platelet binding to collagen.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10339462_20210311_0.5	t807	drug_name_variant	In patients </=50 years of age, the T807 allele was the only overrepresented variable (P =.023; odds ratio, 3.02; 95% confidence interval, 1.20 to 7.61) and an independent risk factor, whereas the presence of conventional risk factors was similar between stroke patients </=50 years of age and non-CVD patients </=50 years of age.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10339462_20210311_0.5	t807	drug_name_variant	Large epidemiological studies should prove whether the platelet collagen receptor GPIa-IIa T807 allele is an independent risk factor for the development of stroke in younger patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Alzheimer’s disease|THK5117|T807|AV1451|PBB3|Tau imaging|autoradiography|Tau PET|Tau PET tracers|Deprenyl	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Autopsy|Autoradiography|Binding, Competitive|Brain|Dose-Response Relationship, Drug|Female|Humans|In Vitro Techniques|Male|Middle Aged|Monoamine Oxidase Inhibitors|Positron-Emission Tomography|Radiopharmaceuticals|Tissue Distribution	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Background The aim of this study was to compare the binding properties of several tau positron emission tomography tracers--THK5117, THK5351, T807 (also known as AV1451; flortaucipir), and PBB3--head to head in the same human brain tissue.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Competition binding assays between THK5351, THK5117, PBB3, and T807, as well as off-target binding of THK5117 and T807 toward monoamine oxidase B (MAO-B), were performed using binding assays in brain homogenates and autoradiography of three AD cases.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Competition studies in the hippocampus between H-THK5351 and unlabeled THK5351, THK5117, and T807 revealed super-high-affinity sites for all three tracers (THK5351 K i  = 0.1 pM; THK5117 K i  = 0.3 pM; T807 K i  = 0.2 pM) and an additional high-affinity site (THK5351 K i  = 16 nM; THK5117 K i  = 20 nM; T807 K i  = 78nM).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	F-T807, C-THK5351, and C-PBB3 autoradiography of large frozen sections from three AD brains showed similar regional binding for the three tracers, with lower binding intensity for C-PBB3.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Unlabeled THK5351 and T807 displaced C-THK5351 to a similar extent and a lower extent, respectively, compared with C-PBB3.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Competition with the MAO-B inhibitor H-l -deprenyl was observed for THK5117 and T807 in the hippocampus (THK5117 K i  = 286 nM; T807 K i  = 227 nM) and the putamen (THK5117 K i  = 148 nM; T807 K i  = 135 nM).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	H-THK5351 binding was displaced using autoradiography competition with unlabeled THK5351 and T807 in cortical areas by 70-80% and 60-77%, respectively, in the basal ganglia, whereas unlabeled deprenyl displaced H-THK5351 binding by 40% in the frontal cortex and 50% in the basal ganglia.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	 Conclusions THK5351, THK5117, and T807 seem to target similar binding sites, but with different affinities, whereas PBB3 seems to target its own binding site.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	t807	drug_name_variant	Both THK5117 and T807 demonstrated off-target binding in the hippocampus and putamen with a ten times lower binding affinity to the MAO-B inhibitor deprenyl compared with H-THK5351.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29630333_20201005_0.5			Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29630333_20201005_0.5			PET tracers|binding free energy calculations|fibril imaging|molecular docking|paired helical filaments|tau fibril|tauopathies	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29630333_20201005_0.5			Amyloid beta-Peptides|Animals|Binding Sites|Humans|Molecular Docking Simulation|Molecular Dynamics Simulation|Positron-Emission Tomography|Protein Aggregation, Pathological|Protein Multimerization|Protein Structure, Secondary|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29630333_20201005_0.5	t807	drug_name_variant	We also find that MK6240 and T807 bind to site 1 specifically.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29630333_20201005_0.5	t807	drug_name_variant	For example, the displacement of T807 by PBB3 as reported experimentally can also be explained and attributed to the larger binding affinity of the latter compound in all binding sites.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	Alzheimer’s disease|Amyloid β|Autoradiography|Imaging|Tau|[(18)F]T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Animals|Autoradiography|Brain|Case-Control Studies|Female|Fluorine Radioisotopes|Humans|Male|Mice|Mice, Transgenic|Middle Aged|Positron-Emission Tomography|Protein Binding|Tissue Distribution|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	 METHODS To screen potential tau binders, human AD brain sections were used as a source of native paired helical filament (PHF)-tau and Aβ rather than synthetic tau aggregates or Aβ fibrils generated in vitro to measure the affinity and selectivity of [(18)F]T807 to tau and Aβ.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	Brain uptake and biodistribution of [(18)F]T807 in mice were also tested.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	 RESULTS In vitro autoradiography results show that [(18)F]T807 exhibits strong binding to PHF-tau-positive human brain sections.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	A dissociation constant (Kd) of [(18)F]T807 (14.6 nM) was measured using brain sections from the frontal lobe of AD patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	A comparison of autoradiography and double immunohistochemical staining of PHF-tau and Aβ on adjacent sections demonstrated that [(18)F]T807 binding colocalized with immunoreactive PHF-tau pathology, but did not highlight Aβ plaques.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	In vivo studies in mice demonstrated that [(18)F]T807 was able to cross the blood-brain barrier and washed out quickly.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID23411393_20201005_0.5	t807	drug_name_variant	 CONCLUSIONS [(18)F]T807 demonstrates high affinity and selectivity to PHF-tau as well as favorable in vivo properties, making this a promising candidate as an imaging agent for AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27765859_20201005_0.5			Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27765859_20201005_0.5			kinetic modeling|positron emission tomography|quantification|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27765859_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Female|Humans|Male|Models, Biological|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27765859_20201005_0.5	t807	drug_name_variant	We describe different strategies for quantification of 18F-AV-1451 (T807) tau binding, including models with blood sampling and noninvasive alternatives.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30421819_20201005_0.5			The anatomy of concussion and chronic traumatic encephalopathy: A comprehensive review.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30421819_20201005_0.5			NFL|brain|football|guidelines|head|injury|return to play|sports|treatment	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30421819_20201005_0.5			Biomarkers|Brain Concussion|Chronic Traumatic Encephalopathy|Diffusion Tensor Imaging|Humans|Magnetic Resonance Imaging|Positron Emission Tomography Computed Tomography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30421819_20201005_0.5	t807	drug_name_variant	Positron emission tomography scans with radioactive ligands such as T807 as an imaging biomarker, and neurofilament light and ubiquitin C-terminal hydrolase as serum biomarkers have shown some promise lately in diagnosing concussion and chronic traumatic encephalopathy and also determining their prognosis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID18556092_20201005_0.5			Differential effects of linear and cyclic polyamines on NMDA receptor activities.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID18556092_20201005_0.5			Animals|Cells, Cultured|Cloning, Molecular|Excitatory Amino Acids|Female|Glycine|Hippocampus|Molecular Conformation|Neuroprotective Agents|Oocytes|Polyamines|Rats|Receptors, N-Methyl-D-Aspartate|Spermine|Xenopus laevis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID18556092_20201005_0.5	t807	drug_name_variant	The inhibitory potency of both CP2323 and spermine was attenuated by the mutations around the vestibule of the channel pore at NR1 W563, N650, T807, and NR2B Y646.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5	t807	drug_name_variant	A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5	t807	drug_name_variant	PET|T807|fluorine-18|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5			Carbolines|Fluorine Radioisotopes|Isotope Labeling|Positron-Emission Tomography|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5	t807	drug_name_variant	No section Fluorine-18 labeled 7-(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole ([(18) F]T807) is a potent and selective agent for imaging paired helical filaments of tau and is among the most promising PET radiopharmaceuticals for this target in early clinical trials.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5	t807	drug_name_variant	The present study reports a simplified one-step method for the synthesis of [(18) F]T807 that is broadly applicable for routine clinical production using a GE TRACERlabTM FXFN radiosynthesis module.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5	t807	drug_name_variant	Formulated [(18) F]T807 was prepared in an uncorrected radiochemical yield of 14 ± 3%, with a specific activity of 216 ± 60 GBq/μmol (5837 ± 1621 mCi/μmol) at the end of synthesis (60 min; n = 3) and validated for human use.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID24339014_20201005_0.5	t807	drug_name_variant	This methodology offers the advantage of faster synthesis in fewer steps, with simpler automation that we anticipate will facilitate widespread clinical use of [(18) F]T807.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5			Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5			Alzheimer's disease|Biomimetic nanosystems|Blood-brain barrier|Neuronal mitochondria	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5			Alzheimer Disease|Animals|Biomimetics|Curcumin|Mice|Mitochondria|Nanoparticles|Neurons	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5	t807	drug_name_variant	Herein, we devised and tested a strategy for functional antioxidant delivery to neuronal mitochondria by loading antioxidants into red blood cell (RBC) membrane-camouflaged human serum albumin nanoparticles bearing T807 and triphenylphosphine (TPP) molecules attached to the RBC membrane surface (T807/TPP-RBC-NPs).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5	t807	drug_name_variant	With the advantage of the suitable physicochemical properties of the nanoparticles and the unique biological functions of the RBC membrane, the T807/TPP-RBC-NPs are stabilized and promote sustained drug release, providing improved biocompatibility and long-term circulation.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5	t807	drug_name_variant	Under the synergistic effects of T807 and TPP, T807/TPP-RBC-NPs can not only penetrate the blood-brain barrier (BBB) but also target nerve cells and further localize in the mitochondria.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5	t807	drug_name_variant	After encapsulating curcumin (CUR) as the model antioxidant, the research data demonstrated that CUR-loaded T807/TPP-RBC-NPs can relieve AD symptoms by mitigating mitochondrial oxidative stress and suppressing neuronal death both in vitro and in vivo.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32251785_20210611_0.5	t807	drug_name_variant	Herein, we designed a red blood cell (RBC) membrane-coated human serum albumin nanoparticle dual-modified with T807 and TPP (T807/TPP-RBC-NPs) to accomplish these objectives.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5491530_20201005_0.5			Imaging tau pathology in Parkinsonisms	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5491530_20201005_0.5			Humans|Tomography, X-Ray Computed|Parkinsonian Disorders|Supranuclear Palsy, Progressive|Tauopathies|tau Proteins|Alzheimer Disease|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Pick Disease of the Brain|Brain|6-((3-fluoro-2-hydroxy)propoxy)-2-(4-methylaminophenyl)quinoline|Aniline Compounds|Frontotemporal Dementia|Quinolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5491530_20201005_0.5	t807	drug_name_variant	These radiotracers include [ F]FDDNP, [ C]PBB3, [ F]THK-5317, [ F]THK-5351, and [ F]AV-1451 ([ F]T807).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID25239654_20201005_0.5			Tau PET imaging in Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID25239654_20201005_0.5			Alzheimer Disease|Humans|Positron-Emission Tomography|Protein Binding|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID25239654_20201005_0.5	t807	drug_name_variant	Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5470083_20201005_0.5	t807	drug_name_variant	Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5470083_20201005_0.5			molecular imaging of neurodegenerative diseases|Alzheimer|biomarker|PET imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5470083_20201005_0.5			Alzheimer Disease|Animals|Benzimidazoles|Brain Chemistry|Fluorine Radioisotopes|Humans|Mice|Mice, Transgenic|Mutation|Plasma|Positron-Emission Tomography|Pyrimidines|Radiopharmaceuticals|Tissue Distribution|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5470083_20201005_0.5	t807	drug_name_variant	No section Early clinical results of two tau tracers, [ F]T808 and [ F]T807, have recently been reported.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5470083_20201005_0.5	t807	drug_name_variant	In the present study, the biodistribution, radiometabolite quantification, and competition-binding studies were performed in order to acquire comparative preclinical data as well as to establish the value of T808 and T807 as benchmark compounds for assessment of binding affinities of eight new/other tau tracers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5470083_20201005_0.5	t807	drug_name_variant	This study provides a straightforward comparison of the binding affinity and selectivity for tau of the reported radiolabeled tracers BF-158, BF-170, THK5105, lansoprazole, astemizole, and novel tau positron emission tomography ligands against T807 and T808.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5			Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5			AV-1451|Alzheimer's disease|Autoradiography|MK6240|THK5117|Tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5			Alzheimer Disease|Autopsy|Brain|Humans|Neurofibrillary Tangles|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5	t807	drug_name_variant	Competitive binding assays were carried out between H-MK6240 and unlabelled MK6240, AV-1451 (aka T807, flortaucipir) and THK5117, and between H-THK5351 and unlabelled MK6240.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27334944_20201005_0.5			18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27334944_20201005_0.5			Animals|Brain|Fluorine Radioisotopes|Humans|Positron-Emission Tomography|Quinolines|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27334944_20201005_0.5	t807	drug_name_variant	Tau positron emission tomography radiolabelled probes such as T807, THK-5117, and PBB3 can image the pathology of the disease in vivo.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27334944_20201005_0.5	t807	drug_name_variant	The 18F-labeled tau imaging agents 18F-THK-5351, 18F-T807 (18F-AV-1451), and 18F-RO6958948 are presently under evaluation in clinical studies and clinical trials worldwide.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7066333_20201005_0.5			Frontal variant of Alzheimer's disease with asymmetric presentation mimicking frontotemporal dementia: Case report and literature review	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7066333_20201005_0.5			behavior variant of frontotemporal dementia|beta‐amyloid|biomarkers|frontal variant of Alzheimer's disease|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7066333_20201005_0.5			Aged|Alzheimer Disease|Amyloid beta-Peptides|Biomarkers|Brain|Diagnosis, Differential|Executive Function|Frontotemporal Dementia|Humans|Male|Middle Aged|Neuroimaging|Neuropsychological Tests|Phosphorylation|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7066333_20201005_0.5	t807	drug_name_variant	However, we observed increased tau depositions based on F‐labeled T807 Tau PET in these areas and diffusely increased amyloid deposition based on C‐labeled Pittsburgh compound B positron emission tomography (PET).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5	t807	drug_name_variant	Fully automated synthesis of [(18)F]T807, a PET tau tracer for Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5	t807	drug_name_variant	Alzheimer’s disease (AD)|Automation|Positron emission tomography (PET)|Tau tracer|[(18)F]T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5			Alzheimer Disease|Carbolines|Chemistry Techniques, Synthetic|Fluorine Radioisotopes|Halogenation|Humans|Positron-Emission Tomography|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5	t807	drug_name_variant	No section The authentic standard T807 and its nitro-precursor T807P as well as t-Boc-protected T807P precursor for radiolabeling were synthesized from (4-bromophenyl)boronic acid, 3-bromo-4-nitropyridine and 3-bromo-6-nitropyridine with overall chemical yield 27% in three steps, 4-7% in three to five steps, and 3-8% in four to five steps, respectively. [(	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5	t807	drug_name_variant	18)F]T807 was synthesized from T807P by the nucleophilic [(18)F]fluorination with K[(18)F]F/Kryptofix 2.2.2 in DMSO at 140 °C followed by reduction with Fe powder/HCOOH through manual synthesis with 5-10% decay corrected radiochemical yield in two steps. [(	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5	t807	drug_name_variant	18)F]T807 was also synthesized from t-Boc-protected T807P by a concurrent [(18)F]fluorination and deprotection with K[(18)F]F/Kryptofix 2.2.2 in DMSO at 140 °C and purified by HPLC-SPE method in a home-built automated [(18)F]radiosynthesis module with 20-30% decay corrected radiochemical yield in one step.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26048805_20201005_0.5	t807	drug_name_variant	The specific activity of [(18)F]T807 at end of bombardment (EOB) was 37-370 GBq/μmol.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID15104219_20201005_0.5			Correlation between the polymorphism of glycoprotein Ia gene and acute coronary syndrome.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID15104219_20201005_0.5			Aged|Alleles|Angina, Unstable|Asian Continental Ancestry Group|Case-Control Studies|China|Female|Gene Frequency|Genetic Predisposition to Disease|Genotype|Humans|Integrin alpha2|Male|Middle Aged|Myocardial Infarction|Odds Ratio|Polymorphism, Genetic	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID15104219_20201005_0.5	t807	drug_name_variant	 RESULTS The frequencies of both homozygotes and heterozygotes for T807 allele (TT+TC) were significantly higher in patients with AMI than in controls (62.16% vs 33.85%, P<0.01; odds ratio 3.21).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID15104219_20201005_0.5	t807	drug_name_variant	Platelet GPIa T807 allele remained significantly associated with AMI and UAP by multiple logistic regression (odds ratio 4.94).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID15104219_20201005_0.5	t807	drug_name_variant	 CONCLUSIONS This study suggests a strong association between presence of GPIa T807 allele and ACS.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID15104219_20201005_0.5	t807	drug_name_variant	T807 allele can be a marker of genetic susceptibility to ACS.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID14687991_20201005_0.5			Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID14687991_20201005_0.5			3' Untranslated Regions|Alleles|Amino Acid Substitution|Factor V|Female|Genetic Predisposition to Disease|Genotype|Hemorrhagic Disorders|Humans|Integrin alpha2beta1|Male|Phenotype|Platelet Glycoprotein GPIIb-IIIa Complex|Platelet Membrane Glycoprotein IIb|Polymorphism, Single Nucleotide|Prothrombin|Severity of Illness Index|Structure-Activity Relationship|Thrombasthenia	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID14687991_20201005_0.5	t807	drug_name_variant	Three GT patients were homozygous for the T807 allele and showed a mild clinical expression of GT whereas none of the patients presenting with a moderate or severe GT phenotype carried the alpha2 TT genotype (p=0.037, two-sided exact test).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID14687991_20201005_0.5	t807	drug_name_variant	In patients carrying the same mutation, the clinical GT phenotype was milder in those with the TT807 genotype.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29278274_20201005_0.5			The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29278274_20201005_0.5	t807	drug_name_variant	T807|biomarker|imaging|off-target binding|progressive supranuclear palsy	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29278274_20201005_0.5			Alzheimer Disease|Animals|Brain|Carbolines|Contrast Media|Dose-Response Relationship, Drug|Humans|Monoamine Oxidase|Positron-Emission Tomography|Protein Binding|Radioligand Assay|Rats|Rats, Sprague-Dawley|Supranuclear Palsy, Progressive|Tritium|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26344059_20201005_0.5	t807	drug_name_variant	Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26344059_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid|Autoradiography|Brain|Cadaver|Carbolines|Dementia|Female|Frontotemporal Lobar Degeneration|Humans|Inclusion Bodies|Intracranial Hemorrhages|Male|Middle Aged|Positron-Emission Tomography|Radiopharmaceuticals|TDP-43 Proteinopathies|Tauopathies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26344059_20201005_0.5	t807	drug_name_variant	OBJECTIVE To examine region- and substrate-specific autoradiographic and in vitro binding patterns of positron emission tomography tracer [F-18]-AV-1451 (previously known as T807), tailored to allow in vivo detection of paired helical filament-tau-containing lesions, and to determine whether there is off-target binding to other amyloid/non-amyloid proteins.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11877061_20201005_0.5			[Study of C807T polymorphism of the platelet collagen receptor alpha2 gene coding sequence in Suzhou Han population].	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11877061_20201005_0.5			Asian Continental Ancestry Group|China|Female|Humans|Integrin alpha2beta1|Male|Polymorphism, Single Nucleotide	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11877061_20201005_0.5	t807	drug_name_variant	 RESULTS The allelic frequencies were 0.291:0.709 for T807 allele: C807 allele in Suzhou Han population.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID21672359_20201005_0.5			Functional effect of platelet membrane glycoprotein ia gene polymorphism in the pathogenesis of unstable angina pectoris.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID21672359_20201005_0.5			Angina, Unstable|Asian Continental Ancestry Group|Case-Control Studies|China|Ethnic Groups|Female|Genetic Predisposition to Disease|Humans|Integrin alpha2|Male|P-Selectin|Platelet Aggregation|Polymorphism, Single Nucleotide	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID21672359_20201005_0.5	t807	drug_name_variant	It was concluded that rapid initiation of collagen-induced platelet aggregation may be associated with the platelet membrane GPIa T807 allele, which may be important in UAP pathogenesis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28697559_20201214_0.5			Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28697559_20201214_0.5			Alzheimer's disease|amyloid|cognitively normal|depression|depressive symptoms|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28697559_20201214_0.5			Aged|Aged, 80 and over|Aniline Compounds|Cross-Sectional Studies|Depression|Entorhinal Cortex|Ethylene Glycols|Female|Humans|Male|Middle Aged|Pilot Projects|Positron-Emission Tomography|Psychiatric Status Rating Scales|Temporal Lobe|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28697559_20201214_0.5	t807	drug_name_variant	 OBJECTIVE The objective of this study was to investigate the cross-sectional association between depressive symptoms and cerebral tau [18F T807 (also known as 18F-AV-1451) tau positron emission tomography (PET) imaging] in cognitively normal (CN) older adults.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28697559_20201214_0.5	t807	drug_name_variant	 METHODS We measured depressive symptoms using the Geriatric Depression Scale (GDS), and in vivo cerebral tau using T807 PET in 111 CN older adults.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5			One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	t807	drug_name_variant	AV-1451|SSM/PCA|T807|flortaucipir|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5			Aged|Amyloid|Carbolines|Case-Control Studies|Female|Humans|Male|Neurodegenerative Diseases|Positron-Emission Tomography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	t807	drug_name_variant	Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5			Humans|Adult|Male|Female|Tauopathies|tau Proteins|Neurofibrillary Tangles|Brain Injury, Chronic|Chronic Traumatic Encephalopathy|florbetapir|Ethylene Glycols|Alzheimer Disease|Positron-Emission Tomography|Aniline Compounds|Brain Concussion|Brain|Brain Injuries, Traumatic|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Football	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	t807	drug_name_variant	However, a new positron emission tomography (PET) ligand, [ F]T807/AV1451, may provide the antemortem detection of tau aggregates, and thus various tauopathies, including CTE.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	t807	drug_name_variant	Our goal was to examine [ F]T807/AV1451 retention in athletes with neuropsychiatric symptoms associated with a history of multiple concussions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	t807	drug_name_variant	The [ F]T807/AV1451 PET showed multifocal areas of retention at the cortical gray matter-white matter junction, a distribution considered pathognomonic for CTE. [	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	t807	drug_name_variant	F]T807/AV1451 standard uptake value (SUV) analysis showed increased uptake (SUVr⩾1.1) in bilateral cingulate, occipital, and orbitofrontal cortices, and several temporal areas.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5048212_20201005_0.5	t807	drug_name_variant	Although definitive identification of the neuropathological underpinnings basis for [ F]T807/AV1451 retention requires postmortem correlation, our data suggest that [ F]T807/AV1451 tauopathy imaging may be a promising tool to detect and diagnose CTE-related tauopathy in living subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5			Tau positron emission tomographic imaging in aging and early Alzheimer disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Biomarkers|Carbolines|Cerebral Cortex|Cognitive Dysfunction|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Temporal Lobe|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5	t807	drug_name_variant	 METHODS We acquired tau positron emission tomography (PET) using (18)F T807 (AV1451), and amyloid-β PET using (11)C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5	t807	drug_name_variant	 RESULTS We found abnormally high cortical (18)F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5	t807	drug_name_variant	Consistent with the neuropathology literature, the presence of elevated neocortical (18)F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5	t807	drug_name_variant	The association of cognitive impairment was stronger with inferior temporal (18)F T807 than with mean cortical (11)C PIB.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5	t807	drug_name_variant	Regional (18)F T807 was correlated with mean cortical (11)C PiB among both impaired and control subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26505746_20201005_0.5	t807	drug_name_variant	 CONCLUSIONS These findings suggest that (18)F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27151986_20201005_0.5	t807	drug_name_variant	Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27151986_20201005_0.5	t807	drug_name_variant	18F-AV-1451 (T807)|PET|kinetics|neurology|radiotracer tissue|tau|tracer	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27151986_20201005_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Carbolines|Cognition|Cognitive Dysfunction|Female|Humans|Kinetics|Male|Middle Aged|Models, Biological|Positron-Emission Tomography|Radioactive Tracers|Young Adult|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	18F-T807|PET|kinetic modeling|pharmacokinetics|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5			Adult|Aged|Brain|Carbolines|Computer Simulation|Humans|Metabolic Clearance Rate|Middle Aged|Models, Biological|Molecular Imaging|Organ Specificity|Positron-Emission Tomography|Radiopharmaceuticals|Reproducibility of Results|Sensitivity and Specificity|Tissue Distribution|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	No section 18F-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	The current study characterizes 18F-T807 pharmacokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input functions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	 Methods Nine subjects (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of 18F-T807 with arterial blood sampling.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	 Results The percentage of unmetabolized 18F-T807 in plasma followed a single exponential with a half-life of 17.0 ± 4.2 min.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	18F-T807 in gray matter peaked quickly (SUV > 2 at ∼5 min).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27660144_20201005_0.5	t807	drug_name_variant	Conclusion:18F-T807 showed rapid clearance from plasma and properties suitable for tau quantification with PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Adult|Age Factors|Alzheimer Disease|Amyloid|Aniline Compounds|Brain|Carbolines|Cognition Disorders|Colombia|Cross-Sectional Studies|Female|Humans|Magnetic Resonance Imaging|Male|Mental Status and Dementia Tests|Middle Aged|Mutation|Neuropsychological Tests|Positron-Emission Tomography|Presenilin-1|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	t807	drug_name_variant	Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	t807	drug_name_variant	AV1451|SUVr|T807|flortaucipir|reference region	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Female|Humans|Image Processing, Computer-Assisted|Male|Positron-Emission Tomography|Reference Standards	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27286736_20201005_0.5			The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27286736_20201005_0.5			Alzheimer’s disease|cerebrospinal fluid|positron emission tomography|preclinical|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27286736_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Biomarkers|Carbolines|Female|Humans|Male|Peptide Fragments|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27286736_20201005_0.5	t807	drug_name_variant	Here we examined tau deposition in 41 cognitively normal and 11 cognitively impaired older adults using the radioactive tau ligand (18)F-AV-1451 (previously known as T807) who also underwent a lumbar puncture to assess cerebrospinal fluid levels of total tau (t-tau), phosphorylated tau181 (p-tau181) and amyloid-β42 Voxel-wise statistical analyses examined spatial patterns of tau deposition associated with cognitive impairment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11812069_20201005_0.5			Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11812069_20201005_0.5			Adult|Case-Control Studies|Humans|Integrins|Logistic Models|Male|Middle Aged|Myocardial Infarction|Odds Ratio|Platelet Glycoprotein GPIIb-IIIa Complex|Polymorphism, Genetic|Receptors, Collagen|Risk Factors	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11812069_20201005_0.5	t807	drug_name_variant	 Methods and Results The frequency of T807 allele carriers was similar among myocardial infarction patients and among controls (54.6% vs 62.3%; odds ratio (OR) 0.73; 95% confidence interval (CI), 0.47-1.12).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11812069_20201005_0.5	t807	drug_name_variant	The T807 allele of the GPIa gene alone or in combination with the PlA2 allele had no major effect on premature myocardial infarction risk.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID16513317_20201005_0.5			Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID16513317_20201005_0.5			Alleles|DNA, Neoplasm|Gene Expression Regulation, Neoplastic|Genetic Predisposition to Disease|Genotype|Humans|In Vitro Techniques|Integrin alpha2|Mouth Neoplasms|Mutation|Polymerase Chain Reaction|Polymorphism, Genetic|Retrospective Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID16513317_20201005_0.5	t807	drug_name_variant	OBJECTIVE In light to association of increased platelet glycoprotein Ia (GPIa) expression with tumor invasion and metastasis in several types of cancer, we investigated the possible contribution of a common polymorphism (C807/T807), affecting the GPIa gene expression, in the development of oral cancer.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID16513317_20201005_0.5	t807	drug_name_variant	 RESULTS The mutant T807 allele homozygotes were significantly increased in the group of patients compared to the control group (P < 0.001).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID16513317_20201005_0.5	t807	drug_name_variant	 CONCLUSIONS The obtained results indicate that the C807/T807 polymorphism is indeed a genetic predisposing factor which contributes to increased risk for oral cancer.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11604562_20201005_0.5			The role of platelet collagen receptor (glycoprotein Ia/IIa; integrin alpha2 beta1) polymorphisms in thrombotic disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11604562_20201005_0.5			Blood Platelets|Collagen|Humans|Integrins|Models, Biological|Platelet Adhesiveness|Platelet Glycoprotein GPIb-IX Complex|Platelet Membrane Glycoproteins|Polymorphism, Genetic|Receptors, Collagen|Thrombosis|Transcription, Genetic	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11604562_20201005_0.5	t807	drug_name_variant	There is substantial evidence that the GPIbalpha variable number of tandem repeats A or B alleles, the -5C allele of GPIbalpha, and the integrin alpha2 allele 1 (T807) each contribute to risk for and morbidity from thrombotic disease.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5			Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloid beta-Peptides|Benzothiazoles|Cerebral Cortex|Cross-Sectional Studies|Female|Fluorine Radioisotopes|Humans|Male|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5	t807	drug_name_variant	 No section Eighty-eight individuals from the general community underwent flortaucipir 18 T807 (18F-T807) and carbon 11-labeled Pittsburgh Compound B (11C-PiB) positron emission tomographic (PET) imaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5	t807	drug_name_variant	A voxel-level hierarchical clustering approach was used to obtain the main clustering partitions corresponding to the cortical distribution maps of 18F-T807 and 11C-PiB. Hierarchical relationships between areas of distinctive pathologic deposits were then studied.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5	t807	drug_name_variant	Using cerebellar gray reference, 18F-T807 data were expressed as standardized uptake value ratio, and 11C-PiB were given as distribution volume ratio.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5			Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5			Tau PET imaging|Off-target binding|Monoamine oxidase B|Alzheimer’s disease|Molecular docking|Binding free energy calculations	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5			Aged|Alanine|Alzheimer Disease|Benzylamines|Binding Sites|Brain|Computational Biology|Computer Simulation|Female|Humans|Ligands|Magnetic Resonance Imaging|Male|Middle Aged|Molecular Docking Simulation|Monoamine Oxidase|Positron-Emission Tomography|Protein Binding|Protein Conformation|Radiopharmaceuticals|Retrospective Studies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5	t807	drug_name_variant	 Methods Molecular docking and dynamics simulations were used to estimate the affinity and free energy for the binding of several tau tracers (FDDNP, THK523, THK5105, THK5317, THK5351, T807 [aka AV-1451, flortaucipir], T808, PBB3, RO-948, MK-6240, JNJ-311 and PI-2620) to MAO-B. These values were then compared with those for safinamide (MAO-B inhibitor).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5			Tau pathology in cognitively normal older adults	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5	t807	drug_name_variant	Tau|AV-1451|T807|Flortaucipir|FTP|PET|Cognition|Volume|Longitudinal|Cognitively normal	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5			Middle Aged|Aged, 80 and over|Male|Humans|Female|Aged|Retrospective Studies|Longitudinal Studies|Tomography, X-Ray Computed|Alzheimer Disease|tau Proteins|Cognition|Cognitive Dysfunction|Positron-Emission Tomography|Amyloid beta-Peptides|Brain|Amyloid|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Ethylene Glycols|Entorhinal Cortex|Aniline Compounds|Amyloidogenic Proteins|Baltimore	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10828008_20210311_0.5			Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10828008_20210311_0.5			Aged|Amino Acid Substitution|Angina Pectoris|Angina, Unstable|Coronary Angiography|Coronary Disease|DNA|Female|Genotype|Humans|Integrin beta1|Integrins|Male|Middle Aged|Polymerase Chain Reaction|Polymorphism, Genetic|Receptors, Collagen|Recurrence|Risk Factors|Stents	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10828008_20210311_0.5	t807	drug_name_variant	The T807/A873 allele is associated with high expression, whereas the C807/G873 allele is associated with low surface expression of GP Ia/IIa.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10828008_20210311_0.5	t807	drug_name_variant	Subsequently, the T807 allele was found to be associated with coronary and cerebral infarction in younger patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5			Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5			Alzheimer’s disease|amyloid|driving performance|imaging|noncognitive outcomes|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid|Automobile Driving|Biomarkers|Carbolines|Female|Humans|Logistic Models|Male|Neuroimaging|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5	t807	drug_name_variant	We examined whether preclinical AD staging, defined using amyloid imaging and tau imaging using the radiotracer T807 (AKA flortaucipir or AV-1451), was associated with receiving a marginal/fail rating on a standardized road test (n = 42).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Brain|Carbolines|Cognitive Dysfunction|Cross-Sectional Studies|Diagnostic Self Evaluation|Entorhinal Cortex|Female|Frontal Lobe|Humans|Male|Middle Aged|Neocortex|Parietal Lobe|Phenanthrolines|Positron-Emission Tomography|Radiopharmaceuticals|Surveys and Questionnaires|Tauopathies|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5	t807	drug_name_variant	 No section This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26936940_20201005_0.5			Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26936940_20201005_0.5			18F-AV-1451|Braak staging|imaging|positron emission tomography (PET)|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26936940_20201005_0.5			Adult|Aged|Aged, 80 and over|Algorithms|Alzheimer Disease|Carbolines|Cognitive Dysfunction|Female|Humans|Male|Middle Aged|Neurofibrillary Tangles|Neuroimaging|Occipital Lobe|Positron-Emission Tomography|Severity of Illness Index|Temporal Lobe|Young Adult|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26936940_20201005_0.5	t807	drug_name_variant	Standardized uptake value ratio images were calculated from 80-100 minute (18)F-AV-1451 (also known as T807) positron emission tomography scans obtained from n = 14 young reference subjects (age 21-39 years, Mini-Mental State Examination 29-30) and n = 173 older test subjects (age 50-95 years) comprising amyloid negative cognitively normal (n = 42), clinically-diagnosed mild cognitive impairment (amyloid positive, n = 47, and amyloid negative, n = 40) and Alzheimer's disease (amyloid positive, n = 28, and amyloid negative, n = 16).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4329416_20201005_0.5			Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4329416_20201005_0.5	t807	drug_name_variant	FTDP-17 |tau aggregation|neurofibrillary tangle|Pick body|tau|[F18]-T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC4329416_20201005_0.5			Brain|Female|Frontotemporal Dementia|Humans|Inclusion Bodies|Magnetic Resonance Imaging|Male|Middle Aged|Mutation|Phosphorylation|Positron-Emission Tomography|Protein Isoforms|Tomography, Emission-Computed|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11395045_20201005_0.5			Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11395045_20201005_0.5			Aged|Base Sequence|Confidence Intervals|Coronary Angiography|Coronary Disease|Female|Genetic Markers|Genotype|Humans|Integrins|Male|Middle Aged|Molecular Sequence Data|Odds Ratio|Platelet Adhesiveness|Polymerase Chain Reaction|Polymorphism, Genetic|Predictive Value of Tests|Probability|Prognosis|Prospective Studies|Receptors, Collagen|Recurrence|Risk Assessment|Risk Factors|Sensitivity and Specificity|Severity of Illness Index|Stents	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11395045_20201005_0.5	t807	drug_name_variant	T807 is associated with increased expression of this integrin receptor.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11395045_20201005_0.5	t807	drug_name_variant	We assessed whether T807 is associated with an increased risk of restenosis in 1769 consecutive patients treated with coronary stenting.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID11395045_20201005_0.5	t807	drug_name_variant	Thus, carriage of the GP Ia T807 allele is not associated with an increased risk of restenosis or unfavorable late outcome following coronary artery stenting.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5	t807	drug_name_variant	Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5	t807	drug_name_variant	tauopathies|Tau PET|biomarker|18F-T807|progressive supranuclear palsy (PSP)|corticobasal syndrome (CBS)	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5			Humans|Male|Middle Aged|Female|Tauopathies|Magnetic Resonance Imaging|Alzheimer Disease|tau Proteins|Fluorine Radioisotopes|Positron-Emission Tomography|Amyloid beta-Peptides|Neurodegenerative Diseases|Radiopharmaceuticals|Brain|Frontotemporal Dementia|Neuroimaging|Carbolines|Atrophy|Plasma	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5	t807	drug_name_variant	All participants underwent clinical assessments, F-T807 tau PET, brain MRI, and plasma tau assay.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5	t807	drug_name_variant	 No section Results: The global cortical standard uptake value ratio (SUVR) of F-T807 PET was comparable between PD and control (p = 0.088).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5	t807	drug_name_variant	Asymmetric F-T807 uptake at the pallidum was noted in patients with CBS and FTD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8039308_20210411_0.5	t807	drug_name_variant	 No section Conclusions: The F-T807 tau tracer uptake was only modestly increased in patients with PSP.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956931_20201005_0.5			Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956931_20201005_0.5	t807	drug_name_variant	Tau PET|Off-target|AV-1451|THK5351|THK5117|THK5317|T807|MAO-B|MAO-A|Flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956931_20201005_0.5			Aged, 80 and over|Aged|Humans|Female|Tauopathies|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|Radiopharmaceuticals|Autoradiography|Brain|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26299160_20201005_0.5			Imaging biomarkers in tauopathies.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26299160_20201005_0.5			Alzheimer|CBD|Dementia|PET|PSP|Tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26299160_20201005_0.5			Alzheimer Disease|Animals|Biomarkers|Brain|Humans|Molecular Imaging|Neurofibrillary Tangles|Positron-Emission Tomography|Supranuclear Palsy, Progressive|Tauopathies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID26299160_20201005_0.5	t807	drug_name_variant	Selective PET ligands including [18F]THK5117, [18F]THK5351, [18F]AV1451 (T807) and [11C]PBB3 now provide in vivo imaging information about the timing and distribution of tau in the early phases of neurodegenerative diseases.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	T807-modified human serum albumin biomimetic nanoparticles for targeted drug delivery across the blood-brain barrier.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	Blood-brain barrier|T807|biomimetic nanoparticles|drug delivery|human serum albumin	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5			Humans|Blood-Brain Barrier|Biomimetics|Serum Albumin, Human|Nanoparticles|Drug Delivery Systems|Biological Transport|Drug Carriers|Brain|Serum Albumin|Microscopy, Electron, Transmission|Endothelial Cells	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	No section Novel biocompatible Human Serum Albumin (HSA) nanoparticles composed of membrane of erythrocytes (ETm)-coated and DSPE-PEG3400-T807 segments have been designed for sustained drug delivery across the blood-brain barrier (BBB).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	The chemical, physical and biocompatible properties of the T807/ETm-HSA nanoparticles have been characterised by hydrogen nuclear magnetic resonance, matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry, transmission electron microscopy, dynamic light scattering and confocal laser scanning microscopy techniques.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	The unique targeting properties of the nanoparticles after fabrication with the brain-targeted ligand T807 was demonstrated by their attaching to brain cells as well as their enhanced transport ability to cross the BBB.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	In a further demonstration of their ability to target brain cells, in vivo living imaging revealed that T807/ETm-HSA nanoparticles accumulated in the mice brain after intravenous injection.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32614677_20210211_0.5	t807	drug_name_variant	The surface modification of ETm/HSA nanoparticles with the brain-targeted T807 demonstrated in this work represents a highly novel and effective strategy to provide efficient brain targeting and shows promise for the future in using modified ETm-coated HSA nanoparticles to penetrate the brain.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Topographic staging of tau positron emission tomography images	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5	t807	drug_name_variant	Tau|PET|Flortaucipir|Alzheimer|Staging|Stage|Classification|Image|Braak|AV-1451|T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Male|Humans|Female|Reproducibility of Results|Positron-Emission Tomography|Alzheimer disease type 2|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Neuroimaging|Amyloid|Aniline Compounds|Brain|Gray Matter|Amyloidogenic Proteins|Amyloidosis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5			Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5			Neuronal p-tau-targeting|Blood–brain barrier|Biomimetic nanosystems|Alzheimer’s disease|CUR	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5			Alzheimer Disease|Animals|Apoptosis|Biomimetic Materials|Blood-Brain Barrier|Cell Line|Curcumin|Disease Models, Animal|Drug Carriers|Hippocampus|Humans|Maze Learning|Mice|Nanoparticles|Neurons|Protective Agents|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5	t807	drug_name_variant	 Results Curcumin (CUR) is loaded onto red blood cell (RBC) membrane-coated PLGA particles bearing T807 molecules attached to the RBC membrane surface (T807/RPCNP).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5	t807	drug_name_variant	Under the synergistic effects of T807, T807/RPCNP can not only effectively penetrate the blood-brain barrier (BBB), but they also possess high binding affinity to hyperphosphorylated tau in nerve cells where they inhibit multiple key pathways in tau-associated AD pathogenesis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5	t807	drug_name_variant	When CUR was encapsulated, our data also demonstrated that CUR-loaded T807/RPCNP NPs can relieve AD symptoms by reducing p-tau levels and suppressing neuronal-like cells death both in vitro and in vivo.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5	t807	drug_name_variant	The memory impairment observed in an AD mouse model is significantly improved following systemic administration of CUR-loaded T807/RPCNP NPs.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7222444_20201005_0.5	t807	drug_name_variant	 Conclusion Intravenous neuronal tau-targeted T807-modified novel biomimetic nanosystems are a promising clinical candidate for the treatment of AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10194421_20210311_0.5			Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10194421_20210311_0.5			Age Factors|Coronary Angiography|Coronary Disease|DNA|Humans|Integrins|Male|Middle Aged|Myocardial Infarction|Point Mutation|Polymorphism, Genetic|Receptors, Collagen|Risk Factors	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10194421_20210311_0.5	t807	drug_name_variant	No section Recently, we have shown that two alleles of the glycoprotein (GP) Ia gene, designated C807 and T807, are associated with low or high platelet GPIa-IIa density and consequently with slower or faster rate of platelet adhesion to type I collagen, respectively.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID10194421_20210311_0.5	t807	drug_name_variant	The odds ratio of MI increased for T807 carriers with decreasing age.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Apolipoprotein E4|Brain|Carbolines|Cross-Sectional Studies|Female|Geriatric Assessment|Humans|Magnetic Resonance Imaging|Male|Mental Status Schedule|Phosphorylation|Positron-Emission Tomography|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	OBJECTIVE To better understand cross-sectional relationships between CSF and PET measures of tau pathology, we compared regional and global measures of (18)F-T807 (AV-1451) PET to CSF protein levels of total tau (t-tau), phosphorylated tau (p-tau), and β-amyloid 1-42 (Aβ42).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	Linear regression was used to compare regional and global measures of (18)F-T807 standardized uptake value ratios (SUVR) to CSF protein levels using data from 31 cognitively unimpaired elderly participants in the Harvard Aging Brain study.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	 RESULTS After controlling for sex and age, total cortical (18)F-T807 binding was significantly correlated with p-tau (partial r = 0.48; p < 0.01) and at trend level with t-tau (partial r = 0.30; p = 0.12).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	Regional (18)F-T807 measures were more strongly correlated with CSF protein levels than the global measure, with both t-tau and p-tau significantly correlated with (18)F-T807 SUVR in entorhinal, parahippocampal, and inferior temporal cortical regions (partial r = 0.53-0.73).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	Finally, we observed significantly higher temporal T807 SUVR in individuals with high amyloid burden.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	 CONCLUSIONS These data support the link between (18)F-T807 PET and CSF measures of tau pathology.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID27473132_20201005_0.5	t807	drug_name_variant	In these cognitively normal individuals with (18)F-T807 binding largely restricted to the temporal lobe, (18)F-T807 SUVR in temporal regions appeared more reflective of CSF t-tau and p-tau than a total cortical measure.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID22119002_20201005_0.5			Antagonism of NMDA receptors by butanesulfonyl-homospermine guanidine and neuroprotective effects in in vitro and in vivo.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID22119002_20201005_0.5			Animals|Brain Ischemia|Cell Line, Tumor|Cell Survival|Excitatory Amino Acid Antagonists|Female|Guanidine|Humans|Memantine|Mice|Neuroprotective Agents|Patch-Clamp Techniques|Polyamines|Receptors, N-Methyl-D-Aspartate|Spermine|Xenopus laevis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID22119002_20201005_0.5	t807	drug_name_variant	The inhibition by BsHSPMG was voltage-dependent, since it was prominent at -100 mV compared to that at -20 mV. Mutations including NR1 N616Q, E621Q, N650A, L655A, T807C, NR2B W559L, M562S, W607L, N616Q, and V620E, among others, reduced the inhibition by BsHSPMG, suggesting that BsHSPMG penetrates the channel pore of NMDA receptors deeply.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir (18f)	drug_umls_atom	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5			tau|amyloid|flortaucipir|PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5			Aged|Aging|Alzheimer Disease|Amyloid|Amyloid beta-Peptides|Brain|Carbolines|Cognition|Cognition Disorders|Cognitive Dysfunction|Dementia|Female|Humans|Longitudinal Studies|Male|Middle Aged|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5			AV-1451|Alzheimer’s disease|flortaucipir|reliability|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Case-Control Studies|Cognitive Dysfunction|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Reproducibility of Results|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	Flortaucipir F 18 is one such tracer.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	To our knowledge, this study reports the first data regarding test-retest reproducibility of flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	 Methods Twenty-one subjects who completed the study (5 healthy controls, 6 mild cognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min beginning 80 min after injection and again at 110 min after injection.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	 Results Test-retest analyses demonstrated low variability in flortaucipir F 18 SUVR.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	 Conclusion Significant test-retest reproducibility for flortaucipir F 18 was found across neocortical and mesial temporal lobe structures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f 18	drug_umls_atom	These preliminary data suggest that flortaucipir F 18 tau imaging could be used to examine changes in tau burden over time.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Topographic staging of tau positron emission tomography images	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Tau|PET|Flortaucipir|Alzheimer|Staging|Stage|Classification|Image|Braak|AV-1451|T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Male|Humans|Female|Reproducibility of Results|Positron-Emission Tomography|Alzheimer disease type 2|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Neuroimaging|Amyloid|Aniline Compounds|Brain|Gray Matter|Amyloidogenic Proteins|Amyloidosis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5	flortaucipir f 18	drug_umls_atom	 Methods Three topographic staging schemes for tau PET, two sampling the temporal and occipital subregions only and one sampling cortical gray matter across the major brain lobes, were evaluated on flortaucipir F 18 PET images in a test-retest scenario and from Alzheimer's Disease Neuroimaging Initiative 2.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Aniline Compounds|Apolipoprotein E4|Brain|Carbolines|Contrast Media|Cross-Sectional Studies|Entorhinal Cortex|Ethylene Glycols|Female|Healthy Volunteers|Humans|Male|Middle Aged|Positron-Emission Tomography|Sex Factors|Temporal Lobe|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5	flortaucipir f 18	drug_umls_atom	Data were collected between January 2016 and February 2018 from 193 clinically normal individuals from the Harvard Aging Brain Study (age range, 55-92 years; 118 women [61%]) who underwent carbon 11-labeled Pittsburgh Compound B and flortaucipir F18 PET and 103 clinically normal individuals from the Alzheimer's Disease Neuroimaging Initiative (age range, 63-94 years; 55 women [51%]) who underwent florbetapir and flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Adult|Age Factors|Alzheimer Disease|Amyloid|Aniline Compounds|Brain|Carbolines|Cognition Disorders|Colombia|Cross-Sectional Studies|Female|Humans|Magnetic Resonance Imaging|Male|Mental Status and Dementia Tests|Middle Aged|Mutation|Neuropsychological Tests|Positron-Emission Tomography|Presenilin-1|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir f 18	drug_umls_atom	Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir f 18	drug_umls_atom	 No section We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f 18	drug_umls_atom	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			AV1451|SUVr|T807|flortaucipir|reference region	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Female|Humans|Image Processing, Computer-Assisted|Male|Positron-Emission Tomography|Reference Standards	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f 18	drug_umls_atom	We present a new technique, PERSI (Parametric Estimation of Reference Signal Intensity), for flortaucipir F 18 count normalization that leverages the advantages of white matter reference regions while mitigating potential partial-volume effects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f 18	drug_umls_atom	 Methods Subjects with a clinical diagnosis of Alzheimer disease, mild cognitive impairment, or normal cognition underwent T1-weighted MRI and florbetapir imaging (to determine amyloid [Aβ] status) at screening and flortaucipir F 18 imaging at single or multiple time points.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f 18	drug_umls_atom	Flortaucipir F 18 images, acquired as 4 × 5 min frames 80 min after a 370-MBq injection, were motion-corrected, averaged, and transformed to Montreal Neurological Institute (MNI) space.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f 18	drug_umls_atom	Baseline SUVr variability and ΔSUVr were minimal in Aβ control subjects with no specific flortaucipir F 18 uptake (SUVr, 1.0 ± 0.04; ΔSUVr, 0.0 ± 0.02).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5			Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Cerebral Cortex|Cognitive Dysfunction|Cross-Sectional Studies|Diagnosis, Differential|Female|Fluorine Radioisotopes|Humans|Magnetic Resonance Imaging, Cine|Male|Middle Aged|Neurodegenerative Diseases|Positron-Emission Tomography|Sweden|White Matter|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir f 18	drug_umls_atom	Generally, tau positron emission tomographic positivity was confined to amyloid β-positive cases or MAPT R406W mutation carriers in this cohort; in patients with semantic variant primary progressive aphasia, RO948 F 18 retention was lower than that for flortaucipir F 18.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir f 18	drug_umls_atom	Evaluation included a comparison of tau PET tracer [ F]RO948 with magnetic resonance imaging (MRI) and cerebrospinal fluid and a head-to-head comparison between [ F]RO948 and flortaucipir F 18 ([ F]flortaucipir) in patients with semantic variant primary progressive aphasia (svPPA).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Brain|Carbolines|Cognitive Dysfunction|Cross-Sectional Studies|Diagnostic Self Evaluation|Entorhinal Cortex|Female|Frontal Lobe|Humans|Male|Middle Aged|Neocortex|Parietal Lobe|Phenanthrolines|Positron-Emission Tomography|Radiopharmaceuticals|Surveys and Questionnaires|Tauopathies|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5	flortaucipir f 18	drug_umls_atom	 No section This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5			AV-1451|Alzheimer’s disease|flortaucipir|reliability|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Case-Control Studies|Cognitive Dysfunction|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Reproducibility of Results|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	Flortaucipir F 18 is one such tracer.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	To our knowledge, this study reports the first data regarding test-retest reproducibility of flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	 Methods Twenty-one subjects who completed the study (5 healthy controls, 6 mild cognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min beginning 80 min after injection and again at 110 min after injection.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	 Results Test-retest analyses demonstrated low variability in flortaucipir F 18 SUVR.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	 Conclusion Significant test-retest reproducibility for flortaucipir F 18 was found across neocortical and mesial temporal lobe structures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir f	drug_umls_atom	These preliminary data suggest that flortaucipir F 18 tau imaging could be used to examine changes in tau burden over time.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Topographic staging of tau positron emission tomography images	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Tau|PET|Flortaucipir|Alzheimer|Staging|Stage|Classification|Image|Braak|AV-1451|T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Male|Humans|Female|Reproducibility of Results|Positron-Emission Tomography|Alzheimer disease type 2|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Neuroimaging|Amyloid|Aniline Compounds|Brain|Gray Matter|Amyloidogenic Proteins|Amyloidosis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5	flortaucipir f	drug_umls_atom	 Methods Three topographic staging schemes for tau PET, two sampling the temporal and occipital subregions only and one sampling cortical gray matter across the major brain lobes, were evaluated on flortaucipir F 18 PET images in a test-retest scenario and from Alzheimer's Disease Neuroimaging Initiative 2.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5			The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5			Alzheimer's disease|Associative memory|Autosomal dominant Alzheimer's disease|Imaging|Neuropsychology|PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5			Humans|Male|Female|Latin America|Tomography, X-Ray Computed|Memory|Alzheimer Disease|Names|Neuropsychological Tests|Face|Presenilin-1|Memory Disorders|Association Learning|Amyloid|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Multiple Pterygium Syndrome, Autosomal Dominant|Arthrogryposis|Positron-Emission Tomography|Heterozygote|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5	flortaucipir f	drug_umls_atom	A subset of participants (31 carriers [12 symptomatic] and 35 non-carriers) traveled from Colombia to Boston to undergo positron emission tomography (PET) using Pittsburgh compound B to measure mean cortical amyloid-β and flortaucipir for regional tau.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Aniline Compounds|Apolipoprotein E4|Brain|Carbolines|Contrast Media|Cross-Sectional Studies|Entorhinal Cortex|Ethylene Glycols|Female|Healthy Volunteers|Humans|Male|Middle Aged|Positron-Emission Tomography|Sex Factors|Temporal Lobe|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5	flortaucipir f	drug_umls_atom	Data were collected between January 2016 and February 2018 from 193 clinically normal individuals from the Harvard Aging Brain Study (age range, 55-92 years; 118 women [61%]) who underwent carbon 11-labeled Pittsburgh Compound B and flortaucipir F18 PET and 103 clinically normal individuals from the Alzheimer's Disease Neuroimaging Initiative (age range, 63-94 years; 55 women [51%]) who underwent florbetapir and flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			An updated radiosynthesis of [18F]AV1451 for tau PET imaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5	flortaucipir f	drug_umls_atom	Tau imaging|Brain PET|[|Flortaucipir F18|Fluorine-18 radiochemistry|Automated radiosynthesis	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Positron-Emission Tomography|Radiopharmaceuticals|Carbolines|Fluorine Radioisotopes|tau Proteins|Alzheimer Disease|Radiochemistry|Tauopathies|Chromatography, High Pressure Liquid	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5			Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5			18F-flortaucipir|Alzheimer's disease|Positron emission tomography|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5			Humans|Male|Middle Aged|Female|Tomography, X-Ray Computed|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Amyloid beta-Peptides|Neuropsychological Tests|Magnetic Resonance Imaging|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5	flortaucipir f	drug_umls_atom	 Methods We enrolled 272 participants who underwent two PET scans [ F-flortaucipir for tau and F-florbetaben for amyloid-β (Aβ)], brain magnetic resonance imaging, and neuropsychological tests as baseline assessments.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Adult|Age Factors|Alzheimer Disease|Amyloid|Aniline Compounds|Brain|Carbolines|Cognition Disorders|Colombia|Cross-Sectional Studies|Female|Humans|Magnetic Resonance Imaging|Male|Mental Status and Dementia Tests|Middle Aged|Mutation|Neuropsychological Tests|Positron-Emission Tomography|Presenilin-1|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir f	drug_umls_atom	Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir f	drug_umls_atom	 No section We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f	drug_umls_atom	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			AV1451|SUVr|T807|flortaucipir|reference region	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Female|Humans|Image Processing, Computer-Assisted|Male|Positron-Emission Tomography|Reference Standards	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f	drug_umls_atom	We present a new technique, PERSI (Parametric Estimation of Reference Signal Intensity), for flortaucipir F 18 count normalization that leverages the advantages of white matter reference regions while mitigating potential partial-volume effects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f	drug_umls_atom	 Methods Subjects with a clinical diagnosis of Alzheimer disease, mild cognitive impairment, or normal cognition underwent T1-weighted MRI and florbetapir imaging (to determine amyloid [Aβ] status) at screening and flortaucipir F 18 imaging at single or multiple time points.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f	drug_umls_atom	Flortaucipir F 18 images, acquired as 4 × 5 min frames 80 min after a 370-MBq injection, were motion-corrected, averaged, and transformed to Montreal Neurological Institute (MNI) space.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir f	drug_umls_atom	Baseline SUVr variability and ΔSUVr were minimal in Aβ control subjects with no specific flortaucipir F 18 uptake (SUVr, 1.0 ± 0.04; ΔSUVr, 0.0 ± 0.02).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5			Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Cerebral Cortex|Cognitive Dysfunction|Cross-Sectional Studies|Diagnosis, Differential|Female|Fluorine Radioisotopes|Humans|Magnetic Resonance Imaging, Cine|Male|Middle Aged|Neurodegenerative Diseases|Positron-Emission Tomography|Sweden|White Matter|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir f	drug_umls_atom	Generally, tau positron emission tomographic positivity was confined to amyloid β-positive cases or MAPT R406W mutation carriers in this cohort; in patients with semantic variant primary progressive aphasia, RO948 F 18 retention was lower than that for flortaucipir F 18.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir f	drug_umls_atom	Evaluation included a comparison of tau PET tracer [ F]RO948 with magnetic resonance imaging (MRI) and cerebrospinal fluid and a head-to-head comparison between [ F]RO948 and flortaucipir F 18 ([ F]flortaucipir) in patients with semantic variant primary progressive aphasia (svPPA).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Brain|Carbolines|Cognitive Dysfunction|Cross-Sectional Studies|Diagnostic Self Evaluation|Entorhinal Cortex|Female|Frontal Lobe|Humans|Male|Middle Aged|Neocortex|Parietal Lobe|Phenanthrolines|Positron-Emission Tomography|Radiopharmaceuticals|Surveys and Questionnaires|Tauopathies|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5	flortaucipir f	drug_umls_atom	 No section This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31287716_20210611_0.5			Emerging advances of in vivo detection of chronic traumatic encephalopathy and traumatic brain injury.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31287716_20210611_0.5			Brain|Brain Injuries, Traumatic|Chronic Traumatic Encephalopathy|Diagnostic Imaging|Humans|Neuroimaging	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31287716_20210611_0.5	flortaucipir	drug_umls_atom	Recent studies using radionucleotides such as flortaucipir and 18F-FDDNP have shown binding patterns that are consistent with the four stages of neurofibrillary tangle (NFT) distribution postmortem.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5			Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5	flortaucipir	drug_umls_atom	Atrophy|Flortaucipir|Longitudinal change|Mild cognitive impairment|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5			Humans|Male|Female|Longitudinal Studies|Tomography, X-Ray Computed|Cognitive Dysfunction|Atrophy|Alzheimer Disease|tau Proteins|Brain|Magnetic Resonance Imaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Data Management|Temporal Lobe|Neuropsychological Tests|Neuroimaging|Disease Progression	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32785820_20201214_0.5	flortaucipir	drug_umls_atom	All participants underwent 18F flortaucipir (FTP) positron emission tomography (PET) and structural magnetic resonance imaging (MRI) scans at the baseline and follow-up visits (12-36 months).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7187298_20201005_0.5			Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7187298_20201005_0.5			APOE|Amyloid|Tau|Neurodegeneration|PET|MRI|Biomarkers|Alzheimer's|Prevention	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7187298_20201005_0.5			Aged|Alleles|Amyloid|Apolipoprotein E4|Brain|Cognition|Cross-Sectional Studies|Female|Healthy Volunteers|Humans|Longitudinal Studies|Magnetic Resonance Imaging|Male|Middle Aged|Neuroimaging|Neuropsychological Tests|Plaque, Amyloid|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7187298_20201005_0.5	flortaucipir	drug_umls_atom	 Methods We analyzed C Pittsburgh compound B (Aβ) positron emission tomography (PET), flortaucipir (tau) PET, and volumetric magnetic resonance imaging data from 164 study participants of age 47-86 years, including 26 APOE ε4 HMs, 48 HTs, and 90 NCs matched for age and sex.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956931_20201005_0.5			Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956931_20201005_0.5	flortaucipir	drug_umls_atom	Tau PET|Off-target|AV-1451|THK5351|THK5117|THK5317|T807|MAO-B|MAO-A|Flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956931_20201005_0.5			Aged, 80 and over|Aged|Humans|Female|Tauopathies|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|Radiopharmaceuticals|Autoradiography|Brain|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5648451_20201005_0.5			Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5648451_20201005_0.5	flortaucipir	drug_umls_atom	[F-18]-AV-1451|Flortaucipir|PET|Parkinson|Off-target binding|Basal ganglia|Choroid plexus|Microhemorrhages	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5648451_20201005_0.5			Adult|Aged|Aged, 80 and over|Autoradiography|Brain|Brain Mapping|Carbolines|Female|Humans|Male|Middle Aged|Parkinson Disease|Positron-Emission Tomography|Radiopharmaceuticals	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33638661_20210611_0.5			Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33638661_20210611_0.5	flortaucipir	drug_umls_atom	Amyloid|Florbetapir|Flortaucipir|Flutemetamol|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33638661_20210611_0.5			Humans|Male|Female|Amyloid|tau Proteins|Alzheimer Disease|Amyloid beta-Peptides|Cognitive Dysfunction|Positron-Emission Tomography|Radiopharmaceuticals|Aniline Compounds|Brain|Amyloidogenic Proteins|Amyloidosis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32368960_20210111_0.5			Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32368960_20210111_0.5			Aged|Alzheimer Disease|Amyloid beta-Peptides|Brain|Cerebral Hemorrhage|Cognitive Dysfunction|Cohort Studies|Cross-Sectional Studies|Female|Humans|Magnetic Resonance Imaging|Male|Positron-Emission Tomography|Prospective Studies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32368960_20210111_0.5	flortaucipir	drug_umls_atom	T2*-weighted gradient-echo MRI was performed to quantify MH, fluorine 18 (18F) flortaucipir (AV-1451) PET was performed to quantify tau, and 18F-florbetaben/18F- florbetapir (AV45) PET was performed to quantify amyloid β to study associations of MH with regional and global tau and amyloid β load.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6093830_20201005_0.5	flortaucipir	drug_umls_atom	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6093830_20201005_0.5			Hippocampus|Positron-Emission Tomography|Temporal Lobe|Fluorodeoxyglucose F18|Radiopharmaceuticals|Phantoms, Imaging|Image Processing, Computer-Assisted|Algorithms|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6093830_20201005_0.5	flortaucipir	drug_umls_atom	Background Off-target binding in the choroid plexus (CP) may cause spill-in of the tau PET tracer [ F] flortaucipir into the adjacent hippocampus region.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6093830_20201005_0.5	flortaucipir	drug_umls_atom	 Methods PVC was performed on 20 [ F] flortaucipir dynamic PET scans (10 probable AD and 10 controls).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5			Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5			Alzheimer’s disease|amyloid|driving performance|imaging|noncognitive outcomes|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid|Automobile Driving|Biomarkers|Carbolines|Female|Humans|Logistic Models|Male|Neuroimaging|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29171997_20201005_0.5	flortaucipir	drug_umls_atom	We examined whether preclinical AD staging, defined using amyloid imaging and tau imaging using the radiotracer T807 (AKA flortaucipir or AV-1451), was associated with receiving a marginal/fail rating on a standardized road test (n = 42).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	AV-1451|Alzheimer’s disease|flortaucipir|reliability|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Case-Control Studies|Cognitive Dysfunction|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Reproducibility of Results|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir F 18 is one such tracer.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	To our knowledge, this study reports the first data regarding test-retest reproducibility of flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Twenty-one subjects who completed the study (5 healthy controls, 6 mild cognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min beginning 80 min after injection and again at 110 min after injection.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	 Results Test-retest analyses demonstrated low variability in flortaucipir F 18 SUVR.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	 Conclusion Significant test-retest reproducibility for flortaucipir F 18 was found across neocortical and mesial temporal lobe structures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29284675_20201005_0.5	flortaucipir	drug_umls_atom	These preliminary data suggest that flortaucipir F 18 tau imaging could be used to examine changes in tau burden over time.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31860018_20210311_0.5			Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31860018_20210311_0.5			Adult|Aged|Biomarkers|Case-Control Studies|Female|Frontotemporal Dementia|Humans|Male|Middle Aged|Neuroimaging|Neuropsychological Tests|Positron-Emission Tomography|Tuberous Sclerosis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31860018_20210311_0.5	flortaucipir	drug_umls_atom	All 3 patients with tuberous sclerosis complex who underwent fluorine 1B-labeled flortaucipir tau positron emission tomographic neuroimaging showed punctate foci of elevated [18F]flortaucipir binding in the frontal and temporal regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6714095_20201005_0.5	flortaucipir	drug_umls_atom	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6714095_20201005_0.5	flortaucipir	drug_umls_atom	THK5351 PET|Flortaucipir PET|Monoamine oxidase B|Creutzfeldt-Jakob disease	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6714095_20201005_0.5			Aged|Aminopyridines|Autopsy|Brain|Carbolines|Creutzfeldt-Jakob Syndrome|Humans|Male|Monoamine Oxidase|Neurofibrillary Tangles|Positron-Emission Tomography|Quinolines|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6714095_20201005_0.5	flortaucipir	drug_umls_atom	Background THK5351 and flortaucipir tau ligands have high affinity for paired helical filament tau, yet diverse off-target bindings have been reported.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6714095_20201005_0.5	flortaucipir	drug_umls_atom	Recent data support the hypothesis that THK5351 binds to monoamine oxidase B (MAO-B) expressed from reactive astrocytes and that flortaucipir has an affinity toward MAO-A and B; however, pathological evidence is lacking.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6714095_20201005_0.5	flortaucipir	drug_umls_atom	F-THK5351 PET, but not F-flortaucipir PET showed high uptake in the left temporo-parieto-occipital regions, largely overlapping with the diffusion restricted areas.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32094584_20210611_0.5			Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32094584_20210611_0.5			Animals|Humans|Rats|Male|Syndrome|Tauopathies|Chronic Traumatic Encephalopathy|Brain|Brain Injury, Chronic|Blast Injuries|Brain Concussion|Veterans|Neurons|Brain Injuries, Traumatic|Anxiety|Neuroimaging|Neurodegenerative Diseases|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Biomarkers|Afghanistan	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32094584_20210611_0.5	flortaucipir	drug_umls_atom	Using positron emission tomography (PET) and the [18F]AV1451 (flortaucipir) tau ligand, we found that five of 10 veterans exhibited excessive retention of [18F]AV1451 at the white/gray matter junction in frontal, parietal, and temporal brain regions, a typical localization of CTE tauopathy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33952655_20210511_0.5			Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33952655_20210511_0.5			Humans|Male|Middle Aged|Female|Alzheimer Disease|Prospective Studies|Cognitive Dysfunction|Magnetic Resonance Imaging|Amyloid beta-Peptides|Positron-Emission Tomography|Brain|tau Proteins|Fluorodeoxyglucose F18|Amyloid|Cognition|Biomarkers|Neuropsychological Tests|Entorhinal Cortex|Aniline Compounds|Aging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33952655_20210511_0.5	flortaucipir	drug_umls_atom	OBJECTIVE To compare how structural MRI, Fluorodeoxyglucose (FDG), and Flortaucipir (FTP) PET signal predict cognitive decline in high-amyloid versus low-amyloid participants with the goal of determining which biomarker combination would result in the highest increase of statistical power for prevention trials.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32989107_20210511_0.5			Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32989107_20210511_0.5			Aged|Amyloid beta-Peptides|Aphasia, Primary Progressive|Atrophy|Cerebral Cortex|Cross-Sectional Studies|Female|Gray Matter|Humans|Longitudinal Studies|Magnetic Resonance Imaging|Male|Middle Aged|Phenotype|Pick Disease of the Brain|Positron-Emission Tomography|Primary Progressive Nonfluent Aphasia|White Matter	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32989107_20210511_0.5	flortaucipir	drug_umls_atom	Thirteen patients had serial MRI for a total of 56 MRIs, 7 had [18F]fluorodeoxyglucose PET, 4 had Pittsburgh compound B (PiB) PET, and 1 patient had [18F]flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32989107_20210511_0.5	flortaucipir	drug_umls_atom	Flortaucipir PET showed elevated uptake in frontotemporal white matter.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5			Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloid beta-Peptides|Benzothiazoles|Cerebral Cortex|Cross-Sectional Studies|Female|Fluorine Radioisotopes|Humans|Male|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28558094_20201005_0.5	flortaucipir	drug_umls_atom	 No section Eighty-eight individuals from the general community underwent flortaucipir 18 T807 (18F-T807) and carbon 11-labeled Pittsburgh Compound B (11C-PiB) positron emission tomographic (PET) imaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5			Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5			Tau PET imaging|Off-target binding|Monoamine oxidase B|Alzheimer’s disease|Molecular docking|Binding free energy calculations	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5			Aged|Alanine|Alzheimer Disease|Benzylamines|Binding Sites|Brain|Computational Biology|Computer Simulation|Female|Humans|Ligands|Magnetic Resonance Imaging|Male|Middle Aged|Molecular Docking Simulation|Monoamine Oxidase|Positron-Emission Tomography|Protein Binding|Protein Conformation|Radiopharmaceuticals|Retrospective Studies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6486902_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Molecular docking and dynamics simulations were used to estimate the affinity and free energy for the binding of several tau tracers (FDDNP, THK523, THK5105, THK5317, THK5351, T807 [aka AV-1451, flortaucipir], T808, PBB3, RO-948, MK-6240, JNJ-311 and PI-2620) to MAO-B. These values were then compared with those for safinamide (MAO-B inhibitor).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7338820_20201005_0.5			Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7338820_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir PET|Older adults|Amyloid|APOE|Sex|Cognitive decline	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7338820_20201005_0.5			Aged|Alzheimer Disease|Amyloid beta-Peptides|Apolipoproteins E|Cognitive Dysfunction|Cross-Sectional Studies|Female|Humans|Male|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7338820_20201005_0.5	flortaucipir	drug_umls_atom	 Methods We included 114 older adults with cross-sectional flortaucipir (FTP) and Pittsburgh Compound-B PET in addition to longitudinal cognitive testing.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30597624_20201005_0.5			Longitudinal tau accumulation and atrophy in aging and alzheimer disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30597624_20201005_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Aniline Compounds|Atrophy|Brain|Carbolines|Case-Control Studies|Cerebral Cortex|Contrast Media|Female|Humans|Longitudinal Studies|Magnetic Resonance Imaging|Male|Middle Aged|Multimodal Imaging|Organ Size|Positron-Emission Tomography|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30597624_20201005_0.5	flortaucipir	drug_umls_atom	 No section Two longitudinal flortaucipir (FTP) positron emission tomography (PET) and magnetic resonance imaging (MRI) scans were acquired from 42 OA (21 Pittsburg compound B [PiB]+ , age = 77.6 ± 4.6 years, 25 female [F]/17 male [M]) and 19 PiB+ patients with AD (age = 63.1 ± 10.3 years, 12 F/7 M) over 1 to 3 years of follow-up.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir PET|Alzheimer disease|structural MRI|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5			Alzheimer Disease|Amnesia|Carbolines|Cognition|Female|Humans|Image Processing, Computer-Assisted|Magnetic Resonance Imaging|Male|Middle Aged|Multimodal Imaging|Positron-Emission Tomography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	We evaluated whether 18F-flortaucipir (also called 18F-AV-1451) PET, targeting tau aggregates, detects these differences, and we compared the results with MRI measures of gray matter (GM) atrophy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Five subjects with posterior cortical atrophy, 4 subjects with the logopenic variant of primary progressive aphasia, 6 age-matched patients with AD, and 6 control subjects underwent 18F-flortaucipir PET and MRI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	 Results The subgroups showed the expected 18F-flortaucipir-binding patterns.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	Group effect sizes were generally stronger with 18F-flortaucipir PET than with MRI volumes.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	There were moderate-to-high correlations between regional GM atrophy and 18F-flortaucipir uptake.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir binding and GM atrophy correlated similarly to cognitive test performance.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28747523_20201005_0.5	flortaucipir	drug_umls_atom	Conclusion:18F-flortaucipir binding corresponds to the expected neurodegeneration patterns in nonamnestic AD, with potential for earlier detection of pathology than is possible with MRI atrophy measures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5			Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5			Alzheimer’s disease|THK5117|T807|AV1451|PBB3|Tau imaging|autoradiography|Tau PET|Tau PET tracers|Deprenyl	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Autopsy|Autoradiography|Binding, Competitive|Brain|Dose-Response Relationship, Drug|Female|Humans|In Vitro Techniques|Male|Middle Aged|Monoamine Oxidase Inhibitors|Positron-Emission Tomography|Radiopharmaceuticals|Tissue Distribution	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5725799_20201005_0.5	flortaucipir	drug_umls_atom	Background The aim of this study was to compare the binding properties of several tau positron emission tomography tracers--THK5117, THK5351, T807 (also known as AV1451; flortaucipir), and PBB3--head to head in the same human brain tissue.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7545921_20210111_0.5			Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7545921_20210111_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|FTP|Pittsburgh compound B|aducanumab|amyloid-related imaging abnormalities|apolipoprotein E|flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7545921_20210111_0.5			Humans|Male|Middle Aged|Aged|aducanumab|Apolipoprotein E4|Tomography, X-Ray Computed|Antibodies, Monoclonal, Humanized|Amyloid beta-Peptides|Alzheimer Disease|Amyloidogenic Proteins|tau Proteins|Amyloid|Positron-Emission Tomography|Magnetic Resonance Imaging|Brain|Amyloidosis|Patients	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	AV-1451|Alzheimer's disease|PET|cognition|flortaucipir|tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5			Middle Aged|Humans|Male|Female|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neurofibrillary Tangles|tau Proteins|Cognitive Dysfunction|Positron-Emission Tomography|Amyloid beta-Peptides|Cognition|florbetapir|Ethylene Glycols|Amyloid|Neuropsychological Tests|Radiopharmaceuticals|Neuropathology|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	 OBJECTIVE Evaluate the relationship between 18F flortaucipir uptake patterns and cognition across multiple cognitive domains.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	 METHODS We acquired flortaucipir PET scans in 84 amyloid-positive control, mild cognitive impairment (MCI), and AD subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	Flortaucipir standardized uptake value ratio (SUVr) values were obtained from a neocortical volume of interest (VOI), a precuneus VOI, and VOIs defined by the correlation between flortaucipir SUVr images and domain-specific cognitive tests.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	Significant correlations were seen between both flortaucipir and florbetapir SUVrs and MMSE, ADAS-Cog, and FAQ.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	Cognitive impairment was associated with increased flortaucipir uptake in regionally specific patterns consistent with the neuroanatomy underlying specific cognitive tests.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682705_20210411_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS Flortaucipir SUVr values demonstrated significant inverse correlations with cognitive scores in domain-specific patterns.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5			Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir|Alzheimer's disease|Positron emission tomography|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5			Humans|Male|Middle Aged|Female|Tomography, X-Ray Computed|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Amyloid beta-Peptides|Neuropsychological Tests|Magnetic Resonance Imaging|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7513482_20201005_0.5	flortaucipir	drug_umls_atom	 Methods We enrolled 272 participants who underwent two PET scans [ F-flortaucipir for tau and F-florbetaben for amyloid-β (Aβ)], brain magnetic resonance imaging, and neuropsychological tests as baseline assessments.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	tau|amyloid|flortaucipir|PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5			Aged|Aging|Alzheimer Disease|Amyloid|Amyloid beta-Peptides|Brain|Carbolines|Cognition|Cognition Disorders|Cognitive Dysfunction|Dementia|Female|Humans|Longitudinal Studies|Male|Middle Aged|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	No section Using flortaucipir, Pontecorvo et al.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	 No section The advent of tau-targeted PET tracers such as flortaucipir ( F) (flortaucipir, also known as F-AV-1451 or F-T807) have made it possible to investigate the sequence of development of tau in relationship to age, amyloid-β, and to the development of cognitive impairment due to Alzheimer's disease.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	Here we report a multicentre longitudinal evaluation of the relationships between baseline tau, tau change and cognitive change, using flortaucipir PET imaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	A total of 202 participants 50 years old or older, including 57 cognitively normal subjects, 97 clinically defined mild cognitive impairment and 48 possible or probable Alzheimer's disease dementia patients, received flortaucipir PET scans of 20 min in duration beginning 80 min after intravenous administration of 370 MBq flortaucipir ( F).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	Follow-up flortaucipir scans and neuropsychological battery assessments were also performed at 9 and 18 months.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	Fifty-five amyloid-β+ and 90 amyloid-β− subjects completed the baseline and 18-month study visits and had valid quantifiable flortaucipir scans at both time points.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	There was a statistically significant increase in the global estimate of cortical tau burden as measured by standardized uptake value ratio (SUVr) from baseline to 18 months in amyloid-β+ but not amyloid-β− subjects (least squared mean change in flortaucipir SUVr : 0.0524 ± 0.0085, P < 0.0001 and 0.0007 ± 0.0024 P = 0.7850, respectively), and a significant association between magnitude of SUVr increase and baseline tau burden.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	Voxel-wise evaluations further suggested that the regional pattern of change in flortaucipir PET SUVr over the 18-month study period (i.e. which regions exhibited the greatest change) also varied as a function of baseline global estimate of tau burden.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	In subjects with lower global SUVr, temporal lobe regions showed the greatest flortaucipir retention, whereas in subjects with higher baseline SUVr, parietal and frontal regions were increasingly affected.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6536847_20201005_0.5	flortaucipir	drug_umls_atom	Finally, baseline flortaucipir and change in flortaucipir SUVr were both significantly (P < 0.0001) associated with changes in cognitive performance.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5			Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5			Alzheimer's Disease (AD)|Chronic Traumatic Encephalopathy (CTE)|Positron Emission Tomography (PET)|case report|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5			Male|Humans|Middle Aged|Chronic Traumatic Encephalopathy|Football|Retirement|Australia|Tomography, X-Ray Computed|Positron-Emission Tomography|Tauopathies|Brain Injury, Chronic|Plaque, Amyloid|tau Proteins|Alzheimer Disease|Brain Concussion|Soccer|Brain|Magnetic Resonance Imaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Amyloid beta-Peptides	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7783156_20210111_0.5	flortaucipir	drug_umls_atom	Flortaucipir PET has shown superior frontal with medial temporal tau binding consistent with the provisional neuropathological criteria for mid-stage CTE in group-level analyses of retired symptomatic NFL players and in one individual with pathologically confirmed CTE.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5			Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|PART|Pittsburgh compound B|atrophy|cortical integrity|flortaucipir|literature review|neurodegeneration|normal aging|positron emission tomography|publication bias|structural magnetic resonance imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5			Humans|Male|Aged, 80 and over|Female|Aged|Amyloid beta-Peptides|Tomography, X-Ray Computed|Positron-Emission Tomography|tau Proteins|Alzheimer Disease|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Magnetic Resonance Imaging|Cognitive Dysfunction|Brain|Amyloid|Neuropsychological Tests|Aging|Cognition|Memory|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33325068_20210111_0.5	flortaucipir	drug_umls_atom	 METHODS We measured cortical thickness using magnetic resonance imaging, Aβ using Pittsburgh compound B positron emission tomography (PiB-PET), and tau using flortaucipir (FTP)-PET in 125 cognitively normal older adults.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33262228_20210411_0.5			Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33262228_20210411_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Aphasia, Primary Progressive|Apolipoprotein E4|Carbolines|Cerebral Cortex|Female|Frontal Lobe|Genotype|Humans|Magnetic Resonance Imaging|Male|Mental Status and Dementia Tests|Middle Aged|Occipital Lobe|Parietal Lobe|Phenotype|Positron-Emission Tomography|Radiopharmaceuticals|Retrospective Studies|Temporal Lobe|Thiazoles|Visual Pathways|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33262228_20210411_0.5	flortaucipir	drug_umls_atom	Pittsburgh compound B (PiB)-Aβ and flortaucipir (tau)-PET standardized uptake value ratio (SUVR) images were created.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33262228_20210411_0.5	flortaucipir	drug_umls_atom	Flortaucipir-PET was commonly elevated in temporoparietal regions, but showed marked phenotype-associated differences, with higher binding observed in occipito-parietal areas for PCA, in left temporal and inferior frontal for lvPPA, and in medial temporal areas for other AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33262228_20210411_0.5	flortaucipir	drug_umls_atom	Cortical flortaucipir-PET binding was higher in younger patients across phenotypes (r = -0.63, 95% confidence interval [CI] -0.72, -0.50), especially in parietal and dorsal prefrontal cortices.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33262228_20210411_0.5	flortaucipir	drug_umls_atom	The presence of APOE4 was associated with a focal medial temporal flortaucipir-SUVR increase, controlling for all other variables (entorhinal: + 0.310 SUVR, 95% CI 0.091, 0.530).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5			Tau pathology in cognitively normal older adults	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5	flortaucipir	drug_umls_atom	Tau|AV-1451|T807|Flortaucipir|FTP|PET|Cognition|Volume|Longitudinal|Cognitively normal	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5			Middle Aged|Aged, 80 and over|Male|Humans|Female|Aged|Retrospective Studies|Longitudinal Studies|Tomography, X-Ray Computed|Alzheimer Disease|tau Proteins|Cognition|Cognitive Dysfunction|Positron-Emission Tomography|Amyloid beta-Peptides|Brain|Amyloid|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Ethylene Glycols|Entorhinal Cortex|Aniline Compounds|Amyloidogenic Proteins|Baltimore	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6732758_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Using F-AV-1451 ( F-flortaucipir) positron emission tomography, we evaluated tau pathology in 54 cognitively normal participants (mean age: 77.5 years, SD: 8.9) from the Baltimore Longitudinal Study of Aging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32572464_20210111_0.5			Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32572464_20210111_0.5			Alzheimer's disease phenotypes|atrophy|longitudinal tau-PET|neuroimaging biomarkers	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32572464_20210111_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Atrophy|Cognitive Dysfunction|Female|Humans|Longitudinal Studies|Magnetic Resonance Imaging|Male|Neuroimaging|Phenotype|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32572464_20210111_0.5	flortaucipir	drug_umls_atom	We have recently described longitudinal patterns of flortaucipir PET uptake and grey matter atrophy in the atypical phenotypes, demonstrating a longitudinal regional disconnect between flortaucipir accumulation and brain atrophy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32572464_20210111_0.5	flortaucipir	drug_umls_atom	However, it is unclear how these longitudinal patterns differ from typical Alzheimer's disease, to what degree flortaucipir and atrophy mirror clinical phenotype in Alzheimer's disease, and whether optimal longitudinal neuroimaging biomarkers would also differ across phenotypes.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32572464_20210111_0.5	flortaucipir	drug_umls_atom	We aimed to address these unknowns using a cohort of 57 participants diagnosed with Alzheimer's disease (18 with typical amnestic Alzheimer's disease, 17 with posterior cortical atrophy and 22 with logopenic progressive aphasia) that had undergone baseline and 1-year follow-up MRI and flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33016911_20210511_0.5			The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33016911_20210511_0.5			Alzheimer's disease|amyloid|cerebral small vessel diseases|cognitive dysfunction|positron emission tomography|tau|vascular dementia	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33016911_20210511_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Brain|Cerebral Small Vessel Diseases|Cognitive Dysfunction|Cohort Studies|Female|Humans|Magnetic Resonance Imaging|Male|Positron-Emission Tomography|Retrospective Studies|Severity of Illness Index|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33016911_20210511_0.5	flortaucipir	drug_umls_atom	 No section We included 60 subcortical vascular cognitive impairment (SVCI) from Samsung Medical Center and 82 Alzheimer's disease-related cognitive impairment (ADCI) from ADNI, who underwent Aβ (florbetaben or florbetapir) and tau (flortaucipir, FTP) PET imaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6547132_20201005_0.5			Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6547132_20201005_0.5			Aged|Middle Aged|Male|Humans|Female|Alzheimer Disease|Cohort Studies|Prospective Studies|Amyloid|Amyloid beta-Peptides|tau Proteins|Cognitive Dysfunction|Cognition|Amyloidogenic Proteins|Positron-Emission Tomography|Amyloidosis|Brain|Cognition Disorders|Neuropsychological Tests|Disease Progression|Boston|Massachusetts	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6547132_20201005_0.5	flortaucipir	drug_umls_atom	 Main Outcomes and Measures A median of 3 Pittsburgh compound B-PET (Aβ, 2010-2017) and 2 flortaucipir-PET (tau, 2013-2017) images were collected.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6547132_20201005_0.5	flortaucipir	drug_umls_atom	An antecedent rise in Aβ was associated with subsequent changes in tau (1.07 flortaucipir standardized uptake value ratios [SUVr]/PiB-SUVr; 95% CI, 0.13-3.46; P  = .02).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31207466_20201005_0.5			The relationship between domain-specific subjective cognitive decline and Alzheimer's pathology in normal elderly adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31207466_20201005_0.5	flortaucipir	drug_umls_atom	Aging|Alzheimer's disease|Amyloid beta plaques|Neurofibrillary tau tangles|Subjective cognitive decline|[(18)F]florbetapir|[(18)F]flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31207466_20201005_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Brain|Cognition|Cognitive Dysfunction|Ethylene Glycols|Fluorine Radioisotopes|Humans|Neuroimaging|Positron-Emission Tomography|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31207466_20201005_0.5	flortaucipir	drug_umls_atom	Regression analyses were conducted to identify whether individual ECog domains (Memory, Language, Organization, Planning, Visuospatial, and Divided Attention) were equally or differentially associated with regional [18F]florbetapir and [18F]flortaucipir uptake and how these associations compared to those obtained with objective cognitive measures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31476153_20201214_0.5	flortaucipir	drug_umls_atom	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31476153_20201214_0.5			Hippocampal sparing|limbic predominant|subtype|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31476153_20201214_0.5			Aged|Aged, 80 and over|Algorithms|Alzheimer Disease|Autopsy|Carbolines|Cognitive Dysfunction|Female|Hippocampus|Humans|Limbic System|Magnetic Resonance Imaging|Male|Middle Aged|Neuropsychological Tests|Positron-Emission Tomography|Prospective Studies|Radiopharmaceuticals|Tauopathies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31476153_20201214_0.5	flortaucipir	drug_umls_atom	Flortaucipir positron emission tomography (PET) images acquired from 45 amyloid-positive participants, defined clinically as mild cognitive impairment or AD, aged 50-92 years, 56% female, and estimated to be Braak V-VI based on their PET pattern of tau pathology, were studied.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31476153_20201214_0.5	flortaucipir	drug_umls_atom	By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31476153_20201214_0.5	flortaucipir	drug_umls_atom	Prospective studies can further validate the flortaucipir SUVR cut-points and the phenotype of the corresponding AD subtypes.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32350558_20210611_0.5			Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32350558_20210611_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir|Alzheimer's disease|Positron emission tomography|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32350558_20210611_0.5			Alzheimer Disease|Amyloid beta-Peptides|Humans|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32350558_20210611_0.5	flortaucipir	drug_umls_atom	 No section A total of 132 participants, who were healthy volunteers or recruited in our memory disorder clinic, completed longitudinal 18F-flortaucipir and 18F-florbetaben PET studies with a mean follow-up time of 2 years.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5			Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Biomarkers|Brain|Female|Humans|Male|Middle Aged|Neuroimaging|Neuropsychological Tests|Phosphorylation|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	Data-driven, clinically relevant thresholds for CSF phosphorylated tau (P-tau) (≥26.64 pg/mL) and flortaucipir-PET meta-regions of interest (ROI) (standard uptake value ratio ≥1.37) indicated participants' tau status as CSF-/PET-, CSF+/PET-, CSF-/PET+, and CSF+/PET+.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	Of 1659 ADNI participants with a CSF or flortaucipir assessment, 588 had both measures (1071 were excluded).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	Among these, 266 were further excluded because they did not have flortaucipir and CSF testing within less than 25 months, leaving 322 for analysis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	 No section We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid β-PET burden, and flortaucipir-PET binding across Braak stage-related ROIs.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	We also compared 5-year rates of CSF P-tau accumulation and cognitive decline prior to flortaucipir-PET scanning.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	The CSF+/PET- participants showed faster 5-year accrual of P-tau and increased flortaucipir-PET binding in early Braak ROIs but similar memory decline compared with CSF-/PET- participants.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	Compared with the CSF-/PET- group, CSF+/PET+ individuals had experienced faster 5-year accrual of CSF P-tau and decline in memory and executive function, resulting in reduced cognitive abilities at the time of flortaucipir-PET assessment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	 No section Suprathreshold CSF P-tau without flortaucipir-PET abnormality may indicate a stage of AD development characterized by early tau abnormality without measurable loss in cognitive performance.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31961372_20210411_0.5	flortaucipir	drug_umls_atom	Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5			In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5	flortaucipir	drug_umls_atom	(18)F-flortaucipir|AV1451|Amyloid negative|Amyloid positive|Atrophy|Braak stages|Logical memory|Medial temporal lobe|Subfield|Subregion|Tau PET|Volume	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5			Aged|Alzheimer Disease|Amyloid|Atrophy|Carbolines|Cognitive Dysfunction|Female|Humans|Magnetic Resonance Imaging|Male|Memory|Neuropsychological Tests|Positron-Emission Tomography|Tauopathies|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5	flortaucipir	drug_umls_atom	No section It is unclear the degree to which tau pathology in the medial temporal lobe (MTL) measured by 18F-flortaucipir positron emission tomography relates to MTL subregional atrophy and whether this relationship differs between amyloid-β-positive and amyloid-β-negative individuals.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5	flortaucipir	drug_umls_atom	 No section We analyzed correlation of MTL 18F-flortaucipir uptake with MTL subregional atrophy measured with high-resolution magnetic resonance imaging in a region of interest and regional thickness analysis and determined the relationship between memory performance and positron emission tomography and magnetic resonance imaging measures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5	flortaucipir	drug_umls_atom	 No section Both groups showed strong correlations between 18F-flortaucipir uptake and atrophy, with similar spatial patterns.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31495603_20201005_0.5	flortaucipir	drug_umls_atom	 No section Correlation patterns between tau burden and atrophy in the amyloid-β-negative group mimicking early Braak stages suggests that 18F-flortaucipir is sensitive to tau pathology in primary age-related tauopathy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5	flortaucipir	drug_umls_atom	Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5	flortaucipir	drug_umls_atom	Correlative Imaging|Molecular Imaging|Neurology|amyloid|dynamic PET|florbetapir|flortaucipir-PET|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5			Humans|Male|Female|Young Adult|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Tomography, X-Ray Computed|Carbolines|tau Proteins|Amyloid|Tauopathies|Alzheimer Disease|Positron-Emission Tomography|Cognitive Dysfunction|florbetapir|Ethylene Glycols|Brain|Hippocampus|Aniline Compounds|Amyloidogenic Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049986_20210611_0.5	flortaucipir	drug_umls_atom	 Methods 120 participants (63 amyloid-positive/57 amyloid-negative) with dynamic 18F-florbetapir-PET and static 18F-flortaucipir-PET scans obtained within 6 months of each other were included.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32512123_20210311_0.5			Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32512123_20210311_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Cortical thinning|Flortaucipir|Imaging|Longitudinal modeling|MRI|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32512123_20210311_0.5			Aged|Aging|Alzheimer Disease|Amyloid beta-Peptides|Brain|Cerebral Cortex|Cerebral Cortical Thinning|Female|Humans|Magnetic Resonance Imaging|Male|Models, Neurological|Neurofibrillary Tangles|Positron-Emission Tomography|Retrospective Studies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32512123_20210311_0.5	flortaucipir	drug_umls_atom	Here, we investigate [18F]-flortaucipir (FTP, a marker of paired helical filament tau) PET as a predictor of atrophy in healthy aging and preclinical AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	(18)F-flortaucipir|Positron emission tomography|Primary progressive aphasia|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5			Aged|Alzheimer Disease|Amyloid|Aphasia, Primary Progressive|Atrophy|Carbolines|Female|Humans|Language|Male|Positron-Emission Tomography|White Matter	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	No section We analyzed 18F-flortaucipir uptake patterns and structural changes in patients with subtypes of primary progressive aphasia (PPA) using 18F-flortaucipir positron emission tomography and volumetric magnetic resonance imaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir uptake was increased in the frontal cortex and underlying white matter, and subcortical nuclei in the 10 nfvPPA and 8 nfvPPA-amyloid-β (Aβ)- subgroup patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir uptake patterns in the 6 lvPPA and the 5 lvPPA-Aβ+ subgroup patients were similar to those seen in the patients with Alzheimer's disease with mild predominance in the left lateral temporal cortex.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	Cortical thinning in each PPA subtype corresponded with increased 18F-flortaucipir uptake.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30594046_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir uptake patterns and cortical atrophy were distinct and corresponded to areas related to the specific language functions that are impaired in each subtype of PPA.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33978461_20210611_0.5	flortaucipir	drug_umls_atom	Beyond the AJR: 'Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease Results From 2 Phase III Clinical Trials'.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5			FWE, family wise error|MCALT, Mayo Clinic Adult Lifespan Template|MDS-PSP, Movement Disorders Society clinical criteria for PSP|MPRAGE, magnetization prepared rapid gradient echo|PSP, progressive supranuclear palsy|PSP-CBS, corticobasal variant of PSP|PSP-F, frontal variant of PSP|PSP-PGF, progressive gait freezing variant of PSP|PSP-RS, Richardson's syndrome|PSP-SL, speech/language variant of PSP|ROI, region of interest|SUVR, standardized uptake value ratio	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5			Aged|Aged, 80 and over|Atrophy|Carbolines|Contrast Media|Female|Humans|Magnetic Resonance Imaging|Male|Neuroimaging|Positron-Emission Tomography|Supranuclear Palsy, Progressive	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	No section All PSP variants showed atrophy or flortaucipir uptake in subcortical structures.. Speech/language, frontal and corticobasal variants showed cortical involvement.. Dentatorubrothalamic tract involvement was only seen in some variants.. PSP variants show different patterns of damage to subcortical-cortical circuitry.. Background and purpose Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy that is associated with different clinical variants, including PSP-Richardson's syndrome (PSP-RS), PSP-parkinsonism (PSP-P), PSP-corticobasal syndrome (PSP-CBS), PSP-frontal (PSP-F), PSP-progressive gait freezing (PSP-PGF) and PSP-speech/language (PSP-SL).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	We aimed to assess and compare regional atrophy on MRI and [ F]flortaucipir uptake on PET across PSP variants.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	 Materials and methods 105 PSP patients (53 PSP-RS, 23 PSP-SL, 12 PSP-P, 8 PSP-CBS, 5 PSP-F and 4 PSP-PGF) underwent volumetric MRI, with 59 of these also undergoing flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	 Results All variants showed evidence for atrophy or increased flortaucipir uptake in striatum, globus pallidus and thalamus.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	The PSP-SL variant showed greater volume loss and flortaucipir uptake in supplementary motor area and motor cortex compared to all other variants, but showed less involvement of subthalamic nucleus and midbrain.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6961761_20201005_0.5	flortaucipir	drug_umls_atom	Compared to PSP-RS, PSP-P had larger midbrain volume and greater flortaucipir uptake in putamen.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6362587_20201005_0.5			Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6362587_20201005_0.5			Early-onset autosomal dominant Alzheimer’s disease|Striatum|Tau PET|Amyloid PET|Memory	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6362587_20201005_0.5			Adult|Alzheimer Disease|Amyloid|Corpus Striatum|Cross-Sectional Studies|Female|Heterozygote|Humans|Male|Memory Disorders|Middle Aged|Positron-Emission Tomography|Tauopathies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6362587_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Fourteen carriers (age = 28-42, Mini-Mental State Examination = 26-30) and 20 age-matched non-carriers were evaluated using PiB, flortaucipir (FTP; tau), and memory testing (CERAD Word List Learning).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5			Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Cerebral Cortex|Cognitive Dysfunction|Cross-Sectional Studies|Diagnosis, Differential|Female|Fluorine Radioisotopes|Humans|Magnetic Resonance Imaging, Cine|Male|Middle Aged|Neurodegenerative Diseases|Positron-Emission Tomography|Sweden|White Matter|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir	drug_umls_atom	Generally, tau positron emission tomographic positivity was confined to amyloid β-positive cases or MAPT R406W mutation carriers in this cohort; in patients with semantic variant primary progressive aphasia, RO948 F 18 retention was lower than that for flortaucipir F 18.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir	drug_umls_atom	Evaluation included a comparison of tau PET tracer [ F]RO948 with magnetic resonance imaging (MRI) and cerebrospinal fluid and a head-to-head comparison between [ F]RO948 and flortaucipir F 18 ([ F]flortaucipir) in patients with semantic variant primary progressive aphasia (svPPA).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir	drug_umls_atom	 Exposures [ F]RO948 (all patients) and [ F]flortaucipir (3 patients with svPPA) tau PET; MRI (hippocampal volume, composite temporal lobe cortical thickness, whole-brain cortical thickness) and cerebrospinal fluid measures (p-tau181 and amyloid Aβ42 and Aβ40 ratio[Aβ42/Aβ40], and Aβ42/p-tau181 ratio).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir	drug_umls_atom	 Main Outcomes and Measures Standard uptake value ratios (SUVRs) in 4 predefined regions of interest (ROIs) reflecting Braak staging scheme for tau pathology and encompass I-II (entorhinal cortex), III-IV (inferior/middle temporal, fusiform gyrus, parahippocampal cortex, and amygdala), I-IV, and V-VI (widespread neocortical areas), area under the receiver operating characteristic curve (AUC) values, and subtraction images between [ F]RO948 and [ F]flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7215644_20201005_0.5	flortaucipir	drug_umls_atom	Retention of [ F]RO948 was not pronounced in patients with svPPA, and head-to-head comparison revealed lower temporal lobe uptake than with [ F]flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	Direct comparison of the tau PET tracers [18F]flortaucipir and [18F]MK-6240 in human subjects.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Neurology|PET|Research Methods|Tau|[F-18]MK-6240|flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5			Humans|Aged|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|MK-6240|Carbolines|Isoquinolines|tau Proteins|Alzheimer Disease|Cognitive Dysfunction|Brain|Positron-Emission Tomography|Gray Matter|Amyloid|Cognition|Choroid Plexus|Research Subjects|Longitudinal Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	This study compares two frequently used tau PET tracers, [18F]flortaucipir (FTP) and [18F]MK-6240, in the same subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	 METHODS [18F]flortaucipir and [18F]MK-6240 scans were collected within two months in 15 elderly subjects varying in terms of clinical diagnosis and cognition.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	SUVR outcomes were determined over 80-100 min ([18F]flortaucipir) or 70-90 min ([18F]MK-6240) normalized to cerebellar grey matter.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	The dynamic range of SUVR values in target regions was approximately two-fold higher for [18F]MK-6240 compared to [18F]flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	Cerebellar SUV values were similar for [18F]MK-6240 and [18F]flortaucipir, suggesting that differences in SUVR values are driven by specific signal.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	Apparent off-target binding in striatum and choroid plexus was often observed with [18F]flortaucipir, and most often in meninges with [18F]MK-6240.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33863821_20210511_0.5	flortaucipir	drug_umls_atom	 CONCLUSION Both [18F]MK-6240 and [18F]flortaucipir are capable of quantifying signal in a common set of brain regions that develop tau pathology in AD and perform equally well in visual interpretations.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5			Parkinson's disease|dementia|melanins|neurofibrillary tangles|positron emission tomography	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5			Aged|Carbolines|Cerebral Cortex|Cognitive Dysfunction|Contrast Media|Female|Follow-Up Studies|Humans|Male|Middle Aged|Parkinson Disease|Positron-Emission Tomography|Substantia Nigra|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	No section Flortaucipir PET, a marker of tau tangles, has shown lower than expected cortical uptake in Parkinson's disease (PD), than would be predicted from neuropathologic estimates of Alzheimer's disease co-pathology.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	Instead, the most characteristic finding of flortaucipir imaging in PD is decreased uptake in the substantia nigra, reflecting reduction in its "off-target" binding to neuromelanin.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	 No section Here, we present two-year follow-up data of cortical and nigral flortaucipir uptake in PD patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	 No section Seventeen PD patients received repeat flortaucipir PET two years after baseline.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	 No section We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson's disease patients over two years and no association with changes in cognitive symptoms.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31815700_20210511_0.5	flortaucipir	drug_umls_atom	 No section No significant increase in tau tangles occurred after a two-year follow-up of Parkinson's disease patients using flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5			TauIQ - A canonical image based algorithm to quantify tau PET scans.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5	flortaucipir	drug_umls_atom	Canonical Images|Flortaucipir|IQ platform|Image Processing|PET|Power in clinical trials|Statistical Analysis|Tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5			Humans|Cross-Sectional Studies|Positron-Emission Tomography|tau Proteins|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Alzheimer Disease|Amyloid beta-Peptides|Cognitive Dysfunction|Radiopharmaceuticals|Amyloid|Disease Progression|Algorithms	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5	flortaucipir	drug_umls_atom	 Methods Cross-sectional (N = 615) and Longitudinal (N = 149) [18F]Flortaucipir data were obtained from ADNI along with necessary adjunct amyloid PET and T1 structural MRI data.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33517326_20210211_0.5	flortaucipir	drug_umls_atom	A subset of these data were used to derive a chronological tau data set, using AmyloidIQ analysis of associated amyloid PET data to calculate the subjects temporal position in the canonical AD disease process, from which canonical images for the non-specific and specific binding components of [18F]Flortaucipir in AD were calculated.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Topographic staging of tau positron emission tomography images	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5	flortaucipir	drug_umls_atom	Tau|PET|Flortaucipir|Alzheimer|Staging|Stage|Classification|Image|Braak|AV-1451|T807	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5			Male|Humans|Female|Reproducibility of Results|Positron-Emission Tomography|Alzheimer disease type 2|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Neuroimaging|Amyloid|Aniline Compounds|Brain|Gray Matter|Amyloidogenic Proteins|Amyloidosis	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956800_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Three topographic staging schemes for tau PET, two sampling the temporal and occipital subregions only and one sampling cortical gray matter across the major brain lobes, were evaluated on flortaucipir F 18 PET images in a test-retest scenario and from Alzheimer's Disease Neuroimaging Initiative 2.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5			Multimodal neuroimaging relationships in progressive supranuclear palsy.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5			DTI|MRI|Multimodal imaging|PSP|Tau-PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5			Aged|Atrophy|Brain|Diffusion Tensor Imaging|Female|Humans|Image Interpretation, Computer-Assisted|Magnetic Resonance Imaging|Male|Middle Aged|Multimodal Imaging|Nerve Degeneration|Neuroimaging|Positron-Emission Tomography|Supranuclear Palsy, Progressive|White Matter	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5	flortaucipir	drug_umls_atom	No section Progressive supranuclear palsy is characterized primarily by 4R tau inclusions, atrophy in the brainstem and basal ganglia, and neurodegeneration along the dentatorubrothalamic tract, which are measurable in vivo using flortaucipir PET, T1-weighted MRI, and MRI with diffusion tensor imaging (DTI).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5	flortaucipir	drug_umls_atom	The aim of this study was to investigate multimodal associations between flortaucipir PET uptake, tissue volume loss on structural MRI and white matter tract disruption on DTI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5	flortaucipir	drug_umls_atom	Thirty-four patients with progressive supranuclear palsy and 29 normal controls underwent flortaucipir PET, MRI and DTI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5	flortaucipir	drug_umls_atom	Sparse canonical correlations analysis was applied on regional measurements of flortaucipir uptake, tissue volume, fractional anisotropy and mean diffusivity of the PSP population.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5	flortaucipir	drug_umls_atom	Sparse canonical correlation analyses identified associations between elevated flortaucipir uptake in the cerebellar dentate, red nucleus and subthalamic nucleus and decreased volume in the same regions, and decreased fractional anisotropy and increased mean diffusivity in tracts including the superior cerebellar peduncle, sagittal striatum and posterior corona radiata.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31279635_20201005_0.5	flortaucipir	drug_umls_atom	Tau uptake measured by flortaucipir PET appears to be related to the neurodegenerative process of progressive supranuclear palsy, including reduced tissue volume and white matter tract degeneration.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5			Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir PET|Alzheimer's disease|apolipoprotein E|dose effect|sex	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5			Humans|Male|Female|Middle Aged|Aged, 80 and over|Aged|Apolipoprotein E4|Cognitive Dysfunction|Brain|Alzheimer Disease|tau Proteins|Neuroimaging|Amyloid beta-Peptides|florbetapir|Ethylene Glycols|Data Management|Positron-Emission Tomography|Magnetic Resonance Imaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Aniline Compounds|Radiopharmaceuticals|Amyloid|Neuropsychological Tests	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5	flortaucipir	drug_umls_atom	The aim of this study was to investigate sex differences in APOE ε4 gene dosage effects on brain tau deposition in cognitively impaired individuals using quantitative 18F-flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5	flortaucipir	drug_umls_atom	Preprocessed 18F-flortaucipir tau PET images, T1-weighted structural MRI images, demographic information, global cortical amyloid-β burden measured by 18F-florbetapir PET, CSF total tau and phosphorylated tau measurements were obtained from the Alzheimer's Disease Neuroimaging Initiative database.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33876815_20210511_0.5	flortaucipir	drug_umls_atom	APOE ε4 dosage by sex interaction effect on 18F-flortaucipir standardized uptake value ratios was assessed using generalized linear models and sex-stratified analysis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5			United States|Humans|Male|Female|Aged|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Prospective Studies|Tomography, X-Ray Computed|Carbolines|Cognitive Dysfunction|Positron-Emission Tomography|tau Proteins|Amyloid beta-Peptides|Neuropsychological Tests|Brain|Mental Status and Dementia Tests	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	Questions What is the association between flortaucipir positron emission tomography (PET) imaging visual classification using a clinically applicable and US Food and Drug Administration-approved method and 18-month cognitive and functional decline in patients with clinically diagnosed mild cognitive impairment and dementia owing to Alzheimer disease (AD)?	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Findings In this analysis of 2 open-label clinical trials, visual read of an advanced flortaucipir PET AD pattern was associated with an increased risk of 18-month cognitive and functional decline compared with other scan patterns.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Meaning Clinically applicable visual reads of flortaucipir PET scans may provide valuable information regarding the risk of near-term clinical deterioration among patients with clinically diagnosed mild cognitive impairment or dementia owing to AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Importance Flortaucipir positron emission tomography (PET) scans, rated with a novel, US Food and Drug Administration-approved, clinically applicable visual interpretation method, provide valuable information regarding near-term clinical progression of patients with Alzheimer disease (AD) or mild cognitive impairment (MCI).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Objective To evaluate the association between flortaucipir PET visual interpretation and patients' near-term clinical progression.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	Study 1 screened 298 patients and enrolled 160 participants who had a flortaucipir scan at baseline visit.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	Out of the 2218 AMARANTH participants, 424 had a flortaucipir scan around randomization, but 219 did not complete 18-month clinical dementia rating (CDR) assessments and thus were excluded.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Main Outcomes and Measures Flortaucipir scans were rated as either advanced or nonadvanced AD pattern using a predetermined visual interpretation method.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Conclusions and Relevance These results suggest that flortaucipir PET scans, when interpreted with an US Food and Drug Administration-approved, clinically applicable visual interpretation method, may provide valuable information regarding the risk of clinical deterioration over 18 months among patients with AD and MCI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7885097_20210511_0.5	flortaucipir	drug_umls_atom	 Trial Registration ClinicalTrials.gov Identifier: and No section This study evaluates the association between flortaucipir positron emission tomography visual interpretation and patients' near-term clinical progression of mild cognitive impairment and dementia owing to Alzheimer disease.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882538_20210311_0.5			Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882538_20210311_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|FDG-PET|MAO-B|QoL-AD|dopamine|flortaucipir|glucose metabolism|rasagiline|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882538_20210311_0.5			Humans|Male|Female|Aged, 80 and over|rasagiline|Alzheimer Disease|Double-Blind Method|Indans|Parkinson Disease|Monoamine Oxidase Inhibitors|Cognition|Severity of Illness Index|Time|Carbohydrate Metabolism|Glucose	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5			Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Cognition|Relative cerebral blood flow|Tau|[18F]flortaucipir PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5			Alzheimer Disease|Cerebrovascular Circulation|Cognition|Cognitive Dysfunction|Humans|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5	flortaucipir	drug_umls_atom	Purpose We aimed to investigate associations between tau pathology and relative cerebral blood flow (rCBF), and their relationship with cognition in Alzheimer's disease (AD), by using a single dynamic [ F]flortaucipir positron emission tomography (PET) scan.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5	flortaucipir	drug_umls_atom	 Methods Seventy-one subjects with AD (66 ± 8 years, mini-mental state examination (MMSE) 23 ± 4) underwent a dynamic 130-min [ F]flortaucipir PET scan.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5	flortaucipir	drug_umls_atom	 Results Higher [ F]flortaucipir BPND was associated with lower R 1 in the lateral temporal, parietal and occipital regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5	flortaucipir	drug_umls_atom	For [ F]flortaucipir R 1 , lower values in the lateral temporal and parietal ROIs were associated with worse executive functioning, language and attention, and lower occipital R 1 with lower language and attention scores.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7680306_20210111_0.5	flortaucipir	drug_umls_atom	When [ F]flortaucipir BPND and R 1 were modelled simultaneously, associations between lower R 1 in the lateral temporal ROI  and worse attention remained, as well as for lower parietal R 1 and worse executive functioning and attention.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30689584_20201005_0.5			Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30689584_20201005_0.5			Alzheimer’s disease|amyloid|apathy|instrumental activities of daily  living|mild cognitive impairment|positron emission tomography|tau. 	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30689584_20201005_0.5			Activities of Daily Living|Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Apathy|Cognitive Dysfunction|Female|Humans|Male|Middle Aged|Neuropsychological Tests|Positron-Emission Tomography|Surveys and Questionnaires|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30689584_20201005_0.5	flortaucipir	drug_umls_atom	Regional tau was assessed using flortaucipir positron emission tomography (PET) and amyloid using Pittsburgh Compound B PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6661099_20201005_0.5			Tau and atrophy: domain-specific relationships with cognition	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6661099_20201005_0.5			Tau|Atrophy|Thickness|Positron emission tomography|Magnetic resonance imaging|Neuropsychology|Cognition|Surface-based analysis	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6661099_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Atrophy|Brain|Carbolines|Cognition|Cognitive Dysfunction|Female|Humans|Magnetic Resonance Imaging|Male|Neuropsychological Tests|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6661099_20201005_0.5	flortaucipir	drug_umls_atom	 Methods We analyzed data from 131 amyloid-β positive participants (55 cognitively normal, 46 mild cognitive impairment, 30 AD) of the Alzheimer's Disease Neuroimaging Initiative who underwent magnetic resonance imaging (MRI), flortaucipir (FTP) positron emission tomography, and neuropsychological testing.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			An updated radiosynthesis of [18F]AV1451 for tau PET imaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5	flortaucipir	drug_umls_atom	Tau imaging|Brain PET|[|Flortaucipir F18|Fluorine-18 radiochemistry|Automated radiosynthesis	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Positron-Emission Tomography|Radiopharmaceuticals|Carbolines|Fluorine Radioisotopes|tau Proteins|Alzheimer Disease|Radiochemistry|Tauopathies|Chromatography, High Pressure Liquid	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31784374_20210611_0.5			Tau-positron emission tomography correlates with neuropathology findings.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31784374_20210611_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Autopsy|Braak tangle stage|PET|Tau|flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31784374_20210611_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Autopsy|Brain|Female|Humans|Male|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31784374_20210611_0.5	flortaucipir	drug_umls_atom	No section Comparison of tau (flortaucipir) positron emission tomography (FTP-PET) to autopsy is important to demonstrate the relationship of FTP-PET to neuropathologic findings.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30293094_20201005_0.5			The Role of Tau Imaging in Parkinsonian Disorders.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30293094_20201005_0.5	flortaucipir	drug_umls_atom	Atypical Parkinson syndromes|Flortaucipir|PBB3|THK-5351|Tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30293094_20201005_0.5			Alzheimer Disease|Diagnosis, Differential|Humans|Parkinsonian Disorders|Positron-Emission Tomography|Supranuclear Palsy, Progressive|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5			Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5			AV1451 PET|Alzheimer's disease|Amyloid-beta|CSF p-tau181|Plasma p-tau181	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5			Male|Humans|Tomography, X-Ray Computed|Amyloid beta-Peptides|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Biomarkers|Peptide Fragments|Positron-Emission Tomography|Cognition Disorders|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Disease Progression|Plasma|Phosphorylation	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5	flortaucipir	drug_umls_atom	Demographic and clinical variables, amyloid-β (Aβ) burden, flortaucipir-PET binding in Braak regions of interest (ROIs), longitudinal changes in clinical outcomes, and conversion risk were compared.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5	flortaucipir	drug_umls_atom	Regarding plasma/PET categories, as expected, PET-positive individuals had increased Aβ burden, elevated flortaucipir retention in Braak ROIs, and accelerated cognitive deterioration than concordant-negative persons.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8094494_20210511_0.5	flortaucipir	drug_umls_atom	Noteworthy, discordant participants with normal PET exhibited reduced flortaucipir uptake in Braak stage ROIs and slower rates of cognitive decline, relative to those PET-positive.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29751288_20201214_0.5			Predicted sequence of cortical tau and amyloid-β deposition in Alzheimer disease spectrum.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29751288_20201214_0.5	flortaucipir	drug_umls_atom	(18)F-flortaucipir|Alzheimer disease|Amyloid-beta|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29751288_20201214_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Cerebral Cortex|Female|Fluorine Radioisotopes|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Neuroimaging|Positron-Emission Tomography|Radiopharmaceuticals|Stilbenes|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29751288_20201214_0.5	flortaucipir	drug_umls_atom	Two hundred twenty participants underwent 18F-flortaucipir and 18F-florbetaben positron emission tomography scans and neuropsychological tests.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5			The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5			Alzheimer's disease|Associative memory|Autosomal dominant Alzheimer's disease|Imaging|Neuropsychology|PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5			Humans|Male|Female|Latin America|Tomography, X-Ray Computed|Memory|Alzheimer Disease|Names|Neuropsychological Tests|Face|Presenilin-1|Memory Disorders|Association Learning|Amyloid|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Multiple Pterygium Syndrome, Autosomal Dominant|Arthrogryposis|Positron-Emission Tomography|Heterozygote|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7488408_20201005_0.5	flortaucipir	drug_umls_atom	A subset of participants (31 carriers [12 symptomatic] and 35 non-carriers) traveled from Colombia to Boston to undergo positron emission tomography (PET) using Pittsburgh compound B to measure mean cortical amyloid-β and flortaucipir for regional tau.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	flortaucipir	drug_umls_atom	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|SRTM|Standardised uptake value|[18F]Florbetapir|[18F]Flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5			Humans|Middle Aged|Male|Female|Aged, 80 and over|Aged|florbetapir|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Tomography, X-Ray Computed|Ethylene Glycols|Positron-Emission Tomography|Carbolines|Aniline Compounds|Alzheimer Disease|tau Proteins|Radiopharmaceuticals|Cognitive Dysfunction|Brain|Neuroimaging|Gray Matter	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	flortaucipir	drug_umls_atom	The aim of this study was to investigate the use of non-invasive standardised uptake value (SUV) approaches, in comparison to VT, as a verification of the previously validated grey matter cerebellum reference region for [18F]flortaucipir and [18F]florbetapir PET imaging in Alzheimer's disease (AD) patients and controls.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	flortaucipir	drug_umls_atom	 METHODS Dynamic 130-min [18F]flortaucipir PET scans obtained from nineteen subjects (10 AD patients) and 90-min [18F]florbetapir dynamic scans obtained from fourteen subjects (8 AD patients) were included.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	flortaucipir	drug_umls_atom	 RESULTS A low SUV corresponded well with a low VT for both [18F]flortaucipir and [18F]florbetapir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443720_20210211_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS In situations where dynamic scanning and arterial sampling is not possible, a low SUV(80-100 min) for [18F]flortaucipir and a low SUV(50-70 min) for [18F]florbetapir may be used as indication for absence of specific binding in the grey matter cerebellum reference region.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5928586_20201005_0.5			Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5928586_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir|THK|Positron emission tomography|Alzheimer’s disease|Tauopathy	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5928586_20201005_0.5			Aged|Aged, 80 and over|Aniline Compounds|Autoradiography|Carbolines|Contrast Media|Dementia|Female|Fluorine Radioisotopes|Humans|Male|Middle Aged|Neurodegenerative Diseases|Positron-Emission Tomography|Protein Binding|Quinolines|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5928586_20201005_0.5	flortaucipir	drug_umls_atom	The first generation of tau PET tracers, including the carbazole flortaucipir and the 2-arylquinolines of the THK series, are now used in clinical research; however, concerns have been raised about off-target binding and low sensitivity.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5			Neuroinflammation is highest in areas of disease progression in semantic dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	MAOB|PBR28 PET|flortaucipir PET|neuroinflammation|semantic variant primary progressive aphasia	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5			Humans|Male|Middle Aged|Female|Frontotemporal Dementia|Aphasia, Primary Progressive|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|tau Proteins|Alzheimer Disease|Positron-Emission Tomography|White Matter|Amyloid|Temporal Lobe|Cerebral Cortex|Atrophy|Disease Progression	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	The pathology starts at the tip of the left temporal lobe where, in addition to cortical atrophy, a strong signal appears with the tau PET tracer 18F-flortaucipir, even though the disease is not typically associated with tau but with TDP-43 protein aggregates.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	We also tested the hypothesis that inflammation, by providing non-specific binding targets, could explain the 18F-flortaucipir signal in semantic variant primary progressive aphasia.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	Eight amyloid-PET-negative patients with semantic variant primary progressive aphasia underwent 11C-PBR28 and 18F-flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	Healthy controls underwent 11C-PBR28 PET (n = 12) or 18F-flortaucipir PET (n = 12).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir standardized uptake value ratios were calculated using the cerebellum as the reference region.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	Since monoamine oxidase B receptors are expressed by astrocytes in affected tissue, selegiline was administered to one patient with semantic variant primary progressive aphasia before repeating 18F-flortaucipir scanning to test whether monoamine oxidase B inhibition blocked flortaucipir binding, which it did not.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	While 11C-PBR28 uptake was mostly cortical, 18F-flortaucipir uptake was greatest in the white matter.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33824991_20210411_0.5	flortaucipir	drug_umls_atom	However, peak uptake of 18F-flortaucipir localized to the left temporal pole, the epicentre of pathology, while the peak of inflammation 11C-PBR28 uptake localized to a more posterior, mid-temporal region and left insula and orbitofrontal cortex, in the periphery of the damage core.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5			Sleep and Tau Pathology in Vietnam War Veterans with Preclinical and Prodromal Alzheimer’s Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5			Amyloid|mild cognitive impairment|positron emission tomography|preclinical AD|sleep|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5			Male|Humans|Middle Aged|Female|Adult|Veterans|Cross-Sectional Studies|Vietnam|Alzheimer Disease|tau Proteins|florbetapir|Ethylene Glycols|Amyloid beta-Peptides|Neuroimaging|Positron-Emission Tomography|Vietnam Conflict|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Cognitive Dysfunction|Aniline Compounds|Amyloid|Sleep|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7903001_20210311_0.5	flortaucipir	drug_umls_atom	 Methods: 66 male participants underwent Florbetapir (AV45) positron emission tomography (PET) and Flortaucipir (FTP) PET and completed the Pittsburgh Sleep Quality Index questionnaire (PSQI) as part of the Department of Defense Alzheimer's Disease Neuroimaging Initiative, a multicenter study collecting data from Vietnam War veterans, some of whom have a history of post-traumatic stress disorder, or non-penetrating traumatic brain injury.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Autopsy|Brain|Carbolines|Contrast Media|Female|Humans|Male|Neurofibrillary Tangles|Neuroimaging|Plaque, Amyloid|Positron-Emission Tomography|Radiopharmaceuticals|Sensitivity and Specificity|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	 No section To determine the accuracy of antemortem [18F]flortaucipir PET images for predicting the presence of AD-type tau pathology at autopsy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	All participants underwent [18F]flortaucipir PET imaging, and scans were interpreted by 5 independent nuclear medicine physicians or radiologists.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	Supplemental autopsy [18F]flortaucipir images and pathological samples were also collected from 16 historically collected cases.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	 No section [18F]flortaucipir PET images were visually assessed and compared with immunohistochemical tau pathology.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	An AD tau pattern of flortaucipir retention was assessed for correspondence with a postmortem B3-level (Braak stage V or VI) pathological pattern of tau accumulation and to the presence of amyloid-β plaques sufficient to meet the criteria for high levels of AD neuropathological change.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	 No section A total of 156 patients were enrolled in the A16 study and underwent [18F]flortaucipir PET imaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	The flortaucipir PET scans predicted a B3 level of tau pathology, with sensitivity ranging from 92.3% (95% CI, 79.7%-97.3%) to 100.0% (95% CI, 91.0%-100.0%) and specificity ranging from 52.0% (95% CI, 33.5%-70.0%) to 92.0% (95% CI, 75.0%-97.8%).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32338734_20210311_0.5	flortaucipir	drug_umls_atom	 No section This study's findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change, supporting a neuropathological diagnosis of AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5			Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5			tau imaging|amyloid imaging|Alzheimer’s disease|mild cognitive impairment|biomarkers	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5			Aged, 80 and over|Male|Humans|Female|Aged|Amyloid beta-Peptides|Tomography, X-Ray Computed|Amyloid|Amyloidogenic Proteins|Amyloidosis|Alzheimer Disease|Positron-Emission Tomography|florbetapir|Ethylene Glycols|tau Proteins|Aniline Compounds|Cognitive Dysfunction|Cognition Disorders|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Peptide Fragments|Brain|Cognition	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7001143_20201005_0.5	flortaucipir	drug_umls_atom	Five hundred twenty-three individuals from the Alzheimer's Disease Neuroimaging Initiative who had undergone flortaucipir positron emission tomography imaging were selected to derive positron emission tomography positivity thresholds using conditional inference decision tree regression.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33480610_20210211_0.5			Cerebral Amyloid Angiopathy-related Inflammation Presenting With a Cystic Lesion in Young-onset Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33480610_20210211_0.5	flortaucipir	drug_umls_atom	Neurofibrillary tangles were present and a flortaucipir positron emission tomography showed bilateral signal highest in the lateral temporal and parietal cortices.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33496930_20210211_0.5	flortaucipir	drug_umls_atom	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33496930_20210211_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|PET|[18F]Flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33496930_20210211_0.5	flortaucipir	drug_umls_atom	OBJECTIVE Dynamic positron emission tomography (PET) protocols allow for accurate quantification of [18F]flortaucipir-specific binding.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33496930_20210211_0.5	flortaucipir	drug_umls_atom	The current study assessed the effect of shorter scan protocols for [18F]flortaucipir on its quantitative accuracy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33496930_20210211_0.5	flortaucipir	drug_umls_atom	All subjects underwent a 130-min dynamic [18F]flortaucipir PET scan consisting of two parts (0-60/80-130 min) post-injection.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33496930_20210211_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS This study demonstrated that [18F]flortaucipir PET scan can be acquired with sufficient quantitative accuracy using only 50 min of dual-time-window scanning time.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7042808_20201005_0.5			Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7042808_20201005_0.5			Age Factors|Aged|Alzheimer Disease|Brain|Cognition|Cognitive Reserve|Cross-Sectional Studies|Disease Progression|Female|Humans|Image Interpretation, Computer-Assisted|Longitudinal Studies|Magnetic Resonance Imaging|Male|Neuroimaging|Positron Emission Tomography Computed Tomography|Risk Factors|Sex Characteristics|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7042808_20201005_0.5	flortaucipir	drug_umls_atom	 Exposures Standard dementia screening, cognitive testing, brain magnetic resonance imaging, amyloid-β PET and cerebrospinal fluid analysis, and flortaucipir (tau) labeled with fluor-18 ( F) PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7042808_20201005_0.5	flortaucipir	drug_umls_atom	 Main Outcomes and Measures Separate linear regression models were performed between whole cortex [ F]flortaucipir uptake and cortical thickness, and standardized residuals were used to obtain a measure of brain resilience.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7042808_20201005_0.5	flortaucipir	drug_umls_atom	The same procedure was performed for whole cortex [ F]flortaucipir uptake vs Mini-Mental State Examination (MMSE) as a measure of cognitive resilience.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5			In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5			Adult|Aged|Amyloid beta-Peptides|Apolipoproteins E|Biomarkers|Brain|Brain Injuries, Traumatic|Carbolines|Case-Control Studies|Female|Genotype|Humans|Male|Middle Aged|Phosphorylation|Survivors|Ubiquitin Thiolesterase|White Matter|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5	flortaucipir	drug_umls_atom	We used flortaucipir positron emission tomography (PET) to investigate whether tau pathology is present many years after a single TBI in humans.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5	flortaucipir	drug_umls_atom	Cerebral flortaucipir binding was variable, with many participants with TBI showing increases in cortical and white matter regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5	flortaucipir	drug_umls_atom	At the group level, flortaucipir binding was increased in the right occipital cortex in TBI when compared to healthy controls.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5	flortaucipir	drug_umls_atom	Flortaucipir binding was associated with increased total tau, phosphorylated tau, and ubiquitin carboxyl-terminal hydrolase L1 CSF concentrations, as well as with reduced fractional anisotropy and white matter tissue density in TBI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31484787_20210111_0.5	flortaucipir	drug_umls_atom	Apolipoprotein E (APOE) ε4 genotype affected the relationship between flortaucipir binding and time since injury, CSF β amyloid 1-42 (Aβ42) concentration, white matter tissue density, and longitudinal Mini-Mental State Examination scores in TBI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	tau|flortaucipir|florbetapir|PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Amyloid|Amyloid beta-Peptides|Analysis of Variance|Aniline Compounds|Brain|Cognitive Dysfunction|Cross-Sectional Studies|Ethylene Glycols|Female|Humans|Male|Mental Status Schedule|Middle Aged|Neuropsychological Tests|Positron-Emission Tomography|Radiopharmaceuticals|Young Adult|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	Using flortaucipir ( F-AV-1451) PET tau imaging in patients with varying amyloid and cognitive status, Pontecorvo et al.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	 No section The advent of tau-targeted positron emission tomography tracers such as flortaucipir ( F-AV-1451, also known as F-T807) have made it possible to investigate the sequence of development of tau and amyloid-β in relationship to age, and to the development of cognitive impairment due to Alzheimer's disease.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	In this study, flortaucipir tau and florbetapir amyloid positron emission tomography were obtained for 217 subjects including 16 young and 58 older cognitively normal subjects, 95 subjects with mild cognitive impairment (Mini-Mental State Examination 24-30) and 48 subjects with clinically-defined possible or probable Alzheimer's disease (Mini-Mental State Examination >10).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	For amyloid positron emission tomography positive (Aβ+) subjects, flortaucipir neocortical standard uptake value ratio was significantly higher with more advanced clinical stage (Alzheimer's disease > mild cognitive impairment > older cognitively normal) and was significantly elevated for Aβ+ mild cognitive impairment and Alzheimer's disease subjects relative to the respective Aβ− subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	In contrast, florbetapir Aβ− older cognitively normal subjects showed an increase in flortaucipir standard uptake value ratios in mesial temporal lobe regions (amygdala, hippocampus/choroid plexus region of interest) compared to younger cognitively normal subjects, but no increased standard uptake value ratios in neocortical regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	Analysis of covariance with planned contrasts showed no differences in regional or composite posterior neocortical flortaucipir standard uptake value ratio as a function of diagnostic group among Aβ− older cognitively normal or clinically diagnosed Alzheimer's disease or mild cognitive impairment subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	The pattern of flortaucipir distribution among Aβ+ subjects was reminiscent of the cross-sectional distribution of tau reported in post-mortem pathology studies, in that the most commonly affected regions were the inferior and lateral temporal lobes, the same regions where the first signs of increased retention appeared in Aβ+ cognitively normal subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	However, there was large variability in extent/density of flortaucipir tau binding among Aβ+ subjects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	Although high neocortical flortaucipir retention was consistently associated with an Aβ+ florbetapir positron emission tomography scan, not all Aβ+ subjects had elevated flortaucipir standard uptake value ratios.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5382945_20201005_0.5	flortaucipir	drug_umls_atom	Finally, within the Aβ+ group, increasing levels of flortaucipir tau binding were associated with increased cognitive impairment, as assessed by Mini-Mental State Examination and Alzheimer's Disease Assessment Scale.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30068637_20210311_0.5			Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30068637_20210311_0.5			Aged|Alzheimer Disease|Amyloid|Cognition Disorders|Cohort Studies|Female|Hippocampus|Humans|Male|Middle Aged|Neuropsychological Tests|Positron-Emission Tomography|Psychiatric Status Rating Scales|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30068637_20210311_0.5	flortaucipir	drug_umls_atom	 No section A total of 152 middle-aged and older adult participants with at least 2 clinical and cognitive assessments, a Clinical Dementia Rating score of 0 or 0.5, and a flortaucipir (18F-AV-1451) tau PET scan, a florbetapir (18F-AV-45) amyloid PET scan, and a structural MRI scan were recruited from the Knight Alzheimer Disease Research Center at Washington University in St. Louis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5			Age Factors|Aged|Aged, 80 and over|Alzheimer Disease|Atrophy|Carbolines|Contrast Media|Entorhinal Cortex|Female|Hippocampus|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Neocortex|Phenotype|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	Objective To assess the relationships between MRI volumetry and [ F]flortaucipir PET of typical and atypical clinical phenotypes of Alzheimer's disease, by genarian (age by decade).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Five‐hundred and sixty‐four participants including those with typical (n  = 86) or atypical (n  = 80) Alzheimer's dementia and normal controls (n  = 398) underwent apolipoprotein E genotyping, MRI, flortaucipir, and C‐PiB; all 166 Alzheimer's participants were beta‐amyloid positive and all controls were beta‐amyloid negative.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	Grey matter volume and flortaucipir standard uptake value ratios were calculated for hippocampus, entorhinal cortex, and neocortex.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	Ratios of hippocampal‐to‐neocortical and entorhinal‐to‐neocortical volume and flortaucipir uptake were also calculated.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	Linear regression models assessed relationships among regional volume, flortaucipir uptake, and ratios and phenotypes, within three genarians (50-59, 60-69, and 70+).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	 Results For 50-59 greater medial temporal atrophy and flortaucipir uptake was observed in the typical compared with atypical phenotype.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	For 60-69 and 70+ there was greater hippocampal volume loss in the typical compared with atypical phenotype while only the 60-69, but not the 70+ group, showed a difference in hippocampal flortaucipir uptake.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	We also observed a pattern for higher neocortical flortaucipir uptake to correlate with younger age decade for both phenotypes.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7261766_20201005_0.5	flortaucipir	drug_umls_atom	 Interpretation MRI volumetry versus flortaucipir PET relationships differ across Alzheimer's clinical phenotypes, and also within phenotype across age decades.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Flortaucipir|Hippocampus|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Carbolines|Choroid Plexus|Cognitive Dysfunction|Cohort Studies|Contrast Media|Female|Hippocampus|Humans|Male|Middle Aged|Neuroimaging|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	Accurate quantification of hippocampal tau signal using the tau-PET tracer 18F-flortaucipir is complicated, however, by off-target binding in the adjacent choroid plexus.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	 No section As off-target binding in the choroid plexus is known to be higher using 18F-flortaucipir compared to 18F-RO948, we created a binary hippocampal mask in template space where 18F-flortaucipir signal was higher than 18F-RO948, using data from 30 patients that underwent both 18F-flortaucipir and 18F-RO948 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	This mask, presumably representing hippocampal voxels affected by off-target binding from the choroid plexus, was then converted to native space and applied as an exclusion mask to 145 patients across the AD-spectrum scanned with 18F-flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	 No section Choroid plexus off-target binding interferes with the estimation of true hippocampal retention using 18F-flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32711062_20210311_0.5	flortaucipir	drug_umls_atom	Using a mask to correct for this off-target signal, we improved the diagnostic accuracy of 18F-flortaucipir in the hippocampus and the correlation between 18F-flortaucipir hippocampal SUVR and cognitive measures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30753379_20201005_0.5			Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30753379_20201005_0.5	flortaucipir	drug_umls_atom	Alzheimer’s|FDG|MRI|amyloid|flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30753379_20201005_0.5			Adult|Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Biomarkers|Brain|Cognition|Cognitive Dysfunction|Dementia|Female|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Neurofibrillary Tangles|Positron-Emission Tomography|Presenilin-1|Tauopathies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Brain|Carbolines|Cognitive Dysfunction|Cross-Sectional Studies|Diagnostic Self Evaluation|Entorhinal Cortex|Female|Frontal Lobe|Humans|Male|Middle Aged|Neocortex|Parietal Lobe|Phenanthrolines|Positron-Emission Tomography|Radiopharmaceuticals|Surveys and Questionnaires|Tauopathies|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28973551_20201005_0.5	flortaucipir	drug_umls_atom	 No section This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5			Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5	flortaucipir	drug_umls_atom	PET|[18F]flortaucipir|alzheimer's disease|tau neurofibrillary tangles (NFTs)|tauvid	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7911942_20210411_0.5			United States|Adult|Humans|Alzheimer Disease|tau Proteins|Cognitive Dysfunction|Positron-Emission Tomography|Radiopharmaceuticals|Brain|Carbolines|Diagnostic Tests, Routine	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	Atrophy|CSF|Cognition|PET|Tau|[18F]flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5			Alzheimer Disease|Carbolines|Cognitive Dysfunction|Humans|Positron-Emission Tomography|Severity of Illness Index|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	Purpose In vivo Alzheimer's disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [ F]flortaucipir positron emission tomography (PET).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	Our aim was to assess associations between CSF p-tau with [ F]flortaucipir PET and the associations of both tau biomarkers with cognition and atrophy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	Dynamic 130 min [ F]flortaucipir PET scans were acquired to generate binding potential (BPND ) images using receptor parametric mapping and standardized uptake values ratios of 80-100 min (SUVr80-100min ) post injection.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	 Results Higher [ F]flortaucipir BPND was associated with higher CSF p-tau (range of standardized betas (sβ) across ROIs, 0.43-0.46; all p  < 0.01). [	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	F]flortaucipir BPND was more strongly associated with cognition and atrophy than CSF p-tau.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	When [ F]flortaucipir BPND and CSF p-tau were entered simultaneously, [ F]flortaucipir BPND (range sβ = − 0.20 to - 0.57, all p  < 0.05) was strongly associated with multiple cognitive domains and atrophy regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7567681_20210111_0.5	flortaucipir	drug_umls_atom	 Conclusion Regional [ F]flortaucipir BPND correlated stronger with cognition and neurodegeneration than CSF p-tau, suggesting that tau PET more accurately reflects disease severity in AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7203856_20201005_0.5			The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7203856_20201005_0.5	flortaucipir	drug_umls_atom	Alzheimer|Neuroinflammation|β-amyloid|Tau|Microglia|PET|MCI|PK11195|PiB|Flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7203856_20201005_0.5			Aged|Alzheimer Disease|Amyloid beta-Peptides|Cognitive Dysfunction|Disease Progression|Female|Humans|Image Interpretation, Computer-Assisted|Inflammation|Longitudinal Studies|Male|Neurofibrillary Tangles|Positron-Emission Tomography|Prodromal Symptoms|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7203856_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Forty-three subjects with mild cognitive impairment (MCI) had serial C-PK11195 PET over 2 years to measure inflammation changes, and C-PiB PET to determine β-amyloid fibril load; 22 also had serial F-Flortaucipir PET to determine tau tangle load.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7203856_20201005_0.5	flortaucipir	drug_umls_atom	Finally, MCI cases which showed both high C-PiB and F-Flortaucipir uptake at baseline (MCI due to AD) showed a further rise in their tau tangle load over 2 years with a correlated rise in levels of inflammation.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5	flortaucipir	drug_umls_atom	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5			Aphasia|Apraxia of speech|Longitudinal|PET|Tauopathy	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5			Humans|Male|Middle Aged|Female|Child, Preschool|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Speech|Carbolines|Apraxias|Positron-Emission Tomography|Aphasia, Primary Progressive|Brain|Amyloid beta-Peptides|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|tau Proteins|Tauopathies|Aphasia|Amyloid|Frontal Lobe|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31830664_20210311_0.5	flortaucipir	drug_umls_atom	Elevated flortaucipir ([18F]AV-1451; FTP) uptake has been observed cross-sectionally in patients with PPAOS and those with aphasia.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5	flortaucipir	drug_umls_atom	Predominant subcortical accumulation of 18F-flortaucipir binding in behavioral variant frontotemporal dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5	flortaucipir	drug_umls_atom	(18)F-flortaucipir|Behavioral variant frontotemporal dementia|Positron emission tomography|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5			Aged|Carbolines|Cerebral Cortex|Female|Fluorine Radioisotopes|Frontotemporal Dementia|Globus Pallidus|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Neuroimaging|Neuropsychological Tests|Positron Emission Tomography Computed Tomography|Putamen|Radiopharmaceuticals|White Matter	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5	flortaucipir	drug_umls_atom	In this study, we sought to investigate 18F-flortaucipir-binding patterns and their correlates in clinically diagnosed bvFTD patients by comparing with results for Alzheimer's disease (AD) patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5	flortaucipir	drug_umls_atom	We enrolled 20 bvFTD, 20 AD, and 20 age-matched healthy subjects who underwent neuropsychological tests, magnetic resonance imaging, and tau positron emission tomography scans with 18F-flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5	flortaucipir	drug_umls_atom	The bvFTD patients showed increased 18F-flortaucipir binding in the putamen and globus pallidus when compared to the healthy controls.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29554554_20201005_0.5	flortaucipir	drug_umls_atom	The bvFTD patients may exhibit predominantly subcortical 18F-flortaucipir-binding pattern that is distinct from the patterns seen in AD patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5			Financial Capacity and Regional Cerebral Tau in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5			Alzheimer's disease|amyloid|financial capacity|instrumental activities of daily living|mild cognitive impairment|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5			Aged, 80 and over|Humans|Male|Female|Aged|Alzheimer Disease|Cross-Sectional Studies|Activities of Daily Living|Tomography, X-Ray Computed|Cognitive Dysfunction|tau Proteins|Amyloid beta-Peptides|Positron-Emission Tomography|Amyloid|Cognition|Neuropsychological Tests|Neuroimaging|Brain|Aniline Compounds|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33386806_20210211_0.5	flortaucipir	drug_umls_atom	 METHODS Cross-sectional financial capacity was assessed using the Financial Capacity Instrument -Short Form (FCI-SF) in 410 CN, 199 MCI, and 61 AD dementia participants who underwent flortaucipir tau positron emission tomography from the Alzheimer's Disease Neuroimaging Initiative (ADNI).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31792573_20210611_0.5			The A/T/N model applied through imaging biomarkers in a memory clinic.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31792573_20210611_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir|A/T/N model|Alzheimer's disease|PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31792573_20210611_0.5			Alzheimer Disease|Biomarkers|Cognitive Dysfunction|Humans|Neurofibrillary Tangles|Positron-Emission Tomography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31792573_20210611_0.5	flortaucipir	drug_umls_atom	The aim of the study is to evaluate the topography of T distribution by 18F-flortaucipir PET in relation to A and N and to describe the A/T/N status through imaging biomarkers in memory clinic patients.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31792573_20210611_0.5	flortaucipir	drug_umls_atom	This is the first study in which the A/T/N model is applied using 18F-flortaucipir PET in a memory clinic population.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Biomarker-based diagnosis|PET|Strategic roadmap|[18F]flortaucipir	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5			Humans|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neurofibrillary Tangles|tau Proteins|Cognitive Dysfunction|Positron-Emission Tomography|Biomarkers	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	With this work, we assess the maturity of [18F]flortaucipir PET and define its research priorities.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	 METHODS The level of maturity of [18F]flortaucipir was assessed based on the AD Biomarker Roadmap.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	18F]Flortaucipir binds with high affinity to paired helical filaments of tau and has favorable kinetic properties and excellent discriminative accuracy for AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	Multiple studies showed high correlations between ante-mortem [18F]flortaucipir PET and post-mortem tau (as assessed by histopathology), and also the effects of covariates on tracer binding are well studied.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33547556_20210611_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS Current literature provides partial evidence for clinical utility of [18F]flortaucipir PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32285577_20210211_0.5			Interaction effect of Alzheimer's disease pathology and education, occupation, and socioeconomic status as a proxy for cognitive reserve on cognitive performance: in vivo positron emission tomography study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32285577_20210211_0.5			Alzheimer's disease|amyloid|cognitive reserve|educational status|positron emission tomography|tau proteins	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32285577_20210211_0.5			Alzheimer Disease|Amyloid beta-Peptides|Cognition|Cognitive Dysfunction|Cognitive Reserve|Humans|Occupations|Positron-Emission Tomography|Social Class|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32285577_20210211_0.5	flortaucipir	drug_umls_atom	We included clinically normal subjects and patients with mild cognitive impairment or Alzheimer's disease who had undergone a florbetapir scan within 1 year of a flortaucipir (AV-1451) scan (n = 127).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6816221_20201005_0.5			[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6816221_20201005_0.5	flortaucipir	drug_umls_atom	Chronic traumatic encephalopathy|[|Flortaucipir|Tau|PET|Autoradiography	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6816221_20201005_0.5			Aged|Aged, 80 and over|Brain|Carbolines|Chronic Traumatic Encephalopathy|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Tauopathies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6816221_20201005_0.5	flortaucipir	drug_umls_atom	Recent studies have shown that positron emission tomography (PET) tracer AV-1451 (Flortaucipir) exhibits high binding affinity for paired helical filament (PHF)-tau aggregates in Alzheimer (AD) brains but relatively low affinity for tau lesions in other tauopathies like temporal lobal degeneration (FTLD)-tau, progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5662681_20201005_0.5			Quantification of Tau Load Using [18F]AV1451 PET	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5662681_20201005_0.5	flortaucipir	drug_umls_atom	[|PET Pharmacokinetic Modeling|Flortaucipir|Alzheimer’s Disease|Tau Imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5662681_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Case-Control Studies|Humans|Kinetics|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5662681_20201005_0.5	flortaucipir	drug_umls_atom	Purpose The tau tracer [ F]AV1451, also known as flortaucipir, is a promising ligand for imaging tau accumulation in Alzheimer's disease (AD).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6357436_20201005_0.5			Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6357436_20201005_0.5			Alzheimer’s disease|Instrumental activities of daily living|Tau|Amyloid|Positron emission tomography|Mild cognitive impairment|Inferior temporal cortex|Entorhinal cortex	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6357436_20201005_0.5			Activities of Daily Living|Aged|Aged, 80 and over|Alzheimer Disease|Amyloid|Cognitive Dysfunction|Cohort Studies|Female|Humans|Longitudinal Studies|Magnetic Resonance Imaging|Male|Neuropsychological Tests|Positron-Emission Tomography|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6357436_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Fifty-one CN elderly, 30 MCI, and 9 AD dementia participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent assessment of regional tau deposition with flortaucipir (FTP) positron emission tomography (PET).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7498941_20201005_0.5			Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer’s disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7498941_20201005_0.5			Alzheimer's disease|Amyloid|Default mode network|Functional connectivity	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7498941_20201005_0.5			Humans|Male|Middle Aged|Aged, 80 and over|Female|Aged|Tomography, X-Ray Computed|Amyloidogenic Proteins|Alzheimer Disease|Amyloid|Amyloidosis|Brain|Magnetic Resonance Imaging|Amyloid beta-Peptides|Positron-Emission Tomography|Nerve Net|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Brain Mapping|Aging|Atrophy|Image Processing, Computer-Assisted|Neuropsychological Tests|Temporal Lobe	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7498941_20201005_0.5	flortaucipir	drug_umls_atom	Participants underwent  C Pittsburgh Compound-B (PiB) PET, F flortaucipir (FTP) PET, and resting-state MRI scans at baseline and longitudinal MRI (3.6 ± 0.96 scans; 5.04 ± 0.8 years).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5			Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Autopsy|Autoradiography|Carbolines|Cohort Studies|Female|Frontotemporal Lobar Degeneration|Humans|Male|Mesencephalon|Middle Aged|Neurofibrillary Tangles|Positron-Emission Tomography|Radiopharmaceuticals|Red Nucleus|Sensitivity and Specificity|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	 No section Twenty-four patients had [18 F]-flortaucipir-PET and died with FTLD (progressive supranuclear palsy [PSP], n = 10; corticobasal degeneration [CBD], n = 10; FTLD-TDP, n = 3; and Pick disease, n = 1).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	Flortaucipir standard uptake value ratios (SUVRs) were calculated in a temporal meta region of interest (meta-ROI), entorhinal cortex and cortical/subcortical regions selected to match the tau lesion analysis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	Flortaucipir correlated with neurofibrillary tangle counts in entorhinal cortex, but entorhinal and meta-ROI SUVRs were not elevated in Braak IV or primary age-related tauopathy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	Flortaucipir uptake patterns differed across FTLD pathologies and could separate PSP and CBD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	Flortaucipir correlated with tau lesion score in red nucleus and midbrain tegmentum across patients, but not in cortical or basal ganglia regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	Autoradiography demonstrated minimal uptake of flortaucipir, although flortaucipir correlated with quantitative tau burden across regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32869362_20210411_0.5	flortaucipir	drug_umls_atom	Regional flortaucipir uptake was able to separate CBD and PSP.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir|[|PET|Alzheimer’s|Tau|NFT|PHF|Autopsy|Histelide	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5			Middle Aged|Humans|Male|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Immunohistochemistry|Pilot Projects|Alzheimer Disease|Carbolines|tau Proteins|Cognitive Dysfunction|Amyloid beta-Peptides|Positron-Emission Tomography|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	Background The objective of this study was to make a quantitative comparison of flortaucipir PET retention with pathological tau and β-amyloid across a range of brain regions at autopsy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Patients with dementia (two with clinical diagnosis of AD, one undetermined), nearing the end of life, underwent 20-min PET, beginning 80 min after an injection of ~370 mBq flortaucipir [ F].	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	When Ptau and Aβ1-42 were both included in the model, the Ptau correlation with flortaucipir SUVr was preserved but there was no correlation of Aβ1-42 with flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	There was also a modest correlation between limbic (hippocampal/entorhinal and amygdala) flortaucipir SUVr and Ptau (Pearson r = 0.52; p < 0.080).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7295920_20201005_0.5	flortaucipir	drug_umls_atom	 Conclusions The results of this pilot study support a quantitative relationship between cortical flortaucipir SUVr values and quantitative measures of Ptau at autopsy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5			Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5	flortaucipir	drug_umls_atom	amyloid PET|cortical thickness, memory|flortaucipir PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid|Amyloid beta-Peptides|Brain|Cognition|Cognitive Dysfunction|Entorhinal Cortex|Female|Humans|Magnetic Resonance Imaging|Male|Memory|Middle Aged|Neuropsychological Tests|Positron-Emission Tomography|Tauopathies|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5	flortaucipir	drug_umls_atom	We evaluated non-demented subjects over age 50 years in the Mayo Clinic Study of Aging, 2037 of whom had undergone 3 T MRI scan, 985 amyloid PET scan with 11C-Pittsburgh compound B (PIB) and MRI, and 577 PIB-PET, 18F-AV1451 flortaucipir PET and MRI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5	flortaucipir	drug_umls_atom	We used Gradient Boosting Machine models to analyse the relationship between regional cortical thickness, flortaucipir PET signal, PIB-PET signal and memory z-scores.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5	flortaucipir	drug_umls_atom	Entorhinal flortaucipir PET signal, PIB-PET signal and entorhinal cortical thickness were independently and additively associated with declining memory z-scores.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5	flortaucipir	drug_umls_atom	In contrast to global PIB-PET signal where only very high amyloid-β levels were associated low memory z-scores, entorhinal flortaucipir PET signal just above background levels was associated with low memory z-scores.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30759182_20210111_0.5	flortaucipir	drug_umls_atom	The lowest memory z-scores occurred with the confluence of elevated entorhinal flortaucipir PET signal and lower entorhinal cortical thickness.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Aniline Compounds|Apolipoprotein E4|Brain|Carbolines|Contrast Media|Cross-Sectional Studies|Entorhinal Cortex|Ethylene Glycols|Female|Healthy Volunteers|Humans|Male|Middle Aged|Positron-Emission Tomography|Sex Factors|Temporal Lobe|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5	flortaucipir	drug_umls_atom	Data were collected between January 2016 and February 2018 from 193 clinically normal individuals from the Harvard Aging Brain Study (age range, 55-92 years; 118 women [61%]) who underwent carbon 11-labeled Pittsburgh Compound B and flortaucipir F18 PET and 103 clinically normal individuals from the Alzheimer's Disease Neuroimaging Initiative (age range, 63-94 years; 55 women [51%]) who underwent florbetapir and flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir PET|off-target binding|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5			Adult|Aged|Aged, 80 and over|Aniline Compounds|Brain|Brain Mapping|Carbolines|Female|Healthy Volunteers|Humans|Image Processing, Computer-Assisted|Linear Models|Magnetic Resonance Imaging|Male|Middle Aged|Positron-Emission Tomography|Protein Binding|Reproducibility of Results|Thiazoles|Young Adult	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	Along with aggregated tau in the form of neurofibrillary tangles, 18F-flortaucipir has been reported to bind to neuromelanin, monoamine oxidase, calcifications, iron, leptomeningeal melanocytes, and microhemorrages.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	Although 18F-flortaucipir successfully differentiates healthy controls (HCs) from subjects with Alzheimer disease, variability exists in the cortical signal in amyloid-negative HCs.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Subjects (n = 139) received 11C-Pittsburgh compound B (PIB) and 18F-flortaucipir PET scans and a magnetization-prepared rapid gradient echo MRI scan.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	In amyloid-negative HCs with 11C-PIB and 18F-flortaucipir scans, correlations were calculated between white and gray matter before and after partial-volume correction.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	 Results The correlation between white and gray matter disappeared after partial-volume correction in 11C-PIB (r 2 = 0) but persisted for 18F-flortaucipir (r 2 = 0.27), demonstrating that the correlation between white and gray matter signal in 18F-flortaucipir is not solely due to partial-volume effects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30877180_20201005_0.5	flortaucipir	drug_umls_atom	 Conclusion The noise in the 18F-flortaucipir measurement could pose challenges when studying early tau accumulation.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28394771_20201005_0.5			Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28394771_20201005_0.5			Age Factors|Age of Onset|Aged|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Atrophy|Cerebral Cortex|Ethylene Glycols|Female|Humans|Male|Middle Aged|Positron-Emission Tomography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28394771_20201005_0.5	flortaucipir	drug_umls_atom	BACKGROUND Flortaucipir (tau) positron emission tomography (PET) binding distinguishes individuals with clinically well-established posterior cortical atrophy (PCA) due to Alzheimer disease (AD) from cognitively normal (CN) controls.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28394771_20201005_0.5	flortaucipir	drug_umls_atom	 METHODS Flortaucipir and florbetapir (β-amyloid) PET imaging were performed in individuals with early-stage PCA (N=5), amnestic AD dementia (N=22), and CN controls (N=47).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28394771_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir uptake was higher in individuals with early-stage symptomatic PCA versus those with early-stage amnestic AD or CN controls, and greatest in posterior regions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28394771_20201005_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS Flortaucipir uptake distinguished individuals with PCA and amnestic AD dementia early in the symptomatic course.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir	drug_umls_atom	AV1451|SUVr|T807|flortaucipir|reference region	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5			Aged|Alzheimer Disease|Carbolines|Female|Humans|Image Processing, Computer-Assisted|Male|Positron-Emission Tomography|Reference Standards	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir	drug_umls_atom	We present a new technique, PERSI (Parametric Estimation of Reference Signal Intensity), for flortaucipir F 18 count normalization that leverages the advantages of white matter reference regions while mitigating potential partial-volume effects.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Subjects with a clinical diagnosis of Alzheimer disease, mild cognitive impairment, or normal cognition underwent T1-weighted MRI and florbetapir imaging (to determine amyloid [Aβ] status) at screening and flortaucipir F 18 imaging at single or multiple time points.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir F 18 images, acquired as 4 × 5 min frames 80 min after a 370-MBq injection, were motion-corrected, averaged, and transformed to Montreal Neurological Institute (MNI) space.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29191858_20201005_0.5	flortaucipir	drug_umls_atom	Baseline SUVr variability and ΔSUVr were minimal in Aβ control subjects with no specific flortaucipir F 18 uptake (SUVr, 1.0 ± 0.04; ΔSUVr, 0.0 ± 0.02).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5			MRI|PET|Primary progressive aphasia|Semantic dementia|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5			Aged|Brain|Carbolines|DNA-Binding Proteins|Dementia|Female|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Positron-Emission Tomography|Radiopharmaceuticals|TDP-43 Proteinopathies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	No section To assess volume loss and flortaucipir uptake in patients with semantic dementia (SD) over time.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	Eight SD patients (3 female) underwent clinical evaluations, flortaucipir positron emission tomography, and brain magnetic resonance imaging at 2 visits.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	Voxel-level comparisons of magnetic resonance imaging gray and white matter volume loss and flortaucipir positron emission tomography uptake were performed in SPM12, comparing SD patients to controls at each visit.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	T-tests on difference images and paired t-tests of flortaucipir uptake were also performed.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	White matter loss and flortaucipir uptake were noted in SD patients in the left temporal lobe only, which appeared to extend posteriorly, without involvement of the right hemisphere at follow-up.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	Longitudinal analyses did not support significant changes in flortaucipir uptake between visits.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	The biological mechanisms of flortaucipir signal in suspected underlying TAR-DNA binding protein 43 pathology are unknown.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32417749_20201214_0.5	flortaucipir	drug_umls_atom	A 1-year interval is not sufficient time to demonstrate significant longitudinal flortaucipir uptake changes in SD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	Flortaucipir|MAO-b|Neuroimaging|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5			Aged|Carbolines|Female|Humans|Male|Monoamine Oxidase|Monoamine Oxidase Inhibitors	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	Utilizing another tau-tracer, flortaucipir ([18F]AV-1451), we previously reported that non-demented Parkinson's disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	 No section We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson's disease patients who received MAO-B inhibitors with those who did not.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	We found no significant flortaucipir uptake differences between the groups at voxel or regional levels.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	 No section Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29127552_20201214_0.5	flortaucipir	drug_umls_atom	Thus, MAO-B does not appear to be a significant binding target of flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5			Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Biomarkers|CSF|Flortaucipir|PET|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5			Humans|Middle Aged|Male|Alzheimer Disease|tau Proteins|Amyloid beta-Peptides|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Peptide Fragments|Positron-Emission Tomography|Biomarkers|Sensitivity and Specificity|Phosphorylation	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33398408_20210611_0.5	flortaucipir	drug_umls_atom	OBJECTIVE To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer's Disease (AD) Research Framework derived from [18F]flortaucipir (FTP) PET visual assessment, FTP quantification, and cerebrospinal fluid (CSF) phosphorylated Tau-181 (PTau181).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	18F-Flortaucipir PET|Alzheimer disease|Dual reference tissues|Logan plot|SRTM|SUVR|Spatially constrained kinetic modeling	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5			Humans|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Carbolines|Positron-Emission Tomography|tau Proteins|Radiopharmaceuticals|Brain|Gray Matter|Magnetic Resonance Imaging|Kinetics|Cognition	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	OBJECTIVE Recent studies have shown that standard compartmental models using plasma input or the cerebellum reference tissue input are generally not reliable for quantifying tau burden in dynamic 18F-flortaucipir PET studies of Alzheimer disease.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	So far, the optimal reference region for estimating 18F-flortaucipir delivery and specific tau binding has yet to be determined.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	The objective of the study is to improve 18F-flortaucipir brain tau PET quantification using a spatially constrained kinetic model with dual reference tissues.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	T1-weighted structural MRI and 105-min dynamic 18F-flortaucipir PET scans were acquired for each participant.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	Cerebellum and CS are the suggested reference tissues to estimate R1 and DVR, respectively, for dynamic 18F-flortaucipir PET studies.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33599811_20210511_0.5	flortaucipir	drug_umls_atom	Cerebellum-based SUVREP and CS-based SUVRLP may be used to simplify 18F-flortaucipir PET study.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29538658_20201005_0.5			FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29538658_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Aniline Compounds|Autopsy|Cohort Studies|Dementia|Female|Fluorodeoxyglucose F18|Hippocampus|Humans|Magnetic Resonance Imaging|Male|Neuropsychological Tests|Positron-Emission Tomography|Sclerosis|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29538658_20201005_0.5	flortaucipir	drug_umls_atom	We evaluated the utility of 18F-FDG-PET to differentiate flortaucipir tau PET negative from flortaucipir positive amnestic mild cognitive impairment and dementia and used an autopsy confirmed cohort to test the hypothesis that hippocampal sclerosis might account for the observed pattern.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29538658_20201005_0.5	flortaucipir	drug_umls_atom	We identified impaired participants (Clinical Dementia Rating > 0) with amnestic presentations ≥ 75 years who had MRI and PET imaging with 18F-FDG (glucose metabolism), Pittsburgh compound B (amyloid) and flortaucipir (tau) performed within a year of cognitive assessment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	flortaucipir	drug_umls_atom	One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	flortaucipir	drug_umls_atom	AV-1451|SSM/PCA|T807|flortaucipir|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5			Aged|Amyloid|Carbolines|Case-Control Studies|Female|Humans|Male|Neurodegenerative Diseases|Positron-Emission Tomography	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	flortaucipir	drug_umls_atom	This study investigated the ability of 18F-flortaucipir PET not only to assess tau positivity but also to differentiate between amyloid-positive and -negative forms of neurodegeneration on the basis of different 18F-flortaucipir PET signatures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	flortaucipir	drug_umls_atom	 Methods The 18F-flortaucipir PET data of 35 patients with amyloid-positive neurodegeneration, 19 patients with amyloid-negative neurodegeneration, and 17 healthy controls were included in a data-driven scaled subprofile model (SSM)/principal-component analysis (PCA) identifying spatial covariance patterns.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	flortaucipir	drug_umls_atom	 Conclusion SSM/PCA-derived binding patterns of 18F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32620704_20210511_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5			Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5			Alzheimer's disease|affective symptoms|amyloid|mild cognitive impairment|neuropsychiatric symptoms|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5			Humans|Male|Female|Alzheimer Disease|Cross-Sectional Studies|Affective Symptoms|Tomography, X-Ray Computed|Cognitive Dysfunction|tau Proteins|Amyloid beta-Peptides|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Neuroimaging|Neuropsychological Tests|Amyloid|Atrophy|Amyloidosis|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33682933_20210611_0.5	flortaucipir	drug_umls_atom	 METHODS Cross-sectional NPS were assessed using the Neuropsychiatric Inventory (NPI) in 410 CN, 199 MCI, and 61 AD dementia participants who underwent flortaucipir tau positron emission tomography as part of the AD Neuroimaging Initiative (ADNI).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31339297_20201005_0.5			Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31339297_20201005_0.5	flortaucipir	drug_umls_atom	Alzheimer’s disease|flortaucipir|monoamine oxidase (MAO)|positron emission tomography (PET) imaging|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31339297_20201005_0.5			Aged|Animals|Autoradiography|Basal Ganglia|Carbolines|Choroid Plexus|Humans|Monoamine Oxidase|Monoamine Oxidase Inhibitors|Positron-Emission Tomography|Primates|Radiopharmaceuticals|Substantia Nigra	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28253546_20201005_0.5			Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28253546_20201005_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Cerebral Cortex|Female|Fluorodeoxyglucose F18|Humans|Male|Memory Disorders|Palmitates|Positron-Emission Tomography|Prognosis|Radiopharmaceuticals|Thiazoles|Thiones|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID28253546_20201005_0.5	flortaucipir	drug_umls_atom	 METHODS We acquired positron emission tomography using F18 flortaucipir (tau), C11 Pittsburgh compound B (amyloid), and F18 fluorodeoxyglucose (FDG) in 90 clinically normal elderly of the Harvard Aging Brain Study.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443955_20210611_0.5	flortaucipir	drug_umls_atom	Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443955_20210611_0.5			Humans|Female|Alzheimer Disease|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|florbetapir|MAPT protein, human|tau Proteins|Carbolines|Ethylene Glycols|Neurofibrillary Tangles|Aniline Compounds|Amyloid beta-Peptides|Cognitive Dysfunction|Plaque, Amyloid|Positron-Emission Tomography|Amyloid|Radiopharmaceuticals	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443955_20210611_0.5	flortaucipir	drug_umls_atom	18F-Flortaucipir PET was recently approved for evaluating the distribution and density of aggregated neurofibrillary tangles.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33443955_20210611_0.5	flortaucipir	drug_umls_atom	We present cases of mild cognitive impairment or suspected AD to depict the nuances of flortaucipir distribution and scan interpretation as well as how combined information from amyloid and tau PET may help with differential diagnosis and prognosis.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5			Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5			AV-1451|Alzheimer's disease|Autoradiography|MK6240|THK5117|Tau imaging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5			Alzheimer Disease|Autopsy|Brain|Humans|Neurofibrillary Tangles|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC8041708_20210511_0.5	flortaucipir	drug_umls_atom	Competitive binding assays were carried out between H-MK6240 and unlabelled MK6240, AV-1451 (aka T807, flortaucipir) and THK5117, and between H-THK5351 and unlabelled MK6240.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33461093_20210611_0.5			Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33461093_20210611_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|Amyloid|Autoimmune encephalitis|Flortaucipir|LGI1|PET imaging|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33461093_20210611_0.5			Aged, 80 and over|Alzheimer Disease|Autoantibodies|Autoantigens|Autoimmune Diseases|Encephalitis|Female|Humans|Intracellular Signaling Peptides and Proteins|Neuroimaging|Positron-Emission Tomography|Recurrence	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33461093_20210611_0.5	flortaucipir	drug_umls_atom	We leveraged emergent molecular biomarkers, including [18F]florbetapir (amyloid) and [18F]flortaucipir AV45 (tau) PET neuroimaging, to evaluate for common neurodegenerative causes of impairment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33461093_20210611_0.5	flortaucipir	drug_umls_atom	18F]Florbetapir and [18F]flortaucipir retention were increased in cerebral cortices in a pattern consistent with symptomatic Alzheimer's disease.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33461093_20210611_0.5	flortaucipir	drug_umls_atom	The patient died 2.4 months following [18F]flortaucipir PET neuroimaging.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32015176_20201005_0.5	flortaucipir	drug_umls_atom	Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32015176_20201005_0.5			Aged|Alzheimer Disease|Brain|Carbolines|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Radiopharmaceuticals|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32015176_20201005_0.5	flortaucipir	drug_umls_atom	No section To investigate relationships between flortaucipir (FTP) uptake, age, and established Alzheimer disease (AD) markers in asymptomatic adults at increased risk of AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30482786_20201005_0.5			Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30482786_20201005_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|PiB|excitotoxicity|fMRI|flortaucipir|memory	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30482786_20201005_0.5			Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Brain Mapping|Female|Hippocampus|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Positron-Emission Tomography|Psychomotor Performance|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|cerebrospinal fluid biomarkers|cognitive function|cortical thickness|flortaucipir|mild cognitive impairment|positron emission tomography|tau PET	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5			Humans|Male|Aged, 80 and over|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Alzheimer Disease|Carbolines|Cognitive Dysfunction|Amyloid beta-Peptides|tau Proteins|Cognition|Neuroimaging|Positron-Emission Tomography|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Neuropsychological Tests|Brain|Radiopharmaceuticals|Benzothiazoles|Magnetic Resonance Imaging|Longitudinal Studies	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	 No section To determine associations between 18F-flortaucipir PET and CSF AD biomarkers, cognitive functioning, and neuroimaging measures in MCI-AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	 No section In 29 participants 50 years or older with MCI-AD, 18F-flortaucipir PET, CSF total tau (T-tau), phosphorylated tau181p (P-tau), amyloid-β (Aβ), structural MRI, and neuropsychological testing were collected as baseline assessments of an ongoing clinical trial.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	Associations between 18F-flortaucipir PET and these measures were assessed by multiple linear regression adjusted for potential confounders and using global, lobar, and voxel-wise standardized uptake value ratio (SUVr).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	 No section Whole brain 18F-flortaucipir SUVr was significantly associated with CSF T-tau (r = 0.68, p < 0.001) and P-tau (r = 0.42, p = 0.04) after adjusting for age, sex, race, and education, with strongest associations in the temporal region (T-tau: r = 0.69, p < 0.001; P-tau: r = 0.49, p = 0.02).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir PET was also associated with CSF Aβ (r = -0.45, p = 0.03), episodic memory (r = -0.61, p = 0.001), visuospatial working memory (r = -0.46, p = 0.02), and brain cortical thickness (r = -0.44, p = 0.03) but not hippocampal volume.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	In the amyloid PET subset, although 11C-PiB PET associated strongly with 18F-flortaucipir (r = 0.79, p≤0.001), associations were stronger between 11C-PiB and key outcomes, compared to 18F-flortaucipir.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32065800_20201214_0.5	flortaucipir	drug_umls_atom	 No section 18F-flortaucipir PET is moderately associated with CSF AD biomarkers and other AD-related phenotypes.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5			The development and validation of tau PET tracers: current status and future directions	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5			Tau|Positron emission tomography|Neurofibrillary tangles|Alzheimer’s disease|Neurodegeneration|Aging	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5			Humans|tau Proteins|Tauopathies|Neurofibrillary Tangles|Alzheimer Disease|Positron-Emission Tomography|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Radiopharmaceuticals|Supranuclear Palsy, Progressive|Brain|Autoradiography|6-((3-fluoro-2-hydroxy)propoxy)-2-(4-methylaminophenyl)quinoline|Quinolines|THK5351|Aminopyridines|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6096533_20201005_0.5	flortaucipir	drug_umls_atom	 Results Different classes of tau tracers such as flortaucipir, THK5317, and PBB3 have been developed and utilized in previous clinical studies.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30926651_20201005_0.5			Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30926651_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir|Alzheimer disease|longitudinal study|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30926651_20201005_0.5			Aged|Alzheimer Disease|Atrophy|Biological Transport|Carbolines|Cognition|Disease Progression|Female|Follow-Up Studies|Humans|Image Processing, Computer-Assisted|Male|Neuropsychological Tests|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30926651_20201005_0.5	flortaucipir	drug_umls_atom	 Methods We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (18F-flortaucipir and 18F-florbetaben), MRI, and neuropsychologic tests.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30926651_20201005_0.5	flortaucipir	drug_umls_atom	18F-flortaucipir PET is an imaging biomarker for monitoring the progression of AD.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6299114_20201005_0.5			Regional tau pathology and loneliness in cognitively normal older adults	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6299114_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Entorhinal Cortex|Female|Humans|Loneliness|Male|Middle Aged|Positron-Emission Tomography|Self Report|Temporal Lobe|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6299114_20201005_0.5	flortaucipir	drug_umls_atom	Using flortaucipir positron emission tomography, we measured tau pathology in the entorhinal cortex, a region of initial accumulation in aging adults with or without elevated amyloid-β, and in the inferior temporal cortex, a region of early accumulation typically associated with elevated amyloid-β and memory impairment.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7705644_20210411_0.5	flortaucipir	drug_umls_atom	Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7705644_20210411_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|[18F]Flortaucipir|parametric methods|test-retest repeatability	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7705644_20210411_0.5			Aged|Alzheimer Disease|Amyloid beta-Peptides|Brain|Carbolines|Cognition|Cognitive Dysfunction|Female|Gray Matter|Humans|Male|Middle Aged|Neuropsychological Tests|Positron-Emission Tomography|Radiopharmaceuticals|Reproducibility of Results|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7705644_20210411_0.5	flortaucipir	drug_umls_atom	No section The aim of this study was to investigate the test-retest (TRT) repeatability of various parametric quantification methods for [ F]Flortaucipir positron emission tomography (PET).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7705644_20210411_0.5	flortaucipir	drug_umls_atom	All underwent two 130-min dynamic [ F]Flortaucipir PET scans within 3 ± 1 weeks.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5			CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5			amyloid beta|apolipoprotein E|cerebrospinal fluid markers|cognitive impairment|family history of Alzheimer's disease|glucose|positron magnetic imaging|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5			Humans|Female|Adult|Alzheimer Disease|Amyloid beta-Peptides|Risk Factors|Apolipoprotein E4|tau Proteins|Cognitive Dysfunction|Disease Progression|Neuroimaging|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Positron-Emission Tomography|Brain|Biomarkers|Glucose	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Cerebrospinal fluid (CSF) glucose was linearly regressed on regional tau (flortaucipir) among 169 Alzheimer's Disease Neuroimaging Initiative (ADNI3) participants.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7443745_20201005_0.5	flortaucipir	drug_umls_atom	Flortaucipir uptake was examined by Braak stages and regions of interest (ROIs).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32273431_20210211_0.5			The presubiculum links incipient amyloid and tau pathology to memory function in older persons.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32273431_20210211_0.5			Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloidogenic Proteins|Female|Hippocampus|Humans|Magnetic Resonance Imaging|Male|Memory|Parahippocampal Gyrus|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID32273431_20210211_0.5	flortaucipir	drug_umls_atom	 No section A total of 127 individuals from the Harvard Aging Brain Study (mean age 76.22 ± 6.42 years, 68 women [53.5%]) with a Clinical Dementia Rating score of 0, a flortaucipir tau-PET scan, a Pittsburgh compound B amyloid-PET scan, a structural MRI scan, and cognitive testing were included.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30790403_20201005_0.5			Tau positron emission tomography imaging in C9orf72 repeat expansion carriers.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30790403_20201005_0.5			AV-1451|C9orf72|amyotrophic lateral sclerosis|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30790403_20201005_0.5			Aged|C9orf72 Protein|Cognitive Dysfunction|Cohort Studies|DNA Repeat Expansion|Entorhinal Cortex|Female|Heterozygote|Humans|Male|Middle Aged|Positron-Emission Tomography|Tauopathies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30790403_20201005_0.5	flortaucipir	drug_umls_atom	No section AV-1451 (18 F-AV-1451, flortaucipir) positron emission tomography was performed in C9orf72 expansion carriers to assess tau accumulation and disease manifestation.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31199481_20201005_0.5			Alzheimer's pathology targets distinct memory networks in the ageing brain.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31199481_20201005_0.5			anterior-temporal (AT)|hyperactivation|memory|posterior-medial (PM)|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31199481_20201005_0.5			Adult|Aged|Aged, 80 and over|Aging|Alzheimer Disease|Amyloid beta-Peptides|Brain|Cognitive Dysfunction|Cross-Sectional Studies|Female|Humans|Magnetic Resonance Imaging|Male|Memory|Middle Aged|Positron-Emission Tomography|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31199481_20201005_0.5	flortaucipir	drug_umls_atom	11C-PiB PET and 18F-flortaucipir uptake was quantified in a sample of 131 cognitively normal adults (age: 20-93 years; 47 amyloid-β-positive) and 20 amyloid-β-positive patients with mild cognitive impairment or Alzheimer's disease dementia (65-95 years).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID31199481_20201005_0.5	flortaucipir	drug_umls_atom	In a multiple regression model including regional measures of both pathologies, higher anterior-temporal flortaucipir (tau) was related to relatively worse object performance (P = 0.010, r = -0.376), whereas higher posterior-medial PiB (amyloid-β) was related to worse scene performance (P = 0.037, r = 0.309).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5			Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5			Thickness|Atrophy|Tau|Amyloid|PET|Positron emission tomography|MRI	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5			Aged, 80 and over|Aged|Middle Aged|Humans|Female|Amyloid beta-Peptides|Cross-Sectional Studies|Positron-Emission Tomography|Alzheimer Disease|Atrophy|tau Proteins|Cognitive Dysfunction|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Carbolines|Brain|Ethylene Glycols|Radiopharmaceuticals|Magnetic Resonance Imaging|Aniline Compounds|Neuropsychological Tests|Cerebral Cortex	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5956934_20201005_0.5	flortaucipir	drug_umls_atom	 Methods Aβ pathology was measured with [ F] AV-45 (florbetapir) positron emission tomography (PET) and tau was assessed with [ F] AV-1451 (flortaucipir) PET in a population of 178 older adults, of which 123 had longitudinal magnetic resonance imaging assessments (average of 5.7 years) that preceded the PET acquisitions.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	Evaluation of a visual interpretation method for tau‐PET with 18F‐flortaucipir	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|flortaucipir|qualitative assessment|tau positron emission tomography|visual assessment	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5			Humans|Male|Middle Aged|Female|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Tomography, X-Ray Computed|Carbolines|Alzheimer Disease|tau Proteins|Positron-Emission Tomography|Cognitive Dysfunction|Amyloid beta-Peptides|Amyloid|Brain|Radiopharmaceuticals	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	 Methods We developed a visual interpretation method for F‐flortaucipir tau‐PET and tested it on 274 individuals (cognitively normal controls, patients with mild cognitive impairment [MCI], AD dementia, and non‐AD diagnoses).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	Two readers interpreted F‐flortaucipir PET using two complementary indices: a global visual score and a visual distribution pattern.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	 Results Global visual scores were reliable, correlated with global cortical F‐flortaucipir standardized uptake value ratio (SUVR) and were associated with clinical diagnosis and amyloid status.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	The AD‐like F‐flortaucipir pattern had good sensitivity and specificity to identify amyloid‐positive patients with AD dementia or MCI.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7699207_20210211_0.5	flortaucipir	drug_umls_atom	 Discussion This F‐flortaucipir visual rating scheme is associated with SUVR quantification, clinical diagnosis, and amyloid status, and constitutes a promising approach to tau measurement in clinical settings.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30969506_20201005_0.5			Tau Positron-Emission Tomography in Former National Football League Players.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30969506_20201005_0.5			Adult|Aged|Aniline Compounds|Brain|Brain Chemistry|Brain Concussion|Case-Control Studies|Chronic Traumatic Encephalopathy|Cognition Disorders|Ethylene Glycols|Football|Humans|Male|Mental Disorders|Middle Aged|Plaque, Amyloid|Positron-Emission Tomography|Radiopharmaceuticals|Tauopathies|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30969506_20201005_0.5	flortaucipir	drug_umls_atom	 No section We used flortaucipir positron-emission tomography (PET) and florbetapir PET to measure deposition of tau and amyloid-beta, respectively, in the brains of former National Football League (NFL) players with cognitive and neuropsychiatric symptoms and in asymptomatic men with no history of traumatic brain injury.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30969506_20201005_0.5	flortaucipir	drug_umls_atom	The mean flortaucipir SUVR was higher among former players than among controls in three regions of the brain: bilateral superior frontal (1.09 vs. 0.98; adjusted mean difference, 0.13; 95% confidence interval [CI], 0.06 to 0.20; P<0.001), bilateral medial temporal (1.23 vs. 1.12; adjusted mean difference, 0.13; 95% CI, 0.05 to 0.21; P<0.001), and left parietal (1.12 vs. 1.01; adjusted mean difference, 0.12; 95% CI, 0.05 to 0.20; P = 0.002).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5			Adult|Age Factors|Alzheimer Disease|Amyloid|Aniline Compounds|Brain|Carbolines|Cognition Disorders|Colombia|Cross-Sectional Studies|Female|Humans|Magnetic Resonance Imaging|Male|Mental Status and Dementia Tests|Middle Aged|Mutation|Neuropsychological Tests|Positron-Emission Tomography|Presenilin-1|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir	drug_umls_atom	Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir	drug_umls_atom	 No section We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID29435558_20210111_0.5	flortaucipir	drug_umls_atom	Spearman correlations characterized the associations between age and mean cortical Pittsburgh Compound B distribution volume ratio levels or regional flortaucipir standardized uptake value ratio levels in both groups.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34041562_20210611_0.5	flortaucipir	drug_umls_atom	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34041562_20210611_0.5	flortaucipir	drug_umls_atom	PET|Tau|[18F]Flortaucipir|[18F]MK6240|[18F]RO948	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34041562_20210611_0.5	flortaucipir	drug_umls_atom	OBJECTIVE This study aims to determine whether comparable target regions of interest (ROIs) and cut-offs can be used across [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau positron emission tomography (PET) tracers for differential diagnosis of Alzheimer's disease (AD) dementia vs either cognitively unimpaired (CU) individuals or non-AD neurodegenerative diseases.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34041562_20210611_0.5	flortaucipir	drug_umls_atom	 METHODS A total of 1755 participants underwent tau PET using either [18F]flortaucipir (n = 975), [18F]RO948 (n = 493), or [18F]MK6240 (n = 287).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34041562_20210611_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS The temporal meta-ROI can be used for differential diagnosis of dementia patients with [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET with high accuracy, and that using very similar cut-offs of around 1.35 SUVR.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33931538_20210511_0.5			Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33931538_20210511_0.5	flortaucipir	drug_umls_atom	 METHODS Three hundred seventy-one cognitively unimpaired and impaired participants enrolled in longitudinal studies of AD had both CSF (amyloid-β42, phosphorylated tau181, total tau, and neurofilament light chain) and neuroimaging (PiB PET, flortaucipir PET, and structural MRI) measures.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33931538_20210511_0.5	flortaucipir	drug_umls_atom	CSF phosphorylated tau181 and flortaucipir PET showed maximal correlation when CSF was collected four to eight years prior to PET (R ≈ 0.4).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33931538_20210511_0.5	flortaucipir	drug_umls_atom	 CONCLUSIONS CSF amyloid-β42 and PiB PET best agree when acquired in close temporal proximity, whereas CSF phosphorylated tau precedes flortaucipir PET by four to eight years.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5			Humans|Male|Aged|Female|Aged, 80 and over|7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Amyloid beta-Peptides|Cohort Studies|Tomography, X-Ray Computed|Carbolines|Cognitive Dysfunction|Positron-Emission Tomography|Alzheimer Disease|tau Proteins|2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole|Aniline Compounds|Neuroimaging|Brain|Aging|Radiopharmaceuticals|Neuropsychological Tests|Magnetic Resonance Imaging|Thiazoles	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	 UNASSIGNED This cohort study included individuals aged 65 to 85 years who were CU and had participated in the Mayo Clinic Study of Aging, with serial cognitive assessments, serial magnetic resonance imaging, 11C-Pittsburgh compound B (Aβ) PET scans, and 18F-flortaucipir PET scans, collected from May 2015 to March 2020.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	 UNASSIGNED Changes over a mean of 2.7 (range, 1.1-4.1) years in flortaucipir PET in entorhinal, inferior temporal, and lateral parietal regions of interest and an AD meta-region of interest (ROI).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	In the Mayo Clinic Study of Aging, longitudinal flortaucipir accumulation rates in the high Aβ group were greater than the suprathreshold, subthreshold, and low Aβ groups in the entorhinal ROI (suprathreshold, 0.025 [95% CI, 0.013-0.037] standardized uptake value ratio [SUVR] units; subthreshold, 0.026 [95% CI, 0.014-0.037] SUVR units; low Aβ, 0.034 [95% CI, 0.02-0.049] SUVR units), inferior temporal ROI (suprathreshold, 0.025 [95% CI, 0.014-0.035] SUVR units; subthreshold, 0.027 [95% CI, 0.017-0.037] SUVR units; low Aβ, 0.035 [95% CI, 0.022-0.047] SUVR units), and the AD meta-ROI (suprathreshold, 0.023 [95% CI, 0.013-0.032] SUVR units; subthreshold, 0.025 [95% CI, 0.016-0.034] SUVR units; low Aβ, 0.032 [95% CI, 0.021-0.043] SUVR units) (all P < .001).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	Flortaucipir accumulation rates in the subthreshold and suprathreshold Aβ groups in temporal regions were nonsignificantly elevated compared with the low Aβ group.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	In the ADNI cohort, the variance was larger than in the Mayo Clinic Study of Aging but point estimates for annualized flortaucipir accumulation in the inferior temporal ROI were very similar.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	An estimated 216 participants who were CU per group with PET Aβ of 68 CL or more would be needed to detect a 25% annualized reduction in flortaucipir accumulation rate in the AD meta-ROI with 80% power.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33074304_20210511_0.5	flortaucipir	drug_umls_atom	 UNASSIGNED Substantial flortaucipir accumulation in temporal regions is greatest in persons aged 65 to 85 years who were CU and had high initial Aβ PET levels, compared with those with lower Aβ levels.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882543_20210311_0.5			Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882543_20210311_0.5	flortaucipir	drug_umls_atom	Alzheimer's disease|amyloid|beta-site amyloid precursor protein-cleaving enzyme BACE inhibitor|cerebral metabolism|cerebral perfusion|florbetapir|flortaucipir|fluorodeoxyglucose|lanabecestat|magnetic resonance imaging|mild cognitive impairment|positron emission tomography|tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882543_20210311_0.5			Humans|Male|Middle Aged|Female|Alzheimer Disease|Amyloid beta-Peptides|Activities of Daily Living|Double-Blind Method|Tomography, X-Ray Computed|Neuroimaging|tau Proteins|Positron-Emission Tomography|Plaque, Amyloid|florbetapir|Ethylene Glycols|Brain|Amyloid beta-Protein Precursor|Cognitive Dysfunction|Magnetic Resonance Imaging|Peptide Fragments|Mental Status and Dementia Tests|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC7882543_20210311_0.5	flortaucipir	drug_umls_atom	Florbetapir positron emission tomography (PET), fluorodeoxyglucose (FDG) PET, flortaucipir PET, and volumetric magnetic resonance imaging (MRI) were used to measure Aβ neuritic plaque burden, cerebral metabolism, aggregated tau neurofibrillary tangles, and brain volume, respectively.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33477009_20210611_0.5			Association of enlarged perivascular spaces with Aβ and tau deposition in cognitively normal older population.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33477009_20210611_0.5	flortaucipir	drug_umls_atom	Enlarged perivascular spaces|Florbetapir|Flortaucipir|MRI	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33477009_20210611_0.5			Humans|Male|Female|Middle Aged|Tomography, X-Ray Computed|Cerebral Small Vessel Diseases|Data Management|Magnetic Resonance Imaging|Basal Ganglia|florbetapir|Ethylene Glycols|Neuroimaging|Positron-Emission Tomography|Cognition|Alzheimer Disease|Logistic Models|Corpus Callosum|Aniline Compounds	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33477009_20210611_0.5	flortaucipir	drug_umls_atom	All the subjects underwent brain MRI, florbetapir positron emission tomography (PET), and flortaucipir PET examinations.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID33477009_20210611_0.5	flortaucipir	drug_umls_atom	High degree of CSO-EPVS was associated with flortaucipir PET positivity (OR: 2.24, 95% CI: 1.02-4.93).	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049062_20210611_0.5			Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049062_20210611_0.5			Alzheimer's disease|Amyloid|Apolipoprotein E|Positron emission tomography|Sex differences|Tau	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049062_20210611_0.5	flortaucipir	drug_umls_atom	Patients underwent 3T-MRI, 11C-PIB amyloid-PET and 18F-Flortaucipir tau-PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049062_20210611_0.5	flortaucipir	drug_umls_atom	Linear ordinary least squares regression models tested sex differences in Flortaucipir-PET SUVR in a summary temporal region of interest as well as global PIB-PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049062_20210611_0.5	flortaucipir	drug_umls_atom	Females had higher global PIB SUVR (ηp2=.043, p=.025) and temporal Flortaucipir SUVR (ηp2=.070, p=.004), adjusting for age and CDR-SoB. Sex differences in temporal Flortaucipir-PET remained significant when controlling additionally for PIB SUVR and APOE4 status (ηp2=.055, p=.013), or when using partial volume-corrected data.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID34049062_20210611_0.5	flortaucipir	drug_umls_atom	No sex differences were present in areas of known Flortaucipir off-target binding.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6093830_20201005_0.5	[18f] flortaucipir	drug_umls_atom	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC6093830_20201005_0.5			Hippocampus|Positron-Emission Tomography|Temporal Lobe|Fluorodeoxyglucose F18|Radiopharmaceuticals|Phantoms, Imaging|Image Processing, Computer-Assisted|Algorithms|Brain	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5			Aged|Aged, 80 and over|Amyloid beta-Peptides|Aniline Compounds|Apolipoprotein E4|Brain|Carbolines|Contrast Media|Cross-Sectional Studies|Entorhinal Cortex|Ethylene Glycols|Female|Healthy Volunteers|Humans|Male|Middle Aged|Positron-Emission Tomography|Sex Factors|Temporal Lobe|Thiazoles|tau Proteins	mesh_terms
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMID30715078_20201005_0.5	flortaucipir f18	drug_umls_atom	Data were collected between January 2016 and February 2018 from 193 clinically normal individuals from the Harvard Aging Brain Study (age range, 55-92 years; 118 women [61%]) who underwent carbon 11-labeled Pittsburgh Compound B and flortaucipir F18 PET and 103 clinically normal individuals from the Alzheimer's Disease Neuroimaging Initiative (age range, 63-94 years; 55 women [51%]) who underwent florbetapir and flortaucipir F 18 PET.	abstract
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			An updated radiosynthesis of [18F]AV1451 for tau PET imaging	title
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5	flortaucipir f18	drug_umls_atom	Tau imaging|Brain PET|[|Flortaucipir F18|Fluorine-18 radiochemistry|Automated radiosynthesis	author_keywords
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	C3885550	tauvid|t-807|ly-3191748	t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole	flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18	inn	PubMed	PMC5824695_20201005_0.5			7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole|Positron-Emission Tomography|Radiopharmaceuticals|Carbolines|Fluorine Radioisotopes|tau Proteins|Alzheimer Disease|Radiochemistry|Tauopathies|Chromatography, High Pressure Liquid	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21597785_20201005_0.5			Phase-ii trial of oral doxifluridine plus oral levo-leucovorin in unresectable hepatocellular-carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21597785_20201005_0.5	levoleucovorin	drug_name	Middle Aged|Adult|Aged|Male|Humans|Female|Mice|Animals|doxifluridine|Carcinoma, Hepatocellular|Levoleucovorin|Liver Neoplasms|Floxuridine|Leucovorin|Antineoplastic Combined Chemotherapy Protocols|Drug Administration Schedule	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8458180_20201005_0.5	levoleucovorin	drug_name	Bioequivalence of oral and injectable levoleucovorin and leucovorin.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8458180_20201005_0.5			Administration, Oral|Adult|Biological Availability|Humans|Injections|Leucovorin|Male|Stereoisomerism|Tetrahydrofolates|Therapeutic Equivalency	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8458180_20201005_0.5	levoleucovorin	drug_name	No section The bioequivalence and bioavailability of oral and intravenous formulations of levoleucovorin and leucovorin were studied, and the absolute bioavailabilities of levoleucovorin and leucovorin tablet formulations were determined.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8458180_20201005_0.5	levoleucovorin	drug_name	The treatment groups were as follows: A = five 2.5-mg levoleucovorin tablets, B = five 5-mg leucovorin tablets, C = one 12.5-mg levoleucovorin tablet, D = one 25-mg leucovorin tablet, in study 1; A = 15-mg levoleucovorin injection, B = two 7.5-mg levoleucovorin tablets, C = 30-mg leucovorin injection, D = two 15-mg leucovorin tablets, in study 2.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8458180_20201005_0.5	levoleucovorin	drug_name	Results from 35 men in study 1 and 33 in study 2 showed that 12.5-mg oral doses and 15-mg intravenous doses of levoleucovorin are bioequivalent to 25-mg oral doses and 30-mg intravenous doses of leucovorin, respectively.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8458180_20201005_0.5	levoleucovorin	drug_name	The absolute bioavailability of levoleucovorin (74%) was not significantly different from that of leucovorin (65%).(ABSTRACT TRUNCATED AT 250 WORDS)	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5			Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Antineoplastic Combined Chemotherapy Protocols|Disseminated Intravascular Coagulation|Female|Fluorouracil|Gastrectomy|Humans|Levoleucovorin|Stomach Neoplasms|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29335817_20201005_0.5			Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29335817_20201005_0.5			AMPK|Drug repurposing|FDA-approved drugs|Virtual screening	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29335817_20201005_0.5			Adenylate Kinase|Animals|Catalytic Domain|Computer-Aided Design|Drug Design|Drug Discovery|Drug Evaluation, Preclinical|Drug Repositioning|Enzyme Activation|Humans|Hydrogen Bonding|Ligands|Longevity|Molecular Docking Simulation|Molecular Dynamics Simulation|United States|United States Food and Drug Administration|User-Computer Interface	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29335817_20201005_0.5	levoleucovorin	drug_name	As Cangrelor, Nacitentan, Levoleucovorin and Glisoxepide had lower binding affinities; we predicted that they would probably prove to be more potential activators than C2.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7581941_20210111_0.5			Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7581941_20210111_0.5			antifolates|belinostat|diffuse B-cell lymphoma|histone deacetylase inhibitors|peripheral T-cell lymphoma|pralatrexate	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7581941_20210111_0.5			Humans|Histone Deacetylase Inhibitors|belinostat|10-propargyl-10-deazaaminopterin|Folic Acid Antagonists|Hydroxamic Acids|Sulfonamides|Aminopterin|Methotrexate|Apoptosis|Cell Cycle|Reduced Folate Carrier Protein|Cell Line, Tumor|Lymphoma, T-Cell, Peripheral|Lymphoma, B-Cell	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7581941_20210111_0.5	levoleucovorin	drug_name	PLX showed a 6-fold better RFC substrate affinity compared to methotrexate, and 2-fold better than levoleucovorin (l-LV).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9703859_20201005_0.5			Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9703859_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Alopecia|Anemia|Antineoplastic Combined Chemotherapy Protocols|Diarrhea|Drug Administration Schedule|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Leukopenia|Levoleucovorin|Male|Middle Aged|Prognosis|Stomach Neoplasms|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8204376_20201005_0.5			Bioavailability of oral etoposide in gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8204376_20201005_0.5	levoleucovorin	drug_name	Administration, Oral|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Biological Availability|Etoposide|Fluorouracil|Gastrectomy|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7278329_20201005_0.5			Letter to the editor: Re: Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol. 2019	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7278329_20201005_0.5	levoleucovorin	drug_name	Humans|Levoleucovorin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5			Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5			colorectal cancer|folinic acid|non oncogene addiction|sodium levofolinate|thymidylate synthase	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5	levoleucovorin	drug_name	Humans|Middle Aged|Female|Leucovorin|Retrospective Studies|Colorectal Neoplasms|Colonic Neoplasms|Fluorouracil|Thymidylate Synthase|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Antineoplastic Agents|Levoleucovorin|Antimetabolites	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	Is levoleucovorin an alternative to racemic leucovorin? A literature review.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5			Antimetabolites, Antineoplastic|Fluorouracil|Gastrointestinal Neoplasms|Humans|Leucovorin|Stereoisomerism	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	OBJECTIVE Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	 METHODS This is an extensive literature review of levoleucovorin use in patients with gastrointestinal tract malignancies.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	 RESULTS Upon our review, there were 2 randomized controlled trials that directly compared racemic leucovorin with levoleucovorin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	In addition, multiple other studies, including randomized, controlled; nonrandomized, controlled; and case studies, demonstrate similar efficacy and tolerability between the use of racemic leucovorin or levoleucovorin as a modulator of 5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	 CONCLUSIONS In many studies of patients with gastrointestinal malignancies, levoleucovorin has been used interchangeably and solely for racemic leucovorin for 5-FU modulation.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19822510_20201005_0.5	levoleucovorin	drug_name	Our literature review demonstrates that levoleucovorin has similar efficacy and tolerability when compared with racemic leucovorin, whether used in combination with other chemotherapeutic agents or alone.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19538878_20201214_0.5			[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19538878_20201214_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Aged|Anemia|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Signet Ring Cell|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Leukopenia|Levoleucovorin|Male|Middle Aged|Nausea|Neoplasm Staging|Organoplatinum Compounds|Oxaliplatin|Remission Induction|Stomach Neoplasms|Survival Rate|Thrombocytopenia|Vomiting	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21607506_20201214_0.5			A short-term infusion regimen of Cisplatin, 5-Fluorouracil and L-folinic Acid in advanced head and neck-carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21607506_20201214_0.5	levoleucovorin	drug_name	Humans|Male|Middle Aged|Female|Cisplatin|Fluorouracil|Leucovorin|Head and Neck Neoplasms|Levoleucovorin|Carcinoma, Squamous Cell|Antineoplastic Combined Chemotherapy Protocols|Remission Induction|Vomiting|Leukopenia	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	Levoleucovorin as replacement for leucovorin in cancer treatment.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	Antineoplastic Agents|Drug Interactions|Humans|Levoleucovorin|Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	OBJECTIVE To comprehensively review the literature regarding the efficacy, safety, and costs associated with the use of levoleucovorin in cancer treatment and to assess whether levoleucovorin would be a reasonable alternative to the use of racemic leucovorin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	 METHODS A MEDLINE search was conducted for English-language human studies published between January 1980 and April 2012 using the terms l-LV, levoleucovorin, d,l-LV, leucovorin, folinic acid, folinate, 5-formyltetrahydrofolate, folic acid, folates, methotrexate, 5-fluorouracil, and clinical trials.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	 METHODS Articles pertinent to clinical trials (Phase 1, 2, 3) related to evaluating the efficacy, interchangeability, and safety of levoleucovorin were collected and their contents reviewed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	 RESULTS From these pharmacokinetics and clinical studies, information on the use of levoleucovorin as a modulator of fluorouracil as well as when combined with other antitumor agents were scrutinized and extracted for comparison with leucovorin whenever possible.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	Two randomized Phase 3 clinical studies comparing the efficacy and adverse effect profiles of leucovorin and levoleucovorin demonstrated that levoleucovorin is as effective as leucovorin in terms of response, toxicity, and survival.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	Six randomized Phase 3 clinical studies demonstrated the safety and efficacy of levoleucovorin as a modulator of fluorouracil in combination with/without other antitumor agents in colorectal cancer patients.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	Levoleucovorin has been studied in other cancers.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	These clinical Phase 1/2/3 studies demonstrated efficacy and safety of levoleucovorin in combination chemotherapeutic regimens comprising fluorouracil and other antitumor agents.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	 CONCLUSIONS The results of the clinical studies suggest that levoleucovorin is efficacious and can be used safely in combination with fluorouracil and other antitumor agents.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	Levoleucovorin can be used interchangeably with leucovorin for modulating fluorouracil.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23032661_20201005_0.5	levoleucovorin	drug_name	The current shortage of the supply of leucovorin centered in North America renders levoleucovorin a reasonable alternative in terms of efficacy and toxicity profile, but from the perspective of cost, leucovorin remains the drug of choice.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5			Role of Intramuscular Levofolinate Administration in the Treatment of Hereditary Folate Malabsorption: Report of Three Cases.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5			CSF 5-MTHF|Hereditary folate malabsorption|Intramuscular|Levofolinic acid|Treatment	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5	levoleucovorin	drug_name	Infant, Newborn|Humans|Female|Folate Malabsorption, Hereditary|Folic Acid Deficiency|SLC46A1 protein, human|Proton-Coupled Folate Transporter|Malabsorption Syndromes|5-methyltetrahydrofolate|Tetrahydrofolates|Folic Acid|Leucovorin|Levoleucovorin|Mutation	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9849466_20201005_0.5			Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9849466_20201005_0.5	levoleucovorin	drug_name	Administration, Oral|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Stomach Neoplasms|Tegafur|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22790056_20201005_0.5			[A case of colorectal neuroendocrine carcinoma effectively treated with bevacizumab+levofolinate+5-FU chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22790056_20201005_0.5	levoleucovorin	drug_name	Aged|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Carcinoma, Neuroendocrine|Colorectal Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Levoleucovorin|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2409717_20201005_0.5			High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2409717_20201005_0.5			gastric cancer|preoperative chemotherapy|curative resection|neoadjuvant	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2409717_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Disease-Free Survival|Drug Administration Schedule|Epirubicin|Female|Filgrastim|Fluorouracil|Glutathione|Granulocyte Colony-Stimulating Factor|Humans|Leucovorin|Leukopenia|Levoleucovorin|Male|Middle Aged|Neoadjuvant Therapy|Recombinant Proteins|Stomach Neoplasms|Thrombocytopenia|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27664775_20201005_0.5			The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27664775_20201005_0.5	levoleucovorin	drug_name	5-Formyltetrahydrofolate (PubChem CID: 143)|5-Methyltetrahydrofolate (PubChem CID: 439234)|CFD|Cerebral folate deficiency|FRα|Folate receptors|Folates|Folic acid|Folic acid (PubChem CID: 6037)|HFM|Hereditary folate malabsorption|Levoleucovorin (PubChem CID: 149436)|Levomefolic acid (PubChem CID: 444412)|Methotrexate|Methotrexate (PubChem CID: 126941)|PCFT|Pemetrexed|Pemetrexed (PubChem CID: 446556)|Proton-coupled folate transporter|RFC|Reduced folate carrier|SLC19A1|SLC46A1	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27664775_20201005_0.5			Animals|Biological Transport|Folic Acid Deficiency|Humans|Intestinal Absorption|Malabsorption Syndromes|Models, Molecular|Proton-Coupled Folate Transporter	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10894863_20201005_0.5			Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10894863_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Doxorubicin|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Methotrexate|Middle Aged|Proportional Hazards Models|Stomach Neoplasms|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7944483_20201005_0.5			[Chemotherapy of scirrhous gastric cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7944483_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma, Scirrhous|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Doxorubicin|Etoposide|Fluorouracil|Humans|Interferon alpha-2|Interferon-alpha|Leucovorin|Levoleucovorin|Mitomycin|Nimustine|Recombinant Proteins|Stomach Neoplasms|Tegafur|Uracil	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3499257_20201005_0.5			Local recurrence of gastric cancer after total gastrectomy: an unusual presentation	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3499257_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Etoposide|Fluorouracil|Gastrectomy|Humans|Levoleucovorin|Male|Neoplasm Recurrence, Local|Stomach Neoplasms|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10078785_20201005_0.5			Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10078785_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Stomach Neoplasms|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9093725_20201005_0.5			Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9093725_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Quality of Life|Stomach Neoplasms|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5103437_20201005_0.5			Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5103437_20201005_0.5			Cost-minimization analysis|Cost-effectiveness|Colorectal cancer|Adjuvant chemotherapy|Regimen selection	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5103437_20201005_0.5	levoleucovorin	drug_name	PRC|Humans|Chemotherapy, Adjuvant|Costs and Cost Analysis|Japan|Retrospective Studies|oxaliplatin|Organoplatinum Compounds|Colorectal Neoplasms|Fluorouracil|Capecitabine|S 1 (combination)|Tegafur|Levoleucovorin|Oxonic Acid|Uracil|gimeracil|Pyridines|Fees, Medical|Hospitals	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5			Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5			Aflibercept|Anti-VEGF drug|Bevacizumab|Colorectal cancer|FOLFIRI|FOLFOXIRI|Second line	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5	levoleucovorin	drug_name	Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Clinical Trials, Phase II as Topic|Colorectal Neoplasms|Female|Fluorouracil|Follow-Up Studies|Humans|Irinotecan|Levoleucovorin|Male|Middle Aged|Multicenter Studies as Topic|Oxaliplatin|Prognosis|Prospective Studies|Receptors, Vascular Endothelial Growth Factor|Recombinant Fusion Proteins|Survival Rate|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16201130_20201005_0.5			Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16201130_20201005_0.5	levoleucovorin	drug_name	Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Etoposide|Female|Fluorouracil|Gastrectomy|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4438152_20201005_0.5			A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4438152_20201005_0.5	levoleucovorin	drug_name	PRC|Humans|Female|Fluorouracil|Cetuximab|Hepatectomy|irinotecan|Leucovorin|Infusions, Intra-Arterial|Antineoplastic Combined Chemotherapy Protocols|Neoplasm Recurrence, Local|Levoleucovorin|Camptothecin|Liver Neoplasms|oxaliplatin|Organoplatinum Compounds|Sigmoid Neoplasms|panitumumab|Antibodies, Monoclonal|Combined Modality Therapy|Adenocarcinoma|Lymphatic System	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8596132_20201005_0.5			Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8596132_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Cost-Benefit Analysis|Doxorubicin|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Mitomycin|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8174205_20201005_0.5			Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8174205_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Etoposide|Female|Fluorouracil|Humans|Interferon alpha-2|Interferon-alpha|Leucovorin|Levoleucovorin|Male|Pilot Projects|Recombinant Proteins|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24773330_20201005_0.5			Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24773330_20201005_0.5	levoleucovorin	drug_name	Antidotes|Azabicyclo Compounds|Benzhydryl Compounds|Bronchodilator Agents|Central Nervous System Stimulants|Cetirizine|Dexlansoprazole|Dexmethylphenidate Hydrochloride|Drug Approval|Drug Prescriptions|Drugs, Generic|Esomeprazole|Eszopiclone|Ethanolamines|Formoterol Fumarate|Histamine H1 Antagonists, Non-Sedating|Humans|Hypnotics and Sedatives|Levoleucovorin|Medicaid|Modafinil|Patents as Topic|Piperazines|Proton Pump Inhibitors|Retrospective Studies|Stereoisomerism|United States|United States Food and Drug Administration|Wakefulness-Promoting Agents	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24773330_20201005_0.5	levoleucovorin	drug_name	 RESULTS From 2001 to 2011, the FDA approved 9 single-enantiomer products: dexlansoprazole, levoleucovorin, levocetirizine, armodafinil, arformoterol, eszopiclone, escitalopram, dexmethylphenidate, and esomeprazole.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23570096_20201005_0.5			New advances in the treatment of gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23570096_20201005_0.5	levoleucovorin	drug_name	Antineoplastic Combined Chemotherapy Protocols|Capecitabine|Chemoradiotherapy, Adjuvant|Chemotherapy, Adjuvant|Cisplatin|Deoxycytidine|Docetaxel|Doxorubicin|Drug Combinations|Etoposide|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Methotrexate|Organoplatinum Compounds|Oxonic Acid|Stomach Neoplasms|Taxoids|Tegafur	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4281361_20201005_0.5			A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4281361_20201005_0.5			Colon cancer|5-FU-based chemotherapy|Levo-leucovorin|Methylenetetrahydrofolate|CH|Tissue and plasma folates|LC-MS/MS	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4281361_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Aged, 80 and over|Antidotes|Antimetabolites, Antineoplastic|Biotransformation|Colonic Neoplasms|Combined Modality Therapy|Dose-Response Relationship, Drug|Female|Fluorouracil|Humans|Injections, Intravenous|Intestinal Mucosa|Levoleucovorin|Male|Middle Aged|Perioperative Period|Prodrugs|Single-Blind Method|Tetrahydrofolates|Tissue Distribution	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10357402_20201005_0.5			Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10357402_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Dose-Response Relationship, Drug|Etoposide|Female|Fluorouracil|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7477301_20201005_0.5			Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7477301_20201005_0.5	levoleucovorin	drug_name	Child|Humans|Autism Spectrum Disorder|Double-Blind Method|FOLR1 protein, human|Folate Receptor 1|Folic Acid|Leucovorin|Metabolic Clearance Rate|Reduced Folate Carrier Protein|Levoleucovorin|Autoantibodies|Inactivation, Metabolic|Calcium, Dietary	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20354823_20201005_0.5			Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20354823_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Colorectal Neoplasms|Drugs, Generic|Female|Fluorouracil|Humans|Levoleucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5			Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5			5-fluorouracil|calcium-folinic acid|concomitant infusion|disodium levofolinate|solubility|synergism	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5	levoleucovorin	drug_name	Humans|Male|Levoleucovorin|Leucovorin|Fluorouracil|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Infusions, Intravenous	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8873837_20201005_0.5			A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8873837_20201005_0.5	levoleucovorin	drug_name	Adult|Antineoplastic Combined Chemotherapy Protocols|Etoposide|Female|Fluorouracil|Hematologic Diseases|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Remission Induction|Stomach Neoplasms|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5065947_20201005_0.5			Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5065947_20201005_0.5			Stomach neoplasms|Drug therapy|5-fluorouracil|Leucovorin	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5065947_20201005_0.5	levoleucovorin	drug_name	Middle Aged|Aged|Adult|Male|Humans|Female|Leucovorin|Retrospective Studies|Prospective Studies|Fluorouracil|Levoleucovorin|Salvage Therapy|Stomach Neoplasms|Antineoplastic Combined Chemotherapy Protocols|Capecitabine|Colorectal Neoplasms|Disease-Free Survival|Drug Administration Schedule|Antimetabolites|Infusions, Intravenous	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21597692_20201005_0.5			5-Fluorouracil combined with the pure L-stereoisomer of leukovorin calcium to treat advanced colon-cancer patients - a phase-ii study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21597692_20201005_0.5	levoleucovorin	drug_name	Middle Aged|Adult|Male|Humans|Female|Leucovorin|Fluorouracil|Stereoisomerism|Calcium|Antimetabolites, Antineoplastic|Colorectal Neoplasms|Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Colon|Remission Induction|Drug Administration Schedule|Leukopenia|Nausea|Vomiting|Levoleucovorin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28392022_20201005_0.5			REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28392022_20201005_0.5			Colorectal carcinoma|Oxaliplatin|Prognosis|Re-challenge|Treatment	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28392022_20201005_0.5			Adenocarcinoma|Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Disease Progression|Female|Humans|Liver Neoplasms|Male|Middle Aged|Mutation|Organoplatinum Compounds|Oxaliplatin|Patient Selection|Proto-Oncogene Proteins p21(ras)|Retreatment|Retrospective Studies|Survival Rate|Time Factors|Treatment Failure|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28392022_20201005_0.5	levoleucovorin	drug_name	The main regimen was 5-fluorouracil, levoleucovorin, and oxaliplatin (mFOLFOX6) (84.3%).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7627739_20201005_0.5	levoleucovorin	drug_name	Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7627739_20201005_0.5			Chemical Precipitation|Drug Incompatibility|Fluorouracil|Humans|Leucovorin|Nephelometry and Turbidimetry	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7627739_20201005_0.5	levoleucovorin	drug_name	No section The physical compatibility of fluorouracil mixed with leucovorin calcium or levoleucovorin calcium, undiluted and modestly diluted with 5% dextrose injection, was evaluated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7627739_20201005_0.5	levoleucovorin	drug_name	Fluorouracil 50 mg/mL was combined in duplicate with leucovorin or levoleucovorin 20 mg/mL (as the calcium salt) in 250-mL polyvinyl chloride (PVC) portable-pump reservoirs in six volume ratios, either undiluted or diluted with 5% dextrose injection (to a final volume 25% greater than the drug volume).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7627739_20201005_0.5	levoleucovorin	drug_name	Fluorouracil and leucovorin calcium or levoleucovorin calcium were not compatible when stored in PVC reservoirs at 4, 23, or 32 degrees C.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID2305269_20201005_0.5			New developments in the treatment of gastric carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID2305269_20201005_0.5	levoleucovorin	drug_name	Adolescent|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Combined Modality Therapy|Doxorubicin|Drug Evaluation|Etoposide|Female|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Prognosis|Remission Induction|Reoperation|Stomach Neoplasms|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7645929_20201005_0.5			Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7645929_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Drug Administration Schedule|Etoposide|Fluorouracil|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Neoplasm Metastasis|Neoplasm Staging|Stomach Neoplasms|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9740078_20201005_0.5	levoleucovorin	drug_name	Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9740078_20201005_0.5			Administration, Oral|Aged|Aged, 80 and over|Antidotes|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Chemotherapy, Adjuvant|Cyclophosphamide|Female|Floxuridine|Fluorouracil|Humans|Leucovorin|Methotrexate|Neoplasm Staging	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9740078_20201005_0.5	levoleucovorin	drug_name	The objective of this Phase II trial was to evaluate the effectiveness and tolerability of oral 5-dFUR, biomodulated with levoleucovorin (1-leucovorin), in elderly patients (age > 70 years) with ABC.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5	levoleucovorin	drug_name	Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5			Adolescent|Adult|Aged|Ambulatory Care|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Disease Progression|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Male|Maximum Tolerated Dose|Middle Aged|Neoplasm Metastasis|Survival Rate|Treatment Outcome|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5	levoleucovorin	drug_name	BACKGROUND Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5	levoleucovorin	drug_name	Each treatment cycle consisted of irinotecan on days 1 and 15; fluorouracil 600 mg/m(2) on days 1, 8, 15 and 22; and levoleucovorin 250 mg/m(2) on days 1, 8, 15 and 22.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5			First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5			gastric cancer|DCF|panitumumab|dose-dense|chemotherapy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5	levoleucovorin	drug_name	PRC|Humans|Leucovorin|Fluorouracil|panitumumab|docetaxel|Cisplatin|Stomach Neoplasms|Antibodies, Monoclonal|Taxoids|Esophagogastric Junction|Levoleucovorin|Neutropenia|pegfilgrastim|Granulocyte Colony-Stimulating Factor|Exanthema|Anorexia|Diarrhea|Asthenia|Disease Progression	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10674448_20201005_0.5			Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10674448_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Aged|Anastomosis, Surgical|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Cisplatin|Etoposide|Female|Fluorouracil|Gastrectomy|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Neoplasm Staging|Neutropenia|Preoperative Care|Stomach Neoplasms|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5			Lessons from the leucovorin shortages between 2009 and 2012 in a medicare advantage population: where do we go from here?	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5			Aged|Humans|Male|United States|Adult|Middle Aged|Female|Leucovorin|Medicare Part C|Retrospective Studies|Drug Costs|Cost Sharing|Health Care Costs|Health Expenditures	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5	levoleucovorin	drug_name	Levoleucovorin, an alternative therapy to leucovorin, failed to demonstrate superiority over leucovorin in clinical trials and is substantially more expensive.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5	levoleucovorin	drug_name	A total of 1542 patients with at least 1 medical or pharmacy claim for either leucovorin or levoleucovorin during the first 3 months of the respective plan year (between 2009 and 2012) who had continuous enrollment for the entirety of the same plan year, were included in this study.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5	levoleucovorin	drug_name	Trends in primary treatment costs-defined as the drug cost of leucovorin or levoleucovorin-over the 4-year evaluation period were assessed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5	levoleucovorin	drug_name	This reduction was accompanied by a 6.6% increase in patients receiving levoleucovorin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5	levoleucovorin	drug_name	The mean annual patient OOP costs were $167 to $714 higher for levoleucovorin than for leucovorin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25237422_20210111_0.5	levoleucovorin	drug_name	Similarly, the mean plan-paid PMPM costs were higher (up to $1667 PMPM) for levoleucovorin than for leucovorin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21597744_20201005_0.5			Weekly 24-hour infusion with high-dose 5-Fluorouracil and 6s-leucovorin as a 2nd-line therapy in advanced colorectal-cancer resistant to a 5-fluorouracil/6s-leucovorin bolus combination.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21597744_20201005_0.5	levoleucovorin	drug_name	Middle Aged|Male|Humans|Female|Fluorouracil|Levoleucovorin|Colorectal Neoplasms|Leucovorin|Colonic Neoplasms|Antineoplastic Combined Chemotherapy Protocols|Infusions, Intravenous|Drug Administration Schedule|Injections, Intravenous|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21078826_20201005_0.5			Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21078826_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Disease-Free Survival|Female|Fluorouracil|Humans|Irinotecan|Kaplan-Meier Estimate|Levoleucovorin|Male|Middle Aged|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2361806_20201005_0.5			Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2361806_20201005_0.5			ELF|5-fluorouracil|gastric|ILF|irinotecan|metastatic	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2361806_20201005_0.5	levoleucovorin	drug_name	Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Esophagogastric Junction|Etoposide|Female|Fluorouracil|Humans|Irinotecan|Leucovorin|Levoleucovorin|Male|Middle Aged|Neoplasm Staging|Peritoneal Neoplasms|Stomach Neoplasms|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19269903_20201005_0.5			Simultaneous determination of 6R-leucovorin, 6S-leucovorin and 5-methyltetrahydrofolate in human plasma using solid phase extraction and chiral liquid chromatography-tandem mass spectrometry.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19269903_20201005_0.5			Chromatography, Liquid|Humans|Leucovorin|Solid Phase Extraction|Tandem Mass Spectrometry|Tetrahydrofolates	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19269903_20201005_0.5	levoleucovorin	drug_name	The method was successfully applied to a comparative pharmacokinetic study between leucovorin calcium and levoleucovorin calcium in 10 volunteers.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19269903_20201005_0.5	levoleucovorin	drug_name	No significant differences between levoleucovorin and leucovorin in pharmacokinetic parameters of 6S-LV and 5-MeTHF were found in volunteers.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5			Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5			Drug stability|calcium levofolinate|chromatography|robotic compounding	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	levoleucovorin	drug_name	Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Glucose|Levoleucovorin|Nylons|Polyenes|Polypropylenes|Saline Solution|Syringes|Temperature|Water	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12025890_20201005_0.5			Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12025890_20201005_0.5	levoleucovorin	drug_name	Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Biomarkers, Tumor|Disease-Free Survival|Etoposide|Female|Fluorouracil|Follow-Up Studies|Humans|Leucovorin|Levoleucovorin|Male|Middle Aged|Prognosis|Stomach Neoplasms|Survival Rate|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9704722_20201005_0.5			Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9704722_20201005_0.5	levoleucovorin	drug_name	Adolescent|Adult|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Combined Modality Therapy|Disease-Free Survival|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Hydroxyurea|Interferon alpha-2|Interferon-alpha|Leucovorin|Levoleucovorin|Male|Middle Aged|Radiotherapy Dosage|Recombinant Proteins|Remission Induction|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5			Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implications	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5			levofolene|5-fluorouracil|apoptosis|keratinocytes|cytotoxicity	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5	levoleucovorin	drug_name	Antidotes|Antimetabolites, Antineoplastic|Apoptosis|Autophagy|Cell Line|Drug Combinations|Drug Synergism|Flow Cytometry|Fluorouracil|Humans|Keratinocytes|Levoleucovorin|Lipid Peroxidation|Oxidative Stress|Reactive Oxygen Species	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33755972_20210411_0.5			Bowel perforation due to methotrexate therapeutic error: an insidious adverse reaction.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33755972_20210411_0.5			Humans|Male|Aged|Methotrexate|Intestinal Perforation|Antirheumatic Agents|Arthritis, Rheumatoid|Abatacept|Leucovorin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33755972_20210411_0.5	lederfolin	drug_synonym	Therapy with Lederfolin 1000 mg (mg/m2/die) and urine alkalinization started.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9862517_20201005_0.5			Treatment of advanced colorectal cancer (CRC) in daily practice: results of a survey in two Italian regions, Piemonte and Valle d'Aosta.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9862517_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Colorectal Neoplasms|Female|Health Care Surveys|Humans|Italy|Male|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9862517_20201005_0.5	lederfolin	drug_synonym	 RESULTS 5FU modulated with Lederfolin according to the classic Machover scheme is the main option in daily practice.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7655146_20201005_0.5			[Physicochemical compatibility of 5-fluorouracil (new french preparation) and folinic acid].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7655146_20201005_0.5			Drug Combinations|Drug Incompatibility|Drug Stability|Drug Storage|Drug Synergism|Fluorouracil|Glass|Humans|Leucovorin|Plastics|Time Factors	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7655146_20201005_0.5	lederfolin	drug_synonym	Based on drug concentrations corresponding to current 5FU-FA chemotherapeutic protocols, we have tested the influence of various factors like the vials, diluents and the type of FA preparation (Lederfoline versus Elvorine).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7655146_20201005_0.5	lederfolin	drug_synonym	The mixture between 5FU and FA leads to the formation of a precipitate which is influenced by the contact time between 5FU and FA (threshold at 24 hr), by the relative concentration of each drug in mixture and its seems necessary to avoid the mixture between undiluted 5FU and FA (d,1 preparation, Lederfoline).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7655146_20201005_0.5	lederfolin	drug_synonym	Finally and above all, the use of pure lFA form (Elvorine) does not lead to the formation of a precipitate seen with the d'1 FA form (Lederfoline) at equal concentration of active folate (1 form).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10464701_20201005_0.5			The integrated treatment of peritoneal carcinomatosis. A preliminary experience.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10464701_20201005_0.5			Abdominal Neoplasms|Adolescent|Adult|Aged|Carcinoma|Chemotherapy, Adjuvant|Chemotherapy, Cancer, Regional Perfusion|Cisplatin|Colorectal Neoplasms|Female|Fluorouracil|Follow-Up Studies|Humans|Hyperthermia, Induced|Male|Middle Aged|Mitomycins|Ovarian Neoplasms|Peritoneal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10464701_20201005_0.5	lederfolin	drug_synonym	Alternatively the immediate postoperative regional chemotherapy is performed with 5-fluorouracil (13.5 mg/Kg) and Lederfolin (125 mg/m2) (colic or appendicular tumor) or cisplatin (25 ng/m2) (ovarian tumor), each day for 5 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15151519_20201005_0.5			Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15151519_20201005_0.5			Adolescent|Child|Child, Preschool|Chromatography, High Pressure Liquid|Drug Combinations|Female|Humans|Infant|Infant, Newborn|Male|Pyrimethamine|Sulfadoxine|Toxoplasmosis, Congenital	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15151519_20201005_0.5	lederfolin	drug_synonym	 METHODS Children were treated with PYR (1.25 mg kg(-1)) and SDX (25 mg kg(-1)) (Fansidar) plus folinic acid (Lederfoline) 5 mg).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9214274_20201005_0.5			[Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9214274_20201005_0.5			Antimetabolites, Antineoplastic|Colorectal Neoplasms|Fluorouracil|Humans|Neoplasm Metastasis|Neoplasm Recurrence, Local	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9214274_20201005_0.5	lederfolin	drug_synonym	 CONCLUSIONS Literature data suggest that biochemical modulation of fluorouracil by lederfolin is effective in the treatment of advanced colorectal cancer such as continuous i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11016471_20201005_0.5			Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11016471_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma|Chemotherapy, Cancer, Regional Perfusion|Cisplatin|Disease-Free Survival|Female|Fluorouracil|Follow-Up Studies|Humans|Hyperthermia, Induced|Male|Middle Aged|Mitomycin|Peritoneal Neoplasms|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11016471_20201005_0.5	lederfolin	drug_synonym	Alternatively, the immediate post-operative regional chemotherapy was performed with 5-fluorouracil (13.5 mg/kg) and Lederfolin (125 mg/m2) (for colonic or appendicular tumours) or cisplatin (25 mg/m2) (for ovarian tumours), each day for 5 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID2320183_20201005_0.5			A new chemotherapeutic regimen in the treatment of advanced gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID2320183_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Cyclophosphamide|Doxorubicin|Female|Fluorouracil|Humans|Leucovorin|Male|Methotrexate|Middle Aged|Mitomycin|Mitomycins|Stomach Neoplasms|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID2320183_20201005_0.5	lederfolin	drug_synonym	The first group (59 patients) was treated by a new regimen consisting of methotrexate, 5-fluorouracil, cyclophosphamide and lederfolin (MFC + CF), the second group (21 patients) was treated by COnFU regimen (cyclophosphamide, vincristine, 5-fluorouracil), and the third group (35 patients) was treated with 5-fluorouracil (5-FU) alone.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5	levofolinate calcium	drug_umls_atom	Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5			Adenocarcinoma|Adult|Antineoplastic Combined Chemotherapy Protocols|Disseminated Intravascular Coagulation|Female|Fluorouracil|Gastrectomy|Humans|Levoleucovorin|Stomach Neoplasms|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5	levofolinate calcium	drug_umls_atom	The fourth-line chemotherapy, infusional 5-fluorouracil and levofolinate calcium was performed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5			Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5			Capecitabine|Fluoropyrimidine|Fluorouracil|Hypertriglyceridemia|Triglyceride	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5			Humans|Female|Fluorouracil|Capecitabine|Hypertriglyceridemia|Deoxycytidine|Tegafur|Irinotecan|Hyperlipidemias|Oxaliplatin|Colorectal Neoplasms|Antineoplastic Combined Chemotherapy Protocols|Bezafibrate|Fenofibrate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5	levofolinate calcium	drug_umls_atom	A woman in her forties who had experienced grade 3 hypertriglyceridemia due to oxaliplatin + capecitabine was administered fluorouracil ± oxaliplatin + levofolinate calcium + panitumumab; however, grade 4 hypertriglyceridemia occurred after the thirteenth administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5	levofolinate calcium	drug_umls_atom	Nine months after cessation, treatment with fluorouracil + irinotecan + levofolinate calcium + ramucirumab was initiated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21224650_20201005_0.5			[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21224650_20201005_0.5			Adult|Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Drug Resistance, Neoplasm|Female|Fluorouracil|Hepatic Artery|Humans|Infusions, Intra-Arterial|Infusions, Parenteral|Leucovorin|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Retrospective Studies|Salvage Therapy	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21224650_20201005_0.5	levofolinate calcium	drug_umls_atom	Patients with unresectable CRLM and history of systemic chemotherapy failure were treated with HAI oxaliplatin (L-OHP 100 mg/body, 2 hours) combined with intravenous (iv) levofolinate calcium (175 mg/body, 2 hours) and iv bolus 5-FU (500 mg/body) every 2 weeks.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9617733_20201005_0.5	levofolinate calcium	drug_umls_atom	Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9617733_20201005_0.5			Animals|Antidotes|Antimetabolites, Antineoplastic|Body Weight|Bone Marrow|Drug Synergism|Eating|Erythrocyte Count|Female|Fluorouracil|Injections, Intravenous|Isomerism|Kidney|Leucovorin|Leukocyte Count|Lymph Nodes|Male|Rats|Spleen	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9617733_20201005_0.5	levofolinate calcium	drug_umls_atom	No section To clarify whether levofolinate calcium (1-LV) enhances 5-fluorouracil (5-FU) toxicity, a 4-week toxicity study of 5-FU (10 mg/kg/day) in combination with 1-LV (6, 20 or 60 mg/kg/day) was conducted in rats.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4376520_20201005_0.5			Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4376520_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Camptothecin|Colorectal Neoplasms|Disease-Free Survival|Drug-Related Side Effects and Adverse Reactions|Female|Fluorouracil|Humans|Kaplan-Meier Estimate|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4376520_20201005_0.5	levofolinate calcium	drug_umls_atom	FOLFIRI and bevacizumab regimen [irinotecan: 180 mg/m , 5-fluorouracil infusion: 2400 mg/m , 5-fluorouracil bolus: 400 mg/m , levofolinate calcium: 200 mg/m , bevacizumab: 5 mg/kg] was repeated every 2 weeks for up to 24 cycles.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5	levofolinate calcium	drug_umls_atom	[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Drug Administration Schedule|Fluorouracil|Gastrectomy|Hepatectomy|Hepatic Artery|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5	levofolinate calcium	drug_umls_atom	He underwent combined hepatic arterial and aortic infusion chemotherapy with cisplatinum (CDDP), 5-fluorouracil (5-FU), and levofolinate calcium (l-LV).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5			A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5			FOLFOX|bevacizumab|colorectal cancer	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5			Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Bevacizumab|Colorectal Neoplasms|DNA-Binding Proteins|Disease-Free Survival|Drug Administration Schedule|Endonucleases|Female|Fluorouracil|Follow-Up Studies|Genotype|Glutathione S-Transferase pi|Humans|Infusions, Intravenous|Japan|Kaplan-Meier Estimate|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Organoplatinum Compounds|Polymorphism, Single Nucleotide|Prospective Studies|Real-Time Polymerase Chain Reaction|Xeroderma Pigmentosum Group D Protein	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5	levofolinate calcium	drug_umls_atom	 Methods Bevacizumab (5 mg/kg) was administered intravenously, and then oxaliplatin (85 mg/m ) and levofolinate calcium (200 mg/m ) were infused intravenously over 2 h. Subsequently, a bolus dose of 5-fluorouracil (400 mg/m ) was injected, followed by infusion of 5-fluorouracil (2400 mg/m ) for 46 h. This regimen was repeated every 2 weeks until 24 cycles unless there was disease progression, unacceptable toxicity or patient refusal.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19011354_20201005_0.5			[A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19011354_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Carcinoembryonic Antigen|Fluorouracil|Humans|Intestinal Neoplasms|Intestine, Small|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Tomography, X-Ray Computed|Treatment Failure	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19011354_20201005_0.5	levofolinate calcium	drug_umls_atom	mFOLFOX6 (oxaliplatin 85 mg/m2, levofolinate calcium 200 mg/m2, 5-FU 400/2,400 mg/m2) was given, and the patient responded.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24956887_20201005_0.5			[A case of nephrotic syndrome during TS-1 therapy after resection of rectal cancer and liver metastasis].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24956887_20201005_0.5			Biopsy|Humans|Liver Neoplasms|Male|Middle Aged|Nephrotic Syndrome|Rectal Neoplasms|Silicates|Titanium|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24956887_20201005_0.5	levofolinate calcium	drug_umls_atom	He received chemotherapy with intravenous infusion of fluorouracil (5-FU) 500 mg, levofolinate calcium 350 mg, and hepatic arterial infusion of 5-FU 250 mg.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5			[A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Bile Duct Neoplasms|Biomarkers, Tumor|Cholangiocarcinoma|Humans|Infusions, Intra-Arterial|Liver Neoplasms|Male|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5	levofolinate calcium	drug_umls_atom	After admission to our hospital, he was treated by hepatic arterial infusion chemotherapy with CDDP, levofolinate calcium (L-LV) and 5-FU with chronomodulation.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5			SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5			Anticancer drugs|Anticancéreux|Anticorps monoclonaux|Dose banding|Monoclonal antibodies|Stabilis(®)|Stability|Stabilité	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5			Antibodies, Monoclonal|Antineoplastic Agents|Chemotherapy, Adjuvant|Drug Stability|Humans|Medical Oncology|Pharmacists|Pharmacy Service, Hospital|Societies, Pharmaceutical	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5	levofolinate calcium	drug_umls_atom	Ten new molecules have been included (asparaginase, azacitidine, bevacizumab, clofarabine, eribuline mesylate, folinate sodium, levofolinate calcium, nelarabine, rituximab, temsirolimus).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19151582_20201005_0.5			[A case of therapy for bevacizumab-induced hypertension].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19151582_20201005_0.5			Aged|Angiotensin Receptor Antagonists|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antihypertensive Agents|Antineoplastic Agents|Bevacizumab|Blood Pressure|Female|Humans|Hypertension|Immunotherapy|Liver Neoplasms|Receptors, Angiotensin|Sigmoid Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19151582_20201005_0.5	levofolinate calcium	drug_umls_atom	She was treated with 5-fluorouracil and levofolinate calcium(sLV5FU2)plus bevacizumab(BV) for advanced colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10700909_20201005_0.5	levofolinate calcium	drug_umls_atom	[Combination of levofolinate calcium and 5-fluorouracil].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10700909_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Clinical Trials, Phase II as Topic|Drug Administration Schedule|Drug Synergism|Fluorouracil|Humans|Leucovorin|Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10700909_20201005_0.5	levofolinate calcium	drug_umls_atom	In Japan, clinical examinations of this combination using Levofolinate calcium (I-LV) have shown its effectiveness, and I-LV/5-FU for gastric and colorectal cancer was authorized by the Ministry of Public Welfare in Oct. 1999.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14579760_20201005_0.5			[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14579760_20201005_0.5			Antibodies, Monoclonal|Antineoplastic Agents|Antineoplastic Agents, Phytogenic|Camptothecin|Colorectal Neoplasms|Fluorouracil|Humans|Irinotecan|Liver Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14579760_20201005_0.5	levofolinate calcium	drug_umls_atom	No section The treatment regimens that are considered to be effective against metastatic colorectal carcinoma and available in Japan are levofolinate calcium (Isovorin)/5-fluorouracil (5-FU), irinotecan hydrochloride (Topotecin, CPT-11), and repeated low-dose cisplatin/5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19106556_20201005_0.5			[A complete response of locally-advanced poorly differentiated adenocarcinoma of the rectum to pre-operative chemo-radiation therapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19106556_20201005_0.5			Adenocarcinoma|Aged|Cell Differentiation|Colonoscopy|Female|Humans|Neoadjuvant Therapy|Neoplasm Staging|Rectal Neoplasms|Remission Induction|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19106556_20201005_0.5	levofolinate calcium	drug_umls_atom	After chemo-radiation therapy of 50.4 Gy and 5-FU plus levofolinate calcium (Isovorin) infusion, the tumor was reduced in size and lymph nodes were extremely decreased.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15553741_20201005_0.5			[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15553741_20201005_0.5			Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Carcinoembryonic Antigen|Cecal Neoplasms|Combined Modality Therapy|Floxuridine|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Neoplasm Seeding|Peritoneal Neoplasms|Reoperation	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15553741_20201005_0.5	levofolinate calcium	drug_umls_atom	After that, he received systemic chemotherapy (5-FU 500 mg/body/week div, levofolinate calcium 250 mg/body/week i.v.)	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24390266_20201005_0.5			[A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24390266_20201005_0.5			Adenocarcinoma|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Cetuximab|Colonic Neoplasms|Fatal Outcome|Female|Fluorouracil|Humans|Leucovorin|Middle Aged|Skin Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24390266_20201005_0.5	levofolinate calcium	drug_umls_atom	Surgical resection of the primary lesion was performed and FOLFIRI (5-fluorouracil, levofolinate calcium, irinotecan) and cetuximab chemotherapy for the metastases was initiated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18045783_20201005_0.5			Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18045783_20201005_0.5			Aged|Antineoplastic Agents|Drug Hypersensitivity|Female|Humans|Immunoglobulin E|Japan|Lymphocyte Activation|Organoplatinum Compounds|Oxaliplatin|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18045783_20201005_0.5	levofolinate calcium	drug_umls_atom	In addition, a drug lymphocyte stimulating test against oxaliplatin and levofolinate calcium (an isomer of leucovorin calcium) gave values of 696% and 107 % respectively, as compared with control serum.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5			Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5			Oxaliplatin|Hypersensitivity reactions|XELOX therapy|FOLFOX therapy|Colorectal cancer	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5			Aged|Anti-Inflammatory Agents|Antimetabolites, Antineoplastic|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Combined Modality Therapy|Deoxycytidine|Dexamethasone|Drug Hypersensitivity|Female|Fluorouracil|Humans|Incidence|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Retrospective Studies|Risk Factors	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5	levofolinate calcium	drug_umls_atom	In this study, we compared the frequency and pattern of HSRs to modified FOLFOX6 (mFOLFOX6; 5-fluorouracil, levofolinate calcium and L-OHP infusions) and XELOX (capecitabine and L-OHP) therapies, and sought to identify risk factors associated with HSRs.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17212159_20201005_0.5			[Utility of arterial infusion chemotherapy and radiation therapy for the pelvic local recurrence of rectal cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17212159_20201005_0.5			Aged|Aged, 80 and over|Combined Modality Therapy|Fluorouracil|Humans|Infusions, Intra-Arterial|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Pelvic Neoplasms|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17212159_20201005_0.5	levofolinate calcium	drug_umls_atom	No section We treated 3 cases of local pelvic recurrence due to a rectal cancer post operation by arterial infusion chemotherapy with 5-FU and levofolinate calcium and also by radiation therapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20037449_20201005_0.5			[A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20037449_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Combined Modality Therapy|Esophageal Neoplasms|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasms, Multiple Primary|Organoplatinum Compounds	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20037449_20201005_0.5	levofolinate calcium	drug_umls_atom	The patient received chemotherapy of modified FOLFOX6 (mFOLFOX6) at dosages of 80% of standard regimen (oxaliplatin 68 mg/m2, levofolinate calcium 160 mg/m2, bolus 5-FU 320 mg/m2, and followed by continuous 5-FU 1,920 mg/m2/ 46 hr) in combination with radiotherapy (total 61.6 Gy).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5			A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5			Adenocarcinoma|Antimetabolites, Antineoplastic|Female|Fluorouracil|Heart Failure|Humans|Middle Aged|Rectal Neoplasms|Takotsubo Cardiomyopathy	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5	levofolinate calcium	drug_umls_atom	Acute heart failure developed during the administration of 5-fluorouracil (5-FU) and levofolinate calcium in a 62-year-old woman who had underwent a Miles operation for rectal adenocarcinoma.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5	levofolinate calcium	drug_umls_atom	Coronary angiography demonstrated normal coronary arteries, and multi-vessel coronary artery vasospasms including microcirculation disorders could be provoked by intracoronary acetylcholine infusion during, but not before, the intravenous administration of levofolinate calcium and 5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17108731_20201005_0.5	levofolinate calcium	drug_umls_atom	[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17108731_20201005_0.5			Adenocarcinoma|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Aorta|Chronotherapy|Cisplatin|Eating|Fluorouracil|Humans|Leucovorin|Lymph Nodes|Lymphatic Metastasis|Male|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17108731_20201005_0.5	levofolinate calcium	drug_umls_atom	Paclitaxel was not effective in treating the lymph node metastases or vomiting; therefore a chronomodulated schedule was used, which involved the administration of low doses of 5-fluorouracil, levofolinate calcium and cis-platinum (FLP) each night.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12921507_20201005_0.5			Photo-induced Stevens-Johnson syndrome due to sulfasalazine therapy.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12921507_20201005_0.5			Adult|Antirheumatic Agents|Arthritis|Humans|Male|Stevens-Johnson Syndrome|Sulfasalazine|Sunlight	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12921507_20201005_0.5	levofolinate calcium	drug_umls_atom	According to his medical record, the patient had received methotrexate, levofolinate calcium, deflazacort, and diclofenac sodium as needed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5			[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Drug Administration Schedule|Fluorouracil|Gastrectomy|Hepatectomy|Hepatic Artery|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5	levofolinate calcium (l-lv)	drug_umls_atom	He underwent combined hepatic arterial and aortic infusion chemotherapy with cisplatinum (CDDP), 5-fluorouracil (5-FU), and levofolinate calcium (l-LV).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5			[A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Bile Duct Neoplasms|Biomarkers, Tumor|Cholangiocarcinoma|Humans|Infusions, Intra-Arterial|Liver Neoplasms|Male|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5	levofolinate calcium (l-lv)	drug_umls_atom	After admission to our hospital, he was treated by hepatic arterial infusion chemotherapy with CDDP, levofolinate calcium (L-LV) and 5-FU with chronomodulation.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20037449_20201005_0.5			[A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20037449_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Combined Modality Therapy|Esophageal Neoplasms|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasms, Multiple Primary|Organoplatinum Compounds	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20037449_20201005_0.5	levofolinate	drug_umls_atom	The patient received chemotherapy of modified FOLFOX6 (mFOLFOX6) at dosages of 80% of standard regimen (oxaliplatin 68 mg/m2, levofolinate calcium 160 mg/m2, bolus 5-FU 320 mg/m2, and followed by continuous 5-FU 1,920 mg/m2/ 46 hr) in combination with radiotherapy (total 61.6 Gy).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27141384_20210211_0.5			Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27141384_20210211_0.5			CTLs|Colon cancer|GOLFIG chemo-immunotherapy|epitope peptides|peptide vaccine|thymidylate synthase	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27141384_20210211_0.5			Humans|Male|Adult|Middle Aged|Female|Thymidylate Synthase|Cancer Vaccines|Epitopes|tetraphenylporphine sulfonate|Vaccines, Subunit|Interleukin-2|Fluorouracil|Immunotherapy|Colonic Neoplasms|gemcitabine|Deoxycytidine|Leucovorin|Oxaliplatin|Colorectal Neoplasms|sargramostim|Granulocyte-Macrophage Colony-Stimulating Factor|Organoplatinum Compounds|Antineoplastic Combined Chemotherapy Protocols|Rectal Neoplasms|Vaccination	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27141384_20210211_0.5	levofolinate	drug_umls_atom	Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin [OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1-2], bolus/infusional 5'-FU [400 mg/800 mg/sqm, days 1-2], sargramostim [50 μg, days 3-7/q30], and interleukin-2 [sc.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5	levofolinate	drug_umls_atom	Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5			Adenocarcinoma|Adult|Antineoplastic Combined Chemotherapy Protocols|Disseminated Intravascular Coagulation|Female|Fluorouracil|Gastrectomy|Humans|Levoleucovorin|Stomach Neoplasms|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29066681_20201005_0.5	levofolinate	drug_umls_atom	The fourth-line chemotherapy, infusional 5-fluorouracil and levofolinate calcium was performed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7278329_20201005_0.5	levofolinate	drug_umls_atom	Letter to the editor: Re: Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol. 2019	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7278329_20201005_0.5			Humans|Levoleucovorin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5			Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5			Capecitabine|Fluoropyrimidine|Fluorouracil|Hypertriglyceridemia|Triglyceride	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5			Humans|Female|Fluorouracil|Capecitabine|Hypertriglyceridemia|Deoxycytidine|Tegafur|Irinotecan|Hyperlipidemias|Oxaliplatin|Colorectal Neoplasms|Antineoplastic Combined Chemotherapy Protocols|Bezafibrate|Fenofibrate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5	levofolinate	drug_umls_atom	A woman in her forties who had experienced grade 3 hypertriglyceridemia due to oxaliplatin + capecitabine was administered fluorouracil ± oxaliplatin + levofolinate calcium + panitumumab; however, grade 4 hypertriglyceridemia occurred after the thirteenth administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7983629_20210411_0.5	levofolinate	drug_umls_atom	Nine months after cessation, treatment with fluorouracil + irinotecan + levofolinate calcium + ramucirumab was initiated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5			Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5	levofolinate	drug_umls_atom	colorectal cancer|folinic acid|non oncogene addiction|sodium levofolinate|thymidylate synthase	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5			Humans|Middle Aged|Female|Leucovorin|Retrospective Studies|Colorectal Neoplasms|Colonic Neoplasms|Fluorouracil|Thymidylate Synthase|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Antineoplastic Agents|Levoleucovorin|Antimetabolites	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7869580_20210311_0.5	levofolinate	drug_umls_atom	In our experience, levofolinate and 5FU together in continuous infusion prolong progression free survival of patients suffering from mCRC, moreover decreasing death risk and showing a clear clinical benefit for patients, irrespective of RAS mutational status, primitive tumor side and metastases surgery.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21224650_20201005_0.5			[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21224650_20201005_0.5			Adult|Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Drug Resistance, Neoplasm|Female|Fluorouracil|Hepatic Artery|Humans|Infusions, Intra-Arterial|Infusions, Parenteral|Leucovorin|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Retrospective Studies|Salvage Therapy	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21224650_20201005_0.5	levofolinate	drug_umls_atom	Patients with unresectable CRLM and history of systemic chemotherapy failure were treated with HAI oxaliplatin (L-OHP 100 mg/body, 2 hours) combined with intravenous (iv) levofolinate calcium (175 mg/body, 2 hours) and iv bolus 5-FU (500 mg/body) every 2 weeks.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9617733_20201005_0.5	levofolinate	drug_umls_atom	Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9617733_20201005_0.5			Animals|Antidotes|Antimetabolites, Antineoplastic|Body Weight|Bone Marrow|Drug Synergism|Eating|Erythrocyte Count|Female|Fluorouracil|Injections, Intravenous|Isomerism|Kidney|Leucovorin|Leukocyte Count|Lymph Nodes|Male|Rats|Spleen	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9617733_20201005_0.5	levofolinate	drug_umls_atom	No section To clarify whether levofolinate calcium (1-LV) enhances 5-fluorouracil (5-FU) toxicity, a 4-week toxicity study of 5-FU (10 mg/kg/day) in combination with 1-LV (6, 20 or 60 mg/kg/day) was conducted in rats.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21969193_20201005_0.5			A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21969193_20201005_0.5			Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Disease-Free Survival|Dose-Response Relationship, Drug|Female|Fluorouracil|Humans|Japan|Leucovorin|Male|Middle Aged|Neutropenia|Organoplatinum Compounds|Prospective Studies	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21969193_20201005_0.5	levofolinate	drug_umls_atom	OBJECTIVE This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4376520_20201005_0.5			Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4376520_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Camptothecin|Colorectal Neoplasms|Disease-Free Survival|Drug-Related Side Effects and Adverse Reactions|Female|Fluorouracil|Humans|Kaplan-Meier Estimate|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4376520_20201005_0.5	levofolinate	drug_umls_atom	FOLFIRI and bevacizumab regimen [irinotecan: 180 mg/m , 5-fluorouracil infusion: 2400 mg/m , 5-fluorouracil bolus: 400 mg/m , levofolinate calcium: 200 mg/m , bevacizumab: 5 mg/kg] was repeated every 2 weeks for up to 24 cycles.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3771374_20201005_0.5			Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3771374_20201005_0.5			Oxaliplatin|Bevacizumab|Stop-and-go|Modified FOLFOX7|Metastatic colorectal cancer	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3771374_20201005_0.5			Adult|Aged|Angiogenesis Inhibitors|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Colorectal Neoplasms|Disease-Free Survival|Female|Fluorouracil|Humans|Leucovorin|Liver Neoplasms|Lung Neoplasms|Lymphatic Metastasis|Male|Middle Aged|Organoplatinum Compounds|Peritoneal Neoplasms|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3771374_20201005_0.5	levofolinate	drug_umls_atom	Methods Previously untreated patients were assigned to mFOLFOX7 (oxaliplatin 85 mg/m , levofolinate [l -LV] 200 mg/m , 5-fluorouracil [5-FU] 2400 mg/m ) + bevacizumab (5 mg/kg) administered every 2 weeks for 8 cycles, maintenance without oxaliplatin for 8 cycles, and reintroduction of mFOLFOX7 + bevacizumab for 8 cycles or until disease progression.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5	levofolinate	drug_umls_atom	[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Drug Administration Schedule|Fluorouracil|Gastrectomy|Hepatectomy|Hepatic Artery|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402439_20201005_0.5	levofolinate	drug_umls_atom	He underwent combined hepatic arterial and aortic infusion chemotherapy with cisplatinum (CDDP), 5-fluorouracil (5-FU), and levofolinate calcium (l-LV).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29743448_20201214_0.5			Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29743448_20201214_0.5			CapeOX plus bevacizumab|colorectal cancer|intermittent oxaliplatin treatment|mFOLFOX6 plus bevacizumab|neuropathy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29743448_20201214_0.5			Adult|Aged|Aged, 80 and over|Asian Continental Ancestry Group|Colorectal Neoplasms|Disease-Free Survival|Female|Humans|Kaplan-Meier Estimate|Male|Middle Aged|Neoplasm Metastasis|Organoplatinum Compounds|Oxaliplatin|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29743448_20201214_0.5	levofolinate	drug_umls_atom	The primary endpoint of the present study is to assess the progression free survival time on patients treated with chemotherapy (mFOLFOX6 (levofolinate, 5-fluorouracil and oxaliplatin combination therapy) plus bevacizumab or CapeOX (oxaliplatin and capecitabine combination therapy) plus bevacizumab) with intermittent oxaliplatin treatment.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21804330_20201005_0.5			[Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21804330_20201005_0.5			Adult|Aged|Aged, 80 and over|Angiogenesis Inhibitors|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Bevacizumab|Blood Pressure|Camptothecin|Colorectal Neoplasms|Disease-Free Survival|Female|Fluorouracil|Forecasting|Humans|Hypertension|Leucovorin|Male|Middle Aged|Molecular Targeted Therapy|Organoplatinum Compounds|Retrospective Studies|Treatment Outcome|Vascular Endothelial Growth Factor A	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21804330_20201005_0.5	levofolinate	drug_umls_atom	Between July 2007 and December 2010, 36 patients (median age 66 years; 36-81 years) with metastatic colorectal cancer were assigned to receive bevacizumab in combination with either mFOLFOX6 (5-FU, levofolinate and oxaliplatin) or FOLFIRI (5-FU, levofolinate and irinotecan) at the Tokushima University Hospital.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5			Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5			Aged|Female|Folic Acid|Homocysteine|Humans|Leucovorin|Linear Models|Male|Middle Aged|Prospective Studies|Renal Dialysis|Statistics, Nonparametric|Vitamin B 6	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5	levofolinate	drug_umls_atom	Patients matched for age, sex and time on HD were assigned to 1 of 2 groups: Those in group A continued to receive their previous supplements while in group B, FA was substituted by calcium levofolinate 5 mg given orally every 48 hours.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5	levofolinate	drug_umls_atom	 CONCLUSIONS After 6 months of calcium-levofolinate supplementation tHcy levels did not decrease and were similar to those in patients given the same dose of FA.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5	levofolinate	drug_umls_atom	Role of Intramuscular Levofolinate Administration in the Treatment of Hereditary Folate Malabsorption: Report of Three Cases.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5			CSF 5-MTHF|Hereditary folate malabsorption|Intramuscular|Levofolinic acid|Treatment	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5			Infant, Newborn|Humans|Female|Folate Malabsorption, Hereditary|Folic Acid Deficiency|SLC46A1 protein, human|Proton-Coupled Folate Transporter|Malabsorption Syndromes|5-methyltetrahydrofolate|Tetrahydrofolates|Folic Acid|Leucovorin|Levoleucovorin|Mutation	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5	levofolinate	drug_umls_atom	To the best of our knowledge, we provide as well for the first time data in regard to the im levofolinate treatment dosage.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15045954_20201005_0.5	levofolinate	drug_umls_atom	[A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15045954_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Aorta, Abdominal|Colonic Neoplasms|Combined Modality Therapy|Drug Administration Schedule|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Lymph Nodes|Lymphatic Metastasis|Middle Aged|Remission Induction	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15045954_20201005_0.5	levofolinate	drug_umls_atom	After surgery, the patient was given 5-FU infused continuously at 500 mg/body per day, and levofolinate was dripped intravenously at 100 mg/body over 2 hours for 5 successive days per week.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15045954_20201005_0.5	levofolinate	drug_umls_atom	She was then intravenously given weekly modulation chemotherapy consisting of 125 mg/body levofolinate and 500 mg/body of 5-FU for about 5 months on an outpatient basis.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15045954_20201005_0.5	levofolinate	drug_umls_atom	As a result, the enlarged paraaortic lymph nodes had completely disappeared by 5 months after administration of levofolinate.5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15045954_20201005_0.5	levofolinate	drug_umls_atom	In conclusion, this case seems significant from the viewpoint of the complete long-term response to a moderate dose of levofolinate.5-FU therapy and the long duration of administration, which was tolerable with few side effects.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19011354_20201005_0.5			[A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19011354_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Carcinoembryonic Antigen|Fluorouracil|Humans|Intestinal Neoplasms|Intestine, Small|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Tomography, X-Ray Computed|Treatment Failure	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19011354_20201005_0.5	levofolinate	drug_umls_atom	mFOLFOX6 (oxaliplatin 85 mg/m2, levofolinate calcium 200 mg/m2, 5-FU 400/2,400 mg/m2) was given, and the patient responded.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5951897_20201005_0.5	levofolinate	drug_umls_atom	Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5951897_20201005_0.5			FOLFOXIRI|Panitumumab|Triplet chemotherapy|Metastatic colorectal cancer	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5951897_20201005_0.5			Adult|Aged|Antibodies, Monoclonal|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Female|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Maximum Tolerated Dose|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Panitumumab|Treatment Outcome|ras Proteins	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28150022_20201005_0.5	levofolinate	drug_umls_atom	Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28150022_20201005_0.5			Neoadjuvant chemotherapy|Preoperative chemotherapy|Rectal cancer|Resectable|mFOLFOX6	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28150022_20201005_0.5			Adult|Aged|Antimetabolites, Antineoplastic|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Combined Modality Therapy|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Male|Middle Aged|Neoadjuvant Therapy|Neoplasm Staging|Organoplatinum Compounds|Oxaliplatin|Postoperative Complications|Prospective Studies|Rectal Neoplasms|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28150022_20201005_0.5	levofolinate	drug_umls_atom	No section A multicenter phase II clinical study was performed in patients with T3 or T4 stage II/III rectal cancer to evaluate the efficacy and safety of neoadjuvant chemotherapy with 5-fluorouracil, levofolinate, and oxaliplatin (mFOLFOX6).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484017_20201005_0.5	levofolinate	drug_umls_atom	[Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484017_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Drug Administration Schedule|Female|Fluorouracil|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484017_20201005_0.5	levofolinate	drug_umls_atom	No section We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484017_20201005_0.5	levofolinate	drug_umls_atom	In this regimen levofolinate (200 mg/m2) was administered for two hours and 5-fluorouracil (500 mg/m2) was administered for thirty minutes as a bolus.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12610881_20201005_0.5	levofolinate	drug_umls_atom	[A case of advanced colon cancer responding to treatment with levofolinate combined with 5-fluorouracil].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12610881_20201005_0.5			Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Drug Administration Schedule|Fluorouracil|Humans|Leucovorin|Lung Neoplasms|Lymphatic Metastasis|Male|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24956887_20201005_0.5			[A case of nephrotic syndrome during TS-1 therapy after resection of rectal cancer and liver metastasis].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24956887_20201005_0.5			Biopsy|Humans|Liver Neoplasms|Male|Middle Aged|Nephrotic Syndrome|Rectal Neoplasms|Silicates|Titanium|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24956887_20201005_0.5	levofolinate	drug_umls_atom	He received chemotherapy with intravenous infusion of fluorouracil (5-FU) 500 mg, levofolinate calcium 350 mg, and hepatic arterial infusion of 5-FU 250 mg.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5	levofolinate	drug_umls_atom	[Pharmacological study on levofolinate in intraperitoneal leucovorin-5-FU chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Female|Fluorouracil|Humans|Infusion Pumps, Implantable|Infusions, Parenteral|Leucovorin|Male|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5	levofolinate	drug_umls_atom	No section We report the pharmacological findings on levofolinate after the intraperitoneal administration of leucovorin-5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5	levofolinate	drug_umls_atom	Levofolinate 300 mg/saline 500 ml and 5-FU 750 mg/saline 500 ml were administered intraperitoneally over 1.5 h. The plasma and intraperitoneal concentrations of levofolinate at 0, 0.5, 1, 2, 4, 8, 22(20) h after the administration were evaluated at 6 points with HPLC analysis.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5	levofolinate	drug_umls_atom	The intraperitoneal levofolinate concentration went up as high as 100 micrograms/ml and remained above 10 micrograms/ml over 8 hours.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5	levofolinate	drug_umls_atom	This suggested that intraperitoneal administration elevated the portal vein and abdominal lymphatic levofolinate levels.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12484036_20201005_0.5	levofolinate	drug_umls_atom	Intraperitoneal levofolinate-5-FU is a promising protocol for gastro-intestinal cancers.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	levofolinate	drug_umls_atom	Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	levofolinate	drug_umls_atom	Calcium levofolinate|FOLFIRI|Sodium levofolinate	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5			Humans|Male|Middle Aged|Adult|Female|Adolescent|Fluorouracil|Prospective Studies|Leucovorin|Colorectal Neoplasms|Camptothecin|Antineoplastic Combined Chemotherapy Protocols|Liver Neoplasms|Sodium	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	levofolinate	drug_umls_atom	CONCLUSIONS The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	levofolinate	drug_umls_atom	A comparison with calcium levofolinate (Ca-Lev) showed a similar toxicity profile.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	levofolinate	drug_umls_atom	 BACKGROUND The objectives of this study were to compare the safety profiles of sodium levofolinate (Na-Lev) and calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) in the FOLFIRI regimen and to measure the organizational impact of the introduction of Na-Lev on drug production and administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22790056_20201005_0.5	levofolinate	drug_umls_atom	[A case of colorectal neuroendocrine carcinoma effectively treated with bevacizumab+levofolinate+5-FU chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22790056_20201005_0.5			Aged|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Carcinoma, Neuroendocrine|Colorectal Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Levoleucovorin|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22790056_20201005_0.5	levofolinate	drug_umls_atom	Following treatment with bevacizumab+levofolinate+5-FU, the tumor disappeared.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22790056_20201005_0.5	levofolinate	drug_umls_atom	Even though colorectal neuroendocrine carcinoma is known to have a poor prognosis, the present case was effectively treated with bevacizumab+levofolinate+5-FU chemotherapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14619505_20201005_0.5			[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14619505_20201005_0.5			Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Drug Administration Schedule|Drug Combinations|Floxuridine|Fluorouracil|Hepatic Artery|Humans|Infusions, Intra-Arterial|Irinotecan|Leucovorin|Liver Neoplasms|Male|Neoplasm Recurrence, Local|Rectal Neoplasms|Tegafur|Uracil	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14619505_20201005_0.5	levofolinate	drug_umls_atom	The third-line treatment was a hepatic arterial infusion (5-FU + levofolinate) and systemic chemotherapy (UFT).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5			A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5			FOLFOX|bevacizumab|colorectal cancer	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5			Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Bevacizumab|Colorectal Neoplasms|DNA-Binding Proteins|Disease-Free Survival|Drug Administration Schedule|Endonucleases|Female|Fluorouracil|Follow-Up Studies|Genotype|Glutathione S-Transferase pi|Humans|Infusions, Intravenous|Japan|Kaplan-Meier Estimate|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Organoplatinum Compounds|Polymorphism, Single Nucleotide|Prospective Studies|Real-Time Polymerase Chain Reaction|Xeroderma Pigmentosum Group D Protein	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3814899_20201005_0.5	levofolinate	drug_umls_atom	 Methods Bevacizumab (5 mg/kg) was administered intravenously, and then oxaliplatin (85 mg/m ) and levofolinate calcium (200 mg/m ) were infused intravenously over 2 h. Subsequently, a bolus dose of 5-fluorouracil (400 mg/m ) was injected, followed by infusion of 5-fluorouracil (2400 mg/m ) for 46 h. This regimen was repeated every 2 weeks until 24 cycles unless there was disease progression, unacceptable toxicity or patient refusal.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23006440_20201005_0.5			Sequential interaction of phenytoin and phenobarbital with fluorouracil.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23006440_20201005_0.5			Drug Interactions|Fluorouracil|Humans|Male|Middle Aged|Phenobarbital|Phenytoin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23006440_20201005_0.5	levofolinate	drug_umls_atom	 METHODS A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ~ 2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5	levofolinate	drug_umls_atom	[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5			Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Diarrhea|Drug Administration Schedule|Female|Fluorouracil|Hepatic Artery|Humans|Infusion Pumps, Implantable|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged|Survival Rate|Vomiting, Anticipatory	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5	levofolinate	drug_umls_atom	No section Hepatic arterial infusion chemotherapy with levofolinate (l-leucovorin) and fluorouracil regimen was performed using an implanted port system on unresectable hepatic metastasis patients with colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5	levofolinate	drug_umls_atom	A comparative study was performed on two groups in which the levofolinate was administered arterially or intravenously.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5	levofolinate	drug_umls_atom	Levofolinate 200-250 mg/m(2) was infused for two hours intra-arterially or intravenously, and 5-FU 400-600 mg/m(2) was administered as a bolus in midinfusion.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5	levofolinate	drug_umls_atom	The response rate was higher in the group in which levofolinate was given intravenously.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16484858_20201005_0.5	levofolinate	drug_umls_atom	When 5-FU and levofolinate was performed using an implanted port system, it seemed better to administer levofolinate intravenously.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5308855_20201005_0.5			Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5308855_20201005_0.5			Adult|Aged|Antineoplastic Agents|Databases, Factual|Dexamethasone|Female|Hiccup|Humans|Japan|Male|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5308855_20201005_0.5	levofolinate	drug_umls_atom	Medicines associated with hiccups included dexamethasone, levofolinate, fluorouracil, oxaliplatin, carboplatin, and irinotecan.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5			[A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Bile Duct Neoplasms|Biomarkers, Tumor|Cholangiocarcinoma|Humans|Infusions, Intra-Arterial|Liver Neoplasms|Male|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18219876_20201005_0.5	levofolinate	drug_umls_atom	After admission to our hospital, he was treated by hepatic arterial infusion chemotherapy with CDDP, levofolinate calcium (L-LV) and 5-FU with chronomodulation.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14518421_20201005_0.5			[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14518421_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Colonic Neoplasms|Drug Administration Schedule|Female|Fluorouracil|Hepatic Artery|Humans|Infusion Pumps, Implantable|Infusions, Intra-Arterial|Infusions, Intravenous|Liver Neoplasms|Middle Aged|Tegafur|Uracil	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14518421_20201005_0.5	levofolinate	drug_umls_atom	PMC was continued, but the hepatic artery became occluded 1 year and 11 months after the operation, and so PMC was replaced by systemic chemotherapy of 5-FU plus levofolinate at 2 years after the operation.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5			Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5	levofolinate	drug_umls_atom	Colon cancer|5-Fluorouracil (5-FU)|Calcium levofolinate (CaLV)|Disodium levofolinate (NaLV)|Synergism|Thymidylate synthetase (TYMS)|SLC19A1	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5			Animals|Antineoplastic Agents|Apoptosis|Cell Line, Tumor|Cell Proliferation|Disease Models, Animal|Dose-Response Relationship, Drug|Drug Synergism|Fluorouracil|Humans|Leucovorin|Male|Mice|Reduced Folate Carrier Protein|Thymidylate Synthase|Time Factors|Tumor Cells, Cultured|Xenograft Model Antitumor Assays	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5	levofolinate	drug_umls_atom	Proliferation and apoptotic assays were performed on human colon cancer cells exposed to 5-FU, calcium (CaLV), or disodium (NaLV) levofolinate or their simultaneous and sequential combination for 24 and 72 h. TYMS and SLC19A1 gene expression was performed with real-time PCR.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	levofolinate	drug_umls_atom	Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	levofolinate	drug_umls_atom	5-Fluorouracil|calcium levofolinate|drug mixtures stability|oxaliplatin|pH effect	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5			Humans|Oxaliplatin|Fluorouracil|Calcium|Leucovorin|Organoplatinum Compounds|Colorectal Neoplasms|Antineoplastic Combined Chemotherapy Protocols	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	levofolinate	drug_umls_atom	It is composed of calcium levofolinate, 5-fluorouracil and oxaliplatin which demonstrated synergistic outcome.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	levofolinate	drug_umls_atom	Herein, we aimed to investigate the stability of a ternary mixture of 5-fluorouracil, oxaliplatin and calcium levofolinate, knowing that coadministering these drugs would improve their efficacy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	levofolinate	drug_umls_atom	The effect of three pHs (5.0, 6.0 and 7.5) and two drug concentrations (8/3/6 and 1/1/1 mg/ml for 5-fluorouracil, oxaliplatin and calcium levofolinate, respectively) were examined.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	levofolinate	drug_umls_atom	5-fluorouracil/oxaliplatin mixture was stable at pH 5.0 over 48 hours while 5-fluorouracil/calcium levofolinate mixture was stable at pHs 6.0 and 7.5 up to 7 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5			SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5			Anticancer drugs|Anticancéreux|Anticorps monoclonaux|Dose banding|Monoclonal antibodies|Stabilis(®)|Stability|Stabilité	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5			Antibodies, Monoclonal|Antineoplastic Agents|Chemotherapy, Adjuvant|Drug Stability|Humans|Medical Oncology|Pharmacists|Pharmacy Service, Hospital|Societies, Pharmaceutical	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24206590_20201005_0.5	levofolinate	drug_umls_atom	Ten new molecules have been included (asparaginase, azacitidine, bevacizumab, clofarabine, eribuline mesylate, folinate sodium, levofolinate calcium, nelarabine, rituximab, temsirolimus).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5360969_20201005_0.5			Three Cases of Pseudo-Meigs' Syndrome Secondary to Ovarian Metastases from Colorectal Cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5360969_20201005_0.5			PRC|Humans|Female|Meigs Syndrome|Neoplasm Recurrence, Local|Krukenberg Tumor|Colorectal Neoplasms|Ascites|Pleural Effusion|Ovariectomy|Chemotherapy, Adjuvant|Drainage	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5360969_20201005_0.5	levofolinate	drug_umls_atom	After two courses of 5-fluorouracil, levofolinate, and oxaliplatin (mFOLFOX6), her ascites could be controlled by diuretics without aspiration and her general condition improved.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5			Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5			Aflibercept|Anti-VEGF drug|Bevacizumab|Colorectal cancer|FOLFIRI|FOLFOXIRI|Second line	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Clinical Trials, Phase II as Topic|Colorectal Neoplasms|Female|Fluorouracil|Follow-Up Studies|Humans|Irinotecan|Levoleucovorin|Male|Middle Aged|Multicenter Studies as Topic|Oxaliplatin|Prognosis|Prospective Studies|Receptors, Vascular Endothelial Growth Factor|Recombinant Fusion Proteins|Survival Rate|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7672899_20210111_0.5	levofolinate	drug_umls_atom	Patients with unresectable or metastatic colorectal cancer who received FOLFOXIRI plus bevacizumab as a first-line therapy will receive aflibercept and FOLFIRI (aflibercept 4 mg/kg, irinotecan 150 mg/m IV over 90 min, with levofolinate 200 mg/m IV over 2 h, followed by fluorouracil 400 mg/m bolus and fluorouracil 2400 mg/m continuous infusion over 46 h) every 2 weeks on day 1 of each cycle.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5			Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Freezing|Glucose|Hydrogen-Ion Concentration|Leucovorin|Microwaves|Pharmaceutical Vehicles|Polyenes|Regression Analysis|Solutions|Temperature|Time Factors|Vitamin B Complex	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	BACKGROUND Calcium levofolinate infusions could be prepared in advance by a centralized intravenous additive service (CIVAS) to improve safety and time management.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	 OBJECTIVE To investigate the effect of freezing, microwave thawing and long-term storage at 5 +/- 3 degrees C on the stability of calcium levofolinate in 5% dextrose solution.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	 METHODS Solutions of 250 mL of 5% dextrose in polyolefin bags (n = 5) containing approximately 400 mg of calcium levofolinate were prepared under aseptic conditions and frozen for 95 days at -20 degrees C. The solutions were then thawed using microwaves and stored at 5 +/- 3 degrees C for 1 month.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	The calcium levofolinate concentrations were measured by high performance liquid chromatography (HPLC).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	Calcium levofolinate infusions were stable when stored at 5 +/- 3 degrees C during 1 month after freeze-thaw treatment.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	levofolinate	drug_umls_atom	 CONCLUSIONS Under the conditions of this study, calcium levofolinate in 5% dextrose infusion may be prepared, frozen in advance by CIVAS, and then microwave thawed before use.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15791825_20201005_0.5	levofolinate	drug_umls_atom	[A case of bilateral multiple liver metastases with distant lymph node metastases due to rectal cancer successfully treated with hepatic arterial infusion (HAI) of levofolinate (l-LV)/5-fluorouracil (5-FU) and radiotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15791825_20201005_0.5			Adenocarcinoma|Adult|Antineoplastic Combined Chemotherapy Protocols|Combined Modality Therapy|Drug Administration Schedule|Fluorouracil|Hepatic Artery|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Lymphatic Metastasis|Male|Neoplastic Cells, Circulating|Radiotherapy Dosage|Rectal Neoplasms|Rectum|Vena Cava, Inferior	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15791825_20201005_0.5	levofolinate	drug_umls_atom	Consequently, HAI of levofolinate (425 mg/body) and 5-FU (1,000 mg/body), once a week, was attempted.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15791825_20201005_0.5	levofolinate	drug_umls_atom	Mediastinal lymph node metastases, paraaortic lymph node metastases and tumor thrombus in the inferior vena cava were successfully treated with systemic chemotherapy using levofolinate and 5-FU and/or radiotherapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19151582_20201005_0.5			[A case of therapy for bevacizumab-induced hypertension].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19151582_20201005_0.5			Aged|Angiotensin Receptor Antagonists|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antihypertensive Agents|Antineoplastic Agents|Bevacizumab|Blood Pressure|Female|Humans|Hypertension|Immunotherapy|Liver Neoplasms|Receptors, Angiotensin|Sigmoid Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19151582_20201005_0.5	levofolinate	drug_umls_atom	She was treated with 5-fluorouracil and levofolinate calcium(sLV5FU2)plus bevacizumab(BV) for advanced colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28982857_20201005_0.5			Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28982857_20201005_0.5			Diabetes|cancer chemotherapy|colorectal cancer|fluorouracil|hyperglycemia|oxaliplatin	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28982857_20201005_0.5			Adenocarcinoma|Animals|Antineoplastic Combined Chemotherapy Protocols|Blood Glucose|Cell Line, Tumor|Cell Proliferation|Colonic Neoplasms|Diabetes Mellitus, Experimental|Dose-Response Relationship, Drug|Fluorouracil|Interleukin-6|Leucovorin|Male|Mice, Inbred BALB C|Organoplatinum Compounds|Serum Albumin|Streptozocin|Time Factors|Tumor Burden	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28982857_20201005_0.5	levofolinate	drug_umls_atom	 No section Starting 7 days after transplantation of colonic adenocarcinoma colon-26 cells, STZ-treated and control mice were intraperitoneally administered oxaliplatin, fluorouracil, and levofolinate (FOLFOX) every 2 weeks.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26124348_20201005_0.5			Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26124348_20201005_0.5			FOLFIRI|Japanese patients|Ramucirumab|metastatic colorectal carcinoma|pharmacokinetics	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26124348_20201005_0.5			Aged|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Camptothecin|Colorectal Neoplasms|Disease Progression|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26124348_20201005_0.5	levofolinate	drug_umls_atom	BACKGROUND This phase Ib study evaluated the pharmacokinetic profile and safety of ramucirumab, a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor 2, in combination with irinotecan, levofolinate and 5-fluorouracil (FOLFIRI) in Japanese patients with metastatic colorectal carcinoma (mCRC).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10700909_20201005_0.5	levofolinate	drug_umls_atom	[Combination of levofolinate calcium and 5-fluorouracil].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10700909_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Clinical Trials, Phase II as Topic|Drug Administration Schedule|Drug Synergism|Fluorouracil|Humans|Leucovorin|Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10700909_20201005_0.5	levofolinate	drug_umls_atom	In Japan, clinical examinations of this combination using Levofolinate calcium (I-LV) have shown its effectiveness, and I-LV/5-FU for gastric and colorectal cancer was authorized by the Ministry of Public Welfare in Oct. 1999.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6132850_20201005_0.5			A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6132850_20201005_0.5			Endometrial cancer|Taxane/platinum|Refractory/resistant|GLIF|Combination chemotherapy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6132850_20201005_0.5			Administration, Intravenous|Adult|Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Deoxycytidine|Dose-Response Relationship, Drug|Drug Monitoring|Drug Resistance, Neoplasm|Endometrial Neoplasms|Endometrium|Female|Fluorouracil|Glutamates|Humans|Irinotecan|Middle Aged|Neoplasm Staging|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6132850_20201005_0.5	levofolinate	drug_umls_atom	The present study was a phase I/II study of gemcitabine, levofolinate, irinotecan, and 5-fluorouracil (5-FU) (GLIF) combination chemotherapy to determine optimal dosages, safety, and efficacy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6132850_20201005_0.5	levofolinate	drug_umls_atom	 Results The dosages recommended for the phase II trial were determined, in the phase I trial, to be: gemcitabine 800 mg/m , levofolinate 100 mg/m , irinotecan 80 mg/m , and 5-FU 1000 mg/m. Thirty patients were enrolled, including the three patients who received GLIF therapy at the same dose as the recommended phase II dose in the phase I study.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15790217_20201005_0.5			Colloid carcinoma arising in an anorectal fistula in Crohn's disease: a case report.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15790217_20201005_0.5			Aged|Anus Diseases|Carcinoma|Crohn Disease|Fatal Outcome|Female|Humans|Rectal Fistula|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15790217_20201005_0.5	levofolinate	drug_umls_atom	She was treated with an abdominoperineal resection and adjuvant chemotherapy (5-fluorouracil and levofolinate) but died.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3717157_20210411_0.5			A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3717157_20210411_0.5			Aflibercept (VEGF trap)|Vascular endothelial growth factor (VEGF)|FOLFIRI|Metastatic colorectal cancer|Phase I study	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3717157_20210411_0.5			Administration, Intravenous|Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Camptothecin|Colorectal Neoplasms|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Receptors, Vascular Endothelial Growth Factor|Recombinant Fusion Proteins|Vascular Endothelial Growth Factor A	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3717157_20210411_0.5	levofolinate	drug_umls_atom	The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in combination with 5-fluorouracil, levofolinate, and irinotecan (FOLFIRI) in patients with previously treated metastatic colorectal cancer (mCRC).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29593186_20201005_0.5			Peritoneal cecal cancer metastasis to a mesh-plug prosthesis:A case report.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29593186_20201005_0.5			colon cancer|mesh‐plug prosthesis.|peritoneal metastasis	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29593186_20201005_0.5			Aged|Cecal Neoplasms|Humans|Male|Peritoneal Neoplasms|Surgical Mesh	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID29593186_20201005_0.5	levofolinate	drug_umls_atom	After four courses of modified infusional intravenous fluorouracil and levofolinate with oxaliplatin (mFOLFOX 6) + bevacizumab, there was no new metastatic lesion and lung metastasis reduction was observed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23225438_20201005_0.5			Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23225438_20201005_0.5			Antineoplastic Agents|Cells, Cultured|Cyclophosphamide|Deoxycytidine|Dose-Response Relationship, Drug|Forkhead Transcription Factors|Humans|Immunosuppressive Agents|Leukocytes, Mononuclear|T-Lymphocytes, Regulatory	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23225438_20201005_0.5	levofolinate	drug_umls_atom	PBMCs were simultaneously treated with cyclophosphamide (CPA), gemcitabine (GEM), 5-fluorouracil, levofolinate, or oxaliplatin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20354823_20201005_0.5	levofolinate	drug_umls_atom	Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20354823_20201005_0.5			Adult|Aged|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Colorectal Neoplasms|Drugs, Generic|Female|Fluorouracil|Humans|Levoleucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20354823_20201005_0.5	levofolinate	drug_umls_atom	No section The efficacy and safety of generic and brand name levofolinate injectable drugs were evaluated in 42 chemotherapy-naïve patients with colorectal cancer who received the combination chemotherapy of levofolinate, 5-fluorouracil, and oxaliplatin with or without bevacizumab.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20354823_20201005_0.5	levofolinate	drug_umls_atom	These findings suggest that both the effectiveness and safety profiles of the generic name levofolinate are comparable to those of the brand name drug, when used in combination with 5-fluorouracil and oxaliplatin in patients with colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5	levofolinate	drug_umls_atom	Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5	levofolinate	drug_umls_atom	5-fluorouracil|calcium-folinic acid|concomitant infusion|disodium levofolinate|solubility|synergism	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5			Humans|Male|Levoleucovorin|Leucovorin|Fluorouracil|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Infusions, Intravenous	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5	levofolinate	drug_umls_atom	The sodium salt of leucovorin-disodium levofolinate (Na-Lv) is a novel molecule with a pharmacological profile similar to Ca-FA.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24873165_20201005_0.5			[Penile metastasis from rectal carcinoma: a case report and literature review].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24873165_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Combined Modality Therapy|Fluorouracil|Humans|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Penile Neoplasms|Quality of Life|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24873165_20201005_0.5	levofolinate	drug_umls_atom	As treatment, we performed colostomy to relieve voiding difficulty, followed by combination chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17630037_20201005_0.5			Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17630037_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Drug Administration Schedule|Female|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Prognosis|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17630037_20201005_0.5	levofolinate	drug_umls_atom	Strategy A (control group) was single-agent fluorouracil (given with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402443_20201005_0.5	levofolinate	drug_umls_atom	[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402443_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Docetaxel|Drug Administration Schedule|Fluorouracil|Humans|Hypopharyngeal Neoplasms|Leucovorin|Male|Paclitaxel|Remission Induction|Taxoids	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402443_20201005_0.5	levofolinate	drug_umls_atom	No section We treated a patient with hypopharyngeal carcinoma who achieved a complete response following three cycles of chemotherapy with docetaxel, cisplatin, 5-FU and levofolinate.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12402443_20201005_0.5	levofolinate	drug_umls_atom	We conclude that chemotherapy using docetaxel, cisplatin, 5-FU, and levofolinate will be useful for treating head and neck cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14579760_20201005_0.5			[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14579760_20201005_0.5			Antibodies, Monoclonal|Antineoplastic Agents|Antineoplastic Agents, Phytogenic|Camptothecin|Colorectal Neoplasms|Fluorouracil|Humans|Irinotecan|Liver Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14579760_20201005_0.5	levofolinate	drug_umls_atom	No section The treatment regimens that are considered to be effective against metastatic colorectal carcinoma and available in Japan are levofolinate calcium (Isovorin)/5-fluorouracil (5-FU), irinotecan hydrochloride (Topotecin, CPT-11), and repeated low-dose cisplatin/5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19106556_20201005_0.5			[A complete response of locally-advanced poorly differentiated adenocarcinoma of the rectum to pre-operative chemo-radiation therapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19106556_20201005_0.5			Adenocarcinoma|Aged|Cell Differentiation|Colonoscopy|Female|Humans|Neoadjuvant Therapy|Neoplasm Staging|Rectal Neoplasms|Remission Induction|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19106556_20201005_0.5	levofolinate	drug_umls_atom	After chemo-radiation therapy of 50.4 Gy and 5-FU plus levofolinate calcium (Isovorin) infusion, the tumor was reduced in size and lymph nodes were extremely decreased.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3109515_20201005_0.5			Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3109515_20201005_0.5			Adenocarcinoma|Administration, Oral|Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Capecitabine|Colorectal Neoplasms|Deoxycytidine|Disease-Free Survival|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Frail Elderly|Humans|Infusions, Intravenous|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Quality of Life|United Kingdom	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3109515_20201005_0.5	levofolinate	drug_umls_atom	After comprehensive health assessment (CHA), patients were randomly assigned by minimisation to: 48-h intravenous fluorouracil with levofolinate (group A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5			A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5			Adenocarcinoma|Antimetabolites, Antineoplastic|Female|Fluorouracil|Heart Failure|Humans|Middle Aged|Rectal Neoplasms|Takotsubo Cardiomyopathy	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5	levofolinate	drug_umls_atom	Acute heart failure developed during the administration of 5-fluorouracil (5-FU) and levofolinate calcium in a 62-year-old woman who had underwent a Miles operation for rectal adenocarcinoma.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19305108_20201005_0.5	levofolinate	drug_umls_atom	Coronary angiography demonstrated normal coronary arteries, and multi-vessel coronary artery vasospasms including microcirculation disorders could be provoked by intracoronary acetylcholine infusion during, but not before, the intravenous administration of levofolinate calcium and 5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5			Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5			Adolescent|Adult|Aged|Ambulatory Care|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Disease Progression|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Male|Maximum Tolerated Dose|Middle Aged|Neoplasm Metastasis|Survival Rate|Treatment Outcome|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5	levofolinate	drug_umls_atom	BACKGROUND Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15553741_20201005_0.5			[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15553741_20201005_0.5			Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Carcinoembryonic Antigen|Cecal Neoplasms|Combined Modality Therapy|Floxuridine|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Neoplasm Seeding|Peritoneal Neoplasms|Reoperation	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15553741_20201005_0.5	levofolinate	drug_umls_atom	After that, he received systemic chemotherapy (5-FU 500 mg/body/week div, levofolinate calcium 250 mg/body/week i.v.)	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24390266_20201005_0.5			[A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24390266_20201005_0.5			Adenocarcinoma|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Cetuximab|Colonic Neoplasms|Fatal Outcome|Female|Fluorouracil|Humans|Leucovorin|Middle Aged|Skin Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24390266_20201005_0.5	levofolinate	drug_umls_atom	Surgical resection of the primary lesion was performed and FOLFIRI (5-fluorouracil, levofolinate calcium, irinotecan) and cetuximab chemotherapy for the metastases was initiated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5			Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5			anemia|hemoglobin|liposomal iron|myelodysplastic syndrome	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5			Humans|Male|Adult|Middle Aged|Female|Epoetin Alfa|Biosimilar Pharmaceuticals|Iron|Vitamin B 12|Retrospective Studies|Erythropoietin|Hematinics|Anemia|Folic Acid|Anemia, Refractory|Hemoglobins|Renal Dialysis|Renal Insufficiency, Chronic|Recombinant Proteins|Liposomes|Treatment Outcome|Europe	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5	levofolinate	drug_umls_atom	In addition, they received liposomal iron (Sideral®), calcium levofolinate and vitamin B12.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	Pulmonary edema caused by levofolinate treatment in patients with liver metastases from colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5			Aged|Colorectal Neoplasms|Fatal Outcome|Folic Acid|Humans|Liver Neoplasms|Male|Pulmonary Edema|Radiography, Abdominal|Radiography, Thoracic|Tomography, X-Ray Computed	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	Because hepatectomy was not indicated, the patient was treated with a combination of oxaliplatin, levofolinate, and fluorouracil (5-FU) (modified FOLFOX 6 regimen).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	After 15 cycles of chemotherapy, this regimen was considered to have been ineffective; therefore, treatment was started with the topoisomerase inhibitor irinotecan and an intravenous infusion of 5-FU and levofolinate (FOLFIRI).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	After receiving irinotecan and levofolinate, the patient had chills, a severe cough, and dyspnea.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	After the third cycle of oxaliplatin and levofolinate, pulmonary edema recurred, and a preshock state developed again.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	We suspected that either oxaliplatin or irinotecan had caused the pulmonary edema and, therefore, administered levofolinate, 200 mg/m(2); 5-FU, 400 mg/m(2); and bevacizumab, 330 mg/m(2); intravenously on day 1, followed by 5-FU, 2,400 mg/m(2), as a continuous intravenous infusion at 46 hours without either of oxaliplatin, levofolanate, and bevacizumab.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	After being treated with levofolinate again, the patient suddenly complained of severe dyspnea; this symptom confirmed that levofolinate had caused the pulmonary edema.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24419719_20201005_0.5	levofolinate	drug_umls_atom	To our knowledge, severe pulmonary edema caused by levofolinate has not been reported previously.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24316553_20201005_0.5	levofolinate	drug_umls_atom	Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24316553_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Deoxycytidine|Female|Fluorouracil|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Interleukin-2|Leucovorin|Lymphocytes, Tumor-Infiltrating|Male|Middle Aged|Neoplasm Grading|Neoplasm Metastasis|Organoplatinum Compounds|Oxaliplatin|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24316553_20201005_0.5	levofolinate	drug_umls_atom	Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m(2), day 1); oxaliplatin (85 mg/m(2), day 2); levofolinate (100 mg/m(2), days 1-2), 5-fluorouracil (5-FU) (400 mg/m(2) in bolus followed by 24 h infusion at 800 mg/m(2),days 1-2), sc.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15332552_20201005_0.5	levofolinate	drug_umls_atom	[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15332552_20201005_0.5			Adenocarcinoma|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Chemotherapy, Adjuvant|Colectomy|Colonic Neoplasms|Drug Administration Schedule|Fluorouracil|Humans|Irinotecan|Leucovorin|Liver Neoplasms|Male|Remission Induction	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18045783_20201005_0.5			Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18045783_20201005_0.5			Aged|Antineoplastic Agents|Drug Hypersensitivity|Female|Humans|Immunoglobulin E|Japan|Lymphocyte Activation|Organoplatinum Compounds|Oxaliplatin|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18045783_20201005_0.5	levofolinate	drug_umls_atom	In addition, a drug lymphocyte stimulating test against oxaliplatin and levofolinate calcium (an isomer of leucovorin calcium) gave values of 696% and 107 % respectively, as compared with control serum.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5			Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5			Oxaliplatin|Hypersensitivity reactions|XELOX therapy|FOLFOX therapy|Colorectal cancer	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5			Aged|Anti-Inflammatory Agents|Antimetabolites, Antineoplastic|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Combined Modality Therapy|Deoxycytidine|Dexamethasone|Drug Hypersensitivity|Female|Fluorouracil|Humans|Incidence|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Retrospective Studies|Risk Factors	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5403874_20201005_0.5	levofolinate	drug_umls_atom	In this study, we compared the frequency and pattern of HSRs to modified FOLFOX6 (mFOLFOX6; 5-fluorouracil, levofolinate calcium and L-OHP infusions) and XELOX (capecitabine and L-OHP) therapies, and sought to identify risk factors associated with HSRs.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24958736_20201005_0.5	levofolinate	drug_umls_atom	Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24958736_20201005_0.5			Adjuvant chemotherapy|Colon cancer|D2/D3 lymph node dissection|UFT/LV	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24958736_20201005_0.5			Administration, Intravenous|Administration, Oral|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Colorectal Neoplasms|Disease-Free Survival|Female|Fluorouracil|Humans|Japan|Leucovorin|Lymph Node Excision|Male|Middle Aged|Neoplasm Staging|Tegafur|Uracil|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24958736_20201005_0.5	levofolinate	drug_umls_atom	This is the first report of JCOG0205, which compared UFT/LV to standard 5-FU/levofolinate (l-LV) for stage III colorectal cancer patients who have undergone Japanese D2/D3 lymph node dissection.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14750335_20201005_0.5	levofolinate	drug_umls_atom	[A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14750335_20201005_0.5			Adenocarcinoma|Antineoplastic Combined Chemotherapy Protocols|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Lymph Nodes|Lymphatic Metastasis|Middle Aged|Rectal Neoplasms|Remission Induction	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14750335_20201005_0.5	levofolinate	drug_umls_atom	After the operation, weekly bolus of 5-fluorouracil combined with levofolinate was carried out.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	levofolinate	drug_umls_atom	Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	levofolinate	drug_umls_atom	Drug stability|calcium levofolinate|chromatography|robotic compounding	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5			Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Glucose|Levoleucovorin|Nylons|Polyenes|Polypropylenes|Saline Solution|Syringes|Temperature|Water	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	levofolinate	drug_umls_atom	Purpose Calcium levofolinate (CaLev) for intravenous administration is commercially available as a powder that must be reconstituted for injection or reconstituted and then diluted before administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5			[Direct resolution of calcium folinate stereoisomers using a bovine serum albumin chiral HPLC column].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5			Chromatography, High Pressure Liquid|Hydrogen-Ion Concentration|Leucovorin|Serum Albumin, Bovine|Stereoisomerism	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5	levofolinate	drug_umls_atom	OBJECTIVE To establish a direct and fast method separating calcium levofolinate and calcium dextrofolinate in a bovine serum albumin stationary phase chiral column.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5	levofolinate	drug_umls_atom	And the retention time of calcium levofolinate and calcium dextrofolinate were 18.5 min and 22.6 min, respectively.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5922357_20201005_0.5			A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5922357_20201005_0.5			FOLFOXIRI|bevacizumab|colorectal cancer|RAS mutant|sidedness	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5922357_20201005_0.5			Middle Aged|Aged|Adult|Male|Humans|Female|Bevacizumab|FOLFOXIRI protocol|Prospective Studies|Antineoplastic Combined Chemotherapy Protocols|Leucovorin|Camptothecin|Organoplatinum Compounds|Fluorouracil|Disease-Free Survival|Colorectal Neoplasms|Antibodies, Monoclonal, Humanized|Kaplan-Meier Estimate|Colonic Neoplasms|Treatment Outcome|Neutropenia|Mutation|Japan	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5922357_20201005_0.5	levofolinate	drug_umls_atom	Patients with an age of 20 to 75 years, and unresectable, measurable tumors harboring RAS mutation were given first-line treatment with bevacizumab (5 mg/kg on day 1) plus modified-FOLFOXIRI (irinotecan 150 mg/m , oxaliplatin 85 mg/m , levofolinate 200 mg/m , and fluorouracil 2400 mg/m as a 46-h continuous infusion on day 1, repeated every 2 weeks).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17108731_20201005_0.5	levofolinate	drug_umls_atom	[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17108731_20201005_0.5			Adenocarcinoma|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Aorta|Chronotherapy|Cisplatin|Eating|Fluorouracil|Humans|Leucovorin|Lymph Nodes|Lymphatic Metastasis|Male|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17108731_20201005_0.5	levofolinate	drug_umls_atom	Paclitaxel was not effective in treating the lymph node metastases or vomiting; therefore a chronomodulated schedule was used, which involved the administration of low doses of 5-fluorouracil, levofolinate calcium and cis-platinum (FLP) each night.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17212159_20201005_0.5			[Utility of arterial infusion chemotherapy and radiation therapy for the pelvic local recurrence of rectal cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17212159_20201005_0.5			Aged|Aged, 80 and over|Combined Modality Therapy|Fluorouracil|Humans|Infusions, Intra-Arterial|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Pelvic Neoplasms|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17212159_20201005_0.5	levofolinate	drug_umls_atom	No section We treated 3 cases of local pelvic recurrence due to a rectal cancer post operation by arterial infusion chemotherapy with 5-FU and levofolinate calcium and also by radiation therapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12921507_20201005_0.5			Photo-induced Stevens-Johnson syndrome due to sulfasalazine therapy.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12921507_20201005_0.5			Adult|Antirheumatic Agents|Arthritis|Humans|Male|Stevens-Johnson Syndrome|Sulfasalazine|Sunlight	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12921507_20201005_0.5	levofolinate	drug_umls_atom	According to his medical record, the patient had received methotrexate, levofolinate calcium, deflazacort, and diclofenac sodium as needed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5	levofolinate	drug_umls_atom	Development and validation of a robust capillary electrophoresis method for impurity profiling of calcium levofolinate including the (6R,2'S)-diastereomer using statistical experimental design.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5			Borates|Buffers|Cyclodextrins|Drug Contamination|Electrophoresis, Capillary|Humans|Leucovorin|Pharmaceutical Preparations|Reproducibility of Results|Research Design|Sensitivity and Specificity|Stereoisomerism|Temperature|Time	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5	levofolinate	drug_umls_atom	No section A chiral capillary electrophoresis assay for the simultaneous determination of the optical purity and of related substances of calcium levofolinate has been developed and validated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5	levofolinate	drug_umls_atom	An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5			Breast cancer|Colorectal cancer|FOLFOX	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5			Adenocarcinoma|Adult|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Carcinoma|Colectomy|Colonic Neoplasms|Female|Fluorouracil|Humans|Leucovorin|Lymph Nodes|Neoplasm Recurrence, Local|Neoplasms, Second Primary|Organoplatinum Compounds|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5	levofolinate	drug_umls_atom	Introduction Therapy comprising 5-fluorouracil, levofolinate, and oxaliplatin is currently the most common chemotherapy for colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5	levofolinate	drug_umls_atom	We experienced a successful case of advanced colon cancer and recurrent breast cancer with 5-fluorouracil, levofolinate, and oxaliplatin therapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5	levofolinate	drug_umls_atom	Therapy of 5-fluorouracil, levofolinate, and oxaliplatin was administered; the therapy included 5-fluorouracil, which is considered to be effective for both colon and breast cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5	levofolinate	drug_umls_atom	After two courses of 5-fluorouracil, levofolinate, and oxaliplatin, the lymph node began to shrink and almost completely disappeared after eight courses of 5-fluorouracil, levofolinate, and oxaliplatin.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4086702_20201005_0.5	levofolinate	drug_umls_atom	 Conclusion We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5			Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5			hepatocellular carcinoma|apatinib|targeted therapy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5			Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Hepatocellular|Chemoembolization, Therapeutic|Disease-Free Survival|Ethiodized Oil|Fluorouracil|Humans|Leucovorin|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Pyridines|Tegafur	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5	levofolinate	drug_umls_atom	After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m on day 1, calcium levofolinate 200 mg/m on day 1 and 2, 5-fluorouracil 400 mg/m intravenously and 5-fluorouracil 600 mg/m intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5			Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5	disodium levofolinate	drug_umls_atom	Colon cancer|5-Fluorouracil (5-FU)|Calcium levofolinate (CaLV)|Disodium levofolinate (NaLV)|Synergism|Thymidylate synthetase (TYMS)|SLC19A1	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5			Animals|Antineoplastic Agents|Apoptosis|Cell Line, Tumor|Cell Proliferation|Disease Models, Animal|Dose-Response Relationship, Drug|Drug Synergism|Fluorouracil|Humans|Leucovorin|Male|Mice|Reduced Folate Carrier Protein|Thymidylate Synthase|Time Factors|Tumor Cells, Cultured|Xenograft Model Antitumor Assays	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5			Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5	disodium levofolinate	drug_umls_atom	5-fluorouracil|calcium-folinic acid|concomitant infusion|disodium levofolinate|solubility|synergism	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5			Humans|Male|Levoleucovorin|Leucovorin|Fluorouracil|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Infusions, Intravenous	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC6552345_20201005_0.5	disodium levofolinate	drug_umls_atom	The sodium salt of leucovorin-disodium levofolinate (Na-Lv) is a novel molecule with a pharmacological profile similar to Ca-FA.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11135086_20201005_0.5	l-folinic acid	drug_umls_atom	Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11135086_20201005_0.5			Aged|Female|Folic Acid|Homocysteine|Humans|Hyperhomocysteinemia|Leucovorin|Male|Middle Aged|Renal Dialysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11135086_20201005_0.5	l-folinic acid	drug_umls_atom	We evaluated whether a high-dose L-folinic acid-based regimen provided improved total homocysteine (tHcy)-lowering efficacy in chronic hemodialysis patients, as suggested by a recent uncontrolled report.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11135086_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS We block-randomized 48 chronic, stable hemodialysis patients based on their screening predialysis tHcy levels, sex, and dialysis center into two groups of 24 subjects treated for 12 weeks with oral FA at 15 mg/day or an equimolar amount (20 mg/day) of oral L-folinic acid (FNA) [L-5-formyltetrahydrofolate].	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11135086_20201005_0.5	l-folinic acid	drug_umls_atom	 CONCLUSIONS Relative to high-dose FA, high-dose oral L-folinic acid-based supplementation does not afford improved tHcy-lowering efficacy in hemodialysis patients.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8419064_20201005_0.5			HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8419064_20201005_0.5			Acetaminophen|Aspirin|Chromatography, High Pressure Liquid|Fluorouracil|Humans|Leucovorin|Quality Control|Stereoisomerism|Tetrahydrofolates	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8419064_20201005_0.5	l-folinic acid	drug_umls_atom	No section We present a rapid, sensitive, and automated HPLC method with direct resolution of l-folinic acid (l-FA), d-folinic acid (d-FA), and 5-methyltetrahydrofolate (5MTHF) from plasma samples.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8528973_20201005_0.5	l-folinic acid	drug_umls_atom	Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8528973_20201005_0.5			Adult|Aged|Antidotes|Antimetabolites, Antineoplastic|Carcinoma, Renal Cell|Chronobiology Phenomena|Colorectal Neoplasms|Drug Administration Schedule|Feasibility Studies|Female|Floxuridine|Humans|Infusions, Intravenous|Kidney Neoplasms|Leucovorin|Male|Middle Aged|Neoplasms|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11331322_20201005_0.5	l-folinic acid	drug_umls_atom	Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11331322_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Combined Modality Therapy|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11331322_20201005_0.5	l-folinic acid	drug_umls_atom	Chemotherapy was oxaliplatin 80, 100, or 130 mg/m2 2-hour infusion on day 1 followed by L-folinic acid 100 mg/m2/d intravenous bolus, and 5-FU 350 mg/m2/d continuous infusion on days 1 to 5 (FolfoR1).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18083404_20201005_0.5			Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18083404_20201005_0.5			Adjuvants, Immunologic|Adult|Aged|Aged, 80 and over|Antimetabolites, Antineoplastic|Colorectal Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Leucovorin|Levamisole|Male|Middle Aged|Neoplasm Recurrence, Local|Vitamin B Complex	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18083404_20201005_0.5	l-folinic acid	drug_umls_atom	Chemotherapy was delivered as six 5-day courses every 4 weeks or as 30 once-weekly courses of intravenous fluorouracil (370 mg/m2) with high-dose (175 mg) L-folinic acid or low-dose (25 mg) L-folinic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21607506_20201214_0.5	l-folinic acid	drug_umls_atom	A short-term infusion regimen of Cisplatin, 5-Fluorouracil and L-folinic Acid in advanced head and neck-carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21607506_20201214_0.5			Humans|Male|Middle Aged|Female|Cisplatin|Fluorouracil|Leucovorin|Head and Neck Neoplasms|Levoleucovorin|Carcinoma, Squamous Cell|Antineoplastic Combined Chemotherapy Protocols|Remission Induction|Vomiting|Leukopenia	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10821362_20201005_0.5			Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10821362_20201005_0.5			Adjuvants, Immunologic|Antimetabolites, Antineoplastic|Chemotherapy, Adjuvant|Colonic Neoplasms|Drug Therapy, Combination|Fluorouracil|Humans|Leucovorin|Levamisole|Neoplasm Recurrence, Local|Radiotherapy, Adjuvant|Rectal Neoplasms|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10821362_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Patients with colorectal cancer, without evident residual disease, were randomly assigned fluorouracil (370 mg/m2) with high-dose (175 mg) or low-dose (25 mg) L-folinic acid and either active or placebo levamisole.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID1557660_20201005_0.5			Clinical pharmacokinetics of fluorouracil and folinic acid.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID1557660_20201005_0.5			Administration, Oral|Fluorouracil|Half-Life|Hepatic Artery|Humans|Infusions, Intra-Arterial|Interferon-alpha|Leucovorin|Liver|Tetrahydrofolates	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID1557660_20201005_0.5	l-folinic acid	drug_umls_atom	After administration of the commercially available d,l-folinic acid (d,l-CHO-THF), the biologically inactive d-form is cleared very slowly with a median half-life of 438 +/- 63 minutes.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID1557660_20201005_0.5	l-folinic acid	drug_umls_atom	After application of the pure l-folinic acid, mean elimination half-live and area under the curve were in the same range as after administration of the d,l-CHO-THF.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID1557660_20201005_0.5	l-folinic acid	drug_umls_atom	Higher doses of oral d,l-folinic acid are always absorbed incompletely.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9291820_20201005_0.5			Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9291820_20201005_0.5			Antidotes|Antimetabolites, Antineoplastic|Biopsy|Drug Screening Assays, Antitumor|Drug Synergism|Female|Fluorouracil|Folic Acid|Humans|Leucovorin|Neoplasms|Peptide Synthases|Tumor Cells, Cultured	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9291820_20201005_0.5	l-folinic acid	drug_umls_atom	No section The purpose of this study was to investigate folate-related predictors of 5-fluorouracil (5-FU) cytotoxicity in the presence or absence of l-folinic acid (l-FA).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12637479_20201005_0.5			Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12637479_20201005_0.5			Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoadjuvant Therapy|Organoplatinum Compounds|Oxaliplatin|Radiotherapy Dosage|Radiotherapy, Adjuvant|Rectal Neoplasms|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12637479_20201005_0.5	l-folinic acid	drug_umls_atom	Two cycles of chemotherapy were given synchronously on weeks 1 and 5, with oxaliplatin 130 mg/m(2) on day 1 followed by 5-day continuous infusion of fluorouracil 350 mg/m(2) and L-folinic acid 100 mg/m(2).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9747816_20201005_0.5			Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9747816_20201005_0.5			Antidotes|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Chemotherapy, Adjuvant|Cisplatin|Esophageal Neoplasms|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Prospective Studies|Radiotherapy Dosage|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9747816_20201005_0.5	l-folinic acid	drug_umls_atom	OBJECTIVE We conducted a prospective study of neoadjuvant treatment for squamous cell carcinoma of the esophagus, modifying the chemotherapy protocol by adding l-folinic acid and giving bifractionated radiotherapy with a cis-diaminedichloroplatinum (CDDP) injection before each fraction.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9747816_20201005_0.5	l-folinic acid	drug_umls_atom	Chemotherapy, CDDP (80 mg/m2 D2), 5-fluorouracil (5-FU; 600 mg/m2, D1-4), and l-folinic acid (200 mg/m2, D1-4), was given in two sessions with a 3-week interval during which the patients received radiotherapy (45 Gy), two fractions per day (150 cGy/fraction).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11038030_20201005_0.5	l-folinic acid	drug_umls_atom	Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11038030_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Colorectal Neoplasms|Combined Modality Therapy|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Levamisole|Male|Middle Aged|Neoplasm Recurrence, Local|Neoplasm Staging|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11038030_20201005_0.5	l-folinic acid	drug_umls_atom	BACKGROUND QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8204356_20201005_0.5			Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8204356_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Diarrhea|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Mouth Mucosa|Neoplasm Metastasis|Remission Induction|Stomatitis|Treatment Outcome|Vomiting	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8204356_20201005_0.5	l-folinic acid	drug_umls_atom	No section Between February 1991 and July 1992, 79 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study of combined 5-fluorouracil (5-FU) and l-folinic acid (FA).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9470809_20201005_0.5			Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9470809_20201005_0.5			Adenocarcinoma|Adult|Aged|Antigens, Neoplasm|Biomarkers, Tumor|CA-19-9 Antigen|Carcinoembryonic Antigen|Colorectal Neoplasms|Female|Follow-Up Studies|Humans|Male|Middle Aged|N-Acetylneuraminic Acid|Sensitivity and Specificity|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9470809_20201005_0.5	l-folinic acid	drug_umls_atom	The study was performed on 44 patients treated for advanced colorectal carcinoma by a weekly 8 h continuous infusion of 5-fluorouracil (1300 mg/m2) plus bolus injection of L-folinic acid (100 mg/m2).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8643221_20201005_0.5	l-folinic acid	drug_umls_atom	Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8643221_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Gastrointestinal Neoplasms|Humans|Leucovorin|Male|Methotrexate|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8643221_20201005_0.5	l-folinic acid	drug_umls_atom	infusion of L-folinic acid (LFA), 250 mg/m2, and 5-fluorouracil (FU), 600 mg/mg2 as an i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC8082275_20210511_0.5			Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC8082275_20210511_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Biliary Tract Neoplasms|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Prospective Studies	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC8082275_20210511_0.5	l-folinic acid	drug_umls_atom	FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m , L-folinic acid 175 mg [or folinic acid 350 mg], fluorouracil 400 mg/m [bolus], and fluorouracil 2400 mg/m as a 46-h continuous intravenous infusion).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11870158_20201005_0.5	l-folinic acid	drug_umls_atom	Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11870158_20201005_0.5			Adult|Aged|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Chronotherapy|Colorectal Neoplasms|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11870158_20201005_0.5	l-folinic acid	drug_umls_atom	OBJECTIVE To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4438152_20201005_0.5	l-folinic acid	drug_umls_atom	A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4438152_20201005_0.5			PRC|Humans|Female|Fluorouracil|Cetuximab|Hepatectomy|irinotecan|Leucovorin|Infusions, Intra-Arterial|Antineoplastic Combined Chemotherapy Protocols|Neoplasm Recurrence, Local|Levoleucovorin|Camptothecin|Liver Neoplasms|oxaliplatin|Organoplatinum Compounds|Sigmoid Neoplasms|panitumumab|Antibodies, Monoclonal|Combined Modality Therapy|Adenocarcinoma|Lymphatic System	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23075717_20201005_0.5			Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23075717_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|CA-19-9 Antigen|Carcinoembryonic Antigen|Colorectal Neoplasms|Female|Fluorouracil|Hepatic Artery|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23075717_20201005_0.5	l-folinic acid	drug_umls_atom	They received a Folfox4 regimen; 1st day: HAI of oxaliplatin 85 mg/m(2) and L-folinic acid 200 mg/m(2), followed by a bolus hepatic arterial injection of 5-fluorouracil 400 mg/m(2), then continuous HAI of 5-FU 600 mg/m(2); 2nd day: infusion of L-folinic acid 200 mg/m(2) i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27647222_20201005_0.5			Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27647222_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Dose-Response Relationship, Drug|Female|Humans|Male|Neoplasm Metastasis|Retrospective Studies|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID27647222_20201005_0.5	l-folinic acid	drug_umls_atom	All patients were treatment-naive and received docetaxel 70 mg/m2 day 1, cisplatin 60 mg/m2 day 1, l-folinic acid 100 mg/m2 days 1-2, followed by 5-fluorouracil 400 mg/m2 bolus days 1-2, and then 600 mg/m2 as a 22-hour continuous infusion days 1-2, every 14 days, plus pegfilgrastim 6 mg on day 3.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2408897_20201005_0.5			Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2408897_20201005_0.5			colorectal cancer|irinotecan|5-fluorouracil (5-FU)|irinotecan and 5-FU combination therapy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2408897_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Diarrhea|Disease-Free Survival|Drug Administration Schedule|Female|Fluorouracil|Humans|Infusions, Intravenous|Injections, Intravenous|Irinotecan|Leucovorin|Leukopenia|Male|Middle Aged|Mouth Mucosa|Neoplasm Metastasis|Stomatitis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2408897_20201005_0.5	l-folinic acid	drug_umls_atom	L-folinic acid 175 mg or d,l folinic acid 350 mg was given over 2 h followed by a bolus of 5-fluorouracil (400 mg m ) and a 46 h continuous infusion of 5-fluorouracil (2.4-2.8 g m ).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17679458_20201005_0.5			A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17679458_20201005_0.5			Adenocarcinoma|Adult|Aged|Anemia|Antineoplastic Combined Chemotherapy Protocols|Bone Neoplasms|Camptothecin|Disease-Free Survival|Female|Fluorouracil|Gastrointestinal Diseases|Humans|Irinotecan|Leucovorin|Liver Neoplasms|Lung Neoplasms|Lymphatic Metastasis|Male|Middle Aged|Neutropenia|Organoplatinum Compounds|Oxaliplatin|Peritoneal Neoplasms|Pilot Projects|Stomach Neoplasms|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17679458_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Patients received oxaliplatin (85 mg/m2 d 1), irinotecan (140 mg/m2 d 1), and L-folinic acid (200 mg/m2 d 1) followed by 5-fluorouracil bolus (400 mg/m2 d 1) and then 5-fluorouracil (2,400 mg/m2 48-h continuous infusion), every 14 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21907007_20201005_0.5			Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21907007_20201005_0.5			Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Female|Fluorouracil|Humans|Leucovorin|Male|Stomach Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21907007_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS In this multicenter non-randomized phase II trial, we administered the FOLFIRI chemotherapy protocol (irinotecan [180 mg/m(2)], fluorouracil [5-FU] [400 mg/m(2)] and folinic acid 400 mg/m(2) or 200mg/m(2) of l-folinic acid) to patients aged over 70 years with locally-advanced or metastatic gastric cancer combined with Comprehensive Geriatric Assessment (CGA).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11205195_20201005_0.5			Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11205195_20201005_0.5			Adult|Aged|Antimetabolites, Antineoplastic|Circadian Rhythm|Colorectal Neoplasms|Disease Progression|Drug Administration Schedule|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Neoplasm Staging|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11205195_20201005_0.5	l-folinic acid	drug_umls_atom	No section Forty three patients with metastatic colorectal cancer (MCC) received a daily administration of 5-fluorouracil (600 mg/m2/d at the first course, 700 mg/m2/d at the second and 800 mg/m2/d at the third course), and l-folinic acid (150 mg/m2/d) or dl-folinic acid (300 mg/m2/d) both chronomodulated from 22:00 to 10.00 am with peak delivery rate at 4.00 for 5 days every 21 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11748463_20201005_0.5			Treatment of advanced colorectal adenocarcinoma with weekly high-dose l-leucovorin and 5-fluorouracil.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11748463_20201005_0.5			Adenocarcinoma|Adolescent|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Drug Administration Schedule|Fluorouracil|Humans|Infusions, Intravenous|Injections, Intravenous|Leucovorin|Lymphatic Metastasis|Magnetic Resonance Imaging|Middle Aged|Tomography, X-Ray Computed|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11748463_20201005_0.5	l-folinic acid	drug_umls_atom	No section We report the results of 5-fluorouracil (5-FU) combined with high-dose l-folinic acid (leucovorin) therapy for patients with advanced colorectal carcinoma.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11748463_20201005_0.5	l-folinic acid	drug_umls_atom	In each treatment course, the patients weekly received both 5-FU (600 mg/m2 by intravenous 15 min infusion) and l-folinic acid (250 mg/m2 by intravenous infusion over a period of 2 h).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16739329_20201005_0.5	l-folinic acid	drug_umls_atom	Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16739329_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoembryonic Antigen|Colorectal Neoplasms|Feasibility Studies|Female|Fluorouracil|Hepatic Artery|Humans|Infusions, Intra-Arterial|Leucovorin|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16739329_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS The feasibility of hepatic arterial infusion (HAI) of oxaliplatin (100 mg/m2 over 6 h) followed by l-folinic acid (L-FA) (400 mg over 2 h i.v.)-modulated continuous HAI of 5-Fluorouracil (5-FU) (60 mg/kg over 42 h; q2w) as second-line chemotherapy for metastatic CRC limited to the liver was investigated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11471389_20201005_0.5			[Neoadjuvant treatment in surgery of esophageal cancer].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11471389_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Esophageal Neoplasms|Esophagectomy|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoadjuvant Therapy|Neoplasm Staging|Prospective Studies|Radiotherapy Dosage|Radiotherapy, Adjuvant|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11471389_20201005_0.5	l-folinic acid	drug_umls_atom	No section We conducted a prospective study on neoadjuvant treatment for squamous cell carcinoma of the esophagus, modifying the chemotherapy protocol by adding l-folinic acid and giving bifractionated radiotherapy with a cis-diaminedichloroplatinum (CDDP) injection before each fraction.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9386863_20201005_0.5	l-folinic acid	drug_umls_atom	Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9386863_20201005_0.5			Adult|Aged|Antibiotics, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Breast Neoplasms, Male|Drug Administration Schedule|Drug Resistance, Neoplasm|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Mitoxantrone|Neoplasm Metastasis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9386863_20201005_0.5	l-folinic acid	drug_umls_atom	Twenty-three patients received mitoxantrone 12 mg/sqm day 1; fluorouracil 370 mg/sqm and L-folinic acid 100 mg/sqm days 1-3 administered every three weeks.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12062610_20201005_0.5			Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12062610_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Chemotherapy, Adjuvant|Combined Modality Therapy|Female|Fluorouracil|Humans|Lymphatic Metastasis|Male|Middle Aged|Mitomycin|Multivariate Analysis|Neoplasm Staging|Prospective Studies|Radiotherapy Dosage|Rectal Neoplasms|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12062610_20201005_0.5	l-folinic acid	drug_umls_atom	Adjuvant chemotherapy (5-FU + l-folinic acid) was delivered to 26 patients in the FUMIR-T4 protocol group.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5			First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5			gastric cancer|DCF|panitumumab|dose-dense|chemotherapy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5			PRC|Humans|Leucovorin|Fluorouracil|panitumumab|docetaxel|Cisplatin|Stomach Neoplasms|Antibodies, Monoclonal|Taxoids|Esophagogastric Junction|Levoleucovorin|Neutropenia|pegfilgrastim|Granulocyte Colony-Stimulating Factor|Exanthema|Anorexia|Diarrhea|Asthenia|Disease Progression	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5762360_20201005_0.5	l-folinic acid	drug_umls_atom	 Methods HER2 negative, PS 0-1 patients, received up to 4 cycles of panitumumab 6 mg/kg d 1, docetaxel 60 mg/m2 d 1, cisplatin 50 mg/m2 d 1, l-folinic acid 100 mg/m2 d 1-2, followed by 5-FU 400 mg/m2 bolus d 1-2, and then 600 mg/m2 as a 22 h c.i.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12427152_20201005_0.5			Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12427152_20201005_0.5			Folic Acid|Hematinics|Humans|Hyperhomocysteinemia|Kidney Failure, Chronic|Renal Dialysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12427152_20201005_0.5	l-folinic acid	drug_umls_atom	BACKGROUND We have previously reported that a daily oral high dose of l-folinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients does not provide significantly greater reduction in fasting total homocysteine (tHcy) levels than an equimolar dose of folic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12427152_20201005_0.5	l-folinic acid	drug_umls_atom	The present study uses the affinity/HPLC method to analyze the distribution of plasma folate forms in patients who received l-folinic acid versus those who received folic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12427152_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Forty-eight chronic and stable hemodialysis patients were block-randomized, based on their screening predialysis tHcy levels, sex, and dialysis center, into two groups treated for 12 weeks with oral folic acid at 15 mg/day or an equimolar amount (20 mg/day) of oral l-folinic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11697844_20201005_0.5			Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11697844_20201005_0.5			Adult|Aged|Antimetabolites, Antineoplastic|Chemotherapy, Adjuvant|Chromatography, High Pressure Liquid|Colorectal Neoplasms|Dihydrouracil Dehydrogenase (NADP)|Female|Fluorouracil|Humans|Leucovorin|Leukocytes, Mononuclear|Male|Middle Aged|Oxidoreductases	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11697844_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Pharmacokinetics and metabolism of 5-FU and activity of DPD in PBMNC were examined in 110 colorectal cancer patients given adjuvant 5-FU 370 mg/m2 plus L-folinic acid 100 mg/m2 for five days every four weeks.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7777248_20201005_0.5	l-folinic acid	drug_umls_atom	Dose-finding study of 5'-deoxy-5-fluorouridine in combination with fixed doses of cisplatin and L-folinic acid for the treatment of advanced or recurrent squamous cell carcinoma of the head and neck.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7777248_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Diarrhea|Female|Floxuridine|Head and Neck Neoplasms|Humans|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Stomatitis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7777248_20201005_0.5	l-folinic acid	drug_umls_atom	and L-folinic acid (100 mg/m2 i.v.),	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17015056_20201005_0.5			A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17015056_20201005_0.5			Adult|Aged|Aged, 80 and over|Antimetabolites, Antineoplastic|Chromatography, High Pressure Liquid|Dihydrouracil Dehydrogenase (NADP)|Female|Fluorouracil|Gastrointestinal Neoplasms|Humans|Leukocytes, Mononuclear|Linear Models|Male|Middle Aged	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17015056_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Pharmacokinetics of 5-FU/5-FDHU and DPD activity in peripheral blood mononuclear cells (PBMCs) were examined in 188 gastrointestinal cancer patients given a test dose of 5-FU, 250 mg/m2, 2 weeks before starting the planned 5-FU treatment of 370 mg/m2 plus l-folinic acid, 100 mg/m2, for 5 days every 4 weeks.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3488188_20201005_0.5			Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3488188_20201005_0.5			Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal|Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Male|Middle Aged|Neoadjuvant Therapy|Neoplasm Staging|Organoplatinum Compounds|Oxaliplatin|Panitumumab|Preoperative Period|Rectal Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3488188_20201005_0.5	l-folinic acid	drug_umls_atom	 Methods In the pilot stage of this randomised controlled trial, 150 patients with radiologically staged locally advanced (T3 with ≥5 mm invasion beyond the muscularis propria or T4) tumours from 35 UK centres were randomly assigned (2:1) to preoperative (three cycles of OxMdG [oxaliplatin 85 mg/m , l-folinic acid 175 mg, fluorouracil 400 mg/m bolus, then 2400 mg/m by 46 h infusion] repeated at 2-weekly intervals followed by surgery and a further nine cycles of OxMdG) or standard postoperative chemotherapy (12 cycles of OxMdG).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20204366_20201005_0.5			Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20204366_20201005_0.5			Adenocarcinoma|Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Cisplatin|Docetaxel|Dose-Response Relationship, Drug|Female|Filgrastim|Fluorouracil|Granulocyte Colony-Stimulating Factor|Humans|Irinotecan|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Organoplatinum Compounds|Oxaliplatin|Polyethylene Glycols|Recombinant Proteins|Stomach Neoplasms|Taxoids|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20204366_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Chemo-naïve patients with metastatic gastric cancer were enrolled to receive 4 cycles of TCF-dd (docetaxel initially 85 mg/m(2) and cisplatin initially 75 mg/m(2) on day 1 [later modified due to toxicity: 70 and 60 mg/m(2) respectively], l-folinic acid 100 mg/m(2) on days 1 and 2, 5-fluorouracil 400 mg/m(2) bolus and then 600 mg/m(2) as a 22 h continuous infusion on day 1 and 2, every 14 days).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20204366_20201005_0.5	l-folinic acid	drug_umls_atom	Subsequently, patients with CR, PR or SD received 4 cycles of COFFI (oxaliplatin 85 mg/m(2), irinotecan 140 mg/m(2), l-folinic acid 200 mg/m(2), 5-fluorouracil bolus 400 mg/m(2) on day 1 followed by 2,400 mg/m(2) as a 48 h continuous infusion, every 14 days).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24282019_20201005_0.5			Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24282019_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Disease-Free Survival|Docetaxel|Drug Administration Schedule|Female|Filgrastim|Fluorouracil|Granulocyte Colony-Stimulating Factor|Humans|Male|Middle Aged|Nausea|Neutropenia|Polyethylene Glycols|Recombinant Proteins|Stomach Neoplasms|Taxoids|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24282019_20201005_0.5	l-folinic acid	drug_umls_atom	 METHODS Patients with histologically confirmed measurable MGC, not previously treated for advanced disease, received docetaxel 70 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, l-folinic acid 100 mg/m(2) days 1 and 2, followed by 5-fluorouracil (5-FU) 400 mg/m(2) bolus days 1 and 2, and then 600 mg/m(2) as a 22-h continuous infusion days 1 and 2, every 14 days, plus pegfilgrastim 6 mg on day 3.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11218187_20201005_0.5	levo-folinic acid	drug_umls_atom	The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11218187_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Disease Progression|Drug Administration Schedule|Female|Fluorouracil|Humans|Infusions, Intravenous|Injections, Intravenous|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Survival Analysis|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11218187_20201005_0.5	levo-folinic acid	drug_umls_atom	OBJECTIVE The phase II trial was designed to evaluate the activity of combined oxaliplatin (L-OHP), continuous infusion (CI) +/- bolus 5-fluorouracil (5FU) and levo-folinic acid (I-FA) in patients with metastatic colorectal cancer progressing after one or more lines of 5FU-based chemotherapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10847467_20201005_0.5			Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10847467_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma|Colonic Neoplasms|Dose-Response Relationship, Drug|Drug Administration Schedule|Drug Interactions|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Quinazolines|Rectal Neoplasms|Thiophenes|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10847467_20201005_0.5	levo-folinic acid	drug_umls_atom	OBJECTIVE To determine the maximum tolerated dose of oxaliplatin (L-OHP) given as a two-hour infusion followed by raltitrexed (Tomudex [TOM]) administered as a 15-min infusion on day 1, and bolus 5-fluorouracil (5-FU) modulated by a fixed dose of levo-folinic acid (LFA) 250 mg/m2 on day 2, recycling every two weeks, and to have preliminary evidence of activity of this combination in pretreated advanced colorectal cancer patients.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15837702_20201005_0.5			Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15837702_20201005_0.5			Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID15837702_20201005_0.5	levo-folinic acid	drug_umls_atom	OBJECTIVE The primary end point of this phase III trial was to compare the response rate (RR) of oxaliplatin (OXA) plus levo-folinic acid (l-FA) and 5-fluorouracil (5-FU) bolus with that of irinotecan (IRI) plus l-FA and 5-FU bolus in advanced colorectal carcinoma.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20472346_20201214_0.5			Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20472346_20201214_0.5			Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Combined Modality Therapy|Diarrhea|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasm Proteins|Neoplasm Staging|Neutropenia|Organoplatinum Compounds|Oxaliplatin|Postoperative Complications|Preoperative Care|Prognosis|Quinazolines|Radiotherapy Dosage|Rectal Neoplasms|Remission Induction|Thiophenes|Thymidylate Synthase|Treatment Outcome|Vitamin B Complex	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20472346_20201214_0.5	levo-folinic acid	drug_umls_atom	 METHODS Sixty-three patients with the following characteristics, a clinical (c) stage T4, cN1-2, or cT3N0 of ≤5 cm from the anal verge and/or with a circumferential resection margin (CRM) of ≤5 mm (by magnetic resonance imaging), received three biweekly courses of chemotherapy with OXA, 100 mg/m2; raltitrexed (RTX), 2.5 mg/m2 on day 1, and 5-fluorouracil (5-FU), 900 mg/m2 (31 patients) or 800 mg/m2 (32 patients); levo-folinic acid (LFA), 250 mg/m2 on day 2, during pelvic RT (45 Gy).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10509152_20201005_0.5	levo-folinic acid	drug_umls_atom	Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10509152_20201005_0.5			Adenocarcinoma|Adult|Aged|Antimetabolites, Antineoplastic|Antineoplastic Agents, Phytogenic|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Confidence Intervals|Disease-Free Survival|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Middle Aged|Prognosis|Severity of Illness Index|Survival Rate|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17295595_20201005_0.5			[Capillary blood flow as an index of the therapeutic effect of folinic acid in ischemia-reperfusion syndrome].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17295595_20201005_0.5			Animals|Capillaries|Intestines|Leucovorin|Male|Rats|Regional Blood Flow|Reperfusion Injury	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17295595_20201005_0.5	levo-folinic acid	drug_umls_atom	A comparison was made of three treatment groups: saline, folinic acid, and levo-folinic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID17295595_20201005_0.5	levo-folinic acid	drug_umls_atom	Levo-folinic acid improved capillary flow in the ileum after 25 minutes of reperfusion, and also reduced mucosal injury in the same stretch of intestine by the seventh day post-reperfusion (p<0.05).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16940809_20201005_0.5			Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16940809_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Disease Progression|Drug Administration Schedule|Female|Fluorouracil|Humans|Injections, Intravenous|Irinotecan|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16940809_20201005_0.5	levo-folinic acid	drug_umls_atom	We carried out this phase II study to assess the activity and toxicity of a biweekly regimen including OXA plus IRI on day 1, and levo-folinic acid (LFA) plus 5FU on day 2 (OXIRIFAFU) in pretreated patients with metastatic colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8983280_20201005_0.5	levo-folinic acid	drug_umls_atom	Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8983280_20201005_0.5			Adenocarcinoma|Adult|Aged|Antimetabolites, Antineoplastic|Digestive System Neoplasms|Drug Synergism|Drug Therapy, Combination|Female|Fluorouracil|Humans|Leucovorin|Male|Methotrexate|Middle Aged|Survival Rate|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8983280_20201005_0.5	levo-folinic acid	drug_umls_atom	No section The aim of this study was to evaluate the activity and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by means of methotrexate (MTX) and levo-folinic acid (LFA) in patients with advanced carcinoma of the digestive tract, and to assess the prognostic significance of MTX serum concentrations achieved in these patients.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10907951_20201005_0.5			Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10907951_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Dose-Response Relationship, Drug|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Leucovorin|Male|Middle Aged|Neutropenia|Quinazolines|Thiophenes|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10907951_20201005_0.5	levo-folinic acid	drug_umls_atom	Raltitrexed (Tomudex) is a direct and specific thymidilate synthase (TS) inhibitor, which has shown clinical activity against SCCHN in a previous phase I study, when combined with 5-FU and levo-folinic acid (LFA).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10907951_20201005_0.5	levo-folinic acid	drug_umls_atom	followed by raltitrexed at the starting dose of 2.5 mg/m2 on day 1; levo-folinic acid at fixed dose of 250 mg/m2, followed by 5-fluorouracil at the starting dose of 750 mg/m2 on day 2.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2375419_20201005_0.5			Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2375419_20201005_0.5			oxaliplatin|ralitrexed|5-fluorouracil|colon carcinoma|salvage regimen	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2375419_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Disease Progression|Drug Resistance, Neoplasm|Female|Fluorouracil|Humans|Infusions, Intravenous|Irinotecan|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Quinazolines|Salvage Therapy|Thiophenes|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC2375419_20201005_0.5	levo-folinic acid	drug_umls_atom	infusion) given on day 1, followed by levo-folinic acid 250 mg m (2 h i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9060527_20201005_0.5	l-isomer of leucovorin	drug_umls_atom	Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9060527_20201005_0.5			Adult|Aged|Agranulocytosis|Antidotes|Antimetabolites, Antineoplastic|Colorectal Neoplasms|Disease Progression|Female|Fluorouracil|Humans|Leucovorin|Leukopenia|Male|Middle Aged|Neoplasm Staging|Stereoisomerism|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9060527_20201005_0.5	l-isomer of leucovorin	drug_umls_atom	OBJECTIVE To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5	levofolene	drug_umls_atom	Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implications	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5	levofolene	drug_umls_atom	levofolene|5-fluorouracil|apoptosis|keratinocytes|cytotoxicity	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5			Antidotes|Antimetabolites, Antineoplastic|Apoptosis|Autophagy|Cell Line|Drug Combinations|Drug Synergism|Flow Cytometry|Fluorouracil|Humans|Keratinocytes|Levoleucovorin|Lipid Peroxidation|Oxidative Stress|Reactive Oxygen Species	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC4383012_20201005_0.5	levofolene	drug_umls_atom	No section 5-Fluorouracil (5-FU), often used in combination with levofolene (LF), can induce, as an important side effect, the hand-foot syndrome (HFS) due to toxicity on keratinocytes.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3461434_20201005_0.5			5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3461434_20201005_0.5			5-Fluorouracil|Doxorubicin|Apoptosis|ROS|Cardiotoxicity|Health workers	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3461434_20201005_0.5			Animals|Antibiotics, Antineoplastic|Antimetabolites, Antineoplastic|Apoptosis|Caspase 3|Cell Line, Tumor|Doxorubicin|Flow Cytometry|Fluorouracil|HT29 Cells|Humans|Myocytes, Cardiac|Oxidative Stress|Rats	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC3461434_20201005_0.5	levofolene	drug_umls_atom	Cells were treated for 24, 48 and 72 h with different concentrations of the two drugs alone or with 5-FU in combination with 10 M of levofolene (LF).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18593999_20201005_0.5			Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18593999_20201005_0.5			Adult|Aged|Aged, 80 and over|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Combined Modality Therapy|Deoxycytidine|Female|Fluorouracil|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Immunotherapy|Injections, Subcutaneous|Interleukin-2|Leucovorin|Male|Middle Aged|Organoplatinum Compounds|Recombinant Proteins|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18593999_20201005_0.5	levofolinic acid	drug_umls_atom	 METHODS This clinical and immunologic study involved 46 patients, 27 males and 19 females, enrolled in the GOLFIG-1 phase II trial who received gemcitabine (1,000 mg/m(2) on days 1 and 15), oxaliplatin (85 mg/m(2) on days 2 and 16), levofolinic acid (100 mg/m(2) on days 1, 2, 15, and 16), and 5-fluorouracil (400 mg/m(2) as a bolus, and 800 mg/m(2) as a 24-hour infusion on days 1, 2, 15, and 16) followed by s.c.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26367522_20201005_0.5			Poor Folate Intake in a North Italian Pregnant Population: an Epidemiological Survey.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26367522_20201005_0.5			folic acid|neural tube defects|periconceptional counselling|prevention	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26367522_20201005_0.5			Adult|Dietary Supplements|Female|Folic Acid|Health Knowledge, Attitudes, Practice|Humans|Italy|Neural Tube Defects|Preconception Care|Pregnancy|Pregnant Women|Prenatal Care|Prospective Studies|Vitamins	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26367522_20201005_0.5	levofolinic acid	drug_umls_atom	Seven hundred thirty-three (31.8%) women consumed multivitamins containing 413 (17.9%) consumed products containing FA only and 17 (0.7%) 15 mg of levofolinic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7530472_20201005_0.5	levofolinic acid	drug_umls_atom	Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7530472_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Dose-Response Relationship, Drug|Female|Fluorouracil|Granulocyte Colony-Stimulating Factor|Humans|Leucovorin|Middle Aged|Mitoxantrone	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5			Development and validation of a robust capillary electrophoresis method for impurity profiling of calcium levofolinate including the (6R,2'S)-diastereomer using statistical experimental design.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5			Borates|Buffers|Cyclodextrins|Drug Contamination|Electrophoresis, Capillary|Humans|Leucovorin|Pharmaceutical Preparations|Reproducibility of Results|Research Design|Sensitivity and Specificity|Stereoisomerism|Temperature|Time	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5	levofolinic acid	drug_umls_atom	The assay allowed the detection and determination of related substances including the diastereomeric (6R,2'S)-impurity of levofolinic acid at the 0.1% level, the identification threshold of impurities for orally administered drugs for human use defined by the International Conference on Harmonization guidelines as well as the European Pharmacopoeia.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21239357_20201005_0.5	levofolinic acid	drug_umls_atom	Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21239357_20201005_0.5			Adenocarcinoma|Administration, Oral|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Deoxycytidine|Disease Progression|Female|Humans|Leucovorin|Male|Middle Aged|Pancreatic Neoplasms|Survival Analysis|Tegafur|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21239357_20201005_0.5	levofolinic acid	drug_umls_atom	We aim to evaluate the efficacy of tegafur and levofolinic acid (LV) associated with gemcitabine, as well as its toxicity, progression-free survival and OS in advanced pancreatic cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16886648_20201005_0.5	levofolinic acid	drug_umls_atom	Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16886648_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Female|Fluorouracil|Humans|Infusions, Intravenous|Injections, Intravenous|Leucovorin|Middle Aged|Neoplasm Metastasis|Neoplasm Recurrence, Local|Retrospective Studies|Stereoisomerism|Vinblastine|Vinorelbine	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16886648_20201005_0.5	levofolinic acid	drug_umls_atom	BACKGROUND This retrospective study evaluated the activity and toxicity profile of a regimen of vinorelbine and 5-fluorouracil with levofolinic acid, given to a large series of patients with recurrent or refractory metastatic breast cancer after first-line chemotherapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16886648_20201005_0.5	levofolinic acid	drug_umls_atom	Two chemotherapy schedules were reviewed: a) the bolus regimen consisted of levofolinic acid 100 mg/m2 and 5-fluorouracil 375 mg/m2, both administered i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16886648_20201005_0.5	levofolinic acid	drug_umls_atom	bolus on days 1 and 8 every 3 weeks; b) the infusional regimen of levofolinic acid 100 mg/m2 given as a 2-hour infusion, followed by 5-fluorouracil 400 mg/m2 i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16886648_20201005_0.5	levofolinic acid	drug_umls_atom	 CONCLUSIONS The results of this large off-trial analysis confirmed the clinical activity and adverse-event profile reported in controlled clinical trials of the vinorelbine/ 5-fluorouracil with levofolinic acid regimen in clinical practice.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10907951_20201005_0.5	levofolinic acid	drug_umls_atom	Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10907951_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Dose-Response Relationship, Drug|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Leucovorin|Male|Middle Aged|Neutropenia|Quinazolines|Thiophenes|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12381902_20201005_0.5	levofolinic acid	drug_umls_atom	Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12381902_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Dose-Response Relationship, Drug|Female|Fluorouracil|Head and Neck Neoplasms|Hematologic Diseases|Humans|Leucovorin|Male|Middle Aged|Neoplasm Staging|Neutropenia|Quinazolines|Thiophenes|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12381902_20201005_0.5	levofolinic acid	drug_umls_atom	We have previously shown that the combination of raltitrexed, levofolinic acid (LFA) and 5-FU has clinical activity against SCCHN; in a subsequent phase I study, cisplatin was added, and the combination of CDDP plus raltitrexed on day 1, followed by LFA and 5-FU on day 2, was judged feasible and active, since a 67% response rate was shown across all dose levels, with a 100% response rate at the recommended dose for phase II.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID32381870_20201005_0.5			[A Case of a Migrating Central Venous Catheter in the Internal Jugular Vein Diagnosed Using Ultrasonography in a Patient with Right-Sided NeckPain during Chemotherapy].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID32381870_20201005_0.5			Catheterization, Central Venous|Central Venous Catheters|Humans|Jugular Veins|Male|Middle Aged|Ultrasonography|Vena Cava, Superior	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID32381870_20201005_0.5	levofolinic acid	drug_umls_atom	On that day, his 6th course of chemotherapy with modified FOLFOX6 (levofolinic acid, 5-fluorouracil[5-FU], oxaliplatin[L-OHP])and panitumumab was administered using a CV port that had been placed 3 months previously from the right subclavian vein in the superior vena cava, and verified using radiography.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7529516_20201005_0.5	levofolinic acid	drug_umls_atom	A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7529516_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Carcinoma|Cyclophosphamide|Drug Administration Schedule|Epirubicin|Female|Fluorouracil|Granulocyte Colony-Stimulating Factor|Humans|Leucovorin|Leukopenia|Middle Aged|Recombinant Proteins|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7529516_20201005_0.5	levofolinic acid	drug_umls_atom	No section Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10955877_20201005_0.5			Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10955877_20201005_0.5			Adenocarcinoma|Adult|Aged|Aged, 80 and over|Antimetabolites, Antineoplastic|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Biliary Tract Neoplasms|Confidence Intervals|Drug Interactions|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Mucous Membrane|Neoplasm Staging|Palliative Care|Pancreatic Neoplasms|Remission Induction|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10955877_20201005_0.5	levofolinic acid	drug_umls_atom	Recently, some reports presented interesting results, in which 5-FU, modulated with levofolinic acid (leucovorin), was active in patients with colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11481095_20201005_0.5	levofolinic acid	drug_umls_atom	[Effects of levofolinic acid on plasma homocysteine concentrations in healthy and young women in preconceptional care].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11481095_20201005_0.5			Adult|Female|Homocysteine|Humans|Leucovorin|Neural Tube Defects|Preconception Care	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11481095_20201005_0.5	levofolinic acid	drug_umls_atom	We studied the effects of levofolinic acid (l,5-formyl-tetrahydrofolic) on the plasmatic tHcylevels in women of child-bearing age.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11481095_20201005_0.5	levofolinic acid	drug_umls_atom	 METHODS Healthy women aged 18-35 years (n = 30) received levofolinic acid, 5 mg/day,orally for 30 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11481095_20201005_0.5	levofolinic acid	drug_umls_atom	The response was greater when the plasmatic tHcy concentration was >= 9 micromol/l. CONCLUSIONS Levofolinic acid leads to a earlier, intense and persistent drop of the plasmatictHcy levels.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID31394027_20201005_0.5			Toxoplasma gondii-induced brachial plexus neuropathy after allogeneic hematopoietic stem cell transplantation.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID31394027_20201005_0.5			 Toxoplasma gondii |allogeneic hematopoietic stem cell transplantation|brachial plexus neuropathy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID31394027_20201005_0.5			Aged|Brachial Plexus|Brachial Plexus Neuropathies|Female|Hematopoietic Stem Cell Transplantation|Humans|Magnetic Resonance Imaging|Toxoplasma|Toxoplasmosis|Transplantation, Homologous	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID31394027_20201005_0.5	levofolinic acid	drug_umls_atom	The patient was treated with pyrimethamine, sulfadiazine, and levofolinic acid during 6 weeks, with a positive outcome.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10629652_20201005_0.5	levofolinic acid	drug_umls_atom	Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10629652_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Drug Resistance, Neoplasm|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Middle Aged|Neoplasm Metastasis|Salvage Therapy|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19712610_20201005_0.5			Management of returned anti-neoplastic treatments and their reuse in oncology patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19712610_20201005_0.5			Antineoplastic Agents|Drug Utilization|Humans|Longitudinal Studies|Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19712610_20201005_0.5	levofolinic acid	drug_umls_atom	Colon neoplasia and treatment with 5-fluorouracil and levofolinic acid presented the highest number of returns.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9095330_20201005_0.5	levofolinic acid	drug_umls_atom	Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9095330_20201005_0.5			Adult|Aged|Antidotes|Antimetabolites, Antineoplastic|Antineoplastic Agents|Antineoplastic Agents, Alkylating|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Cyclophosphamide|Female|Fluorouracil|Granulocyte Colony-Stimulating Factor|Humans|Italy|Leucovorin|Middle Aged|Mitoxantrone	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID9095330_20201005_0.5	levofolinic acid	drug_umls_atom	No section Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10091727_20201005_0.5	levofolinic acid	drug_umls_atom	5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10091727_20201005_0.5			Adenocarcinoma|Adult|Aged|Analysis of Variance|Antidotes|Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Female|Fluorouracil|Humans|Interferon alpha-2|Interferon-alpha|Leucovorin|Liver Neoplasms|Male|Middle Aged|Neoplasm Staging|Prospective Studies|Recombinant Proteins|Rectal Neoplasms|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10091727_20201005_0.5	levofolinic acid	drug_umls_atom	BACKGROUND The objectives of the current study were: 1) to verify whether the addition of modulating low doses of interferon-2b (IFN) to 5-fluorouracil (5-FU) and levofolinic acid (1-FA) could improve clinical results in patients with advanced colorectal carcinoma; and 2) to evaluate the role of tumor burden and liver involvement as prognostic factors.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16760296_20201005_0.5	levofolinic acid	drug_umls_atom	Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16760296_20201005_0.5			Adenocarcinoma|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Male|Neoplasm Metastasis|Neoplasm Recurrence, Local|Quinazolines|Thiophenes	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16760296_20201005_0.5	levofolinic acid	drug_umls_atom	BACKGROUND The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID16760296_20201005_0.5	levofolinic acid	drug_umls_atom	plus levofolinic acid and 5-fluorouracil according to the De Gramont' schedule given every 2 weeks as first-line chemotherapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10632324_20201005_0.5	levofolinic acid	drug_umls_atom	Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10632324_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Colorectal Neoplasms|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Leucovorin|Male|Middle Aged|Quinazolines|Thiophenes	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10632324_20201005_0.5	levofolinic acid	drug_umls_atom	Incubation of different types of head and neck and colorectal cancer cells with levofolinic acid (LFA) plus 5-FU for 4 or 24 h, after 24-h incubation with Tomudex, produces a clear synergism.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18467257_20201005_0.5			Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18467257_20201005_0.5			Adjuvants, Immunologic|Antineoplastic Combined Chemotherapy Protocols|Autoimmunity|Colonic Neoplasms|Deoxycytidine|Female|Flow Cytometry|Fluorouracil|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Immunotherapy|Interleukin-2|Leucovorin|Middle Aged|Neoplasm Metastasis|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18467257_20201005_0.5	levofolinic acid	drug_umls_atom	No section GOLFIG-1 chemo-immunotherapy is a new translational anticancer regimen based on the combined use of gemcitabine, oxalipatin, levofolinic acid and infusional 5-fluorouracil together with the subcutaneous administration immunoadjuvant cytokines (GM-CSF and ultra low dose IL-2).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11600613_20201005_0.5	levofolinic acid	drug_umls_atom	Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11600613_20201005_0.5			Bias|Carcinoma, Non-Small-Cell Lung|Clinical Trials, Phase III as Topic|Humans|Lung Neoplasms|Time Factors|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18343754_20201005_0.5	levofolinic acid	drug_umls_atom	Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18343754_20201005_0.5			Antineoplastic Combined Chemotherapy Protocols|Deoxycytidine|Feasibility Studies|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasm Staging|Organoplatinum Compounds|Oxaliplatin|Pancreatic Neoplasms|Prospective Studies	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18343754_20201005_0.5	levofolinic acid	drug_umls_atom	No section GOLF is a triple translational combination chemotherapy regimen with gemcitabine, oxaliplatin, and 5-fluorouracil (5-FU) (plus levofolinic acid), cytotoxic drugs currently used in the treatment of pancreatic carcinoma.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID18343754_20201005_0.5	levofolinic acid	drug_umls_atom	All patients received biweekly gemcitabine (1000 mg/m(2 )on day 1), oxaliplatin (85 mg/m(2 )on day 2); levofolinic acid (100 mg/m 2) and 5-FU (400 mg/m(2 )as bolus, and 800 mg/m(2 )in 24-h infusion) on days 1 and 2.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22576349_20201005_0.5			Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22576349_20201005_0.5			Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Camptothecin|Case-Control Studies|Cell Line, Tumor|Cetuximab|Colorectal Neoplasms|Dendritic Cells|Deoxycytidine|Drug Administration Schedule|ErbB Receptors|Female|Fluorouracil|Humans|Immunomodulation|Immunotherapy|Interleukin-2|Irinotecan|Killer Cells, Natural|Male|Middle Aged|Recombinant Proteins|T-Lymphocyte Subsets	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID22576349_20201005_0.5	levofolinic acid	drug_umls_atom	At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase II trial aimed to test the toxicity and the biological and antitumor activity of a novel biochemotherapy regimen combining polychemotherapy with gemcitabine, irinotecan, levofolinic acid, and fluorouracil with cetuximab and with subcutaneous low-dose metronomic aldesleukin (GILFICet regimen).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11269736_20201005_0.5	levofolinic acid	drug_umls_atom	Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11269736_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Leucovorin|Male|Middle Aged|Mitoxantrone|Neoplasms|Quinazolines|Thiophenes	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID11269736_20201005_0.5	levofolinic acid	drug_umls_atom	OBJECTIVE We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8233292_20201005_0.5	levofolinic acid	drug_umls_atom	A phase II study of levofolinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8233292_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Combined Modality Therapy|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Leucovorin|Male|Middle Aged|Neoplasm Staging|Stereoisomerism	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8233292_20201005_0.5	levofolinic acid	drug_umls_atom	No section Forty patients with advanced squamous cell carcinoma of the head and neck (SCHNC) were treated with a combination of levofolinic acid 100 mg/m2+5-fluorouracil 375 mg/m2 in a 4-hour infusion plus cisplatin 20 mg/m2 in a 2-hour infusion for 5 consecutive days, repeated every 21-28 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10365114_20201005_0.5	levofolinic acid	drug_umls_atom	5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10365114_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Hepatocellular|Female|Fluorouracil|Humans|Hydroxyurea|Leucovorin|Leukopenia|Liver Neoplasms|Male|Middle Aged|Thrombocytopenia|Vomiting	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10365114_20201005_0.5	levofolinic acid	drug_umls_atom	No section A phase II trial of 5FU in modulation with intravenous high-dose levofolinic acid and oral hydroxyurea (HU) in advanced unresectable hepatocellular carcinoma (HCC).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10365114_20201005_0.5	levofolinic acid	drug_umls_atom	The treatment plan included: levofolinic acid 100 mg/m2 diluted in 500 cc of normal saline over 2 hour infusion followed by 5FU 600 mg/m2 i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10365114_20201005_0.5	levofolinic acid	drug_umls_atom	The combination of 5FU with levofolinic acid and oral HU on a weekly schedule is largely inactive against unresectable or metastatic HCC and results are no better than historical data reported for 5FU alone.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23053320_20201005_0.5			Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23053320_20201005_0.5			Adult|Aged|Chemoradiotherapy|Female|Fluorodeoxyglucose F18|Humans|Male|Middle Aged|Neoplasm Recurrence, Local|Neoplasm Staging|Positron-Emission Tomography|Preoperative Period|Radiopharmaceuticals|Rectal Neoplasms|Remission Induction|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23053320_20201005_0.5	levofolinic acid	drug_umls_atom	 METHODS Forty-two patients with poor prognosis LARC underwent three biweekly courses of chemotherapy with oxaliplatin, raltitrexed and 5-fluorouracil modulated by levofolinic acid during pelvic radiotherapy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10472346_20201005_0.5	levofolinic acid	drug_umls_atom	Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10472346_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Breast Neoplasms|Disease-Free Survival|Female|Fluorouracil|Humans|Infusions, Intravenous|Leucovorin|Middle Aged|Neoplasm Metastasis|Neoplasm Staging|Salvage Therapy	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7977165_20201005_0.5	levofolinic acid	drug_umls_atom	Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7977165_20201005_0.5			Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Drug Administration Schedule|Female|Fluorouracil|Gastrointestinal Neoplasms|Humans|Hydroxyurea|Leucovorin|Male|Middle Aged|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID7977165_20201005_0.5	levofolinic acid	drug_umls_atom	In the Phase I part of the study we identified the MTD of 5-fluorouracil (5FU) in combination with levofolinic acid 100 mg/m2 per week intravenously plus hydroxyurea 1 g/m2 per week given by mouth in 3 refracted doses starting 6 hours after 5FU was administered.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10091775_20201005_0.5	levofolinic acid	drug_umls_atom	A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10091775_20201005_0.5			Adult|Aged|Antidotes|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Squamous Cell|Cisplatin|Combined Modality Therapy|Female|Fluorouracil|Head and Neck Neoplasms|Humans|Leucovorin|Male|Methotrexate|Middle Aged|Neoplasm Staging|Radionuclide Imaging|Survival Analysis	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10091775_20201005_0.5	levofolinic acid	drug_umls_atom	 METHODS To improve further the results that could be obtained with an induction regimen of cisplatin (CDDP) plus 5-fluorouracil (5-FU), the authors treated 50 patients with locally advanced or metastatic SCCHN with a combination of CDDP 65 mg/m2 on Day 1, methotrexate 500 mg/m2 on Day 1, levofolinic acid 250 mg/m2 on Day 2, and 5-FU 800 mg/m2 on Day 2.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21590223_20201005_0.5	levofolinic acid	drug_umls_atom	A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21594413_20201005_0.5			Single agent vinorelbine in the treatment of unresectable lung metastases from colorectal cancer.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21594413_20201005_0.5	levofolinic acid	drug_umls_atom	5-fluorouracil and oral levamisole, 5 patients had adjuvant radiotherapy, and 1 patient had chemotherapy with levofolinic acid and 5-fluorouracil for advanced disease.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10509152_20201005_0.5			Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10509152_20201005_0.5			Adenocarcinoma|Adult|Aged|Antimetabolites, Antineoplastic|Antineoplastic Agents, Phytogenic|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Confidence Intervals|Disease-Free Survival|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Middle Aged|Prognosis|Severity of Illness Index|Survival Rate|Treatment Outcome	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID10509152_20201005_0.5	levofolinic acid	drug_umls_atom	OBJECTIVE To determine the maximum tolerable doses (MTDs) of irinotecan (CPT-11) and 5-fluorouracil (5-FU) plus levofolinic acid (LFA) administered together every two weeks, to define the toxicity profile of this regimen, and to have a preliminary evidence of its activity in the first-line management of advanced colorectal cancer patients.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21566939_20201005_0.5			Elf regimen in advanced gastrointestinal malignancies - an analysis of its clinical effectiveness and toxicity.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21566939_20201005_0.5			Middle Aged|Aged|Male|Humans|Female|Fluorouracil|Leucovorin|Gastrointestinal Neoplasms|Stomach Neoplasms|Antineoplastic Combined Chemotherapy Protocols|Cisplatin|Treatment Outcome|Carcinoma, Hepatocellular|Leukopenia|Drug Administration Schedule|Liver Neoplasms	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID21566939_20201005_0.5	levofolinic acid	drug_umls_atom	No section A multi-institutional phase 11 study of the combination of levofolinic acid 100 mg/m2, VP16 120 mg/m2 and 5-fluorouracil 500 mg/m2 for 3 consecutive days was carried out on a series of 73 evaluable patients with low performance status affected by locally advanced and/or metastatic gastrointestinal carcinomas.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826605_20201005_0.5	levofolinic acid	drug_umls_atom	Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826605_20201005_0.5			Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Humans|Injections, Subcutaneous|Interleukin-2|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Salvage Therapy	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826605_20201005_0.5	levofolinic acid	drug_umls_atom	No section Thirty-three consecutive patients with recurrent and/or metastatic colorectal carcinoma (CRC) refractory to previous chemotherapy have been treated with levofolinic acid (I-FA) 100 mg/m2 i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24704391_20201005_0.5			A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24704391_20201005_0.5			5-Fluorouracil|Cardiotoxicity|Occupational health|Rat cardiocytes model	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24704391_20201005_0.5			Animals|Antimetabolites|Cell Death|Cell Line, Tumor|Cell Proliferation|Drug Synergism|Fluorouracil|Free Radical Scavengers|Heart Diseases|Humans|Leucovorin|Myocytes, Cardiac|Nitric Oxide|Occupational Exposure|Oxidative Stress|Rats|Thiobarbituric Acid Reactive Substances	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID24704391_20201005_0.5	levofolinic acid	drug_umls_atom	Moreover, we have found that the addition of Levofolinic Acid (LF) to 5-FU potentiated the growth inhibition induced by 5-FU.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826954_20201005_0.5	levofolinic acid	drug_umls_atom	Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826954_20201005_0.5			Adenocarcinoma|Administration, Oral|Aged|Antidotes|Antimetabolites, Antineoplastic|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Carcinoma|Disease Progression|Drug Administration Schedule|Female|Fluorouracil|Gallbladder Neoplasms|Humans|Hydroxyurea|Infusions, Intravenous|Injections, Intravenous|Italy|Leucovorin|Leukopenia|Male|Middle Aged|Pancreatic Neoplasms|Remission Induction|Survival Rate	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826954_20201005_0.5	levofolinic acid	drug_umls_atom	high dose levofolinic acid and oral hydroxyurea.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826954_20201005_0.5	levofolinic acid	drug_umls_atom	The treatment schedule was: levofolinic acid, 100 mg/m2, in 500 mL of normal saline over 2-hour infusion followed by 5-FU, 600 mg/m2 i.v.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826954_20201005_0.5	levofolinic acid	drug_umls_atom	levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID8826954_20201005_0.5	levofolinic acid	drug_umls_atom	Although response rate and overall survival for patients with pancreatic adenocarcinoma are far from acceptable, the 30% overall response rate achieved in patients with advanced gallbladder carcinoma suggests that 5-FU in modulation with levofolinic acid and hydroxyurea is active in this neoplasm.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25291957_20201005_0.5	levofolinic acid	drug_umls_atom	Differential behavior of serum and red blood cell folate during a treatment with levofolinic acid. Gender differences.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25291957_20201005_0.5			Administration, Oral|Adolescent|Adult|Dietary Supplements|Drug Administration Schedule|Erythrocytes|Female|Homocysteine|Humans|Leucovorin|Male|Sex Factors|Time Factors|Vitamin B Complex|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25291957_20201005_0.5	levofolinic acid	drug_umls_atom	In the present work, the changes in the folate-homocysteine (Hcy) metabolic axis were studied in response to treatment with levofolinic acid.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID25291957_20201005_0.5	levofolinic acid	drug_umls_atom	 METHODS 49 college students (23 men and 26 women) underwent a treatment voluntarily with 5 mg/day levofolinic acid for one month.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5			Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5			Aged|Female|Folic Acid|Homocysteine|Humans|Leucovorin|Linear Models|Male|Middle Aged|Prospective Studies|Renal Dialysis|Statistics, Nonparametric|Vitamin B 6	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5	levofolinic acid	drug_umls_atom	OBJECTIVE A greater decrease in total homocystein (tHcy) has been reported in patients on hemodialysis (HD) following the administration of reduced forms of folic acid (FA), however, the effect of the administration of moderated doses of oral levofolinic acid has not been compared with that of FA.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5	levofolinic acid	drug_umls_atom	We decided to perform a study to evaluate the therapeutic effectiveness of oral levofolinic acid, the pharmacologically active form of folinic acid in our population of HD patients already on treatment with oral FA and vitamin B6.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5			Role of Intramuscular Levofolinate Administration in the Treatment of Hereditary Folate Malabsorption: Report of Three Cases.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5	levofolinic acid	drug_umls_atom	CSF 5-MTHF|Hereditary folate malabsorption|Intramuscular|Levofolinic acid|Treatment	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5			Infant, Newborn|Humans|Female|Folate Malabsorption, Hereditary|Folic Acid Deficiency|SLC46A1 protein, human|Proton-Coupled Folate Transporter|Malabsorption Syndromes|5-methyltetrahydrofolate|Tetrahydrofolates|Folic Acid|Leucovorin|Levoleucovorin|Mutation	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5	levofolinic acid	drug_umls_atom	The active isomer of 5-formyltetrahydrofolate, also known as levofolinic acid, is available for administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID28685492_20201005_0.5	levofolinic acid	drug_umls_atom	We report our experience in achieving normal (age dependent) CSF 5-Methyltetrahydrofolate (5-MTHF) levels following daily intramuscular administration of levofolinic acid in three patients with HFM.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12647013_20201005_0.5			Population pharmacokinetics of oxaliplatin.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12647013_20201005_0.5			Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Colorectal Neoplasms|Female|Fluorouracil|Hematopoiesis|Humans|Kidney|Leucovorin|Male|Organoplatinum Compounds|Oxaliplatin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID12647013_20201005_0.5	levofolinic acid	drug_umls_atom	Data from 40 patients receiving oxaliplatin combined with 5-fluorouracil and levofolinic acid as standard treatment for advanced colorectal cancer were analysed.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20399639_20201005_0.5			Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20399639_20201005_0.5			Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antibody-Dependent Cell Cytotoxicity|Antineoplastic Agents|Blotting, Western|Camptothecin|Cell Line, Tumor|Cetuximab|Colonic Neoplasms|Deoxycytidine|Drug Synergism|ErbB Receptors|Fluorouracil|Genes, ras|Humans|Irinotecan|Killer Cells, Lymphokine-Activated|Mutation|Panitumumab|Up-Regulation	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20399639_20201005_0.5	levofolinic acid	drug_umls_atom	These drugs were able to up-regulate EGFR expression on the surface of all the colon cancer cell lines with a maximal effect observed few hours after the exposure to GILF regimen (Gem, Iri, Levofolinic acid and 5-FU).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5			Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Freezing|Glucose|Hydrogen-Ion Concentration|Leucovorin|Microwaves|Pharmaceutical Vehicles|Polyenes|Regression Analysis|Solutions|Temperature|Time Factors|Vitamin B Complex	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	BACKGROUND Calcium levofolinate infusions could be prepared in advance by a centralized intravenous additive service (CIVAS) to improve safety and time management.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	 OBJECTIVE To investigate the effect of freezing, microwave thawing and long-term storage at 5 +/- 3 degrees C on the stability of calcium levofolinate in 5% dextrose solution.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	 METHODS Solutions of 250 mL of 5% dextrose in polyolefin bags (n = 5) containing approximately 400 mg of calcium levofolinate were prepared under aseptic conditions and frozen for 95 days at -20 degrees C. The solutions were then thawed using microwaves and stored at 5 +/- 3 degrees C for 1 month.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	The calcium levofolinate concentrations were measured by high performance liquid chromatography (HPLC).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	Calcium levofolinate infusions were stable when stored at 5 +/- 3 degrees C during 1 month after freeze-thaw treatment.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID19583675_20201005_0.5	calcium levofolinate	drug_umls_atom	 CONCLUSIONS Under the conditions of this study, calcium levofolinate in 5% dextrose infusion may be prepared, frozen in advance by CIVAS, and then microwave thawed before use.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	calcium levofolinate	drug_umls_atom	Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	calcium levofolinate	drug_umls_atom	5-Fluorouracil|calcium levofolinate|drug mixtures stability|oxaliplatin|pH effect	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5			Humans|Oxaliplatin|Fluorouracil|Calcium|Leucovorin|Organoplatinum Compounds|Colorectal Neoplasms|Antineoplastic Combined Chemotherapy Protocols	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	calcium levofolinate	drug_umls_atom	It is composed of calcium levofolinate, 5-fluorouracil and oxaliplatin which demonstrated synergistic outcome.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	calcium levofolinate	drug_umls_atom	Herein, we aimed to investigate the stability of a ternary mixture of 5-fluorouracil, oxaliplatin and calcium levofolinate, knowing that coadministering these drugs would improve their efficacy.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	calcium levofolinate	drug_umls_atom	The effect of three pHs (5.0, 6.0 and 7.5) and two drug concentrations (8/3/6 and 1/1/1 mg/ml for 5-fluorouracil, oxaliplatin and calcium levofolinate, respectively) were examined.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID34053358_20210611_0.5	calcium levofolinate	drug_umls_atom	5-fluorouracil/oxaliplatin mixture was stable at pH 5.0 over 48 hours while 5-fluorouracil/calcium levofolinate mixture was stable at pHs 6.0 and 7.5 up to 7 days.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5			Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5	calcium levofolinate	drug_umls_atom	Colon cancer|5-Fluorouracil (5-FU)|Calcium levofolinate (CaLV)|Disodium levofolinate (NaLV)|Synergism|Thymidylate synthetase (TYMS)|SLC19A1	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7841196_20210311_0.5			Animals|Antineoplastic Agents|Apoptosis|Cell Line, Tumor|Cell Proliferation|Disease Models, Animal|Dose-Response Relationship, Drug|Drug Synergism|Fluorouracil|Humans|Leucovorin|Male|Mice|Reduced Folate Carrier Protein|Thymidylate Synthase|Time Factors|Tumor Cells, Cultured|Xenograft Model Antitumor Assays	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5			Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5			anemia|hemoglobin|liposomal iron|myelodysplastic syndrome	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5			Humans|Male|Adult|Middle Aged|Female|Epoetin Alfa|Biosimilar Pharmaceuticals|Iron|Vitamin B 12|Retrospective Studies|Erythropoietin|Hematinics|Anemia|Folic Acid|Anemia, Refractory|Hemoglobins|Renal Dialysis|Renal Insufficiency, Chronic|Recombinant Proteins|Liposomes|Treatment Outcome|Europe	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID26171179_20201005_0.5	calcium levofolinate	drug_umls_atom	In addition, they received liposomal iron (Sideral®), calcium levofolinate and vitamin B12.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5			[Direct resolution of calcium folinate stereoisomers using a bovine serum albumin chiral HPLC column].	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5			Chromatography, High Pressure Liquid|Hydrogen-Ion Concentration|Leucovorin|Serum Albumin, Bovine|Stereoisomerism	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5	calcium levofolinate	drug_umls_atom	OBJECTIVE To establish a direct and fast method separating calcium levofolinate and calcium dextrofolinate in a bovine serum albumin stationary phase chiral column.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14966932_20201005_0.5	calcium levofolinate	drug_umls_atom	And the retention time of calcium levofolinate and calcium dextrofolinate were 18.5 min and 22.6 min, respectively.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5			Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5			Adolescent|Adult|Aged|Ambulatory Care|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Disease Progression|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Fluorouracil|Humans|Leucovorin|Male|Maximum Tolerated Dose|Middle Aged|Neoplasm Metastasis|Survival Rate|Treatment Outcome|Young Adult	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID20225907_20201005_0.5	calcium levofolinate	drug_umls_atom	BACKGROUND Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23006440_20201005_0.5			Sequential interaction of phenytoin and phenobarbital with fluorouracil.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23006440_20201005_0.5			Drug Interactions|Fluorouracil|Humans|Male|Middle Aged|Phenobarbital|Phenytoin	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID23006440_20201005_0.5	calcium levofolinate	drug_umls_atom	 METHODS A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ~ 2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU).	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5	calcium levofolinate	drug_umls_atom	Development and validation of a robust capillary electrophoresis method for impurity profiling of calcium levofolinate including the (6R,2'S)-diastereomer using statistical experimental design.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5			Borates|Buffers|Cyclodextrins|Drug Contamination|Electrophoresis, Capillary|Humans|Leucovorin|Pharmaceutical Preparations|Reproducibility of Results|Research Design|Sensitivity and Specificity|Stereoisomerism|Temperature|Time	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14981706_20201005_0.5	calcium levofolinate	drug_umls_atom	No section A chiral capillary electrophoresis assay for the simultaneous determination of the optical purity and of related substances of calcium levofolinate has been developed and validated.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5			Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5			Aged|Female|Folic Acid|Homocysteine|Humans|Leucovorin|Linear Models|Male|Middle Aged|Prospective Studies|Renal Dialysis|Statistics, Nonparametric|Vitamin B 6	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID14524579_20201005_0.5	calcium levofolinate	drug_umls_atom	Patients matched for age, sex and time on HD were assigned to 1 of 2 groups: Those in group A continued to receive their previous supplements while in group B, FA was substituted by calcium levofolinate 5 mg given orally every 48 hours.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	calcium levofolinate	drug_umls_atom	Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	calcium levofolinate	drug_umls_atom	Drug stability|calcium levofolinate|chromatography|robotic compounding	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5			Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Glucose|Levoleucovorin|Nylons|Polyenes|Polypropylenes|Saline Solution|Syringes|Temperature|Water	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC7903855_20210411_0.5	calcium levofolinate	drug_umls_atom	Purpose Calcium levofolinate (CaLev) for intravenous administration is commercially available as a powder that must be reconstituted for injection or reconstituted and then diluted before administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5			Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	calcium levofolinate	drug_umls_atom	Calcium levofolinate|FOLFIRI|Sodium levofolinate	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5			Humans|Male|Middle Aged|Adult|Female|Adolescent|Fluorouracil|Prospective Studies|Leucovorin|Colorectal Neoplasms|Camptothecin|Antineoplastic Combined Chemotherapy Protocols|Liver Neoplasms|Sodium	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	calcium levofolinate	drug_umls_atom	A comparison with calcium levofolinate (Ca-Lev) showed a similar toxicity profile.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMID33764600_20210511_0.5	calcium levofolinate	drug_umls_atom	 BACKGROUND The objectives of this study were to compare the safety profiles of sodium levofolinate (Na-Lev) and calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) in the FOLFIRI regimen and to measure the organizational impact of the introduction of Na-Lev on drug production and administration.	abstract
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5			Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review	title
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5			hepatocellular carcinoma|apatinib|targeted therapy	author_keywords
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5			Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Carcinoma, Hepatocellular|Chemoembolization, Therapeutic|Disease-Free Survival|Ethiodized Oil|Fluorouracil|Humans|Leucovorin|Liver Neoplasms|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Pyridines|Tegafur	mesh_terms
levoleucovorin	C2721771	cl-307,782|fusilev|khapzory|lederfolin	cl 307,782|cl307,782	levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate	inn	PubMed	PMC5386780_20201005_0.5	calcium levofolinate	drug_umls_atom	After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m on day 1, calcium levofolinate 200 mg/m on day 1 and 2, 5-fluorouracil 400 mg/m intravenously and 5-fluorouracil 600 mg/m intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID9490587_20201005_0.5			[Effects of leukocyte depletion on the storage quality of whole blood].	title
leukotrap	Z0000082417				trade_name	PubMed	PMID9490587_20201005_0.5			Adult|Blood Component Removal|Blood Preservation|Blood Transfusion, Autologous|Erythrocytes|Filtration|Humans|In Vitro Techniques|Leukocytes|Time Factors	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID9490587_20201005_0.5	leukotrap	drug_name	 METHODS Whole blood was donated by healthy volunteers (n = 14,500 ml, 70 ml CPDA-1) and was filtered using an integrated whole blood filter system (Leukotrap A1, Fa.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID9490587_20201005_0.5	leukotrap	drug_name	 CONCLUSIONS The Leukotrap A1 whole blood filter system is an interesting option for hospitals lacking the technical capacity to separate whole blood into components.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID16635068_20201005_0.5	leukotrap	drug_name	Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID16635068_20201005_0.5			Animals|Blotting, Western|Cell Separation|Creutzfeldt-Jakob Syndrome|Cricetinae|Densitometry|Erythrocytes|Filtration|Hemorheology|Humans|Leukocytes|Mesocricetus|PrPSc Proteins|Scrapie	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID2754259_20201005_0.5	leukotrap	drug_name	Recovery of functional human lymphocytes from Leukotrap filters.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID2754259_20201005_0.5			Cell Separation|Filtration|Humans|Lymphocyte Activation|Lymphocytes	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID2754259_20201005_0.5	leukotrap	drug_name	No section We report here a method by which functional human PBL may be recovered from a blood product preparation unit (Leukotrap) which is normally employed by blood banks to prepare a leukocyte-poor blood product and which is commonly discarded after use.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID2754259_20201005_0.5	leukotrap	drug_name	The results from our study indicate that Leukotrap filters provide a readily available, easily processed and convenient source of functional human PBL for use in the in vitro study of the human immune system.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID12047513_20201005_0.5			Influence of prestorage leucocyte depletion and storage time on rheologic properties of erythrocyte concentrates.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID12047513_20201005_0.5			Adenosine Triphosphate|Adult|Aged|Blood Viscosity|Erythrocyte Transfusion|Erythrocytes|Female|Humans|Leukocytes|Male|Middle Aged|Specimen Handling|Time Factors	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID12047513_20201005_0.5	leukotrap	drug_name	 METHODS Blood viscosity, erythrocyte morphology and ATP levels were determined in filtered samples (Leukotrap WB filter system) and their unfiltered counterparts during storage with saline-adenine-glucose-mannitol (SAG-M) for 42 days.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID12047513_20201005_0.5	leukotrap	drug_name	 CONCLUSIONS Prestorage leucocyte depletion by Leukotrap WB filters improves biophysical properties of erythrocyte concentrates throughout storage, which is, however, outweighed by a time-dependent echinocytic shape transformation and deterioration of these properties.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID16078926_20201005_0.5			In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID16078926_20201005_0.5			Blood Platelets|Blood Preservation|Humans|Hydrogen-Ion Concentration|Leukocyte Reduction Procedures|Plastics|Time Factors	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID16078926_20201005_0.5	leukotrap	drug_name	 METHODS Two whole-blood units were collected from each subject into a leuko-reduction filtration system (Leukotrap RC-PL system, Pall Medical) in a paired design, the second 2 days after the first.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID16078926_20201005_0.5	leukotrap	drug_name	These were leukoreduced (Leukotrap PL) and stored for 7 and 5 days.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID12126201_20201005_0.5			Lymphocyte subsets in inline filtered packed red blood cell units: comparison between low and high spin procedures.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID12126201_20201005_0.5			Antigens, CD|Blood Specimen Collection|Cell Separation|Centrifugation|Erythrocyte Transfusion|Erythrocytes|Filtration|Flow Cytometry|Humans|Immunophenotyping|Leukocyte Count|Lymphocyte Subsets	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID12126201_20201005_0.5	leukotrap	drug_name	No section Lymphocyte subsets were determined in 20 packed red blood cell units (PRC) before and after filtration (FPRC) with the Pall Leukotrap RC inline filter system; 10 units were prepared by low spin and platelet rich plasma (PRP) removal (Group A) and 10 with high spin, plasma and buffy-coat (BC) removal (Group B).	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID1419784_20201005_0.5			Improved post-transfusion quality of density separated AS-3 red cells after extended storage.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID1419784_20201005_0.5			Blood Component Transfusion|Blood Preservation|Cell Separation|Centrifugation, Density Gradient|Erythrocyte Aging|Erythrocyte Transfusion|Female|Humans|Male|Time Factors	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID1419784_20201005_0.5	leukotrap	drug_name	Each unit was passed through a Leukotrap filter to remove white cells prior to density separation.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID3824473_20201005_0.5			Effective leukocyte removal from platelet preparations by centrifugation in a new pooling bag.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID3824473_20201005_0.5			Blood Platelets|Cell Biology|Cell Separation|Centrifugation|Erythrocytes|Humans|Leukocytes	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID3824473_20201005_0.5	leukotrap	drug_name	No section A pooling bag (Leukotrap, Cutter Laboratories, Berkeley, CA) with a protruding pocket at the bottom into which heavier cellular elements are collected after centrifugation at 390 X g for 10 minutes, was studied.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID1284694_20201005_0.5	leukotrap	drug_name	[Leukocyte depletion, a comparison of the 'Leukotrap in-line' filter system with a sterile added 4-bag Speacell-R-500-A filter system].	title
leukotrap	Z0000082417				trade_name	PubMed	PMID1284694_20201005_0.5			Adsorption|Blood Component Transfusion|Equipment Design|Humans|Leukapheresis|Leukocyte Count|Lymphocyte Depletion|Lymphocyte Subsets|Ultrafiltration	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID1284694_20201005_0.5	leukotrap	drug_name	Filtration with the Leukotrap system at the day of preparation led to an overall reduction of leukocytes of 82.2%, i.e. an average of 5.4 x 10(8) leukocytes/RBC concentrate.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID1284694_20201005_0.5	leukotrap	drug_name	The determination of lymphocyte subpopulations by flow cytometry after filtration with the Leukotrap system showed a more effective adsorption of B cells than of T and natural killer cells.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID31478761_20201005_0.5			Interval analysis of blood filtration efficacy in novel device for autotransfusion in postpartum hemorrhage.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID31478761_20201005_0.5			Postpartum haemorrhage|global health|medical device|microbial filtration|obstetrics	author_keywords
leukotrap	Z0000082417				trade_name	PubMed	PMID31478761_20201005_0.5			Bacteria, Anaerobic|Blood Transfusion, Autologous|Female|Filtration|Humans|Leukocytes|Postpartum Hemorrhage|Pregnancy	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID31478761_20201005_0.5	leukotrap	drug_name	In this study, we investigate the filtration efficacy of the device using configurations comprised of three different leukocyte depletion filter designs: the Pall Leukoguard RS leukocyte reduction filter (PLRF), the Haemonetics BPF4TM (BPF4) leukocyte reduction filter, and the Haemonetics SCRC Leukotrap® (SCRC) filter.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID31478761_20201005_0.5	leukotrap	drug_name	Configurations containing 2 Haemonetics SCRC Leukotrap®filters (configuration 5 and 6) consistently reduced anaerobic bacteria by at least 73%.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID17486885_20201005_0.5			Characterization of scrapie-infected and normal hamster blood as an experimental model for TSE-infected human blood.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID17486885_20201005_0.5			Animals|Cell Count|Cell Separation|Centrifugation|Cricetinae|Evaluation Studies as Topic|Humans|Mesocricetus|Models, Animal|Prion Diseases	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID17486885_20201005_0.5	leukotrap	drug_name	Two leukotrap filtration systems were used to assess the similarities and differences in cell separation and distribution between human and hamster blood.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID19555418_20201005_0.5			Maintenance of in vitro properties of leukoreduced whole blood-derived pooled platelets after a 24-hour interruption of agitation.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID19555418_20201005_0.5			Blood Component Removal|Blood Platelets|Blood Preservation|Humans|Time Factors|Vibration	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID19555418_20201005_0.5	leukotrap	drug_name	 METHODS Eleven ABO-identical leukoreduced whole blood-derived PCs (Leukotrap RC-PL, Pall), pooled in a transfer container, were equally divided into each of two CLX-HP containers (Acrodose PL, Pall).	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID10858843_20201005_0.5			[Quality of whole blood as a result of storage and preparation (inline-leukocyte depletion). Evidence for autologous predeposit].	title
leukotrap	Z0000082417				trade_name	PubMed	PMID10858843_20201005_0.5			Adenosine Triphosphate|Blood Banks|Blood Cell Count|Blood Chemical Analysis|Blood Coagulation|Blood Preservation|Blood Transfusion|Blood Transfusion, Autologous|Humans|Leukocytes	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID10858843_20201005_0.5	leukotrap	drug_name	Six units were filtered with the Leukotrap A1-System (PALL Comp.,	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID23458181_20201005_0.5			Stored blood transfusion induces transient pulmonary arterial hypertension without impairing coagulation in an ovine model of nontraumatic haemorrhage.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID23458181_20201005_0.5			TRALI|hemostasis|red cell components|transfusion reactions	author_keywords
leukotrap	Z0000082417				trade_name	PubMed	PMID23458181_20201005_0.5			Acute Lung Injury|Animals|Blood Preservation|Disease Models, Animal|Erythrocyte Transfusion|Hemorrhage|Hypertension, Pulmonary|Male|Sheep|Time Factors	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID23458181_20201005_0.5	leukotrap	drug_name	 METHODS Anaesthetized sheep had 33% of their total blood volume collected into Leukotrap bags (Pall Medical), which were processed into packed red blood cells and cross-matched for transfusion into other sheep.	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID16262755_20201005_0.5	leukotrap	drug_name	In-vitro evaluation of the PALL Leukotrap Affinity Prion Reduction Filter as a secondary device following primary leucoreduction.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID16262755_20201005_0.5			Erythrocyte Transfusion|Hemofiltration|Humans|Leukocyte Reduction Procedures|Plasma|PrPC Proteins	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID7947280_20201005_0.5			Effects of 3-5 log10 pre-storage leucocyte depletion on red cell storage and metabolism.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID7947280_20201005_0.5			Adenosine Triphosphate|Blood Glucose|Blood Preservation|Cell Separation|Erythrocytes|Filtration|Hemolysis|Humans|Lactates|Lactic Acid|Leukocytes|Osmotic Fragility|Potassium|Temperature|Time Factors	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID7947280_20201005_0.5	leukotrap	drug_name	No section A new, in-line high-efficiency 3-5 log10 leucodepletion filter system (Leukotrap RC system) was used to investigate the effect of pre-storage white cell removal on the quality of AS-3 red cell concentrates stored for 42 d at 4 degrees C. Median residual white cell content was 4 x 10(5) when filtration was performed at 22 degrees C within 8 h of phlebotomy (n = 20) and 3.2 x 10(4) when filtration was performed at 4 degrees C 12-24 h after phlebotomy (n = 24).	abstract
leukotrap	Z0000082417				trade_name	PubMed	PMID3660768_20201005_0.5			Comparison of three different methods used in the preparation of leukocyte-poor platelet concentrates.	title
leukotrap	Z0000082417				trade_name	PubMed	PMID3660768_20201005_0.5			Blood Platelets|Centrifugation|Hemofiltration|Humans|Leukocyte Count|Leukocytes	mesh_terms
leukotrap	Z0000082417				trade_name	PubMed	PMID3660768_20201005_0.5	leukotrap	drug_name	No section We compared three methods for preparing leukocyte-poor platelet concentrates from random donors: the centrifugation procedure 400 g/6 min, the filtration by Immugard TFIG 500 Y and the Cutter Leukotrap platelet pooling system.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11686825_20201005_0.5			The effect of polyvinyl pyrrolidone on the clinical activity of 0.09% and 0.2% chlorhexidine mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11686825_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Chlorhexidine|Confidence Intervals|Cross-Over Studies|Dental Calculus|Dental Plaque|Dose-Response Relationship, Drug|Drug Interactions|Female|Follow-Up Studies|Gingivitis|Humans|Male|Middle Aged|Mouthwashes|Oils, Volatile|Pigmentation Disorders|Placebos|Povidone|Single-Blind Method|Statistics as Topic|Statistics, Nonparametric|Tongue Diseases|Tooth Discoloration|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11686825_20201005_0.5	chlorhexidine rinse	drug_umls_atom	BACKGROUND Previous studies have shown that polyvinyl pyrrolidone (PVP) added to a chlorhexidine rinse reduced extrinsic dental stain but at the expense of a reduction in plaque inhibitory activity.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11686825_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The aim of these 2 clinical studies was to determine if PVP could be added to chlorhexidine rinses to maintain efficacy and reduce staining.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11686825_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There were no significant differences between the chlorhexidine rinse and the chlorhexidine/PVP rinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3164781_20201005_0.5			The use of chlorhexidine in the management of gingivitis in children.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3164781_20201005_0.5			Adolescent|Child|Chlorhexidine|Double-Blind Method|Gingivitis|Humans|Male|Mouthwashes|Oral Hygiene|Periodontal Index|Placebos	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3164781_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The use of a chlorhexidine rinse twice per day and as adjunct to regular oral hygiene procedures achieved a considerable benefit against gingivitis in children in two studies extending over ten and 12 weeks.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10916334_20201005_0.5			Third-party reimbursement and use of fluoride varnish in adults among general dentists in Washington State.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10916334_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Attitude of Health Personnel|Chlorhexidine|Cost-Benefit Analysis|Dental Caries|Dental Caries Susceptibility|Female|Fluorides, Topical|General Practice, Dental|Humans|Insurance, Health, Reimbursement|Male|Mouthwashes|Pit and Fissure Sealants|Practice Patterns, Dentists'|Surveys and Questionnaires|Treatment Refusal|Washington	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10916334_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Dentists' rates of use of other caries-control services (chlorhexidine rinses for caries control and adult pit-and-fissure sealants) did not change.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3056555_20201005_0.5			Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3056555_20201005_0.5			Adolescent|Adult|Bacterial Infections|Bone Marrow Transplantation|Candidiasis, Oral|Child|Child, Preschool|Chlorhexidine|Clinical Trials as Topic|Double-Blind Method|Gram-Negative Aerobic Bacteria|Humans|Infant|Middle Aged|Mouth Mucosa|Prospective Studies|Stomatitis|Streptococcal Infections	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3056555_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Persistent clinical oral candidiasis (thrush) was observed in 15 to 27 control group patients (56%), but only transiently in two (8%) of 24 patients who used chlorhexidine rinse (p less than 0.001).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12117201_20201005_0.5			The clinical and microbiological effects of a novel acidified sodium chlorite mouthrinse on oral bacterial mucosal infections.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12117201_20201005_0.5			Adult|Aged|Aged, 80 and over|Anti-Infective Agents, Local|Bacteria, Aerobic|Bacterial Infections|Chlorhexidine|Chlorides|Colony Count, Microbial|Cross-Over Studies|Double-Blind Method|Female|Gluconates|Gram-Negative Bacteria|Humans|Malates|Male|Middle Aged|Mouth Mucosa|Mouthwashes|Saliva|Staphylococcus aureus|Stomatitis	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12117201_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In this study, sodium chlorite mouthrinses (ASC) acidified with either malic or gluconic acids were compared to each other and with a chlorhexidine rinse and sterile water for their effect on salivary bacterial counts.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12117201_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The sodium chlorite rinses acidified with malic and gluconic acids and the chlorhexidine rinse caused significant reductions in salivary bacterial counts up to 7 h after a single rinse compared with water.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12117201_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Patients who received the ASC rinse reported significantly less discomfort following treatment than those receiving the chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2262582_20201005_0.5			The effect of triclosan, stannous fluoride and chlorhexidine products on: (II) Salivary bacterial counts.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2262582_20201005_0.5			Adult|Analysis of Variance|Bacteria|Chlorhexidine|Colony Count, Microbial|Humans|Mouthwashes|Saliva|Sodium Chloride|Sodium Fluoride|Time Factors|Tin Fluorides|Toothpastes|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2262582_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Comparison was also made with a chlorhexidine rinse as the positive control.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9378830_20201005_0.5			The comparative effect of acidified sodium chlorite and chlorhexidine mouthrinses on plaque regrowth and salivary bacterial counts.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9378830_20201005_0.5			Anti-Infective Agents, Local|Bacteria|Bacteria, Anaerobic|Chlorhexidine|Chlorides|Chlorine Compounds|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Double-Blind Method|Erythrosine|Fluorescent Dyes|Follow-Up Studies|Humans|Mouthwashes|Oxides|Placebos|Saliva	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9378830_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The 3 ASC and chlorhexidine rinses produced similar reductions in salivary bacterial counts which remained significantly below the placebo control to 7 h. There were no significant differences between ASC and chlorhexidine rinses except at 30 and 60 min when significantly greater reductions were produced by 2 ASC rinses compared to the chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9378830_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Plaque indices and areas were considerably and significantly lower with the ASC and chlorhexidine rinses compared to the placebo rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9378830_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There were no significant differences between plaque scores for the 3 ASC rinses and the chlorhexidine rinse, although for 2 ASC rinses plaque scores were lower than for the chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19051866_20201005_0.5			The role of chlorhexidine in caries prevention.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19051866_20201005_0.5			Anti-Infective Agents, Local|Cariostatic Agents|Chlorhexidine|Dental Caries|Drug Combinations|Dysgeusia|Fluorides, Topical|Gels|Humans|Mouthwashes|Streptococcus mutans|Thymol|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19051866_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Based on the available reviews, chlorhexidine rinses have not been highly effective in preventing caries, or at least the clinical data are not convincing.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19051866_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Due to the current lack of long-term clinical evidence for caries prevention and reported side effects, chlorhexidine rinses should not be recommended for caries prevention.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19051866_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Based on the published reviews, it was concluded that chlorhexidine rinses, gels and varnishes or combinations of these items with fluoride have variable effects.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19051866_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Due to the current lack of evidence on long-term clinical outcomes and reported side effects, chlorhexidine rinse, which is currently the only treatment mode available in the US, should not be recommended for caries prevention.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16367850_20201005_0.5			A method to study sustained antimicrobial activity of rinse and dentifrice components on biofilm viability in vivo.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16367850_20201005_0.5			Anti-Infective Agents, Local|Biofilms|Chlorhexidine|Dental Plaque|Dentifrices|Humans|Microbial Viability|Microscopy, Confocal|Mouthwashes|Outcome Assessment, Health Care|Research Design|Tin Fluorides	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16367850_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Seventy-two-hour-old plaques were less susceptible to antimicrobials, although dentifrices appeared more effective after 6 h than initially, whereas efficacy of chlorhexidine rinse continued to drop with time post-treatment.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11940138_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Anti-plaque effect of tempered 0.2% chlorhexidine rinse: an in vivo study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11940138_20201005_0.5			Adult|Anti-Infective Agents, Local|Bacteria|Chlorhexidine|Dental Plaque|Female|Humans|Male|Mouthwashes|Statistics, Nonparametric|Temperature	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11940138_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS In this study, warm 0.2% chlorhexidine rinse showed a significantly more intensive anti-plaque effect than cold chlorhexidine solution at the same concentration.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20560997_20201005_0.5			Preferences for caries prevention agents in adult patients: findings from the dental practice-based research network.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20560997_20201005_0.5			Adolescent|Adult|Anti-Infective Agents, Local|Cariostatic Agents|Chewing Gum|Child|Child, Preschool|Chlorhexidine|Community-Based Participatory Research|Decision Making|Dental Caries|Dental Offices|Dental Restoration, Permanent|Dentists, Women|Drug Prescriptions|Education, Dental|Ethnic Groups|Female|Fluorides|Fluorides, Topical|Humans|Infant|Insurance, Dental|Male|Mouthwashes|Patient Care Planning|Pit and Fissure Sealants|Practice Patterns, Dentists'|Risk Assessment	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20560997_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Regarding at-home preventive agents, there was little difference in preference between nonprescription fluoride, prescription fluoride, or chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31473729_20201005_0.5			Efficacy of Two Pre-Procedural Rinses at Two Different Temperatures in Reducing Aerosol Contamination Produced During Ultrasonic Scaling in a Dental Set-up - A Microbiological Study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31473729_20201005_0.5			aerosol|cetylpyridinium chloride|chlorhexidine|pre-procedural mouthrinse|temperature|ultrasonic scaling	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31473729_20201005_0.5			Adult|Young Adult|Male|Humans|Ultrasonics|Temperature|Dental Scaling|Chlorhexidine|Cetylpyridinium|Anti-Infective Agents, Local|Mouthwashes|Aerosols|Air Microbiology|Infection Control, Dental|Bacterial Load|Bacteria	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31473729_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Cetylpyridinium chloride (0.05%) as a pre-procedural rinse was found to be equally effective in reducing aerosol contamination when compared with 0.2% chlorhexidine rinse (p > 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4320426_20201005_0.5			A randomized clinical trial compared the effect of intra-alveolar 0.2 %  Chlorohexidine bio-adhesive gel versus 0.12% Chlorohexidine rinse in  reducing alveolar osteitis following molar teeth extractions	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4320426_20201005_0.5			Adhesives|Chlorhexidine|Dry Socket|Female|Gels|Humans|Male|Molar|Mouthwashes|Prospective Studies|Tooth Extraction|Tooth Socket	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4320426_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 No section Key words: Chlorhexidine rinse, bio adhesive gel, alveolarosteitis, dry socket, molar teeth extraction, post-extraction socket.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22942146_20210611_0.5			Dental disease prevalence among methamphetamine and heroin users in an urban setting: a pilot study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22942146_20210611_0.5			Adolescent|Adult|Amphetamine-Related Disorders|Central Nervous System Stimulants|Cohort Studies|Cross-Sectional Studies|DMF Index|Dental Calculus|Dental Caries|Dental Deposits|Feeding Behavior|Female|Heroin Dependence|Humans|Male|Methamphetamine|Oral Hygiene Index|Pilot Projects|Prevalence|Risk Factors|Saliva|San Francisco|Smoking|Substance Abuse, Intravenous|Tooth Root|Toothbrushing|Xerostomia|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22942146_20210611_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS Given the high level of dental disease observed in this population of young adult IDUs, one next step may be to explore the feasibility and effectiveness of providing low-intensity preventive measures (such as distribution of chlorhexidine rinses or xylitol gum or application of fluoride varnishes) through outreach workers.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5			Effects of typified propolis on mutans streptococci and lactobacilli: a randomized clinical trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5			Chlorhexidine|Lactobacilli|Mutans Streptococci|Randomized clinical trial|Typified propolis	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5			Humans|Middle Aged|Male|Adult|Female|Propolis|Lactobacillus|Double-Blind Method|Streptococcus mutans|Chlorhexidine|Mouthwashes|Dental Caries|Saliva|Anti-Infective Agents, Local|Colony Count, Microbial	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5	chlorhexidine rinse	drug_umls_atom	OBJECTIVE The aim of this study was to determine in a randomized, double-blind, placebo-controlled clinical trial the effects of typified propolis and chlorhexidine rinses on salivary levels of mutans streptococci (MS) and lactobacilli (LACT).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5	chlorhexidine rinse	drug_umls_atom	After restoration of cavitated lesions patients were randomized to 3 experimental groups: 1) PROP-alcohol-free 2% typified propolis rinse (n = 20); 2) CHX- 0.12% chlorhexidine rinse; 3) PL-placebo mouthrinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12167896_20201005_0.5			Use of a whitening dentifrice for control of chlorhexidine stain.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12167896_20201005_0.5			Adolescent|Adult|Aged|Anti-Infective Agents|Chlorhexidine|Dentifrices|Humans|Middle Aged|Silicic Acid|Silicon Dioxide|Sodium Fluoride|Statistics, Nonparametric|Tooth Bleaching|Tooth Discoloration|Toothpastes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12167896_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section A major drawback to clinicians prescribing and patients using chlorhexidine rinse is the development of extrinsic staining.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12167896_20201005_0.5	chlorhexidine rinse	drug_umls_atom	It is advantageous to recommend a whitening dentifrice that has demonstrated stain suppression when prescribing a chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4080614_20201005_0.5			Oral Care in Trauma Patients Admitted to the ICU: Viewpoints of ICU Nurses	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4080614_20201005_0.5			Oral Hygiene|Respiration, Artificial|Wounds and Injuries|Intensive Care Units	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4080614_20201005_0.5			Adult|Male|Humans|Middle Aged|Female|Cross-Sectional Studies|Intensive Care Units|Pneumonia, Ventilator-Associated|Respiration, Artificial|Oral Hygiene|Chlorhexidine|Critical Care|Intubation|Clinical Competence|Hospitalization|Iran	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4080614_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The most frequent oral care provided was oral suctioning, normal saline irrigation, and chlorhexidine rinse with 95%, 90%, and 81.3% frequency, respectively.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7808365_20210211_0.5	chlorhexidine rinse	drug_umls_atom	Preventing Alveolar Osteitis After Molar Extraction Using Chlorhexidine Rinse and Gel: A Meta-Analysis of Randomized Controlled Trials	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7808365_20210211_0.5			chlorhexidine|rinse|gel|alveolar osteitis	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7808365_20210211_0.5			Humans|Chlorhexidine|Dry Socket|Randomized Controlled Trials as Topic|Molar, Third|Data Management|Tooth Extraction|Molar|Anti-Infective Agents, Local|Mouthwashes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23786404_20201005_0.5			Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23786404_20201005_0.5			Adult|Aged|Aged, 80 and over|Alveolar Bone Loss|Anti-Bacterial Agents|Anti-Infective Agents, Local|Bisphosphonate-Associated Osteonecrosis of the Jaw|Case-Control Studies|Chlorhexidine|Dental Plaque Index|Diphosphonates|Female|Gingival Hemorrhage|Humans|Infusions, Intravenous|Male|Middle Aged|Mouthwashes|Periodontal Attachment Loss|Periodontal Index|Periodontal Pocket|Periodontitis|Radiography, Panoramic|Risk Factors|Tooth Loss	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23786404_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Group differences in antibiotics and chlorhexidine rinse usage may have masked differences in the other clinical measures.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15366527_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Reduction of salivary S. aureus and mutans group streptococci by a preprocedural chlorhexidine rinse and maximal inhibitory dilutions of chlorhexidine and cetylpyridinium.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15366527_20201005_0.5			Adolescent|Adult|Aged|Anti-Infective Agents, Local|Antibiotic Prophylaxis|Cetylpyridinium|Chlorhexidine|Colony Count, Microbial|Dose-Response Relationship, Drug|Female|Humans|Linear Models|Male|Microbial Sensitivity Tests|Middle Aged|Mouthwashes|Oral Surgical Procedures|Saliva|Staphylococcus aureus|Streptococcus mutans|Surgical Wound Infection	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1900602_20201005_0.5			The efficacy of chlorhexidine gel in reduction of Streptococcus mutans and Lactobacillus species in patients treated with radiation therapy.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1900602_20201005_0.5			Adult|Aged|Chlorhexidine|Colony Count, Microbial|Dental Caries|Female|Head and Neck Neoplasms|Humans|Lactobacillus|Male|Middle Aged|Radiotherapy, High-Energy|Saliva|Salivation|Streptococcus mutans|Xerostomia	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1900602_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Use of chlorhexidine rinse was shown to reduce S. mutans counts 1.1 logs and lactobacilli 1.1 logs.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1848567_20201005_0.5			Triclosan and sodium lauryl sulphate mouthrinses. (II). Effects of 4-day plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1848567_20201005_0.5			Adult|Chlorhexidine|Dental Plaque|Dental Plaque Index|Erythrosine|Female|Humans|Male|Mouthwashes|Single-Blind Method|Sodium Dodecyl Sulfate|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1848567_20201005_0.5	chlorhexidine rinse	drug_umls_atom	This investigation compared the effects on 4-day plaque regrowth of a 1% SLS, 0.2% triclosan and 0.2% chlorhexidine rinse with a 0.9% saline rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30888120_20201005_0.5			Design and characteristics of new experimental chlorhexidine dental gels with anti-staining properties.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30888120_20201005_0.5	chlorhexidine rinse	drug_umls_atom	anti-staining properties|chlorhexidine rinse|disintegration time|gel|viscosity	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30888120_20201005_0.5			Anti-Infective Agents, Local|Chlorhexidine|Dental Materials|Gels|Glass Ionomer Cements|Humans|Tooth Discoloration|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21226852_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Biofilm reduction and staining potential of a 0.05% chlorhexidine rinse containing essential oils.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21226852_20201005_0.5			Animals|Anti-Infective Agents, Local|Biofilms|Cattle|Chlorhexidine|Colony Count, Microbial|Drug Combinations|Mouthwashes|Oils, Volatile|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2406296_20201005_0.5			The effects of 0.5% chlorhexidine and 0.2% triclosan containing toothpastes on salivary bacterial counts.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2406296_20201005_0.5			Adult|Bacteria|Chlorhexidine|Clinical Trials as Topic|Colony Count, Microbial|Dental Plaque|Dentifrices|Double-Blind Method|Female|Humans|Male|Mouthwashes|Phenyl Ethers|Random Allocation|Saliva|Single-Blind Method|Time Factors|Toothpastes|Triclosan|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2406296_20201005_0.5	chlorhexidine rinse	drug_umls_atom	All toothpastes were brushed for 1 min and comparison made with a 0.2% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1452799_20201005_0.5			A comparison of delmopinol and chlorhexidine on plaque regrowth over a 4-day period and salivary bacterial counts.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1452799_20201005_0.5			Adult|Analysis of Variance|Chlorhexidine|Colony Count, Microbial|Dental Plaque|Double-Blind Method|Humans|Male|Matched-Pair Analysis|Morpholines|Mouthwashes|Saliva	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1452799_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Comparisons were made with a 0.2% chlorhexidine rinse and a placebo rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11737509_20201005_0.5			Effect of a polyhexamethylene biguanide mouthrinse on bacterial counts and plaque.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11737509_20201005_0.5			Adult|Analysis of Variance|Bacteria|Biguanides|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Disinfectants|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Humans|Male|Mouth Mucosa|Mouthwashes|Reproducibility of Results|Statistics, Nonparametric	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11737509_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In this study, a 0.04% PHMB mouthrinse (A) was compared with a negative control placebo rinse (10% ethanol, flavour) (B) and 2 positive control chlorhexidine rinses, one of which was a 0.12% aqueous solution (C) and the other a commercially available mouthrinse (Skinsept mucosa) diluted to a chlorhexidine concentration of 0.12% (D).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7713526_20201005_0.5			The effectiveness of oral hygiene programmes for elderly people--a review.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7713526_20201005_0.5			Aged|Chlorhexidine|Dental Care for Aged|Dental Caries|Health Education, Dental|Humans|Middle Aged|Mouthwashes|Oral Hygiene|Periodontal Diseases|Program Evaluation	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7713526_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effective early intervention strategies are: promotion of over-all general health, obviation of stereotypes, education by dental hygienists, instruction and demonstration combined with systematic evaluation, use of a fluoride containing dentifrice, and regular professional support and use of chlorhexidine rinses for less well and confused elderly.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9461972_20201005_0.5			Chlorhexidine rinsing in physically handicapped pupils in Katlehong.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9461972_20201005_0.5			Adolescent|Adult|Child|Chlorhexidine|Cross-Over Studies|Dental Care for Disabled|Double-Blind Method|Female|Gingivitis|Humans|Male|Mouthwashes|Oral Hygiene|Periodontal Index|South Africa	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9461972_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The chlorhexidine rinse produced 34 per cent to 54 per cent improvement in PI values and 48 per cent to 52 per cent improvement in GI values.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9461972_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The chlorhexidine rinse may be successfully used in physically handicapped children but the low gingival inflammation in the group suggests that simple oral hygiene improvement might produce the same effect.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451766_20201005_0.5			The comparative effects of 0.12% chlorhexidine and herbal oral rinse on dental plaque-induced gingivitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451766_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Chlorhexidine|Dental Plaque|Dental Plaque Index|Female|Gingivitis|Humans|Linear Models|Male|Mouthwashes|Periodontal Index|Phytotherapy|Plant Preparations|Statistics, Nonparametric	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451766_20201005_0.5	chlorhexidine rinse	drug_umls_atom	OBJECTIVE The purpose of this study was to determine the effects of two oral rinses-one 0.12% chlorhexidine rinse (CHX) and one herbal rinse (HBR)-on gingival health status over time.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1403591_20201005_0.5			The effect of a number of commercial mouthrinses compared with toothpaste on plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1403591_20201005_0.5			Adult|Analysis of Variance|Benzoates|Borates|Cetylpyridinium|Chlorhexidine|Dental Plaque|Female|Fluorides|Humans|Male|Mouthwashes|Phosphates|Placebos|Single-Blind Method|Sodium Dodecyl Sulfate|Toothpastes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1403591_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The formulations were a cetylpyridinium chloride rinse, a prebrushing detergent rinse, a peroxyborate rinse a toothpaste slurry rinse, a chlorhexidine rinse, and a saline rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195440_20201005_0.5			Dose response of chlorhexidine against plaque and comparison with triclosan.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195440_20201005_0.5			Adult|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dose-Response Relationship, Drug|Double-Blind Method|Female|Humans|Male|Mouthwashes|Placebos|Taste|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195440_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The findings of this study suggest that consideration could be given to low concentration chlorhexidine rinses as adjuncts to oral hygiene.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2693684_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The effect of a 0.125% chlorhexidine rinse on inflammation after periodontal surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2693684_20201005_0.5			Adult|Alveolar Process|Chlorhexidine|Dental Plaque|Double-Blind Method|Female|Gingival Crevicular Fluid|Gingivitis|Humans|Male|Middle Aged|Mouthwashes|Periodontal Diseases|Postoperative Care	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2693684_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The chlorhexidine rinse significantly reduced the amount of plaque at both 1 and 2 weeks, and gingival inflammation remained similar to base line measurements at 2 weeks.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2693684_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There was an increase in amount of perceived postoperative pain and gingival swelling with the use of the chlorhexidine rinse, but no difference in the number of pain pills taken during this study.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2693684_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The chlorhexidine rinse was an effective plaque preventive agent after surgical procedures.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8636452_20201005_0.5			The efficacy of an anti-gingivitis chewing gum.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8636452_20201005_0.5			Anti-Infective Agents, Local|Chewing Gum|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dental Prophylaxis|Female|Gingival Hemorrhage|Gingivitis|Humans|Male|Mouthwashes|Periodontal Index|Placebos|Single-Blind Method|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8636452_20201005_0.5	chlorhexidine rinse	drug_umls_atom	At week 8, stain extent was significantly lower in the chlorhexidine gum group than chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8636452_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In conclusion, the results of this study demonstrate that this chlorhexidine chewing gum used with normal tooth cleaning provides similar adjunctive benefits to oral hygiene and gingival health as a 0.2% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6985300_20201005_0.5			Gingival bleeding after chlorhexidine mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6985300_20201005_0.5			Chlorhexidine|Dental Plaque|Gingival Hemorrhage|Humans|Mouthwashes|Oral Hemorrhage|Oral Hygiene|Periodontics|Physical Stimulation	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6985300_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section During a clinical trial for evaluating the antiplaque effect of two flavoured chlorhexidine rinses, the observation was made that bleeding after gentle massage of the gingival margin occurred more often after chemical than after mechanical oral hygiene measures.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9066218_20201005_0.5			Adoption of innovative caries-control services in dental practice: a survey of Washington State dentists.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9066218_20201005_0.5			Adult|Attitude of Health Personnel|Cariostatic Agents|Chlorhexidine|Composite Resins|Dental Caries|Dentists|Diffusion of Innovation|Female|Fluorides, Topical|Health Knowledge, Attitudes, Practice|Humans|Male|Mouthwashes|Pit and Fissure Sealants|Practice Patterns, Dentists'|Preventive Dentistry|Saliva|Surveys and Questionnaires|Washington	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9066218_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section To assess the adoptability of the medical model for caries control, the authors surveyed general dentists about their use of four caries-control services among adult patients: salivary functioning tests, fluoride varnishes, chlorhexidine rinses, and pit-and-fissure sealants.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23094273_20210311_0.5			Efficacy of chlorhexidine mouthrinses with and without alcohol - a clinical study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23094273_20210311_0.5			Adult|Chlorhexidine|Dental Plaque|Dental Plaque Index|Ethanol|Follow-Up Studies|Gingivitis|Humans|Middle Aged|Mouthwashes|Periodontal Index|Placebos|Single-Blind Method	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23094273_20210311_0.5	chlorhexidine rinse	drug_umls_atom	 RESULTS There were significant differences in plaque and gingival indices with both chlorhexidine rinses compared to the placebo.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33367297_20210111_0.5			[Prevention of white spot lesion formation during treatment with fixed orthodontic appliances].	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33367297_20210111_0.5			Cariostatic Agents|Dental Caries|Fluorides|Humans|Netherlands|Orthodontic Appliances|Orthodontic Appliances, Fixed	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33367297_20210111_0.5	chlorhexidine rinse	drug_umls_atom	Additional measures, like using fluoride-releasing adhesives, CPP-ACP(F) or a chlorhexidine rinse appear to be less effective in reducing demineralisations.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28266113_20201005_0.5			Mechanical and chemical plaque control in the simultaneous management of gingivitis and caries: a systematic review.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28266113_20201005_0.5			 DMF |caries|chemical plaque control|gingival index|gingivitis|mechanical plaque control|meta-analyses|plaque index|systematic review	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28266113_20201005_0.5			Dental Caries|Dental Plaque|Fluorides|Gingivitis|Humans|Mechanical Phenomena	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28266113_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The addition of fluoride to mechanical plaque control is relevant for caries management [n = 5; WMD = 1.159; 95% CI (0.145; 2.172); p = 0.025] while chlorhexidine rinses are relevant for gingivitis.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28266113_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinse has a positive effect on gingivitis and inconclusive role in caries.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2188158_20201005_0.5			Oral antimicrobial agents--chlorhexidine.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2188158_20201005_0.5			Bone Marrow Transplantation|Chlorhexidine|Humans|Mouth Diseases|Mouthwashes|Neoplasms	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2188158_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Although no toxic or serious adverse effects of chlorhexidine rinse have been observed in the short-term studies to date, the effects of longer-term chlorhexidine administration should be evaluated.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16685298_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Comparison of two chlorhexidine rinse protocols on the incidence of alveolar osteitis following the surgical removal of impacted third molars.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16685298_20201005_0.5			Adolescent|Adult|Anti-Infective Agents, Local|Chlorhexidine|Double-Blind Method|Dry Socket|Feasibility Studies|Humans|Molar, Third|Mouthwashes|Postoperative Care|Preoperative Care|Prospective Studies|Smoking|Tooth Extraction|Tooth, Impacted	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16685298_20201005_0.5	chlorhexidine rinse	drug_umls_atom	This study was undertaken to compare the effect of two chlorhexidine rinse protocols on the incidence of alveolar osteitis in patients undergoing surgical removal of impacted mandibular third molar teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16685298_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Subjects were instructed to rinse twice daily with 15 ml of chlorhexidine rinse 30 seconds for one week before and one week after surgery (group I) or one week after surgery (group II).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16685298_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS To reduce alveolar osteitis after impacted third molar surgery, it was observed use of postoperative chlorhexidine rinse was adequate.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9350557_20201005_0.5			A short-term clinical study design to investigate the chemical plaque inhibitory properties of mouthrinses when used as adjuncts to toothpastes: applied to chlorhexidine.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9350557_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Chemoprevention|Chlorhexidine|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Dentifrices|Drug Interactions|Effect Modifier, Epidemiologic|Evaluation Studies as Topic|Female|Humans|Male|Mouthwashes|Oral Hygiene|Patient Compliance|Placebos|Silicic Acid|Silicon Dioxide|Single-Blind Method|Sodium Fluoride|Toothbrushing|Toothpastes|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9350557_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The study suggests that, outside the Hawthorne effect, chlorhexidine rinses would be less effective in reducing plaque when used with toothpaste than when used alone.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5	chlorhexidine rinse	drug_umls_atom	A comparison of a new alcohol-free 0.2% chlorhexidine oral rinse to an established 0.2% chlorhexidine rinse with alcohol for the control of dental plaque accumulation.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5			chlorhexidine mouthrinse|dental biofilm|gingivitis|staining	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5			Chlorhexidine|Cross-Over Studies|Dental Plaque|Double-Blind Method|Ethanol|Female|Gingivitis|Humans|Male|Mouthwashes|Tooth Discoloration|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS The non-alcoholic chlorhexidine rinse had comparable levels of action as the generally recognized gold standard alcoholic rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6701906_20201005_0.5			Comparative Evaluation of Cocoa Bean Husk, Ginger and Chlorhexidine Mouth Washes in the Reduction of Steptococcus Mutans and Lactobacillus Count in Saliva: A Randomized Controlled Trial	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6701906_20201005_0.5			ginger|cocoa bean husk|chlorhexidine|s.mutans|lactobacillus|mouth rinse	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6701906_20201005_0.5			Adolescent|Humans|Male|Female|Young Adult|Adult|Mouthwashes|Chlorhexidine|Ginger|Saliva|Lactobacillus|Dental Caries|Streptococcus mutans|Anti-Infective Agents, Local|Dental Plaque|Colony Count, Microbial|Mouth	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6701906_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 No section Results No section Cocoa bean husk and chlorhexidine rinses produced a significant reduction of S. mutans (p < 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22622144_20201005_0.5			Chlorhexidine for the prevention of alveolar osteitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22622144_20201005_0.5			Anti-Infective Agents, Local|Antibiotic Prophylaxis|Chlorhexidine|Clinical Trials as Topic|Dry Socket|Humans|Mouthwashes|Publication Bias|Tooth Extraction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22622144_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Two of six application protocols favoured chlorhexidine over placebo: Single application of 0.2% chlorhexidine gel placed in the socket immediately after extraction versus placebo gel (RR 0.40; 95% CI: 0.18-0.90; p=0.03) and 0.12% chlorhexidine rinse applied on day of surgery and used twice daily for 7 days postoperatively versus placebo rinse (RR 0.50; 95% CI: 0.27-0.93; p=0.03).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12592918_20201005_0.5			Evidence-based prevention, management, and monitoring of dental caries.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12592918_20201005_0.5			Adolescent|Adult|Anti-Infective Agents, Local|Cariostatic Agents|Child|Chlorhexidine|Combined Modality Therapy|Dental Caries|Dental Caries Susceptibility|Dental Hygienists|Evidence-Based Medicine|Fluorides|Humans|Pit and Fissure Sealants|Self Care|Xylitol	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12592918_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Conservative strategies of a concentrated program include initial infection control with a chlorhexidine rinse; extra daily fluoride exposures; placement of pit and fissure sealants where indicated; control of sucrose exposures; use of sugar substitutes, particularly xylitol-containing sugar-free chewing gum; and an emphasis on a daily bacterial plaque removal routine.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21290979_20201005_0.5			An in vitro comparative study determining bactericidal activity of stabilized chlorine dioxide and other oral rinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21290979_20201005_0.5			Actinomyces|Aggregatibacter actinomycetemcomitans|Anti-Bacterial Agents|Anti-Infective Agents, Local|Bacterial Load|Cetylpyridinium|Chlorhexidine|Chlorine Compounds|Drug Combinations|Enterococcus faecalis|Gingivitis|Haemophilus influenzae|Humans|Klebsiella pneumoniae|Materials Testing|Mouthwashes|Oxides|Peptostreptococcus|Periodontitis|Porphyromonas gingivalis|Prevotella nigrescens|Pseudomonas aeruginosa|Salicylates|Staphylococcus aureus|Streptococcus|Streptococcus mutans|Streptococcus oralis|Terpenes|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21290979_20201005_0.5	chlorhexidine rinse	drug_umls_atom	ClōSYS and chlorhexidine rinses proved identical 100% kills against the periodontal pathogens at five minutes; in some cases, ClōSYS oral rinse achieved a higher kill at the one-minute mark over the chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23579300_20201005_0.5			Prevention and treatment of dry socket.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23579300_20201005_0.5			Adult|Humans|Dry Socket|Mouthwashes|Stomatitis|Chlorhexidine|Tooth Extraction|Antifungal Agents|Mouth Mucosa	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23579300_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The number of patients needed to be treated (0.12% and 0.2%) with chlorhexidine rinse to prevent one patient having dry socket (NNT) was 232 (95% CI 176 to 417), 47 (95% CI 35 to 84) and 8 (95% CI 6 to 14) at prevalences of dry socket of 1%, 5% and 30% respectively.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7890110_20201005_0.5			Clinical management of the avulsed tooth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7890110_20201005_0.5			Dental Restoration, Permanent|Dental Restoration, Temporary|Humans|Periodontal Splints|Root Canal Obturation|Tooth Avulsion|Tooth Replantation	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7890110_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Administer systemic antibiotics (penicillin V potassium if possible) Chlorhexidine rinses and stringent oral hygiene while the splint is in place (7 to 10 days).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17153649_20210311_0.5			Measuring early plaque formation clinically.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17153649_20210311_0.5			Adult|Anti-Infective Agents, Local|Chlorhexidine|Cross-Over Studies|Dental Plaque|Double-Blind Method|Early Diagnosis|Humans|Male|Mouthwashes|Observer Variation|Reproducibility of Results	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17153649_20210311_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinses inhibit both the plaque colonization of the dental surfaces as well as its subgingival extension.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3470323_20201214_0.5			Lacking anti-plaque efficacy of 2 sanguinarine mouth rinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3470323_20201214_0.5			Alkaloids|Anti-Infective Agents|Benzophenanthridines|Chlorhexidine|Chlorides|Dental Plaque|Drug Combinations|Humans|Isoquinolines|Mouthwashes|Random Allocation|Zinc|Zinc Compounds	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3470323_20201214_0.5	chlorhexidine rinse	drug_umls_atom	When measured according to the plaque index or in terms of plaque wet weight, only the chlorhexidine rinse further reduced the low Monday scores.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28189661_20201005_0.5			Does Chlorhexidine Prevent Alveolar Osteitis After Third Molar Extractions? Systematic Review and Meta-Analysis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28189661_20201005_0.5			Anti-Infective Agents, Local|Chlorhexidine|Dry Socket|Humans|Molar, Third|Postoperative Complications|Tooth Extraction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28189661_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There were no relevant differences between chlorhexidine rinse (RR = 0.58; 95% CI, 0.47-0.71) and gel (RR = 0.47; 95% CI, 0.37-0.60).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15735555_20201005_0.5			Peripheral ameloblastoma.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15735555_20201005_0.5			Aged|Ameloblastoma|Humans|Male|Mandibular Neoplasms	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15735555_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In the last 2 months the patient has used chlorhexidine rinses, and is not wearing his dentures; the lesions fail to heal, however.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8613561_20201005_0.5			The comparative effects on plaque regrowth of phenolic chlorhexidine and anti-adhesive mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8613561_20201005_0.5			Anti-Infective Agents, Local|Bacterial Adhesion|Chlorhexidine|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Dental Prophylaxis|Humans|Male|Mouthwashes|Oils, Volatile|Oral Hygiene|Phenols|Polyethylene Glycols|Polymethacrylic Acids|Single-Blind Method|Surface-Active Agents|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8613561_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The rinses were the antiadhesive (1%), the antiadhesive with 0.02% chlorhexidine, a 0.2% chlorhexidine rinse product, an essential oil/phenolic rinse product and water.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8613561_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The chlorhexidine rinse was significantly more effective than the essential oil/phenolic rinse which in turn was significantly more effective than the other rinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33993407_20210611_0.5			Adolescents and primary herpetic gingivostomatitis: an Italian overview.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33993407_20210611_0.5			Adolescent|Gingivitis|Herpes|Therapy|Verbascoside	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33993407_20210611_0.5			Humans|Male|Adolescent|Female|Stomatitis, Herpetic|Italy|Acyclovir|Antiviral Agents|Gingivitis|Anti-Bacterial Agents	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID33993407_20210611_0.5	chlorhexidine rinse	drug_umls_atom	Fifteen patients had been treated with non alcoholic chlorhexidine rinses (group A), 29 patients with non alcoholic chlorhexidine rinses plus hyaluronic acid gel (group B); 30 patients with non alcoholic chlorhexidine rinses plus Mucosyte® (group C).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20516100_20201005_0.5			General practitioners' use of caries-preventive agents in adult patients versus pediatric patients: findings from the dental practice-based research network.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20516100_20201005_0.5			Adolescent|Adult|Age Factors|Aged|Anti-Infective Agents, Local|Cariostatic Agents|Chewing Gum|Child|Child, Preschool|Chlorhexidine|Female|Fluorides|Fluorides, Topical|General Practice, Dental|Humans|Infant|Insurance, Dental|Male|Middle Aged|Mouthwashes|Pit and Fissure Sealants|Practice Patterns, Dentists'|Risk Assessment|Scandinavian and Nordic Countries|Self Care|Sweetening Agents|United States|Xylitol|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20516100_20201005_0.5	chlorhexidine rinse	drug_umls_atom	They asked dentists to identify the percentage of their patients for whom they had administered or recommended dental sealants, in-office and at-home fluoride, chlorhexidine rinse and xylitol gum.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10460956_20201005_0.5			Caries prevention in a community-dwelling older population.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10460956_20201005_0.5			Aged|Aged, 80 and over|Cariostatic Agents|Chlorhexidine|Community Dentistry|DMF Index|Dental Care for Aged|Dental Caries|Dental Scaling|Educational Status|Fluorides, Topical|Health Education, Dental|Humans|Incidence|Likelihood Functions|Marital Status|Middle Aged|Minority Groups|Poverty|Regression Analysis|Root Caries|United States	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10460956_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Group 3 received the educational program plus a 0.12% chlorhexidine rinse weekly.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12060421_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12060421_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Bacteria|Biguanides|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Double-Blind Method|Drug Combinations|Female|Humans|Male|Mouth Mucosa|Mouthwashes|Normal Distribution|Oils, Volatile|Placebos|Reproducibility of Results|Salicylates|Statistics as Topic|Terpenes|Tooth	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12060421_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In this study, a 0.12% PHMB mouthrinse (A) was compared with a negative control placebo rinse (10% ethanol, flavour) (B), a positive control 0.12% chlorhexidine rinse (C), and a commercially available mouthrinse containing essential oils (Listerine) (D).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12931087_20201005_0.5			Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12931087_20201005_0.5			Adult|Anti-Infective Agents, Local|Antifungal Agents|Candida albicans|Candidiasis, Oral|Cause of Death|Chemoprevention|Chlorhexidine|Female|Gingivitis, Necrotizing Ulcerative|Hematopoietic Stem Cell Transplantation|Humans|Length of Stay|Male|Middle Aged|Mouth|Mouthwashes|Nystatin|Stomatitis|Transplantation, Autologous|Transplantation, Homologous|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12931087_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In patients undergoing systemic antifungal prophylaxis, chlorhexidine rinse was statistically more effective in reducing colonization by Candida than chlorhexidine and nystatin combined (P =.046).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3048596_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effect of a daily 0.2% chlorhexidine rinse on the oral health of an institutionalized elderly population.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3048596_20201005_0.5			Aged|Chlorhexidine|Dental Caries|Dental Plaque|Female|Gingival Diseases|Humans|Institutionalization|Male|Middle Aged|Mouthwashes|Oral Hygiene|Streptococcus mutans|Tooth Diseases	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327643_20201005_0.5			Effects of low dose chlorhexidine mouthrinses on oral bacteria and salivary microflora including those producing hydrogen sulfide.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327643_20201005_0.5			Actinomyces viscosus|Adult|Aged|Anti-Infective Agents, Local|Bacteria|Chlorhexidine|Coloring Agents|Cross-Over Studies|Dental Plaque|Dose-Response Relationship, Drug|Halitosis|Humans|Hydrogen Sulfide|Microbial Sensitivity Tests|Middle Aged|Mouthwashes|Oxazines|Saliva|Xanthenes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327643_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Clinical studies examined the effects 1.5 h and 3 h post-treatment on salivary bacteria and bacteria producing H(2)S. The first study compared the control rinse with the 0.03% and 0.06% chlorhexidine rinses; a second study compared the effects of the control rinse and the 0.06% and 0.12% chlorhexidine mouthrinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327643_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In both studies, chlorhexidine rinses demonstrated significant dose-dependent effects post-treatment on salivary bacteria vs. the control rinse (P < 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327643_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Significant decreases in H(2)S-producing bacteria were noted with these chlorhexidine rinses vs. the control rinse (P < 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6928855_20201005_0.5			Histological evaluation of probing depth following periodontal treatment.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6928855_20201005_0.5			Connective Tissue|Dental Instruments|Dental Plaque|Epithelial Attachment|Evaluation Studies as Topic|Gingivitis|Humans|Periodontal Index|Periodontal Ligament|Periodontal Pocket|Periodontics|Periodontitis|Periodontium|Subgingival Curettage|Tooth Root	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6928855_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The average probing depth for teeth exposed to scaling, root planing, curettage and chlorhexidine rinses for 1 month was 0.31 mm coronal of the connective tissue attachment within the junctional epithelium.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18755618_20201005_0.5			Decontamination of autogenous bone grafts collected from dental implant sites via osteotomy: a review.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18755618_20201005_0.5			Animals|Antibiotic Prophylaxis|Bone Transplantation|Chin|Decontamination|Dental Implantation, Endosseous|Filtration|Humans|Mouthwashes|Osteotomy|Suction|Tissue and Organ Harvesting|Tooth Socket|Transplantation, Autologous	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18755618_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Stringent aspiration protocol, preoperative oral chlorhexidine rinse, and antibiotic prophylaxis are important precautions to be implemented when collected bone particles are to be implanted.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9126183_20201005_0.5			The effects of simple interventions on tooth mortality: findings in one trial and implications for future studies.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9126183_20201005_0.5			Aged|Analysis of Variance|Anti-Infective Agents|Behavior Therapy|Chlorhexidine|Clinical Trials as Topic|Dental Care for Aged|Dental Caries|Dental Prophylaxis|Dental Research|Female|Fluorides, Topical|Humans|Male|Middle Aged|Periodontal Diseases|Proportional Hazards Models|Regression Analysis|Research Design|Survival Analysis|Tooth Loss	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9126183_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In the PGT, 296 subjects were recruited and randomly assigned to five treatment groups: (1) usual procedures (UP); (2) UP + a cognitive-behavioral intervention (CB); (3) UP + CB + weekly chlorhexidine rinse (CHX); (4) UP + CB + CHX + semi-annual fluoride varnish (F); and (5) UP + CB + CHX + F + semi-annual prophylaxis, including scaling (P).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8682921_20201005_0.5			The effect of oxidising mouthrinses compared with chlorhexidine on salivary bacterial counts and plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8682921_20201005_0.5			Analysis of Variance|Anti-Infective Agents, Local|Bacteria|Borates|Carbonates|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Humans|Mouthwashes|Oxidants|Saliva|Single-Blind Method|Sodium Chloride	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8682921_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In this study, 2 mouthrinses containing peroxyborate (Bocasan) and peroxycarbonate (Kavosan) were compared alongside a negative control saline rinse and a positive control chlorhexidine rinse (Corsodyl) for their ability to inhibit plaque reformation.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7600202_20210111_0.5			Patient compliance to postoperative instructions after third molar surgery comparing traditional verbally and written form versus the effect of a postoperative phone call follow-up a: A randomized clinical study	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7600202_20210111_0.5			Humans|Male|Adult|Female|Middle Aged|Molar, Third|Follow-Up Studies|Mandible|Tooth Extraction|Patient Compliance|Postoperative Care|Telephone|Chlorhexidine|Postoperative Period	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7600202_20210111_0.5	chlorhexidine rinse	drug_umls_atom	To brief written and written extended instructions groups, the main points of non-compliance were hygiene and smoking (p <0.001, p =0.026, respectively), and tended towards significance for chlorhexidine rinses and antibiotic, analgesic and anti-inflammatories medication prescribed.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7600202_20210111_0.5	chlorhexidine rinse	drug_umls_atom	The main factors of non-compliance were not maintain a proper hygiene and not smoking, followed by not performing chlorhexidine rinses and not following medication prescribed.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28406129_20201005_0.5			Prevention of alveolar osteitis after third molar surgery: Comparative study of the effect of warm saline and chlorhexidine mouth rinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28406129_20201005_0.5			Adolescent|Adult|Chlorhexidine|Dry Socket|Female|Follow-Up Studies|Humans|Incidence|Male|Middle Aged|Molar, Third|Mouthwashes|Nigeria|Postoperative Complications|Prospective Studies|Saline Solution|Single-Blind Method|Tooth Extraction|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28406129_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There was no statistically significant difference between application of warm saline and 0.12% chlorhexidine rinse with respect to the development of alveolar osteitis (P = 0.648).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1447382_20201005_0.5			A comparison of natural product, triclosan and chlorhexidine mouthrinses on 4-day plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1447382_20201005_0.5			Adult|Alkaloids|Astringents|Benzophenanthridines|Chamomile|Chlorhexidine|Chlorides|Dental Plaque|Double-Blind Method|Eugenol|Female|Flavonoids|Humans|Isoquinolines|Krameriaceae|Male|Mouthwashes|Oils, Volatile|Plants, Medicinal|Resins, Plant|Sodium Dodecyl Sulfate|Tannins|Terpenes|Thymol|Triclosan|Zinc|Zinc Compounds	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1447382_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The 0.2% chlorhexidine rinse (positive control) was significantly more effective, and the saline rinse (negative control) significantly less effective, than other rinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7614176_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effect of chlorhexidine rinse on the incidence of dry socket in impacted mandibular third molar extraction sites.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7614176_20201005_0.5			Adult|Chi-Square Distribution|Chlorhexidine|Contraceptives, Oral|Dry Socket|Female|Humans|Male|Mandible|Molar, Third|Mouthwashes|Postoperative Care|Preoperative Care|Prospective Studies|Smoking|Tooth Extraction|Tooth, Impacted|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4246385_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Staining and calculus formation after 0.12% chlorhexidine rinses in plaque-free and plaque covered surfaces: a randomized trial	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4246385_20201005_0.5			Chlorhexidine|Adverse effects|Staining|Tooth discoloration|Dental calculus	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4246385_20201005_0.5			Adult|Chlorhexidine|Dental Calculus|Dental Plaque|Dental Prophylaxis|Gingivitis|Humans|Male|Mouthwashes|Periodontal Index|Single-Blind Method|Surface Properties|Time Factors|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638182_20201005_0.5			Toothpastes containing 0.3% and 0.5% triclosan. II. Effects of single brushings on salivary bacterial counts.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638182_20201005_0.5			Adult|Chlorhexidine|Colony Count, Microbial|Dental Plaque|Dentifrices|Female|Humans|Male|Phenyl Ethers|Saliva|Toothpastes|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638182_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Intertreatment comparisons showed the chlorhexidine rinse more effective than all other preparations in all time periods.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7593704_20201005_0.5			An approach to efficacy screening of mouthrinses: studies on a group of French products (II). Inhibition of salivary bacteria and plaque in vivo.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7593704_20201005_0.5			Anti-Infective Agents, Local|Bacteria|Cetylpyridinium|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Double-Blind Method|France|Hexetidine|Humans|Mouthwashes|Saliva|Single-Blind Method|Taste|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7593704_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Salivary bacterial count reductions with time were highly significantly greater for Parodex to 5 h and Hibident and Prexidine to 7 h; There were no significant differences between the latter three chlorhexidine rinses except at 3 h, when decrements were significantly less with Parodex.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17380175_20201005_0.5			Systemic doxycycline and nonsurgical periodontal treatment in diabetic patients.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17380175_20201005_0.5			Middle Aged|Male|Humans|Aged|Female|Doxycycline|Root Planing|Dental Scaling|Dental Plaque Index|Chlorhexidine|Periodontal Pocket|Periodontal Attachment Loss|Anti-Infective Agents, Local|Anti-Bacterial Agents|Diabetes Mellitus	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17380175_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 METHODS Group 1 (30 patients) was given oral-hygiene instruction, scaling and root planing, chlorhexidine rinses twice a day and doxycycline (100 mg/day for 15 days).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2797737_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinse in prevention of dental caries in patients following radiation therapy.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2797737_20201005_0.5			Adolescent|Adult|Aged|Child|Chlorhexidine|DMF Index|Dental Caries|Dental Caries Susceptibility|Female|Humans|Lactobacillus|Male|Middle Aged|Mouthwashes|Radiotherapy|Saliva|Streptococcus mutans|Xerostomia	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2797737_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The use of chlorhexidine rinse to reduce the counts of S. mutans and lactobacillus was studied.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9565284_20201005_0.5			Periodontal effects of a biobehavioral prevention program.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9565284_20201005_0.5			Age Factors|Aged|Aged, 80 and over|Analysis of Variance|Anti-Infective Agents|Behavior Therapy|Chlorhexidine|Cognition|Dental Care for Aged|Dental Prophylaxis|Ethnic Groups|Female|Fluorides, Topical|Health Education, Dental|Humans|Male|Marital Status|Middle Aged|Mouthwashes|Oral Hygiene|Periodontal Diseases|Periodontal Index|Regression Analysis|Sex Factors|Socioeconomic Factors|Statistics, Nonparametric	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9565284_20201005_0.5	chlorhexidine rinse	drug_umls_atom	297 persons aged 60-90 (mean age 72.8; 43% ethnic minorities), were randomly assigned to either a control group or four interventions with incrementally more complex preventive strategies; behavioral training (group 2), added weekly chlorhexidine rinse (group 3), added semi-annual fluoride varnish (group 4), and added semi-annual prophylaxis (group 5).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7738271_20201005_0.5			Dietary staining in vitro by mouthrinses as a comparative measure of antiseptic activity and predictor of staining in vivo.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7738271_20201005_0.5			Analysis of Variance|Anti-Infective Agents, Local|Cetylpyridinium|Chlorhexidine|Drug Combinations|Drug Synergism|Food Coloring Agents|Hexetidine|Materials Testing|Methylmethacrylate|Methylmethacrylates|Models, Structural|Mouthwashes|Oils, Volatile|Phenols|Salicylates|Saliva|Spectrophotometry|Tea|Terpenes|Tooth Discoloration|Triclosan|Zinc Compounds	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7738271_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Some cetylpyridinium chloride (CPC) rinses stained comparably to a chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7738271_20201005_0.5	chlorhexidine rinse	drug_umls_atom	A 0.1% chlorhexidine rinse stained slightly more than a 0.2%.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28916206_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No benefits important to patients from the use of chlorhexidine rinse as an adjunct to scaling and root planing in patients with chronic periodontitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28916206_20201005_0.5			Anti-Infective Agents, Local|Chlorhexidine|Chronic Periodontitis|Dental Scaling|Humans|Mouthwashes|Root Planing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4581405_20201005_0.5			Non-operative anti-caries agents and dental caries increment among adults at high caries risk: a retrospective cohort study	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4581405_20201005_0.5			Dental caries|Epidemiology|Caries management|Longitudinal studies|Health outcomes research	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4581405_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Anti-Infective Agents, Local|Cariostatic Agents|Chlorhexidine|Cohort Studies|DMF Index|Dental Caries|Dental Caries Susceptibility|Electronic Health Records|Female|Fluorides|Follow-Up Studies|Humans|Male|Medicaid|Middle Aged|Mouthwashes|Retrospective Studies|Risk Assessment|Toothpastes|Treatment Outcome|United States|Xylitol|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4581405_20201005_0.5	chlorhexidine rinse	drug_umls_atom	We calculated and compared adjusted mean estimates for the number of new decayed or restored teeth (DFT increment) from baseline to the next completed oral evaluation (N  = 2,724 patients with follow-up) across three categories of delivery of non-operative anti-caries agents (e.g., high-concentration fluoride toothpaste, chlorhexidine rinse, xylitol products): never, at a single appointment, or at ≥2 appointments ≥4 weeks apart.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451518_20201005_0.5			Oral health care for pregnant and postpartum women.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451518_20201005_0.5			Anti-Infective Agents, Local|Cariostatic Agents|Chlorhexidine|Dental Care|Dental Caries|Female|Humans|Infant|Infectious Disease Transmission, Vertical|Oral Hygiene|Patient Education as Topic|Postpartum Period|Pregnancy|Streptococcus mutans|Xylitol	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451518_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinses and xylitol containing chewing gum will be discussed as possible solutions to this tremendous public health problem.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1886022_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The effect of a chlorhexidine rinse on the incidence of alveolar osteitis following the surgical removal of impacted mandibular third molars.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1886022_20201005_0.5			Adolescent|Adult|Chlorhexidine|Double-Blind Method|Dry Socket|Female|Humans|Incidence|Male|Molar, Third|Prospective Studies|Tooth Extraction|Tooth, Impacted	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327641_20201005_0.5			A simple approach to examine early oral microbial biofilm formation and the effects of treatments.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327641_20201005_0.5			Actinomyces viscosus|Anti-Infective Agents, Local|Biofilms|Cetylpyridinium|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Dentifrices|Humans|Maleates|Mouthwashes|Polyethylenes|Streptococcus mutans|Streptococcus sanguis|Toothbrushing|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15327641_20201005_0.5	chlorhexidine rinse	drug_umls_atom	A dose-dependent inhibition was noted with chlorhexidine rinses (P < 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11210271_20201005_0.5			Effect of saccharin on antibacterial activity of chlorhexidine gel.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11210271_20201005_0.5			Anti-Infective Agents, Local|Chemistry, Pharmaceutical|Chlorhexidine|Colony Count, Microbial|Dental Plaque|Diffusion|Dose-Response Relationship, Drug|Flavoring Agents|Gels|Humans|Saccharin|Statistics as Topic|Streptococcus mutans|Sweetening Agents	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11210271_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Saccharin has been considered a compatible substance to use in chlorhexidine rinse or gel preparations; however, the effect of a range of concentrations has not been studied.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1499250_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effect of a twice daily 0.12% chlorhexidine rinse on the oral health of a geriatric population.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1499250_20201005_0.5			Aged|Aged, 80 and over|Analysis of Variance|Chlorhexidine|Dental Care for Aged|Denture, Overlay|Denture, Partial, Removable|Female|Humans|Male|Middle Aged|Mouthwashes|Stomatitis, Denture	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1499250_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section The inhibitory effect of a chlorhexidine rinse on gingival inflammation and plaque accumulation has been well documented.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2388139_20201005_0.5			Irrigation with 0.06% chlorhexidine in naturally occurring gingivitis. II. 6 months microbiological observations.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2388139_20201005_0.5			Adult|Bacteria|Bacteroides|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dentifrices|Gingival Hemorrhage|Gingival Pocket|Gingivitis|Humans|Mouthwashes|Periodontal Index|Sodium Fluoride|Therapeutic Irrigation	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2388139_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinse also significantly (P less than or equal to 0.008) reduced log10 CFU of black-pigmented Bacteroides at 6 months.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17589485_20201214_0.5			Pre-operative chlorhexidine mouth rinses reduce the incidence of dry socket.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17589485_20201214_0.5			Humans|Dry Socket|Chlorhexidine|Mouthwashes|Incidence|Molar, Third|Mandible|Anti-Infective Agents, Local|Tooth Extraction|Data Management|Molar|Tetracycline|Anti-Bacterial Agents|Antifibrinolytic Agents	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17589485_20201214_0.5	chlorhexidine rinse	drug_umls_atom	The effect of chlorhexidine rinses for prevention of AO was studied in five RCT with ARR ranging from 3-25% (NNT, four to 36 treatments).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17589485_20201214_0.5	chlorhexidine rinse	drug_umls_atom	Overall, evidence about chlorhexidine rinses on the prevention of AO was inconclusive, but the available data indicate that 0.12% chlorhexidine rinsing pre-operatively and 7 days postoperatively reduces the frequency of AO following surgical removal of lower third molars.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2892434_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinse for prevention of urethritis in men linked to oral sex	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2892434_20201005_0.5			Adolescent|Male|Humans|Chlorhexidine|Urethritis|Sexual Behavior|Mouthwashes|Anti-Infective Agents, Local|Bacterial Infections|Bacteria|Prostatitis|Urethra|Saliva	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2892434_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The recommendation for rinsing will be: 15 ml of a 0.12% or 10 ml of 0.2% chlorhexidine rinse for 30 seconds.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15752094_20201005_0.5			The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15752094_20201005_0.5			Halitosis|Humans|Probiotics|Tongue|Viridans Streptococci	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15752094_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In our preliminary trials of the use of a chlorhexidine rinse followed by strain K12 lozenges, the majority (8/13) of subjects with confirmed halitosis maintained reduced breath levels of volatile sulphur compounds for at least 2 weeks.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3323451_20201005_0.5			Adhesion of Candida albicans to buccal epithelial cells exposed to chlorhexidine gluconate.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3323451_20201005_0.5			Adhesiveness|Adult|Candida albicans|Cheek|Child|Chlorhexidine|Female|Humans|Male|Mouth Mucosa	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3323451_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Also a significant positive correlation was noted (r = 0.99) between the time which elapsed after a chlorhexidine rinse and yeast adhesion to BEC.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9763329_20201005_0.5			Evaluation of tetracycline fiber therapy with digital image analysis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9763329_20201005_0.5			Adult|Alveolar Bone Loss|Alveolar Process|Anti-Bacterial Agents|Anti-Infective Agents, Local|Bone Density|Chlorhexidine|Colony Count, Microbial|Combined Modality Therapy|Dental Scaling|Drug Implants|Evaluation Studies as Topic|Follow-Up Studies|Gingival Hemorrhage|Humans|Image Processing, Computer-Assisted|Mouthwashes|Periodontal Pocket|Periodontitis|Periodontium|Porphyromonas gingivalis|Radiography|Root Planing|Tetracycline	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9763329_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Upon removal of the fibers, scaling and root planing was performed on these 2 teeth, while the rest of the dentition remained untreated, and no chlorhexidine rinse was applied.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8122590_20201005_0.5			ATP content in 3-day-old bacterial plaques with or without a 0.2% chlorhexidine mouth rinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8122590_20201005_0.5			Adenosine Triphosphate|Adult|Bacteria|Chlorhexidine|Dental Plaque|Female|Humans|Male|Middle Aged|Mouthwashes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8122590_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The results, expressed in bacterial equivalents, show a reduction of dental plaque metabolism after 3 days of chlorhexidine rinses to 19.5% of its value in the control tests without mouth-washes.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2127318_20201005_0.5			Further in vivo studies on the plaque-inhibiting effect of chlorhexidine and its binding mechanisms.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2127318_20201005_0.5			Adult|Chlorhexidine|Dental Plaque|Double-Blind Method|Edetic Acid|Humans|Hydrogen-Ion Concentration|Middle Aged|Mouthwashes|Phosphates|Placebos|Receptors, Drug|Streptococcus sanguis	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2127318_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Rinsing with 0.02 M EDTA was performed prior to the chlorhexidine rinse, because this procedure has been shown to enhance the antibacterial effect of chlorhexidine in vitro.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11924590_20201005_0.5			Efficacy of chlorhexidine mouthrinses with and without alcohol: a clinical study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11924590_20201005_0.5			Adult|Analysis of Variance|Chlorhexidine|Dental Plaque|Dental Plaque Index|Double-Blind Method|Ethanol|Female|Gingivitis|Humans|Male|Mouthwashes|Periodontal Index|Statistics, Nonparametric	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11924590_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 RESULTS There were significant differences in plaque, gingivitis, and papilla bleeding indexes in both chlorhexidine rinses compared to placebo, but no differences between the 2 CHX products.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25443306_20201005_0.5			Prophylactic oral health procedures to prevent hospital-acquired and ventilator-associated pneumonia: a systematic review.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25443306_20201005_0.5			Aspiration pneumonia|Dentistry|Hospital-acquired pneumonia|Oral health|Oral prophylaxis|Ventilator-associated pneumonia	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25443306_20201005_0.5			Cross Infection|Humans|Oral Health|Pneumonia, Ventilator-Associated	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25443306_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS Current evidence suggests that chlorhexidine rinses, gels and swabs may be effective oral disinfectants in patients at high risk for hospital-acquired and ventilator-associated pneumonia.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089241_20201005_0.5			The magnitude and duration of the effects of some mouthrinse products on salivary bacterial counts.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089241_20201005_0.5			Adult|Anti-Bacterial Agents|Bacteria|Chlorhexidine|Colony Count, Microbial|Dental Plaque|Female|Humans|Male|Mouthwashes|Saliva|Single-Blind Method|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089241_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effects over a 7-h period were compared with a chlorhexidine rinse product (positive control) and saline (negative control).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451383_20201005_0.5			A non-staining chlorhexidine mouthwash? Probably not: a study in vitro.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451383_20201005_0.5			Chlorhexidine|Dental Plaque|Humans|Mouthwashes|Tea|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451383_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 METHODS Optically clear acrylic specimens were cycled through human saliva (2 min), one of the three chlorhexidine rinses (two ADS and a positive control) (2 min) or water and then soaked in tea (60 min).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451383_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS Based on extensive literature for the correlation of this test in vitro with chlorhexidine anti-plaque activity and propensity to stain in vivo these ADS rinses will have the same anti-plaque efficacy and potential to cause stain as established chlorhexidine rinse products.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16178133_20201005_0.5			A 6-month clinical study assessing the safety and efficacy of two cetylpyridinium chloride mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16178133_20201005_0.5			Adolescent|Adult|Aged|Anti-Infective Agents, Local|Cetylpyridinium|Chlorhexidine|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Follow-Up Studies|Gingival Hemorrhage|Gingivitis|Humans|Male|Middle Aged|Mouth Mucosa|Mouthwashes|Periodontal Index|Placebos|Safety|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16178133_20201005_0.5	chlorhexidine rinse	drug_umls_atom	A 0.12% chlorhexidine rinse served as the positive control for validation of the methodology.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9736367_20201005_0.5			In vitro studies on the effect of cleaning methods on different implant surfaces.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9736367_20201005_0.5			Air|Animals|Biocompatible Materials|Cell Division|Cell Survival|Cells, Cultured|Chlorhexidine|Coated Materials, Biocompatible|Curettage|Dental Implants|Dental Polishing|Dental Prophylaxis|Dental Scaling|Diamond|Disinfectants|Durapatite|Fibroblasts|Humans|Metals|Mice|Microscopy, Electron, Scanning|Plastics|Powders|Sodium Bicarbonate|Surface Properties|Titanium|Ultrasonic Therapy|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9736367_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The air-powder-abrasive system, chlorhexidine rinse, and curettage with a plastic instrument caused little or no surface damage in all but the hydroxyapatite-coated fixtures.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9344275_20201005_0.5			Oral health promotion and prevention for older adults.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9344275_20201005_0.5			Adult|Aged|Anti-Infective Agents, Local|Cariostatic Agents|Chewing Gum|Child|Chlorhexidine|Dental Care for Aged|Dental Caries|Dental Devices, Home Care|Equipment Design|Fluorides|Health Promotion|Health Services Needs and Demand|Humans|Mouth Diseases|Mouth Neoplasms|Mouthwashes|Oral Health|Oral Hygiene|Risk Assessment|Risk Factors|Tooth Diseases|Toothbrushing|Xylitol	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9344275_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Other preventive agents such as chlorhexidine rinses and xylitol gum supplement the program as risk factors increase or when health and disability limit the ability to effectively perform oral hygiene procedures.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28362061_20210111_0.5			Chlorhexidine mouthrinse as an adjunctive treatment for gingival health.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28362061_20210111_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Chemotherapy, Adjuvant|Child|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dental Prophylaxis|Female|Gingivitis|Humans|Male|Middle Aged|Mouthwashes|Oral Hygiene|Publication Bias|Randomized Controlled Trials as Topic|Time Factors|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28362061_20210111_0.5	chlorhexidine rinse	drug_umls_atom	There is no evidence that one concentration of chlorhexidine rinse is more effective than another.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11022781_20201005_0.5			The relationship between peripheral levels of leukocytes and neutrophils and periodontal disease status in a patient with congenital neutropenia.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11022781_20201005_0.5			Adult|Blood Cell Count|Dental Scaling|Granulocyte Colony-Stimulating Factor|Humans|Male|Neutropenia|Periodontal Diseases|Periodontal Index|Recombinant Proteins	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11022781_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Scaling and root planing were performed and the patient received antibiotics and chlorhexidine rinses twice each day for 2 weeks.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8463939_20201005_0.5			The plaque removal effects of single rinsings and brushings.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8463939_20201005_0.5			Adult|Analysis of Variance|Benzoates|Borates|Cetylpyridinium|Chlorhexidine|Dental Plaque|Dental Plaque Index|Female|Fluorides|Humans|Male|Mouthwashes|Phosphates|Single-Blind Method|Sodium Dodecyl Sulfate|Tartrates|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8463939_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Most statistically significant differences arose with the chlorhexidine rinse being apparently less effective.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6486980_20201005_0.5			The antiplaque/anticariogenic efficacy of Salvadora persica (Miswak) mouthrinse in comparison to that of chlorhexidine: a systematic review and meta-analysis	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6486980_20201005_0.5			Anti-Infective Agents|Anti-Infective Agents, Local|Bacterial Infections|Chlorhexidine|Dental Caries|Dental Plaque|Humans|Microbial Sensitivity Tests|Mouthwashes|Oral Hygiene|Plant Extracts|Salvadoraceae	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6486980_20201005_0.5	chlorhexidine rinse	drug_umls_atom	However, its effects were inferior compared to those by chlorhexidine rinse (P  = 0.04, MD: 0.19, and 95% CI: 0.01 to 0.37).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Clinical effects of a 0.12% chlorhexidine rinse as an adjunct to scaling and root planing.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5			Analysis of Variance|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dental Scaling|Double-Blind Method|Gingival Pocket|Gingivitis|Humans|Longitudinal Studies|Periodontal Index|Root Planing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section This trial tested the adjunctive effects of a 0.12% chlorhexidine rinse (Peridex) upon gingival healing following scaling and root planing.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Subjects were separated by sex and periodontal classification, arrayed by GI scores, and randomly assigned to either the chlorhexidine rinse or a placebo rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Gingival healing following scaling and root planing in subjects using a chlorhexidine rinse (0.12%) was significantly better than subjects using the placebo rinse as evidenced by less gingivitis (29%), fewer GI bleeding sites (48%) and less plaque (54%).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16197748_20201005_0.5			Benefits of sodium hexametaphosphate-containing chewing gum for extrinsic stain inhibition.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16197748_20201005_0.5			Adult|Analysis of Variance|Chewing Gum|Chlorhexidine|Cross-Over Studies|Dentifrices|Female|Humans|Male|Middle Aged|Mouthwashes|Phosphates|Photography, Dental|Single-Blind Method|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16197748_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The three-day stain induction phase consisted of the patient using a 10 ml 0.2% chlorhexidine rinse for 60 seconds, followed by chewing two pellets/sticks of their assigned gum for five minutes and rinsing with 10 ml of cold tea solution for 60 seconds.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1388952_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Comparison of a chlorhexidine rinse and a wooden interdental cleaner in reducing interdental gingivitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1388952_20201005_0.5			Adult|Chlorhexidine|Dental Devices, Home Care|Female|Gingivitis|Humans|Male|Middle Aged|Mouthwashes|Oral Hygiene|Periodontal Index	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31153513_20201005_0.5			Liquid mycobacterial culture outcomes after different sputum collection techniques before and during treatment.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31153513_20201005_0.5			Chlorhexidine|HIV-Infection|Mouth wash|Sputum collection|Tuberculosis	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31153513_20201005_0.5			Adult|Antitubercular Agents|Bacteriological Techniques|Chlorhexidine|Coinfection|Drinking Water|Female|HIV Infections|Humans|Male|Microbial Viability|Mouthwashes|Mycobacterium tuberculosis|Predictive Value of Tests|Reproducibility of Results|Specimen Handling|Sputum|Time Factors|Treatment Outcome|Tuberculosis, Pulmonary	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31153513_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The odds of contamination were higher with home collection and with water rinse than with chlorhexidine rinse (OR: 12.5, p < 0.001 and OR: 6.7, p = 0.015).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31153513_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinse increased the odds of a negative culture compared to water rinse (OR: 3.5, p = 0.002).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID31153513_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 No section Compared to sputum collected at home, chlorhexidine rinse reduces culture contamination and water rinse increases the rate and viable mycobacterial load of positive cultures.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12631184_20201005_0.5			Effect of toothpaste on the plaque inhibitory properties of a cetylpyridinium chloride mouth rinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12631184_20201005_0.5			Adult|Anti-Infective Agents, Local|Cetylpyridinium|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Drug Antagonism|Female|Humans|Male|Mouthwashes|Single-Blind Method|Time Factors|Toothpastes|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12631184_20201005_0.5	chlorhexidine rinse	drug_umls_atom	This in part may explain the reported lack of adjunctive benefits of CPC rinses to normal oral hygiene practices and supports the suggestion, made for chlorhexidine rinses, that their use should follow toothpaste by at least 60 min.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7484104_20201005_0.5			Mouth-rinsing with chlorhexidine causes a delayed, temporary increase in the levels of oral viridans streptococci.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7484104_20201005_0.5			Adult|Anti-Infective Agents, Local|Bacterial Adhesion|Chlorhexidine|Colony Count, Microbial|Female|Humans|Linear Models|Longitudinal Studies|Male|Mouth Mucosa|Mouthwashes|Saliva|Statistics, Nonparametric|Streptococcus	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7484104_20201005_0.5	chlorhexidine rinse	drug_umls_atom	One day after the chlorhexidine rinse, however, the numbers of the epithelial cell-adherent bacteria exceeded the base-line level, and a similar decrease-increase pattern of changes was detected for the salivary alpha-hemolytic streptococcal counts.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC3200021_20201005_0.5			Evaluation of two mouth rinses in reduction of oral malodor using a spectrophotometric technique	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC3200021_20201005_0.5			Chlorhexidine|halitosis|organoleptic|spectrophotometry|volatile sulfur compounds (VSCs)	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC3200021_20201005_0.5			Middle Aged|Adult|Male|Humans|Female|Mouthwashes|Halitosis|Chlorhexidine|Anti-Infective Agents, Local|Sulfhydryl Compounds|Oils, Volatile|Spectrophotometry	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC3200021_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In the present study, 0.2% chlorhexidine rinse and an essential oil mouth rinse are compared for their efficacy in reducing the breath mercaptan levels.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2642826_20201005_0.5			Factors influencing periodontal therapy for the geriatric patient.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2642826_20201005_0.5			Aged|Aging|Health Services for the Aged|Humans|Periodontal Diseases	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2642826_20201005_0.5	chlorhexidine rinse	drug_umls_atom	If there are physical or mental disabilities that make effective home care difficult, antimicrobial agents, such as the extensively tested chlorhexidine rinse, may be valuable adjuncts.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7808776_20201005_0.5			Effect of chlorhexidine and toothbrushing on the presence of bacteria on gingival and buccal epithelial cells.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7808776_20201005_0.5			Adult|Bacteria, Anaerobic|Bacterial Adhesion|Chlorhexidine|Female|Humans|Microscopy, Fluorescence|Mouth Mucosa|Single-Blind Method|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7808776_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Four hours after a chlorhexidine rinse, the number of cells with > 50 attached bacteria had almost completely vanished.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18633464_20201005_0.5			Alterations in HbA1c following minimal or enhanced non-surgical, non-antibiotic treatment of gingivitis or mild periodontitis in type 2 diabetic patients: a pilot trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18633464_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Analysis of Variance|Anti-Infective Agents, Local|Chlorhexidine|Dental Plaque Index|Dental Scaling|Diabetes Mellitus, Type 2|Gingivitis|Glycated Hemoglobin A|Humans|Middle Aged|Oral Hygiene|Oral Hygiene Index|Periodontal Index|Pilot Projects|Statistics, Nonparametric|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18633464_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Participants randomized to the "frequent therapy" (FT) protocol received scaling, root planing, and oral hygiene instructions at two-month intervals and were provided a 0.12% chlorhexidine rinse for home use twice daily.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID14600693_20201005_0.5			The effect of chlorhexidine as an endodontic disinfectant.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID14600693_20201005_0.5			Adolescent|Adult|Aged|Anti-Infective Agents, Local|Bacteria|Calcium Hydroxide|Chi-Square Distribution|Child|Chlorhexidine|Dental Pulp Cavity|Dental Pulp Necrosis|Disinfectants|Drug Combinations|Follow-Up Studies|Humans|Middle Aged|Periapical Periodontitis|Root Canal Filling Materials|Root Canal Irrigants|Single-Blind Method|Sodium Hypochlorite	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID14600693_20201005_0.5	chlorhexidine rinse	drug_umls_atom	OBJECTIVE The purpose of this study was to establish whether addition of a 2% chlorhexidine rinse to a conventional treatment protocol enhances the rate of the successful disinfection of the root canal system in vivo.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19486461_20201005_0.5			Caregiver acceptability and preferences for early childhood caries preventive treatments for Hispanic children.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19486461_20201005_0.5			Adult|Caregivers|Cariostatic Agents|Chewing Gum|Child|Child, Preschool|Chlorhexidine|Dental Caries|Early Intervention, Educational|Female|Fluorides, Topical|Hispanic Americans|Humans|Male|Mouthwashes|Parents|Patient Acceptance of Health Care|Patient Preference|Toothbrushing|United States|Xylitol	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19486461_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Treatments assessed were toothbrushing with fluoride toothpaste, fluoride varnish, and xylitol in food for children, and xylitol gum and chlorhexidine rinse for mothers.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28642555_20201005_0.5			Chlorhexidine mouthwash plaque levels and gingival health.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28642555_20201005_0.5			Chlorhexidine|Dental Plaque|Gingivitis|Humans|Mouthwashes|Oral Hygiene	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28642555_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There is no evidence that one concentration of chlorhexidine rinse is more effective than another.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11885176_20201005_0.5			Implant survival in patients with type 2 diabetes: placement to 36 months.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11885176_20201005_0.5			Adult|Aged|Aged, 80 and over|Anti-Infective Agents, Local|Antibiotic Prophylaxis|Chi-Square Distribution|Chlorhexidine|Cluster Analysis|Coated Materials, Biocompatible|Databases as Topic|Dental Implantation, Endosseous|Dental Implants|Dental Prosthesis Design|Dental Prosthesis, Implant-Supported|Dental Restoration Failure|Diabetes Mellitus, Type 2|Durapatite|Follow-Up Studies|Humans|Logistic Models|Middle Aged|Mouthwashes|Risk Factors|Surface Properties|Survival Analysis|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11885176_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The use of chlorhexidine rinses following implant placement resulted in a slight improvement (2.5%) in survival in non-Type 2 patients and a greater improvement in Type 2 patients (9.1%); the use of preoperative antibiotics improved survival by 4.5% in non-Type 2 patients and 10.5% in Type 2 patients.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID44385_20201005_0.5			Effect of chlorhexidine on acidogenicity of dental plaque in vivo.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID44385_20201005_0.5			Adult|Chlorhexidine|Dental Plaque|Humans|Hydrogen-Ion Concentration|Mouthwashes|Oral Hygiene|Sucrose	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID44385_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The results showed that a 0.2% chlorhexidine mouthrinse inhibited acid production for a period of 24 h, whereas a 0.05% chlorhexidine rinse showed an inhibitory effect for 4 h. It is suggested that the mechanism involved may be related to the retention of chlorhexidine in the mouth and in plaque providing a bacteriostatic milieu which may be of importance in the observed long-term effect.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8583018_20201005_0.5			Comparative staining in vitro and plaque inhibitory properties in vivo of 0.12% and 0.2% chlorhexidine mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8583018_20201005_0.5			Acrylic Resins|Adult|Anti-Infective Agents, Local|Chlorhexidine|Coloring Agents|Cross-Over Studies|Dental Plaque|Double-Blind Method|Female|Humans|Male|Middle Aged|Mouthwashes|Saliva|Spectrophotometry, Ultraviolet|Tea|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8583018_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The aim of this study was to compare a new 0.12% chlorhexidine containing rinse with a well researched 0.2% chlorhexidine rinse product.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8583018_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The results showed that the 2 chlorhexidine rinses were similar in efficacy by comparison with the control rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7823270_20201005_0.5			Efficacy of mouthrinses in inhibiting the development of supragingival plaque over a 4-day period of no oral hygiene.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7823270_20201005_0.5			Adult|Cetylpyridinium|Chlorhexidine|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Gingiva|Humans|Male|Mouthwashes|Oils, Volatile|Oral Hygiene|Placebos|Polymers|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7823270_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The order of efficacy from the most effective was: chlorhexidine rinse (positive control); experimental CPC/essential oil rinse; triclosan/copolymer rinse; and the negative control rinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8526801_20201005_0.5			Effects of chlorhexidine on human taste perception.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8526801_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Chi-Square Distribution|Chlorhexidine|Citrates|Citric Acid|Female|Humans|Male|Mouthwashes|Quinine|Sodium Chloride|Statistics, Nonparametric|Sucrose|Taste	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8526801_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinses reduced the perceptual intensity of sodium chloride and quinine hydrochloride, not sucrose or citric acid.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2919059_20201005_0.5			Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2919059_20201005_0.5			Adult|Aged|Aged, 80 and over|Bacteria|Chlorhexidine|Colony Count, Microbial|Double-Blind Method|Female|Head and Neck Neoplasms|Humans|Male|Middle Aged|Mouth Mucosa|Pharynx|Prospective Studies|Radiography|Random Allocation|Stomatitis	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2919059_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The colonization patterns of Candida species, Streptococcus faecalis, staphylococci, and Enterobacteriaceae, Pseudomonadaceae, and Acinetobacter species were not influenced by 5 weeks of use of chlorhexidine rinses when compared with the placebo.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12116726_20201005_0.5			Experimental gingivitis studies: effects of triclosan and triclosan-containing dentifrices on dental plaque and gingivitis in three-week randomized controlled clinical trials.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12116726_20201005_0.5			Adolescent|Adult|Analysis of Variance|Anti-Infective Agents, Local|Dental Plaque|Dentifrices|Drug Combinations|Female|Gingivitis|Humans|Least-Squares Analysis|Male|Middle Aged|Mouthwashes|Statistics, Nonparametric|Treatment Failure|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12116726_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In study 3, statistically significant treatment differences in plaque regrowth and gingivitis were observed at day 21 for the chlorhexidine rinse versus all other rinses (p < 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18172232_20201005_0.5			Dental students' opinions and knowledge about caries management and prevention.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18172232_20201005_0.5			Adult|Attitude of Health Personnel|Chlorhexidine|Clinical Competence|Dental Caries|Education, Dental|Female|Florida|Health Knowledge, Attitudes, Practice|Humans|Male|Mouthwashes|Preventive Dentistry|Risk Assessment|Schools, Dental|Students, Dental	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18172232_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In their responses, 83 percent reported they would use chlorhexidine rinses for caries control, and 51 percent would use salivary tests for detecting cariogenic bacteria.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18446389_20201005_0.5			The effect of periodontal treatment on metabolic control of type 1 diabetes mellitus.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18446389_20201005_0.5			Adolescent|Adult|Anti-Bacterial Agents|Anti-Infective Agents, Local|Chlorhexidine|Dental Scaling|Diabetes Mellitus, Type 1|Doxycycline|Female|Fructosamine|Glycated Hemoglobin A|Humans|Linear Models|Male|Middle Aged|Mouthwashes|Periodontitis|Prospective Studies|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18446389_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Group 1 (30 patients) was treated with scaling, root planning, and chlorhexidine rinses for 3 months in conjunction with systemic administration of doxycycline (100 mg once a day for 15 days).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12005141_20201005_0.5			The effects of an immediately pre-surgical chlorhexidine oral rinse on the bacterial contaminants of bone debris collected during dental implant surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12005141_20201005_0.5			Actinomyces|Anti-Infective Agents, Local|Bacteria|Bone Transplantation|Chlorhexidine|Clostridium|Colony Count, Microbial|Dental Implantation, Endosseous|Drug Resistance, Bacterial|Female|Fusobacterium|Gram-Positive Bacteria|Humans|Jaw, Edentulous, Partially|Male|Maxilla|Middle Aged|Mouthwashes|Peptostreptococcus|Preoperative Care|Prevotella intermedia|Propionibacterium|Staphylococcus|Statistics, Nonparametric|Streptococcus|Suction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12005141_20201005_0.5	chlorhexidine rinse	drug_umls_atom	In group T a pre-operative chlorhexidine rinse was used, whilst in group C sterile water was used.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17233164_20201005_0.5			Effectiveness of antimicrobial mouthrinses on aerosols produced by an air polisher.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17233164_20201005_0.5			Adult|Aerosols|Air Microbiology|Anti-Infective Agents, Local|Bronchi|Chlorhexidine|Colony Count, Microbial|Dental Prophylaxis|Drug Combinations|Female|Humans|Male|Mouthwashes|Particle Size|Pharynx|Pulmonary Alveoli|Salicylates|Single-Blind Method|Terpenes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17233164_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 METHODS Forty-five adult subjects were randomly assigned to one of three groups and asked to rinse for 30 seconds with 15 ml of either a 0.12% chlorhexidine rinse, an essential oil mouthrinse, or water prior to air polishing.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30535817_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Efficacy of chlorhexidine rinses after periodontal or implant surgery: a systematic review.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30535817_20201005_0.5			Chlorhexidine|Dental implant|Mouthwashes|Periodontitis	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30535817_20201005_0.5			Anti-Infective Agents, Local|Biofilms|Chlorhexidine|Dental Implantation|Gingivitis|Humans|Mouthwashes|Periodontal Diseases|Surgical Wound Infection	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID275276_20201005_0.5			Use of Hibitane following periodontal surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID275276_20201005_0.5			Biguanides|Chlorhexidine|Gels|Humans|Mouthwashes|Periodontal Dressings|Periodontium|Postoperative Care|Wound Healing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID275276_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Available data suggest that rinsing with a 0.2% chlorhexidine gluconate solution does not influence healing while a conventional dressing is in place, but once this is removed healing is enhanced by either a chlorhexidine rinse or gel.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22874549_20201005_0.5			An evidence-based oral care protocol to decrease ventilator-associated pneumonia.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22874549_20201005_0.5			Chlorhexidine|Cross Infection|Humans|Infection Control|Intensive Care Units|Nursing Audit|Oral Hygiene|Pneumonia, Ventilator-Associated|Respiration, Artificial	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22874549_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section The purpose of this study was to examine the impact of 0.12% chlorhexidine rinses and an oral care protocol on ventilator-associated pneumonia rates.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28067086_20201005_0.5	chlorhexidine rinse	drug_umls_atom	[Prospective randomized study regarding the effect of the preoperative antibiotic and chlorhexidine rinse on wound healing after mandibular third molar surgery].	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28067086_20201005_0.5			alsó bölcsességfog|antibiotic prophylaxis|antibiotikum-profilaxis|chlorhexidine|klórhexidin|mandibular third molar|postoperative complications|sebgyógyulás|wound healing	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28067086_20201005_0.5			Amoxicillin|Anti-Bacterial Agents|Antibiotic Prophylaxis|Clindamycin|Female|Humans|Male|Mandible|Molar, Third|Pain, Postoperative|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28067086_20201005_0.5	chlorhexidine rinse	drug_umls_atom	OBJECTIVE The study compares the antibiotic prophylaxis combined with postoperative antibiotic therapy to preoperative chlorhexidine rinse combined with postoperative antibiotic therapy in preventing complications after surgical removal of a mandibular third molar.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10100042_20201005_0.5			Comparative antiplaque effectiveness of an essential oil and an amine fluoride/stannous fluoride mouthrinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10100042_20201005_0.5			Adult|Amines|Anti-Infective Agents|Anti-Infective Agents, Local|Chlorhexidine|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Dental Prophylaxis|Drug Combinations|Female|Humans|Male|Mouthwashes|Placebos|Salicylates|Single-Blind Method|Terpenes|Tin Fluorides|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10100042_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Compared to the respective placebos, the median percent plaque reductions at 5 days were 23.0%, 12.2%, and 38.2% for the essential oil, amine/stannous fluoride, and chlorhexidine rinses, respectively.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10100042_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The plaque reductions seen in the essential oil and chlorhexidine rinse groups were statistically significant (p < 0.001), while the plaque reduction in the amine/stannous fluoride rinse group was not statistically significant (p > 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1939804_20201005_0.5			Management of oral complications associated with cancer therapy in pediatric patients.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1939804_20201005_0.5			Antineoplastic Agents|Child|Humans|Mouth Diseases|Neoplasms|Radiotherapy	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1939804_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Consequently, use of multiagent mouthrinses is declining in favor of 0.12 percent chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10682411_20201005_0.5			The influence of a 0.2% chlorhexidine mouthrinse on plaque regrowth in orthodontic patients. A randomized prospective study. Part I: clinical parameters.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10682411_20201005_0.5			Adolescent|Chlorhexidine|Cross-Over Studies|Dental Plaque|Double-Blind Method|Female|Gingivitis|Humans|Male|Mouthwashes|Oral Hygiene|Orthodontic Appliances|Prospective Studies|Recurrence|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10682411_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Until the 5th day of washout a clear-cut carryover effect of the chlorhexidine rinse on the gingival index was observed.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9248694_20201005_0.5			Intentional replantation.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9248694_20201005_0.5			Alveolectomy|Analgesics, Opioid|Anti-Bacterial Agents|Anti-Inflammatory Agents|Cell Survival|Chlorhexidine|Curettage|Disinfectants|Humans|Isotonic Solutions|Lenses|Lighting|Microscopy|Microsurgery|Periapical Tissue|Periodontal Ligament|Premedication|Root Canal Therapy|Splints|Time Factors|Tissue Preservation|Tooth Replantation|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9248694_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Narcotic pain medication was prescribed routinely; now clinicians premedicate with chlorhexidine rinse, anti-inflammatory medication, and sometimes antibiotics, rarely using narcotics.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15058377_20201005_0.5			Polymer-assisted regeneration therapy with Atrisorb barriers in human periodontal intrabony defects.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15058377_20201005_0.5			Absorbable Implants|Adult|Alveolar Bone Loss|Anti-Bacterial Agents|Biocompatible Materials|Bone Transplantation|Dental Plaque Index|Female|Follow-Up Studies|Gingival Recession|Guided Tissue Regeneration, Periodontal|Humans|Lactic Acid|Male|Membranes, Artificial|Middle Aged|Minocycline|Periodontal Attachment Loss|Periodontal Pocket|Periodontitis|Polyesters|Polyglactin 910|Polymers	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15058377_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Postoperative care included 0.10% chlorhexidine rinse daily and antibiotic medication for 2 weeks.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2689627_20201005_0.5			A clinical comparison of antibacterial mouthrinses: effects of chlorhexidine, phenolics, and sanguinarine on dental plaque and gingivitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2689627_20201005_0.5			Adult|Alkaloids|Anti-Infective Agents|Benzophenanthridines|Chlorhexidine|Clinical Trials as Topic|Dental Plaque|Double-Blind Method|Female|Gingival Hemorrhage|Gingivitis|Humans|Isoquinolines|Male|Mouthwashes|Phenol|Phenols|Placebos|Random Allocation|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2689627_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Both the phenolic and sanguinarine groups showed moderate, yet significant, reductions in plaque compared to placebo (24% and 12% respectively) yet were significantly less effective than the 0.12% chlorhexidine rinse (P less than 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1860286_20201005_0.5			Taurolin as an oral rinse. II. Effects on in vitro and in vivo plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1860286_20201005_0.5			Analysis of Variance|Chlorhexidine|Dental Plaque|Female|Gingivitis|Humans|Male|Mouthwashes|Streptococcus mutans|Taurine|Thiadiazines	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1860286_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The findings showed that the Taurolin reduced in vitro bacterial surface growth and in vivo plaque regrowth compared to saline, but was not as effective as a chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11238242_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Reduction of saltiness and bitterness after a chlorhexidine rinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11238242_20201005_0.5			Adult|Chlorhexidine|Disinfectants|Female|Humans|Male|Mouthwashes|Quinine|Salts|Sodium Chloride|Taste	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11238242_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The purpose of the present study was to examine the effect of acute chlorhexidine rinses on taste intensity and quality of 11 stimuli representing sweet, salt, sour, bitter and savory.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11238242_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The bitter taste of urea, sucrose octa-acetate and quinine were suppressed after chlorhexidine rinses relative to water rinses, but were only marginally suppressed relative to quinine rinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6593327_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effect of chlorhexidine rinses on the morphology of early dental plaque formed on plastic film.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6593327_20201005_0.5			Chlorhexidine|Dental Plaque|Drug Evaluation|Humans|Microscopy, Electron|Mouthwashes|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15842266_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The effect of a polyhexamethylene biguanide mouthrinse compared with a triclosan rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque re-growth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15842266_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Bacteria|Benzoates|Biguanides|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Humans|Male|Maleates|Mouth Mucosa|Mouthwashes|Polyethylenes|Reproducibility of Results|Sodium Dodecyl Sulfate|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1923397_20201005_0.5			Therapeutic effects of daily or weekly chlorhexidine rinsing on oral health of a geriatric population.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1923397_20201005_0.5			Aged|Aged, 80 and over|Analysis of Variance|Candida albicans|Chi-Square Distribution|Chlorhexidine|Colony Count, Microbial|DMF Index|Dental Care for Aged|Dental Plaque|Dental Plaque Index|Humans|Lactobacillus|Middle Aged|Mouthwashes|Saliva|Secretory Rate|Single-Blind Method|Streptococcus mutans|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1923397_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section The effects of a chlorhexidine rinse on salivary Streptococcus mutans, Lactobacillus, and Candida albicans counts and on periodontal conditions (gingival index, plaque index, pocket depths) were studied in 42 elderly subjects.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Effectiveness of chlorhexidine gel versus chlorhexidine rinse in reducing alveolar osteitis in mandibular third molar surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5			Adolescent|Adult|Age Factors|Chi-Square Distribution|Chlorhexidine|Contraceptives, Oral, Hormonal|Disinfectants|Dry Socket|Female|Gels|Humans|Male|Middle Aged|Molar, Third|Mouthwashes|Prospective Studies|Risk Factors|Sex Factors|Smoking|Tooth Extraction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The purpose of this study was to compare the effectiveness of chlorhexidine gel versus a chlorhexidine rinse in reducing postoperative alveolar osteitis after the extraction of mandibular third molars.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 METHODS The experimental or gel group (n = 41) applied the bioadhesive 0.2% chlorhexidine gel to the wound during the first postoperative week and a control or rinse group (n = 32) used a 0.12% chlorhexidine rinse during the first week postextraction.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3511101_20201005_0.5			Hemangioendothelioma of the gingiva. Histopathologic and therapeutic considerations.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3511101_20201005_0.5			Adolescent|Dental Plaque|Dental Scaling|Gingival Neoplasms|Gingivectomy|Hemangioendothelioma|Humans|Male|Tooth Root	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID3511101_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The treatment consisted of a meticulous mechanical plaque control, chlorhexidine rinses, gingivectomy procedures and a monthly professional prophylaxis.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15015941_20201005_0.5			Surface characteristics of implants influence their bone integration after simultaneous placement of implant and GBR membrane.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15015941_20201005_0.5			Alveolar Process|Alveolectomy|Animals|Bicuspid|Bone Regeneration|Coated Materials, Biocompatible|Dental Implantation, Endosseous|Dental Implants|Dental Prosthesis Design|Dental Prosthesis Retention|Dogs|Female|Guided Tissue Regeneration, Periodontal|Implants, Experimental|Mandible|Membranes, Artificial|Osseointegration|Polytetrafluoroethylene|Surface Properties|Titanium|Tooth Extraction|Wound Healing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15015941_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinses were performed three times a week.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23235637_20201005_0.5			Local interventions for the management of alveolar osteitis (dry socket).	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23235637_20201005_0.5			Adult|Chlorhexidine|Dry Socket|Humans|Molar, Third|Mouthwashes|Randomized Controlled Trials as Topic	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23235637_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The number of patients needed to be treated with (0.12% and 0.2%) chlorhexidine rinse to prevent one patient having dry socket (NNT) was 232 (95% CI 176 to 417), 47 (95% CI 35 to 84) and 8 (95% CI 6 to 14) for control prevalences of dry socket of 1%, 5% and 30% respectively.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638949_20201005_0.5			Comparison of two commercially available chlorhexidine mouthrinses: I. Staining and antimicrobial effects in vitro.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638949_20201005_0.5			Chlorhexidine|Humans|Microbial Sensitivity Tests|Mouthwashes|Reproducibility of Results|Tea|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638949_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section Several commercially produced chlorhexidine rinses are now available.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638949_20201005_0.5	chlorhexidine rinse	drug_umls_atom	One formulation, a 0.1% chlorhexidine rinse, anecdotally has been reported to not produce the characteristic dental staining.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2638949_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The aim of this study was to compare the 0.1% formulation with a 0.2% commercially produced chlorhexidine rinse for staining and antimicrobial effects in vitro.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID32461752_20210111_0.5			METHODS FOR CARIES PREVENTION IN ADULTS AMONG DENTISTS FROM A BRAZILIAN COMMUNITY: Adult' caries prevention among Brazilian dentists.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID32461752_20210111_0.5			Dental caries|Practice patterns|Prevention & control|dentist	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID32461752_20210111_0.5			Humans|Male|Adolescent|Adult|Female|United States|Fluorides, Topical|Cariostatic Agents|Fluorides|Practice Patterns, Dentists'|Mouthwashes|Chlorhexidine|Pit and Fissure Sealants|Brazil|Anti-Infective Agents, Local|Dentists, Women|Private Practice	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID32461752_20210111_0.5	chlorhexidine rinse	drug_umls_atom	Other predictors included private practice (dental sealant), percentage of patients 65 years or older (in-office fluoride), graduation from a private dental school (non-prescription fluoride), years since dental school graduation (chlorhexidine rinse) and using a preventive method (recommending sealant/fluoride/chlorhexidine rinse/sugarless, xylitol gum).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8934920_20201005_0.5			Current treatment modalities of oral problems of patients with Sjögren's syndrome: caries prevention.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8934920_20201005_0.5			Cariostatic Agents|Chlorhexidine|Dental Care for Chronically Ill|Dental Caries|Fluorides, Topical|Humans|Sjogren's Syndrome|Xerostomia	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8934920_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Recent innovations that show promise for treatment of high-caries-risk patients with hyposalivation are the use of fluoride rinses in combination with chlorhexidine rinses or gels and the professional application of high-concentration chlorhexidine varnishes to the teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2914291_20201005_0.5			A systematic review of dental disease in patients undergoing cancer therapy	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2914291_20201005_0.5			Cancer therapy|Dental caries|Periodontal disease	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2914291_20201005_0.5			Dental Caries|Fluorides|Gingival Diseases|Humans|Neoplasms|Periodontal Diseases|Severity of Illness Index|Tooth Diseases	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC2914291_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The use of fluoride products and chlorhexidine rinses are beneficial in patients who are post-radiotherapy.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24155621_20201005_0.5			Efficacy of two commercially available Oral Rinses - Chlorohexidine and Listrine on Plaque and Gingivitis - A Comparative Study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24155621_20201005_0.5			Gingivitis|Mouthrinse|Oral Hygiene|Plaque	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24155621_20201005_0.5			Humans|Male|Middle Aged|Female|Mouthwashes|Gingivitis|Chlorhexidine|Anti-Infective Agents, Local|Double-Blind Method|Listerine|Terpenes|Salicylates|Periodontal Index|Oral Hygiene|Oils, Volatile|Drug Combinations|Analysis of Variance|Plaque, Amyloid|Plaque, Atherosclerotic	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24155621_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS Chlorehexidine (0.2%) and a phenolic mouth rinse significantly reduced plaque growth and gingival inflammation compared to a placebo mouthrinse, however chlorhexidine rinse was more effective against plaque regrowth than the phenolic rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1884574_20201005_0.5			Comparison of a phenolic and a 0.2% chlorhexidine mouthwash on the development of plaque and gingivitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1884574_20201005_0.5			Adult|Analysis of Variance|Chlorhexidine|Dental Plaque|Dental Plaque Index|Female|Gingivitis|Humans|Male|Mouthwashes|Periodontal Index|Phenols|Single-Blind Method	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1884574_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The plaque area increased 3-fold with the phenolic rinse and 6-fold with the saline rinse compared to the chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1884574_20201005_0.5	chlorhexidine rinse	drug_umls_atom	It is concluded that the 0.2% chlorhexidine rinse offers greater oral hygiene benefits than the phenolic rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6607936_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Gingival bleeding after chlorhexidine rinses with or without mechanical oral hygiene.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6607936_20201005_0.5			Chlorhexidine|Dental Plaque Index|Gingiva|Gingival Hemorrhage|Humans|Microscopy, Electron, Scanning|Mouthwashes|Oral Hemorrhage|Oral Hygiene|Students, Dental|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6607936_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section In a previous paper a slight increase in gingival bleeding tendency was reported after the use of chlorhexidine rinses in dental students with clinically healthy gingivae.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID6607936_20201005_0.5	chlorhexidine rinse	drug_umls_atom	A SEM analysis of the 2 sides of the dentition indicated that bleeding after chlorhexidine rinses may be associated with irritation from debris which, after the 7-day period of no mechanical oral hygiene measures, seemed to obliterate the gingival sulcus.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9667160_20201005_0.5			Chlorhexidine, fluoride varnish, and xylitol chewing gum: underutilized preventive therapies?	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9667160_20201005_0.5			Chewing Gum|Chlorhexidine|Dental Caries|Fluorides|Fluorides, Topical|Humans|Mouthwashes|Pit and Fissure Sealants|Streptococcus mutans|Xylitol	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9667160_20201005_0.5	chlorhexidine rinse	drug_umls_atom	To ensure that high-risk patients who have cariogenic bacteria are adequately treated, chlorhexidine rinses may be required on a periodic basis.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10518864_20201005_0.5			Preliminary report: laboratory-induced stain removal as assessed by environmental scanning electron microscopy.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10518864_20201005_0.5			Chlorhexidine|Humans|Hydrogen Peroxide|Microscopy, Electron, Scanning|Molar|Silicic Acid|Silicon Dioxide|Sodium Bicarbonate|Sodium Fluoride|Tooth Discoloration|Toothbrushing|Toothpastes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10518864_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Three extracted molars were cleaned, placed into a 96-hour broth culture of Streptococcus mutans, and stain was produced with undiluted chlorhexidine rinse, concentrated coffee and tea for a period of 23 days.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17970690_20201005_0.5			Sarcoidosis affecting the periodontium: a long-term follow-up case.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17970690_20201005_0.5			Alveolar Bone Loss|Candidiasis, Oral|Follow-Up Studies|Gingival Recession|Humans|Male|Mandibular Diseases|Maxillary Diseases|Middle Aged|Periodontal Diseases|Radiography|Sarcoidosis	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17970690_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Initial treatment consisted of reinforcement of oral hygiene, scaling and root planing, chlorhexidine rinses, and periodontal maintenance.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25279395_20210311_0.5	chlorhexidine rinse	drug_umls_atom	Dental plaque, gingival inflammation and tooth -discolouration with different commercial -formulations of 0.2% chlorhexidine rinse: a double-blind randomised controlled clinical trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25279395_20210311_0.5			Adult|Anti-Infective Agents, Local|Ascorbic Acid|Chemistry, Pharmaceutical|Chlorhexidine|Coffee|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Follow-Up Studies|Gingivitis|Humans|Male|Mouthwashes|Periodontal Index|Photography, Dental|Placebos|Spectrophotometry|Sulfites|Tea|Tooth Discoloration|Treatment Outcome|Wine|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2262581_20201005_0.5			The effect of triclosan, stannous fluoride and chlorhexidine products on: (I) Plaque regrowth over a 4-day period.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2262581_20201005_0.5			Adult|Analysis of Variance|Chlorhexidine|Cohort Studies|Dental Plaque|Dental Plaque Index|Female|Humans|Male|Mouthwashes|Single-Blind Method|Sodium Chloride|Sodium Fluoride|Tin Fluorides|Toothpastes|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2262581_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Plaque regrowth was significantly less with the chlorhexidine rinse and significantly greater with the saline rinse compared to the toothpaste and gel products.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Evaluation of 0.12% chlorhexidine rinse on the prevention of alveolar osteitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5			Adult|Chlorhexidine|Double-Blind Method|Dry Socket|Female|Humans|Male|Mandibular Diseases|Molar, Third	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	chlorhexidine rinse	drug_umls_atom	No section A double-blind study evaluated the ability of 0.12% chlorhexidine rinse to decrease the incidence of localized alveolar osteitis after the removal of mandibular third molar teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	chlorhexidine rinse	drug_umls_atom	A statistically significant decrease in the incidence of dry socket was seen in patients using the chlorhexidine rinse with no significant adverse reactions.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Thus a 0.12% chlorhexidine rinse is shown to be an effective means of decreasing alveolar osteitis that may follow removal of third molar teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15058367_20201005_0.5			Development of methods to enhance extrinsic tooth discoloration for comparison of toothpastes. 2. Two-product clinical study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15058367_20201005_0.5			Adult|Analysis of Variance|Chlorhexidine|Complex Mixtures|Cross-Over Studies|Dentifrices|Female|Humans|Male|Middle Aged|Mouthwashes|Peroxides|Placebos|Polyphosphates|Polyvinyls|Silicic Acid|Single-Blind Method|Sodium Fluoride|Tea|Time Factors|Tongue|Tooth|Tooth Bleaching|Tooth Discoloration|Toothpastes|Water	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15058367_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The treatment interventions were at 09:00 and 16:00 hours and before the chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7908594_20210311_0.5			Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7908594_20210311_0.5			bisphosphonates|denosumab|medication-induced maxillary osteonecrosis|osteonecrosis|osteonecrosis treatment	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7908594_20210311_0.5			Bisphosphonate-Associated Osteonecrosis of the Jaw|Bone Density Conservation Agents|Conservative Treatment|Humans|Quality of Life|Wound Healing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7908594_20210311_0.5	chlorhexidine rinse	drug_umls_atom	Conservative treatment with antibiotics, chlorhexidine rinses and minimally invasive surgical intervention with necrotic bone resection is effective in treating stage 2 of MRONJ.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8550858_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The effect of a commercially available triclosan-containing toothpaste compared to a sodium-fluoride-containing toothpaste and a chlorhexidine rinse on 4-day plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8550858_20201005_0.5			Adolescent|Adult|Anti-Infective Agents, Local|Chlorhexidine|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Female|Humans|Male|Mouthwashes|Single-Blind Method|Sodium Chloride|Sodium Fluoride|Toothpastes|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8550858_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The study was designed to stratify the relative efficacy plaque inhibitory action of the products, comparisons were made with a positive control, chlorhexidine rinse and a negative control, saline.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22916697_20201005_0.5			What strategies are helpful in the operative management of third molars?	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22916697_20201005_0.5			Analgesics|Anti-Infective Agents, Local|Anti-Inflammatory Agents|Antibiotic Prophylaxis|Humans|Molar, Third|Postoperative Complications|Recovery of Function|Smoking|Surgical Flaps|Tooth, Impacted|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22916697_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The use of chlorhexidine rinses to prevent alveolar osteitis and surgical site infection has been studied extensively, but meta-analyses have not convincingly proved this effect.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5			Studies on the effect of polyvinyl pyrrolidone on the activity of chlorhexidine mouthrinses: plaque and stain.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5			Adolescent|Adult|Anti-Infective Agents, Local|Chlorhexidine|Coffee|Color|Cross-Over Studies|Dental Plaque|Double-Blind Method|Female|Humans|Male|Middle Aged|Mouthwashes|Pharmaceutic Aids|Placebos|Povidone|Statistics, Nonparametric|Tea|Tongue|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The aim of these studies in vivo was to determine whether PVP affected plaque and dietary staining by a low concentration chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Plaque scores increased with increasing concentrations of PVP in the 0.06% chlorhexidine rinse and were significantly higher than 0.06% chlorhexidine without PVP rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Tooth stain areas were comparable for placebo, 0.03% and 0.06% chlorhexidine rinses, but significantly reduced with the PVP/chlorhexidine rinses compared to the 0.06% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Tooth stain intensity was significantly increased with 0.06% chlorhexidine rinses compared to placebo and chlorhexidine/PVP rinses.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Tongue stain area and intensity were significantly reduced with 5% and 10% PVP/chlorhexidine rinses compared to 0.06% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11350523_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 CONCLUSIONS PVP, at the concentrations tested, reduced the stain propensity of a 0.06% chlorhexidine rinse but at the expense of some loss of plaque inhibition.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5			Comparison of 2 chlorhexidine mouthwashes on plaque regrowth in vivo and dietary staining in vitro.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5			Chlorhexidine|Color|Dental Plaque|Dental Plaque Index|Double-Blind Method|Drug Combinations|Humans|Methylmethacrylates|Mouthwashes|Sodium Fluoride|Tea|Time Factors|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The 1st study compared the effect of a 0.12% chlorhexidine rinse with a 0.12% chlorhexidine/0.022% sodium fluoride rinse for effects on plaque regrowth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The 2nd study assessed the propensity of the chlorhexidine rinses to induce dietary staining in vitro.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089248_20201005_0.5			A comparison of cetylpyridinium chloride, triclosan and chlorhexidine mouthrinse formulations for effects on plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089248_20201005_0.5			Adult|Analysis of Variance|Cetylpyridinium|Chlorhexidine|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Humans|Male|Mouthwashes|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089248_20201005_0.5	chlorhexidine rinse	drug_umls_atom	All rinses produced lower mean plaque values compared to control, but unlike the CPC and chlorhexidine rinses, the differences with triclosan did not always reach significance.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089248_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The CPC and chlorhexidine rinses were always significantly more effective than the triclosan rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089248_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The greatest plaque inhibition was with 0.1% CPC although rarely significantly greater than the 0.05% CPC and chlorhexidine rinses which were similar in efficacy.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5			The effect of a dentifrice containing chlorhexidine and zinc on plaque, gingivitis, calculus and tooth staining.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5			Adolescent|Adult|Aged|Analysis of Variance|Chlorhexidine|Dental Calculus|Dental Plaque|Dental Plaque Index|Dentifrices|Double-Blind Method|Female|Gingivitis|Humans|Male|Middle Aged|Periodontal Index|Tooth Discoloration|Zinc	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The participants either used a 0.12% chlorhexidine rinse and a gum care dentifrice (positive control) or a placebo rinse and the gum care dentifrice (control) or the placebo rinse and an experimental dentifrice containing 0.4% chlorhexidine and 0.34% Zn2+ (experimental group).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5	chlorhexidine rinse	drug_umls_atom	It is concluded that the experimental dentifrice will contribute to a significant improvement in oral hygiene with less staining compared with using a 0.12% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10783565_20201005_0.5			The influence of a 0.2% chlorhexidine mouthrinse on plaque regrowth in orthodontic patients. A randomized prospective study. Part II: Bacteriological parameters.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10783565_20201005_0.5			Adolescent|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Double-Blind Method|Female|Humans|Male|Mouthwashes|Prospective Studies|Recurrence|Statistics, Nonparametric|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10783565_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Until the 5th day of washout a clear-cut carry over of the chlorhexidine rinse on mutans streptococci as well as on the gingival index was evident.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5			Pilot testing of intervention protocols to prevent pneumonia in nursing home residents.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5			Aged, 80 and over|Chlorhexidine|Comorbidity|Connecticut|Feasibility Studies|Female|Humans|Male|Mouthwashes|Nursing Homes|Oral Hygiene Index|Pilot Projects|Pneumonia|Posture|Prospective Studies|Risk Factors|Risk Reduction Behavior|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 RESULTS Daily manual oral brushing plus 0.12% chlorhexidine rinse demonstrated high feasibility, high staff adherence, and effectiveness in improving oral hygiene (P<.001 vs baseline); this combination administered twice per day showed the highest plaque score reduction.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7560400_20201005_0.5			Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7560400_20201005_0.5			Adult|Bacterial Infections|Chlorhexidine|Chronic Disease|Combined Modality Therapy|Dental Calculus|Dental Plaque|Dental Scaling|Disinfectants|Double-Blind Method|Female|Follow-Up Studies|Gels|Humans|Male|Middle Aged|Mouthwashes|Oral Hygiene|Periodontal Pocket|Periodontitis|Root Planing|Spirochaetales Infections|Therapeutic Irrigation|Tongue	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID7560400_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The recolonization of the pockets was retarded by oral hygiene and 0.2% chlorhexidine rinses during two weeks.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15998278_20201005_0.5			Effect of non-surgical periodontal treatment with or without doxycycline on the periodontium of type 1 diabetic patients.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15998278_20201005_0.5			Adult|Anti-Bacterial Agents|Dental Care for Chronically Ill|Dental Plaque Index|Dental Scaling|Diabetes Complications|Diabetes Mellitus, Type 1|Doxycycline|Female|Humans|Male|Middle Aged|Periodontal Diseases|Periodontal Index|Single-Blind Method|Time Factors|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15998278_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Group 1 (30 patients) was treated with oral hygiene instruction, scaling and root planing, chlorhexidine rinses twice a day and doxycycline (100 mg/day for 15 days).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20074477_20201005_0.5			Bevacizumab-related osteneocrosis of the jaw.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20074477_20201005_0.5			Adenocarcinoma|Alveolar Bone Loss|Amoxicillin-Potassium Clavulanate Combination|Angiogenesis Inhibitors|Anti-Bacterial Agents|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Bevacizumab|Bone Neoplasms|Chlorhexidine|Humans|Jaw Diseases|Lung Neoplasms|Male|Middle Aged|Mouthwashes|Osteonecrosis|Pain|Tooth Extraction|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20074477_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Treatment with amoxicillin and clavulanate every 12 hours for 15 days and 0.2% chlorhexidine rinses was administered and there was a remission of infective complications, but not the closure of the exposed alveolar bone.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6797456_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The influence of intra-alveolar application of honey versus Chlorhexidine rinse on the incidence of Alveolar Osteitis following molar teeth extraction. A randomized clinical parallel trial	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6797456_20201005_0.5			Adult|Humans|Male|Female|Middle Aged|Dry Socket|Chlorhexidine|Incidence|Honey|Tooth Extraction|Molar|Molar, Third|Tooth, Impacted|Anti-Infective Agents, Local|Mouthwashes|Tooth Socket|Mandible|Gels|Wound Healing|Research Design	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22088634_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Re: chlorhexidine rinse for prevention of urethritis in men linked to oral sex.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22088634_20201005_0.5			Male|Humans|Chlorhexidine|Urethritis|Mouthwashes|Dental Plaque Index|Sexual Behavior	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2329393_20201005_0.5			Effects of a chlorhexidine gluconate oral rinse on the incidence of alveolar osteitis in mandibular third molar surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2329393_20201005_0.5			Adolescent|Adult|Cetylpyridinium|Chi-Square Distribution|Chlorhexidine|Dry Socket|Female|Humans|Male|Mandible|Molar, Third|Random Allocation|Tooth Extraction|Tooth, Impacted	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2329393_20201005_0.5	chlorhexidine rinse	drug_umls_atom	This study compares the effectiveness of 0.12% chlorhexidine used as a preoperative rinse and immediate postextraction irrigant with 1) similarly used 0.05% cetylpyridium, preoperative chlorhexidine rinse and postextraction saline irrigation, and 2) only postextraction irrigation with normal saline in the reduction of alveolar osteitis in mandibular third molar extractions.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24685786_20201214_0.5			Compare the effcacy of two commercially available mouthrinses in reducing viable bacterial count in dental aerosol produced during ultrasonic scaling when used as a preprocedural rinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24685786_20201214_0.5			Adult|Aerosols|Air Microbiology|Air Pollutants|Air Pollution, Indoor|Anti-Infective Agents, Local|Bacterial Load|Chlorhexidine|Dental Scaling|Humans|Infection Control, Dental|Microbial Viability|Middle Aged|Mouthwashes|Phytotherapy|Placebos|Single-Blind Method|Tea Tree Oil|Treatment Outcome|Ultrasonics	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24685786_20201214_0.5	chlorhexidine rinse	drug_umls_atom	Chlorhexidine rinses were found to be superior to tea tree when used preprocedurally in reducing aerolized bacteria.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID29568017_20201005_0.5			The use of chlorhexidine in the prevention of alveolar osteitis after third molar extractions.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID29568017_20201005_0.5			Chlorhexidine|Dry Socket|Humans|Molar, Third|Spain|Tooth Extraction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID29568017_20201005_0.5	chlorhexidine rinse	drug_umls_atom	There were no differences between chlorhexidine rinse (RR = 0.58; 95% CI, 0.47-0.71) and gel (RR = 0.47; 95% CI, 0.37-0.60) for the prevention of AO after third molar extractions.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1923415_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Oral Candida albicans in bone marrow transplant patients given chlorhexidine rinses: occurrence and susceptibilities to the agent.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1923415_20201005_0.5			Bone Marrow Transplantation|Candida albicans|Candidiasis, Oral|Chlorhexidine|Colony Count, Microbial|Drug Hypersensitivity|Drug Resistance, Microbial|Humans|Immunocompromised Host|Immunosuppression|Mouth Mucosa|Tongue	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21436858_20201005_0.5			The association between cancer treatments and oral diseases.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21436858_20201005_0.5			Humans|Adult|United States|Dental Caries|MEDLINE|Mouth Diseases|PubMed|Tooth Diseases	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID21436858_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The use of fluoride products and chlorhexidine rinses is beneficial in patients who are post-radiotherapy.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15857064_20201005_0.5			Post-surgical infections: prevalence associated with various periodontal surgical procedures.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15857064_20201005_0.5			Alveolar Ridge Augmentation|Anti-Infective Agents, Local|Antibiotic Prophylaxis|Bone Transplantation|Chlorhexidine|Curettage|Dental Implants|Gingiva|Gingivectomy|Guided Tissue Regeneration, Periodontal|Humans|Membranes, Artificial|Oral Surgical Procedures|Osteotomy|Periodontal Diseases|Periodontal Dressings|Retrospective Studies|Surgical Flaps|Surgical Wound Infection|Tooth Root	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15857064_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The impact of various treatment variables was examined including the use of bone grafts, membranes, soft tissue grafts, post-surgical chlorhexidine rinses, systemic antibiotics, and dressings.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2760250_20201005_0.5			Studies on the effect of toothpaste rinses on plaque regrowth. (I). Influence of surfactants on chlorhexidine efficacy.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2760250_20201005_0.5			Adult|Chlorhexidine|Citrates|Citric Acid|Dental Plaque|Dentifrices|Detergents|Drug Interactions|Female|Humans|Male|Mouthwashes|Phenyl Ethers|Placebos|Surface-Active Agents|Toothpastes|Triclosan	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2760250_20201005_0.5	chlorhexidine rinse	drug_umls_atom	All toothpastes significantly reduced plaque by comparison with a control toothpaste, but were significantly less effective than a 0.2% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23039819_20201005_0.5			Antimicrobial efficacy of 0·05% cetylpyridinium chloride mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23039819_20201005_0.5			Adolescent|Adult|Aged|Anti-Bacterial Agents|Bacteria|Biofilms|Cetylpyridinium|Chlorhexidine|Dental Plaque|Ethanol|Fluorides|Humans|Microbial Sensitivity Tests|Middle Aged|Mouthwashes|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID23039819_20201005_0.5	chlorhexidine rinse	drug_umls_atom	Ex-vivo tests on supragingival plaque micro-organisms demonstrated significantly greater antimicrobial activity by the CPC mouthrinses (>90% killing, P < 0·001) and the chlorhexidine rinse (>98% killing, P < 0·05) compared to the control fluoride mouthrinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15882209_20201005_0.5			The prevention of plaque re-growth by toothpastes and solutions containing block copolymers with and without polypeptide.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15882209_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Cariostatic Agents|Chlorhexidine|Cross-Over Studies|Dental Plaque|Female|Fluorides|Humans|Male|Middle Aged|Mouthwashes|Peptides|Polymers|Toothpastes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15882209_20201005_0.5	chlorhexidine rinse	drug_umls_atom	 METHODS A total of 21 subjects took part in a partially blind, seven cell cross-over study which compared the effects on plaque re-growth of a binary system containing block copolymers, a ternary system containing block copolymers and polypeptide, both used as toothpaste slurry rinses, their corresponding solution rinses, a conventional fluoride toothpaste rinse, a positive control chlorhexidine rinse and a negative water control.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15882209_20201005_0.5	chlorhexidine rinse	drug_umls_atom	As expected plaque recorded following use of the chlorhexidine rinse was significantly less than that seen with any of the other rinses (p<0.001).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11723431_20201005_0.5			[Double blind placebo-controlled study on efficacy, acceptability and safety of mouthwash diclofenac in oral or periodontal postoperative period].	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11723431_20201005_0.5			Adult|Aged|Anti-Inflammatory Agents, Non-Steroidal|Diclofenac|Double-Blind Method|Female|Humans|Male|Middle Aged|Mouth Diseases|Mouthwashes|Periodontal Diseases|Postoperative Care|Postoperative Complications	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID11723431_20201005_0.5	chlorhexidine rinse	drug_umls_atom	The patients rinsed for 1 min twice a day with diclofenac mouthwash or placebo (15 mL) at least after 1 hour since the chlorhexidine rinse for 7 days.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2630622_20201005_0.5	chlorhexidine gluconate 0.12% oral rinse	drug_umls_atom	The use of Peridex (chlorhexidine gluconate 0.12% oral rinse) in maxillomandibular fixation patients.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2630622_20201005_0.5			Adolescent|Adult|Chlorhexidine|Female|Humans|Male|Maxillofacial Injuries|Mouthwashes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	Effect of oral hygiene and 0.12% chlorhexidine gluconate oral rinse in preventing ventilator-associated pneumonia after cardiovascular surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5			cardiovascular surgery|chlorhexidine|prevention|ventilator-associated pneumonia	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5			Anti-Infective Agents, Local|Cardiovascular Surgical Procedures|Chlorhexidine|Female|Historically Controlled Study|Humans|Incidence|Length of Stay|Male|Middle Aged|Mouthwashes|Pneumonia, Ventilator-Associated|Postoperative Complications|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	 OBJECTIVE Determine the effect of toothbrushing plus 0.12% chlorhexidine gluconate oral rinse in preventing VAP after CVS.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1432922_20201005_0.5			How the FDA and the ADA affect development of prescription drugs for oral care.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1432922_20201005_0.5			American Dental Association|Dental Care|Drug Approval|Drug Prescriptions|Drug and Narcotic Control|Humans|Oral Hygiene|United States|United States Food and Drug Administration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1432922_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	An example of a prescription drug approved by the FDA and accepted by the ADA is 0.12 percent chlorhexidine gluconate oral rinse (Peridex).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10225548_20201005_0.5			Effectiveness of a sanguinarine regimen after scaling and root planing.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10225548_20201005_0.5			Adult|Aged|Alkaloids|Anti-Infective Agents|Benzophenanthridines|Chemoprevention|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dental Scaling|Female|Follow-Up Studies|Gingival Hemorrhage|Gingivitis|Humans|Isoquinolines|Male|Middle Aged|Mouthwashes|Periodontal Index|Periodontitis|Phenanthridines|Root Planing|Toothpastes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10225548_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	 METHODS Sixty patients diagnosed as having adult periodontitis received initial periodontal therapy including scaling and root planing, followed by a 2-week oral care regimen which included rinsing with 0.2% chlorhexidine gluconate oral rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12425407_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12425407_20201005_0.5			Anti-Bacterial Agents|Antibiotic Prophylaxis|Cardiac Surgical Procedures|Case-Control Studies|Chi-Square Distribution|Chlorhexidine|Cross Infection|Drug Combinations|Humans|Mouthwashes|Oropharynx|Pneumonia, Bacterial|Prevalence|Prospective Studies|Risk Factors|Salicylates|Sputum|Terpenes|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12425407_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	 OBJECTIVE To test the effectiveness of 0.12% chlorhexidine gluconate oral rinse in decreasing microbial colonization of the respiratory tract and nosocomial pneumonia in patients undergoing open heart surgery.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25349099_20201005_0.5			Oral care for intubated patients: a survey of intensive care unit nurses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25349099_20201005_0.5			Intensive care unit|Intubated patients|Nurses|Nursing|Oral care	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25349099_20201005_0.5			Analysis of Variance|Attitude of Health Personnel|Critical Care Nursing|Cross-Sectional Studies|Female|Humans|Intensive Care Units|Malaysia|Male|Nurse's Role|Oral Hygiene|Patient Satisfaction|Quality Improvement|Surveys and Questionnaires	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25349099_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	Chlorhexidine gluconate oral rinse was the preferred mouthwash (97·8%) and swabs (93·5%) solution although few used non-optimal products such as sodium bicarbonate (14·0%), tap water (4·3%) and hydrogen peroxide (3·2%) to wash their patients' mouths.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20194614_20201005_0.5			Oral care practices for orally intubated critically ill adults.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20194614_20201005_0.5			Adult|Critical Illness|Cross-Sectional Studies|Guideline Adherence|Health Care Surveys|Humans|Intensive Care Units|Internet|Intubation, Intratracheal|Mouth|Oral Hygiene|Pneumonia, Ventilator-Associated|Practice Guidelines as Topic|Respiration, Artificial|United States	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID20194614_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	Nurses whose units had an oral care policy (72%) reported that the policy indicated using a toothbrush (63%), using toothpaste (40%), brushing with a foam swab (90%), using chlorhexidine gluconate oral rinse (49%), suctioning the oral cavity (84%), and assessing the oral cavity (73%).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30106529_20201214_0.5			Post-prophylaxis gingivitis prevention with two-step stannous fluoride dentifrice plus whitening gel sequence or chlorhexidine gluconate mouthrinse.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30106529_20201214_0.5			Adult|Chlorhexidine|Dentifrices|Double-Blind Method|Gels|Gingivitis|Humans|Mouthwashes|Sodium Fluoride|Tin Fluorides|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID30106529_20201214_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	Eligible subjects received a dental prophylaxis and were randomly assigned to twice daily unsupervised use of either (1) two-step oral hygiene sequence:0.454% stannous fluoride dentifrice followed by 3.0% hydrogen peroxide whitening gel for the test group; or (2) 0.12% chlorhexidine gluconate oral rinse and 0.76% sodium monofluorophosphate dentifrice for the control group.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2329393_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	Effects of a chlorhexidine gluconate oral rinse on the incidence of alveolar osteitis in mandibular third molar surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2329393_20201005_0.5			Adolescent|Adult|Cetylpyridinium|Chi-Square Distribution|Chlorhexidine|Dry Socket|Female|Humans|Male|Mandible|Molar, Third|Random Allocation|Tooth Extraction|Tooth, Impacted	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22133962_20201005_0.5			Gram-negative periodontal pathogens and bacterial endotoxin in metallic orthodontic brackets with or without an antimicrobial agent: an in-vivo study.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22133962_20201005_0.5			Adolescent|Adult|Anti-Infective Agents, Local|Chi-Square Distribution|Child|Chlorhexidine|DNA, Bacterial|Dental Plaque Index|Endotoxins|Female|Gram-Negative Bacteria|Humans|Limulus Test|Male|Metals|Mouthwashes|Nucleic Acid Hybridization|Orthodontic Brackets|Periodontitis|Statistics, Nonparametric|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22133962_20201005_0.5	chlorhexidine gluconate oral rinse	drug_umls_atom	 CONCLUSIONS The 0.12% chlorhexidine gluconate oral rinses can be useful to reduce the levels of gram-negative periodontal pathogenic microorganisms in patients with fixed orthodontic appliances.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26443484_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Reduced occurrence of ventilator-associated pneumonia after cardiac surgery using preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26443484_20201005_0.5			Cardiac surgery|Chlorhexidine|Prophylaxis|Ventilator-associated pneumonia	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26443484_20201005_0.5			Adolescent|Adult|Aged|Chlorhexidine|Disinfectants|Female|Humans|Incidence|Male|Middle Aged|Mouthwashes|Pneumonia, Ventilator-Associated|Prospective Studies|Single-Blind Method|Thoracic Surgery|Treatment Outcome|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6252557_20201005_0.5			1267. Nonventilator Hospital Acquired Pneumonia (NV-HAP) Prevention Initiative in Colombia, Bogotá	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6252557_20201005_0.5			Middle Aged|Adult|Male|Humans|Female|Healthcare-Associated Pneumonia|Colombia|Pneumonia, Ventilator-Associated|Cross Infection|Patient Care Bundles|Intensive Care Units|Ventilators, Mechanical|Hospitals, University|Decontamination|Drive	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6252557_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	In a period of 2 years, a care bundle for prevention of NV-HAP was implemented in adult patients in a university hospital that consisted of: (1) identification of patients at risk (patients over 60 years of age, or with altered consciousness, or swallowing disorder, or patients with tracheostomy), (2) marking the patient with a sticker on the head of the bed, and (3) implementation of the following measures: head of the bed elevation to 30°-45°, oral care every 12 hours, chlorhexidine oral rinse decontamination every 12 hours and aspiration of secretions as needed.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12931087_20201005_0.5			Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12931087_20201005_0.5			Adult|Anti-Infective Agents, Local|Antifungal Agents|Candida albicans|Candidiasis, Oral|Cause of Death|Chemoprevention|Chlorhexidine|Female|Gingivitis, Necrotizing Ulcerative|Hematopoietic Stem Cell Transplantation|Humans|Length of Stay|Male|Middle Aged|Mouth|Mouthwashes|Nystatin|Stomatitis|Transplantation, Autologous|Transplantation, Homologous|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12931087_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Chlorhexidine oral rinses were also routinely provided.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24346989_20201005_0.5			The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized clinical trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24346989_20201005_0.5			Aged|Blood Glucose|Chlorhexidine|Chronic Periodontitis|Dental Scaling|Diabetes Complications|Diabetes Mellitus, Type 2|Female|Glycated Hemoglobin A|Humans|Male|Middle Aged|Mouthwashes|Root Planing|Single-Blind Method|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24346989_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 METHODS The treatment group (n = 257) received scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7778055_20210211_0.5	chlorhexidine oral rinse	drug_umls_atom	634. Chlorhexidine Oral Rinses to Alter the Oral and Sputum Microbiota in COPD (CLIMB): a Randomized, Double-blinded, Placebo-controlled, Parallel-group Pilot Study	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7778055_20210211_0.5			Humans|Male|Middle Aged|Adult|Female|Chlorhexidine|Pilot Projects|Sputum|Double-Blind Method|Microbiota|Pulmonary Disease, Chronic Obstructive|Dysbiosis|Leukocyte Count|Respiratory System	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7778055_20210211_0.5	chlorhexidine oral rinse	drug_umls_atom	Chlorhexidine oral rinses are known to alter the oral microbiota.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7778055_20210211_0.5	chlorhexidine oral rinse	drug_umls_atom	We hypothesized that subjects randomized to 8 weeks of chlorhexidine oral rinses (vs. placebo) will demonstrate decreased microbiota biomass compared to baseline and those on placebo.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7778055_20210211_0.5	chlorhexidine oral rinse	drug_umls_atom	 Methods We performed a randomized, double-blind, placebo-controlled, 8-week study of the effects of twice-daily chlorhexidine oral rinses on 44 subjects with COPD.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC7778055_20210211_0.5	chlorhexidine oral rinse	drug_umls_atom	 Conclusion Among those with COPD, use of twice-daily chlorhexidine oral rinses resulted in decreased oral and sputum microbiota alpha diversity and clinically significant improvement in COPD symptoms.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4061299_20201005_0.5			The effectiveness of a pre-procedural mouthrinse in reducing bacteria on radiographic phosphor plates	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4061299_20201005_0.5			Diagnostic Imaging|Listerine|Chlorhexidine|Delmopinol	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4061299_20201005_0.5			Male|Humans|Adult|Mouthwashes|Chlorhexidine|Listerine|Terpenes|Anti-Infective Agents, Local|Salicylates|Bacteria|Colony Count, Microbial|Drug Combinations|Mouth|Anti-Infective Agents|Sterilization	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4061299_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 Materials and Methods Prior to performing a full-mouth radiographic survey (FMX), subjects were asked to rinse with one of the three test rinses (Listerine®, Decapinol®, or chlorhexidine oral rinse 0.12%) or to refrain from rinsing.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22917599_20201005_0.5			Efficacy and effectiveness as aspects of cluster randomized trials with nursing home residents: methodological insights from a pneumonia prevention trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22917599_20201005_0.5			Aged|Chlorhexidine|Comparative Effectiveness Research|Deglutition Disorders|Female|Homes for the Aged|Humans|Male|Medicaid|Medicare|Mouthwashes|Nursing Homes|Oral Hygiene|Pneumonia|Research Design|United States	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22917599_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	It has used a multicomponent intervention consisting of manual tooth/gum brushing, 0.12% chlorhexidine oral rinse administered twice daily by nurses, and upright feeding positioning at meals to reduce rates of radiographically documented pneumonia.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5			Effect of oral hygiene and 0.12% chlorhexidine gluconate oral rinse in preventing ventilator-associated pneumonia after cardiovascular surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5			cardiovascular surgery|chlorhexidine|prevention|ventilator-associated pneumonia	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5			Anti-Infective Agents, Local|Cardiovascular Surgical Procedures|Chlorhexidine|Female|Historically Controlled Study|Humans|Incidence|Length of Stay|Male|Middle Aged|Mouthwashes|Pneumonia, Ventilator-Associated|Postoperative Complications|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24106323_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Seventy-two hours before surgery, a dentist provided instruction and supervised oral hygiene with toothbrushing and chlorhexidine oral rinses to patients in Group 1.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12594876_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Prophylactic chlorhexidine oral rinse decreases ventilator-associated pneumonia in surgical ICU patients.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12594876_20201005_0.5			Aged|Anti-Infective Agents, Local|Chlorhexidine|Combined Modality Therapy|Critical Care|Cross Infection|Female|Humans|Male|Middle Aged|Mouthwashes|Postoperative Complications|Prospective Studies|Time Factors|Treatment Outcome|Ventilator Weaning|Ventilators, Mechanical	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5			Pilot testing of intervention protocols to prevent pneumonia in nursing home residents.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5			Aged, 80 and over|Chlorhexidine|Comorbidity|Connecticut|Feasibility Studies|Female|Humans|Male|Mouthwashes|Nursing Homes|Oral Hygiene Index|Pilot Projects|Pneumonia|Posture|Prospective Studies|Risk Factors|Risk Reduction Behavior|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 METHODS Thirty residents with impaired oral hygiene were randomly assigned to manual oral brushing plus 0.12% chlorhexidine oral rinse at different frequencies daily.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 CONCLUSIONS Manual oral brushing, 0.12% chlorhexidine oral rinse, and upright feeding positioning demonstrated high feasibility, high staff adherence, and effectiveness in pneumonia risk factor reduction.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1527659_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Evaluation of the substantivity of a chlorhexidine oral rinse in irradiated head and neck cancer patients.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1527659_20201005_0.5			Chemistry, Pharmaceutical|Chlorhexidine|Drug Administration Schedule|Head and Neck Neoplasms|Humans|Microbial Sensitivity Tests|Mouthwashes|Radiotherapy Dosage|Staphylococcus epidermidis	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12005141_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	The effects of an immediately pre-surgical chlorhexidine oral rinse on the bacterial contaminants of bone debris collected during dental implant surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12005141_20201005_0.5			Actinomyces|Anti-Infective Agents, Local|Bacteria|Bone Transplantation|Chlorhexidine|Clostridium|Colony Count, Microbial|Dental Implantation, Endosseous|Drug Resistance, Bacterial|Female|Fusobacterium|Gram-Positive Bacteria|Humans|Jaw, Edentulous, Partially|Male|Maxilla|Middle Aged|Mouthwashes|Peptostreptococcus|Preoperative Care|Prevotella intermedia|Propionibacterium|Staphylococcus|Statistics, Nonparametric|Streptococcus|Suction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25520333_20201005_0.5			A cluster-randomized controlled trial of a multicomponent intervention protocol for pneumonia prevention among nursing home elders.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25520333_20201005_0.5			chlorhexidine|nursing homes|oral care|pneumonia|prevention	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25520333_20201005_0.5			Aged|Aged, 80 and over|Chlorhexidine|Connecticut|Female|Follow-Up Studies|Homes for the Aged|Humans|Incidence|Male|Mouthwashes|Nursing Homes|Pneumonia|Radiography|Risk Factors|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID25520333_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	This clinical trial sought to determine if a multicomponent intervention protocol, including manual tooth/gum brushing plus 0.12% chlorhexidine oral rinse, twice per day, plus upright positioning during feeding, could reduce the incidence of radiographically documented pneumonia among nursing home residents, compared with usual care.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26471464_20201005_0.5			Efficacy of chlorhexidine, dexpanthenol, allantoin and chitosan gel in comparison with bicarbonate oral rinse in controlling post-interventional inflammation, pain and cicatrization in subjects undergoing dental surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26471464_20201005_0.5			Chitosan|Chlorhexidine|Controlled clinical trial|Dexpanthenol|Oral rinse|Oral surgery	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26471464_20201005_0.5			Adult|Allantoin|Analgesics|Bicarbonates|Chitosan|Chlorhexidine|Cicatrix|Cross-Over Studies|Female|Humans|Inflammation|Male|Middle Aged|Pain Measurement|Pain, Postoperative|Pantothenic Acid|Prospective Studies|Tooth Extraction|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26471464_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Chlorhexidine oral rinse is commonly used with this aim.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17606496_20201005_0.5			The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17606496_20201005_0.5			Adult|Aged|Aged, 80 and over|Bone Density Conservation Agents|Diphosphonates|Female|Humans|Jaw Diseases|Male|Membranes, Artificial|Middle Aged|Oral Surgical Procedures|Osteonecrosis|Platelet-Derived Growth Factor|Platelet-Rich Plasma	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17606496_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 CONCLUSIONS BON has been shown to be refractory to antibiotics, minor local débridement and 0.12 percent chlorhexidine oral rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC5477106_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	The effect of a daily application of a 0.05% chlorhexidine oral rinse solution on the incidence of aspiration pneumonia in nursing home residents: a multicenter study	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC5477106_20201005_0.5			Oral health care|Oral hygiene care|Chlorhexidine|Pneumonia|Aspiration pneumonia|Dysphagia|Nursing home	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC5477106_20201005_0.5			Administration, Oral|Aged|Aged, 80 and over|Anti-Infective Agents, Local|Chlorhexidine|Drug Administration Schedule|Female|Humans|Incidence|Male|Mouthwashes|Netherlands|Nursing Homes|Pharmaceutical Solutions|Pneumonia, Aspiration|Risk Factors|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC5477106_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	The aim of the study was to examine if the daily application of 0.05% chlorhexidine oral rinse solution is effective in reducing the incidence of aspiration pneumonia in nursing home residents with dysphagia.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC5477106_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 Methods This study is a multicenter study in which for 1 year participants with dysphagia in the intervention group received the usual oral hygiene care with the addition of a 0.05% chlorhexidine oral rinse solution, whereas participants in the control group received only oral hygiene care.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC5477106_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 Conclusions Chlorhexidine oral rinse solution 0.05% as an adjunctive intervention in daily oral hygiene care was not found to reduce incidence of aspiration pneumonia.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22726656_20201214_0.5			Randomized evidence for reduction of perioperative mortality.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22726656_20201214_0.5			Humans|Internationality|Perioperative Care|Randomized Controlled Trials as Topic	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22726656_20201214_0.5	chlorhexidine oral rinse	drug_umls_atom	Interventions that might reduce mortality include chlorhexidine oral rinse, clonidine, insulin, intra-aortic balloon pump, leukodepletion, levosimendan, neuraxial anesthesia, noninvasive respiratory support, hemodynamic optimization, oxygen, selective decontamination of the digestive tract, and volatile anesthetics.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6814100_20201005_0.5			Protocol for a multi-centered, stepped wedge, cluster randomized controlled trial of the de-adoption of oral chlorhexidine prophylaxis and implementation of an oral care bundle for mechanically ventilated critically ill patients: the CHORAL study	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6814100_20201005_0.5			Chlorhexidine|Critical care|Ventilator-associated pneumonia|Oral care|Stepped-wedge cluster randomized controlled trial|Process evaluation|Mechanical ventilation	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6814100_20201005_0.5			Anti-Infective Agents, Local|Chlorhexidine|Critical Illness|Cross-Over Studies|Drainage|Humans|Mouthwashes|Multicenter Studies as Topic|Ontario|Oral Hygiene|Patient Care Bundles|Pneumonia, Ventilator-Associated|Randomized Controlled Trials as Topic|Respiration, Artificial|Time Factors|Toothbrushing|Treatment Outcome	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6814100_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Background Routine application of chlorhexidine oral rinse is recommended to reduce risk of ventilator-associated pneumonia (VAP) in mechanically ventilated patients.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8064937_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Effect of Plax and chlorhexidine oral rinses on plaque, gingivitis, and plaque bacteria vitality.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8064937_20201005_0.5			Adult|Analysis of Variance|Bacteria|Benzoates|Chlorhexidine|Colony Count, Microbial|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Gingivitis|Humans|Male|Microbial Sensitivity Tests|Mouthwashes|Periodontal Index|Sodium Dodecyl Sulfate	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15187525_20201005_0.5			Prevention of hospital-associated pneumonia and ventilator-associated pneumonia.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15187525_20201005_0.5			Cross Infection|Equipment Contamination|Humans|Pneumonia|Ventilators, Mechanical	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID15187525_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	The evidence-based interventions focus on the prevention of aerodigestive tract colonization (avoidance of unnecessary antibiotics and stress ulcer prophylaxis, use of sucralfate for stress ulcer prophylaxis, chlorhexidine oral rinse, selective digestive decontamination, short-course parenteral prophylactic antibiotics in high-risk patients) and the prevention of aspiration of contaminated secretions (preferred oral intubation, appropriate intensive care unit staffing, avoidance of tracheal intubation with the use of mask ventilation, application of weaning protocols and optimal use of sedation to shorten the duration of mechanical ventilation, semirecumbent positioning, minimization of gastric distension, subglottic suctioning, avoidance of ventilator circuit changes/manipulation, routine drainage of ventilator circuit condensate).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9660340_20201005_0.5			Rapid progression of bone loss in HIV-associated necrotizing ulcerative stomatitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9660340_20201005_0.5			AIDS-Related Opportunistic Infections|Adult|Alveolar Bone Loss|Anti-Infective Agents|Anti-Infective Agents, Local|Chlorhexidine|Debridement|Disease Progression|Gingivitis, Necrotizing Ulcerative|Humans|Immunocompromised Host|Male|Metronidazole|Mouth Mucosa|Mouthwashes|Palate|Tooth Extraction|Tooth Mobility	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID9660340_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	With only partial compliance to local debridement, chlorhexidine oral rinses, and systemic metronidazole therapy, alveolar bone loss resulted in tooth mobility necessitating extraction of 2 involved teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	A comparison of a new alcohol-free 0.2% chlorhexidine oral rinse to an established 0.2% chlorhexidine rinse with alcohol for the control of dental plaque accumulation.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5			chlorhexidine mouthrinse|dental biofilm|gingivitis|staining	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID26449740_20201005_0.5			Chlorhexidine|Cross-Over Studies|Dental Plaque|Double-Blind Method|Ethanol|Female|Gingivitis|Humans|Male|Mouthwashes|Tooth Discoloration|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6410424_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	Comparative Evaluation of Plaque Inhibitory and Antimicrobial Efficacy of Probiotic and Chlorhexidine Oral Rinses in Orthodontic Patients: A Randomized Clinical Trial	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6410424_20201005_0.5			Child|Male|Humans|Female|Chlorhexidine|Anti-Infective Agents|Probiotics|Mouthwashes|Dental Plaque Index|Anti-Infective Agents, Local|Periodontal Index|Gingivitis|Anti-Bacterial Agents|Phytotherapy|Plant Extracts|Bacteria	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC6410424_20201005_0.5	chlorhexidine oral rinse	drug_umls_atom	 Aim and Objective To compare efficacy of probiotic and chlorhexidine oral rinses in orthodontic patients.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5			The effect of a dentifrice containing chlorhexidine and zinc on plaque, gingivitis, calculus and tooth staining.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5			Adolescent|Adult|Aged|Analysis of Variance|Chlorhexidine|Dental Calculus|Dental Plaque|Dental Plaque Index|Dentifrices|Double-Blind Method|Female|Gingivitis|Humans|Male|Middle Aged|Periodontal Index|Tooth Discoloration|Zinc	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	The participants either used a 0.12% chlorhexidine rinse and a gum care dentifrice (positive control) or a placebo rinse and the gum care dentifrice (control) or the placebo rinse and an experimental dentifrice containing 0.4% chlorhexidine and 0.34% Zn2+ (experimental group).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8089246_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	It is concluded that the experimental dentifrice will contribute to a significant improvement in oral hygiene with less staining compared with using a 0.12% chlorhexidine rinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451766_20201005_0.5			The comparative effects of 0.12% chlorhexidine and herbal oral rinse on dental plaque-induced gingivitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451766_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Chlorhexidine|Dental Plaque|Dental Plaque Index|Female|Gingivitis|Humans|Linear Models|Male|Mouthwashes|Periodontal Index|Phytotherapy|Plant Preparations|Statistics, Nonparametric	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16451766_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	OBJECTIVE The purpose of this study was to determine the effects of two oral rinses-one 0.12% chlorhexidine rinse (CHX) and one herbal rinse (HBR)-on gingival health status over time.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5			Effectiveness of chlorhexidine gel versus chlorhexidine rinse in reducing alveolar osteitis in mandibular third molar surgery.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5			Adolescent|Adult|Age Factors|Chi-Square Distribution|Chlorhexidine|Contraceptives, Oral, Hormonal|Disinfectants|Dry Socket|Female|Gels|Humans|Male|Middle Aged|Molar, Third|Mouthwashes|Prospective Studies|Risk Factors|Sex Factors|Smoking|Tooth Extraction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18280375_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	 METHODS The experimental or gel group (n = 41) applied the bioadhesive 0.2% chlorhexidine gel to the wound during the first postoperative week and a control or rinse group (n = 32) used a 0.12% chlorhexidine rinse during the first week postextraction.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5			Pilot testing of intervention protocols to prevent pneumonia in nursing home residents.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5			Aged, 80 and over|Chlorhexidine|Comorbidity|Connecticut|Feasibility Studies|Female|Humans|Male|Mouthwashes|Nursing Homes|Oral Hygiene Index|Pilot Projects|Pneumonia|Posture|Prospective Studies|Risk Factors|Risk Reduction Behavior|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID19558483_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	 RESULTS Daily manual oral brushing plus 0.12% chlorhexidine rinse demonstrated high feasibility, high staff adherence, and effectiveness in improving oral hygiene (P<.001 vs baseline); this combination administered twice per day showed the highest plaque score reduction.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16178133_20201005_0.5			A 6-month clinical study assessing the safety and efficacy of two cetylpyridinium chloride mouthrinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16178133_20201005_0.5			Adolescent|Adult|Aged|Anti-Infective Agents, Local|Cetylpyridinium|Chlorhexidine|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Follow-Up Studies|Gingival Hemorrhage|Gingivitis|Humans|Male|Middle Aged|Mouth Mucosa|Mouthwashes|Periodontal Index|Placebos|Safety|Toothbrushing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID16178133_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	A 0.12% chlorhexidine rinse served as the positive control for validation of the methodology.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5			Effects of typified propolis on mutans streptococci and lactobacilli: a randomized clinical trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5			Chlorhexidine|Lactobacilli|Mutans Streptococci|Randomized clinical trial|Typified propolis	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5			Humans|Middle Aged|Male|Adult|Female|Propolis|Lactobacillus|Double-Blind Method|Streptococcus mutans|Chlorhexidine|Mouthwashes|Dental Caries|Saliva|Anti-Infective Agents, Local|Colony Count, Microbial	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID24494174_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	After restoration of cavitated lesions patients were randomized to 3 experimental groups: 1) PROP-alcohol-free 2% typified propolis rinse (n = 20); 2) CHX- 0.12% chlorhexidine rinse; 3) PL-placebo mouthrinse.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1499250_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Effect of a twice daily 0.12% chlorhexidine rinse on the oral health of a geriatric population.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1499250_20201005_0.5			Aged|Aged, 80 and over|Analysis of Variance|Chlorhexidine|Dental Care for Aged|Denture, Overlay|Denture, Partial, Removable|Female|Humans|Male|Middle Aged|Mouthwashes|Stomatitis, Denture	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Evaluation of 0.12% chlorhexidine rinse on the prevention of alveolar osteitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5			Adult|Chlorhexidine|Double-Blind Method|Dry Socket|Female|Humans|Male|Mandibular Diseases|Molar, Third	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	No section A double-blind study evaluated the ability of 0.12% chlorhexidine rinse to decrease the incidence of localized alveolar osteitis after the removal of mandibular third molar teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1745508_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Thus a 0.12% chlorhexidine rinse is shown to be an effective means of decreasing alveolar osteitis that may follow removal of third molar teeth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17233164_20201005_0.5			Effectiveness of antimicrobial mouthrinses on aerosols produced by an air polisher.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17233164_20201005_0.5			Adult|Aerosols|Air Microbiology|Anti-Infective Agents, Local|Bronchi|Chlorhexidine|Colony Count, Microbial|Dental Prophylaxis|Drug Combinations|Female|Humans|Male|Mouthwashes|Particle Size|Pharynx|Pulmonary Alveoli|Salicylates|Single-Blind Method|Terpenes	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID17233164_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	 METHODS Forty-five adult subjects were randomly assigned to one of three groups and asked to rinse for 30 seconds with 15 ml of either a 0.12% chlorhexidine rinse, an essential oil mouthrinse, or water prior to air polishing.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18633464_20201005_0.5			Alterations in HbA1c following minimal or enhanced non-surgical, non-antibiotic treatment of gingivitis or mild periodontitis in type 2 diabetic patients: a pilot trial.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18633464_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Analysis of Variance|Anti-Infective Agents, Local|Chlorhexidine|Dental Plaque Index|Dental Scaling|Diabetes Mellitus, Type 2|Gingivitis|Glycated Hemoglobin A|Humans|Middle Aged|Oral Hygiene|Oral Hygiene Index|Periodontal Index|Pilot Projects|Statistics, Nonparametric|Time Factors	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID18633464_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Participants randomized to the "frequent therapy" (FT) protocol received scaling, root planing, and oral hygiene instructions at two-month intervals and were provided a 0.12% chlorhexidine rinse for home use twice daily.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10460956_20201005_0.5			Caries prevention in a community-dwelling older population.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10460956_20201005_0.5			Aged|Aged, 80 and over|Cariostatic Agents|Chlorhexidine|Community Dentistry|DMF Index|Dental Care for Aged|Dental Caries|Dental Scaling|Educational Status|Fluorides, Topical|Health Education, Dental|Humans|Incidence|Likelihood Functions|Marital Status|Middle Aged|Minority Groups|Poverty|Regression Analysis|Root Caries|United States	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID10460956_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Group 3 received the educational program plus a 0.12% chlorhexidine rinse weekly.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12060421_20201005_0.5			The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12060421_20201005_0.5			Adult|Analysis of Variance|Anti-Infective Agents, Local|Bacteria|Biguanides|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Double-Blind Method|Drug Combinations|Female|Humans|Male|Mouth Mucosa|Mouthwashes|Normal Distribution|Oils, Volatile|Placebos|Reproducibility of Results|Salicylates|Statistics as Topic|Terpenes|Tooth	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID12060421_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	In this study, a 0.12% PHMB mouthrinse (A) was compared with a negative control placebo rinse (10% ethanol, flavour) (B), a positive control 0.12% chlorhexidine rinse (C), and a commercially available mouthrinse containing essential oils (Listerine) (D).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2689627_20201005_0.5			A clinical comparison of antibacterial mouthrinses: effects of chlorhexidine, phenolics, and sanguinarine on dental plaque and gingivitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2689627_20201005_0.5			Adult|Alkaloids|Anti-Infective Agents|Benzophenanthridines|Chlorhexidine|Clinical Trials as Topic|Dental Plaque|Double-Blind Method|Female|Gingival Hemorrhage|Gingivitis|Humans|Isoquinolines|Male|Mouthwashes|Phenol|Phenols|Placebos|Random Allocation|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID2689627_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Both the phenolic and sanguinarine groups showed moderate, yet significant, reductions in plaque compared to placebo (24% and 12% respectively) yet were significantly less effective than the 0.12% chlorhexidine rinse (P less than 0.05).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5			Comparison of 2 chlorhexidine mouthwashes on plaque regrowth in vivo and dietary staining in vitro.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5			Chlorhexidine|Color|Dental Plaque|Dental Plaque Index|Double-Blind Method|Drug Combinations|Humans|Methylmethacrylates|Mouthwashes|Sodium Fluoride|Tea|Time Factors|Tooth Discoloration	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID8195448_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	The 1st study compared the effect of a 0.12% chlorhexidine rinse with a 0.12% chlorhexidine/0.022% sodium fluoride rinse for effects on plaque regrowth.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Clinical effects of a 0.12% chlorhexidine rinse as an adjunct to scaling and root planing.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5			Analysis of Variance|Chlorhexidine|Dental Plaque|Dental Plaque Index|Dental Scaling|Double-Blind Method|Gingival Pocket|Gingivitis|Humans|Longitudinal Studies|Periodontal Index|Root Planing	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID1524682_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	No section This trial tested the adjunctive effects of a 0.12% chlorhexidine rinse (Peridex) upon gingival healing following scaling and root planing.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28406129_20201005_0.5			Prevention of alveolar osteitis after third molar surgery: Comparative study of the effect of warm saline and chlorhexidine mouth rinses.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28406129_20201005_0.5			Adolescent|Adult|Chlorhexidine|Dry Socket|Female|Follow-Up Studies|Humans|Incidence|Male|Middle Aged|Molar, Third|Mouthwashes|Nigeria|Postoperative Complications|Prospective Studies|Saline Solution|Single-Blind Method|Tooth Extraction|Young Adult	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID28406129_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	There was no statistically significant difference between application of warm saline and 0.12% chlorhexidine rinse with respect to the development of alveolar osteitis (P = 0.648).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22874549_20201005_0.5			An evidence-based oral care protocol to decrease ventilator-associated pneumonia.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22874549_20201005_0.5			Chlorhexidine|Cross Infection|Humans|Infection Control|Intensive Care Units|Nursing Audit|Oral Hygiene|Pneumonia, Ventilator-Associated|Respiration, Artificial	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22874549_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	No section The purpose of this study was to examine the impact of 0.12% chlorhexidine rinses and an oral care protocol on ventilator-associated pneumonia rates.	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22622144_20201005_0.5			Chlorhexidine for the prevention of alveolar osteitis.	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22622144_20201005_0.5			Anti-Infective Agents, Local|Antibiotic Prophylaxis|Chlorhexidine|Clinical Trials as Topic|Dry Socket|Humans|Mouthwashes|Publication Bias|Tooth Extraction	mesh_terms
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMID22622144_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Two of six application protocols favoured chlorhexidine over placebo: Single application of 0.2% chlorhexidine gel placed in the socket immediately after extraction versus placebo gel (RR 0.40; 95% CI: 0.18-0.90; p=0.03) and 0.12% chlorhexidine rinse applied on day of surgery and used twice daily for 7 days postoperatively versus placebo rinse (RR 0.50; 95% CI: 0.27-0.93; p=0.03).	abstract
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4246385_20201005_0.5	0.12% chlorhexidine rinse	drug_umls_atom	Staining and calculus formation after 0.12% chlorhexidine rinses in plaque-free and plaque covered surfaces: a randomized trial	title
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4246385_20201005_0.5			Chlorhexidine|Adverse effects|Staining|Tooth discoloration|Dental calculus	author_keywords
acclean chlorhexidine rinse	Z0000023109			chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse	inn	PubMed	PMC4246385_20201005_0.5			Adult|Chlorhexidine|Dental Calculus|Dental Plaque|Dental Prophylaxis|Gingivitis|Humans|Male|Mouthwashes|Periodontal Index|Single-Blind Method|Surface Properties|Time Factors|Tooth Discoloration	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29602822_20201005_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29602822_20201005_0.5	18f-fluoroestradiol	drug_name	18F-fluoroestradiol PET|breast cancer|estrogen receptor|tumor heterogeneity|tumor microenvironment	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29602822_20201005_0.5			Adult|Aged|Aged, 80 and over|Biological Transport|Breast Neoplasms|Estradiol|Female|Gene Expression Regulation, Neoplastic|Humans|Middle Aged|Neoplasm Metastasis|Positron Emission Tomography Computed Tomography|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID21982568_20201005_0.5	18f-fluoroestradiol	drug_name	Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID21982568_20201005_0.5			Adult|Aged|Aged, 80 and over|Biological Transport|Body Mass Index|Breast Neoplasms|Estradiol|Female|Humans|Menopause|Middle Aged|Positron-Emission Tomography|Receptors, Estrogen|Sex Factors|Sex Hormone-Binding Globulin|Young Adult	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29903931_20201005_0.5	18f-fluoroestradiol	drug_name	Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29903931_20201005_0.5			Breast Neoplasms|Humans|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32859700_20210611_0.5			Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32859700_20210611_0.5			18F-FDG|18F-FES|18F-FFNP PET/CT|ESR1 mutation|fulvestrant	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32859700_20210611_0.5			Animals|Breast Neoplasms|Cell Line, Tumor|Cell Transformation, Neoplastic|Estradiol|Estrogen Receptor alpha|Estrogens|Female|Fluorodeoxyglucose F18|Gene Expression Regulation, Neoplastic|Glycosylation|Humans|Longitudinal Studies|Mice|Mutation|Positron Emission Tomography Computed Tomography|Receptors, Progesterone|Treatment Outcome	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32859700_20210611_0.5	18f-fluoroestradiol	drug_name	This study investigated the effect of an activating ESR1 mutation on pretreatment 18F-fluoroestradiol (18F-FES) uptake and early assessment of endocrine therapy response using 18F-FDG and 18F-fluorofuranylnorprogesterone (18F-FFNP) PET/CT imaging of tumor glucose metabolism and progesterone receptor (PR) expression, respectively.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28221191_20201005_0.5	18f-fluoroestradiol	drug_name	The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28221191_20201005_0.5			Adult|Aged|Breast Neoplasms|Estradiol|Female|Fluorine Radioisotopes|Humans|Middle Aged|Positron Emission Tomography Computed Tomography|ROC Curve|Receptors, Estrogen|Retrospective Studies	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID31732674_20210111_0.5			Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID31732674_20210111_0.5			PET/CT|breast cancer|estrogen receptor|progesterone receptor	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID31732674_20210111_0.5			Breast Neoplasms|Diagnostic Imaging|Humans|Prognosis|Receptors, Estrogen|Receptors, Progesterone	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID31732674_20210111_0.5	18f-fluoroestradiol	drug_name	Recent investigations of ER imaging with 18F-fluoroestradiol have focused on diagnosing ER-positive metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28912144_20201005_0.5			Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28912144_20201005_0.5			FDHT PET|FES PET|androgen receptor|breast cancer|estrogen receptor	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28912144_20201005_0.5			Biopsy|Breast Neoplasms|Cell Nucleus|Feasibility Studies|Female|Humans|Immunohistochemistry|Male|Middle Aged|Neoplasm Metastasis|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Androgen|Receptors, Estrogen|Tomography, Emission-Computed|Whole Body Imaging	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28912144_20201005_0.5	18f-fluoroestradiol	drug_name	ER expression in tumor lesions can be visualized by 18F-fluoroestradiol (18F-FES) PET, and AR expression has been visualized in prostate cancer patients with 18F-fluorodihydrotestosterone (18F-FDHT) PET.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33369181_20210611_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol PET in the evaluation of probable oligometastatic breast cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33369181_20210611_0.5			breast imaging|nuclear imaging|oncologic imaging	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33369181_20210611_0.5			Humans|Male|Female|Breast Neoplasms|Positron Emission Tomography Computed Tomography|Receptors, Estrogen|Fluorine Radioisotopes|Positron-Emission Tomography|Estradiol|Biopsy|Sensitivity and Specificity|Probability|FOLH1 protein, human|Antigens, Surface|Glutamate Carboxypeptidase II	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33369181_20210611_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol (FES) is a novel PET tracer that has been demonstrated to have high specificity for oestrogen receptor (ER) in breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30770494_20201005_0.5	18f-fluoroestradiol	drug_name	Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29488712_20201005_0.5			[Advances on correlation of PET-CT findings with breast cancer molecular subtypes, treatment response and prognosis].	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29488712_20201005_0.5			Breast Neoplasms|Humans|Positron Emission Tomography Computed Tomography|Positron-Emission Tomography|Prognosis|Radiopharmaceuticals	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29488712_20201005_0.5	18f-fluoroestradiol	drug_name	New tracers, such as 18F-fluoroestradiol (18F-FES) and[89Zr]trastuzumab play an important role in molecular subtyping of breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC5436319_20201005_0.5	18f-fluoroestradiol	drug_name	Can 18F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor-positive Breast Cancer Patient: A Prospective Comparative Study with 18F-Fluorodeoxyglucose Positron Emission Tomography?	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC5436319_20201005_0.5			diagnostic strength|estrogen receptor-positive breast cancer|incremental value	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC5436319_20201005_0.5			Aged|Female|Humans|Positron Emission Tomography Computed Tomography|Receptors, Estrogen|Fluorodeoxyglucose F18|Fluorine Radioisotopes|Positron-Emission Tomography|Breast Neoplasms|Radiopharmaceuticals|Estradiol|Sensitivity and Specificity	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27856629_20201214_0.5			Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27856629_20201214_0.5	18f-fluoroestradiol	drug_name	18F-fluoroestradiol|breast cancer|estrogen receptor|molecular imaging|neoadjuvant therapy	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27856629_20201214_0.5			Aged|Breast Neoplasms|Estradiol|Feasibility Studies|Female|Humans|Middle Aged|Neoadjuvant Therapy|Positron Emission Tomography Computed Tomography|Postmenopause|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC8021033_20210511_0.5			[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC8021033_20210511_0.5	18f-fluoroestradiol	drug_name	18F-fluoro-deoxyglucose (18F-FDG)|18F-fluoroestradiol (18F-FES)|granulosa cell tumors (GCTs)|hormone receptors|positron emission tomography (PET)	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC8021033_20210511_0.5			Humans|Adult|Middle Aged|Male|Female|Fluorodeoxyglucose F18|Ovary|Granulosa Cell Tumor|Tomography, X-Ray Computed|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Estrogen Receptor alpha|Biological Transport|Immunohistochemistry|Ovarian Neoplasms	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID21903739_20201005_0.5	18f-fluoroestradiol	drug_name	Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID21903739_20201005_0.5			Adult|Aged|Analysis of Variance|Breast Neoplasms|Estradiol|Female|Fluorine Radioisotopes|Fluorodeoxyglucose F18|Humans|Middle Aged|Neoplasm Metastasis|Observer Variation|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Retrospective Studies	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27872957_20210311_0.5	18f-fluoroestradiol	drug_name	Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27872957_20210311_0.5			18F-FES|Fluoroestradiol|Pharmacodynamic marker|Positron emission tomography (PET)|Z-endoxifen	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27872957_20210311_0.5			Adult|Aged|Breast Neoplasms|Breast Neoplasms, Male|Estradiol|Estrogen Antagonists|Female|Genital Neoplasms, Female|Humans|Male|Middle Aged|Positron Emission Tomography Computed Tomography|Radiopharmaceuticals|Receptors, Estrogen|Tamoxifen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27688475_20201005_0.5	18f-fluoroestradiol	drug_name	A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27688475_20201005_0.5			18F-FES|breast cancer|estrogen receptor-positive|neoadjuvant therapy|positron emission tomography	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27688475_20201005_0.5			Aged|Biological Transport|Breast Neoplasms|Estradiol|Feasibility Studies|Female|Humans|Middle Aged|Neoadjuvant Therapy|Positron Emission Tomography Computed Tomography|Postmenopause|Receptors, Estrogen|Survival Analysis|Treatment Outcome	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27688475_20201005_0.5	18f-fluoroestradiol	drug_name	No section The aim of this study was to explore the ability of 18F-fluoroestradiol (18F-FES) PET/CT imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor (ER)-rich breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28011460_20201005_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28011460_20201005_0.5			Adult|Aged|Biomarkers, Pharmacological|Breast Neoplasms|Cinnamates|Dose-Response Relationship, Drug|Estradiol|Estrogen Receptor alpha|Female|Fulvestrant|Humans|Indazoles|Middle Aged|Molecular Imaging|Molecular Targeted Therapy|Positron Emission Tomography Computed Tomography|Receptors, Estrogen|Tamoxifen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID28011460_20201005_0.5	18f-fluoroestradiol	drug_name	Purpose Evaluate 18F-fluoroestradiol (FES) PET/CT as a biomarker of estrogen receptor (ER) occupancy and/or downregulation during phase I dose escalation of the novel ER targeting therapeutic GDC-0810 and help select drug dosage for subsequent clinical trials.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID26850484_20201005_0.5	18f-fluoroestradiol	drug_name	Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID26850484_20201005_0.5			Bone Neoplasms|Bone and Bones|Breast Neoplasms|Female|Humans|Middle Aged|Molecular Imaging|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5			ER+ breast cancer|FES|estrogen receptors|metastatic breast cancer|vorinostat	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5			Adult|Aged|Breast Neoplasms|Estradiol|Female|Humans|Image Processing, Computer-Assisted|Middle Aged|Neoplasm Metastasis|Positron-Emission Tomography|Receptor, ErbB-2|Receptors, Estrogen|Vorinostat	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5	18f-fluoroestradiol	drug_name	We tested whether 18F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine therapy.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5	18f-fluoroestradiol	drug_name	18F-fluoroestradiol PET and 18F-FDG PET scans were performed at baseline, week 2, and week 8.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5	18f-fluoroestradiol	drug_name	Higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5	18f-fluoroestradiol	drug_name	18F-fluoroestradiol uptake did not systematically increase with vorinostat exposure, indicating no change in regional ER estradiol binding, and 18F-FDG uptake did not show a significant decrease, as would have been expected with tumor regression.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32591490_20210511_0.5	18f-fluoroestradiol	drug_name	Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5	18f-fluoroestradiol	drug_name	18F-fluoroestradiol|breast cancer|estrogen receptor mutation|positron emission tomography|tumor xenografts	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5			Animals|Breast Neoplasms|Cell Line, Tumor|Estradiol|Estrogen Receptor alpha|Female|Humans|Inhibitory Concentration 50|Kinetics|Ligands|Mice|Mice, Nude|Mutation|Neoplasm Transplantation|Positron Emission Tomography Computed Tomography|Protein Binding|Tissue Distribution	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5	18f-fluoroestradiol	drug_name	No section The purpose of this study was to determine the effect of estrogen receptor-α gene (ESR1) mutations at the tyrosine (Y) 537 amino acid residue within the ligand binding domain on 18F-fluoroestradiol (18F-FES) binding and in vivo tumor uptake compared with wild-type (WT)-estrogen receptor α (ER).	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321025_20201005_0.5			PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321025_20201005_0.5			Head-neck cancer|Lymphoma|Oncology|PET-CT|Personalized medicine|Precision medicine	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321025_20201005_0.5			Humans|Medical Oncology|Neoplasms|Positron Emission Tomography Computed Tomography|Positron-Emission Tomography|Precision Medicine	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321025_20201005_0.5	18f-fluoroestradiol	drug_name	The potential of multitracer PET imaging (particularly new and novel tracers, eg, 68Ga-DOTA-TOC/NOC/TATE in NET, 68Ga-PSMA and 18F-fluorocholine in prostate carcinoma, 18F-fluoroestradiol in breast carcinoma) has provided a scientific basis to stratify and select appropriate targeted therapies (both radionuclide and nonradionuclide treatment), a major boost for individualized disease management in clinical oncology.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27932559_20201005_0.5	18f-fluoroestradiol	drug_name	Reply: 18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27932559_20201005_0.5			Breast Neoplasms|Fluorodeoxyglucose F18|Humans|Neoadjuvant Therapy|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Treatment Outcome	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5			Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5			18F-FES (fluoroestradiol)|breast cancer|estrogen receptor imaging|molecular breast imaging|patient outcomes|patient response to therapy	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5			Humans|Middle Aged|Female|Receptors, Estrogen|Breast Neoplasms|Fluorine Radioisotopes|Estradiol|Radiopharmaceuticals|Positron-Emission Tomography|Molecular Imaging|Biopsy|Survival Rate	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5	18f-fluoroestradiol	drug_name	A potential new PET tracer, 18F-fluoroestradiol (currently under Food and Drug Administration review for approval), may be a valuable tool for noninvasive evaluation of the estrogen receptor site status of a patients' primary tumor and secondary metastatic lesions.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5	18f-fluoroestradiol	drug_name	18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5	18f-fluoroestradiol	drug_name	18F-fluoroestradiol|breast cancer|estrogen receptor|positron emission tomography	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5			Breast Neoplasms|Estradiol|Forecasting|Humans|Image Enhancement|Molecular Imaging|Positron-Emission Tomography|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5	[18f]fluoroestradiol	drug_umls_atom	Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[18F]fluoroestradiol ([18F]FES) for human breast cancer imaging.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5			16alpha-[(18)F]Fluoroestradiol ([(18)F]FES)|Automation|Breast cancer imaging|Estrogen receptor (ER)|Positron emission tomography (PET)|Radiosynthesis	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5			Automation|Breast Neoplasms|Chromatography, High Pressure Liquid|Estradiol|Female|Fluorine Radioisotopes|Humans|Quality Control|Radiopharmaceuticals|Receptors, Estrogen|Solid Phase Extraction	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5	[18f]fluoroestradiol	drug_umls_atom	No section 16α-[18F]Fluoroestradiol ([18F]FES) is the most successful estrogen receptor (ER) targeting radiopharmaceutical to date. [	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7546761_20210111_0.5			Quick Automatic Synthesis of Solvent-Free 16α-[18F] Fluoroestradiol: Comparison of Kryptofix 222 and Tetrabutylammonium Bicarbonate	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7546761_20210111_0.5	[18f]fluoroestradiol	drug_umls_atom	16alpha-[18F]fluoroestradiol|automatic synthesis|breast cancer|estrogen receptor|phase transfer catalyst	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7546761_20210111_0.5			Humans|Female|Bicarbonates|cryptating agent 222|tetrabutylammonium|Solvents|Bridged Bicyclo Compounds, Heterocyclic|Quaternary Ammonium Compounds|Radiopharmaceuticals|Fluorine Radioisotopes|Radiochemistry|Receptors, Estrogen|Positron-Emission Tomography|Breast Neoplasms|Estradiol|Chromatography, High Pressure Liquid|Automation	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	Rapid synthesis of [18F]fluoroestradiol: remarkable advantage of microwaving over conventional heating.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5			F-18|PET|fluoroestradiol|microwave	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5			Breast Neoplasms|Chemistry Techniques, Synthetic|Estradiol|Fluorine Radioisotopes|Hot Temperature|Humans|Isotope Labeling|Kinetics|Microwaves|Positron-Emission Tomography|Quality Control|Radiochemistry|Radiopharmaceuticals	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5			Alternative synthesis for the preparation of 16α-[(18) F]fluoroestradiol.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	16α-[18F]Fluoroestradiol|PET|[18F]FES|imaging of estrogen receptor|radiopharmaceutical	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5			Estradiol|Isotope Labeling|Radiopharmaceuticals	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID3019933_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	NCA 16 alpha-[18F]fluoroestradiol-17 beta: the effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID3019933_20201005_0.5			Estradiol|Fluorine|Isotope Labeling|Radioisotopes|Radioligand Assay	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30137103_20201005_0.5			Fast and reliable generation of [18F]triflyl fluoride, a gaseous [18F]fluoride source.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30137103_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	The reactivity of the [18F]fluoride has been confirmed by reaction with several model compounds and by the synthesis of the PET tracers [18F]fluoroestradiol ([18F]FES) and O-2-[18F]fluoroethyl-l-tyrosine ([18F]FET), providing good isolated radiochemical yields and molar activities of up to 123 GBq μmol-1.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID7769466_20201005_0.5			Designing steroid receptor-based radiotracers to image breast and prostate tumors.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID7769466_20201005_0.5			Breast Neoplasms|Female|Humans|Male|Molecular Structure|Prostatic Neoplasms|Radioisotopes|Radionuclide Imaging|Receptors, Androgen|Receptors, Estrogen|Receptors, Progesterone|Receptors, Steroid	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID7769466_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	Breast tumors in patients have been imaged with [18F]fluoroestradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	Automated SPE-based synthesis of 16α-[18F]fluoroestradiol without HPLC purification step.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5			16α-[(18)F]fluoroestradiol|Estrogen receptor|Fluorine-18|PET|SPE purification|[(18)F]FES	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5			Automation|Breast Neoplasms|Chromatography, High Pressure Liquid|Estradiol|Female|Fluorine Radioisotopes|Humans|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Solid Phase Extraction	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	No section [18F]fluoroestradiol ([18F]FES) is well-established PET radiotracer for diagnosing and monitoring treatment of estrogen-positive breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	All purity parameters were well within specifications recommended in the Investigator's Brochure for [18F]Fluoroestradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5			Breast cancer|Estrogen receptor|[|[	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5			Middle Aged|Humans|Female|Fluorodeoxyglucose F18|Breast Neoplasms|Prospective Studies|Neoplasm Recurrence, Local|Positron Emission Tomography Computed Tomography|Positron-Emission Tomography|Fluorine Radioisotopes|Receptors, Estrogen|Tomography, X-Ray Computed|Estradiol|Fluorine Compounds|Chronic Disease|Estrogens	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC4554736_20201005_0.5	[18f]fluoroestradiol	drug_umls_atom	Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC4554736_20201005_0.5			Oestrogen receptor|Imaging|Breast cancer|Oestradiol therapy	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC4554736_20201005_0.5			Adult|Aged|Biological Transport|Biomarkers, Tumor|Bone and Bones|Breast Neoplasms|Drug Resistance, Neoplasm|Estradiol|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Predictive Value of Tests|Treatment Outcome	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5			Long-term Trace of Radiation Pneumonitis With 18F-Fluoroestradiol.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5			Asymptomatic Diseases|Breast Neoplasms|Estradiol|Female|Fluorine Radioisotopes|Humans|Positron-Emission Tomography|Radiation Pneumonitis	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5	f fluoroestradiol	drug_umls_atom	Only 1 case of fluoroestradiol uptake contemporary of metabolic FDG changes attributed to RP is reported.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5			Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5	fluoroestradiol	drug_umls_atom	18F-FES (fluoroestradiol)|breast cancer|estrogen receptor imaging|molecular breast imaging|patient outcomes|patient response to therapy	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5			Humans|Middle Aged|Female|Receptors, Estrogen|Breast Neoplasms|Fluorine Radioisotopes|Estradiol|Radiopharmaceuticals|Positron-Emission Tomography|Molecular Imaging|Biopsy|Survival Rate	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32111662_20210311_0.5	fluoroestradiol	drug_umls_atom	A potential new PET tracer, 18F-fluoroestradiol (currently under Food and Drug Administration review for approval), may be a valuable tool for noninvasive evaluation of the estrogen receptor site status of a patients' primary tumor and secondary metastatic lesions.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321033_20201005_0.5			PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321033_20201005_0.5	fluoroestradiol	drug_umls_atom	(18)F-16α-17β-Fluoroestradiol PET/CT|(18)F-FDG PET/CT|Breast cancer|Receptor imaging	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321033_20201005_0.5			Breast|Breast Neoplasms|Humans|Positron Emission Tomography Computed Tomography|Precision Medicine	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27321033_20201005_0.5	fluoroestradiol	drug_umls_atom	In the present article, we reviewed the use of whole-body FDG-PET/CT and (18)F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5	fluoroestradiol	drug_umls_atom	Rapid synthesis of [18F]fluoroestradiol: remarkable advantage of microwaving over conventional heating.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5	fluoroestradiol	drug_umls_atom	F-18|PET|fluoroestradiol|microwave	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5			Breast Neoplasms|Chemistry Techniques, Synthetic|Estradiol|Fluorine Radioisotopes|Hot Temperature|Humans|Isotope Labeling|Kinetics|Microwaves|Positron-Emission Tomography|Quality Control|Radiochemistry|Radiopharmaceuticals	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25476421_20201005_0.5	fluoroestradiol	drug_umls_atom	No section 16α-[(18)F]fluoroestradiol ([(18)F]FES) is known as a clinically important tracer in nuclear medicine as an estrogen receptor ligand for investigating primary and metastatic breast cancers.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5	fluoroestradiol	drug_umls_atom	18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5	fluoroestradiol	drug_umls_atom	18F-fluoroestradiol|breast cancer|estrogen receptor mutation|positron emission tomography|tumor xenografts	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5			Animals|Breast Neoplasms|Cell Line, Tumor|Estradiol|Estrogen Receptor alpha|Female|Humans|Inhibitory Concentration 50|Kinetics|Ligands|Mice|Mice, Nude|Mutation|Neoplasm Transplantation|Positron Emission Tomography Computed Tomography|Protein Binding|Tissue Distribution	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30850489_20201005_0.5	fluoroestradiol	drug_umls_atom	No section The purpose of this study was to determine the effect of estrogen receptor-α gene (ESR1) mutations at the tyrosine (Y) 537 amino acid residue within the ligand binding domain on 18F-fluoroestradiol (18F-FES) binding and in vivo tumor uptake compared with wild-type (WT)-estrogen receptor α (ER).	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC3804456_20201005_0.5	fluoroestradiol	drug_umls_atom	Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? ----A Pilot Study	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC3804456_20201005_0.5			Adult|Aged|Breast Neoplasms|Chemotherapy, Adjuvant|Estradiol|Female|Fluorine|Fluorodeoxyglucose F18|Humans|Middle Aged|Neoadjuvant Therapy|Pilot Projects|Positron-Emission Tomography|Radiopharmaceuticals|Tomography, X-Ray Computed	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC3804456_20201005_0.5	fluoroestradiol	drug_umls_atom	Objective To assess the clinical value of dual tracers Positron emission tomography/computed tomography (PET/CT) F-fluoroestradiol ( F-FES) and F-fluorodeoxyglucose ( F-FDG) in predicting neoadjuvant chemotherapy response (NAC) of breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32699974_20210511_0.5			Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using 18F-FES and 18F-4FMFES PET Imaging.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32699974_20210511_0.5			4FMFES|Brain PET|Estrogen receptor|FES	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32699974_20210511_0.5	fluoroestradiol	drug_umls_atom	Animals|Humans|Female|Mice|Rats|Middle Aged|Receptors, Estrogen|11-methoxy-4,16-difluoroestradiol|Retrospective Studies|Tomography, X-Ray Computed|Rats, Sprague-Dawley|Estradiol|16-fluoroestradiol|Positron-Emission Tomography|Estrogens|Breast Neoplasms|Cell Line, Tumor|Brain	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32699974_20210511_0.5	fluoroestradiol	drug_umls_atom	No section A retrospective analysis was performed of preclinical and clinical data acquired during the evaluation of the estrogen receptor (ER) PET tracer 4-fluoro-11β-methoxy-16α-[18F]-fluoroestradiol (4FMFES) and its comparison with 16α-[18F]-fluoroestradiol (FES) in mice, rats, and humans with a focus on the brain uptake.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5	fluoroestradiol	drug_umls_atom	Long-term Trace of Radiation Pneumonitis With 18F-Fluoroestradiol.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5			Asymptomatic Diseases|Breast Neoplasms|Estradiol|Female|Fluorine Radioisotopes|Humans|Positron-Emission Tomography|Radiation Pneumonitis	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5	fluoroestradiol	drug_umls_atom	Only 1 case of fluoroestradiol uptake contemporary of metabolic FDG changes attributed to RP is reported.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32657871_20210211_0.5	fluoroestradiol	drug_umls_atom	We report a case of a breast cancer patient with asymptomatic RP, who at 1 year later, at sequelar stage on CT, showed long-term memory of RP by F-fluoroestradiol PET imaging with nonmetabolic FDG PET.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27491481_20201005_0.5			Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27491481_20201005_0.5			Breast cancer|FES-PET|Lapatinib|Letrozole|Neoadjuvant|Postmenopausal|TILs	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27491481_20201005_0.5			Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Biomarkers, Tumor|Breast Neoplasms|Combined Modality Therapy|Female|Humans|Lapatinib|Letrozole|Lymphocyte Count|Lymphocytes, Tumor-Infiltrating|Mastectomy|Middle Aged|Neoadjuvant Therapy|Nitriles|Positron-Emission Tomography|Postmenopause|Quinazolines|Receptor, ErbB-2|Receptors, Estrogen|Triazoles	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27491481_20201005_0.5	fluoroestradiol	drug_umls_atom	Baseline fluorine-18 fluorodeoxyglucose and fluorine-18 fluoroestradiol PET-CT scans were performed.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33008930_20210611_0.5			Prognostic Value of 16α-18F-Fluoro-17β-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33008930_20210611_0.5			18F-FDG|16alpha-18F-fluoro-17beta-estradiol (18F-FES)|PET/CT|endometrial cancer|prognostic marker	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33008930_20210611_0.5	fluoroestradiol	drug_umls_atom	Humans|Middle Aged|Adult|Female|Prospective Studies|Prognosis|Fluorodeoxyglucose F18|Positron-Emission Tomography|Endometrial Neoplasms|Radiopharmaceuticals|16-fluoroestradiol|Estradiol|Lymphatic Metastasis|Gene Expression Regulation, Neoplastic	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7546761_20210111_0.5	fluoroestradiol	drug_umls_atom	Quick Automatic Synthesis of Solvent-Free 16α-[18F] Fluoroestradiol: Comparison of Kryptofix 222 and Tetrabutylammonium Bicarbonate	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7546761_20210111_0.5	fluoroestradiol	drug_umls_atom	16alpha-[18F]fluoroestradiol|automatic synthesis|breast cancer|estrogen receptor|phase transfer catalyst	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7546761_20210111_0.5			Humans|Female|Bicarbonates|cryptating agent 222|tetrabutylammonium|Solvents|Bridged Bicyclo Compounds, Heterocyclic|Quaternary Ammonium Compounds|Radiopharmaceuticals|Fluorine Radioisotopes|Radiochemistry|Receptors, Estrogen|Positron-Emission Tomography|Breast Neoplasms|Estradiol|Chromatography, High Pressure Liquid|Automation	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30137103_20201005_0.5			Fast and reliable generation of [18F]triflyl fluoride, a gaseous [18F]fluoride source.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30137103_20201005_0.5	fluoroestradiol	drug_umls_atom	The reactivity of the [18F]fluoride has been confirmed by reaction with several model compounds and by the synthesis of the PET tracers [18F]fluoroestradiol ([18F]FES) and O-2-[18F]fluoroethyl-l-tyrosine ([18F]FET), providing good isolated radiochemical yields and molar activities of up to 123 GBq μmol-1.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7745867_20210111_0.5			Evaluation of estrogen expression of breast cancer using 18F-FES PET CT-A novel technique	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7745867_20210111_0.5	fluoroestradiol	drug_umls_atom	Breast cancer|estrogen receptor|fluoroestradiol positron emission tomography|positron emission tomography	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7745867_20210111_0.5	fluoroestradiol	drug_umls_atom	Humans|Middle Aged|Female|Positron Emission Tomography Computed Tomography|Breast Neoplasms|16-fluoroestradiol|estradiol-16|Estradiol|Receptors, Estrogen|Estrogens|Fluorine Radioisotopes|Positron-Emission Tomography|Immunohistochemistry|Biopsy|ROC Curve	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7745867_20210111_0.5	fluoroestradiol	drug_umls_atom	The aim was to study ER expression using 16α- F-fluoro-17β-estradiol or F-fluoroestradiol ( F FES) positron emission tomography (PET) computed tomography (CT).	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	fluoroestradiol	drug_umls_atom	Automated SPE-based synthesis of 16α-[18F]fluoroestradiol without HPLC purification step.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	fluoroestradiol	drug_umls_atom	16α-[(18)F]fluoroestradiol|Estrogen receptor|Fluorine-18|PET|SPE purification|[(18)F]FES	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5			Automation|Breast Neoplasms|Chromatography, High Pressure Liquid|Estradiol|Female|Fluorine Radioisotopes|Humans|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Solid Phase Extraction	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	fluoroestradiol	drug_umls_atom	No section [18F]fluoroestradiol ([18F]FES) is well-established PET radiotracer for diagnosing and monitoring treatment of estrogen-positive breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID30176563_20201005_0.5	fluoroestradiol	drug_umls_atom	All purity parameters were well within specifications recommended in the Investigator's Brochure for [18F]Fluoroestradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29602822_20201005_0.5	fluoroestradiol	drug_umls_atom	18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29602822_20201005_0.5	fluoroestradiol	drug_umls_atom	18F-fluoroestradiol PET|breast cancer|estrogen receptor|tumor heterogeneity|tumor microenvironment	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID29602822_20201005_0.5			Adult|Aged|Aged, 80 and over|Biological Transport|Breast Neoplasms|Estradiol|Female|Gene Expression Regulation, Neoplastic|Humans|Middle Aged|Neoplasm Metastasis|Positron Emission Tomography Computed Tomography|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25829085_20201005_0.5			PET Imaging of Breast Cancer: Role in Patient Management.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25829085_20201005_0.5	fluoroestradiol	drug_umls_atom	Breast cancer imaging|FDG PET|FES|Fluoroestradiol imaging|Metabolic imaging|Prognosis	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID25829085_20201005_0.5			Adult|Aged|Breast Neoplasms|Carcinoma, Ductal, Breast|Estradiol|Female|Fluorodeoxyglucose F18|Humans|Middle Aged|Neoadjuvant Therapy|Neoplasm Recurrence, Local|Positron-Emission Tomography|Radiopharmaceuticals	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5	fluoroestradiol	drug_umls_atom	Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[18F]fluoroestradiol ([18F]FES) for human breast cancer imaging.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5	fluoroestradiol	drug_umls_atom	16alpha-[(18)F]Fluoroestradiol ([(18)F]FES)|Automation|Breast cancer imaging|Estrogen receptor (ER)|Positron emission tomography (PET)|Radiosynthesis	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5			Automation|Breast Neoplasms|Chromatography, High Pressure Liquid|Estradiol|Female|Fluorine Radioisotopes|Humans|Quality Control|Radiopharmaceuticals|Receptors, Estrogen|Solid Phase Extraction	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID32174461_20210511_0.5	fluoroestradiol	drug_umls_atom	No section 16α-[18F]Fluoroestradiol ([18F]FES) is the most successful estrogen receptor (ER) targeting radiopharmaceutical to date. [	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27856629_20201214_0.5			Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27856629_20201214_0.5	fluoroestradiol	drug_umls_atom	18F-fluoroestradiol|breast cancer|estrogen receptor|molecular imaging|neoadjuvant therapy	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27856629_20201214_0.5			Aged|Breast Neoplasms|Estradiol|Feasibility Studies|Female|Humans|Middle Aged|Neoadjuvant Therapy|Positron Emission Tomography Computed Tomography|Postmenopause|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID16682724_20201005_0.5	fluoroestradiol	drug_umls_atom	Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID16682724_20201005_0.5			Adult|Aged|Antineoplastic Agents, Hormonal|Aromatase Inhibitors|Bone Neoplasms|Breast Neoplasms|Estradiol|Female|Fluorine Radioisotopes|Humans|Male|Middle Aged|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Salvage Therapy|Tamoxifen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID16682724_20201005_0.5	fluoroestradiol	drug_umls_atom	OBJECTIVE In breast cancer, [(18)F]fluoroestradiol (FES) positron emission tomography (PET) correlates with estrogen receptors (ER) expression and predicts response to tamoxifen.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33990400_20210611_0.5			Value of 18F-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33990400_20210611_0.5			FES-PET|Molecular Imaging|Oncology: Breast|PET/CT|breast cancer|clinical dilemma|conventional imaging	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID33990400_20210611_0.5	fluoroestradiol	drug_umls_atom	Humans|Adult|Middle Aged|Female|Retrospective Studies|Breast Neoplasms|Tomography, X-Ray Computed|Receptors, Estrogen|16-fluoroestradiol|Estradiol|Positron-Emission Tomography|Fluorodeoxyglucose F18|Positron Emission Tomography Computed Tomography|Biopsy	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5	fluoroestradiol	drug_umls_atom	Alternative synthesis for the preparation of 16α-[(18) F]fluoroestradiol.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5	fluoroestradiol	drug_umls_atom	16α-[18F]Fluoroestradiol|PET|[18F]FES|imaging of estrogen receptor|radiopharmaceutical	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5			Estradiol|Isotope Labeling|Radiopharmaceuticals	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID24285238_20201005_0.5	fluoroestradiol	drug_umls_atom	No section We have developed a new precursor, 3,17β-O-bis(methoxymethyl)-16β-O-p-nitrobenzenesulfonylestriol (14c) of 16α-[(18) F]fluoroestradiol ([(18) F]FES).	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID7769466_20201005_0.5			Designing steroid receptor-based radiotracers to image breast and prostate tumors.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID7769466_20201005_0.5			Breast Neoplasms|Female|Humans|Male|Molecular Structure|Prostatic Neoplasms|Radioisotopes|Radionuclide Imaging|Receptors, Androgen|Receptors, Estrogen|Receptors, Progesterone|Receptors, Steroid	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID7769466_20201005_0.5	fluoroestradiol	drug_umls_atom	Breast tumors in patients have been imaged with [18F]fluoroestradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27872957_20210311_0.5	fluoroestradiol	drug_umls_atom	Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27872957_20210311_0.5	fluoroestradiol	drug_umls_atom	18F-FES|Fluoroestradiol|Pharmacodynamic marker|Positron emission tomography (PET)|Z-endoxifen	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27872957_20210311_0.5			Adult|Aged|Breast Neoplasms|Breast Neoplasms, Male|Estradiol|Estrogen Antagonists|Female|Genital Neoplasms, Female|Humans|Male|Middle Aged|Positron Emission Tomography Computed Tomography|Radiopharmaceuticals|Receptors, Estrogen|Tamoxifen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC4554736_20201005_0.5	fluoroestradiol	drug_umls_atom	Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC4554736_20201005_0.5			Oestrogen receptor|Imaging|Breast cancer|Oestradiol therapy	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC4554736_20201005_0.5			Adult|Aged|Biological Transport|Biomarkers, Tumor|Bone and Bones|Breast Neoplasms|Drug Resistance, Neoplasm|Estradiol|Female|Humans|Male|Middle Aged|Positron-Emission Tomography|Predictive Value of Tests|Treatment Outcome	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5			Catechol formation of fluoro- and bromo-substituted estradiols by hamster liver microsomes. Evidence for dehalogenation.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5			Animals|Biotransformation|Bromine|Chromatography, High Pressure Liquid|Cricetinae|Estradiol|Estrogens|Estrogens, Catechol|Fluorine|Hydroxylation|In Vitro Techniques|Kidney Neoplasms|Male|Mesocricetus|Microsomes, Liver	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5	fluoroestradiol	drug_umls_atom	Liver microsomes from castrated hamsters were incubated with 2-fluoro-, 4-fluoro-, or 2,4-difluoroestradiols and analogous bromo-substituted estradiols to determine the extent of 2- and 4-hydroxylation with these substrates.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5	fluoroestradiol	drug_umls_atom	The monosubstituted fluoroestradiols exhibited more than a 2-fold enhanced ability to form catechol estrogens compared with their corresponding bromoestradiols.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5	fluoroestradiol	drug_umls_atom	Data presented herein indicate substantial defluorination when 2-fluoroestradiol was the substrate, which amounted to 36% of the total product formed, and 32% of the rate of 2-hydroxylation found with unsubstituted 17 beta-estradiol as substrate.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5	fluoroestradiol	drug_umls_atom	Interestingly, the rate of 4-hydroxylation was elevated 20- and 6.7-fold, respectively, when 2-fluoroestradiol and 2,4-difluoroestradiol were the substrates compared to the rate with 17 beta-estradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5	fluoroestradiol	drug_umls_atom	Moreover, both 4-fluoroestradiol and 2,4-difluoroestradiol exhibited at least a 1.6-fold greater rate of 2-hydroxylation compared with 17 beta-estradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2985951_20201005_0.5	fluoroestradiol	drug_umls_atom	In contrast, the rate of dehalogenation with 2-bromoestradiol was only 12% of that found with 2-fluoroestradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC8021033_20210511_0.5			[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC8021033_20210511_0.5	fluoroestradiol	drug_umls_atom	18F-fluoro-deoxyglucose (18F-FDG)|18F-fluoroestradiol (18F-FES)|granulosa cell tumors (GCTs)|hormone receptors|positron emission tomography (PET)	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC8021033_20210511_0.5			Humans|Adult|Middle Aged|Male|Female|Fluorodeoxyglucose F18|Ovary|Granulosa Cell Tumor|Tomography, X-Ray Computed|Positron-Emission Tomography|Radiopharmaceuticals|Receptors, Estrogen|Estrogen Receptor alpha|Biological Transport|Immunohistochemistry|Ovarian Neoplasms	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5	fluoroestradiol	drug_umls_atom	18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5	fluoroestradiol	drug_umls_atom	18F-fluoroestradiol|breast cancer|estrogen receptor|positron emission tomography	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5			Breast Neoplasms|Estradiol|Forecasting|Humans|Image Enhancement|Molecular Imaging|Positron-Emission Tomography|Receptors, Estrogen	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID27307345_20201005_0.5	fluoroestradiol	drug_umls_atom	However, recent advances have allowed in vivo evaluation of ER expression with (18)F-fluoroestradiol ((18)F-FES) PET.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2013803_20201005_0.5			The applications of PET in clinical oncology.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2013803_20201005_0.5			Brain Neoplasms|Colorectal Neoplasms|Deoxyglucose|Fluorodeoxyglucose F18|Humans|Lung Neoplasms|Neoplasms|Tomography, Emission-Computed	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID2013803_20201005_0.5	fluoroestradiol	drug_umls_atom	A variety of radiopharmaceuticals are described that are currently included in clinical tumor-imaging protocols, including metabolic substrates such as fluorine-18-fluorodeoxyglucose and carbon-11-methionine, and analogs of chemotherapeutic agents such as fluorine-18-fluorouracil and fluoroestradiol.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID3019933_20201005_0.5	fluoroestradiol	drug_umls_atom	NCA 16 alpha-[18F]fluoroestradiol-17 beta: the effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID3019933_20201005_0.5			Estradiol|Fluorine|Isotope Labeling|Radioisotopes|Radioligand Assay	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID3019933_20201005_0.5	fluoroestradiol	drug_umls_atom	Reduction in the amount of carrier fluoride in the target water improved the effective specific activity of the product, but with a concommitant decrease in the resolubilized yield of the fluoroestradiol (12.7%).	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID3019933_20201005_0.5	fluoroestradiol	drug_umls_atom	Of the vessels (Pt crucible, borosilicate glass, siliconized borosilicate glass, Vacutainer), the Vacutainer afforded the highest resolubilization of 18F into THF (90%), resulting in an improved resolubilized yield for the fluoroestradiol (28%) and an increased effective specific activity at EOS for the product (1600-3939 Ci/mmol).	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID23787040_20201005_0.5	fluoroestradiol	drug_umls_atom	Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID23787040_20201005_0.5	fluoroestradiol	drug_umls_atom	Breast cancer|Estrogen receptor|Fluorine-18 fluorodeoxyglucose positron emission tomography|Heterogeneity|fluorine-18 fluoroestradiol positron emission tomography	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID23787040_20201005_0.5			Adult|Aged|Breast Neoplasms|Estradiol|Female|Fluorine Radioisotopes|Genetic Heterogeneity|Humans|Middle Aged|Multimodal Imaging|Neoplasm Metastasis|Positron-Emission Tomography|Receptors, Estrogen|Retrospective Studies|Tomography, X-Ray Computed	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID23787040_20201005_0.5	fluoroestradiol	drug_umls_atom	OBJECTIVE Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5	fluoroestradiol	drug_umls_atom	The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5			Cyclic S-Oxides|Estradiol|Estriol|Fluorine Radioisotopes|Hydrolysis|Indicators and Reagents|Isotope Labeling|Magnetic Resonance Spectroscopy|Molecular Structure|Time Factors	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5	fluoroestradiol	drug_umls_atom	No section We have prepared 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone (1c) and used it as a substrate for the production of F-18 16 alpha-fluoroestradiol, via nucleophilic fluorination with fluoride ion.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5	fluoroestradiol	drug_umls_atom	Labeled fluoroestradiol is isolated at the end of a 1-2 h synthesis, depending on the hydrolysis method of 30-45% chemical (decay corrected) yield with respect to fluoride, with a specific activity > 1 Ci per micromole.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5	fluoroestradiol	drug_umls_atom	Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5			Breast cancer|Estrogen receptor|[|[	author_keywords
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5			Middle Aged|Humans|Female|Fluorodeoxyglucose F18|Breast Neoplasms|Prospective Studies|Neoplasm Recurrence, Local|Positron Emission Tomography Computed Tomography|Positron-Emission Tomography|Fluorine Radioisotopes|Receptors, Estrogen|Tomography, X-Ray Computed|Estradiol|Fluorine Compounds|Chronic Disease|Estrogens	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMC7246280_20201005_0.5	fluoroestradiol	drug_umls_atom	Background To compare the diagnostic sensitivity of [ F]fluoroestradiol ([ F]FES) and [ F]fluorodeoxyglucose ([ F]FDG) positron emission tomography/computed tomography (PET/CT) for breast cancer recurrence in patients with estrogen receptor (ER)-positive primary breast cancer.	abstract
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5	f-18 16 alpha-fluoroestradiol	drug_umls_atom	The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol.	title
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5			Cyclic S-Oxides|Estradiol|Estriol|Fluorine Radioisotopes|Hydrolysis|Indicators and Reagents|Isotope Labeling|Magnetic Resonance Spectroscopy|Molecular Structure|Time Factors	mesh_terms
18f-fluoroestradiol	Z0000017145			fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol	inn	PubMed	PMID8971859_20201005_0.5	f-18 16 alpha-fluoroestradiol	drug_umls_atom	No section We have prepared 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone (1c) and used it as a substrate for the production of F-18 16 alpha-fluoroestradiol, via nucleophilic fluorination with fluoride ion.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29300107_20201005_0.5	dextrose monohydrate	drug_name	Dextrose monohydrate as a non-animal sourced alternative diluent in high shear wet granulation tablet formulations.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29300107_20201005_0.5	dextrose monohydrate	drug_name	Dextrose monohydrate|disintegration time|high shear wet granulation|in vitro dissolution|tensile strength	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29300107_20201005_0.5			Desiccation|Excipients|Glucose|Powders|Tablets|Tensile Strength|Theophylline|Water	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29300107_20201005_0.5	dextrose monohydrate	drug_name	No section The feasibility of dextrose monohydrate as a non-animal sourced diluent in high shear wet granulation (HSWG) tablet formulations was determined.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29300107_20201005_0.5	dextrose monohydrate	drug_name	Following post-granulation drying at 60 °C, dextrose monohydrate lost 9% water and converted into the anhydrate form.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29300107_20201005_0.5	dextrose monohydrate	drug_name	This study clearly demonstrated the utility of dextrose monohydrate as a non-animal sourced diluent in a HSWG tablet formulation.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7581924_20210111_0.5			Assessing the biodegradability of common pharmaceutical products (PPs) on the Zambian market	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7581924_20210111_0.5			Biodegradation|Inoculum|Pharmaceutical chemistry|Pharmaceuticals|Theoretical carbon dioxide	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7581924_20210111_0.5			Humans|Pharmaceutical Preparations|Ecosystem|Biodegradation, Environmental|Waste Disposal, Fluid|Sewage|Water Pollutants, Chemical|Organic Chemicals|Bacteria|Carbon Dioxide	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7581924_20210111_0.5	dextrose monohydrate	drug_name	The inoculum was derived from the secondary effluent of the UNZA WWTP plant and Dextrose monohydrate was used as a system control.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7581924_20210111_0.5	dextrose monohydrate	drug_name	Using this guideline, the system control, dextrose monohydrate biodegraded 77 ± 0.270% in seven days.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29380296_20201005_0.5			A Novel 2-Keto-D-Gluconic Acid High-Producing Strain Arthrobacter globiformis JUIM02.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29380296_20201005_0.5			2-Keto-D-gluconic acid|Arthrobacter globiformis|Bioconversion|Fermentation|Resting cell	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29380296_20201005_0.5			Arthrobacter|Fermentation|Sugar Acids	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29380296_20201005_0.5	dextrose monohydrate	drug_name	The 2KGA synthetic capacity of A. globiformis JUIM02 was evaluated by both fermentation and bioconversion, with 180 g/L dextrose monohydrate as substrates, in shake flasks and 5 L fermenters.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID9829362_20201005_0.5			Effects of diabetes and hyperglycemia on disaccharidase activities in the rat.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID9829362_20201005_0.5			Animals|Blood Glucose|Diabetes Mellitus, Experimental|Disaccharidases|Hyperglycemia|Intestinal Mucosa|Intestine, Small|Kidney Cortex|Male|Rats|Rats, Wistar	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID9829362_20201005_0.5	dextrose monohydrate	drug_name	The rats were made hyperglycemic with an intravenous instillation of a solution containing 40% dextrose monohydrate at a rate of 1.5 ml/h for 24 h. RESULTS The blood glucose level was 387+/-45 mg/dl and 382+/-35 mg/dl (mean +/- standard deviation) in diabetic and hyperglycemic rats, respectively.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID23630052_20201005_0.5			The effect of beta-alanine supplementation on isokinetic force and cycling performance in highly trained cyclists.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID23630052_20201005_0.5			Administration, Oral|Adolescent|Adult|Athletes|Athletic Performance|Bicycling|Dietary Supplements|Double-Blind Method|Humans|Hydrogen-Ion Concentration|Lactic Acid|Male|Muscle Strength|Oxygen Consumption|Physical Endurance|Sports Nutritional Physiological Phenomena|Young Adult|beta-Alanine	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID23630052_20201005_0.5	dextrose monohydrate	drug_name	Sixteen highly trained cyclists (mean ± SD; age = 24 ± 7 yr; mass = 70 ± 7 kg; VO2max = 67 ± 4 ml · kg(-1) · min(-1)) supplemented with either beta-alanine (n = 8, 65 mg · kg - 1BM) or a placebo (n = 8; dextrose monohydrate) over 4 weeks.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6795923_20201005_0.5			Stability of amino acids and the availability of acid in total parenteral nutrition solutions containing hydrochloric acid.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6795923_20201005_0.5			Alkalosis|Amino Acids|Colorimetry|Drug Stability|Humans|Hydrochloric Acid|Hydrogen-Ion Concentration|Parenteral Nutrition|Parenteral Nutrition, Total|Tryptophan	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6795923_20201005_0.5	dextrose monohydrate	drug_name	Hydrochloric acid in the concentrations of 40 (TPN 1), 60 (TPN 2), and 100 (TPN 3) meq/liter was added to TPN solutions (4.25% amino acids, 25% dextrose monohydrate) containing various electrolytes (TPN control).	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID16942848_20201005_0.5			Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID16942848_20201005_0.5			Aerosols|Albuterol|Chemistry, Pharmaceutical|Chromatography, High Pressure Liquid|Crystallization|Glass|Glucose|Lactose|Lasers|Maltose|Microscopy, Electron, Scanning|Particle Size|Powders|Scattering, Radiation|Sorbitol	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID16942848_20201005_0.5	dextrose monohydrate	drug_name	Five different formulations were prepared, each containing 1.5% (w/w) micronised salbutamol base (volume median diameter: 2.42 microm) blended with the sieved fraction (63-90 microm) of one of the following sugars: regular crystalline lactose, spray dried lactose "Zeparox", sorbitol, maltose and dextrose monohydrate.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3190967_20201005_0.5			Fetal blood flow during intrathecal anaesthesia for elective caesarean section.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3190967_20201005_0.5			Adult|Anesthesia, Obstetrical|Anesthesia, Spinal|Aorta, Thoracic|Blood Flow Velocity|Blood Pressure|Cesarean Section|Female|Fetus|Heart Rate|Humans|Pregnancy|Pulsatile Flow|Regional Blood Flow|Umbilical Arteries	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3190967_20201005_0.5	glucose monohydrate	drug_umls_atom	Spinal anaesthesia with 0.5% bupivacaine hydrochloride 2.5 ml in 8% glucose monohydrate solution was administered after preloading with 2 litre of lactated Ringer's solution.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID28657863_20201005_0.5			Carbohydrate intake and training efficacy - a randomized cross-over study.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID28657863_20201005_0.5	glucose monohydrate	drug_umls_atom	Glucose monohydrate|aerobic exercise|maximum oxygen uptake|physiological adaptation	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID28657863_20201005_0.5			Adaptation, Physiological|Adult|Anaerobic Threshold|Blood Glucose|Cross-Over Studies|Dietary Carbohydrates|Exercise Test|Female|Heart Rate|Humans|Male|Middle Aged|Oxygen Consumption|Physical Conditioning, Human|Physical Endurance|Prospective Studies|Pulmonary Gas Exchange	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3432196_20201005_0.5			Metabolizable energy content of pearl millet [Pennisetum americanum (L.) Leeke].	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3432196_20201005_0.5			Animal Feed|Animals|Chickens|Edible Grain|Energy Metabolism|Nutritive Value	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3432196_20201005_0.5	glucose monohydrate	drug_umls_atom	On a dry matter basis, 40% ground pearl millet was substituted for an equivalent amount of glucose monohydrate (reference substance) to determine MEn using male broiler chicks.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID20494339_20201005_0.5			Amorphization of sugar hydrates upon milling.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID20494339_20201005_0.5			Calorimetry, Differential Scanning|Carbohydrates|Food Handling|Glucose|Lactose|Phase Transition|Trehalose|Water|X-Ray Diffraction	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID20494339_20201005_0.5	glucose monohydrate	drug_umls_atom	We test here the possibility to amorphize the corresponding crystalline hydrates: lactose monohydrate, trehalose dihydrate and glucose monohydrate using fully identical milling procedures.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6585801_20201005_0.5			Complex carbohydrate diets are not capable of maintaining normal plasma calcium and phosphorus levels in vitamin D-deficient rats.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6585801_20201005_0.5			Animals|Calcium|Dietary Carbohydrates|Flour|Glucose|Phosphates|Rats|Vitamin D Deficiency	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6585801_20201005_0.5	glucose monohydrate	drug_umls_atom	No section Substitution of Cerelose (glucose monohydrate) for complex carbohydrate (whole wheat flour) does not alter plasma calcium levels in vitamin D-deficient rats, contrary to a previous report.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5331566_20201005_0.5			The Acute Effects of Simple Sugar Ingestion on Appetite, Gut-Derived Hormone Response, and Metabolic Markers in Men	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5331566_20201005_0.5			glucose|fructose|sucrose|sugar ingestion|appetite|gut hormones|ghrelin|GLP-1|hepatic metabolism	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5331566_20201005_0.5			Adult|Appetite|Biomarkers|Blood Glucose|Body Mass Index|Body Weight|Fatty Acids, Nonesterified|Fructose|Gastric Inhibitory Polypeptide|Gastrointestinal Hormones|Ghrelin|Glucagon-Like Peptide 1|Humans|Hydroxybutyrate Dehydrogenase|Insulin|Lactic Acid|Male|Nutritive Sweeteners|Single-Blind Method|Surveys and Questionnaires|Triglycerides|Young Adult	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5331566_20201005_0.5	glucose monohydrate	drug_umls_atom	Seven healthy men ingested water (W) and equicaloric solutions containing 39.6 g glucose monohydrate (G), 36 g fructose (F), 36 g sucrose (S), and 19.8 g glucose monohydrate + 18 g fructose (C), in a randomised order.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID19997292_20201005_0.5			Dual-frequency imaging using an electrically tunable terahertz quantum cascade laser.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID19997292_20201005_0.5			Glucose|Lactose|Lasers, Semiconductor|Optics and Photonics|Pentaerythritol Tetranitrate|Powders|Quantum Theory|Sucrose|Terahertz Radiation|Terahertz Spectroscopy	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID19997292_20201005_0.5	glucose monohydrate	drug_umls_atom	By taking the difference of the natural logarithms of the transmission coefficients obtained at each frequency, the difference-attenuation coefficient is determined, and evaluated for samples of lactose monohydrate, glucose monohydrate, sucrose, and the high explosive PETN.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID19335244_20201005_0.5			Efficacy of oral rehydration therapy solutions containing sodium bicarbonate or sodium acetate for treatment of calves with naturally acquired diarrhea, moderate dehydration, and strong ion acidosis.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID19335244_20201005_0.5			Abomasum|Acid-Base Equilibrium|Acidosis|Animals|Animals, Newborn|Cattle|Cattle Diseases|Dehydration|Diarrhea|Dose-Response Relationship, Drug|Fluid Therapy|Prospective Studies|Random Allocation|Sodium Acetate|Sodium Bicarbonate|Treatment Outcome	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID19335244_20201005_0.5	glucose monohydrate	drug_umls_atom	The 4 test solutions contained acetaminophen (50 mg/kg [22.7 mg/lb]) and 50 g of glucose monohydrate.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7411459_20201005_0.5			Does lying on the right side increase the rate of gastric emptying?	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7411459_20201005_0.5			Functional Laterality|Gastric Emptying|Humans|Middle Aged|Posture	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7411459_20201005_0.5	glucose monohydrate	drug_umls_atom	test meals of a solution of glucose monohydrate (100 g/l.) given to the same subjects in the same positions, but the recoveries of this more slowly emptying solution were made at 20 min.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3891706_20201005_0.5			Effect of 1,3-butanediol and short chain acids in sow gestation diets on maternal plasma metabolites and fetal energy storage.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3891706_20201005_0.5			3-Hydroxybutyric Acid|Acetates|Acetic Acid|Animal Feed|Animals|Animals, Newborn|Blood Glucose|Butylene Glycols|Energy Metabolism|Fasting|Fatty Acids, Nonesterified|Female|Glucagon|Glucose|Hydroxybutyrates|Insulin|Lactates|Lactic Acid|Liver Glycogen|Male|Pregnancy|Pregnancy, Animal|Swine	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3891706_20201005_0.5	glucose monohydrate	drug_umls_atom	No section Gestating sows were fed diets in which 15% of the metabolizable energy was in the form of glucose monohydrate (control), 1,3-butanediol (BD) or an equimolar mixture of acetate and lactate (AL) in order to study the effects of ketogenic, glucogenic and lipogenic substrates on fetal energy storage.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID935025_20201005_0.5			Influence of carbohydrate source on liver fat accumulation in hens.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID935025_20201005_0.5			Animal Feed|Animals|Chickens|Dietary Carbohydrates|Edible Grain|Eggs|Female|Glucose|Lipid Metabolism|Liver|Male|Oviposition|Triticum|Zea mays	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID935025_20201005_0.5	glucose monohydrate	drug_umls_atom	No difference in liver weight, liver fat content and total fat per liver was observed among hens fed diets containing either zero, one-half, or all glucose monohydrate substituted for corn.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID833670_20201005_0.5			Dietary influences on gastric emptying of carbohydrate versus fat in the rat.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID833670_20201005_0.5			Animals|Dietary Carbohydrates|Dietary Fats|Dietary Proteins|Gastric Mucosa|Glucose|Intestinal Absorption|Male|Rats|Starvation|Time Factors	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID833670_20201005_0.5	glucose monohydrate	drug_umls_atom	Use of finely divided glucose monohydrate, dried crystalline glucose or of cornstarch resulted, respectively, in high, intermediate and low gastric emptying ratios.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID1156929_20201005_0.5			The utilisation of various fats by turkeys of different ages.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID1156929_20201005_0.5			Age Factors|Animals|Body Weight|Dietary Fats|Energy Metabolism|Fatty Acids|Female|Intestinal Absorption|Male|Turkeys	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID1156929_20201005_0.5	glucose monohydrate	drug_umls_atom	The utilisation of fat and fatty acids supplied as maize oil, tallow or lard in the diet of 2-, 4- and 8-week old turkeys has been investigated: a mixture of 10% fat and 15% cellulose replaced glucose monohydrate in a low-fat basal diet.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29982786_20201005_0.5			Effects of Feeding Honey Bees (Hymenoptera: Apidae) With Industrial Sugars Produced by Plants Using Different Photosynthetic Cycles (Carbon C3 and C4) on the Colony Wintering Ability, Lifespan, and Forage Behavior.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29982786_20201005_0.5			Animals|Beekeeping|Bees|Behavior, Animal|Dietary Sugars|Longevity|Seasons	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID29982786_20201005_0.5	glucose monohydrate	drug_umls_atom	No section In the study, 130 honey bee colonies fed with different levels (5, 20, and 100 liters/colony) of various industrial commercial sugars, including High-Fructose Corn 85 (Fructose-85), High-Fructose Corn 55 (Fructose-55), Glucose Monohydrate (Glucose), Bee feed, and Sucrose syrups, for 2 mo were compared with colonies fed with no sugar (control) in terms of their colony development of worker bee population, hive weight, wax production, wintering ability, foraging behavior, and lifespan of worker bee.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3760995_20201214_0.5			Expressing the variability in results of metabolizable energy assays.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3760995_20201214_0.5			Analysis of Variance|Animal Feed|Animals|Energy Metabolism|Food|Mathematics	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3760995_20201214_0.5	glucose monohydrate	drug_umls_atom	No section In estimating the metabolizable energy of a food or feedstuff (MEf), the ME of a reference diet (MEr, containing glucose monohydrate) and the ME of a test (MEt, containing the feedstuff substituted for glucose) are determined from a feeding trial: MEf = MEglucose -1/P (MEr - MEt) where P is a proportion of substitution.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID866412_20201005_0.5			Lyoluminescence dosimetry with some saccharides.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID866412_20201005_0.5			Disaccharides|Fast Neutrons|Gamma Rays|Glucose|Luminescent Measurements|Mannose|Monosaccharides|Radiometry|Sucrose|Trehalose|X-Rays	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID866412_20201005_0.5	glucose monohydrate	drug_umls_atom	No section Lyoluminescent properties of mannose, glucose monohydrate, sucrose and trehalose dihydrate were investigated from the point of view of suitability as dosimetric materials in a new system of solid state dosimetry.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21831365_20201005_0.5	glucose monohydrate	drug_umls_atom	Kinetic studies on the loss of water from α-D-glucose monohydrate.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21831365_20201005_0.5			Diffusion|Glucose|Kinetics|Water	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21831365_20201005_0.5	glucose monohydrate	drug_umls_atom	No section Although the dehydration of α-D-glucose monohydrate is an important aspect of several industrial processes, there is uncertainty with regard to the applicable rate law and other factors that affect dehydration.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21831365_20201005_0.5	glucose monohydrate	drug_umls_atom	Therefore, the dehydration of three glucose monohydrate samples has been studied using isothermal gravimetric analysis.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3447140_20201005_0.5			Deficient amino acids in protein of dehulled soybean meal for young turkeys.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3447140_20201005_0.5			Amino Acids|Animal Feed|Animals|Dietary Proteins|Plant Proteins|Soybeans|Turkeys	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3447140_20201005_0.5	glucose monohydrate	drug_umls_atom	A 22% protein basal diet composed of 43.3% glucose monohydrate, 45.4% dehulled soybean meal, .5% DL-methionine, 6% stabilized fat, and added minerals and vitamins served as the negative control.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3447140_20201005_0.5	glucose monohydrate	drug_umls_atom	Two positive control diets were formed by substituting either 16.5% dehulled soybean meal or a mixture containing amounts of essential amino acids equivalent to those in the added dehulled soybean meal in place of an equal amount of glucose monohydrate in the basal diet.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8401124_20201005_0.5			Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8401124_20201005_0.5			Blood Glucose|Body Mass Index|Case-Control Studies|Coronary Disease|Female|Glucose Tolerance Test|Humans|Isomerism|Lipoprotein(a)|Male|Middle Aged	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8401124_20201005_0.5	glucose monohydrate	drug_umls_atom	 METHODS Serum Lp(a) lipoprotein concentration, plasma glucose concentration before and after oral challenge with 75 g glucose monohydrate, and Lp(a) lipoprotein isoforms.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25308254_20201005_0.5			Determining the mechanism and parameters of hydrate formation and loss in glucose.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25308254_20201005_0.5	glucose monohydrate	drug_umls_atom	anhydrous glucose|glucose monohydrate|hydrate formation|hydrate loss|solid-state kinetics	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25308254_20201005_0.5			Crystallization|Glucose|Spectrum Analysis, Raman|Temperature|Thermogravimetry|Water	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25308254_20201005_0.5	glucose monohydrate	drug_umls_atom	Hydrate formation in alpha-anhydrous glucose (α-AG) and hydrate loss in glucose monohydrate (GM) were studied under equilibrium conditions at various relative humidity (RH) values using saturated salt slurries for 1 y. The mechanism of hydrate formation and hydrate loss were determined through mathematical modeling of Dynamic Vapor Sorption data and Raman spectroscopy was used to confirm the mechanisms.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID14325281_20210611_0.5			HETEROTROPHIC GROWTH AND PRODUCTION OF XANTHOPHYLLS BY CHLORELLA PYRENOIDOSA.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID14325281_20210611_0.5			ALGAE|CARBOHYDRATE METABOLISM|CARBON|CULTURE MEDIA|EQUIPMENT AND SUPPLIES|ERYTHROMYCIN|EXPERIMENTAL LAB STUDY|FERMENTATION|GLUCOSE METABOLISM|METABOLISM|NEOMYCIN|PENICILLIN|PHARMACOLOGY|POLYMYXIN|RISTOCETIN|SPECTROPHOTOMETRY|TETRACYCLINE|UREA|XANTHOPHYLL	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID14325281_20210611_0.5			Animals|Anti-Bacterial Agents|Bioreactors|Carbohydrate Metabolism|Carbon|Chickens|Chlorella|Culture Media|Equipment and Supplies|Erythromycin|Eukaryota|Fermentation|Glucose|Heterotrophic Processes|Lutein|Metabolism|Neomycin|Penicillins|Pharmacology|Polymyxins|Research|Ristocetin|Spectrophotometry|Tetracycline|Urea|Xanthophylls	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID14325281_20210611_0.5	glucose monohydrate	drug_umls_atom	A dry cell weight of 90 g per liter and total xanthophylls of 450 mg per liter were obtained from 190 g per liter of glucose monohydrate in 168-hr illuminated shaken flasks.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8559737_20201005_0.5			Atherosclerosis in Japanese Quail males selected for high or low plasma cholesterol.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8559737_20201005_0.5			Animals|Aorta|Arteriosclerosis|Bird Diseases|Cholesterol|Cholesterol, Dietary|Coturnix|Male|Selection, Genetic|Species Specificity	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8559737_20201005_0.5	glucose monohydrate	drug_umls_atom	In a second experiment, males of the three lines were fed from 6 to 14 wk of age four plant source diets to which were added: 1) 10% glucose monohydrate (cerelose); 2) 10% cerelose + .1% cholesterol; 3) 4% corn oil; or 4) 4% coconut oil.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6669505_20201005_0.5			Supplementary inorganic sulfate and methionine for young turkeys.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6669505_20201005_0.5			Animals|Body Weight|Diet|Female|Food, Fortified|Male|Methionine|Stereoisomerism|Sulfates|Turkeys	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6669505_20201005_0.5	glucose monohydrate	drug_umls_atom	Experimental diets, in which a corn-soybean meal basal diet was supplemented with inorganic sulfate either in the form of sodium sulfate (0, .0952, and .1904%) or potassium sulfate (0, .1180, and .2360%), and with methionine (0, .05, .10 and .15%) in the place of glucose monohydrate, were fed in a 3 X 2 X 4 experimental design.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID694414_20201005_0.5			Gastric emptying of a liquid meal in health and duodenal ulcer disease.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID694414_20201005_0.5			Adult|Aged|Duodenal Ulcer|Food|Gastric Emptying|Humans|Methods|Middle Aged|Statistics as Topic|Time Factors	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID694414_20201005_0.5	glucose monohydrate	drug_umls_atom	The aim of the study was to find out whether ther is any difference in gastric emptying rate of a liquid meal of 750 ml 10% glucose (glucose monohydrate, mol.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21232587_20201005_0.5			Investigating the effect of dehydration conditions on the compactability of glucose.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21232587_20201005_0.5			Adsorption|Calorimetry, Differential Scanning|Crystallization|Desiccation|Glucose|Hardness|Microscopy, Electron, Scanning|Powders|Surface Properties|Tablets|Technology, Pharmaceutical|Water|X-Ray Diffraction	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID21232587_20201005_0.5	glucose monohydrate	drug_umls_atom	In this work, glucose monohydrate powder was dehydrated at four different conditions and then compressed to see the effect on the hardness of the compacts.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7479517_20201005_0.5			Dietary cholesterol and fat saturation effects on plasma esterified and unesterified cholesterol in selected lines of Japanese quail females.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7479517_20201005_0.5			Analysis of Variance|Animal Nutritional Physiological Phenomena|Animals|Arteriosclerosis|Cholesterol|Cholesterol Esters|Cholesterol, Dietary|Coturnix|Dietary Fats|Fats, Unsaturated|Female|Species Specificity	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7479517_20201005_0.5	glucose monohydrate	drug_umls_atom	In a second experiment, females of the three lines were fed, from 6 to 14 wk of age, four isocaloric, isonitrogenous plant-source diets to which were added: 1) 10% glucose monohydrate (cerelose); 2) 10% cerelose + .1% cholesterol; 3) 4% corn oil; or 4) 4% coconut oil.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7338296_20201005_0.5	glucose monohydrate	drug_umls_atom	Glucose or glucose monohydrate for glucose tolerance tests?	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID7338296_20201005_0.5			Adult|Glucose|Glucose Tolerance Test|Humans	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID32051744_20201005_0.5			Use of modified Custodiol-N as perfusion solution in ex vivo lung perfusion.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID32051744_20201005_0.5			Custodiol-N|Marginal donor lungs|ex-vivo lung perfusion|lung transplantation|organ preservation	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID32051744_20201005_0.5			Swine|Animals|Humans|Custodiol-N solution|Organ Preservation Solutions|Perfusion|Extracorporeal Circulation|Organ Preservation|Lung Transplantation|Lung|Tissue Donors|Pulmonary Gas Exchange	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID32051744_20201005_0.5	glucose monohydrate	drug_umls_atom	 METHODS In a porcine DCD model, lungs were perfused either with STEEN SolutionTM (Standard SS, n=8) or modified Custodiol-N with added 1.1 g/l glucose monohydrate and 50 g/l dextran 40 (CD, n=8).	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7315427_20201005_0.5			Clean Production of Levulinic Acid from Fructose and Glucose in Salt Water by Heterogeneous Catalytic Dehydration	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7315427_20201005_0.5			Fructose|levulinic acid|Glucose|Dehydration|Levulinic Acids|Catalysis|Furaldehyde|Carbohydrates|Acids|Sodium Chloride|Water|Temperature|Cation Exchange Resins|Salts	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC7315427_20201005_0.5	glucose monohydrate	drug_umls_atom	Even 10% (w/w) glucose monohydrate was directly dehydrated to LA (with 70.7% yield) under similar conditions but at 145 °C.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5457009_20201005_0.5			New Elastomeric Materials Based on Natural Rubber Obtained by Electron Beam Irradiation for Food and Pharmaceutical Use	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5457009_20201005_0.5			polyfunctional monomers|natural rubber|electron beam irradiation|gel fraction|crosslink density|apsorption tests	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5457009_20201005_0.5			Rubber|Electrons|Elasticity|trimethylolpropane trimethacrylate|Methacrylates|Spectroscopy, Fourier Transform Infrared|ethylene dimethacrylate|Microscopy, Electron, Scanning|Water|Physical Phenomena|Radiation Dosage|Pharmaceutical Preparations	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMC5457009_20201005_0.5	glucose monohydrate	drug_umls_atom	The absorption tests were done in accordance with the SR ISI 1817:2015 using distilled water, acetic acid (10%), sodium hydroxide (1%), ethylic alcohol (96%), physiological serum (sodium chloride 0.9%) and glucose (glucose monohydrate 10%).	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID11055856_20201005_0.5			Influence of dietary protein level on the broiler chicken's response to methionine and betaine supplements.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID11055856_20201005_0.5			Adipose Tissue|Animals|Betaine|Body Composition|Chickens|Diet|Dietary Proteins|Dietary Supplements|Energy Intake|Energy Metabolism|Lipids|Liver|Male|Methionine|Muscle Proteins|Muscle, Skeletal|Proteins|Tibia|Weight Gain	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID11055856_20201005_0.5	glucose monohydrate	drug_umls_atom	In Experiment 2, glucose monohydrate was also added, so that identical amino acid profiles could be maintained in the 17 and 24% protein diets.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID22775216_20201005_0.5			The chick chorioallantoic membrane imaging method as a platform to evaluate vasoactivity and assess irritancy of compounds.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID22775216_20201005_0.5			Animals|Blood Vessels|Caffeine|Chick Embryo|Chorioallantoic Membrane|Drug Evaluation, Preclinical|Glucagon|Glycerol|Homeostasis|Irritants|Nicotine|Propranolol|Solvents|Vasoconstriction|Vasoconstrictor Agents|Vasodilation|Vasodilator Agents	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID22775216_20201005_0.5	glucose monohydrate	drug_umls_atom	Solvents and drugs such as 70% v/v ethanol, normal saline, 5% w/v glucose monohydrate, glycerin, glucagon, N-methylpyrrolidone, nicotine, glyceryl trinitrate, glucagon, propranolol and caffeine were tested on the CAM.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6518403_20201005_0.5			Influence of substitution method and of food intake on bioassays to determine metabolisable energy with chickens.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6518403_20201005_0.5			Animal Feed|Animals|Body Weight|Chickens|Energy Metabolism|Glucose|Male|Methods|Nitrogen|Zea mays	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID6518403_20201005_0.5	glucose monohydrate	drug_umls_atom	Over a 24-h period fasted cockerels lost more energy and nitrogen in their excreta than those fed 15 g maize and 15 g glucose monohydrate.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17995643_20201005_0.5	glucose monohydrate	drug_umls_atom	A comparative study on the effects of glucose monohydrate, hot water, and sodium pyrophosphate on quality parameters and microbial flora of deboned and matured brisket.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17995643_20201005_0.5			Animals|Bacteria|Cattle|Colony Count, Microbial|Consumer Product Safety|Diphosphates|Disinfectants|Dose-Response Relationship, Drug|Drug Synergism|Food Contamination|Glucose|Hot Temperature|Humans|Meat|Pigmentation|Water	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17995643_20201005_0.5	glucose monohydrate	drug_umls_atom	In this study, briskets were treated with 6 different applications: D (+) glucose monohydrate (GM) (16.51 g/100 mL, 15%) dip, HW dip, sodium pyrophosphate (SPP) and HW dip, GM + SPP + HW, and GM + HW combined dip.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID22420658_20201005_0.5			The CAM-LDPI method: a novel platform for the assessment of drug absorption.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID22420658_20201005_0.5			Animals|Caffeine|Chick Embryo|Chickens|Chorioallantoic Membrane|Excipients|Laser-Doppler Flowmetry|Nitroglycerin|Regional Blood Flow|Solvents|Vasoconstrictor Agents|Vasodilator Agents	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID22420658_20201005_0.5	glucose monohydrate	drug_umls_atom	 RESULTS Insignificant changes in blood perfusion were observed with deionized water, 0.9% w/v soldium chloride and 5% w/v glucose monohydrate, as well as theophylline and glucagon.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8572919_20201005_0.5			The energy value for and nutritive value of para-rubber seed for rats.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8572919_20201005_0.5			Animal Feed|Animals|Diet|Digestion|Energy Metabolism|Nutritive Value|Rats|Rats, Wistar|Rubber|Seeds|Weight Gain	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID8572919_20201005_0.5	glucose monohydrate	drug_umls_atom	No section The digestible (DE) and metabolizable energy (ME) of full-fat and defatted rubber seed meals (FRS and DRS) were determined with weanling albino rats fed diets in which the meals replaced either 20 or 40% glucose monohydrate in the reference diet.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17679559_20201005_0.5			Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17679559_20201005_0.5			Adult|Aerosols|Anti-Asthmatic Agents|Biological Availability|Chemistry, Pharmaceutical|Cromolyn Sodium|Cross-Over Studies|Drug Compounding|Drug Storage|Excipients|Glucose|Humans|Humidity|Lactose|Lung|Male|Powders|Sorbitol	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17679559_20201005_0.5	glucose monohydrate	drug_umls_atom	No section Glucose monohydrate and sorbitol were evaluated as alternative carriers to á-lactose monohydrate in dry powder inhalations.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID17679559_20201005_0.5	glucose monohydrate	drug_umls_atom	Glucose monohydrate and sorbitol-containing formulae that were inhaled via a Handihaler showed significantly higher drug fine particle fractions (P<0.001) than that of the same formulae aerosolized via other devices.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25280410_20201005_0.5			Short-term dietary supplementation with fructose accelerates gastric emptying of a fructose but not a glucose solution.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25280410_20201005_0.5			Appetite|Diet|Fructose supplementation|Gastrointestinal adaptation|Monosaccharide solutions	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25280410_20201005_0.5			Adult|Appetite|Cross-Over Studies|Dietary Carbohydrates|Dietary Supplements|Fructose|Gastric Emptying|Glucose|Humans|Male|Prospective Studies|Young Adult	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID25280410_20201005_0.5	glucose monohydrate	drug_umls_atom	 METHODS The gastric emptying rate of a fructose solution containing 36 g of fructose and an equicaloric glucose solution containing 39.6 g glucose monohydrate were measured in 10 healthy non-smoking men with and without prior fructose supplementation (water control) using a randomized crossover design.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID33029600_20201214_0.5			Synthesis of low dimensional hierarchical transition metal oxides via a direct deep eutectic solvent calcining method for enhanced oxygen evolution catalysis.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID33029600_20201214_0.5			Oxygen|Solvents|Oxides|Catalysis|Cobalt|Graphite|Electrodes|Electrochemical Techniques|Nanostructures|Biosensing Techniques|Oxidation-Reduction|Porosity|Glucose	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID33029600_20201214_0.5	glucose monohydrate	drug_umls_atom	Glucose monohydrate and urea can form a glucose-urea DES, which was calcined under a N2 atmosphere to produce 2D N,O-doped graphene.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID1982833_20201005_0.5			One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID1982833_20201005_0.5			Adult|Anemia|Erythropoietin|Female|Humans|Injections, Subcutaneous|Kidney Failure, Chronic|Male|Peritoneal Dialysis, Continuous Ambulatory|Recombinant Proteins|Time Factors|Ultrafiltration	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID1982833_20201005_0.5	glucose monohydrate	drug_umls_atom	UF improved from 0.70 +/- 0.22 to 1.03 +/- 0.47 ml/min (4 hr dwell time, 1.5% glucose monohydrate) (p less than 0.03).	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3737508_20201005_0.5			The lack of effect of a pyridoxine deficiency on the utilization of the hydroxyl analogue of methionine by the chick.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3737508_20201005_0.5			Animals|Aspartate Aminotransferases|Chickens|Diet|Methionine|Pyridoxine|Vitamin B 6 Deficiency	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID3737508_20201005_0.5	glucose monohydrate	drug_umls_atom	The basal diet used for this purpose was based on peas, peanut meal, and glucose monohydrate and was low in both methionine and pyridoxine.	abstract
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID24594168_20201005_0.5			Detection of adulterated honey produced by honeybee (Apis mellifera L.) colonies fed with different levels of commercial industrial sugar (C₃ and C₄ plants) syrups by the carbon isotope ratio analysis.	title
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID24594168_20201005_0.5			(13)C/(12)C isotope|Adulterated|Colony|Feeding|Honey|Patterns|Sugars	author_keywords
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID24594168_20201005_0.5			Animals|Beekeeping|Bees|Carbohydrate Metabolism|Carbohydrates|Carbon Isotopes|Discriminant Analysis|Food Contamination|Honey	mesh_terms
dextrose monohydrate	C0017734			glucose monohydrate	inn	PubMed	PMID24594168_20201005_0.5	glucose monohydrate	drug_umls_atom	No section In the present study, one hundred pure and adulterated honey samples obtained from feeding honeybee colonies with different levels (5, 20 and 100 L/colony) of various commercial sugar syrups including High Fructose Corn Syrup 85 (HFCS-85), High Fructose Corn Syrup 55 (HFCS-55), Bee Feeding Syrup (BFS), Glucose Monohydrate Sugar (GMS) and Sucrose Sugar (SS) were evaluated in terms of the δ(13)C value of honey and its protein, difference between the δ(13)C value of protein and honey (Δδ(13)C), and C4% sugar ratio.	abstract
Kolorz	C1829334				trade_name	PubMed	PMID26219142_20201005_0.5			The effect of topical fluoride varnish on the shear bond strength of orthodontic brackets.	title
Kolorz	C1829334				trade_name	PubMed	PMID26219142_20201005_0.5			Adhesiveness|Cariostatic Agents|Dental Bonding|Dental Stress Analysis|Fluorides, Topical|Humans|Light-Curing of Dental Adhesives|Materials Testing|Orthodontic Brackets|Resin Cements|Saliva, Artificial|Shear Strength|Sodium Fluoride|Stress, Mechanical|Surface Properties|Temperature|Time Factors	mesh_terms
Kolorz	C1829334				trade_name	PubMed	PMID26219142_20201005_0.5	kolorz	drug_name	The teeth were divided into a control group and six test groups: Kolorz ClearShield 5% NaFl varnish Day 1, 8, and 15; and Vanish 5% NaFl varnish Day 1, 8, and 15.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33793172_20210411_0.5	bamlanivimab	drug_name	Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for Clinical Nurse Specialist Practice.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33793172_20210411_0.5			Antibodies, Monoclonal, Humanized|COVID-19|Drug Approval|Humans|Nurse Clinicians|Practice Patterns, Nurses'|Severity of Illness Index|United States|United States Food and Drug Administration	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5			The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5	bamlanivimab	drug_name	COVID-19|bamlanivimab|casirivimab|etesevimab|imdevimab|monoclonal antibodies|pragmatic trial|protocol|randomised controlled trial	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5	bamlanivimab	drug_name	From November 2020 to February 2021, FDA issued EUAs for three mAB treatments (bamlanivimab; bamlanivimab and etesevimab; and casirivimab and imdevimab), and at trial launch on March 10, 2021 we evaluated all three.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5	bamlanivimab	drug_name	Due to a sustained increase in SARS-CoV-2 variants in the United States resistant to bamlanivimab administered alone, on March 24, 2021 the U.S. Government halted distribution of bamlanivimab alone, and UPMC accordingly halted bamlanivimab monotherapy on March 31, 2021.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5	bamlanivimab	drug_name	On April 16, 2021, FDA revoked the EUA for bamlanivimab monotherapy.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5	bamlanivimab	drug_name	At the time of manuscript submission, we are therefore evaluating the two mAB treatments authorized by EUAs (bamlanivimab and etesevimab; and casirivimab and imdevimab).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8144687_20210611_0.5	bamlanivimab	drug_name	As noted above, due to U.S. Government decisions, UPMC Health System halted bamlanivimab monotherapy on March 31, 2021.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8013486_20210411_0.5			A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8013486_20210411_0.5	bamlanivimab	drug_name	COVID-19|SARS-CoV-2|bamlanivimab|casirivimab|monoclonal antibodies	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8013486_20210411_0.5			Aged|Antibodies, Monoclonal, Humanized|COVID-19|Drug Combinations|Female|Humans|Male|Minnesota|Mobile Health Units|Patients|Referral and Consultation|Retrospective Studies|Skilled Nursing Facilities	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8013486_20210411_0.5	bamlanivimab	drug_name	 Exposure Emergency use treatment with bamlanivimab and casirivimab-imdevimab.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8109198_20210611_0.5	bamlanivimab	drug_name	Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8109198_20210611_0.5	bamlanivimab	drug_name	bamlanivimab|covid-19|covid-19 treatment|long-term care facility|ly-cov555|monoclonal antibody|non-hospital setting|nursing home|sars-cov-2	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8109198_20210611_0.5			Humans|Male|Female|Aged, 80 and over|Aged|Retrospective Studies|Antibodies, Monoclonal|Case-Control Studies|COVID-19|SARS-CoV-2|Nursing Homes|Hospitalization|Skilled Nursing Facilities|Antineoplastic Agents, Immunological|Patients|Hospital Mortality|Risk Factors|Hospitals|New York	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8096193_20210511_0.5	bamlanivimab	drug_name	Administration of Bamlanivimab to Skilled Nursing Facility Residents during a COVID-19 Outbreak, January-February 2021, Arizona	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8096193_20210511_0.5			COVID-19|monoclonal antibody therapy|skilled nursing facility	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5			Humans|Male|Female|Middle Aged|Adult|Aged|COVID-19|SARS-CoV-2|Hospitalization|Intensive Care Units|Infusions, Intravenous|Diabetes Mellitus|Severity of Illness Index|Administration, Intravenous	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	UNASSIGNED Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	 UNASSIGNED 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	 UNASSIGNED The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34075387_20210611_0.5	bamlanivimab	drug_name	 UNASSIGNED Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8155772_20210611_0.5			Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8155772_20210611_0.5	bamlanivimab	drug_name	bamlanivimab|casirivimab|covid_19|imdevimab|monoclonal antibodies|patient outcomes|sars_cov-2	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8155772_20210611_0.5			Humans|Male|Middle Aged|Adult|Female|Antibodies, Monoclonal|COVID-19|Retrospective Studies|COVID-19 Testing|SARS-CoV-2|Antineoplastic Agents, Immunological|Immunotherapy|Social Support|Ethnic Groups|European Continental Ancestry Group|Informed Consent	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8155772_20210611_0.5	bamlanivimab	drug_name	 Methods This retrospective cohort study enrolled 2820 adult patients who were offered monoclonal antibody therapies, bamlanivimab and casirivimab-imdevimab, for COVID-19 at Mayo Clinic in the Midwest between 11/19/2020 and 12/31/2020.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34074219_20210611_0.5	bamlanivimab	drug_name	501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34074219_20210611_0.5	bamlanivimab	drug_name	ACE2|B.1.1.7/501Y.V1|B.1.351/501Y.V2|COVID-19|P.1/501Y.V3|RBD, Bamlanivimab|SARS-COV-2	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34074219_20210611_0.5			Angiotensin-Converting Enzyme 2|Antibodies, Monoclonal, Humanized|Antiviral Agents|Binding Sites|COVID-19|Host-Pathogen Interactions|Humans|Molecular Docking Simulation|Mutation|Protein Binding|Protein Interaction Domains and Motifs|Receptors, Virus|SARS-CoV-2	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34074219_20210611_0.5	bamlanivimab	drug_name	The mutated version of RBD also completely abolishes the binding of bamlanivimab, a therapeutic antibody, in vitro.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34074219_20210611_0.5	bamlanivimab	drug_name	Mutation of E484K leads to the loss of bamlanivimab binding to RBD, although this mutation does not affect the binding between RBD and ACE2.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33724631_20210411_0.5			Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33724631_20210411_0.5	bamlanivimab	drug_name	B.1.1.7|B.1.351|BNT162b2|COVID-19|LY-CoV555|LyCoV016|P.1|P.2|REGN10933|REGN10987|SARS-CoV-2|bamlanivimab|casirivimab|convalescent plasma|etesevimab|imdevimab|immune escape|mRNA-1273|mutations|neutralising antibody|polyclonal immunoglobulins	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33724631_20210411_0.5			Humans|spike protein, SARS-CoV-2|Spike Glycoprotein, Coronavirus|Antibodies, Neutralizing|COVID-19|SARS-CoV-2|Phylogeny|Vaccines|Viral Envelope Proteins|Antibodies, Viral|Membrane Glycoproteins|Risk Assessment|Brazil	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33619479_20210611_0.5	bamlanivimab	drug_name	501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33619479_20210611_0.5			Humans|SARS-CoV-2|COVID-19|Antibodies, Neutralizing|Antibodies, Viral|Spike Glycoprotein, Coronavirus|Protein Binding|Antibodies, Monoclonal|Mutation|Biophysical Phenomena|South Africa|Brazil	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33619479_20210611_0.5	bamlanivimab	drug_name	This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro .	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5			Humans|Male|Female|United States|COVID-19|Assisted Living Facilities|Incidence|Double-Blind Method|SARS-CoV-2|Antibodies, Neutralizing	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	 UNASSIGNED To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	 UNASSIGNED Participants were randomized to receive a single intravenous infusion of bamlanivimab, 4200 mg (n = 588), or placebo (n = 587).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	Bamlanivimab significantly reduced the incidence of COVID-19 in the prevention population compared with placebo (8.5% vs 15.2%; odds ratio, 0.43 [95% CI, 0.28-0.68]; P < .001; absolute risk difference, -6.6 [95% CI, -10.7 to -2.6] percentage points).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	Among 1175 participants who received study product (safety population), the rate of participants with adverse events was 20.1% in the bamlanivimab group and 18.9% in the placebo group.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	The most common adverse events were urinary tract infection (reported by 12 participants [2%] who received bamlanivimab and 14 [2.4%] who received placebo) and hypertension (reported by 7 participants [1.2%] who received bamlanivimab and 10 [1.7%] who received placebo).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081073_20210611_0.5	bamlanivimab	drug_name	 UNASSIGNED Among residents and staff in skilled nursing and assisted living facilities, treatment during August-November 2020 with bamlanivimab monotherapy reduced the incidence of COVID-19 infection.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8002405_20210411_0.5			In Translation: FcRn across the Therapeutic Spectrum	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8002405_20210411_0.5			Fc-fusion protein|immune complex|immunoglobulin G|monoclonal antibody|neonatal Fc receptor|pharmacokinetics|physiologically-based pharmacokinetic modeling	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8002405_20210411_0.5			Animals|Antibodies, Monoclonal|COVID-19|Histocompatibility Antigens Class I|Humans|Immunoglobulin G|Receptors, Fc|Tissue Distribution	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8002405_20210411_0.5	bamlanivimab	drug_name	We further comment on therapeutic antibodies authorized for treating SARS-CoV-2 (bamlanivimab, casirivimab, and imdevimab) and evaluate their potential to saturate FcRn-mediated recycling.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33820835_20210611_0.5			The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33820835_20210611_0.5			Animals|Humans|Antibodies, Neutralizing|COVID-19|SARS-CoV-2|Macaca mulatta|Spike Glycoprotein, Coronavirus|Antibodies, Viral|Antibodies, Monoclonal|Virus Replication|Protein Binding	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33820835_20210611_0.5	bamlanivimab	drug_name	Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33793179_20210411_0.5	bamlanivimab	drug_name	Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for CNS Practice.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34000267_20210611_0.5	bamlanivimab	drug_name	Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081820_20210611_0.5	bamlanivimab	drug_name	Initial Experience of Bamlanivimab Monotherapy Use in Solid Organ Transplant Recipients.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081820_20210611_0.5			COVID-19|monoclonal antibody|transplant|viral infection	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081820_20210611_0.5			Humans|Male|Adult|Middle Aged|Female|COVID-19 drug treatment|Cohort Studies|Retrospective Studies|COVID-19|SARS-CoV-2|Coronavirus Infections|Transplant Recipients|Pandemics|Organ Transplantation|Hospitalization	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081820_20210611_0.5	bamlanivimab	drug_name	This retrospective single center cohort study evaluated the outcomes of SOT recipients with mild to moderate COVID-19 who received bamlanivimab monotherapy.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081820_20210611_0.5	bamlanivimab	drug_name	In this small cohort of SOT recipients, bamlanivimab monotherapy appeared to be a well-tolerated option for treatment of mild to moderate COVID-19, but it was not completely effective in preventing hospitalization.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34081820_20210611_0.5	bamlanivimab	drug_name	For this reason, bamlanivimab is now recommended to be used only in combination with etesevimab.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33459118_20210511_0.5			Antibodies to watch in 2021.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33459118_20210511_0.5			Antibody therapeutics|COVID-19|European Medicines Agency|Food and Drug Administration|Sars-CoV-2|cancer|immune-mediated disorders	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33459118_20210511_0.5			Animals|Antibodies|Antiviral Agents|COVID-19|Diffusion of Innovation|Drug Approval|Drug Development|Drug Discovery|Drug Repositioning|Forecasting|Host-Pathogen Interactions|Humans|SARS-CoV-2	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33459118_20210511_0.5	bamlanivimab	drug_name	Remarkably, by late November 2020, two anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 in Russia and India, respectively.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33213544_20201214_0.5	bamlanivimab	drug_name	Antimicrobial stewardship and bamlanivimab: Opportunities for outpatient preauthorization?	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7694556_20210411_0.5			Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7694556_20210411_0.5			Antiviral Agents|COVID-19|COVID-19 Vaccines|Compassionate Use Trials|Drug Approval|Humans|SARS-CoV-2|United States	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7694556_20210411_0.5	bamlanivimab	drug_name	We also provide a description of, and clinical rationale for, each of the EA- or EUA-approved drugs (e.g. remdesivir, convalescent plasma, propofol 2%, hydroxychloroquine, ruxolitinib, bamlanivimab, baricitinib, casirivimab plus imdevimab) during the pandemic and concluding reflections on the EA program and its potential future uses.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33177042_20201214_0.5	bamlanivimab	drug_name	Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7980144_20210411_0.5			SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7980144_20210411_0.5			B.1.1.7|B.1.351|COVID-19|P.1|SARS-CoV-2|VOC|antibodies|escape|host cell entry|neutralization|spike protein|variants|variants of concern	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7980144_20210411_0.5			Animals|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|Cell Line|Drug Resistance, Viral|Humans|Immunization, Passive|Kinetics|Membrane Fusion|Models, Molecular|Neutralization Tests|SARS-CoV-2|Serine Endopeptidases|Solubility|Spike Glycoprotein, Coronavirus|Vaccination|Virus Internalization	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7980144_20210411_0.5	bamlanivimab	drug_name	In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	COVID-19|SARS-CoV-2|bamlanivimab|monoclonal antibody	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	 Methods We conducted a retrospective case-control study across a single healthcare system of non-hospitalized patients, age 18 years or older, with documented positive SARS-CoV-2 testing, risk factors for severe COVID-19, and referrals for bamlanivimab via emergency use authorization.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	Cases were defined as patients who received bamlanivimab; contemporary controls had a referral order placed but did not receive bamlanivimab.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	 Results Between November 20, 2020 and January 19, 2021, 218 patients received bamlanivimab (cases) and 185 were referred but did not receive drug (controls).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	Thirty-day hospitalization rate was significantly lower among patients who received bamlanivimab (7.3% v 20.0%, RR 0.37, 95% CI 0.21-0.64, p<0.001), and the number needed to treat was 8.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	On logistic regression, odds of hospitalization were increased in patients not receiving bamlanivimab and with a higher number of pre-specified comorbidities (OR 4.19 CI: 1.31-2.16, p<0.001; OR 1.68, CI: 2.12-8.30, p<0.001, respectively).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	 Conclusion Ambulatory patients with COVID-19 who received bamlanivimab had a lower 30-day hospitalization than control patients in real-world experience.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8083260_20210511_0.5	bamlanivimab	drug_name	We identified receipt of bamlanivimab and fewer comorbidities as protective factors against hospitalization.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8071770_20210511_0.5			Development and application of therapeutic antibodies against COVID-19	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8071770_20210511_0.5			COVID-19|SARS-CoV-2|antibody cocktail|convalescent plasma|monoclonal antibody|therapeutic antibody	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8071770_20210511_0.5			Antibodies, Monoclonal|Antibodies, Neutralizing|COVID-19|Humans|Immunization, Passive|SARS-CoV-2	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8071770_20210511_0.5	bamlanivimab	drug_name	Four products, i.e. , convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8092710_20210511_0.5			Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8092710_20210511_0.5			SARS-CoV-2|coronavirus|fluorescent|luciferase|reporter virus|reverse genetics	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8092710_20210511_0.5			Chlorocebus aethiops|Animals|Humans|SARS-CoV-2|Pandemics|Genes, Reporter|COVID-19|Virus Replication|Antibodies, Neutralizing|Vero Cells|Antiviral Agents|Antibodies, Viral|Genome, Viral|Luciferases|Antibodies, Monoclonal|Family Characteristics	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8092710_20210511_0.5	bamlanivimab	drug_name	To date, only one Food and Drug Administration (FDA)-approved therapeutic drug (remdesivir) and a monoclonal antibody (MAb), bamlanivimab, are available for the treatment of SARS-CoV-2.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799019_20210211_0.5			Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799019_20210211_0.5	bamlanivimab	drug_name	Bamlanivimab|COVID-19|Casirivimab|Imdevimab|Pediatric	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799019_20210211_0.5			Adolescent|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antiviral Agents|COVID-19|Child|Drug Approval|Female|Humans|Male|Pandemics|Pneumonia, Viral|SARS-CoV-2|United States|United States Food and Drug Administration	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799019_20210211_0.5	bamlanivimab	drug_name	Background In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for two novel virus-neutralizing monoclonal antibody therapies, bamlanivimab, and REGN-COV2 (casirivimab plus imdevimab), for the treatment of mild to moderate COVID-19 in adolescents and adults in specified high-risk groups.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799019_20210211_0.5	bamlanivimab	drug_name	 Conclusions Based on evidence available as of December 20, 2020, the panel suggests against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab), for treatment of COVID-19 in children or adolescents, including those designated by the FDA as at high risk of progression to hospitalization or severe disease.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34088863_20210611_0.5			SARS CoV-2 (COVID-19) Current Pharmacotherapy for Mother and Infant.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34088863_20210611_0.5	bamlanivimab	drug_name	COVID-19|SARS-Cov-2|bamlanivimab|dexamethasone|hydroxychloroquine/chloroquine|ivermectin|lopinavir/ritonavir|remdesivir|vaccines	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID34088863_20210611_0.5			Female|Infant, Newborn|Humans|Infant|United States|COVID-19|SARS-CoV-2|Mothers|SARS Virus|Pandemics|Hydroxychloroquine|Lopinavir|Ritonavir|Antiviral Agents|Adenosine Monophosphate|Alanine	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8135369_20210611_0.5			Pharmacist outreach Program for COVID-19 monoclonal antibody distribution	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8135369_20210611_0.5	bamlanivimab	drug_name	COVID-19 drug treatment|Federally Qualified Health Center partnership|bamlanivimab|monoclonal antibody therapy|pharmacist outreach|pharmacy services	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8135369_20210611_0.5			Humans|Pandemics|COVID-19|SARS-CoV-2|Pharmacists|Antibodies, Monoclonal|Peer Review, Research	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33830966_20210511_0.5	bamlanivimab	drug_name	An EUA for bamlanivimab and etesevimab for COVID-19.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33830966_20210511_0.5	bamlanivimab	drug_name	COVID-19|adverse effects|bamlanivimab|casirivimab|dosage|efficacy|etesevimab|imdevimab|safety	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33830966_20210511_0.5			Antibodies, Monoclonal, Humanized|Antiviral Agents|COVID-19|Drug Approval|Humans|SARS-CoV-2|Treatment Outcome|United States|United States Food and Drug Administration	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8020059_20210411_0.5			Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8020059_20210411_0.5	bamlanivimab	drug_name	SARS-CoV-2|antibody escape|bamlanivimab|deep mutational scanning	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8020059_20210411_0.5			Humans|Antibodies, Monoclonal|SARS-CoV-2|SARS-CoV-2 variants|COVID-19|Spike Glycoprotein, Coronavirus|Neutralization Tests|Epitopes|Antibodies, Viral|Viral Envelope Proteins|Antineoplastic Agents, Immunological|Mutation|Membrane Glycoproteins	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8020059_20210411_0.5	bamlanivimab	drug_name	report a complete map of all of the SARS-CoV-2 mutations that escape binding by the LY-CoV555 (bamlanivimab) antibody and its cocktail with LY-CoV016.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33443490_20210311_0.5	bamlanivimab	drug_name	An EUA for bamlanivimab - a monoclonal antibody for COVID-19.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33443490_20210311_0.5	bamlanivimab	drug_name	COVID-19|adverse effects|bamlanivimab|coronavirus|dosage|efficacy|safety	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33443490_20210311_0.5			Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antiviral Agents|Clinical Trials, Phase II as Topic|Drug Approval|Female|Hospitalization|Humans|Male|Middle Aged|United States|United States Food and Drug Administration	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7850379_20210211_0.5			Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading?	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7850379_20210211_0.5	bamlanivimab	drug_name	COVID-19, kidney transplant, bamlanivimab, immunosuppression, ivermectin, CNI.	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7850379_20210211_0.5			Algorithms|COVID-19|Humans|Immunosuppression|Immunosuppressive Agents|Kidney Transplantation|Renal Insufficiency	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7759095_20210111_0.5			COVID-19 vaccines: The status and perspectives in delivery points of view	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7759095_20210111_0.5			Coronavirus disease 2019 (COVID-19)|Immune response|Neutralizing antibodies|Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)|Vaccine delivery	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7759095_20210111_0.5			Animals|Antiviral Agents|COVID-19|COVID-19 Vaccines|Drug Development|Humans|Immunization Programs|SARS-CoV-2	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7759095_20210111_0.5	bamlanivimab	drug_name	Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5	bamlanivimab	drug_name	Bamlanivimab Use in a Military Treatment Facility.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5			Humans|Male|Adult|Middle Aged|Female|Cohort Studies|Retrospective Studies|Military Personnel|COVID-19|SARS-CoV-2|Hospitalization|Ambulatory Care|Double-Blind Method|Antibodies, Monoclonal|China	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5	bamlanivimab	drug_name	In November 2020, the monoclonal antibody bamlanivimab was approved by the FDA for non-hospitalized patients with SARS-CoV-2 (COVID-19) who possessed risk factors for progression to severe COVID-19.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5	bamlanivimab	drug_name	 METHODS Patients who regularly received ambulatory care at a military treatment facility and who were diagnosed with mild-to-moderate COVID-19 and possessed risk factors for progression to severe COVID-19 were treated with a single, intravenous infusion (700 mg) of the virus-neutralizing monoclonal antibody bamlanivimab.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5	bamlanivimab	drug_name	Bamlanivimab was administered in accordance with the FDA's approval and Defense Health Agency's guidance, including follow-up within 72 hours of administration.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5	bamlanivimab	drug_name	 RESULTS Of the COVID-19 patients who were given the option of a bamlanivimab infusion, 40 accepted and 6 did not (40/46, 86.9%).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33993281_20210611_0.5	bamlanivimab	drug_name	 CONCLUSIONS Global improvement of symptoms within 24 to 72 hours of infusion was reported by 94.4% of patients receiving bamlanivimab; however, statistical significance could not be determined due to the small sample size and lack of placebo group due to study design.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5	bamlanivimab	drug_name	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5			Adult|Aged|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|COVID-19|Dose-Response Relationship, Drug|Double-Blind Method|Drug Therapy, Combination|Female|Hospitalization|Humans|Infusions, Intravenous|Male|Middle Aged|SARS-CoV-2|Severity of Illness Index|Viral Load	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5	bamlanivimab	drug_name	 No section To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5	bamlanivimab	drug_name	Patients who received bamlanivimab monotherapy or placebo were enrolled first (June 17-August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22-September 3).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5	bamlanivimab	drug_name	 No section Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n = 101], 2800 mg [n = 107], or 7000 mg [n = 101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of etesevimab [n = 112]), or placebo (n = 156).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5	bamlanivimab	drug_name	Immediate hypersensitivity reactions were reported in 9 patients (6 bamlanivimab, 2 combination treatment, and 1 placebo).	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33475701_20210411_0.5	bamlanivimab	drug_name	 No section Among nonhospitalized patients with mild to moderate COVID-19 illness, treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11; no significant difference in viral load reduction was observed for bamlanivimab monotherapy.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5			Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5			SARS-CoV-2|spike or S protein|human antibody|cocktail therapy|single domain antibody or nanobody	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5			Animals|Humans|spike protein, SARS-CoV-2|SARS-CoV-2|Pandemics|COVID-19|Spike Glycoprotein, Coronavirus|Neutralization Tests|Antibodies, Neutralizing|Viral Envelope Proteins|Antibodies, Viral|Antibodies, Monoclonal|Epitopes|Membrane Glycoproteins|Antigens, Viral|COVID-19 drug treatment|Coronavirus Infections|Immunization|Amino Acid Sequence	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5	bamlanivimab	drug_name	On November 9, 2020, the US FDA issued an emergency use authorization for bamlanivimab (LY3819253/LY-CoV555) for the treatment of mild-to-moderate COVID-19.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33564771_20210611_0.5			The basis of a more contagious 501Y.V1 variant of SARS-COV-2.	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33564771_20210611_0.5			Humans|SARS-CoV-2|COVID-19|Spike Glycoprotein, Coronavirus|Pandemics|Protein Binding|Binding Sites|Protein Domains|United Kingdom	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMID33564771_20210611_0.5	bamlanivimab	drug_name	Nevertheless, a therapeutic antibody, Bamlanivimab, still binds to the Y501-RBD as efficiently as its binds to N501-RBD.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8067572_20210511_0.5			Neutralizing Antibody Therapeutics for COVID-19	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8067572_20210511_0.5	bamlanivimab	drug_name	COVID-19|SARS-CoV-2|bamlanivimab|casirivimab|etesevimab|imdevimab|neutralizing antibody|resistance	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8067572_20210511_0.5			Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|COVID-19|Humans|SARS-CoV-2|Spike Glycoprotein, Coronavirus|United States|United States Food and Drug Administration	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC8067572_20210511_0.5	bamlanivimab	drug_name	Two nAb cocktails (casirivimab/imdevimab and bamlanivimab/etesevimab) and one nAb monotherapy (bamlanivimab) have been granted Emergency Use Authorization by the US Food and Drug Administration for the treatment of ambulatory patients who have a high risk of progressing to severe disease, and the European Medicines Agency has similarly recommended both cocktails and bamlanivimab monotherapy for use in COVID-19 patients who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7755170_20210211_0.5			Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7755170_20210211_0.5	bamlanivimab	drug_name	BGB-DXP593|COVID-19|CT-P59|GSK4182136|LY-CoV016|LY-CoV555|REGN-COV2|SARS-CoV-2|VIR-7831|bamlanivimab|monoclonal antibody	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7755170_20210211_0.5			Antibodies, Monoclonal|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|Clinical Trials, Phase II as Topic|Clinical Trials, Phase III as Topic|Humans|Immunization, Passive|SARS-CoV-2	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5			Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5			SARS-CoV-2|spike or S protein|human antibody|cocktail therapy|single domain antibody or nanobody	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5			Animals|Humans|spike protein, SARS-CoV-2|SARS-CoV-2|Pandemics|COVID-19|Spike Glycoprotein, Coronavirus|Neutralization Tests|Antibodies, Neutralizing|Viral Envelope Proteins|Antibodies, Viral|Antibodies, Monoclonal|Epitopes|Membrane Glycoproteins|Antigens, Viral|COVID-19 drug treatment|Coronavirus Infections|Immunization|Amino Acid Sequence	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5	ly3819253	drug_name_variant	As of October 11, 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819253/LY-CoV555, and VIR-7831/VIR-7832) in phase 3.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7717131_20210111_0.5	ly3819253	drug_name_variant	On November 9, 2020, the US FDA issued an emergency use authorization for bamlanivimab (LY3819253/LY-CoV555) for the treatment of mild-to-moderate COVID-19.	abstract
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799234_20210211_0.5			Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective	title
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799234_20210211_0.5			SARS-CoV-2|COVID-19|spike protein|neutralizing antibodies|hACE2	author_keywords
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799234_20210211_0.5			United States|Humans|Antibodies, Neutralizing|SARS-CoV-2|COVID-19|Neutralization Tests|Spike Glycoprotein, Coronavirus|Antibodies, Viral|Viral Envelope Proteins|Cross Reactions|Membrane Glycoproteins|Cell Line|COVID-19 drug treatment|Coronavirus Infections	mesh_terms
bamlanivimab	C5421805	ly-3819253	ly 3819253|ly3819253		inn	PubMed	PMC7799234_20210211_0.5	ly3819253	drug_name_variant	NAbs-based therapeutics against SARS-CoV-2 are being expedited to preclinical and clinical studies with two antibody drugs, LY3819253 (LY-CoV555) and REGN-COV2 (REGN10933 and REGN10987), approved by the US Food and Drug Administration for emergency use authorization for treating COVID-19.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC6357762_20201005_0.5			Catalyst-free, highly selective synthesis of ammonia from nitrogen and water by a plasma electrolytic system	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC6357762_20201005_0.5			Ammonia|Nitrogen|Water|Catalysis|Hydrogen|Protons|Electrolysis|Electrons|Temperature|Adsorption	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC6357762_20201005_0.5	ammonia measurement	drug_name	Ammonia measurements under varying reaction conditions in combination with scavengers reveal that the unprecedented selectivity is achieved by solvated electrons produced at the plasma-water interface, which react favorably with protons to produce the key hydrogen radical intermediate.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11296293_20201005_0.5			Correlation of breath ammonia with blood urea nitrogen and creatinine during hemodialysis.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11296293_20201005_0.5			Ammonia|Blood Urea Nitrogen|Breath Tests|Creatinine|Humans|Kidney Failure, Chronic|Renal Dialysis	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11296293_20201005_0.5	ammonia measurement	drug_name	For each breath ammonia measurement, taken at 15-30 min intervals during the dialysis, we also sampled the patient's blood for BUN and creatinine.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11296293_20201005_0.5	ammonia measurement	drug_name	These preliminary data indicate the possibility of using the real-time breath ammonia measurements for determining efficacy and endpoint of hemodialysis.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17408610_20201005_0.5	ammonia measurement	drug_name	False positives in plasma ammonia measurement and their clinical impact in a pediatric population.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17408610_20201005_0.5			Ammonia|Clinical Laboratory Techniques|False Positive Reactions|Humans|Infant|Infant, Newborn|Retrospective Studies	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17408610_20201005_0.5	ammonia measurement	drug_name	OBJECTIVE Plasma ammonia measurement is greatly influenced by pre-analytical conditions, which may lead to false positives.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17408610_20201005_0.5	ammonia measurement	drug_name	 RESULTS 1880 Ammonia measurements were available in 479 patients.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17408610_20201005_0.5	ammonia measurement	drug_name	 CONCLUSIONS There is a high proportion of false positives among elevated plasma ammonia measurements.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27976989_20201005_0.5			A breath ammonia analyser for monitoring patients with end-stage renal disease on haemodialysis.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27976989_20201005_0.5			Uremic breath|ammonia|haemodialysis|renal failure	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27976989_20201005_0.5			Adult|Ammonia|Breath Tests|Female|Glomerular Filtration Rate|Humans|Kidney Failure, Chronic|Male|Pilot Projects|Renal Dialysis|Saliva|Urea	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27976989_20201005_0.5	ammonia measurement	drug_name	OBJECTIVE Breath ammonia measurement has attracted increasing interest for clinical diagnosis and metabolic status monitoring.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID30873989_20201005_0.5	ammonia measurement	drug_name	Ammonia measurements with femtosecond laser-induced plasma spectroscopy.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID30873989_20201005_0.5			Ammonia|Lasers|Spectrum Analysis|Photolysis	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID30873989_20201005_0.5	ammonia measurement	drug_name	This work is the first attempt, to the best of our knowledge, for ammonia measurements with a femtosecond laser, and the results are useful for the development of ammonia diagnostics.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33019029_20201214_0.5			Validating sweat ammonia as physiological parameter for wearable devices in sports science.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33019029_20201214_0.5			Ammonia|Ammonium Compounds|Humans|Sports|Sweat|Wearable Electronic Devices	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33019029_20201214_0.5	ammonia measurement	drug_name	In this study, we conducted ammonia measurements in blood and sweat during a stepwise incremental cycle ergometer test in 40 subjects under completely controlled conditions in a clinical environment to determine the correlation between the ammonium concentrations in blood and sweat.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11843965_20201005_0.5			The effect of Helicobacter pylori eradication on gastric juice and blood ammonia concentrations and on visual evoked potentials in cirrhotics.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11843965_20201005_0.5			Ammonia|Evoked Potentials, Visual|Gastric Juice|Helicobacter Infections|Helicobacter pylori|Humans|Liver Cirrhosis|Male|Middle Aged	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11843965_20201005_0.5	ammonia measurement	drug_name	Ammonia measurements and VEP recordings were evaluated in the 24 patients in whom eradication was successful.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID22001454_20201005_0.5			Clinical significance of plasma ammonia in patients with generalized convulsion.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID22001454_20201005_0.5			Ammonia|Cross-Sectional Studies|Female|Humans|Male|Middle Aged|Retrospective Studies|Seizures	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID22001454_20201005_0.5	ammonia measurement	drug_name	The clinical significance of plasma ammonia measurements in the diagnosis of generalized convulsions is investigated in this study.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6421986_20201005_0.5	ammonia measurement	drug_name	Blood ammonia measurement using a simple reflectometer.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6421986_20201005_0.5			Ammonia|Colorimetry|Humans|Liver Diseases|Quality Control|Valproic Acid	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6421986_20201005_0.5	ammonia measurement	drug_name	The Ammonia Checker is simple, convenient and reliable and is ideally suited for a laboratory required to perform an urgent blood ammonia measurement.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC5803234_20201005_0.5			Repeated Measures of Blood and Breath Ammonia in Response to Control, Moderate and High Protein Dose in Healthy Men	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC5803234_20201005_0.5			Adolescent|Adult|Ammonia|Breath Tests|Diet, High-Protein|Exhalation|Healthy Volunteers|Humans|Male|Pilot Projects	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC5803234_20201005_0.5	ammonia measurement	drug_name	Changes in blood and breath ammonia were detectable by fast, minimally-invasive (blood) or non-invasive (breath) point-of-care ammonia measurement methods.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15839409_20201005_0.5			Relative ammonia concentrations, dust concentrations, and presence of Salmoneua species and Escherichia coli inside and outside commercial layer facilities.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15839409_20201005_0.5			Air Pollutants|Ammonia|Animal Husbandry|Animals|Chickens|Dust|Environmental Monitoring|Escherichia coli|Housing, Animal|Manure|Ohio|Salmonella	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15839409_20201005_0.5	ammonia measurement	drug_name	The ammonia measurement trends inside of the facilities were affected by the temperature-dependent ventilation systems.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID22540295_20201005_0.5	ammonia measurement	drug_name	Is the effect of hemolysis on plasma ammonia measurement overrated?	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID22540295_20201005_0.5			Ammonia|Blood Chemical Analysis|Hemolysis|Humans|Plasma	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7010930_20210311_0.5			Beneficial Effects of Ketogenic Diet on Phosphofructokinase Deficiency (Glycogen Storage Disease Type VII)	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7010930_20210311_0.5			GSDVII|Tarui disease|ammonia|cardiopulmonary exercise capacity|glykogen storage disease|ketogenic diet|lactate	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7010930_20210311_0.5			Humans|Male|Female|Glycogen Storage Disease Type VII|Diet, Ketogenic|Exercise|Glycogen Storage Disease|Exercise Tolerance|Muscle, Skeletal|Muscular Diseases|Exercise Test|Glucose|Phosphofructokinases	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7010930_20210311_0.5	ammonia measurement	drug_name	Cardiopulmonary exercise testing, including breath gas analysis and venous lactate and ammonia measurements, was performed before KD and at 3, 8 months and 5 years after initiation of KD.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33279903_20201214_0.5			Extracorporeal Ammonia Clearance for Hyperammonemia in Critically Ill Patients: A Scoping Review.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33279903_20201214_0.5			Ammonia|Clearance|Continuous renal replacement therapy|Hemodialysis|Inborn errors of metabolism|Liver failure|Urea cycle	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33279903_20201214_0.5			Adult|Humans|Male|Child|Ammonia|Hyperammonemia|Critical Illness|Data Management|Renal Dialysis|Liver Failure|Kinetics	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33279903_20201214_0.5	ammonia measurement	drug_name	We included all publications reporting ammonia clearance by extracorporeal treatment in adult and pediatric patients with clearance estimated by direct dialysate ammonia measurement or calculated by formula.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10925811_20201005_0.5	ammonia measurement	drug_name	A review of the literature on the application of blood ammonia measurement in sports science.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10925811_20201005_0.5			Ammonia|Exercise|Glycogen|Humans|Muscle Fibers, Skeletal|Physical Endurance|Running	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10925811_20201005_0.5	ammonia measurement	drug_name	These reveal the possibility of applying blood ammonia measurement in monitoring and prescribing exercise, indirect measurement of muscle fiber composition, and muscle glycogen levels.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10925811_20201005_0.5	ammonia measurement	drug_name	However, more studies need to be conducted to evaluate these possibilities before blood ammonia measurement can be widely used.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID18200872_20201005_0.5	ammonia measurement	drug_name	A laboratory intercomparison of real-time gaseous ammonia measurement methods.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID18200872_20201005_0.5			Ammonia|Diffusion|Gases|Luminescence|Sensitivity and Specificity	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31855649_20201005_0.5			Advances in sensing ammonia from agricultural sources.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31855649_20201005_0.5			Ammonia|Fertiliser Application|Livestock production|Nitrogen losses|Sensors	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31855649_20201005_0.5			Animals|Humans|Ammonia|Ecosystem|Agriculture|Particulate Matter|Air Pollution|Air Pollutants|Atmosphere|Livestock|Farms|Nitrogen	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31855649_20201005_0.5	ammonia measurement	drug_name	This review considers how ammonia measurements are made and applied, including the need for sensors that are suitable for routine monitoring by non-specialists.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11817778_20201005_0.5			Role of Helicobacter pylori infection in hyperammonemia and subclinical hepatic encephalopathy in cirrhosis of liver.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11817778_20201005_0.5			Adolescent|Adult|Biopsy, Needle|Case-Control Studies|Comorbidity|Female|Helicobacter Infections|Helicobacter pylori|Hepatic Encephalopathy|Humans|Hyperammonemia|Incidence|India|Liver Cirrhosis|Male|Middle Aged|Risk Factors|Sensitivity and Specificity	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11817778_20201005_0.5	ammonia measurement	drug_name	 METHODS Patients with cirrhosis of liver but no hepatic encephalopathy underwent venous blood ammonia measurement, psychometric tests (number connection tests [NCT] and figure connection tests [FCT]), and gastric biopsies for presence of H. pylori infection.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27533447_20201005_0.5			Applications of external cavity diode laser-based technique to noninvasive clinical diagnosis using expired breath ammonia analysis: chronic kidney disease, epilepsy.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27533447_20201005_0.5			Ammonia|Breath Tests|Epilepsy|Humans|Lasers, Semiconductor|Renal Insufficiency, Chronic	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27533447_20201005_0.5	ammonia measurement	drug_name	The results suggest that our breath ammonia measurement system has great potential as an easy, noninvasive, real-time, and continuous monitor of the clinical parameters related to epilepsy and CKD.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6675166_20201005_0.5			Erythrocyte ammonia in liver disease.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6675166_20201005_0.5			Adolescent|Adsorption|Adult|Ammonia|Blood Specimen Collection|Erythrocytes|Female|Hepatic Encephalopathy|Humans|Liver Diseases|Male|Middle Aged	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6675166_20201005_0.5	ammonia measurement	drug_name	We conclude that erythrocyte ammonia measurement is a better biochemical index of PSE than plasma ammonia.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17685471_20201005_0.5			Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17685471_20201005_0.5			Adult|Aged|Ammonia|Brain Edema|Female|Hepatic Encephalopathy|Humans|Intracranial Hypertension|Liver Failure, Acute|Male|Middle Aged|Risk Factors|Severity of Illness Index	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17685471_20201005_0.5	ammonia measurement	drug_name	Ammonia measurements could form part of risk stratification for HE and ICH, identifying patients for ammonia-lowering therapies and invasive monitoring.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4815113_20201005_0.5			Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4815113_20201005_0.5			Carglumic acid|Hyperammonaemia|Organic acidurias (OAs)|OA decompensation episodes	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4815113_20201005_0.5			Amino Acid Metabolism, Inborn Errors|Ammonia|Female|Glutamates|Humans|Hyperammonemia|Infant, Newborn|Male|Propionic Acidemia|Retrospective Studies|Treatment Outcome	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4815113_20201005_0.5	ammonia measurement	drug_name	The primary outcome was change in plasma ammonia from baseline to endpoint (last available ammonia measurement at ≤18 hours after the last carglumic acid administration, or on Day 15) for each episode.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15766089_20201005_0.5			[Direct fluorophotometric and flow-injection fluorophotometric methods for the determination of trace ammonia].	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15766089_20201005_0.5			Ammonia|Calibration|Catalysis|Flow Injection Analysis|Fluorophotometry|Mercaptoethanol|Sensitivity and Specificity|Spectrometry, Fluorescence	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15766089_20201005_0.5	ammonia measurement	drug_name	No section Direct fluorophotometric and flow-injection fluorophotometric methods for trace ammonia measurement involving the fluorescent reaction of ammonia with o-phthaldlaldehyde (OPA) and 2-mercaptoethanol (ME) producing derivant of iso-indol in alkaline solution are described.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17163021_20201005_0.5			Aeration control for simultaneous nitrification-denitrification in a biological aerated filter using internal model approach.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17163021_20201005_0.5			Algorithms|Bioreactors|Filtration|Models, Theoretical|Nitrogen|Waste Disposal, Fluid	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID17163021_20201005_0.5	ammonia measurement	drug_name	The strategy proposed makes use of ammonia measurements and the inlet and outlet: a Feedback/Feedforward block.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31543304_20210111_0.5			Estimated time-varying exposures to air emissions from animal feeding operations and childhood asthma.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31543304_20210111_0.5			Agriculture|Air pollution|Animal feeding operations|Dairy farms|Industrial food production|Pediatric asthma	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31543304_20210111_0.5			Air Pollutants|Air Pollution|Ammonia|Animal Husbandry|Animals|Asthma|Child|Environmental Exposure|Female|Forced Expiratory Volume|Humans|Longitudinal Studies|Male|Respiratory Function Tests	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID31543304_20210111_0.5	ammonia measurement	drug_name	 No section Estimates of daily AFO air pollution correlated moderately well with outdoor ammonia measurements (N = 842; r = 0.62).	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6723050_20201005_0.5			Influences of specimen processing and storage conditions on results for plasma ammonia.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6723050_20201005_0.5			Ammonia|Blood Preservation|Centrifugation|Freezing|Hemolysis|Heparin|Humans|Specimen Handling|Time Factors	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6723050_20201005_0.5	ammonia measurement	drug_name	Using replicate specimens from healthy volunteers, we studied influences of specimen processing and storage procedures on ammonia measurements made with a self-contained reagent system.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24691936_20201005_0.5			Multiple low doses of erythropoietin delay the proliferation of hepatocytes but promote liver function in a rat model of subtotal hepatectomy.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24691936_20201005_0.5			Animals|Apoptosis|Cell Proliferation|Dose-Response Relationship, Drug|Erythropoietin|Hepatectomy|Hepatocytes|Interleukin-6|Liver|Liver Regeneration|Male|Models, Animal|Rats|Rats, Wistar|Stimulation, Chemical|Time Factors	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24691936_20201005_0.5	ammonia measurement	drug_name	We analyzed survival and hepatocyte proliferation in animals treated with or without EPO and assessed liver function by blood ammonia measurement and the indocyanine green 15-min retention test.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11921813_20201005_0.5			Detection of ammonia by photoacoustic spectroscopy with semiconductor lasers.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11921813_20201005_0.5	ammonia measurement	drug_name	The results are compared with recent ammonia measurements with a NIR diode and absorption spectroscopy used for detection and photoacoustic experiments performed with an infrared quantum-cascade laser.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID2361785_20201005_0.5			Medical implications of the lactate and ammonia relationship in anaerobic exercise.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID2361785_20201005_0.5			AMP Deaminase|Adult|Ammonia|Anaerobiosis|Biopsy|Creatine Kinase|Diagnosis, Differential|Exercise|Exercise Test|Female|Glycolysis|Humans|Lactates|Magnetic Resonance Spectroscopy|Male|Muscle Contraction|Muscles|Muscular Diseases|Nucleotide Deaminases	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID2361785_20201005_0.5	ammonia measurement	drug_name	The role of the ammonia measurement is emphasized here because the lactate response is more familiar.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID2361785_20201005_0.5	ammonia measurement	drug_name	The roles of hypoxanthine responses and of muscle ammonia measurements in the evaluation of cases are examined, and some pertinent and recently introduced analytic methods are cited.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27913270_20201005_0.5			Comparison of plasma ammonia results from seven different automated platforms in use throughout Central Australia.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27913270_20201005_0.5			Ammonia|Ammonium|Comparison|Correlation|Hyperammonemia|Quality assurance	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27913270_20201005_0.5			Ammonia|Australia|Automation, Laboratory|Hematology|Humans|Metabolic Diseases|Reference Values|Reproducibility of Results	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27913270_20201005_0.5	ammonia measurement	drug_name	 RESULTS Passing-Bablok regression analysis showed slopes ranging from 1.00 to 1.10 and y-intercepts ranging from -10μmol/L to 1μmol/L. CONCLUSIONS Despite the absence of a reference method or reference material and troublesome pre-analytical effects in ammonia measurement, plasma ammonia results from the different platforms in general compare well.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27913270_20201005_0.5	ammonia measurement	drug_name	The study also demonstrates that samples for ammonia measurement can be transported over great distances and still correlate well.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID32974_20201005_0.5			Automated enzymatic assay for plasma ammonia.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID32974_20201005_0.5			Adenosine Diphosphate|Ammonia|Autoanalysis|Glutamate Dehydrogenase|Humans|Kinetics|L-Lactate Dehydrogenase|Malate Dehydrogenase|NAD|NADP	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID32974_20201005_0.5	ammonia measurement	drug_name	The assay requires a sample volume of 500 muL for a kinetic ammonia measurement.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10791209_20201005_0.5			Breath and blood ammonia in liver cirrhosis.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10791209_20201005_0.5			Adult|Aged|Ammonia|Antibodies, Bacterial|Breath Tests|Disease Progression|Female|Helicobacter Infections|Helicobacter pylori|Hepatic Encephalopathy|Hepatitis C, Chronic|Humans|Liver Cirrhosis|Male|Middle Aged|Predictive Value of Tests|Reference Values	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10791209_20201005_0.5	ammonia measurement	drug_name	 CONCLUSIONS Breath ammonia measurement may be useful in diagnosis, treatment assessment, and follow-up in hepatic encephalopathy.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11776140_20201005_0.5			Changes in serum ammonia concentration in cirrhotic patients with Helicobacter pylori infection.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11776140_20201005_0.5			Ammonia|Helicobacter Infections|Helicobacter pylori|Humans|Liver Cirrhosis|Portal Vein|Veins	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID11776140_20201005_0.5	ammonia measurement	drug_name	 CONCLUSIONS H. pylori infection can induce an increase in serum ammonia in patients with liver dysfunction, and the peripheral serum ammonia measurement may replace the portal vein serum ammonia as a monitoring method.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25690729_20201005_0.5			Evaluation of Implementation, Adaptation and Use of the Recently Proposed Urea Cycle Disorders Guidelines.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25690729_20201005_0.5			Child|Humans|Male|Female|Urea Cycle Disorders, Inborn|Hospitals|Acclimatization|Austria|Germany	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25690729_20201005_0.5	ammonia measurement	drug_name	iv) The implementation process improved the availability of ammonia measurements and access to emergency medication, patient care processes, and cooperation between nonspecialists and specialists.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26658550_20201005_0.5			Clinical utility of breath ammonia for evaluation of ammonia physiology in healthy and cirrhotic adults.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26658550_20201005_0.5			Adult|Ammonia|Breath Tests|Case-Control Studies|Female|Humans|Liver Cirrhosis|Male|Young Adult	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26658550_20201005_0.5	ammonia measurement	drug_name	Each participant contributed 5 breath samples and blood for ammonia measurement within 1 h. We calculated the coefficient of variation (CV) for 5 breath ammonia values, reported medians of healthy and cirrhotic participants, and used scatterplots to display breath and blood ammonia.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26658550_20201005_0.5	ammonia measurement	drug_name	Given the many differences between breath and blood ammonia measurement, we examined biological explanations for our findings in healthy and cirrhotic participants.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID18408261_20201005_0.5	ammonia measurement	drug_name	The breath ammonia measurement of the hemodialysis with a QCM-NH3 sensor.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID18408261_20201005_0.5			Aged|Aged, 80 and over|Ammonia|Biosensing Techniques|Blood Urea Nitrogen|Breath Tests|Creatinine|Female|Gases|Humans|Male|Middle Aged|Renal Dialysis	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26076508_20201005_0.5			[Pilot test for Helicobacter pylori detection with ammonia breath test].	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26076508_20201005_0.5			Adult|Ammonia|Breath Tests|Endoscopy, Gastrointestinal|Female|Helicobacter Infections|Helicobacter pylori|Humans|Male|Predictive Value of Tests|Sensitivity and Specificity|Young Adult	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26076508_20201005_0.5	ammonia measurement	drug_name	The subjects with both negative tests (non-infected) or positive (infected) were selected for ammonia measurement in exhaled air.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26466167_20201005_0.5			First data on the biological variation and quality specifications for plasma ammonia concentrations in healthy subjects.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26466167_20201005_0.5			Adult|Ammonia|Female|Healthy Volunteers|Humans|Male|Middle Aged|Young Adult	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26466167_20201005_0.5	ammonia measurement	drug_name	BACKGROUND Most of the factors causing preanalytical and analytical variation in ammonia measurement have been identified.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26907707_20201005_0.5			The Measurement of Ammonia in Human Breath and its Potential in Clinical Diagnostics.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26907707_20201005_0.5			Ammonia|blood|breath|diagnostics	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26907707_20201005_0.5			Amino Acid Metabolism, Inborn Errors|Ammonia|Breath Tests|Humans|Hyperinsulinism|Hypoglycemia|Reye Syndrome|Urea Cycle Disorders, Inborn	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26907707_20201005_0.5	ammonia measurement	drug_name	This review explores the diagnostic applications of ammonia measurement and the impact that the move from blood to breath analysis could have on how these processes and diseases are studied and managed.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC6087568_20201005_0.5			Blood Ammonia Level Correlates with Severity of Cirrhotic Portal Hypertensive Gastropathy	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC6087568_20201005_0.5			Child|Middle Aged|Adult|Male|Aged|Humans|Female|Cross-Sectional Studies|Ammonia|Hypertension, Portal|Esophageal and Gastric Varices|Stomach Diseases|Liver Cirrhosis|Liver Function Tests|Portal Vein|Splenic Vein|Liver|Spleen	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC6087568_20201005_0.5	ammonia measurement	drug_name	A full clinical examination, routine laboratory tests, abdominal ultrasonography, child score calculation, and blood ammonia measurement were performed for all patients.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25574663_20201005_0.5	ammonia measurement	drug_name	A statistical comparison of active and passive ammonia measurements collected at Clean Air Status and Trends Network (CASTNET) sites.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25574663_20201005_0.5			Air Pollutants|Air Pollution|Ammonia|Atmosphere|Environmental Monitoring|Seasons|United States	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID20577487_20201005_0.5	ammonia measurement	drug_name	Atmospheric ammonia measurement using a VUV/photo-fragmentation laser-induced fluorescence technique.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID20577487_20201005_0.5			Fluorescence|Ammonia|Air Pollutants|Environmental Monitoring	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID20577487_20201005_0.5	ammonia measurement	drug_name	Average ammonia measurements at Stone Mountain, GA, ranged from approximately 110 pptv for air temperatures <5 degrees C to approximately 240 pptv for air temperatures >/=<5 degrees C over the period from Dec. 1987 to the end of Apr. 1988.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7957887_20210411_0.5	ammonia measurement	drug_name	Low-Cost Fluorescence Sensor for Ammonia Measurement in Livestock Houses	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7957887_20210411_0.5			NH3|ammonia|fluorescence sensor|pigs	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC7957887_20210411_0.5			Agriculture|Ammonia|Animals|Livestock|Spectrum Analysis|Swine	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID7511436_20201005_0.5			Changes in blood ammonia induced by a maximum effort in trained and untrained subjects.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID7511436_20201005_0.5			Ammonia|Humans|Lactates|Lactic Acid|Male|Physical Education and Training|Reference Values	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID7511436_20201005_0.5	ammonia measurement	drug_name	In conclusion, ammonia measurements during exercise provide a valuable information about muscle cell oxidative capacity.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID7649702_20201005_0.5			Blood ammonia response to treadmill and bicycle exercise in man.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID7649702_20201005_0.5			Adult|Ammonia|Bicycling|Exercise Test|Humans|Lactates|Male|Oxygen Consumption|Physical Endurance|Running|Work	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID7649702_20201005_0.5	ammonia measurement	drug_name	The finding that blood ammonia accumulation during exercise is critically dependent upon the test procedure has to be taken into account whenever blood ammonia measurements are used in the physiological monitoring of athletes.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33527916_20210211_0.5	ammonia measurement	drug_name	Real-time breath ammonia measurement using a novel cuprous bromide sensor device in patients with chronic liver disease: a feasibility and pilot study.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33527916_20210211_0.5			Humans|Male|Adult|Middle Aged|Female|Pilot Projects|Bromides|Ammonia|Feasibility Studies|Breath Tests|Liver Diseases|Exhalation|Liver Cirrhosis|Renal Insufficiency, Chronic|Body Fluids	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID18609575_20201005_0.5			Development of an enzyme membrane reactor for treatment of cyanide-containing wastewaters from the food industry.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID18609575_20201005_0.5	ammonia measurement	drug_name	For monitoring continuous-membrane reactor operation, a new unsegmented ammonia measurement system was developed and applied.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24915632_20201005_0.5	ammonia measurement	drug_name	The evidence based practice for optimal sample quality for ammonia measurement.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24915632_20201005_0.5			Ammonia|Centrifugation|Phlebotomy|Preanalytical error|Storage conditions	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24915632_20201005_0.5			Adult|Ammonia|Evidence-Based Practice|Healthy Volunteers|Humans|Middle Aged|Young Adult	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24915632_20201005_0.5	ammonia measurement	drug_name	We aimed to investigate several pre-analytical factors influencing ammonia measurement, and to quantify their effect on the apparent increase in ammonia concentration.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24915632_20201005_0.5	ammonia measurement	drug_name	 CONCLUSIONS Pre-analytical factors cause significant errors in ammonia measurement.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10378279_20201005_0.5	ammonia measurement	drug_name	Evaluation of ammonia measurements in dogs with two analysers for use in veterinary practice.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10378279_20201005_0.5			Ammonia|Animals|Autoanalysis|Dog Diseases|Dogs|Evaluation Studies as Topic|Hepatic Encephalopathy|Immunoenzyme Techniques|Reagent Kits, Diagnostic|Reference Standards	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10378279_20201005_0.5	ammonia measurement	drug_name	No section The measurement of ammonia in biological fluids is the only way to diagnose and evaluate hepatic encephalopathy, but samples for ammonia measurement cannot be stored or sent by post.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID10378279_20201005_0.5	ammonia measurement	drug_name	Two analysers for use in veterinary practice have recently become available, the VetTest and the Blood Ammonia Checker II; the reliability of ammonia measurements in canine blood with these two analysers has been evaluated by comparing the results with a standard automated enzymatic assay.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24299143_20201005_0.5	ammonia measurement	drug_name	Point of care monitoring of hemodialysis patients with a breath ammonia measurement device based on printed polyaniline nanoparticle sensors.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID24299143_20201005_0.5			Ammonia|Aniline Compounds|Breath Tests|Calibration|Humans|Nanoparticles|Point-of-Care Systems|Printing|Renal Dialysis	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33524596_20210311_0.5	ammonia measurement	drug_name	Erroneous Ammonia Measurement is Not Synonymous With a Lack of Efficacy of Ammonia-Lowering Therapies in Hepatic Encephalopathy.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12637132_20201005_0.5			Correlation between ammonia levels and the severity of hepatic encephalopathy.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12637132_20201005_0.5			Adult|Aged|Ammonia|Biomarkers|Blood Chemical Analysis|Blood Pressure Determination|Female|Hepatic Encephalopathy|Humans|Logistic Models|Male|Middle Aged|Ohio|Partial Pressure|Predictive Value of Tests|Prospective Studies|Severity of Illness Index|Statistics as Topic	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12637132_20201005_0.5	ammonia measurement	drug_name	Four types of ammonia measurements were analyzed: arterial and venous total ammonia, and arterial and venous partial pressure of ammonia.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12637132_20201005_0.5	ammonia measurement	drug_name	Venous sampling is adequate for ammonia measurement.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID603099_20201005_0.5			[Electrometric determination of urinary ammonia using a continuous-flow automatic method].	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID603099_20201005_0.5			Ammonia|Autoanalysis|Humans|Kidney Function Tests|Methods	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID603099_20201005_0.5	ammonia measurement	drug_name	The simplification of the ammonia measurement procedure thus achieved will allow an important increase in the number of renal function tests that a clinical routine laboratory can handle in a hospital.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15554426_20201005_0.5			Blood ammonia levels and hepatic encephalopathy.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15554426_20201005_0.5			Ammonia|Animals|Blood Chemical Analysis|Blood-Brain Barrier|Brain|Diffusion|Gases|Hepatic Encephalopathy|Humans	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15554426_20201005_0.5	ammonia measurement	drug_name	The value of blood ammonia measurements is limited by the fact that this is not the variable that is the most important.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID8880492_20210611_0.5			Quantitative study of Helicobacter pylori in gastric mucus by competitive PCR using synthetic DNA fragments.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID8880492_20210611_0.5			Adult|Aged|Base Sequence|DNA, Bacterial|Female|Gastric Juice|Helicobacter pylori|Humans|Male|Middle Aged|Molecular Sequence Data|Polymerase Chain Reaction	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID8880492_20210611_0.5	ammonia measurement	drug_name	The results obtained by this method were compared with the results of histological examination, the rapid urease test, bacterial culture, the [13C]urea breath test, and urea and ammonia measurements in gastric juice.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25936660_20201005_0.5			Simple and inexpensive quantification of ammonia in whole blood.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25936660_20201005_0.5			Ammonia|Blood|Hyperammonemia|Indophenol|Membrane	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25936660_20201005_0.5			Ammonia|Blood Chemical Analysis|Humans|Hyperammonemia|Indophenol	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID25936660_20201005_0.5	ammonia measurement	drug_name	Current techniques for ammonia measurement suffer from limited range, poor resolution, false positives or large, complex sensor set-ups.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15011224_20201005_0.5			Unusual causes of hyperammonemia in the ED.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15011224_20201005_0.5			Adult|Aged|Anticonvulsants|Antimetabolites, Antineoplastic|Emergency Service, Hospital|Female|Fluorouracil|Humans|Hyperammonemia|Male|Middle Aged|Multiple Myeloma|Ornithine Carbamoyltransferase Deficiency Disease|Valproic Acid	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID15011224_20201005_0.5	ammonia measurement	drug_name	No section Plasma ammonia measurement is a simple yet important screening in the ED for patients with unexplained stupor or delirium.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID19067141_20201005_0.5			Gut ammonia production and its modulation.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID19067141_20201005_0.5			Ammonia|Animals|Genetic Predisposition to Disease|Glutaminase|Glutamine|Hepatic Encephalopathy|Humans|Hyperammonemia|Intestine, Small|Liver Circulation|Liver Failure, Acute|Mutation	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID19067141_20201005_0.5	ammonia measurement	drug_name	The lack of correlation between ammonia levels and grade of hepatic encephalopathy in some cases has been considered a weakness of the ammonia hypothesis, but new methods for ammonia measurements and the implication of systemic inflammation in the modulation of ammonia neurotoxicity could explain this gap; b) the source of ammonia production.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33069881_20210111_0.5			Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33069881_20210111_0.5			Altered Mental Status|Liver Fibrosis|NH3|Portal Hypertension	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33069881_20210111_0.5			Humans|Male|Adult|Middle Aged|Female|Hepatic Encephalopathy|ornithine phenylacetate|Double-Blind Method|Ornithine|Lactulose|Liver Cirrhosis|Ammonia|Dipeptides|Australia|Europe|Israel|North America	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID33069881_20210111_0.5	ammonia measurement	drug_name	 RESULTS Median times to clinical improvement, based on ammonia measurements at local laboratories, did not differ significantly between the groups given OP vs the placebo group (P = .129).	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID30719899_20201005_0.5			Hyperammonaemia in Neonates and Young Children: Potential Metabolic Causes, Diagnostic Approaches and Clinical Consequences	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID30719899_20201005_0.5			Ammonia|Arginine|Biomarkers|Brain Diseases, Metabolic, Inborn|Carnitine|Critical Illness|Diet, Protein-Restricted|Early Diagnosis|Emergencies|Female|Humans|Hyperammonemia|Infant|Infant, Newborn|Male|Phenylbutyrates|Sodium Benzoate|Treatment Outcome	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID30719899_20201005_0.5	ammonia measurement	drug_name	In children with acute overwhelming illness and progressive neurological deterioration plasma ammonia measurement should be included in the urgent diagnostic work-up.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC3292136_20201005_0.5			Time Delay for Aerial Ammonia Concentration Measurements in Livestock Buildings	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC3292136_20201005_0.5	ammonia measurement	drug_name	photo acoustic spectroscopy|ammonia measurement|time delay	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC3292136_20201005_0.5			Ammonia|Animals|Environmental Monitoring|Housing, Animal|Livestock|Photoacoustic Techniques|Time Factors	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID16624991_20201005_0.5			Evidence from knockout mice against physiologically significant aquaporin 8-facilitated ammonia transport.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID16624991_20201005_0.5			Ammonia|Ammonium Chloride|Animals|Aquaporins|Biological Transport|Ion Channels|Liver|Male|Mice|Mice, Knockout|Mice, Transgenic|Rats|Testis	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID16624991_20201005_0.5	ammonia measurement	drug_name	A series of in vivo studies were done in mice, including 1) serum ammonia measurements before and after ammonia infusion, 2) renal ammonia clearance, 3) colonic ammonia absorption, and 4) liver ammonia accumulation and renal ammonia excretion after acute and chronic ammonia loading.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4432089_20201005_0.5	ammonia measurement	drug_name	Intercomparison of real-time tailpipe ammonia measurements from vehicles tested over the new world-harmonized light-duty vehicle test cycle (WLTC)	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4432089_20201005_0.5			Ammonia|Vehicle emissions|FTIR|QCL-IR|BLAQ-Sys|Raw exhaust measurements	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC4432089_20201005_0.5			Ammonia|Gasoline|Italy|Reproducibility of Results|Vehicle Emissions	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC3253684_20201005_0.5			A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC3253684_20201005_0.5			Administration, Oral|Adult|Aged|Ammonia|Biomarkers|Capillaries|Cohort Studies|Female|Follow-Up Studies|Glutamine|Hematologic Tests|Hepatic Encephalopathy|Humans|Incidence|Liver Cirrhosis|Male|Middle Aged|Point-of-Care Systems|Predictive Value of Tests|Prevalence|Psychometrics	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMC3253684_20201005_0.5	ammonia measurement	drug_name	After psychometric tests and capillary (ear lobe) blood ammonia measurements, 20 gr of glutamine was administered orally.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12452390_20201005_0.5	ammonia measurement	drug_name	Breath ammonia measurement in Helicobacter pylori infection.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12452390_20201005_0.5			Adult|Ammonia|Breath Tests|Female|Helicobacter Infections|Helicobacter pylori|Humans|Male|Middle Aged|Urea	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12452390_20201005_0.5	ammonia measurement	drug_name	No section Our aim was to define the utility of breath ammonia measurement in assessing Helicobacter pylori infection.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12452390_20201005_0.5	ammonia measurement	drug_name	In conclusion, breath ammonia measurement for H. Pylori-positive and negative subjects showed distinct patterns.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID12452390_20201005_0.5	ammonia measurement	drug_name	Breath ammonia measurement may be feasible as a diagnostic test for H. pylori.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27296306_20201005_0.5			Feasibility Study of Using Breath Ammonia Analysis Based on Off-Axis Cavity-Enhanced Absorption Spectroscopy with External Cavity Diode Laser for Noninvasive Real-Time Diagnosis of Helicobacter Pylori.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27296306_20201005_0.5			External cavity lasers|Helicobacter pylori|off-axis cavity enhanced absorption spectroscopy	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27296306_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Ammonia|Breath Tests|Child|Child, Preschool|Female|Helicobacter Infections|Helicobacter pylori|Humans|Male|Middle Aged|Signal Processing, Computer-Assisted|Spectrum Analysis|Young Adult	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID27296306_20201005_0.5	ammonia measurement	drug_name	The reported results suggest that our breath ammonia measurement system has the potential for future use in easy, noninvasive diagnosis of HP infection.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID29076371_20201005_0.5			Ammonia concentrations in canine whole blood, EDTA-anticoagulated whole blood, and plasma measured by use of a point-of-care ammonia meter.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID29076371_20201005_0.5			Ammonia|Animals|Blood Specimen Collection|Dog Diseases|Dogs|Edetic Acid|Point-of-Care Systems|Reference Values	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID29076371_20201005_0.5	ammonia measurement	drug_name	One drop of plasma was applied to a test strip; the remainder of the plasma sample was transported on ice and used for ammonia measurement with a reference laboratory instrument.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID32735981_20201214_0.5	ammonia measurement	drug_name	Transportation and handling of blood samples prior to ammonia measurement in the real life of a large university hospital.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID32735981_20201214_0.5			Ammonia|Pneumatic transport|Preanalytical delays|Stability	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID32735981_20201214_0.5			Ammonia|Hospitals, University|Transportation|Centrifugation|Hyperammonemia|Biological Assay|Emergency Service, Hospital|Neurotoxicity Syndromes|Plasma|Specimen Handling	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID20856407_20201005_0.5			Laser Stark spectrometer for the measurement of ammonia in flue gas.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID20856407_20201005_0.5	ammonia measurement	drug_name	The dependence of the ammonia measurement on temperature and pressure variations is derived and verified experimentally.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26178875_20201005_0.5	ammonia measurement	drug_name	Serial ammonia measurement in patients poisoned with glufosinate ammonium herbicide.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26178875_20201005_0.5			Ammonia|glufosinate ammonium|poisoning	author_keywords
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26178875_20201005_0.5			Aminobutyrates|Ammonia|Female|Glasgow Coma Scale|Herbicides|Humans|Male|Middle Aged|Neurotoxicity Syndromes|Predictive Value of Tests|Time Factors	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID26178875_20201005_0.5	ammonia measurement	drug_name	This study showed that serial ammonia measurements in GLA-poisoned patients may identify those who are at high risk of developing neurotoxicity.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6791359_20201005_0.5			[Distribution of rabies antigen in the central nervous system of rats and mice experimentally infected with rabies strains isolated from hamsters (Cricetus cricetus)].	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6791359_20201005_0.5			Animals|Antigens, Viral|Central Nervous System|Cricetinae|Mice|Rabies|Rabies virus|Rats|Rodent Diseases	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID6791359_20201005_0.5	ammonian	drug_umls_atom	In this period the rabies antigen strain 9 E was not detected in lumbar spinal cord and that with strain 1151 was detected only in the Ammonian horns.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID28922211_20201005_0.5	ammonia inhalants	drug_umls_atom	Acute Effects of Ammonia Inhalants on Strength and Power Performance in Trained Men.	title
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID28922211_20201005_0.5			Adult|Ammonia|Athletes|Central Nervous System Stimulants|Cross-Over Studies|Humans|Isometric Contraction|Male|Movement|Muscle Strength|Muscle, Skeletal|Resistance Training|Young Adult	mesh_terms
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID28922211_20201005_0.5	ammonia inhalants	drug_umls_atom	No section Bartolomei, S, Nigro, F, Luca, G, Gabriele, S, Ciacci, S, Hoffman, JR, and Merni, F. Acute effects of ammonia inhalants on strength and power performance in trained men.	abstract
Ammonia measurement	C0201879			ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13	trade_name	PubMed	PMID28922211_20201005_0.5	ammonia inhalants	drug_umls_atom	J Strength Cond Res 32(1): 244-247, 2018-The aim of the present study was to investigate the influence of ammonia inhalants on lower body power and maximal isometric strength in trained men.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID10923595_20201005_0.5			Localized pustulosis induced by betalactams.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID10923595_20201005_0.5			Adult|Ceftibuten|Cephalosporins|Drug Hypersensitivity|Exanthema|Facial Dermatoses|Female|Humans|Mastitis	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID10923595_20201005_0.5	benzylpenicilloyl polylysine	drug_name	The following tests were performed: prick and intradermal tests with benzylpenicilloyl polylysine, minor determinant mixture, benzylpenicillin and amoxicillin; patch tests were also carried out with benzylpenicillin, amoxicillin, cloxacillin, cefuroxime, ceftriaxone, cefazolin, ceftibuten and cefaclor.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1576461_20201005_0.5			Penicillin anaphylaxis: a review of sensitization, treatment, and prevention.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1576461_20201005_0.5			Anaphylaxis|Drug Hypersensitivity|False Negative Reactions|Humans|Penicillins|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1576461_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Skin testing with a mixture of benzylpenicilloyl polylysine (major determinant) and a minor determinant mixture detects all patients at risk of major anaphylaxis.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC5691303_20201005_0.5			Utility of basophil activation testing to assess perioperative anaphylactic reactions in real‐world practice	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC5691303_20201005_0.5			Basophil activation test|drug allergy|perioperative anaphylaxis	author_keywords
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC5691303_20201005_0.5			Adult|Aged|Anaphylaxis|Anesthesia, General|Basophils|Biomarkers|Disease Management|Female|Flow Cytometry|Humans|Immunoglobulin E|Male|Middle Aged|Perioperative Period|Serologic Tests|Skin Tests|Young Adult	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC5691303_20201005_0.5	benzylpenicilloyl polylysine	drug_name	BATs based on stimulation of whole blood cells measuring CD63 activation of basophils and using CCR3 as basophil marker by flow cytometry (Flow CAST®, BÜHLMANN Laboratories AG, Schönenbuch, Switzerland) were performed with the following substances (in dependence on the history and the skin tests of the patient): analgesics (acetylsalicylic acid, celecoxib, diclofenac, ibuprofen, indometacin, metamizole, paracetamol, propyphenazone, tramadol), antibiotics (PPL (benzylpenicilloyl polylysine), MDM (minor determinant mixture), amoxicillin, cefuroxime, ciprofloxacin, doxycycline, erythromycin, roxithromycin, sulfamethoxazole, trimethoprim), local anesthetics (articaine, bupivacaine, lidocaine, prilocaine, procaine, methyl‐4‐hydroxybenzoate), narcotics and NMBA (atracurium, cisatracurium, etomidate, neostigmine, midazolam, mivacurium, pancuronium, propofol, pyridostigmine, succinylcholine, sufentanil, thiopental, vecuronium), and other individual substances.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID8230623_20201005_0.5			Clinical experience with penicillin skin testing in a large inner-city STD clinic.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID8230623_20201005_0.5			Adult|Aged|Ambulatory Care Facilities|Baltimore|Benzeneacetamides|Drug Hypersensitivity|Female|Humans|Intradermal Tests|Male|Middle Aged|Penicillin G|Penicillins|Predictive Value of Tests|Reproducibility of Results|Sexually Transmitted Diseases|Skin Tests|Time Factors|Urban Health	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID8230623_20201005_0.5	benzylpenicilloyl polylysine	drug_name	OBJECTIVE To establish (1) the prevalence of positive penicillin skin tests among outpatients with well-defined but variable history of penicillin allergy and (2) the reproducibility, safety, and negative predictive value of skin testing with benzylpenicilloyl polylysine (PPL) and a minor-determinant mixture (MDM).	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID25017533_20201005_0.5			Penicillin skin testing is a safe and effective tool for evaluating penicillin allergy in the pediatric population.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID25017533_20201005_0.5			Adverse drug reaction|Pediatric|Penicillin allergy|Penicillin skin testing|Safe	author_keywords
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID25017533_20201005_0.5			Aged|Benzeneacetamides|Child|Child, Preschool|Contraindications|Drug Hypersensitivity|Female|Humans|Infant|Male|Middle Aged|Penicillin G|Penicillins|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID25017533_20201005_0.5	benzylpenicilloyl polylysine	drug_name	However, the commercially available benzylpenicilloyl polylysine (Pre-Pen) is not indicated in the pediatric population.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID18034982_20201005_0.5			Perioperative anaphylaxis in a 44-year-old man.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID18034982_20201005_0.5			Adult|Anaphylaxis|Anesthesia, General|Anti-Bacterial Agents|Cefazolin|Drug Hypersensitivity|Humans|Male|Perioperative Care|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID18034982_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Initial prick and intradermal skin tests (excluding skin testing for unavailable benzylpenicilloyl polylysine) and IgE immunoassays for penicillin and cefazolin were negative.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID19463208_20201005_0.5			The acceptability of a four-part protocol for penicillin allergy testing by practicing allergists.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID19463208_20201005_0.5			Benzeneacetamides|Clinical Protocols|Demography|Desensitization, Immunologic|Drug Hypersensitivity|Humans|Penicillin G|Penicillins|Physicians|Practice Guidelines as Topic|Skin Tests|Surveys and Questionnaires	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID19463208_20201005_0.5	benzylpenicilloyl polylysine	drug_name	No section Currently, there is no standard protocol to test for penicillin (PCN) allergy since PrePen (manufactured benzylpenicilloyl polylysine; AllerQuest, West Hartford, CT) was discontinued in 2004.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID19463208_20201005_0.5	benzylpenicilloyl polylysine	drug_name	This study was performed to determine whether fellows of the American Academy of Allergy, Asthma, and Immunology (AAAAI) would use a two-challenge PCN allergy protocol to test for PCN allergy while skin testing to the major determinant, benzylpenicilloyl polylysine, is unavailable.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID23712569_20201005_0.5			Penicillin skin testing: potential implications for antimicrobial stewardship.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID23712569_20201005_0.5	benzylpenicilloyl polylysine	drug_name	antimicrobial stewardship|benzylpenicilloyl polylysine|penicillin allergy|penicillin skin test|β-Lactam allergy	author_keywords
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID23712569_20201005_0.5			Anti-Bacterial Agents|Drug Hypersensitivity|Emergency Service, Hospital|History, 20th Century|Humans|Intensive Care Units|Penicillins|Pharmacists|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID11035685_20201005_0.5			A pilot study of penicillin skin testing in patients with a history of penicillin allergy admitted to a medical ICU.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID11035685_20201005_0.5			Adult|Aged|Aged, 80 and over|Benzeneacetamides|Drug Hypersensitivity|Female|Humans|Incidence|Intensive Care Units|Male|Middle Aged|Ohio|Patient Admission|Penicillin G|Penicillins|Pilot Projects|Prospective Studies|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID11035685_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Skin testing was performed with benzylpenicilloyl polylysine and penicillin G. We determined the incidence of true allergy, the percentage of patients in whom antibiotic coverage was modified, and the safety of the test.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID9385509_20201005_0.5			Skin tests in the diagnosis of eruptions caused by betalactams.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID9385509_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Anti-Bacterial Agents|Cross Reactions|Drug Eruptions|Female|Humans|Intradermal Tests|Lactams|Male|Middle Aged|Patch Tests|Penicillins|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID9385509_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Skin testing is usually carried out intradermally with benzylpenicilloyl polylysine (BPO-PPL) and minor determinant mixture (MDM), but these are often unsuitable for the detection of sensitivity to betalactam antibiotics.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1880322_20201005_0.5			Penicillin resensitization among hospitalized patients.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1880322_20201005_0.5			Adult|Aged|Anti-Bacterial Agents|Child|Drug Hypersensitivity|Female|Hospitalization|Humans|Lactams|Male|Middle Aged|Penicillins|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1880322_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Seventeen adults (aged 24 to 76 years) and one child (aged 10 years) were treated intravenously and/or orally with beta-lactam antibiotics after negative skin tests were obtained with benzylpenicilloyl polylysine, potassium penicillin G, and alkaline hydrolysis products of penicillin G as minor determinant mixture.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID1880322_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Two patients reacted to potassium penicillin G alone, and the other patient reacted to benzylpenicilloyl polylysine and minor determinant mixture.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID7436456_20201005_0.5			Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID7436456_20201005_0.5			Ampicillin|Child|Drug Hypersensitivity|Humans|Hypersensitivity, Immediate|Immunoglobulin E|Penicillins|Skin Tests|Time Factors	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID7436456_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Skin tests were conducted by the scratch/prick and intradermal techniques, using benzylpenicilloyl polylysine conjugate and a mixture of minor determinants of penicillin.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID17694698_20201005_0.5			Assessment of a new brand of determinants for skin testing in a large group of patients with suspected beta-lactam allergy.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID17694698_20201005_0.5			Allergens|Benzeneacetamides|Drug Hypersensitivity|Humans|Penicillin G|Penicillins|Prospective Studies|Skin Tests|Spain|beta-Lactams	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID17694698_20201005_0.5	benzylpenicilloyl polylysine	drug_name	 METHODS Prick tests and intradermal tests were performed with benzylpenicilloyl polylysine (PPL) and minor determinant mixture (MDM).	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID28743423_20201005_0.5			Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID28743423_20201005_0.5			Anti-Bacterial Agents|Drug Hypersensitivity|Humans|Inpatients|Penicillins|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID28743423_20201005_0.5	benzylpenicilloyl polylysine	drug_name	All patients underwent skin prick testing to benzylpenicilloyl polylysine (major determinant), penicillin G, penicilloate, penilloate (minor determinants), amoxicillin, and positive and negative controls.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5			Prevalence, Incidence, and Sensitization Profile of β-lactam Antibiotic Allergy in Hong Kong	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5			Adult|Anti-Bacterial Agents|Asian Continental Ancestry Group|Cross-Sectional Studies|Demography|Drug Hypersensitivity|Female|Hong Kong|Humans|Incidence|Male|Prevalence|Skin Tests|beta-Lactams	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5	benzylpenicilloyl polylysine	drug_name	No section This cross-sectional study examines the reported penicillin allergies and sensitization to skin-testing compounds benzylpenicilloyl polylysine and minor determinants among patients in Hong Kong.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Only 13.8% of patients who underwent skin testing had positive results, but 47% had high rates of sensitization to the reagent benzylpenicilloyl polylysine or a minor determinant (benzylpenicilloate).	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5	benzylpenicilloyl polylysine	drug_name	 Meaning These findings suggest that benzylpenicilloyl polylysine and a minor determinant (benzylpenicilloate) should be included in β-lactam antibiotic allergy skin testing for the large and rapidly growing burden of β-lactam antibiotic allergies reported among patients in Hong Kong.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5	benzylpenicilloyl polylysine	drug_name	The sensitization rate to either benzylpenicilloyl polylysine or a minor determinant (benzylpenicilloate) was 47.0% (n = 23; 95% CI, 34.85%-63.21%), with 10 patients monosensitized to benzylpenicilloyl polylysine only (20.4%; 95% CI, 11.74%-35.48%) and 5 to benzylpenicilloate only (10.2%; 95% CI, 4.45%-23.42%).	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMC7203606_20201005_0.5	benzylpenicilloyl polylysine	drug_name	 Conclusions and Relevance Results of this study suggest that patients in Hong Kong with β-lactam antibiotic allergy had much higher rates of monosensitization to benzylpenicilloyl polylysine and benzylpenicilloate, making these reagents essential in β-lactam antibiotic skin tests.	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID11101176_20201005_0.5			Frequency of systematic reactions to penicillin skin tests.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID11101176_20201005_0.5			Aged|Child|Drug Hypersensitivity|Follow-Up Studies|Humans|Male|Penicillins|Skin Tests|Time Factors	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID11101176_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Patients were tested with benzylpenicilloyl polylysine (Pre-Pen) (6.0 X 10(-5) M), freshly prepared penicillin G (10,000 units/ml), and penicilloate (0.01 M).	abstract
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID15317318_20201005_0.5			Penicillin hypersensitivity: value of clinical history and skin testing in daily practice.	title
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID15317318_20201005_0.5			Adolescent|Adult|Aged|Drug Hypersensitivity|Female|Humans|Immunoglobulin E|Male|Medical History Taking|Middle Aged|Penicillins|Reproducibility of Results|Sexually Transmitted Diseases, Bacterial|Skin Diseases, Bacterial|Skin Tests	mesh_terms
benzylpenicilloyl polylysine	C0053327				trade_name	PubMed	PMID15317318_20201005_0.5	benzylpenicilloyl polylysine	drug_name	Six hundred thirty-eight patients with prior beta-lactam intake had a current indication for penicillin therapy and were referred for testing with the major (benzylpenicilloyl polylysine) and minor (minor determinant mixture) penicillin determinants from the inpatient and outpatient service of Athens University Dermatological hospital from January 2000 to December 2002.	abstract
Klor-Con	C0721242			klor con m	trade_name	PubMed	PMID11762675_20201005_0.5			Sustained-release potassium chloride overdose.	title
Klor-Con	C0721242			klor con m	trade_name	PubMed	PMID11762675_20201005_0.5			Adolescent|Delayed-Action Preparations|Drug Overdose|Electrocardiography|Female|Heroin Dependence|Humans|Hyperkalemia|Male|Middle Aged|Potassium Chloride|Radiography	mesh_terms
Klor-Con	C0721242			klor con m	trade_name	PubMed	PMID11762675_20201005_0.5	klor-con	drug_name	The second patient was a 17-year-old man who ingested 20 to 30 Klor-Con tablets (each tablet containing 750 mg KCl or 10 mEq potassium) in a suicide attempt 10 hours prior to presentation.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID33305521_20210411_0.5			The effects of additive solutions on the development of storage lesions in stored canine platelet concentrates.	title
intersol	Z0000098200				trade_name	PubMed	PMID33305521_20210411_0.5			lactate dehydrogenase|platelets|thrombocytopenia|transfusion	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID33305521_20210411_0.5	intersol	drug_name	 METHODS Platelet concentrates were aliquoted into 4 units and stored at room temperature (22°C) under constant agitation in either 100% plasma (control) or 35% plasma and 65% of 1 of 3 different PAS (Plasma-Lyte A, Isoplate, and InterSol) for 7 days.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5			Validation of a microbial detection system for use with ACD-A platelets with PAS III platelet additive solution.	title
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5			Anticoagulants|Bacteria, Aerobic|Bacteria, Anaerobic|Bacteriological Techniques|Blood Platelets|Blood Safety|Citric Acid|Colony Count, Microbial|False Negative Reactions|False Positive Reactions|Glucose|Humans|Leukocyte Reduction Procedures|Plasma|Plateletpheresis|Preservatives, Pharmaceutical	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5	intersol	drug_name	Platelet additive solutions (PASs) such as InterSol (PAS III) may be used to reduce the amount of plasma transfused in LR-AP.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5	intersol	drug_name	This study evaluated the performance of the two-bottle BTA testing scheme in the recovery of seeded microorganisms from LR-AP in InterSol-plasma compared to a reference plate culture method.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5	intersol	drug_name	 METHODS Hyperconcentrated, double LR-AP were collected from healthy donors; InterSol was added (65% Intersol:35% plasma), equally divided into two containers, and then inoculated with an isolate of 1 of 10 clinically relevant index organisms at two levels.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5	intersol	drug_name	 CONCLUSIONS Seeded organism recovery was superior in the two-bottle BTA test system compared to the two-plate BAP system using InterSol platelets (PLTs).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21517894_20201005_0.5	intersol	drug_name	The use of InterSol does not appear to have a detrimental effect on the performance of the two-bottle BTA system.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID33295030_20210311_0.5			Effects of Intercept pathogen reduction treatment on extended cold storage of apheresis platelets.	title
intersol	Z0000098200				trade_name	PubMed	PMID33295030_20210311_0.5			cold storage|pathogen reduction technology|platelets	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID33295030_20210311_0.5			Blood Platelets|Plateletpheresis|Blood Preservation|Platelet Function Tests|Plasma|Cryopreservation|Blood Banks|Blood Coagulation|Refrigeration	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID33295030_20210311_0.5	intersol	drug_name	 METHODS Double-dose apheresis platelets were collected with use of a Trima or Amicus system into either 100% plasma or 65% InterSol PAS/35% plasma and split equally between two bags.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID24251374_20201005_0.5			The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME).	title
intersol	Z0000098200				trade_name	PubMed	PMID24251374_20201005_0.5			Blood Component Removal|Blood Platelets|Humans|Models, Theoretical|Platelet Transfusion|Retrospective Studies	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID24251374_20201005_0.5	intersol	drug_name	We evaluated the impact of InterSol platelet additive solution (PAS) apheresis platelets (APs) on the incidence of ATRs and the posttransfusion platelet (PLT) increment.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID15597347_20201005_0.5			In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.	title
intersol	Z0000098200				trade_name	PubMed	PMID15597347_20201005_0.5			Blood Component Removal|Blood Platelets|Blood Preservation|Body Weight|Furocoumarins|Glucose|Humans|Hydrogen-Ion Concentration|In Vitro Techniques|L-Lactate Dehydrogenase|Light|Plateletpheresis|Specimen Handling|Time Factors|Ultraviolet Rays	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID15597347_20201005_0.5	intersol	drug_name	The platelets were transferred to the preparation set and plasma was removed after centrifugation to resuspend the platelets in approximately 37% plasma and 63% platelet additive solution InterSol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID20497516_20201005_0.5			In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.	title
intersol	Z0000098200				trade_name	PubMed	PMID20497516_20201005_0.5			Acetates|Blood Platelets|Blood Preservation|Blood Transfusion, Autologous|Citrates|Gamma Rays|Humans|In Vitro Techniques|Platelet Count|Platelet Transfusion|Platelet-Rich Plasma|Plateletpheresis|Solutions	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID20497516_20201005_0.5	intersol	drug_name	We evaluated Amicus-collected PLTs stored in platelet additive solution (PAS) III (InterSol) for 5 days.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5			Additive solutions differentially affect metabolic and functional parameters of platelet concentrates.	title
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5			additive solution|aggregation capacity|platelets|storage lesion	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5			Adult|Blood Platelets|Blood Preservation|Humans|Middle Aged|P-Selectin|Peptide Fragments|Platelet Activation|Platelet Function Tests|Preservatives, Pharmaceutical	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5	intersol	drug_name	Each highly concentrated product was divided into three equal parts, and the additive solutions (Composol® or SSP+® or IntersolTM) were added to a final concentration of 56% PAS and 44% plasma.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5	intersol	drug_name	These changes were particularly evident in Intersol PCs on days 5 and 7 compared with Composol® PCs or SSP+® PCs (P < 0·05).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5	intersol	drug_name	Platelets from Intersol PCs exhibited the highest baseline activation of p-selectin and showed reduced collagen- and TRAP-6-induced aggregation.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID26274931_20201005_0.5	intersol	drug_name	 CONCLUSIONS Resuspension of platelets in Intersol for 7 days results in increased platelet activation and platelet metabolism compared with SSP+® or Composol®.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21544995_20201005_0.5			[The quality of platelet concentrates in dependence on storage time before pathogen inactivation].	title
intersol	Z0000098200				trade_name	PubMed	PMID21544995_20201005_0.5			Blood Banks|Blood Platelets|Blood Preservation|Cost-Benefit Analysis|Humans|Microbial Viability|Plateletpheresis|Poland|Virus Inactivation	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID21544995_20201005_0.5	intersol	drug_name	 METHODS PCs preparated from buffy-coats were suspended in platelet additive solution (Intersol, Baxter Healthcare Corporation, Belgium).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID29473178_20201005_0.5			PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets.	title
intersol	Z0000098200				trade_name	PubMed	PMID29473178_20201005_0.5			ABO Blood-Group System|Antibody Affinity|Antibody Specificity|Blood Group Incompatibility|Blood Platelets|Blood Preservation|Blood Proteins|Epitopes|Female|HLA Antigens|Hemagglutinins|Histocompatibility Testing|Humans|Isoantibodies|Male|Organ Preservation Solutions|Plasma|Plateletpheresis|Transfusion-Related Acute Lung Injury	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID29473178_20201005_0.5	intersol	drug_name	No section Platelets (PLTs) collected and stored in PLT additive solution Intersol (PAS-C) are presumed to reduce recipient exposure to donor plasma components; however, the effects of PAS-C on PLT supernatant composition are poorly defined.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID18034788_20201005_0.5			In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution.	title
intersol	Z0000098200				trade_name	PubMed	PMID18034788_20201005_0.5			Blood Platelets|Blood Preservation|Cell Physiological Phenomena|Cell Survival|Humans|Magnesium|Organ Preservation Solutions|Pharmaceutical Solutions|Platelet Transfusion|Plateletpheresis|Potassium|Radioisotopes|Time Factors	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID18034788_20201005_0.5	intersol	drug_name	 METHODS Apheresis platelets from 10 donors were divided and stored in two different platelet additive solutions (PAS) (Intersol and SSP+) for a paired comparison.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID18034788_20201005_0.5	intersol	drug_name	Platelet recovery on day 7 was higher for Intersol as compared to SSP+, 65 +/- 11 vs. 53 +/- 13% (P = 0.023), and survival showed no difference 4.2 +/- 1.9 vs. 3.6 +/- 1.4 days.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID16430671_20201005_0.5			In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.	title
intersol	Z0000098200				trade_name	PubMed	PMID16430671_20201005_0.5			Blood Platelets|Blood-Borne Pathogens|Furocoumarins|Humans|In Vitro Techniques|Photochemistry|Photosensitizing Agents|Plasma Volume|Plateletpheresis|Solutions|Ultraviolet Rays	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID16430671_20201005_0.5	intersol	drug_name	No section Pathogen inactivation using the INTERCEPT Blood System requires platelet resuspension in InterSol and reduced plasma.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID16430671_20201005_0.5	intersol	drug_name	Platelets in plasma collected on the Haemonetics MCS+ were processed on the INTERCEPT Preparation Set for plasma volume reduction and addition of InterSol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID14996187_20201005_0.5			Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation.	title
intersol	Z0000098200				trade_name	PubMed	PMID14996187_20201005_0.5			Bacterial Infections|Blood Platelets|Blood Preservation|Carbon Dioxide|Cell Survival|Furocoumarins|Glucose|Humans|Hydrogen-Ion Concentration|L-Lactate Dehydrogenase|Osmotic Pressure|Oxygen|Photochemistry|Platelet Aggregation|Platelet Count	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID14996187_20201005_0.5	intersol	drug_name	 METHODS A two-arm in vitro study was conducted to compare pooled buffy-coat-derived PLT concentrates (PCs) treated with the INTERCEPT blood system, resuspended in PLT additive solution (PAS) III (InterSol, Baxter Transfusion Therapies), and stored for up to 7 days (test units, n = 20) with unpaired, nontreated PCs, resuspended in PAS II (T-Sol, Baxter Transfusion Therapies), and prepared at the same center in the same manner (control units, n = 18).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID30203458_20201005_0.5			In vivo viability of extended 4°C-stored autologous apheresis platelets.	title
intersol	Z0000098200				trade_name	PubMed	PMID30203458_20201005_0.5			Blood Platelets|Blood Preservation|Cell Survival|Cold Temperature|Humans|Platelet Transfusion|Plateletpheresis|Solutions|Time Factors|Transplantation, Autologous	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID30203458_20201005_0.5	intersol	drug_name	One unit was stored at 4°C in plasma for 3 days ("control unit"), and the CSP "test" unit was stored for 10 or 15 days in plasma or 10 days in 35% plasma with either 65% Intersol or Isoplate.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID30203458_20201005_0.5	intersol	drug_name	 No section For 10-day storage, both the plasma and the Intersol units had significantly better PLT recoveries than the Isoplate units (24% ± 8% vs. 11% ± 3% [55% ± 11% vs. 21% ± 8% as percentage of control data], p = 0.002; and 18% ± 4% vs. 11% ± 3% [43% ± 6% vs. 21% ± 8% as percentage of control data], p = 0.004, respectively).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID30203458_20201005_0.5	intersol	drug_name	There was a trend for lower PLT recoveries with Intersol compared to plasma (p = 0.056).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID30203458_20201005_0.5	intersol	drug_name	 No section While the in vitro variables suggest largely comparable results between plasma and PASs, in vivo recoveries were higher with plasma compared with both Intersol and Isoplate (p = 0.057 and p = 0.002, respectively).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21077911_20201005_0.5			Bacterial growth kinetics in ACD-A apheresis platelets: comparison of plasma and PAS III storage.	title
intersol	Z0000098200				trade_name	PubMed	PMID21077911_20201005_0.5			Blood Platelets|Blood Preservation|Escherichia coli|Escherichia coli Infections|Humans|Klebsiella Infections|Klebsiella oxytoca|Plasma|Plateletpheresis|Serratia Infections|Serratia marcescens|Solutions|Staphylococcal Infections|Staphylococcus aureus|Staphylococcus epidermidis|Streptococcal Infections|Viridans Streptococci	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID21077911_20201005_0.5	intersol	drug_name	BACKGROUND Our objective was to determine the growth kinetics of bacteria in leukoreduced apheresis platelets (LR-AP) in a platelet (PLT) additive solution (PAS; InterSol, Fenwal, Inc.) compared to LR-AP stored in plasma.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21077911_20201005_0.5	intersol	drug_name	LR-AP were evenly divided, InterSol was added to half (65% InterSol:35% plasma [PAS]), and PLTs in autologous plasma were used for a paired control (PL).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21077911_20201005_0.5	intersol	drug_name	 CONCLUSIONS We observed that five index organisms will grow in LR-AP stored in a 35%:65% ratio of plasma to InterSol where initial bacterial concentrations are 0.5 to 1.6 CFUs/mL. The more rapid initiation of log-phase growth for bacteria within a PAS storage environment resulted in a bacterial concentration up to 4 logs higher in the PAS units compared to the plasma units at 24 hours, but with no difference in the conc-max.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID19930144_20201005_0.5			In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system.	title
intersol	Z0000098200				trade_name	PubMed	PMID19930144_20201005_0.5			Bacterial Infections|Blood Platelets|Blood Preservation|Humans|Platelet Transfusion|Platelet-Rich Plasma	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID19930144_20201005_0.5	intersol	drug_name	Plasma served as reference; two centres used InterSol followed by PR (InterSol+PR) and InterSol without PR; T-sol, SSP+ and Composol were also studied.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID19930144_20201005_0.5	intersol	drug_name	Marked differences were seen for other parameters, including CD62P expression: 28 +/- 5; 31 +/- 7; and 39 +/- 9% for T-sol, Intersol+PR and without PR, respectively, which were higher as found for Composol (12 +/- 3%), SSP+ (15 +/- 5%) and plasma (15 +/- 6%).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID19930144_20201005_0.5	intersol	drug_name	Three parameters (CD62P, Annexin A5, and lactate concentration) were collapsed into one rating value (6 = good quality, 0 = poor quality); PLTs in plasma had a rating of 2.8 +/- 1.0, which was higher as for T-Sol (1.5 +/- 0.5), InterSol+PR (1.3 +/- 0.6) and without PR (1.7 +/- 0.5).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID19930144_20201005_0.5	intersol	drug_name	 CONCLUSIONS PLT concentrates in plasma, SSP+ and Composol scored better using an arbitrary rating system as PLTs stored in T-Sol or InterSol; PR further impaired rating parameters.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID33233079_20210611_0.5			Characterisation of thermal and structural behaviour of lipid blends composed of fish oil and milkfat.	title
intersol	Z0000098200				trade_name	PubMed	PMID33233079_20210611_0.5	intersol	drug_name	Fat crystallization|Fish oil|Melting behaviour|Milkfat|Polymorphism|Triacylglycerol intersolubility	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID33233079_20210611_0.5			Crystallization|Fatty Acids|Fish Oils|Oxidation-Reduction|Phase Transition	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID29603238_20201005_0.5			Cold storage of platelets in platelet additive solution: an in vitro comparison of two Food and Drug Administration-approved collection and storage systems.	title
intersol	Z0000098200				trade_name	PubMed	PMID29603238_20201005_0.5			Blood Platelets|Blood Preservation|Cryopreservation|Humans|Plateletpheresis|United States|United States Food and Drug Administration	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID29603238_20201005_0.5	intersol	drug_name	In this study, we compared the metabolic, functional, and activation status of PLTs collected on a Trima apheresis collection system and stored refrigerated in Isoplate (ISO) PAS to PLTs collected on an Amicus collection system and stored refrigerated in Intersol (INT) PAS.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID31563447_20201005_0.5			Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.	title
intersol	Z0000098200				trade_name	PubMed	PMID31563447_20201005_0.5			Additive solution|Inactivation des pathogènes|Lésion de stockage|Pathogen inactivation|Pathogen reduction|Platelet storage lesion|Riboflavin|Riboflavine|Réduction des pathogènes|Solution additive	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID31563447_20201005_0.5			Blood Platelets|Blood Preservation|Blood Proteins|Blood Safety|Blood-Borne Pathogens|Epinephrine|Humans|Organ Preservation Solutions|Osmotic Pressure|Phosphates|Photosensitizing Agents|Platelet Aggregation|Platelet-Rich Plasma|Potassium Chloride|Riboflavin|Sodium|Sodium Acetate|Sodium Chloride|Sodium Citrate|Ultraviolet Rays	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID31563447_20201005_0.5	intersol	drug_name	A two-arm study was then designed to compare Intersol and T-PAS+ additive solutions (n=3).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5			Parallel comparison of apheresis-collected platelet concentrates stored in four different additive solutions.	title
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5			C3a|CD62P|RANTES|glucose consumption|platelet additive solution|sCD40L	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5			Blood Platelets|Blood Preservation|Glucose|Humans|Platelet Activation|Plateletpheresis|Solutions	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5	intersol	drug_name	 METHODS Platelets collected four times by apheresis from three donors were suspended in Intersol, SSP+, Composol or M-sol with 35% autologous plasma.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5	intersol	drug_name	 RESULTS Mean PLT volumes were decreased in SSP+, Composol and M-sol after 5-day storage, with significant differences, whereas the hypertonic shock response (HSR) was decreased only in Intersol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5	intersol	drug_name	Glucose consumption was faster in Intersol and M-sol than in SSP+ or Composol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5	intersol	drug_name	PLT activation, determined as CD62P, sCD62P, sCD40L and RANTES, was significantly higher in Intersol than the other three PASs.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID23802810_20201005_0.5	intersol	drug_name	PLT activation was significantly enhanced in Intersol compared with the other three PASs.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID19788514_20201005_0.5			Storage of buffy-coat-derived platelets in additive solutions: in vitro effects on platelets stored in reformulated PAS supplied by a 20% plasma carry-over.	title
intersol	Z0000098200				trade_name	PubMed	PMID19788514_20201005_0.5			Adult|Blood Platelets|Blood Preservation|Cell Separation|Glucose|Humans|Hydrogen-Ion Concentration|Magnesium|Organ Preservation Solutions|Osmotic Fragility|Phosphates|Plasma|Platelet Count|Potassium	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID19788514_20201005_0.5	intersol	drug_name	 METHODS Platelets from eight pools of 25 buffy coats were aliquoted and prepared for storage in plasma and different PAS units: InterSol and three alternate PAS named PSM1, PSM2 and PSM3.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID19788514_20201005_0.5	intersol	drug_name	Results During storage, PLTs stored in InterSol displayed significantly lower glucose concentration (P < 0.01), lower adenosine triphosphate levels (P < 0.01), a higher mean PLT volume (P < 0.01), a lower response to hypotonic shock response activity (P < 0.01) and a higher CD62P expression (P < 0.01) when compared with PLTs stored in plasma and PSM1-3 solutions.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID6717931_20201005_0.5	intersol	drug_name	[New materials for intersole layers of orthopedic footwear].	title
intersol	Z0000098200				trade_name	PubMed	PMID6717931_20201005_0.5			Humans|Orthopedic Equipment|Polyethylenes|Polyvinyls|Shoes	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID30393391_20201005_0.5			Winds measured by the Rover Environmental Monitoring Station (REMS) during the Mars Science Laboratory (MSL) rover's Bagnold Dunes Campaign and comparison with numerical modeling using MarsWRF.	title
intersol	Z0000098200				trade_name	PubMed	PMID30393391_20201005_0.5			Wind|Environmental Monitoring|Mars|Air Pollution|Air Pollutants|Extraterrestrial Environment|Seasons	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID30393391_20201005_0.5	intersol	drug_name	The timings of these direction changes are relatively consistent from sol to sol; however, the wind direction and speed at any given time shows considerable intersol variability.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID24735171_20201005_0.5			A comparison of adverse reaction rates for PAS C versus plasma platelet units.	title
intersol	Z0000098200				trade_name	PubMed	PMID24735171_20201005_0.5			Adolescent|Adult|Aged|Allergens|Anaphylaxis|Blood Preservation|Child|Child, Preschool|Female|Fever|Humans|Hypersensitivity|Hypotension|Incidence|Infant|Infant, Newborn|Male|Middle Aged|Plasma|Platelet Transfusion|Plateletpheresis|Retrospective Studies|Risk|Solutions|Young Adult	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID24735171_20201005_0.5	intersol	drug_name	Leukoreduced apheresis PLTs stored in InterSol have 65% less plasma than apheresis PLTs stored in 100% plasma (PPs).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID24735171_20201005_0.5	intersol	drug_name	This study compared transfusion reaction rates in InterSol PLTs (PLT additive solution [PAS] C) versus PPs.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21330915_20201005_0.5			The influence of platelets, plasma and red blood cells on functional haemostatic assays.	title
intersol	Z0000098200				trade_name	PubMed	PMID21330915_20201005_0.5			Blood Platelets|Erythrocyte Count|Erythrocytes|Hematocrit|Hemostasis|Humans|Plasma|Platelet Aggregation|Thrombelastography	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID21330915_20201005_0.5	intersol	drug_name	Pure platelets were investigated by removing plasma components from platelet concentrates by diafiltration against the platelet storage solution Intersol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID21330915_20201005_0.5	intersol	drug_name	Plasma was readded by diafiltration against plasma in Intersol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID16686848_20201005_0.5			Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage.	title
intersol	Z0000098200				trade_name	PubMed	PMID16686848_20201005_0.5			Blood Platelets|Blood Preservation|Cytokines|Drug Contamination|Gamma Rays|Humans|Leukocytes|Photochemistry|Time Factors	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID16686848_20201005_0.5	intersol	drug_name	PCs that had added PAS-III (Intersol) were treated with amotosalen and ultraviolet A light.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID15383024_20201005_0.5			Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.	title
intersol	Z0000098200				trade_name	PubMed	PMID15383024_20201005_0.5			Bacteremia|Bacteria|Bacteria, Aerobic|Bacteria, Anaerobic|Blood Platelets|Borrelia burgdorferi|Furocoumarins|Humans|Photochemistry|Photosensitizing Agents|Platelet Transfusion|Sterilization|Treponema pallidum|Ultraviolet Rays	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID15383024_20201005_0.5	intersol	drug_name	 METHODS High titers of pathogenic aerobic and anaerobic Gram-positive bacteria (10 species), aerobic Gram-negative bacteria (7 species), and spirochetes (2 species) were added to single-donor PLT concentrates containing 3.0 x 10(11) to 6.0 x 10(11) PLTs in approximately 300 mL of 35 percent plasma and 65 percent PLT additive solution (InterSol, Baxter Healthcare) or saline.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID30638959_20210111_0.5			Irreversible oxidations of platelet proteins after riboflavin-UVB pathogen inactivation.	title
intersol	Z0000098200				trade_name	PubMed	PMID30638959_20210111_0.5			Concentre plaquettaire|Esperes reactives de l'oxygene|Inactivation des pathogenes|Oxidation|Oxydation|Pathogen inactivation|Platelet concentrate|Proteomics|Proteomique|ROS|Riboflavin|Riboflavine|Shotgun	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID30638959_20210111_0.5			Adult|Amino Acid Sequence|Amino Acids|Blood Platelets|Blood Proteins|Blood Safety|Humans|Oxidation-Reduction|Platelet Aggregation|Proteomics|Riboflavin|Tandem Mass Spectrometry|Ultraviolet Rays	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID30638959_20210111_0.5	intersol	drug_name	Here, platelet concentrates were prepared from buffy-coats in Intersol additive solution, leukoreduced and pathogen inactivated using a riboflavin/UVB treatment.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID27887865_20201005_0.5			Overcoming the bottleneck of platelet lysate supply in large-scale clinical expansion of adipose-derived stem cells: A comparison of fresh versus three types of platelet lysates from outdated buffy coat-derived platelet concentrates.	title
intersol	Z0000098200				trade_name	PubMed	PMID27887865_20201005_0.5			adipose-derived stem cells|cell proliferation|cell therapy|gene expression|growth factors|platelet lysate	author_keywords
intersol	Z0000098200				trade_name	PubMed	PMID27887865_20201005_0.5			Adipose Tissue|Adult|Adult Stem Cells|Blood Buffy Coat|Blood Platelets|Blood Preservation|Blood Specimen Collection|Cell Culture Techniques|Cell Extracts|Cell Proliferation|Cell Separation|Culture Media|Female|Freezing|Humans|Plasma|Platelet Transfusion|Platelet-Rich Plasma|Refrigeration|Time Factors	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID27887865_20201005_0.5	intersol	drug_name	 No section PLs were prepared by the freeze-thaw method from freshly drawn platelets or from outdated buffy coat-derived PCs stored in the platelet additive solution, InterSol.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID27887865_20201005_0.5	intersol	drug_name	Three types of PLs were prepared from outdated PCs with platelets suspended in either (1) InterSol (not manipulated), (2) InterSol + supplemented with plasma or (3) plasma alone (InterSol removed).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID27887865_20201005_0.5	intersol	drug_name	 No section Of the three PL compositions produced from outdated PCs, removal of Intersol and resuspension in plasma prior to the first freezing process was overall the best.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID18294916_20201005_0.5			Effects of intercept pathogen inactivation on platelet function as analysed by free oscillation rheometry.	title
intersol	Z0000098200				trade_name	PubMed	PMID18294916_20201005_0.5			Blood Coagulation|Blood Preservation|Blood-Borne Pathogens|Hemorheology|Humans|Oscillometry|P-Selectin|Pilot Projects|Platelet Activation|Reference Values|Rheology|Solubility|Whole Blood Coagulation Time	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID18294916_20201005_0.5	intersol	drug_name	BACKGROUND The Intercept Blood System, using InterSol as additive solution, is used for inactivation of contaminating pathogens in PCs, thus reducing the risk for transfusion transmitted infection and making it possible to prolong the storage period.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID18294916_20201005_0.5	intersol	drug_name	 METHODS Seventy-four single-donor platelet units were diluted in InterSol (n=27) or T-Sol (n=47) to a mean plasma concentration of 38%.	abstract
intersol	Z0000098200				trade_name	PubMed	PMID18294916_20201005_0.5	intersol	drug_name	The Intercept treatment was performed by addition of amotosalen HCl to the InterSol PCs followed by UVA irradiation and treatment with a compound adsorption device (CAD).	abstract
intersol	Z0000098200				trade_name	PubMed	PMID20497408_20201005_0.5			Comparison between in vitro qualities of platelets washed with commercially available additive solutions and those washed with M-sol.	title
intersol	Z0000098200				trade_name	PubMed	PMID20497408_20201005_0.5			Blood Platelets|Blood Preservation|Humans|Isotonic Solutions|Organ Preservation Solutions	mesh_terms
intersol	Z0000098200				trade_name	PubMed	PMID20497408_20201005_0.5	intersol	drug_name	After centrifugation of both groups and removal of as much supernatant as possible, the pellet of the control group was resuspended in M-sol and those of the test group were resuspended in other ASs, and subsequently stored in polyolefin bags with agitating at 20-24 degrees C. RESULTS Compared with those stored in M-sol, the qualities of PLTs stored in PAS-B (alternative name; PAS-II or T-sol), PAS- C (alternative name; PAS-III or Intersol) or Plasma Lyte were degraded as early as 24 h after washing.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC4327555_20201005_0.5			Ophthalmic Manifestations of Vitamin A and D Deficiency in Two Autistic Teenagers: Case Reports and a Review of the Literature	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC4327555_20201005_0.5	rynoderm	drug_synonym	Vitamin A|Autism|Phrynoderma|Bitot's spots|Xerophthalmia	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC4327555_20201005_0.5			Child|Adolescent|Male|Humans|Vitamin A|Autistic Disorder|Vitamin A Deficiency|Xerophthalmia|Feeding Behavior|Eye	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24596740_20201005_0.5	rynoderm	drug_synonym	Therapeutic Response of Vitamin A, Vitamin B Complex, Essential Fatty Acids (EFA) and Vitamin E in the Treatment of Phrynoderma: A Randomized Controlled Study.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24596740_20201005_0.5	rynoderm	drug_synonym	Essential fatty acids|Follicular hyperkeratosis|Nutritional deficiency disorders|Phrynoderma|Vitamin A|Vitamin B complex|Vitamin E ligament	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24596740_20201005_0.5			Adult|Male|Humans|Middle Aged|Female|Aged|Vitamin B Complex|Vitamin A|Vitamin E|Folic Acid|Keratosis|Fatty Acids, Essential|Hair Diseases|Injections, Intramuscular	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24596740_20201005_0.5	rynoderm	drug_synonym	BACKGROUND In the treatment of phrynoderma, various nutrients have been tried in different dosages and routes with variable therapeutic outcomes.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24596740_20201005_0.5	rynoderm	drug_synonym	 OBJECTIVE The present study was undertaken to compare the efficacy of various nutrients in the treatment of phrynoderma.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24596740_20201005_0.5	rynoderm	drug_synonym	 CONCLUSIONS Intramuscular injections of Vitamin A or Vitamin B are effective in the treatment of phrynoderma.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27026724_20201005_0.5	xurea	drug_synonym	Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27026724_20201005_0.5	xurea	drug_synonym	Sickle cell|clinical severity|hydroxurea|mortality|pharmacogenetics|prognosis	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27026724_20201005_0.5			Anemia, Sickle Cell|Antisickling Agents|Fetal Hemoglobin|Humans|Hydroxyurea|Prognosis|Severity of Illness Index|Treatment Outcome	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33428701_20210211_0.5			Structural evolution of iron forming iron oxide in a deep eutectic-solvothermal reaction.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33428701_20210211_0.5			ferric oxide|Solvents|Ferric Compounds|Water|Choline|Hydrolysis|Ligands|Iron|Urea|Scattering, Small Angle|Ions	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33428701_20210211_0.5	xurea	drug_synonym	Here we present the first static structural and in situ studies of the formation of iron oxide (hematite) nanoparticles in a DES of choline chloride : urea where xurea = 0.67 (aka.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27123883_20201005_0.5			Systemic therapy for recurrent meningioma.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27123883_20201005_0.5	xurea	drug_synonym	Meningioma|bevacizumab|hydroyxurea|sunitinib|systemic therapy|trabectedin|valitinib	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27123883_20201005_0.5			Gefitinib|Humans|Meningeal Neoplasms|Meningioma|Prospective Studies|Quinazolines|Vascular Endothelial Growth Factor A	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID27123883_20201005_0.5	xurea	drug_synonym	 Expert commentary Hydroxurea, temozolomide, irinotecan, the combination of cyclophosphamide/adriamycine/vincristine, interferon-alpha, somatostatin analogs, mifepristone, megestrol acetate, imatinib, erlotinib and gefitinib are considered as having limited efficacy.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC6543870_20201005_0.5			Machine Learning Analysis of τRAMD Trajectories to Decipher Molecular Determinants of Drug-Target Residence Times	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC6543870_20201005_0.5	ure-k	drug_synonym	drug-protein residence time|machine learning|drug-target binding kinetics|structure-kinetic relationships (SKRs)|heat shock protein 90 (HSP90)|molecular dynamics simulation|tauRAMD	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC6543870_20201005_0.5			Ligands|Molecular Dynamics Simulation|Protein Binding|Binding Sites|Machine Learning|Kinetics|HSP90 Heat-Shock Proteins|Drug Delivery Systems|Hydrophobic and Hydrophilic Interactions	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMC6543870_20201005_0.5	ure-k	drug_synonym	For this purpose, computational methods to predict residence times, τ, for drug-like compounds and to derive structure-kinetic relationships are desirable.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33783249_20210611_0.5	ure-k	drug_synonym	A Novel High-Throughput FLIPR Tetra-Based Method for Capturing Highly Confluent Kinetic Data for Structure-Kinetic Relationship Guided Early Drug Discovery.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33783249_20210611_0.5	ure-k	drug_synonym	FLIPR Tetra|association rate|covalent inhibition|dissociation rate|high-throughput screening|kinetics|progress curve analysis|slow-onset inhibition|structure-kinetic relationship	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33783249_20210611_0.5			Humans|Drug Discovery|Kinetics|High-Throughput Screening Assays|Structure-Activity Relationship|Chemistry, Pharmaceutical|Biological Assay|Research Design|Thermodynamics	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33783249_20210611_0.5	ure-k	drug_synonym	It is becoming clearer, however, that understanding the kinetics of the interaction between a small-molecule inhibitor and the biological target [structure-kinetic relationship (SKR)] is critical for selection of the optimum candidate drug molecule for clinical trial.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24591302_20201214_0.5			Binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24591302_20201214_0.5	ure-k	drug_synonym	G protein-coupled receptors|antagonism|binding kinetics|structure-activity relationships|structure-kinetics relationships	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24591302_20201214_0.5			Adenosine A2 Receptor Antagonists|Binding Sites|Dose-Response Relationship, Drug|Humans|Kinetics|Molecular Structure|Receptor, Adenosine A2A|Structure-Activity Relationship|Triazines|Triazoles	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID24591302_20201214_0.5	ure-k	drug_synonym	In the present study, we performed an extensive structure-kinetics relationship (SKR) study in addition to a traditional SAR analysis at the adenosine A2A receptor (A2A R).	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID28408223_20201005_0.5			Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID28408223_20201005_0.5	ure-k	drug_synonym	Allosteric cooperativity|Allosteric modulators|Biased signaling|Binding kinetics|Covalent allosteric modulators|Structure-Bias Relationships|Structure-Cooperativity Relationships|Structure-Kinetic Relationships|Transducer coefficients|Transducer ratios|log(max/EC(50))|log(αβ)|log(τ/K(A))	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID28408223_20201005_0.5			Allosteric Regulation|Chemistry, Pharmaceutical|Humans|Ligands|Structure-Activity Relationship	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33497606_20210611_0.5	ure-k	drug_synonym	Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33497606_20210611_0.5	ure-k	drug_synonym	NanoBRET|focal adhesion kinase (FAK)|kinase inhibitor|ligand residence time|proline-rich tyrosine kinase 2 (PYK2)|structure-kinetic-relationship|tauRAMD	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33497606_20210611_0.5			PTK2B protein, human|Focal Adhesion Kinase 2|PTK2 protein, human|Focal Adhesion Kinase 1|Phosphorylation|Proteins|Kinetics	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26506404_20201005_0.5			The Role of Target Binding Kinetics in Drug Discovery.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26506404_20201005_0.5	ure-k	drug_synonym	G protein-coupled receptors|binding kinetics|residence time|structure-affinity relationships|structure-kinetics relationships	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26506404_20201005_0.5			Binding Sites|Drug Discovery|Kinetics|Pharmaceutical Preparations|Structure-Activity Relationship	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26506404_20201005_0.5	ure-k	drug_synonym	However, structure-kinetics relationships (SKR) can be very informative too.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29305857_20210111_0.5			A binding kinetics study of human adenosine A3 receptor agonists.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29305857_20210111_0.5	ure-k	drug_synonym	2-Cl-IB-MECA (PubChem CID: 3035850)|Adenosine A(3) receptor|Binding kinetics|IB-MECA (PubChem CID: 123683)|MRS3558 (PubChem CID: 11248240)|MRS5698 (PubChem CID: 57523213)|Nucleosides|PSB-11 (PubChem CID: 9882625)|Residence time|Structure-kinetics relationships	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29305857_20210111_0.5			Adenosine A3 Receptor Agonists|Animals|CHO Cells|Cricetinae|Cricetulus|Dose-Response Relationship, Drug|Humans|Kinetics|Protein Binding	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29305857_20210111_0.5	ure-k	drug_synonym	The structure-kinetics relationships (SKR) were derived and longer residence times were associated with methanocarba and enlarged adenine N6 and C2 substitutions.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26210506_20201005_0.5	ure-k	drug_synonym	Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26210506_20201005_0.5	ure-k	drug_synonym	Adenosine A(1) receptor|Extracellular loops|Residence time|Structure-affinity relationships|Structure-kinetics relationships	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26210506_20201005_0.5			Adenosine A1 Receptor Agonists|Aminopyridines|Dose-Response Relationship, Drug|Humans|Kinetics|Models, Molecular|Molecular Structure|Receptor, Adenosine A1|Structure-Activity Relationship|Thiazoles	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26210506_20201005_0.5	ure-k	drug_synonym	Structure-affinity and structure-kinetics relationships were established, and computational studies of a homology model of the hA1AR revealed crucial interactions for both the affinity and dissociation kinetics of this family of ligands.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33759127_20210511_0.5			A Protocol to Use Comparative Binding Energy Analysis to Estimate Drug-Target Residence Time.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33759127_20210511_0.5	ure-k	drug_synonym	Comparative binding energy (COMBINE) analysis|Dissociation rate constant|Drug-protein binding kinetics|Quantitative structure-kinetics relationship (QSKR)|Residence time	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33759127_20210511_0.5			Drug Discovery|HSP90 Heat-Shock Proteins|Kinetics|Ligands|Pharmaceutical Preparations|Protein Binding|Proteins|Quantitative Structure-Activity Relationship|Software|Thermodynamics	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID33759127_20210511_0.5	ure-k	drug_synonym	Here, we describe the process of setting up and running COMBINE analysis to derive a Quantitative Structure-Kinetics Relationship (QSKR) for the dissociation rate constants (koff) of inhibitors of a drug target.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29102677_20201005_0.5	ure-k	drug_synonym	Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29102677_20201005_0.5	ure-k	drug_synonym	Antagonist 1 (CAS Registry Number: 1207203-10-8)|Antagonist 2 (CAS Registry Number: 1207203-08-4)|Antagonist 3 (CAS Registry Number: 1207203-09-5)|Antagonist 4 (CAS Registry Number: 1207203-19-7)|Antagonist 5 (CAS Registry Number: 1207203-16-4)|Antagonist 6 (CAS Registry Number: 1207203-15-3)|Antagonist 7 (CAS Registry Number: 1207202-94-5)|Antagonist 8 (CAS Registry Number: 1207203-14-2)|Antagonist 9 (CAS Registry Number: 1207203-18-6)|CP55940 (PubChem CID: 104895)|Cannabinoid 1 receptor|Insurmountable antagonism|Preincubation|Radioligand binding|Residence time|Rimonabant (PubChem CID: 104850)|Structure-kinetics relationships	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29102677_20201005_0.5			Animals|Binding, Competitive|CHO Cells|Cannabinoid Receptor Antagonists|Cricetulus|Cyclohexanols|Kinetics|Ligands|Protein Binding|Radioligand Assay|Receptor, Cannabinoid, CB1|Structure-Activity Relationship	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID29102677_20201005_0.5	ure-k	drug_synonym	This assay yielded Kinetic Rate Index (KRI) values from which structure-kinetics relationships (SKR) of hCB1 receptor antagonists could be established.	abstract
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26922232_20201005_0.5	ure-k	drug_synonym	Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of sulphone-based CRTh2 antagonists.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26922232_20201005_0.5	ure-k	drug_synonym	CRTh2 antagonist|Receptor residence time|Structure-activity relationship (SAR)|Structure-kinetic relationship (SKR)	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26922232_20201005_0.5			Dose-Response Relationship, Drug|Humans|Kinetics|Molecular Structure|Receptors, Immunologic|Receptors, Prostaglandin|Structure-Activity Relationship|Sulfones	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26033831_20201005_0.5			Evaluation of (4-Arylpiperidin-1-yl)cyclopentanecarboxamides As High-Affinity and Long-Residence-Time Antagonists for the CCR2 Receptor.	title
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26033831_20201005_0.5	ure-k	drug_synonym	antagonists|cytokines|kinetics|structure-affinity relationships|structure-kinetics relationships	author_keywords
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26033831_20201005_0.5			Animals|Cyclopentanes|Dose-Response Relationship, Drug|Kinetics|Molecular Conformation|Piperidines|Receptors, CCR2|Structure-Activity Relationship|Time Factors	mesh_terms
urea	C0041942	utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k		carbamide	inn	PubMed	PMID26033831_20201005_0.5	ure-k	drug_synonym	We previously described a new approach for the design of CCR2 antagonists by the use of structure-kinetics relationships (SKRs).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1588671_20201005_0.5	resonium-a	drug_synonym	In vitro binding characteristics for cesium of two qualities of prussian blue, activated charcoal and Resonium-A.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1588671_20201005_0.5			Cesium Radioisotopes|Charcoal|Ferrocyanides|Hemoperfusion|Hydrogen-Ion Concentration|In Vitro Techniques|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1588671_20201005_0.5	resonium-a	drug_synonym	No section The in vitro binding characteristics of radioactive 137Cs to two forms of Prussian blue [colloidally (soluble) K3Fe[Fe(CN)6] and insoluble Fe4[Fe(CN)6]3] and to activated charcoal and sodium polystyrene sulfonate (Resonium-A) were investigated by constructing Langmuir isotherms at pH = 1.0, 6.5 and 7.5 at 37 degrees C. At the three pHs investigated, 137Cs binding to activated charcoal and sodium polystyrene sulfonate was negligible.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9113442_20201005_0.5			Colon perforation after renal transplantation: a single-institution review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9113442_20201005_0.5			Adolescent|Adult|Aged|Child|Child, Preschool|Colonic Diseases|Female|Graft Survival|Humans|Infant|Intestinal Perforation|Kidney Transplantation|Male|Middle Aged|Risk Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9113442_20201005_0.5	kayexalate	drug_synonym	Risk factors for CP included a cadaver graft (versus a living donor), high body weight, history of diverticulitis, and Kayexalate use.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	An electronic alert to decrease Kayexalate ordering.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5			Electronic alert|hyperkalemia|patient safety|potassium|quality improvement	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5			Cation Exchange Resins|Drug Monitoring|Drug Utilization|Humans|Hyperkalemia|Massachusetts|Medical Order Entry Systems|Patient Safety|Polystyrenes|Quality Improvement|Tertiary Care Centers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	No section Important safety concerns have recently emerged regarding the use of sodium polystyrene sulfonate (Kayexalate), a cation-exchange resin commonly used for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	We implemented an electronic alert system at a tertiary care academic medical center to warn providers of the safety concerns of Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	We assessed the number of Kayexalate prescriptions per month, as well as the number of grams of Kayexalate ordered per month, one year before versus one year after implementing the alert.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	The mean (±SD) number of Kayexalate orders decreased from 123 (±12) to 76 (±14) orders/month (38% absolute reduction, p < 0.001) after implementing the alert.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	Additionally, the mean (±SD) amount of Kayexalate prescribed decreased from 3332 (±329) to 1885 (±358) g/month (43% absolute reduction, p < 0.001).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	kayexalate	drug_synonym	We conclude that an electronic alert is an effective tool to decrease Kayexalate ordering.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19373153_20201005_0.5	kayexalate	drug_synonym	Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19373153_20201005_0.5			Adult|Aged|Aged, 80 and over|Cathartics|Cation Exchange Resins|Cohort Studies|Female|Humans|Hyperkalemia|Intestinal Mucosa|Ischemia|Kidney Failure, Chronic|Male|Middle Aged|Necrosis|Polystyrenes|Retrospective Studies|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19373153_20201005_0.5	kayexalate	drug_synonym	BACKGROUND Sodium polystyrene sulfonate (SPS, Kayexalate) has been implicated in the development of intestinal necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5			Sodium polystyrene sulfonate crystals in the gastric wall of a patient with upper gastrointestinal bleeding and gastric perforation: an incidental finding or a pathogenic factor?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5			Male|Humans|Middle Aged|polystyrene sulfonic acid|Incidental Findings|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Stomach|Gastrointestinal Hemorrhage|Sorbitol|Stomach Diseases|Necrosis|Intestinal Diseases|Ulcer|Abdominal Injuries	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate, or Kayexalate, is an ion-exchange resin used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5	kayexalate	drug_synonym	Small and large bowel necrosis and perforation due to Kayexalate were previously reported.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5	kayexalate	drug_synonym	Pathological examination revealed no abnormalities except fibrinoleukocytic debris with Kayexalate crystals in the gastric wall.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5	kayexalate	drug_synonym	Kayexalate is believed to be a trigger for the gastric injury in a patient with tissues impaired by corticosteroids, CKD and immunosuppressors.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID14996269_20201005_0.5	kayexalate	drug_synonym	Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID14996269_20201005_0.5			Cation Exchange Resins|Female|Humans|Hyperkalemia|Hypernatremia|Infant, Newborn|Infant, Premature, Diseases|Infant, Very Low Birth Weight|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID14996269_20201005_0.5	kayexalate	drug_synonym	Administration of cation-exchange resin such as sodium polystyrene sulphonate (Kayexalate) is effective in lowering plasma potassium, although complications following oral or rectal administration are reported in newborns.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID14996269_20201005_0.5	kayexalate	drug_synonym	We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious hypernatraemia, that has never been reported before in preterm infants.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5	kayexalate	drug_synonym	Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5			Cation Exchange Resins|Enterocolitis, Necrotizing|Humans|Hyperkalemia|Infant, Extremely Low Birth Weight|Infant, Newborn|Infant, Premature|Male|Polystyrenes|Sepsis|Streptococcal Infections|Streptococcus agalactiae	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5	kayexalate	drug_synonym	On the fourth day of life, after he failed treatment with diuretics, salbutamol, insulin, calcium gluconate and sodium bicarbonate, he was treated with sorbitol-free Kayexalate enemas.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5	kayexalate	drug_synonym	Usually, Kayexalate is suspended in hyperosmolar sorbitol solutions and the elevated osmolarity seems to be responsible for hemorrhagic colitis, transmural necrosis and definitely NEC.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5	kayexalate	drug_synonym	Our case report shows that Kayexalate per se, and not necessarily suspended in sorbitol, can lead to gastrointestinal tract complications and NEC in preterm infants.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15628898_20210611_0.5	kayexalate	drug_synonym	Kayexalate (sodium polystyrene sulfonate) aspiration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15628898_20210611_0.5			Fatal Outcome|Female|Humans|Hyperkalemia|Middle Aged|Pneumonia, Aspiration|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6776927_20201005_0.5			[Cardiac surgery under extracorporeal circulation in patients with chronic renal insufficiency. Apropos of 4 cases and review of the literature].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6776927_20201005_0.5			Adolescent|Adult|Coronary Disease|Endocarditis, Bacterial|Extracorporeal Circulation|Female|Heart Valves|Humans|Kidney Failure, Chronic|Male|Middle Aged|Postoperative Care|Resuscitation	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6776927_20201005_0.5	kayexalate	drug_synonym	Post-operative care is directed to the control of the fluid balance, the neutralisation of metabolic acidosis with alkaline fluids (sodium lactate) and the correction of hyperkalaemia by kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5	kayexalate	drug_synonym	Rectal stenosis caused by foreign body reaction to sodium polystyrene sulfonate crystals (Kayexalate).	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5			Acute Kidney Injury|Cation Exchange Resins|Colitis, Ischemic|Constriction, Pathologic|Crystallization|Foreign-Body Reaction|Humans|Intestinal Mucosa|Male|Middle Aged|Polystyrenes|Rectum	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate (SPS) (Kayexalate) is a cation-exchange resin used to treat hyperkaliema.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5	kayexalate	drug_synonym	During his hospitalization, he presented traumatic acute pancreatitis with ischemic colitis because of hypotension, and acute renal insufficiency treated by hemofiltration and Kayexalate administered by nasogastric tube without sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24815941_20201005_0.5			Drug-induced injury in the gastrointestinal tract.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24815941_20201005_0.5	kayexalate	drug_synonym	Colchicine|Kayexalate|Mycophenolate mofetil|Olmesartan|Paclitaxel|Tetracycline	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24815941_20201005_0.5			Alendronate|Angiotensin II Type 1 Receptor Blockers|Anti-Inflammatory Agents|Antineoplastic Agents, Phytogenic|Bone Density Conservation Agents|Cation Exchange Resins|Colchicine|Ferrous Compounds|Gastrointestinal Diseases|Gastrointestinal Tract|Gout Suppressants|Humans|Imidazoles|Immunosuppressive Agents|Mycophenolic Acid|Paclitaxel|Polystyrenes|Tetracycline|Tetrazoles	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31026044_20201005_0.5			Pathology of Resin-Induced Gastrointestinal Damage: Report of 15 Cases and Review of Literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31026044_20201005_0.5			Adult|Aged|Aged, 80 and over|Cation Exchange Resins|Female|Gastrointestinal Diseases|Humans|Male|Middle Aged|Polystyrenes|Retrospective Studies|Sevelamer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31026044_20201005_0.5	kayexalate	drug_synonym	No section < strong > Objective < /strong > Medication resins such as Kayexalate and Sevelamer used in the setting of chronic kidney disease for the correction of hyperkalemia and hyperphosphatemia are associated with gastrointestinal mucosal injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31026044_20201005_0.5	kayexalate	drug_synonym	< strong > Results < /strong > Of the 15 cases, Kayexalate crystals were identified in 7 cases, Sevelamer in 5 cases and both together were seen in 3 cases.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6550989_20201005_0.5			MON-373 Pseudohypoaldosteronism Type 1, a Masquerader: Case Study	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6550989_20201005_0.5			Infant, Newborn|Humans|Female|Child|Male|Pseudohypoaldosteronism|Hypoaldosteronism|Aldosterone|Hyperkalemia|Hyponatremia|Failure to Thrive|Renin|NR3C2 protein, human|Receptors, Mineralocorticoid|Sodium|Fludrocortisone|Dehydration|Inappropriate ADH Syndrome|Kidney|17-alpha-Hydroxyprogesterone|Epithelial Sodium Channels|Birth Weight	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6550989_20201005_0.5	kayexalate	drug_synonym	Treatment with sodium containing IVF and kayexalate improved her electrolytes.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5			Dissociation of the diurnal variation of aldosterone and cortisol in anephric subjects.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5			Adult|Aldosterone|Cation Exchange Resins|Circadian Rhythm|Female|Humans|Hydrocortisone|Kidney Failure, Chronic|Male|Middle Aged|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5	kayexalate	drug_synonym	Six anephric subjects received Kayexalate (sodium polystyrene sulfonate) during the studies to prevent potassium accumulation and increase in plasma potassium concentration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5	kayexalate	drug_synonym	There was a highly significant correlation between plasma aldosterone and potassium concentration in the anephric subjects studied without Kayexalate administration (P less than 0.001).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5	kayexalate	drug_synonym	In the anephric subjects who received Kayexalate, plasma aldosterone and potassium concentration remained stable, and no correlation could be demonstrated.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30904892_20210411_0.5			Reversible iatrogenic paraparesis secondary to masked hypokalaemia in thrombocytosis-associated pseudohyperkalaemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30904892_20210411_0.5			emergency medicine|fluid electrolyte and acid-base disturbances|pharmacology and therapeutics|spinal cord	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30904892_20210411_0.5			Aged|Humans|Hypokalemia|Iatrogenic Disease|Male|Paraparesis|Polystyrenes|Splenectomy|Thrombocytosis|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30904892_20210411_0.5	kayexalate	drug_synonym	He was receiving multiple medications including kayexalate, which was started a few weeks prior, and the dose increased, due to hyperkalaemia up to 6.3 mEq/L. Although the postsplenectomy thrombocytosis was not striking (700×109/L), spurious hyperkalaemia (pseudohyperkalaemia) was suspected when no cause of hyperkalaemia could be identified and widely fluctuating serum potassium levels were noted.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30904892_20210411_0.5	kayexalate	drug_synonym	Once kayexalate was stopped and normokalaemia (in plasma) achieved by replacement therapy, paraparesis completely resolved (5/5 muscle strength) and no more falls occurred after discharge.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8888546_20201005_0.5			Intestinal pseudo-obstruction (Ogilvie's syndrome) in theophylline overdose.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8888546_20201005_0.5			Administration, Oral|Anti-Bacterial Agents|Antidotes|Charcoal|Clindamycin|Colonic Pseudo-Obstruction|Combined Modality Therapy|Drug Overdose|Female|Humans|Injections, Intravenous|Intensive Care Units|Male|Middle Aged|Potassium|Renal Dialysis|Respiration, Artificial|Theophylline|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8888546_20201005_0.5	kayexalate	drug_synonym	The patient's potassium rose to 6.5 mEq/L and he was given kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11493807_20201005_0.5	kayexalate	drug_synonym	Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11493807_20201005_0.5			Colon|Colonic Diseases|Critical Care|Enema|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2622869_20201005_0.5	kayexalate	drug_synonym	Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2622869_20201005_0.5			Animals|Charcoal|Intestinal Absorption|Lithium|Male|Mice|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2622869_20201005_0.5	kayexalate	drug_synonym	No section To determine whether sodium polystyrene sulfonate (SPS; Kayexalate) is effective in decreasing the absorption of lithium (Li) and to test the assumption that Li is poorly adsorbed by activated charcoal, 130 mice were administered an orogastric dose of LiCl (250 mg/kg) followed immediately by orogastric SPS (10 g/kg, SPS Group), activated charcoal (6.7 g/kg, AC Group), or water in an equivalent volume (Control Group).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5			Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5			Adult|Aged|Aged, 80 and over|Artifacts|Biopsy|Chelating Agents|Colon|Coloring Agents|Crystallization|Eosine Yellowish-(YS)|Esophagus|Female|Hematoxylin|Humans|Intestinal Mucosa|Intestine, Small|Male|Middle Aged|Polyamines|Predictive Value of Tests|Prospective Studies|Risk Factors|Sevelamer|Staining and Labeling|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5	kayexalate	drug_synonym	The possibility of Kayexalate (sodium polystyrene sulfonate) and cholestyramine had been raised in error.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5	kayexalate	drug_synonym	However, Kayexalate has narrow, rectangular "fish scales" and is violet on H&E and magenta on PAS/D; cholestyramine lacks internal "fish scales," is bright orange on H&E, variably gray or hot pink on PAS/D, and is unassociated with mucosal injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5	kayexalate	drug_synonym	Further study is required to determine whether sevelamer plays a causal role in these injuries; however, its crystal is an important mimic of both Kayexalate and choleystyramine.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3021625_20201005_0.5			Mechanisms by which nephrectomy stimulates adrenal renin.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3021625_20201005_0.5			Adrenal Cortex|Adrenocorticotropic Hormone|Angiotensin II|Animals|Female|Hypophysectomy|Nephrectomy|Potassium|Rats|Rats, Inbred Strains|Renin	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3021625_20201005_0.5	kayexalate	drug_synonym	Potassium also plays an important role, since prevention of hyperkalemia after nephrectomy by treatment with a cation exchange resin, sodium polystyrene sulfonate (Kayexalate), significantly reduced the adrenal renin response to nephrectomy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5			Effects of water soaking and/or sodium polystyrene sulfonate addition on potassium content of foods.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5			Hyperkalemia|potassium exchange resin|potassium-restricted diet|renal insufficiency|soaking	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5			Adolescent|Appetite|Cation Exchange Resins|Child|Cooking|Diet|Food Handling|Humans|Kidney Failure, Chronic|Pleasure|Polystyrenes|Potassium|Water	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5	kayexalate	drug_synonym	No section In this study, we determined, by atomic absorption spectrophotometry, the potassium amount leached by soaking or boiling foods identified by children suffering from chronic renal failure as "pleasure food" and that they cannot eat because of their low-potassium diet, and evaluated whether addition of sodium polystyrene sulfonate resin (i.e. Kayexalate®) during soaking or boiling modulated potassium loss.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5	kayexalate	drug_synonym	Although Kayexalate® efficiently dose-dependently removed potassium from drinks (by 48% to 73%), resin addition during soaking or boiling did not eliminate more potassium from solid foods.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5			Treatment of hyperkalemia: something old, something new.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5			cation exchange resins|hyperkalemia|insulin|potassium|renal dialysis|sodium bicarbonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5			Animals|Biomarkers|Cation Exchange Resins|Chelating Agents|Diuretics|Down-Regulation|Humans|Hyperkalemia|Potassium|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5	kayexalate	drug_synonym	No section Treatment options for hyperkalemia have not changed much since the introduction of the cation exchange resin, sodium polystyrene sulfonate (Kayexalate, Covis Pharmaceuticals, Cary, NC), over 50 years ago.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5	kayexalate	drug_synonym	Kayexalate is not effective as acute therapy, but a new randomized controlled trial suggests that it is effective when given more chronically.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5	kayexalate	drug_synonym	Gastrointestinal side effects and safety concerns about Kayexalate remain.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25032877_20201005_0.5	kayexalate	drug_synonym	Refractory hypoxemia due to sodium polystyrene sulfonate (kayexalate) aspiration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25032877_20201005_0.5			Diagnosis, Differential|Fatal Outcome|Female|Humans|Hypoxia|Inhalation Exposure|Polystyrenes|Radiography, Thoracic|Respiratory Distress Syndrome, Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5	kayexalate	drug_synonym	Rectal ulcer in a hemodialysis patient receiving Kayexalate® 	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5	kayexalate	drug_synonym	hemodialysis|hyperkalemia|kayexalate crystals|kayexalate(R)|rectal ulcer	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5			Humans|polystyrene sulfonic acid|Ulcer|Polystyrenes|Rectal Diseases|Colonic Diseases|Cation Exchange Resins|Hyperkalemia|Renal Dialysis|Hand|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5	kayexalate	drug_synonym	No section Kayexalate can cause severe unrecognized GI lesions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5	kayexalate	drug_synonym	Diagnosis of kayexalate crystals in GI biopsy samples is important.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5	kayexalate	drug_synonym	 No section Kayexalate can cause severe unrecognized GI lesions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8077330_20210511_0.5	kayexalate	drug_synonym	Diagnosis of kayexalate crystals in GI biopsy samples is important.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5			Colitis induced by sodium polystyrene sulfonate in sorbitol: A report of six cases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5	kayexalate	drug_synonym	Hyperkalemia|Kayexalate colitis|Uremia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5			Administration, Oral|Aged|Colitis|Colon|Diagnosis, Differential|Drug Combinations|Enema|Female|Humans|Intestinal Mucosa|Laxatives|Male|Middle Aged|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5	kayexalate	drug_synonym	Kayexalate or sodium polystyrene sulfonate (SPS), a linear polymer derived from polystyrene containing sulfonic acid and sulfonate functional groups is used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5	kayexalate	drug_synonym	This combination has been implicated in causing damage to different parts of the gastrointestinal (GI) tract especially the colon and causes an established pattern of injury, recognizable by the presence of characteristic crystals, is presented to create a greater awareness of the Kayexalate colitis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5	kayexalate	drug_synonym	[Granulomatous lung disease induced by kayexalate inhalation during immunotherapy for metastatic melanoma].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5			Immunotherapy|Immunotherapie|Macrophages|Melanoma|Melanome|Pneumonia, Aspiration|Pneumopathie d'inhalation|Polystyrenes|Polystyrene	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5			Humans|Male|polystyrene sulfonic acid|Neoplasm Recurrence, Local|Polystyrenes|Melanoma|Ipilimumab|Immunotherapy|Nivolumab|Skin Neoplasms|pembrolizumab|Antibodies, Monoclonal, Humanized|Antineoplastic Agents, Immunological|Sarcoidosis|Granuloma|Biopsy|Neoplasms, Second Primary|Tomography, X-Ray Computed|Lung Diseases|Dyspnea	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5	kayexalate	drug_synonym	We report a case of acute granulomatous lung disease secondary to repeated kayexalate inhalations, and probably stimulated by immunotherapy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5	kayexalate	drug_synonym	Histopathological examination of a lung biopsy showed a foreign body granulomatous macrophage reaction associated with crystalline, basophilic, purple and laminated elements, evoking kayexalate particles.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5	kayexalate	drug_synonym	These elements helped rewrite the diagnosis and confirmed a kayexalate-induced granulomatous lung disease secondary to repeated aspiration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID34024647_20210611_0.5	kayexalate	drug_synonym	The patient's respiratory condition got better following discontinuation of kayexalate together with systemic corticosteroids.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12087810_20201005_0.5	kayexalate	drug_synonym	[Colonic necrosis caused by sodium polystyrene (kayexalate) in hemodialysis: myth or reality? Two case reports].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12087810_20201005_0.5			Cation Exchange Resins|Colon|Humans|Iatrogenic Disease|Necrosis|Polystyrenes|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12087810_20201005_0.5	kayexalate	drug_synonym	No section Among gastro-intestinal complications reported in uremic or transplanted patients, colonic necrosis due to Kayexalate and sorbitol is not so unusual for english authors.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID621606_20201005_0.5	kayexalate	drug_synonym	Metabolic alkalosis in an anephric child caused by the combined use of Kayexalate and Basaljel.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID621606_20201005_0.5			Adolescent|Alkalosis|Aluminum|Female|Humans|Kidney|Kidney Failure, Chronic|Polystyrenes|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27018102_20201005_0.5	kayexalate	drug_synonym	Image of the Month: Emphysematous Gastritis and Necrosis as a Result of Orally Ingested Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27018102_20201005_0.5			Acute Kidney Injury|Aged|Cathartics|Chelating Agents|Gastritis|Gastroscopy|Humans|Hyperkalemia|Ischemia|Male|Necrosis|Polystyrenes|Sorbitol|Stomach|Tomography, X-Ray Computed	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	kayexalate	drug_synonym	Kayexalate-Induced Esophageal Ulceration in a Patient with Decompensated Cirrhosis: A Review of the Literature	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5			Humans|Male|Middle Aged|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Esophageal Diseases|Hyperkalemia|Peptic Ulcer|Ulcer|Sorbitol|Colon|Necrosis|Esophagus|Gastrointestinal Tract|Liver Cirrhosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	kayexalate	drug_synonym	The treatment of hyperkalemia includes removal of excess potassium from the body using cation exchange resins, e.g., sodium polystyrene sulfonate (Kayexalate) is one of the most practiced modalities in clinical medicine.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	kayexalate	drug_synonym	Due to the risk of colonic necrosis, the FDA has issued a warning to avoid concomitant sorbitol use with Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	kayexalate	drug_synonym	We present an individual with acute hematemesis due to bleeding esophageal ulcer immediately after treatment with Kayexalate therapy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	kayexalate	drug_synonym	Though the exact mechanism by which Kayexalate causes esophageal ulcer to be elucidated, nonetheless it is worthwhile to be vigilant about its potential adverse effects.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	kayexalate	drug_synonym	Our case highlights the rare but certainly the life-threatening complication of Kayexalate therapy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3817834_20201005_0.5	kayexalate	drug_synonym	The effectiveness of a cation resin (Kayexalate) as an adsorbent of paraquat: experimental and clinical studies.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3817834_20201005_0.5			Animals|Cation Exchange Resins|Humans|Ion Exchange Resins|Male|Paraquat|Polystyrenes|Rats|Rats, Inbred Strains	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3817834_20201005_0.5	kayexalate	drug_synonym	No section The cation-exchange-resin Kayexalate has an adsorption capacity for paraquat 15 times greater than activated charcoal and 6 times greater than Adsorbin.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3817834_20201005_0.5	kayexalate	drug_synonym	The oral LD50 of paraquat in rats rose 2.1 times by intragastric injection of Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3817834_20201005_0.5	kayexalate	drug_synonym	In the present study, the survival rate of rats given Kayexalate or Adsorbin after paraquat administration was examined.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5	kayexalate	drug_synonym	Kayexalate: a new cause of neonatal bowel opacification.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5			Cation Exchange Resins|Female|Humans|Infant, Newborn|Infant, Newborn, Diseases|Intestinal Diseases|Ion Exchange Resins|Polystyrenes|Radiography	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5	kayexalate	drug_synonym	No section Two cases of neonatal bowel opacification secondary to oral and rectal administration of Kayexalate (sodium polystyrene sulfonate) are presented.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5	kayexalate	drug_synonym	The properties of Kayexalate and its possible interactions with the gastrointestinal tract are discussed.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5	kayexalate	drug_synonym	Kayexalate administration should be included in the differential diagnosis of bowel opacification.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24511728_20201005_0.5			Acute intestinal obstruction due to Kalimate, a potassium-lowering agent: a case report and literature review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24511728_20201005_0.5			Acute Disease|Amputation|Cation Exchange Resins|Fasciitis, Necrotizing|Humans|Intestinal Obstruction|Leg|Male|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24511728_20201005_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate (Kayexalate) and calcium polystyrene sulfonate (CPS, Kalimate) are commonly used to reduce serum potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8101678_20210611_0.5	kayexalate	drug_synonym	A Rare Case of Kayexalate and CMV Colitis in a Patient of Sarcoidosis and Chronic Kidney Disease	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8101678_20210611_0.5			Humans|Male|polystyrene sulfonic acid|Polystyrenes|Cytomegalovirus Infections|Enterocolitis|Colitis|Sarcoidosis|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30653476_20201005_0.5			Sodium zirconium cyclosilicate (Lokelma) for hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30653476_20201005_0.5	kayexalate	drug_synonym	Kayexalate|Lokelma|Resonium Calcium|Veltassa|adverse effects|dosage|drug interactions|efficacy|hyperkalemia|patiromer|pregnancy|safety|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30653476_20201005_0.5			Biomarkers|Chelating Agents|Drug Interactions|Humans|Hyperkalemia|Potassium|Silicates|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28169559_20201005_0.5			Challenges in Diagnosing Medication Resins in Surgical Pathology Specimens: A Crystal-Clear Review Guide.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28169559_20201005_0.5			Cation Exchange Resins|Gastrointestinal Tract|Humans|Pathology, Surgical|Polystyrenes|Sequestering Agents|Sevelamer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28169559_20201005_0.5	kayexalate	drug_synonym	BACKGROUND - Medication resins, including Kayexalate, sevelamer, and bile acid sequestrants, can be encountered in gastrointestinal tract specimens.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28169559_20201005_0.5	kayexalate	drug_synonym	Additionally, the presence of resins should prompt the pathologist to search for potentially related diagnoses (namely, causes of diarrhea in patients on bile acid sequestrants and diagnoses associated with renal failure in patients on Kayexalate or sevelamer).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22678034_20201005_0.5	kayexalate	drug_synonym	Pulmonary disease due to kayexalate aspiration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22678034_20201005_0.5			Anti-Infective Agents|Fatal Outcome|Humans|Lung Diseases|Male|Middle Aged|Pneumonia, Aspiration|Polystyrenes|Radiography	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6259213_20201005_0.5			Mechanism of adrenal angiotensin II receptor changes after nephrectomy in rats.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6259213_20201005_0.5			Adrenal Glands|Aldosterone|Animals|Cation Exchange Resins|Muscle, Smooth|Nephrectomy|Polystyrenes|Potassium|Rats|Receptors, Angiotensin|Receptors, Cell Surface	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6259213_20201005_0.5	kayexalate	drug_synonym	Serum K+ was controlled with Na polystyrene sulfonate (Kayexalate), a resin designed to exchange Na+ for K+ in the gastrointestinal tract.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6259213_20201005_0.5	kayexalate	drug_synonym	Acutely nephrectomized rats were divided into two groups: experimental animals received Kayexalate resin every 12 h for four doses, and controls received Kayexalate exchanged with KCl in vitro before gavage.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6259213_20201005_0.5	kayexalate	drug_synonym	Kayexalate maintained a normal serum K+ of 5.9 +/- 0.2 meq/liter (n = 27), aldosterone 25 +/- 3 ng/dl (n = 27) and adrenal receptor concentration of 934 +/- 156 fmol/mg protein (n = 4).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29786183_20201005_0.5			[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29786183_20201005_0.5	kayexalate	drug_synonym	ARB|ZS-9|aceinhibitors|hyperkalemia|kayexalate|patiromer|potassium|renal failure|sodium zieconium cyclosylate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29786183_20201005_0.5			Aldosterone|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Diuretics|Humans|Hyperkalemia|Mineralocorticoid Receptor Antagonists|Polymers|Polystyrenes|Potassium|Potassium, Dietary|Renal Insufficiency, Chronic|Renin-Angiotensin System|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24921636_20201005_0.5			Colesevelam and colestipol: novel medication resins in the gastrointestinal tract.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24921636_20201005_0.5			Adult|Aged|Allylamine|Anticholesteremic Agents|Biopsy|Cholestyramine Resin|Colesevelam Hydrochloride|Colestipol|Female|Gastrointestinal Agents|Humans|Intestinal Mucosa|Intestines|Ion Exchange Resins|Male|Middle Aged|Prospective Studies|Risk Assessment|Risk Factors|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24921636_20201005_0.5	kayexalate	drug_synonym	Rare, irregular "fracture" lines presented diagnostic pitfalls by mimicking the true "fish-scales" of Kayexalate and sevelamer.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24921636_20201005_0.5	kayexalate	drug_synonym	Moreover, Kayexalate is violet on H&E and black on acid fast bacillus, and sevelamer characteristically displays a 2-tone color on H&E and is magenta on acid fast bacillus.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	Adverse Gastrointestinal Effects with Kayexalate or Kalimate: A Comprehensive Review	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	Kalimate|Kayexalate|gastrointestinal injury|hyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5			Humans|Male|Adult|Female|Middle Aged|polystyrene sulfonic acid|Polystyrenes|Data Management|Cation Exchange Resins|Gastrointestinal Tract|Hyperkalemia|Iatrogenic Disease|Sorbitol|Colon|Drug-Related Side Effects and Adverse Reactions|Uremia|Necrosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	Background Patients with hyperkalemia are commonly treated with Kayexalate or Kalimate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	 Aim To assess the clinical characteristics and outcomes of GI AEs induced by Kayexalate or Kalimate from published case reports.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	 Methods We conducted a systematic review of case reports of Kayexalate or Kalimate-induced GI AEs, from PubMed, Medline, Cochrane Library, Clinical Key, and Google Scholar databases (1948 to March 31, 2020).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	 Results We identified 41 published articles describing 135 cases of GI AEs induced by Kayexalate (103 cases) or Kalimate (32 cases).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	 Conclusion Kayexalate or Kalimate, without or with sorbitol combination, may be related to fatal GI damage.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7810591_20210211_0.5	kayexalate	drug_synonym	Clinicians should be careful in prescribing Kayexalate or Kalimate to patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19842945_20201005_0.5			Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19842945_20201005_0.5			Adult|Aged|Algorithms|Antidotes|Antimanic Agents|Area Under Curve|Cohort Studies|Drug Overdose|Female|Half-Life|Humans|Lithium Chloride|Male|Middle Aged|Poisoning|Polystyrenes|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19842945_20201005_0.5	kayexalate	drug_synonym	Sodium polystyrene sulfonate (SPS, Kayexalate), a cation exchanger, has been promising in animal models and human reports to reduce absorption and enhance elimination of Li.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5	kayexalate	drug_synonym	Rectal ulcer due to Kayexalate deposition - an unusual case.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5			Acute Kidney Injury|Aged, 80 and over|Biopsy|Cation Exchange Resins|Colonoscopy|Female|Humans|Hyperkalemia|Polystyrenes|Rectal Diseases|Risk Factors|Sorbitol|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate (PSP) or Kayexalate is a cation-exchange resin, widely used in the management of hyperkalaemia due to renal disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5	kayexalate	drug_synonym	A colonoscopy was performed and revealed a rectal ulcer which histological findings were suggestive of mucosal injury due to Kayexalate deposition.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19269913_20201005_0.5	kayexalate	drug_synonym	[Digestive adverse effects due to sodium polystyrene sulfonate (Kayexalate) in dialysis patients].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19269913_20201005_0.5			Humans|Intestinal Diseases|Polystyrenes|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19269913_20201005_0.5	kayexalate	drug_synonym	No section Administered to reduce hyperkaliema in patients with chronic renal failure, sodium polystyrene sulfonate (Kayexalate) can cause digestive complications.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5			Ileum and colon perforation following peritoneal dialysis-related peritonitis and high-dose calcium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5			Kalimate|bowel/intestinal perforation|end-stage renal disease	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5			Colon|Fatal Outcome|Female|Humans|Hyperkalemia|Ileum|Intestinal Perforation|Kidney Failure, Chronic|Middle Aged|Necrosis|Peritoneal Dialysis|Peritonitis|Polystyrenes|Shock, Septic|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5	kayexalate	drug_synonym	No section A rare but severe complication, intestinal necrosis, has been reported after sodium polystyrene sulfonate (SPS; Kayexalate) and sorbitol intake.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9496569_20201005_0.5			[Effect of ion exchange resins on the composition of milk].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9496569_20201005_0.5			Animals|Calcium|Cation Exchange Resins|Child|Female|Humans|Infant Food|Milk|Milk, Human|Polystyrenes|Potassium|Renal Insufficiency|Resins, Synthetic|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9496569_20201005_0.5	kayexalate	drug_synonym	We therefore studied the in vitro effects of Kayexalate and Calcium Sorbisterit on potassium, sodium and calcium concentrations in 3 standard formulas and in human milk.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2441607_20201005_0.5	kayexalate	drug_synonym	Sodium polystyrene sulfonate (Kayexalate) aspiration	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2441607_20201005_0.5			Male|Humans|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Sorbitol|Colon|Rectum|Necrosis|Crystallization|Administration, Oral	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6496116_20201005_0.5	kayexalate	drug_synonym	Alleviation of paraquat toxicity by Kayexalate and Kalimate in rats.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6496116_20201005_0.5			Administration, Oral|Animals|Carbon Radioisotopes|Male|Paraquat|Polystyrenes|Rats|Rats, Inbred Strains	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23859454_20201005_0.5			Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23859454_20201005_0.5			Cation Exchange Resins|Colon|Humans|Hyperkalemia|Necrosis|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23859454_20201005_0.5	kayexalate	drug_synonym	These resins were associated with gastrointestinal tract lesions, especially sodium polystyrene sulfonate (Kayexalate) mixed with sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4868944_20201005_0.5			A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4868944_20201005_0.5			Hypophosphatemia|Ibrutinib|Phosphate wasting|Tyrosine kinase inhibitors	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4868944_20201005_0.5			PRC|Male|Humans|PCI 32765|Phosphorus|Pyrazoles|Pyrimidines|Agammaglobulinaemia tyrosine kinase|Protein-Tyrosine Kinases|Leukemia, Lymphocytic, Chronic, B-Cell|Hematologic Neoplasms|Potassium|Hypophosphatemia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4868944_20201005_0.5	kayexalate	drug_synonym	Because of these changes, ibrutinib was held, and the patient was given kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5			Aged|Aged, 80 and over|Cation Exchange Resins|Crystallization|Duodenum|Endoscopy, Gastrointestinal|Esophagus|Female|Gastrointestinal Diseases|Humans|Hyperkalemia|Male|Middle Aged|Mucous Membrane|Polystyrenes|Sorbitol|Stomach|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	No section Kayexalate (sodium polystyrene sulfonate) in sorbitol has been demonstrated to cause colonic necrosis in a subset of uremic patients who are administered the cation exchange resin for treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	Upper gastrointestinal damage associated with Kayexalate in sorbitol is reported far less frequently, and the clinicopathologic spectrum of disease in cases with upper gastrointestinal damage has not been investigated previously.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	The authors studied the clinical, endoscopic, and histologic features of 11 patients with Kayexalate crystals in biopsies from the esophagus (n = 7), stomach (n = 6), and duodenum (n = 2).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	In four patients with mucosal injury, no other etiology apart from Kayexalate in sorbitol could be identified.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	In comparison with a cohort of patients with Kayexalate crystals in lower gastrointestinal specimens identified during the same period (11 patients) the frequency of associated mucosal damage was not significantly different (55%, p = 0.19), but no patient with upper gastrointestinal Kayexalate required surgical resection or died as a result of Kayexalate-induced mucosal injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	The results of this study provide evidence that Kayexalate in sorbitol can induce damage to the upper gastrointestinal tract.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	kayexalate	drug_synonym	Recognition of Kayexalate crystals in histologic sections as a marker for sorbitol-induced mucosal damage may aid in establishing the correct diagnosis for clinically or endoscopically misleading lesions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7421136_20201005_0.5			Thallium elimination kinetics in acute thallotoxicosis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7421136_20201005_0.5			Adult|Autopsy|Central Nervous System|Ferrocyanides|Humans|Liver|Male|Thallium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7421136_20201005_0.5	kayexalate	drug_synonym	Kayexalate did not appear to contribute to the therapy in this case.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	kayexalate	drug_synonym	Inflammatory Pseudotumor Containing Kayexalate Crystals: A Case Report and Review of the Literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	kayexalate	drug_synonym	Kayexalate|inflammatory pseudotumor|myofibroblastic|perihepatic pseudotumor|pseudotumor	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5			Cation Exchange Resins|Female|Granuloma, Plasma Cell|Humans|Hyperkalemia|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	kayexalate	drug_synonym	No section Kayexalate (sodium polystyrene sulfonate), a cation exchange resin often used to treat hyperkalemia, is known to produce gastrointestinal complications in a minority of patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	kayexalate	drug_synonym	We present a unique case of Kayexalate crystals embedded in a perihepatic inflammatory pseudotumor, developing adjacent to a colostomy site in a 62-year-old woman following Kayexalate treatment.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	kayexalate	drug_synonym	Microscopically, the lesion demonstrated a myofibroblastic proliferation rich in histiocytes and inflammation (lymphocytes, plasma cells, and eosinophils) as well as the presence of scattered typical Kayexalate crystals.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	kayexalate	drug_synonym	This is the first report of extraintestinal Kayexalate identification in association with an inflammatory pseudotumor.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33318260_20210311_0.5	kayexalate	drug_synonym	Kayexalate-induced colitis and rectal stricture.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33318260_20210311_0.5			GI-stents|endoscopy|gastrointestinal system	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33318260_20210311_0.5			Anastomosis, Surgical|Cation Exchange Resins|Colitis|Colonoscopy|Colostomy|Constriction, Pathologic|Crohn Disease|Diabetic Ketoacidosis|Humans|Hyperkalemia|Male|Middle Aged|Polystyrenes|Rectum|Stents	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33318260_20210311_0.5	kayexalate	drug_synonym	Six months later, on rereview of all the biopsies, it was noted that a key element of presence of crystals suggestive of Kayexalate on the initial colorectal biopsies was missed.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33318260_20210311_0.5	kayexalate	drug_synonym	It was later found out that the patient had received rectal Kayexalate for treatment of DKA at the other facility.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17965530_20201005_0.5			Successful treatment of a colonic ulcer penetrating the urinary bladder caused by the administration of calcium polystyrene sulfonate and sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17965530_20201005_0.5			Aged|Colonic Diseases|Cystectomy|Digestive System Surgical Procedures|Female|Humans|Hypokalemia|Intestinal Fistula|Polystyrenes|Sigmoid Diseases|Sorbitol|Treatment Outcome|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17965530_20201005_0.5	kayexalate	drug_synonym	Rhomboidal, dark violet Kayexalate crystals were observed on microscope examination in the submucosa in both the first and second colonic biopsy specimens.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7449548_20201005_0.5			Small bowel necrosis and perforation due to sodium polystyrene sulfonate in the setting of graft versus host disease and fulminant Clostridium difficile infection	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7449548_20201005_0.5			Female|Humans|Male|polystyrene sulfonic acid|Graft vs Host Disease|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Sorbitol|Gastrointestinal Diseases|Intestine, Small|Renal Insufficiency, Chronic|Necrosis|Clostridium Infections	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7449548_20201005_0.5	kayexalate	drug_synonym	No section Gastrointestinal injury is a common adverse event associated with use of sodium polystyrene sulfonate (SPS), tradename Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	Salbutamol versus cation-exchange resin (kayexalate) for the treatment of nonoliguric hyperkalemia in preterm infants.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5			Adrenergic beta-Agonists|Albuterol|Cation Exchange Resins|Female|Humans|Hyperkalemia|Infant, Newborn|Infant, Premature|Infant, Premature, Diseases|Infant, Very Low Birth Weight|Male|Polystyrenes|Potassium|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	No section Our objective was to compare the efficacy and safety of rectal cation-exchange resin (Kayexalate) versus salbutamol infusion for the treatment of nonoliguric hyperkalemia (NOHK) in preterm infants.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	This before-after study was divided according to the date of admission; the first 15 patients were treated with Kayexalate enema 1 g/kg every 4 hours, and the remaining 30 patients were treated with intravenous salbutamol infusion as 4 mug/kg every 4 hours.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	Mean gestational age was 26 and 28 weeks for salbutamol and Kayexalate, respectively.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	The peak of SK ranged between 7 and 9.3 mmol/L in the Kayexalate group and between 7 and 8.7 mmol/L in the salbutamol group ( P = 0.64).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	At 12 hours of treatment, SK became normal in only 4 patients (26%) in the Kayexalate group compared with 18 patients (60%) in the salbutamol group ( P = 0.003).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	The number of doses of Kayexalate administration was significantly higher than the doses of salbutamol ( P = 0.003).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18425722_20201005_0.5	kayexalate	drug_synonym	We concluded that salbutamol infusion is more effective with faster action and safer than cation-exchange resin (Kayexalate) for the treatment of NOHK in preterm infants.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5			[Thrombocytopenia associated with sodium polystyrene sulfonate].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5			Aged|Aged, 80 and over|Humans|Hyperkalemia|Male|Polystyrenes|Thrombocytopenia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	kayexalate	drug_synonym	Sodium polystyrene sulfonate (Kayexalate) was administered orally for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	kayexalate	drug_synonym	However, after 7 days from the start of Kayexalate therapy, thrombocytopenia progressed gradually, and 12 days later the initial platelet count of 20.7 x 10(4)/microliter decreased to 8.6 x 10(4)/microliter.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	kayexalate	drug_synonym	This thrombocytopenia rapidly improved after cessation of Kayexalate administration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	kayexalate	drug_synonym	In December 1995, readministration of Kayexalate for the treatment of hyperkalemia induced thrombocytopenia again.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	kayexalate	drug_synonym	The complication of thrombocytopenia associated with Kayexalate has not been reported.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	kayexalate	drug_synonym	This is the first reported case of thrombocytopenia caused by Kayexalate administration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID538636_20201005_0.5	kayexalate	drug_synonym	Effect of kayexalate and sorbitol on colon of normal and uremic rats.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID538636_20201005_0.5			Animals|Colon|Enema|Male|Nephrectomy|Polystyrenes|Rats|Sorbitol|Uremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID5466528_20201005_0.5	kayexalate	drug_synonym	[Treatment of hyperkalemia associated with renal insufficiency--clinical effects and side reactions of positive-ion-exchange resins, sodium polystyrene sulfonate (Kayexalate)].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID5466528_20201005_0.5			Adult|Humans|Hyperkalemia|Ion Exchange Resins|Kidney Diseases|Male|Polystyrenes|Sulfonic Acids	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5	kayexalate	drug_synonym	Colonic necrosis in a young patient receiving oral kayexalate in sorbitol: case report and literature review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5			Administration, Oral|Adult|Colon|Colonoscopy|Crystallization|Humans|Male|Necrosis|Polystyrenes|Sorbitol|Staining and Labeling	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5	kayexalate	drug_synonym	No section Kayexalate (sodium polystyrene sulfonate) is a cation-exchange resin used to treat patients with hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5	kayexalate	drug_synonym	Concomitant administration of kayexalate and sorbitol may induce gastrointestinal injury, which is potentially lethal.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5	kayexalate	drug_synonym	Kayexalate-induced colonic ulcer	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5	kayexalate	drug_synonym	Kayexalate|medication|side effect|gastrointestinal bleed	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5			PRC|Male|polystyrene sulfonic acid|Ulcer|Polystyrenes|Colonic Diseases|Kidney Failure, Chronic|Sorbitol|Necrosis|Stomach|Colitis|Biopsy	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5	kayexalate	drug_synonym	Pertinent medications include pantoprazole and sodium polystyrene sulfonate in sorbitol (Kayexalate 30 g/d orally).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8026121_20201005_0.5	kayexalate	drug_synonym	Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8026121_20201005_0.5			Aged|Aged, 80 and over|Aluminum Hydroxide|Cation Exchange Resins|Drug Therapy, Combination|Humans|Hyperkalemia|Intestinal Obstruction|Kidney Failure, Chronic|Male|Morphine|Polystyrenes|Resins, Synthetic|Trigeminal Neuralgia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5	kayexalate	drug_synonym	Colonic necrosis due to oral kayexalate in a critically-ill patient.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5			Cation Exchange Resins|Colon|Critical Illness|Female|Humans|Hyperkalemia|Middle Aged|Necrosis|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5	kayexalate	drug_synonym	No section Kayexalate (sodium polystyrene sulfonate in sorbitol) is commonly used for treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5	kayexalate	drug_synonym	We describe the case of a critically ill patient who developed colonic necrosis after oral administration of kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28811210_20201005_0.5			Safe and effective administration of lactulose retention enema in the ED using specialized rectal medication administration catheter.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28811210_20201005_0.5	kayexalate	drug_synonym	Kayexalate enema|Lactulose enema|Macy catheter|Rectal absorption|Rectal catheter|Rectal medication|Retention enema	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28811210_20201005_0.5			Administration, Rectal|Catheters|Emergency Service, Hospital|Enema|Gastrointestinal Agents|Hepatic Encephalopathy|Humans|Lactulose|Male|Middle Aged	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3614505_20201005_0.5			[Magnesium hydroxide treatment of hyperphosphatemia in chronic hemodialysis patients with an aluminum overload].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3614505_20201005_0.5			Adult|Aged|Aluminum Hydroxide|Female|Humans|Hypercalcemia|Magnesium|Magnesium Hydroxide|Male|Middle Aged|Phosphates|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3614505_20201005_0.5	kayexalate	drug_synonym	Metabolic alkalosis has been observed in association with the increase of ion exchange resin (sodium polystyrene sulfonate: Kayexalate) to treat progressive hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5			Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5			Cation Exchange Resins|Dose-Response Relationship, Drug|Enteral Nutrition|Food, Formulated|Humans|Polystyrenes|Potassium|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	kayexalate	drug_synonym	BACKGROUND Sodium polystyrene sulfonate (Kayexalate) commonly is used in treating hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	kayexalate	drug_synonym	This study evaluates the use of Kayexalate to reduce potassium in one high-protein enteral formula and describes the quantitative analysis of the product.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	kayexalate	drug_synonym	Three sample concentrations were analyzed: a control not subjected to potassium reduction, 0.5 g of Kayexalate per mEq K+ sample, and a 1 g/mEq K+ sample.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	kayexalate	drug_synonym	 RESULTS Compared with the control, the percentage decrease of potassium ranged from 25% to 36%, depending on the concentration of Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5			Lower Gastrointestinal Bleeding Associated With Sodium Polystyrene Sulfonate Use	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5			Humans|Male|Aged, 80 and over|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Gastrointestinal Hemorrhage|Ulcer|Colonic Diseases|Colonoscopy|Intestinal Perforation|Gastrointestinal Tract|Sorbitol|Acute Kidney Injury	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate (kayexalate) is a cation-exchange resin widely used in the management of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5	kayexalate	drug_synonym	Colonoscopy revealed colonic ulceration, and histopathological findings were compatible with ulceration due to kayexalate injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6489262_20201005_0.5			Potassium regulates angiotensin II-induced aldosterone biosynthesis in acutely nephrectomized rats.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6489262_20201005_0.5			Adrenal Glands|Aldosterone|Angiotensin II|Animals|Cation Exchange Resins|Female|In Vitro Techniques|Kinetics|Nephrectomy|Polystyrenes|Potassium|Rats|Rats, Inbred Strains|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID6489262_20201005_0.5	kayexalate	drug_synonym	Kayexalate, which exchanges sodium for potassium in the gastrointestinal tract, was used to achieve the desired level of serum potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID20656279_20201005_0.5			[Mesenteric ischemia following a left radical nephrectomy].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID20656279_20201005_0.5			Humans|Ischemia|Male|Mesentery|Middle Aged|Nephrectomy	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID20656279_20201005_0.5	kayexalate	drug_synonym	The cause of this ischemia was plurifactorial with, on one hand, a splanchnic hypoperfusion due to post-procedure hypovolemia caused by an important depletion during the dialysis as well as the use of vasoactive amines and, on the other hand, the peripheral mesenteric microvascularisation occlusion due to a kayexalate crystal deposit.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10832954_20201005_0.5	kayexalate	drug_synonym	Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10832954_20201005_0.5			Abdomen, Acute|Administration, Oral|Administration, Rectal|Cathartics|Cation Exchange Resins|Colectomy|Colon|Diagnosis, Differential|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Resins, Synthetic|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10832954_20201005_0.5	kayexalate	drug_synonym	No section Colonic necrosis is an unusual complication after treatment of hyperkalemia with sodium polystyrene sulfonate (SPS, Kayexalate) in sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9214411_20201005_0.5	kayexalate	drug_synonym	Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral kayexalate in sorbital therapy.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9214411_20201005_0.5			Administration, Oral|Adult|Cation Exchange Resins|Cecal Diseases|Female|Humans|Ileal Diseases|Polystyrenes|Stomach Ulcer|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9214411_20201005_0.5	kayexalate	drug_synonym	No section Kayexalate (Roxane Labs, Columbus, OH) in sorbitol is commonly administered by the oral and rectal route for the treatment of hyperkalemia in patients with renal failure.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9214411_20201005_0.5	kayexalate	drug_synonym	We herein report on a patient who developed identical serpiginous ulcers in the stomach and the terminal ileum after the use of Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9214411_20201005_0.5	kayexalate	drug_synonym	We believe that this drug could have significant gastrointestinal toxicity in specific patient groups and suggest tentative guidelines, both for the identification of such patients and for the safer use of Kayexalate in these circumstances.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29627281_20201005_0.5	kayexalate	drug_synonym	Colonic perforation associated with sodium polystyrene sulfonate (Kayexalate) use.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29627281_20201005_0.5	kayexalate	drug_synonym	Advent event|Colonic perforation|Computed tomography (CT)|Ogilvie syndrome|Sodium polystyrene sulfonate (Kayexalate)	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29627281_20201005_0.5			Cation Exchange Resins|Colonic Diseases|Humans|Intestinal Perforation|Male|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33389507_20210611_0.5			Extra-intestinal sodium polystyrene sulfonate crystal-induced inflammatory pseudotumour in an asymptomatic haemodialysis patient.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33389507_20210611_0.5	kayexalate	drug_synonym	Inflammatory pseudotumour|Kayexalate|Resonium|Sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33389507_20210611_0.5			Humans|polystyrene sulfonic acid|Granuloma, Plasma Cell|Polystyrenes|Cation Exchange Resins|Intestines|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5			Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5			Tumor lysis|Osteosarcoma|Case report|Uricemia|Kalemia|Rasburicase	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5			Abdominal Pain|Acute Kidney Injury|Aged|Antineoplastic Agents|Bone Neoplasms|Female|Gout Suppressants|Humans|Osteosarcoma|Peritoneal Neoplasms|Renal Dialysis|Treatment Outcome|Tumor Lysis Syndrome|Urate Oxidase	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5	kayexalate	drug_synonym	After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	Glucose and insulin infusion versus kayexalate for the early treatment of non-oliguric hyperkalemia in very-low-birth-weight infants.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5			Enema|Female|Glucose Solution, Hypertonic|Humans|Hyperkalemia|Infant, Newborn|Infant, Premature, Diseases|Infant, Very Low Birth Weight|Infusions, Intravenous|Insulin|Male|Polystyrenes|Resins, Synthetic|Survival Rate|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	They were randomly divided into 2 groups, regular insulin (RI) infusion group and kayexalate resin enema group.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	In Kayexalate group (n = 20), the dose of Kayexalate was 1 gm/Kg body weight given rectally every four hours.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	The mean gestational ages were 27.4 +/- 1.8 weeks in RI group and 28.4 +/- 2.4 weeks in Kayexalate group, respectively.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	Mean birth weights were 935 +/- 259 gm (RI) and 1065 +/- 214 gm (Kayexalate).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	The ages at onset of hyperkalemia were 24.6 +/- 8.2 (RI) and 22.2 +/- 8.1 (Kayexalate) hours after birth.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	The mean urine outputs during the 8-hour interval prior to development of hyperkalemia were 5.4 +/- 1.3 (RI) and 5.5 +/- 0.9 (Kayexalate) ml/kg/min.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	The durations of hyperkalemia were 26.4 +/- 14.9 (RI) and 38.6 +/- 13.3 (Kayexalate) hours.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10910540_20201005_0.5	kayexalate	drug_synonym	We conclude that to use early continuous regular insulin infusion therapy for the treatment of non-oliguric hyperkalemia in VLBW infants is more effective than kayexalate in decreasing the duration of hyperkalemia and reducing the incidence of intraventricular hemorrhage.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8500380_20201005_0.5	kayexalate	drug_synonym	Colonic necrosis following sodium polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8500380_20201005_0.5			Colon|Enema|Humans|Hyperkalemia|Kidney Transplantation|Male|Middle Aged|Necrosis|Polystyrenes|Postoperative Complications	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8500380_20201005_0.5	kayexalate	drug_synonym	The onset of symptoms was temporally related to the administration of sodium polystyrene (Kayexalate; Sanofi Winthrop Pharmaceuticals, New York, NY)-sorbitol enemas for treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8500380_20201005_0.5	kayexalate	drug_synonym	It is suggested that Kayexalate-sorbitol enemas be avoided in renal transplant patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15094686_20201214_0.5	kayexalate	drug_synonym	[Colonic ulcer after prolongated administration of Kayexalate (sodium polystyrene sulfonate)].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15094686_20201214_0.5			Anti-Infective Agents|Colonic Diseases|Drug Administration Schedule|Humans|Kidney Failure, Chronic|Male|Middle Aged|Polystyrenes|Sepsis|Serratia Infections|Serratia marcescens|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5			Intestinal necrosis after co‐administration of sodium polystyrene sulfonate and activated charcoal	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5	kayexalate	drug_synonym	activated charcoal|end‐stage renal disease|intentional drug overdose|kayexalate|kidney transplant	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5			Humans|polystyrene sulfonic acid|Charcoal|Polystyrenes|Intestinal Diseases|Cation Exchange Resins|Hyperkalemia|Vascular Diseases|Sorbitol|Necrosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5	kayexalate	drug_synonym	No section Development of acute abdominal pain after Kayexalate and activated charcoal administration should prompt clinician to consider intestinal necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5	kayexalate	drug_synonym	 No section Development of acute abdominal pain after Kayexalate and activated charcoal administration should prompt clinician to consider intestinal necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31295160_20210211_0.5	kayexalate	drug_synonym	Fractal Deposits of a Hemostatic Hydrophilic Polymer in Mohs Micrographic Surgery Frozen Sections: A Histologic Analysis and Comparison With Sodium Polystyrene Sulfonate (Kayexalate).	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31295160_20210211_0.5			Aged|Artifacts|Carcinoma, Basal Cell|Hemostatics|Humans|Iron Compounds|Male|Mohs Surgery|Polystyrenes|Potassium Compounds|Skin Neoplasms	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5	kayexalate	drug_synonym	Esophageal necrosis associated with sodium polystyrene sulfonate (Kayexalate) use.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5	kayexalate	drug_synonym	Acute esophageal necrosis|Gurvits syndrome|Kayexalate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5			Humans|polystyrene sulfonic acid|Polystyrenes|African Americans|Alcoholism|Caustics|Colon|Color|Gastric Juice|Gastrointestinal Hemorrhage|Gastrointestinal Tract|Margins of Excision|Necrosis|Risk Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5	kayexalate	drug_synonym	Kayexalate (sodium polystyrene sulphonate) in sorbitol associated with intestinal necrosis in uremic patients.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5			Aged|Cation Exchange Resins|Colon|Diuretics, Osmotic|Drug Therapy, Combination|Fatal Outcome|Female|Gastrointestinal Hemorrhage|Humans|Hyperkalemia|Intestinal Diseases|Male|Necrosis|Polystyrenes|Sorbitol|Uremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5	kayexalate	drug_synonym	BACKGROUND Kayexalate (sodium polystyrene sulphonate) in sorbitol is commonly used to treat hyperkalemia in patients with renal insufficiency.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5	kayexalate	drug_synonym	Isolated case reports and one recent large series have documented intestinal necrosis following administration of kayexalate in sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5	kayexalate	drug_synonym	 METHODS Two patients with luminal kayexalate crystals associated with intestinal pathology were first identified in the pathology department, and clinicopathological correlation was carried out.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5	kayexalate	drug_synonym	Examination of autopsy and colonic resection showed luminal kayexalate crystals associated with underlying mucosal necrosis, submucosal edema and transmural inflammation.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9395757_20201005_0.5	kayexalate	drug_synonym	 CONCLUSIONS Although occurring in complex clinical settings, the pathological findings provide additional evidence that kayexalate in sorbitol may be associated with intestinal necrosis and inflammation in uremic patients and that this may be a clinically and pathologically under-recognized iatrogenic bowel injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID637049_20201005_0.5			The microscopic appearance of a sodium-potassium exchange resin in histologic sections.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID637049_20201005_0.5			Asphyxia Neonatorum|Bronchi|Female|Foreign Bodies|Humans|Infant, Newborn|Inhalation|Ion Exchange Resins|Pulmonary Alveoli	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID637049_20201005_0.5	kayexalate	drug_synonym	No section The histologic appearance of Kayexalate, an ion-exchange resin, in bronchioles and alveolar spaces is described.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID637049_20201005_0.5	kayexalate	drug_synonym	A solution of Kayexalate prepared for comparison appears to be identical to that found in the lung sections.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12147952_20201005_0.5			Differential effects of direct antagonism of AII compared to ACE inhibitors on serum potassium levels and azotemia in patients with severe congestive heart failure.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12147952_20201005_0.5			Middle Aged|Male|Humans|Female|Angiotensin-Converting Enzyme Inhibitors|Azotemia|Losartan|Heart Failure|Hyperkalemia|Angiotensin II Type 1 Receptor Blockers|Potassium|Renal Insufficiency|Creatinine	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12147952_20201005_0.5	kayexalate	drug_synonym	Two patients who had required kayexalate were withdrawn.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5			Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5	kayexalate	drug_synonym	Kayexalate|hyperkalemia|sodium polystyrene sulfonate (SPS)	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5			Middle Aged|Aged|Male|Humans|Adult|Female|Hyperkalemia|polystyrene sulfonic acid|Retrospective Studies|Prospective Studies|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Chelating Agents	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10624095_20201005_0.5			[Induction of protective immunity for Bordetella pertussis by nasal inoculation of pertussis vaccine in mice].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10624095_20201005_0.5			Animals|Bordetella pertussis|Female|Immunity, Cellular|Immunoglobulin G|Mice|Mice, Inbred BALB C|Nasal Mucosa|Pertussis Vaccine|Vaccination	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10624095_20201005_0.5	kayexalate	drug_synonym	In the present study, we inoculated purified Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA) with or without adjuvant (kayexalate), or Diphtheria acellular Pertussis Tetanus (DaPT) combined vaccine to mice intranasally three times every four weeks to investigate the references of the immunoresponses between nasal and intramuscular vaccination.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5			Treatment of pediatric hyperkalemia with sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5	kayexalate	drug_synonym	Adverse events|Efficacy|Hyperkalemia|Kayexalate|Pediatric	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5			Administration, Oral|Administration, Rectal|Adolescent|Body Weight|Cation Exchange Resins|Child|Child, Preschool|Diarrhea|Female|Humans|Hyperkalemia|Infant|Male|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Retrospective Studies|Texas|Treatment Outcome|Vomiting	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5	kayexalate	drug_synonym	SPS(Kayexalate)/CPS(K-Bind) crystals in the gastrointestinal tract-An experience from a tertiary center.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5			GI injury|SPS/CPS crystals|hyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5			Humans|Male|Female|Middle Aged|Adult|Aged|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Renal Insufficiency, Chronic|Gastrointestinal Tract|Sorbitol|Pharmaceutical Preparations|India	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5	kayexalate	drug_synonym	UNASSIGNED Kayexalate (Sodium Polystyrene Sulfonate/SPS) and K-bind (Calcium Polystyrene Sulfonate/CPS) are cation exchange resins, commonly used for treatment of hyperkalaemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5	kayexalate	drug_synonym	 UNASSIGNED Study population comprised patients with SPS/CPS (Kayexalate or its analogues) crystals identified in gastrointestinal specimens from 2017-2019 at a tertiary care centre.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5			The Successful Treatment of Sodium Polystyrene Sulfonate-induced Enteritis Diagnosed by Small Bowel Endoscopy	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5			sodium polystyrene sulfonate|chronic kidney disease|small bowel necrosis	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5			Aged|Cation Exchange Resins|Endoscopy, Gastrointestinal|Enteritis|Humans|Hyperkalemia|Intestine, Small|Laparoscopy|Male|Necrosis|Polystyrenes|Renal Insufficiency, Chronic|Tomography, X-Ray Computed	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate (SPS: Kayexalate ) is an ion-exchange resin used to treat hyperkalemia in patients with chronic kidney disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5			Treatment of Severe Hyperkalemia: Confronting 4 Fallacies	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5	kayexalate	drug_synonym	colonic necrosis|Kayexalate|low potassium dialysate|severe hyperkalemia|sodium bicarbonate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5			Humans|Hyperkalemia|Potassium|Cation Exchange Resins|polystyrene sulfonic acid|Polystyrenes|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5	kayexalate	drug_synonym	It is of concern then that, based on questions about effectiveness and safety, many physicians no longer use 3 key modalities in the treatment of severe hyperkalemia: sodium bicarbonate, sodium polystyrene sulfonate (Kayexalate [Concordia Pharmaceuticals Inc., Oakville, ON, Canada], SPS [CMP Pharma, Farmville, NC]), and hemodialysis with low potassium dialysate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5908587_20201005_0.5			Spontaneous conversion of atrial fibrillation caused by severe hyperkalemia	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5908587_20201005_0.5			arterial thrombosis|hyperkalemia|sinoventricular conduction|spontaneous defibrillation	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5908587_20201005_0.5			Aged, 80 and over|Atrial Fibrillation|Electrocardiography|Humans|Hyperkalemia|Hypertension|Male|Remission, Spontaneous	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5908587_20201005_0.5	kayexalate	drug_synonym	 Interventions: He was treated with an intravenous infusion of calcium gluconate, insulin and dextrose, an oral kayexalate, and emergency hemodialysis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5			Successful management of severe acute respiratory distress syndrome caused by sodium polystyrene sulfonate aspiration	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5	kayexalate	drug_synonym	acute respiratory distress syndrome|extracorporeal membrane oxygenation|Kayexalate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5			Bronchoscopy|Extracorporeal Membrane Oxygenation|Humans|Male|Middle Aged|Polystyrenes|Respiration, Artificial|Respiratory Aspiration|Respiratory Distress Syndrome|Severity of Illness Index	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16740839_20201005_0.5			Reported medication use in the neonatal intensive care unit: data from a large national data set.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16740839_20201005_0.5			Drug Utilization|Female|Humans|Infant, Newborn|Intensive Care Units, Neonatal|Male|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16740839_20201005_0.5	kayexalate	drug_synonym	Medications used for patient populations with >20% mortality rates included amphotericin, clonazepam, dobutamine, epinephrine, ethacrynic acid, insulin, lidocaine, metolazone, milrinone, inhaled nitric oxide, nitroglycerin, octreotide, pancuronium, phenytoin, sodium nitroprusside, sodium polystyrene sulfonate (Kayexalate), tris-hydroxymethylaminomethane acetate buffer, and tolazoline.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5055282_20201005_0.5	kayexalate	drug_synonym	Total colectomy for colon perforation after kayexalate administration: a case report and literature review of a rare complication	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5055282_20201005_0.5			Humans|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Colectomy|Hyperkalemia|Colon|Sorbitol|Colonic Diseases|Intestinal Perforation|Necrosis|Ulcer|Uremia|Administration, Oral	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5055282_20201005_0.5	kayexalate	drug_synonym	No section Kayexalate is an ion exchange resin that is commonly used to acutely treat patients with hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5055282_20201005_0.5	kayexalate	drug_synonym	Bowel ulceration and necrosis is a rare and uncommonly recognized complication of kayexalate administration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5055282_20201005_0.5	kayexalate	drug_synonym	More often, concomitant administration with sorbitol is reported to damage the bowel; however, there are reports of kayexalate administration causing bowel necrosis without sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5055282_20201005_0.5	kayexalate	drug_synonym	We present a case of a critically ill patient who underwent total colectomy for colonic necrosis secondary to oral kayexalate administration that was not recognized until late in the pathologic process.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2775877_20201005_0.5			Colonic Mucosal Necrosis Following Administration of Calcium Polystryrene Sulfonate (Kalimate) in a Uremic Patient	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2775877_20201005_0.5			Polystyrene Sulfonic Acid|Colon|Necrosis	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2775877_20201005_0.5			Adult|Colon|Gastrointestinal Hemorrhage|Humans|Hyperkalemia|Intestinal Mucosa|Male|Necrosis|Polystyrenes|Uremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2775877_20201005_0.5	kayexalate	drug_synonym	No section Colonic necrosis is known as a rare complication following the administration of Kayexalate (sodium polystryrene sulfonate) in sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2775877_20201005_0.5	kayexalate	drug_synonym	We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2775877_20201005_0.5	kayexalate	drug_synonym	Microscopic examination of random colonic biopsies by two consecutive sigmoidoscopies revealed angulated crystals with a characteristic crystalline mosaic pattern on the ulcerated mucosa, which were consistent with Kayexalate crystals.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19385154_20201005_0.5			Positive intraluminal bowel contrast on computed tomography following oral ingestion of kayexelate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19385154_20201005_0.5			Administration, Oral|Aged|Female|Humans|Hyperkalemia|Intestines|Male|Middle Aged|Polystyrenes|Tomography, X-Ray Computed	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19385154_20201005_0.5	kayexalate	drug_synonym	Five patients with whom kayexalate appeared as high-attenuating intraluminal enteric content, similar to oral contrast material or leakage of intravascular contrast, are reported.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4421671_20201005_0.5			Colonic necrosis and perforation due to calcium polystyrene sulfonate in a uraemic patient: a case report	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4421671_20201005_0.5			calcium polystyrene sulfonate|chronic kidney disease|colon perforation|hyperkalaemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4421671_20201005_0.5			Humans|polystyrene sulfonic acid|Colon|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Necrosis|Sorbitol|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4421671_20201005_0.5	kayexalate	drug_synonym	No section Sodium or calcium polystyrene sulfonate (Kayexalate or analog) is an ion-exchange resin commonly used to treat hyperkalaemia in patients with chronic kidney disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5			Patiromer for the treatment of hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5			Dialysis|heart failure|hyperkalemia|hypertension|kidney disease|patiromer|potassium	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5			Animals|Chelating Agents|Humans|Hyperkalemia|Polymers|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5	kayexalate	drug_synonym	 UNASSIGNED Pubmed was used to search from 1960 to 2020 on free subject terms: Hyperkalemia, Potassium, Patiromer, Veltassa, Kayexalate, Sodium polystyrene sulfonate, and Sodium Zirconium cyclosilicate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16878438_20201005_0.5			Hyperkalemia after acute metabolic decompensation in two children with vitamin B12-unresponsive methylmalonic acidemia and normal renal function.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16878438_20201005_0.5			Child, Preschool|Female|Fumarates|Humans|Hyperkalemia|Hypoaldosteronism|Infant|Kidney|Male|Maleates|Metabolism, Inborn Errors|Vitamin B 12	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16878438_20201005_0.5	kayexalate	drug_synonym	They showed hyporeninemic hypoaldosteronism and significant hyperkalemia requiring sodium potassium exchange resin (Kayexalate) therapy after an episode of metabolic decompensation leading to diagnosis of MMA.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18271158_20201005_0.5			Disaster management of chronic dialysis patients.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18271158_20201005_0.5			Ambulatory Care Facilities|Disaster Planning|Emergency Medical Services|Humans|Kidney Failure, Chronic|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18271158_20201005_0.5	kayexalate	drug_synonym	Appropriate planning and stockpiling of medications such as Kayexalate are critical to minimizing morbidity and mortality.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5	kayexalate	drug_synonym	Vancomycin-resistant Enterococcus faecium bacteraemia as a complication of Kayexalate (sodium polystyrene sulfonate, SPS) in sorbitol-induced ischaemic colitis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5			contraindications and precautions|drugs: gastrointestinal system|endoscopy|gi bleeding|infectious diseases	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5			Aged, 80 and over|Bacteremia|Colitis, Ischemic|Female|Humans|Hypokalemia|Polystyrenes|Renal Insufficiency, Chronic|Sorbitol|Tomography, X-Ray Computed|Vancomycin-Resistant Enterococci	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5	kayexalate	drug_synonym	Sodium polystyrene sulfonate (SPS, Kayexalate) in sorbitol suspension was given orally to treat her hyperkalaemia, which precipitated an episode of SPS in sorbitol-induced ischaemic colitis with the subsequent complication of vancomycin-resistant Enterococcus (VRE) bacteraemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5	kayexalate	drug_synonym	SPS (Kayexalate) in sorbitol suspension has been implicated in the development of intestinal necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31392771_20201005_0.5	kayexalate	drug_synonym	The ice cream challenge: A favourable extemporaneous Kayexalate formulation improves compliance in paediatric patients.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31392771_20201005_0.5			Cation Exchange Resins|Child, Preschool|Drug Compounding|Humans|Ice Cream|Male|Medication Adherence|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8865238_20201005_0.5			Severe pseudohypoaldosteronism in a pair of twins not associated with hydramnios.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8865238_20201005_0.5			Body Height|Female|Fludrocortisone|Humans|Infant|Male|Mineralocorticoids|Polyhydramnios|Pregnancy|Pseudohypoaldosteronism|Twins, Dizygotic|Weight Gain	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8865238_20201005_0.5	kayexalate	drug_synonym	Despite continuous treatment with sodium chloride and sodium bicarbonate (< or = 20 g/day) and cation exchange resin (Kayexalate, sodium polystyrene sulfonate, < or = 4 g/kg per day), the children had repeated episodes of dehydration, hyponatremia, and hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17460460_20201005_0.5			Pulmonary disease due to aspiration of food and other particulate matter: a clinicopathologic study of 59 cases diagnosed on biopsy or resection specimens.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17460460_20201005_0.5			Adult|Aged|Aged, 80 and over|Biopsy|Cryptogenic Organizing Pneumonia|Female|Foreign Bodies|Foreign-Body Reaction|Humans|Lung|Male|Middle Aged|Pneumonia, Aspiration|Radiography, Thoracic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17460460_20201005_0.5	kayexalate	drug_synonym	Foreign material was identified in all cases, including most commonly vegetable or food remnants (54 cases), and less often talc or microcrystalline cellulose (7), crospovidone (4), and kayexalate (2).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5			Adolescent|Adult|Animals|Colon|Enema|Female|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Rats|Sorbitol|Uremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	All patients were uremic and received sodium polystyrene (Kayexalate) in sorbitol enemas for the treatment of hyperkalemia shortly before the development of signs and symptoms of colonic necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	In all specimens extensive ischemic necrosis was present, and Kayexalate crystals were noted in the intestinal lumen.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	To further investigate the occurrence of colonic necrosis after the administration of Kayexalate in sorbitol enemas, a series of experiments were performed in rats.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	Enemas of saline, Kayexalate alone, sorbitol alone, or Kayexalate in sorbitol were administered.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	In nonuremic rats, transmural necrosis was noted in seven of 10 rats receiving sorbitol enemas and in six of 10 rats receiving Kayexalate in sorbitol enemas.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3824154_20201005_0.5	kayexalate	drug_synonym	In uremic rats, extensive transmural necrosis was noted in all rats receiving enemas of sorbitol or Kayexalate in sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5	kayexalate	drug_synonym	[Colonic ulcers associated with taking Kayexalate(®) (sodium polystyrene sulfonate): about two cases].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5	kayexalate	drug_synonym	Colon|Côlon|Kayexalate(®)|Polystyrène sulfonate de sodium|Sodium polystyrene sulfonate|Ulcers|Ulcérations	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5			Adult|Colonic Diseases|Female|Humans|Male|Middle Aged|Polystyrenes|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5	kayexalate	drug_synonym	No section We report two cases of patients with chronic renal failure showing rectal bleeding due to digestive ulcers, associated with Kayexalate(®) alone.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5	kayexalate	drug_synonym	Kayexalate(®) crystals correspond to a typical histological picture and it is important to know how to identify them in order to discuss a possible pathogenicity.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5			Adult|Aged|Cation Exchange Resins|Child, Preschool|Cholestyramine Resin|Crystallization|Digestive System|Diuretics, Osmotic|Female|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Sorbitol|Uremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	No section Sodium polystyrene sulfonate (Kayexalate) in sorbitol given as an enema or orally to treat hyperkalemia has been reported to induce intestinal necrosis in uremic patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	We studied the clinical and pathologic features of 15 patients in whom Kayexalate crystals were observed in specimens from gastrointestinal surgical resections (n = 9) or endoscopic biopsies (n = 7).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	Oral or nasogastric tube administration of Kayexalate in sorbitol was documented in 10 patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	No other cause of colorectal necrosis apart from Kayexalate in sorbitol was apparent in seven patients, and four also had necrosis of the small intestine.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	Kayexalate crystals were observed in upper gastrointestinal tract specimens from four patients, including one with hemorrhagic gastritis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	kayexalate	drug_synonym	Our findings provide additional evidence that Kayexalate in sorbitol administered orally or by nasogastric tube can produce necrosis in the gastrointestinal tract.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5	kayexalate	drug_synonym	Kayexalate Intake (in Sorbitol) and Jejunal Diverticulitis, a Causative Role or an Innocent Bystander?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5	kayexalate	drug_synonym	Jejunal diverticulosis|Diverticulitis|Kayexalate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5			Male|Humans|polystyrene sulfonic acid|Sorbitol|Polystyrenes|Jejunum|Cation Exchange Resins|Hyperkalemia|Diverticulitis|Colon|Necrosis|Uremia|Mucous Membrane	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5	kayexalate	drug_synonym	Kayexalate (sodium polystyrene sulfonate) in sorbitol has been associated with colonic necrosis and less frequently with upper gastrointestinal injuries in a subset of uremic patients treated for hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5	kayexalate	drug_synonym	We report a case of jejunal diverticulosis with mucosal injury and diverticulitis in a uremic patient treated with Kayexalate and discuss the potential role of Kayexalate in the pathogenesis of diverticulitis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	kayexalate	drug_synonym	Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5			Cation Exchange Resins|Colonic Diseases|Drug Therapy, Combination|Female|Gastrointestinal Diseases|Gastrointestinal Tract|Humans|Male|Middle Aged|Necrosis|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	kayexalate	drug_synonym	BACKGROUND Sodium polystyrene sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5			[The presence of crystals of sodium polystyrene sulfonate in the colonic wall: innocent bystander or pathogenic factor?].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5			Body Mass Index|Cation Exchange Resins|Diabetes Complications|Humans|Kidney Failure, Chronic|Male|Middle Aged|Polystyrenes|Renal Dialysis|Risk Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5	kayexalate	drug_synonym	Sodium polystyrene sulfonate (SPS; Kayexalate) is a resin widely used for hyperkalemia treatment.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5	kayexalate	drug_synonym	We report the case of a 64-year-old male diabetic patient, suffering from ESRD on hemodialysis, who was treated with 30 g of Kayexalate twice a week (long interdialytic interval).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5	kayexalate	drug_synonym	Histological examination, showed the presence of crystals of Kayexalate in the colonic mucosa leading to the suspect of iatrogenic intestinal damage caused by Kayexalate administration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5	kayexalate	drug_synonym	This case does not assess if the crystals deposited in the colonic mucosa are inert or have contributed to the final event, but it shows that Kayexalate is a drug with potential harmful effect even when used orally, at very low dosage and without sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1361139_20201005_0.5			Efficacy of whole bowel irrigation using solutions with or without adsorbent in the removal of paraquat in dogs.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1361139_20201005_0.5			Animals|Body Weight|Chromatography, High Pressure Liquid|Dogs|Female|Hemodynamics|Intestinal Absorption|Male|Metabolic Clearance Rate|Paraquat|Polyethylene Glycols|Polystyrenes|Therapeutic Irrigation	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1361139_20201005_0.5	kayexalate	drug_synonym	The efficacy of whole bowel irrigation with a solution containing either polyethylene glycol (PEG) with electrolyte or an adsorbent (Kayexalate with a cathartic (sorbitol) was investigated in 18 dogs who had been given 250 mg kg-1 paraquat dichloride via a jejunal tube to eliminate the influence of gastric absorption.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31997484_20210611_0.5			Intestinal necrosis related to administration of cation exchange resin without sorbitol: A retrospective analysis of 61 patients with end-stage renal diseases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31997484_20210611_0.5	kayexalate	drug_synonym	calcium polystyrene sulfonate (Kalimate)|cation exchange resin|end-stage renal disease|intestinal necrosis|sodium polystyrene sulfonate (Kayexalate)	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31997484_20210611_0.5			Adult|Aged|Aged, 80 and over|Cation Exchange Resins|Female|Humans|Intestines|Kidney Failure, Chronic|Male|Middle Aged|Necrosis|Retrospective Studies|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5			Small crystals with severe consequences	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5			Humans|Male|Young Adult|Adult|Cation Exchange Resins|polystyrene sulfonic acid|Polystyrenes|Hyperkalemia|Stomach|Gastrointestinal Tract|Ulcer|Sorbitol|Heterocyclic Compounds|Necrosis|Ischemia|Diagnostic Tests, Routine	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5	kayexalate	drug_synonym	Histopathology showed kayexalate crystals in the gastric wall, suggesting SPS-related ischemic gastritis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5	kayexalate	drug_synonym	Although effective, the widespread use of SPS to treat hyperpotassemia remains a debated topic because of rare but serious adverse events like the forming of kayexalate crystal residues in the gastrointestinal tract.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27318747_20201005_0.5	kayexalate	drug_synonym	Moving away from Kayexalate, sodium polystyrene sulfate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27318747_20201005_0.5			Cation Exchange Resins|Humans|Hyperkalemia|Polystyrenes|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	kayexalate	drug_synonym	Sodium polystyrene sulfonate (kayexalate) aspiration: histologic appearance and infrared microspectrophotometric analysis of two cases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5			Cation Exchange Resins|Child, Preschool|Fatal Outcome|Female|Humans|Hyperkalemia|Infant, Newborn|Lung|Pneumonia, Aspiration|Polystyrenes|Spectrophotometry, Infrared	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	kayexalate	drug_synonym	OBJECTIVE Sodium polystyrene sulfonate (kayexalate) is a cation-exchange resin given enterally for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5			Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5	kayexalate	drug_synonym	Kayexalate|dose-response|hyperkalemia|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5			Administration, Oral|Administration, Rectal|Adult|Chelating Agents|Dose-Response Relationship, Drug|Female|Humans|Hyperkalemia|Hypokalemia|Inpatients|Male|Medical Records|Middle Aged|Polystyrenes|Potassium|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28288853_20201005_0.5			Establishing evidence-based thresholds and laboratory practices to reduce inappropriate treatment of pseudohyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28288853_20201005_0.5			Diagnostic error|Hyperkalemia|Leukocytosis|Pseudohyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28288853_20201005_0.5			Blood Platelets|Chelating Agents|Diagnostic Errors|Humans|Hyperkalemia|Leukocyte Count|Leukocytes|Leukocytosis|Linear Models|Platelet Count|Polystyrenes|Potassium|Retrospective Studies|Thrombocytosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28288853_20201005_0.5	kayexalate	drug_synonym	Medication administration records were queried to compare rates of kayexalate use pre- and post-intervention.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28288853_20201005_0.5	kayexalate	drug_synonym	The rate of kayexalate administration prior to confirmatory testing decreased from 37% to 16% after the laboratory started verbally communicating the possibility of PHK to treating providers.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29668438_20201005_0.5			Renastart Use in an Infant on Peritoneal Dialysis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29668438_20201005_0.5			Body Weight|Humans|Infant|Infant Formula|Milk, Human|Nutritional Status|Peritoneal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29668438_20201005_0.5	kayexalate	drug_synonym	A 9-month-old infant received EBM with Similac PM 60/40 treated with Kayexalate (Concordia Pharmaceuticals, Bridgetown, Barbados) because of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23707305_20201005_0.5	kayexalate	drug_synonym	Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23707305_20201005_0.5			Bicarbonates|Blood Urea Nitrogen|Calcium|Chlorides|Creatinine|Endpoint Determination|Humans|Hyperkalemia|Infant|Infant Formula|Magnesium|Milk, Human|Phosphorus|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Retrospective Studies|Sodium|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18557300_20201005_0.5			Chronic diseases and natural hazards: impact of disasters on diabetic, renal, and cardiac patients.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18557300_20201005_0.5			Chronic Disease|Diabetes Mellitus|Disaster Medicine|Disaster Planning|Disasters|Emergency Medical Services|Heart Diseases|Humans|Kidney Diseases	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18557300_20201005_0.5	kayexalate	drug_synonym	Patients must be familiar with emergency diet and renal fluid restriction plans, possible modification of dialysis schedules and methods, and rescue treatments such as the administration of kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11900946_20201005_0.5	kayexalate	drug_synonym	Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate in a burn patient.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11900946_20201005_0.5			Anti-Infective Agents|Burns|Colon|Diarrhea|Female|Humans|Hyperkalemia|Intestinal Perforation|Middle Aged|Necrosis|Polystyrenes|Self-Injurious Behavior	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19373153_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19373153_20201005_0.5			Adult|Aged|Aged, 80 and over|Cathartics|Cation Exchange Resins|Cohort Studies|Female|Humans|Hyperkalemia|Intestinal Mucosa|Ischemia|Kidney Failure, Chronic|Male|Middle Aged|Necrosis|Polystyrenes|Retrospective Studies|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19373153_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	BACKGROUND Sodium polystyrene sulfonate (SPS, Kayexalate) has been implicated in the development of intestinal necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5			An electronic alert to decrease Kayexalate ordering.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5			Electronic alert|hyperkalemia|patient safety|potassium|quality improvement	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5			Cation Exchange Resins|Drug Monitoring|Drug Utilization|Humans|Hyperkalemia|Massachusetts|Medical Order Entry Systems|Patient Safety|Polystyrenes|Quality Improvement|Tertiary Care Centers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27183825_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Important safety concerns have recently emerged regarding the use of sodium polystyrene sulfonate (Kayexalate), a cation-exchange resin commonly used for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate crystals in the gastric wall of a patient with upper gastrointestinal bleeding and gastric perforation: an incidental finding or a pathogenic factor?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5			Male|Humans|Middle Aged|polystyrene sulfonic acid|Incidental Findings|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Stomach|Gastrointestinal Hemorrhage|Sorbitol|Stomach Diseases|Necrosis|Intestinal Diseases|Ulcer|Abdominal Injuries	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6007406_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate, or Kayexalate, is an ion-exchange resin used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5			Cation Exchange Resins|Enterocolitis, Necrotizing|Humans|Hyperkalemia|Infant, Extremely Low Birth Weight|Infant, Newborn|Infant, Premature|Male|Polystyrenes|Sepsis|Streptococcal Infections|Streptococcus agalactiae	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17377608_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Histologic examination of the ileum specimen revealed areas of necrosis with fibrosis and giant cell reaction to a nonpolarizable material consistent with sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15628898_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	Kayexalate (sodium polystyrene sulfonate) aspiration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15628898_20210611_0.5			Fatal Outcome|Female|Humans|Hyperkalemia|Middle Aged|Pneumonia, Aspiration|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Rectal stenosis caused by foreign body reaction to sodium polystyrene sulfonate crystals (Kayexalate).	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5			Acute Kidney Injury|Cation Exchange Resins|Colitis, Ischemic|Constriction, Pathologic|Crystallization|Foreign-Body Reaction|Humans|Intestinal Mucosa|Male|Middle Aged|Polystyrenes|Rectum	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17498597_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (SPS) (Kayexalate) is a cation-exchange resin used to treat hyperkaliema.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26159448_20201005_0.5			Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26159448_20201005_0.5			ZS-9|hyperkalemia|potassium|renin-angiotensin-aldosterone system|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26159448_20201005_0.5			Animals|Chronic Disease|Clinical Trials as Topic|Heart Failure|Humans|Hyperkalemia|Mineralocorticoid Receptor Antagonists|Renin-Angiotensin System|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26159448_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Acute treatments that cause the intracellular translocation of potassium can be effective in the short-term but they simply buy time until definitive removal by dialysis or binding agents (e.g., sodium polystyrene sulfonate) can occur.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7595773_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hematochezia associated with the use of hypertonic sodium polystyrene sulfonate enemas in premature infants.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7595773_20201005_0.5			Colon|Colonic Diseases|Enema|Gastrointestinal Hemorrhage|Humans|Hypertonic Solutions|Infant, Newborn|Infant, Premature, Diseases|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7595773_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The onset of hematochezia with the use of sodium polystyrene sulfonate enemas in an index case prompted us to review our experience with the use of such enemas in neonates.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7595773_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate enemas were used in 20 of 2317 patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7595773_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Approximately 20% sorbitol (1098 mOsm/L) was the vehicle for suspension of the sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3108779_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hypernatremia in a patient treated with sodium polystyrene sulfonate	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3108779_20201005_0.5			SPS|hyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3108779_20201005_0.5			Adult|Middle Aged|Humans|Female|polystyrene sulfonic acid|Hypernatremia|Cation Exchange Resins|Polystyrenes|Hyperkalemia|Necrosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3108779_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS) is a cation exchange resin commonly used in the management of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3108779_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hypernatremia in adults in the setting of sodium polystyrene sulfonate therapy has not been described in the literature.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3576716_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	To Bind or to Let Loose: Effectiveness of Sodium Polystyrene Sulfonate in Decreasing Serum Potassium	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3576716_20201005_0.5			Humans|polystyrene sulfonic acid|Retrospective Studies|Polystyrenes|Biophysical Phenomena|Potassium|Colitis, Ischemic|Creatinine|Hyponatremia|Resins, Plant|Death|Reconstructive Surgical Procedures|Records	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3576716_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The use of sodium polystyrene sulfonate in decreasing serum potassium has recently been questioned due to the lack of documented effectiveness.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3576716_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A retrospective cohort analysis of all hospitalized patients who received sodium polystyrene sulfonate over four months was performed.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3576716_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The administration of sodium polystyrene sulfonate reduced serum potassium by 16.7% (P < 0.001) as compared to the baseline serum potassium over a period of 24 hours.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3576716_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We conclude that sodium polystyrene sulfonate is effective in lowering serum potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15028505_20201005_0.5			Amperometric method for determining the degree of complexation of polyelectrolytes with cationic surfactants.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15028505_20201005_0.5			Calorimetry|Cations|Electrochemistry|Electrolytes|Particle Size|Polymers|Polystyrenes|Surface Properties|Surface-Active Agents	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15028505_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The complexation of sodium polystyrene sulfonate with monovalent cationic surfactants at a microsized liquid/liquid interface has been studied using electrochemistry.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5			Dissociation of the diurnal variation of aldosterone and cortisol in anephric subjects.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5			Adult|Aldosterone|Cation Exchange Resins|Circadian Rhythm|Female|Humans|Hydrocortisone|Kidney Failure, Chronic|Male|Middle Aged|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID572442_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Six anephric subjects received Kayexalate (sodium polystyrene sulfonate) during the studies to prevent potassium accumulation and increase in plasma potassium concentration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31682691_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	An Alternative to Sodium Polystyrene Sulfonate and Patiromer for the Treatment of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31682691_20210511_0.5			Humans|Hyperkalemia|Polymers|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22380063_20201005_0.5			Dynamic exchange of counterions of polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22380063_20201005_0.5			polystyrene sulfonic acid|Diffusion|Polystyrenes|Ions|Solutions|rhodamine 6G|Rhodamines|Spectrometry, Fluorescence|Polymers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22380063_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Adopting a cationic fluorescent molecule, rhodamine 6G, as the probe of the counterions of the model anionic polyelectrolyte (sodium polystyrene sulfonate, PSSNa), the diffusion of the counterion probes inside the solution of PSSNa was studied by fluorescence correlation spectroscopy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16894389_20201005_0.5			The management of tumor lysis syndrome.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16894389_20201005_0.5			Acute Kidney Injury|Antineoplastic Agents|Humans|Hyperkalemia|Hyperuricemia|Hypocalcemia|Neoplasms|Tumor Lysis Syndrome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16894389_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Treatment options of hyperkalemia include sodium polystyrene sulfonate, hypertonic glucose and insulin, loop diuretics, and bicarbonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21510397_20201005_0.5			[The excimer of thioflavin T induced by polyelectrolyte and its fluorescence ratiometric sensing for temperature].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21510397_20201005_0.5			thioflavin T|Fluorescence|Temperature|Polyelectrolytes|Benzothiazoles|Fluorescent Dyes|Amyloid|Water|Anions|Cations	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21510397_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section In the present paper, the authors studied the effects of anionic polyelectrolyte sodium polystyrene sulfonate (PSS) on the cationic dye thioflavin T (ThT) fluorescence spectra in aqueous solution.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11493807_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11493807_20201005_0.5			Colon|Colonic Diseases|Critical Care|Enema|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8239115_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Use of sodium polystyrene sulfonate in a lithium overdose.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8239115_20201005_0.5			Acute Disease|Adult|Bipolar Disorder|Cation Exchange Resins|Chronic Disease|Drug Overdose|Female|Humans|Lithium|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8239115_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section A 23-year-old woman with an acute-on-chronic lithium overdose received multiple oral doses of sodium polystyrene sulfonate totaling 150 g over a 24-hour period.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8239115_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Multiple-dose sodium polystyrene sulfonate may be useful in lowering the serum lithium level of select patients with acute lithium overdoses but is not a substitute for hemodialysis in severely ill patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8729888_20201214_0.5			Multiple delayed peak lithium concentrations following acute intoxication with an extended-release product.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8729888_20201214_0.5			Adult|Antidepressive Agents|Delayed-Action Preparations|Humans|Lithium|Male	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8729888_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Two hemodialysis sessions lasting 4 hours each were performed along with administration of sodium polystyrene sulfonate in sorbitol 20% to enhance lithium elimination and decrease absorption.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26230206_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Giant intragastric sodium polystyrene sulfonate bezoar.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26230206_20201005_0.5			Acute Kidney Injury|Bezoars|Chelating Agents|Fatal Outcome|Humans|Hyperkalemia|Male|Middle Aged|Polystyrenes|Stomach	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2622869_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2622869_20201005_0.5			Animals|Charcoal|Intestinal Absorption|Lithium|Male|Mice|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2622869_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section To determine whether sodium polystyrene sulfonate (SPS; Kayexalate) is effective in decreasing the absorption of lithium (Li) and to test the assumption that Li is poorly adsorbed by activated charcoal, 130 mice were administered an orogastric dose of LiCl (250 mg/kg) followed immediately by orogastric SPS (10 g/kg, SPS Group), activated charcoal (6.7 g/kg, AC Group), or water in an equivalent volume (Control Group).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5			Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5			Adult|Aged|Aged, 80 and over|Artifacts|Biopsy|Chelating Agents|Colon|Coloring Agents|Crystallization|Eosine Yellowish-(YS)|Esophagus|Female|Hematoxylin|Humans|Intestinal Mucosa|Intestine, Small|Male|Middle Aged|Polyamines|Predictive Value of Tests|Prospective Studies|Risk Factors|Sevelamer|Staining and Labeling|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24061514_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The possibility of Kayexalate (sodium polystyrene sulfonate) and cholestyramine had been raised in error.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5367739_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5367739_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	hyperkalemia|patiromer|sodium zirconium cyclosilicate|sodium polystyrene sulfonate|evidence-based review	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5367739_20201005_0.5			Humans|Male|Hyperkalemia|polystyrene sulfonic acid|patiromer|ZS-9 compound|Polystyrenes|Polymers|Silicates|Potassium|Renal Insufficiency, Chronic|Heart Failure|Sodium Potassium Chloride Symporter Inhibitors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5367739_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 Aim The objective of this article was to review the efficacy and safety evidence for patiromer, sodium zirconium cyclosilicate (ZS9), and sodium polystyrene sulfonate (SPS) for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18783708_20201005_0.5			[The in vitro effect of the addition of ion exchange resins on the bioavailability of electrolytes in artificial enteral feeding formulas].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18783708_20201005_0.5			Biological Availability|Calcium|Enteral Nutrition|Food, Formulated|Ion Exchange Resins|Magnesium|Potassium|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18783708_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The ion exchange resins used were: Sodium Polystyrene Sulfonate and Calcium Polystyrene Sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18783708_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS The addition of Sodium Polystyrene Sulfonate to different types of enteral feeding formulas reduced the concentrations of potassium, calcium and magnesium ions by 70%.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5593397_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5593397_20201005_0.5			hyperkalemia|potassium|heart failure|chronic kidney disease|adherence|drug formulation	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5593397_20201005_0.5			Adult|Aged|Chelating Agents|Chemistry, Pharmaceutical|Cross-Over Studies|Female|Flavoring Agents|Humans|Male|Middle Aged|Particle Size|Polystyrenes|Single-Blind Method|Taste|Viscosity|Young Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5593397_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS), a current treatment, binds potassium within the gastrointestinal tract to reduce potassium absorption.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3021625_20201005_0.5			Mechanisms by which nephrectomy stimulates adrenal renin.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3021625_20201005_0.5			Adrenal Cortex|Adrenocorticotropic Hormone|Angiotensin II|Animals|Female|Hypophysectomy|Nephrectomy|Potassium|Rats|Rats, Inbred Strains|Renin	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3021625_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Potassium also plays an important role, since prevention of hyperkalemia after nephrectomy by treatment with a cation exchange resin, sodium polystyrene sulfonate (Kayexalate), significantly reduced the adrenal renin response to nephrectomy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2773964_20201005_0.5			Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2773964_20201005_0.5			Acquired Immunodeficiency Syndrome|Acute Kidney Injury|Adolescent|Adult|Amidines|Female|Humans|Hyperkalemia|Kidney|Male|Middle Aged|Pentamidine|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2773964_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Of the 19 patients exhibiting these abnormalities, most required sodium polystyrene sulfonate and two required dialysis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5678840_20201005_0.5			The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5678840_20201005_0.5			chronic kidney disease|potassium	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5678840_20201005_0.5			Animals|Humans|Middle Aged|Potassium|Hyperkalemia|Renin-Angiotensin System|Kidney|Mineralocorticoid Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Heart Failure|Homeostasis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5678840_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate has long been the mainstay for treating hyperkalemia, but its administration is fraught with challenges related to patient discomfort and colonic necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33027094_20210211_0.5			Novel approaches to management of hyperkalaemia in kidney transplantation.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33027094_20210211_0.5			Humans|Hyperkalemia|Kidney Transplantation|Potassium|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|polystyrene sulfonic acid|Polystyrenes|Mineralocorticoid Receptor Antagonists|Renin-Angiotensin System|sodium zirconium cyclosilicate|Silicates|Renal Insufficiency, Chronic|Heart Failure|Chelating Agents|Polymers|Diabetes Mellitus	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33027094_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	Both agents are efficacious in the treatment of chronic or recurrent hyperkalaemia and may result in fewer gastrointestinal side effects than older potassium binders such as sodium polystyrene sulfonate and calcium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24732395_20201005_0.5			Facile synthesis of soluble graphene quantum dots and its improved property in detecting heavy metal ions.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24732395_20201005_0.5			Cutting|Electrochemical detection|Graphene quantum dot|Heavy metal ions	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24732395_20201005_0.5			Calibration|Electrochemical Techniques|Electrodes|Graphite|Ions|Metals, Heavy|Nanotechnology|Photoelectron Spectroscopy|Quantum Dots|Solutions|Spectrometry, Fluorescence|Spectrophotometry, Ultraviolet|Spectroscopy, Fourier Transform Infrared	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24732395_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section An effective approach to produce graphene quantum dots (GQDs) has been developed, which based on the cutting of graphene oxide (GO) powder into smaller pieces and being reduced by a green approach, using sodium polystyrene sulfonate (PSS) as a dispersant and l-ascorbic acid (l-AA) as the reducing agent, which is environmentally friendly.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24970612_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Is sodium polystyrene sulfonate truly guilty without sorbitol?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24970612_20201005_0.5			Cation Exchange Resins|Female|Gastrointestinal Diseases|Humans|Male|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6946143_20201005_0.5			Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6946143_20201005_0.5			Aged|Aged, 80 and over|Angiotensin-Converting Enzyme Inhibitors|Female|Humans|Hyperkalemia|Male|Patient Acceptance of Health Care|Polymers|Polystyrenes|Retrospective Studies|Sample Size|Socioeconomic Factors|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6946143_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We described the association between use of K binders (Patiromer and sodium polystyrene sulfonate [SPS]) and renin-angiotensin-aldosterone system inhibitor (RAASi), on healthcare resource utilization (HRU).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Effects of water soaking and/or sodium polystyrene sulfonate addition on potassium content of foods.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5			Hyperkalemia|potassium exchange resin|potassium-restricted diet|renal insufficiency|soaking	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5			Adolescent|Appetite|Cation Exchange Resins|Child|Cooking|Diet|Food Handling|Humans|Kidney Failure, Chronic|Pleasure|Polystyrenes|Potassium|Water	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24720622_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section In this study, we determined, by atomic absorption spectrophotometry, the potassium amount leached by soaking or boiling foods identified by children suffering from chronic renal failure as "pleasure food" and that they cannot eat because of their low-potassium diet, and evaluated whether addition of sodium polystyrene sulfonate resin (i.e. Kayexalate®) during soaking or boiling modulated potassium loss.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12947618_20201005_0.5			[Spectral analysis on self-assembly ultrathin film of polyaminobenzonitrile].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12947618_20201005_0.5			Macromolecular Substances|Nitriles|Polymers|Polystyrenes|Spectrophotometry, Ultraviolet|Spectroscopy, Fourier Transform Infrared	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12947618_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	With the self-assembly techniques, an ultrathin film of PABN and NaPSS (sodium polystyrene sulfonate) was successfully prepared.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5			Treatment of hyperkalemia: something old, something new.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5			cation exchange resins|hyperkalemia|insulin|potassium|renal dialysis|sodium bicarbonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5			Animals|Biomarkers|Cation Exchange Resins|Chelating Agents|Diuretics|Down-Regulation|Humans|Hyperkalemia|Potassium|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26880451_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Treatment options for hyperkalemia have not changed much since the introduction of the cation exchange resin, sodium polystyrene sulfonate (Kayexalate, Covis Pharmaceuticals, Cary, NC), over 50 years ago.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5987854_20201005_0.5			Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5987854_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	hyperkalemia|patiromer|potassium|RDX7675|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5987854_20201005_0.5			Animals|Cation Exchange Resins|Chelating Agents|Disease Models, Animal|Hyperkalemia|Male|Mice|Polymers|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5987854_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This study evaluated the pharmacodynamic effects of RDX7675 in mice, compared to 2 current treatments, sodium polystyrene sulfonate (SPS) and patiromer.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21387549_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21387549_20201005_0.5			Aged|Aged, 80 and over|Cohort Studies|Female|Hospitalization|Humans|Hyperkalemia|Male|Middle Aged|Polystyrenes|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21387549_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	BACKGROUND Limited data exist on the precise dose of sodium polystyrene sulfonate (SPS) needed for specific potassium concentrations in the management of mild to moderate hyperkalemia in an inpatient hospital setting.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29027620_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29027620_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	CKD|Efficacy|Hyperkalemia|Sodium polystyrene sulfonate|Tolerability	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29027620_20201005_0.5			Aged|Aged, 80 and over|Calcium|Cation Exchange Resins|Female|Follow-Up Studies|Humans|Hyperkalemia|Male|Middle Aged|Polystyrenes|Potassium|Recurrence|Renal Insufficiency, Chronic|Retrospective Studies|Sodium|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29027620_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE Sodium polystyrene sulfonate (SPS) is a cation-exchanging resin that has been widely used for several decades as first-line therapy of mild chronic hyperkalemia in patients with chronic kidney disease (CKD).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21877748_20201005_0.5			Hofmeister effect on the interfacial dynamics of single polymer molecules.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21877748_20201005_0.5			Adsorption|Diffusion|Hydrophobic and Hydrophilic Interactions|Polystyrenes|Solutions|Surface Properties|Thermodynamics|Water	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21877748_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The Hofmeister effect on interfacial dynamics has been discovered for single charged polymer molecules (sodium polystyrene sulfonate) adsorbed on a hydrophobic surface from an aqueous solution.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25415544_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Asymptomatic Cecal Perforation in a Renal Transplant Recipient After Sodium Polystyrene Sulfonate Administration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25415544_20201005_0.5			Cation Exchange Resins|Cecum|Female|Humans|Hyperkalemia|Intestinal Perforation|Kidney Transplantation|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25415544_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (SPS) is a medication commonly used for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3902433_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Amitriptyline, clomipramine, and doxepin adsorption onto sodium polystyrene sulfonate	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3902433_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Adsorption|Tricyclic antidepressants|Activated charcoal|Sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3902433_20201005_0.5			Amitriptyline|Doxepin|Clomipramine|polystyrene sulfonic acid|Adsorption|Antidepressive Agents, Tricyclic|Polystyrenes|Charcoal|Antidotes|Stomach	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3902433_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Purpose of the study Comparative in vitro studies were carried out to determine the adsorption characteristics of 3 drugs on activated charcoal (AC) and sodium polystyrene sulfonate (SPS).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25032877_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Refractory hypoxemia due to sodium polystyrene sulfonate (kayexalate) aspiration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25032877_20201005_0.5			Diagnosis, Differential|Fatal Outcome|Female|Humans|Hypoxia|Inhalation Exposure|Polystyrenes|Radiography, Thoracic|Respiratory Distress Syndrome, Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1277599_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate resin candy for control of potassium in chronic dialysis patients.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1277599_20201005_0.5			Candy|Cation Exchange Resins|Chronic Disease|Humans|Hyperkalemia|Ion Exchange Resins|Kidney Diseases|Polystyrenes|Renal Dialysis|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1277599_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section A stable candy with 5.0 g sodium polystyrene sulfonate resin per piece was developed.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29731287_20201005_0.5			Controversies in Management of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29731287_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	acidosis|beta-agonist|calcium|cardiac arrest|dialysis|diuresis|electrocardiogram|excretion|hyperkalemia|insulin|patiromer|sodium polystyrene sulfonate|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29731287_20201005_0.5			Acidosis|Buffers|Cation Exchange Resins|Dialysis|Drug Combinations|Electrocardiography|Glucose|Humans|Hyperkalemia|Hypoglycemia|Insulin|Polystyrenes|Potassium|Receptor, Insulin|Sodium Bicarbonate|Transcytosis|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29731287_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate is not efficacious.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27725623_20201005_0.5			Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27725623_20201005_0.5			Angiotensin II Type 1 Receptor Blockers|Angiotensin-Converting Enzyme Inhibitors|Arrhythmias, Cardiac|Biomarkers|Comorbidity|Heart Failure|Humans|Hyperkalemia|Polymers|Potassium|Renal Insufficiency, Chronic|Risk Factors|Silicates|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27725623_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Until recently, options for treating hyperkalemia were limited to the use of thiazide and loop diuretics and sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31107688_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Risk of Perforated Colonic Diverticulitis in Patients With Chronic Kidney Disease Requiring Sodium Polystyrene Sulfonate: Not to Be Forgotten.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31107688_20201005_0.5			Aged, 80 and over|Cation Exchange Resins|Colon|Diverticulitis, Colonic|Humans|Intestinal Perforation|Male|Middle Aged|Polystyrenes|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colitis induced by sodium polystyrene sulfonate in sorbitol: A report of six cases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5			Hyperkalemia|Kayexalate colitis|Uremia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5			Administration, Oral|Aged|Colitis|Colon|Diagnosis, Differential|Drug Combinations|Enema|Female|Humans|Intestinal Mucosa|Laxatives|Male|Middle Aged|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27033844_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Kayexalate or sodium polystyrene sulfonate (SPS), a linear polymer derived from polystyrene containing sulfonic acid and sulfonate functional groups is used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4587365_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colon Necrosis Due to Sodium Polystyrene Sulfonate with and without Sorbitol: An Experimental Study in Rats	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4587365_20201005_0.5			Animals|Colon|Humans|Male|Necrosis|Polystyrenes|Rats|Rats, Sprague-Dawley|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4587365_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Introduction Based on a single rat study by Lillemoe et al, the consensus has been formed to implicate sorbitol rather than sodium polystyrene sulfonate (SPS) as the culprit for colon necrosis in humans treated with SPS and sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6195644_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	One Oral Dose of Sodium Polystyrene Sulfonate Associated with Ischemic Colitis and Crystal Deposition in Colonic Mucosa	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6195644_20201005_0.5			Humans|Aged|Colitis, Ischemic|polystyrene sulfonic acid|Polystyrenes|Colon|Intestinal Mucosa	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27310563_20201005_0.5			Huge Differences in the Kinetics of Swelling Enhancement and De-enhancement of Permanently Charged Polyelectrolyte Brushes.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27310563_20201005_0.5			counterions|kinetics|polyelectrolyte brushes|polymers|swelling	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27310563_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	By developing an effective approach to quantify the response in QCM-D, a vast difference in swelling enhancement and de-enhancement of a model permanently charged polyelectrolyte brush (sodium polystyrene sulfonate, NaPSS) was discovered.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27018102_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Image of the Month: Emphysematous Gastritis and Necrosis as a Result of Orally Ingested Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27018102_20201005_0.5			Acute Kidney Injury|Aged|Cathartics|Chelating Agents|Gastritis|Gastroscopy|Humans|Hyperkalemia|Ischemia|Male|Necrosis|Polystyrenes|Sorbitol|Stomach|Tomography, X-Ray Computed	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5			Kayexalate-Induced Esophageal Ulceration in a Patient with Decompensated Cirrhosis: A Review of the Literature	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5			Humans|Male|Middle Aged|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Esophageal Diseases|Hyperkalemia|Peptic Ulcer|Ulcer|Sorbitol|Colon|Necrosis|Esophagus|Gastrointestinal Tract|Liver Cirrhosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	sodium polystyrene sulfonate	drug_umls_atom	The treatment of hyperkalemia includes removal of excess potassium from the body using cation exchange resins, e.g., sodium polystyrene sulfonate (Kayexalate) is one of the most practiced modalities in clinical medicine.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7935595_20210411_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colonic mucosal necrosis and perforation are the serious gastrointestinal side effects associated with sodium polystyrene sulfonate (SPS) use, which have been reported with or without concomitant use of sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8010635_20210411_0.5			Growth characteristics of human bone marrow mesenchymal stromal cells at cultivation on synthetic polyelectrolyte nanofilms in vitro	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8010635_20210411_0.5			Adhesion|Cell proliferation|Culture|Mesenchymal stromal cells|Nanofilms|Polyelectrolytes	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8010635_20210411_0.5			Humans|Polyelectrolytes|Mesenchymal Stem Cells|Bone Marrow|polyallylamine|Polyamines|polystyrene sulfonic acid|Polystyrenes|Cell Proliferation|Polymers|Cell Adhesion|Surface Properties|Cells, Cultured|Biological Phenomena|Cell Survival|Polyethyleneimine	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8010635_20210411_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section This study examines the adhesive properties and cytotoxicity of polyelectrolyte nanofilms from polyethyleneimine (PEI), polyallylamine hydrochloride (PAH) and sodium polystyrene sulfonate (PSS) on human bone marrow mesenchymal stromal cells (h-MSCs) and mouse adipose tissue (m-MSC) in vitro.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21304040_20201005_0.5			Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate Without Sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21304040_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	adverse effects|calcium polystyrene sulfonate|chemically induced pathology|intestinal diseases|oral cation exchange resins|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21304040_20201005_0.5			Aged|Cecum|Colonic Pseudo-Obstruction|Fatal Outcome|Female|Humans|Hyperkalemia|Intestinal Mucosa|Intestinal Perforation|Intubation, Gastrointestinal|Ischemia|Jejunum|Necrosis|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21304040_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The most commonly used and best-established resin is sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21304040_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Like sodium polystyrene sulfonate, calcium polystyrene sulfonate is an ion-exchanging resin that can promote bowel necrosis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6085982_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium Polystyrene Sulfonate and Cytomegalovirus-Associated Hemorrhagic Duodenitis: More than Meets the Eye	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6085982_20201005_0.5			Cytomegalovirus Infections|Duodenitis|Hyperkalemia|Kidney Transplantation	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6085982_20201005_0.5			Cation Exchange Resins|Cytomegalovirus|Cytomegalovirus Infections|Duodenitis|Gastrointestinal Hemorrhage|Humans|Hyperkalemia|Kidney Transplantation|Male|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6085982_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Patient: Male, 56 No section Final Diagnosis: Hemorrhagic duodenitis No section Symptoms: Abdominal pain • melena No section Medication: -- No section Clinical Procedure: CT scan • gastroscopy • colonoscopy • blood transfusion No section Specialty: General and Internal Medicine Objective: Challenging differential diagnosis Background: Hemorrhagic duodenitis is an exceptionally rare adverse event of sodium polystyrene sulfonate (SPS) treatment and is a common manifestation of cytomegalovirus (CMV) reactivation.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24511728_20201005_0.5			Acute intestinal obstruction due to Kalimate, a potassium-lowering agent: a case report and literature review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24511728_20201005_0.5			Acute Disease|Amputation|Cation Exchange Resins|Fasciitis, Necrotizing|Humans|Intestinal Obstruction|Leg|Male|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24511728_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (Kayexalate) and calcium polystyrene sulfonate (CPS, Kalimate) are commonly used to reduce serum potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5			Kayexalate: a new cause of neonatal bowel opacification.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5			Cation Exchange Resins|Female|Humans|Infant, Newborn|Infant, Newborn, Diseases|Intestinal Diseases|Ion Exchange Resins|Polystyrenes|Radiography	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7455099_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Two cases of neonatal bowel opacification secondary to oral and rectal administration of Kayexalate (sodium polystyrene sulfonate) are presented.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29645278_20210211_0.5			An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29645278_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	RDX227675|RDX7675|hyperkalemia|pharmacodynamics|potassium binder|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29645278_20210211_0.5			Humans|Male|Middle Aged|Female|RDX7675|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Potassium|Renin-Angiotensin System|Chelating Agents|Renal Insufficiency, Chronic|Heart Failure|Polymers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29645278_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	The most widely used treatment, sodium polystyrene sulfonate (SPS), limits gastrointestinal potassium absorption, but has poor palatability.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9773794_20210611_0.5			Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9773794_20210611_0.5			Analysis of Variance|Cathartics|Chlorides|Dose-Response Relationship, Drug|Drug Therapy, Combination|Feces|Female|Glucose|Humans|Kidney Failure, Chronic|Male|Phenolphthalein|Polystyrenes|Potassium|Renal Dialysis|Resins, Synthetic|Sodium|Sodium Bicarbonate|Sorbitol|Treatment Outcome|Water-Electrolyte Balance	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9773794_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Hyperkalemia in patients with renal failure is frequently treated with a cation exchange resin (sodium polystyrene sulfonate, hereafter referred to as resin) in combination with a cathartic, but the effect of such therapy on serum potassium concentration has not been established.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28382468_20201005_0.5			Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28382468_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Angiotensin converting enzyme inhibitors|Angiotensin receptor blockers|Chronic kidney disease|Heart failure|Hyperkalemia|Mineralocorticoid receptor antagonist|Patiromer|Renin-angiotensin-aldosterone system inhibitors and sodium polystyrene sulfonate|Sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28382468_20201005_0.5			Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Blood Pressure|Chelating Agents|Heart Failure|Humans|Hyperkalemia|Mineralocorticoid Receptor Antagonists|Polymers|Polystyrenes|Renin-Angiotensin System|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4722246_20201005_0.5			Pseudohypoaldosteronism type 1 due to novel variants of SCNN1B gene	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4722246_20201005_0.5			United States|Humans|Female|Adult|Pseudohypoaldosteronism|Epithelial Sodium Channels|Aldosterone|Mutation|Pedigree|Hyperkalemia|Failure to Thrive|SCNN1B protein, human	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4722246_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 Learning points PHA1 is a rare genetic condition, causing functional abnormalities of the amiloride-sensitive ENaC.. PHA1 was caused by previously unreported SCNN1B gene mutations (c.1288delC and c.1466+1 G>A).. Early recognition of this condition and adherence to symptomatic therapy is important, as the electrolyte abnormalities found may lead to severe dehydration, cardiac arrhythmias and even death.. High doses of sodium polystyrene sulfonate, sodium chloride and sodium bicarbonate are required for symptomatic treatment..	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31668450_20201005_0.5			Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31668450_20201005_0.5			Humans|Hyperkalemia|Polymers|Polystyrenes|Potassium, Dietary|Renal Dialysis|Renal Insufficiency, Chronic|Renin-Angiotensin System|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31668450_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	These agents offer alternatives to sodium polystyrene sulfonate, which is associated with serious gastrointestinal adverse effects.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31668450_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	For this review, PubMed was searched for English-language articles published in 2014-2018 using the terms patiromer, sodium zirconium cyclosilicate, sodium polystyrene sulfonate, hyperkalemia, renin-angiotensin-aldosterone, diet, and dialysis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24960144_20201005_0.5			Swelling enhancement of polyelectrolyte brushes induced by external ions.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24960144_20201005_0.5			Polyelectrolytes|Ions|Electrolytes|Surface Properties|Quartz Crystal Microbalance Techniques|Polymers|polystyrene sulfonic acid|Polystyrenes|Hydrogen-Ion Concentration|Molecular Weight|Sodium Chloride|Water|Solvents	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24960144_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We systematically investigated a few strong polyelectrolyte brush systems, including sodium polystyrene sulfonate (PSSNa), poly([2-(methacryloyloxy)ethyl] trimethylammonium chloride) (PMETAC) and potassium poly(3-sulfopropyl methacrylate) (PSPMA) with different molecular weights and grafting density using a combination of methods, including ellipsometry, quartz crystal microbalance with dissipation (QCM-D) and atomic force microscope (AFM).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23586269_20201005_0.5			[Spectral characteristics of refractive index based on nanocoated optical fiber F-P sensor].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23586269_20201005_0.5			Biosensing Techniques|Fiber Optic Technology|Nanostructures|Optical Fibers|Polyethylenes|Polystyrenes|Quaternary Ammonium Compounds|Refractometry	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23586269_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Poly diallyldimethylammonium chloride (PDDA) and sodium polystyrene sulfonate (PSS) were chosen as nano-film materials.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24269907_20201005_0.5			Hollow-fiber liquid-phase microextraction combined with capillary electrophoresis for trace analysis of sulfonamide compounds.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24269907_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Capillary electrophoresis|DLLME|ED|EFs|Electrochemical detection|HF-LPME|Hollow-fiber liquid-phase microextraction|LLE|PSS|SCE|SDM|SDME|SDZ|SLM|SMR|SMX|SMZ|STZ|Sulfonamides|Water analysis|dispersive liquid–liquid microextraction|electrochemical detection|enrichment factors|hollow-fiber liquid-phase microextraction|liquid–liquid extraction|saturated calomel electrode|single-drop liquid-phase microextraction|sodium polystyrene sulfonate|sulfadiazine|sulfadimethoxine|sulfamerazine|sulfamethazine|sulfamethoxazole|sulfathiazole|supported liquid membrane	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24269907_20201005_0.5			Electrophoresis, Capillary|Hydrogen-Ion Concentration|Limit of Detection|Linear Models|Liquid Phase Microextraction|Membranes, Artificial|Reproducibility of Results|Rivers|Sodium Chloride|Sulfonamides|Waste Water|Water Pollutants, Chemical	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7482089_20201005_0.5			Investigating Adsorbing Viscoelastic Fluids Using the Quartz Crystal Microbalance	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7482089_20201005_0.5			Quartz Crystal Microbalance Techniques|Adsorption|Viscosity|Surface Properties|Elasticity|Quartz|Aluminum Oxide	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7482089_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In the current study, both Newtonian (sucrose) and viscoelastic (sodium polystyrene sulfonate (NaPSS)) fluids were introduced into the QCM, and the sensor responses were compared.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9365427_20201005_0.5			Methods used to decrease lithium absorption or enhance elimination.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9365427_20201005_0.5			Animals|Antimanic Agents|Digestive System|Dopamine|Drug Overdose|Humans|Intestinal Absorption|Lithium Carbonate|Polystyrenes|Renal Dialysis|Resins, Synthetic|Sodium Chloride|Theophylline|Therapeutic Irrigation	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9365427_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate resin administration has been shown to be effective in binding lithium elimination in animal and human models.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9365427_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	However, the lower limits of effective sodium polystyrene sulfonate dosing and the extent of potassium lowering in humans are questions that need to be answered before sodium polystyrene sulfonate resin can be recommended for routine, use.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28421299_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28421299_20201005_0.5			Calcium|Chronic kidney disease|Hyperkalemia|Potassium|Secondary hyperparathyroidism|Sodium	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28421299_20201005_0.5			Aged|Aged, 80 and over|Bone and Bones|Calcium|Cross-Over Studies|Female|Humans|Hyperkalemia|Magnesium|Male|Middle Aged|Minerals|Parathyroid Hormone|Polystyrenes|Prospective Studies|Renal Dialysis|Renal Insufficiency, Chronic|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3592514_20201005_0.5			A novel pulsed drug-delivery system: polyelectrolyte layer-by-layer coating of chitosan–alginate microgels	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3592514_20201005_0.5			polyelectrolyte|chitosan-alginate|microgels|layer-by-layer|pulsed drug delivery	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3592514_20201005_0.5			Alginates|Animals|Chitosan|Delayed-Action Preparations|Dextrans|Drug Delivery Systems|Fluorescein-5-isothiocyanate|Gels|Glucuronic Acid|Hexuronic Acids|Male|Mice|Microtechnology|Polyamines|Polystyrenes|Pressure|Technology, Pharmaceutical	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3592514_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The semipermeable membrane outside the microgel was made of polyelectrolytes including polycation poly(allylamine hydrochloride) and sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23329388_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pretreatment of infant formula with sodium polystyrene sulfonate : focus on optimal amount and contact time.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23329388_20201214_0.5			Humans|Hyperkalemia|Infant|Infant Formula|Polystyrenes|Potassium|Potassium, Dietary|Sodium|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23329388_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Oral or rectal sodium polystyrene sulfonate (SPS) has several potential adverse effects, and dietary potassium restriction may compromise nutrition.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29535436_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Another RESIN for Pouchitis: Chronic Pouchitis With Erosion Secondary to Sodium Polystyrene Sulfonate Crystals.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29535436_20201005_0.5			Acute Kidney Injury|Aged|Cation Exchange Resins|Colitis, Ulcerative|Diarrhea|Female|Humans|Hyperkalemia|Polystyrenes|Pouchitis|Proctocolectomy, Restorative	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25930981_20201005_0.5			Renal formulas pretreated with medications alters the nutrient profile.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25930981_20201005_0.5			Follow-Up Studies|Humans|Hyperkalemia|Hyperphosphatemia|Infant|Infant Formula|Nutritional Support|Phosphorus|Potassium|Renal Insufficiency, Chronic|Sevelamer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25930981_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We examine whether nutrient composition is affected by pretreating renal formulas with sodium polystyrene sulfonate (SPS) suspension and sevelamer carbonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22683337_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22683337_20201005_0.5			Administration, Oral|Age Distribution|Aged|Aged, 80 and over|Biopsy, Needle|Cohort Studies|Colonic Diseases|Confidence Intervals|Drug Prescriptions|Drug Therapy, Combination|Female|Follow-Up Studies|Hospitalization|Humans|Immunohistochemistry|Incidence|Inpatients|Intestinal Mucosa|Male|Necrosis|Polystyrenes|Reference Values|Retrospective Studies|Risk Assessment|Sex Distribution|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22683337_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	BACKGROUND Colonic necrosis has been reported after sodium polystyrene sulfonate (SPS)/sorbitol use, but the incidence and relative risk (RR) are not established.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1588671_20201005_0.5			In vitro binding characteristics for cesium of two qualities of prussian blue, activated charcoal and Resonium-A.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1588671_20201005_0.5			Cesium Radioisotopes|Charcoal|Ferrocyanides|Hemoperfusion|Hydrogen-Ion Concentration|In Vitro Techniques|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1588671_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The in vitro binding characteristics of radioactive 137Cs to two forms of Prussian blue [colloidally (soluble) K3Fe[Fe(CN)6] and insoluble Fe4[Fe(CN)6]3] and to activated charcoal and sodium polystyrene sulfonate (Resonium-A) were investigated by constructing Langmuir isotherms at pH = 1.0, 6.5 and 7.5 at 37 degrees C. At the three pHs investigated, 137Cs binding to activated charcoal and sodium polystyrene sulfonate was negligible.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5			double-blind method|humans|hyperkalemia|kidney failure, chronic|outpatients|polystyrene sulfonic acid|polystyrenes|potassium|randomized controlled trial|renal insufficiency, chronic	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5			Aged|Aged, 80 and over|Biomarkers|Double-Blind Method|Down-Regulation|Female|Humans|Hyperkalemia|Male|Middle Aged|Polystyrenes|Potassium|Quebec|Renal Insufficiency, Chronic|Time Factors|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate has long been prescribed for this condition, although evidence is lacking on its efficacy for the treatment of mild hyperkalemia over several days.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This study aimed to evaluate the efficacy of sodium polystyrene sulfonate in the treatment of mild hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We randomly assigned these patients to receive either placebo or sodium polystyrene sulfonate of 30 g orally one time per day for 7 days.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate was superior to placebo in the reduction of serum potassium levels (mean difference between groups, -1.04 mEq/L; 95% confidence interval, -1.37 to -0.71).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A higher proportion of patients in the sodium polystyrene sulfonate group attained normokalemia at the end of their treatment compared with those in the placebo group, but the difference did not reach statistical significance (73% versus 38%; P=0.07).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	There was a trend toward higher rates of electrolytic disturbances and an increase in gastrointestinal side effects in the group receiving sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26576619_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Sodium polystyrene sulfonate was superior to placebo in reducing serum potassium over 7 days in patients with mild hyperkalemia and CKD.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25465585_20201005_0.5			Daptomycin-induced hyperkalemia in a patient with normal renal function.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25465585_20201005_0.5			Abscess|Administration, Oral|Anti-Bacterial Agents|Chelating Agents|Daptomycin|Female|Humans|Hyperkalemia|Middle Aged|Polystyrenes|Skin Diseases, Bacterial	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25465585_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Reversal of hyperkalemia was achieved with oral sodium polystyrene sulfonate and other agents, and daptomycin was withheld for one day, during which time the patient's serum potassium level normalized.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25465585_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	With a further dosage reduction and continued administration of sodium polystyrene sulfonate, the patient completed the full course of daptomycin therapy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18601377_20201005_0.5			Theory of competitive counterion adsorption on flexible polyelectrolytes: divalent salts.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18601377_20201005_0.5			Adsorption|Cations, Divalent|Models, Chemical|Models, Theoretical|Molecular Conformation|Osmolar Concentration|Polymers|Salts|Static Electricity|Temperature	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18601377_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The theory further predicts that at modest physical conditions for a flexible polyelectrolytes such as sodium polystyrene sulfonate in aqueous solutions polymer charge is compensated and reversed with increasing divalent salt.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26599956_20201005_0.5			Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26599956_20201005_0.5			Aged|Case-Control Studies|Diabetes Complications|Diabetes Mellitus, Type 2|Female|Humans|Hyperkalemia|Male|Prevalence|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26599956_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Prevalence of hyperkalemia was defined as potassium >5 mEq/l or use of sodium polystyrene sulfonate, and further by potassium >5, ≥5.2 and ≥5.5 mEq/l. It was calculated in both groups in whole and CKD stages separately.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27521112_20201005_0.5			Gastrointestinal potassium binding-more than just lowering serum [K(+)]: patiromer, potassium balance, and the renin angiotensin aldosterone axis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27521112_20201005_0.5			Aldosterone|Angiotensins|Humans|Hyperkalemia|Polymers|Potassium|Renin|Renin-Angiotensin System	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27521112_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This can be managed by efforts to increase kaliuresis and by gastrointestinal potassium binding with sodium polystyrene sulfonate, a relatively ineffective agent.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19842945_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19842945_20201005_0.5			Adult|Aged|Algorithms|Antidotes|Antimanic Agents|Area Under Curve|Cohort Studies|Drug Overdose|Female|Half-Life|Humans|Lithium Chloride|Male|Middle Aged|Poisoning|Polystyrenes|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19842945_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS, Kayexalate), a cation exchanger, has been promising in animal models and human reports to reduce absorption and enhance elimination of Li.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6181421_20201005_0.5			Impact of chemical and physical treatments on the mechanical properties of poly(ε-caprolactone) fibers bundles for the anterior cruciate ligament reconstruction	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6181421_20201005_0.5			Animals|Anterior Cruciate Ligament|Anterior Cruciate Ligament Injuries|Biomechanical Phenomena|Cells, Cultured|Female|In Vitro Techniques|Polyesters|Sheep|Stress, Mechanical|Weight-Bearing	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6181421_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This article evaluates the mechanical consistency of poly(ε-caprolactone) fibers bundles grafted with sodium polystyrene sulfonate, as a candidate for ligament prosthesis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5			Rectal ulcer due to Kayexalate deposition - an unusual case.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5			Acute Kidney Injury|Aged, 80 and over|Biopsy|Cation Exchange Resins|Colonoscopy|Female|Humans|Hyperkalemia|Polystyrenes|Rectal Diseases|Risk Factors|Sorbitol|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (PSP) or Kayexalate is a cation-exchange resin, widely used in the management of hyperkalaemia due to renal disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30673037_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A rare, yet potentially dangerous, adverse event related to sodium polystyrene sulfonate use is intestinal mucosal injury, especially in the colon.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12777710_20201005_0.5			Coating and selective deposition of nanofilm on silicone rubber for cell adhesion and growth.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12777710_20201005_0.5			Animals|Arteries|Cattle|Cell Adhesion|Cell Culture Techniques|Cell Division|Coated Materials, Biocompatible|Coronary Vessels|Crystallography|Endothelium, Vascular|Materials Testing|Membranes, Artificial|Nanotechnology|Polyethyleneimine|Polylysine|Polystyrenes|Silicones|Surface Properties	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12777710_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The surfaces studied consisted of a precursor, with alternating cationic polyethyleneimine (PEI) and anionic sodium polystyrene sulfonate (PSS) layers followed by alternating gelatin and poly-D-lysine (PDL) layers.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Use of sodium polystyrene sulfonate for reduction of plasma lithium concentrations after chronic lithium dosing in mice.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5			Administration, Oral|Animals|Drug Overdose|Lithium|Lithium Chloride|Male|Mice|Poisoning|Polystyrenes|Random Allocation|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE Previous studies have shown that oral sodium polystyrene sulfonate lowers plasma lithium concentrations after acutely administered oral doses of lithium chloride.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This study was designed to determine whether multiple oral doses of sodium polystyrene sulfonate are effective in reducing plasma lithium concentrations after chronic dosing.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	At the end of that period, half of the animals were given orogastric sodium polystyrene sulfonate at 5 g/kg/dose 0, 60, 120, 180, and 360 minutes after the cessation of lithium chloride; the remaining half received orogastric water at equivalent times.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS Lithium concentration was lower overall in the animals treated with sodium polystyrene sulfonate (p < .0001) and specifically at 150, 330, and 480 minutes after lithium chloride cessation (p < .05).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Repetitive oral doses of sodium polystyrene sulfonate effectively lowered plasma lithium concentrations.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9711196_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Further study may ultimately define a role for the use of sodium polystyrene sulfonate in the treatment of patients with chronic lithium toxicity.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19269913_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Digestive adverse effects due to sodium polystyrene sulfonate (Kayexalate) in dialysis patients].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19269913_20201005_0.5			Humans|Intestinal Diseases|Polystyrenes|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19269913_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Administered to reduce hyperkaliema in patients with chronic renal failure, sodium polystyrene sulfonate (Kayexalate) can cause digestive complications.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22900907_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Small intestinal transplant mucosal necrosis associated with enteral sodium polystyrene sulfonate administration.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22900907_20201005_0.5			Biopsy, Needle|Child, Preschool|Diarrhea|Emergency Service, Hospital|Follow-Up Studies|Humans|Ileostomy|Ileum|Immunohistochemistry|Intestinal Mucosa|Male|Necrosis|Organ Transplantation|Polystyrenes|Risk Assessment	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22900907_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium Polystyrene Sulfonate administration has been associated with significant bowel injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5			Ileum and colon perforation following peritoneal dialysis-related peritonitis and high-dose calcium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5			Kalimate|bowel/intestinal perforation|end-stage renal disease	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5			Colon|Fatal Outcome|Female|Humans|Hyperkalemia|Ileum|Intestinal Perforation|Kidney Failure, Chronic|Middle Aged|Necrosis|Peritoneal Dialysis|Peritonitis|Polystyrenes|Shock, Septic|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23602017_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section A rare but severe complication, intestinal necrosis, has been reported after sodium polystyrene sulfonate (SPS; Kayexalate) and sorbitol intake.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27009290_20201005_0.5			Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27009290_20201005_0.5			hyperkalemia|ion exchange resin|potassium|renin-angiotensin-aldosterone system	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27009290_20201005_0.5			Angiotensin-Converting Enzyme Inhibitors|Chelating Agents|Humans|Hyperkalemia|Hypokalemia|Male|Middle Aged|Mineralocorticoid Receptor Antagonists|Polyelectrolytes|Polymers|Polystyrenes|Potassium|Randomized Controlled Trials as Topic|Renin-Angiotensin System|Silicates|Spironolactone|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27009290_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Seven articles met inclusion criteria: 1 retrospective case series for sodium polystyrene sulfonate (SPS), 1 noncontrolled study using patiromer, and 5 randomized, placebo-controlled trials using 3 different agents-2 patiromer, 2 sodium zirconium cyclosilicate (SZC), and 1 cross-linked polyelectrolyte (CLP).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29781623_20201005_0.5			Response of a Permanently Charged Polyelectrolyte Brush to External Ions: The Aspects of Structure and Dynamics.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29781623_20201005_0.5			Polyelectrolytes|Ions|Electrolytes|polystyrene sulfonic acid|Polystyrenes|Static Electricity|Polymers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29781623_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Structure and dynamics inside permanently charged polyelectrolyte brushes, sodium polystyrene sulfonate brushes, during their response to the introduction of external ions (NaCl) are investigated by neutron reflectivity and dielectric spectroscopy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2441607_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (Kayexalate) aspiration	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2441607_20201005_0.5			Male|Humans|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Sorbitol|Colon|Rectum|Necrosis|Crystallization|Administration, Oral	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC2441607_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section In this short report we illustrate a case of extensive sodium polystyrene sulfonate (SPS) aspiration as an immediate cause of death in a terminally ill patient.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30248645_20201005_0.5			Interaction of a cationic amphiphile with monomeric and polymeric electrolytes: From morphological transition to associative phase separation.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30248645_20201005_0.5			Co-sphere overlap model|Dynamic light scattering|Israelachvili model|Morphological transition|Phase separation	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30248645_20201005_0.5			Alkanes|Anisotropy|Anthracenes|Cations|Dynamic Light Scattering|Electrolytes|Micelles|Particle Size|Phase Transition|Polymers|Polystyrenes|Quaternary Ammonium Compounds|Spectrometry, Fluorescence|Surface-Active Agents	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30248645_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium Polystyrene Sulfonate (NaPSS) electrolytes towards the morphological and/or aggregation properties of Octadecyl-trimethyl Ammonium Bromide (OTAB) micelles have been quantified spectroscopically by means of the modulations of the absorption and emission spectral properties of an extrinsic anthracene-based probe 9-methyl anthroate (9-MA) within the concerned media.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27393581_20201005_0.5			Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27393581_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	ZS-9|hyperkalemia|patiromer|potassium|sodium polystyrene sulfonate|zirconium|zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27393581_20201005_0.5			Humans|Hyperkalemia|Polystyrenes|Randomized Controlled Trials as Topic|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27393581_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Treatment for this condition has remained largely unchanged since the release of sodium polystyrene sulfonate (SPS) in 1958.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800076_20201005_0.5			Hyperkalemia in patients with chronic renal failure.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800076_20201005_0.5			CKD|chronic renal failure|epidemiology|hyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800076_20201005_0.5			Global Health|Humans|Hyperkalemia|Incidence|Kidney Failure, Chronic|Potassium|Renin-Angiotensin System|Risk Factors|Survival Rate	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800076_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate has been used commonly for decades to treat hyperkalemia in CKD patients, but without any high-quality clinical data to support its efficacy and with an increased risk of rare but serious colonic complications.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23859454_20201005_0.5			Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23859454_20201005_0.5			Cation Exchange Resins|Colon|Humans|Hyperkalemia|Necrosis|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23859454_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	These resins were associated with gastrointestinal tract lesions, especially sodium polystyrene sulfonate (Kayexalate) mixed with sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3504257_20201005_0.5			Fludrocortisone Therapy in Renal Transplant Recipients with Persistent Hyperkalemia	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3504257_20201005_0.5			Middle Aged|Humans|Fludrocortisone|Hyperkalemia|Kidney Transplantation|Kidney|Transplant Recipients|Mineralocorticoids|Aldosterone|Potassium|Water-Electrolyte Imbalance	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3504257_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Our three renal transplant recipients with multiple emergency room visits for elevated serum potassium levels despite treatment with diuretics, sodium bicarbonate, and sodium polystyrene sulfonate responded well to fludrocortisones therapy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12113338_20201005_0.5			Determining the molar mass of a plasma substitute succinylated gelatin by size exclusion chromatography-multi-angle laser light scattering, sedimentation equilibrium and conventional size exclusion chromatography.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12113338_20201005_0.5			Calibration|Chromatography, Gel|Gelatin|Light|Plasma Substitutes|Scattering, Radiation|Succinates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12113338_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	SEC calibrated using succinylated gelatin fractions correlated well with size exclusion chromatography-multi-angle laser light scattering (SEC-MALLS) and sedimentation equilibrium whereas SEC calibrated with unmodified gelatin, sodium polystyrene sulfonates or pullulans overestimated M(w) by over 20%.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7178180_20201005_0.5			Comparative Study of Constipation Exacerbation by Potassium Binders Using a Loperamide-Induced Constipation Model	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7178180_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	hemodialysis|constipation|rat|calcium polystyrene sulfonate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7178180_20201005_0.5			Animals|Antidiarrheals|Constipation|Defecation|Disease Models, Animal|Humans|Injections, Intraperitoneal|Loperamide|Male|Polystyrenes|Potassium|Rats|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7178180_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Patients on dialysis are frequently administered high doses of potassium binders such as calcium polystyrene sulfonate (CPS) and sodium polystyrene sulfonate (SPS), which exacerbate constipation.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID817399_20201214_0.5			Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID817399_20201214_0.5			Alkalosis|Cation Exchange Resins|Constipation|Drug Therapy, Combination|Epilepsy, Tonic-Clonic|Humans|Hyperkalemia|Ion Exchange Resins|Magnesium Oxide|Male|Middle Aged	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID817399_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section A patient with chronic renal failure received sodium polystyrene sulfonate and magnesium hydroxide for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID343583_20201005_0.5			Acute digoxin poisonings: review of therapy.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID343583_20201005_0.5			Acute Disease|Adolescent|Adult|Aged|Child, Preschool|Digoxin|Drug Therapy|Female|Humans|Infant|Infant, Newborn|Male|Middle Aged	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID343583_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Supportive management may include treatment with atropine, phenytoin, lidocaine, propranolol, glucose, insulin and sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28122118_20201005_0.5			Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28122118_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	ZS-9|hyperkalemia|patiromer|sodium polystyrene sulfonate|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28122118_20201005_0.5			Dose-Response Relationship, Drug|Humans|Hyperkalemia|Polymers|Potassium|Severity of Illness Index|Silicates|Time Factors|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5			Adult|Cation Exchange Resins|Cost-Benefit Analysis|Female|Heart Failure|Humans|Hyperkalemia|Kidney Failure, Chronic|Male|Monte Carlo Method|Polystyrenes|Quality-Adjusted Life Years|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Treatment options include sodium polystyrene sulfonate potassium binding resins, but safety and efficacy concerns exist, including associated colonic necrosis (CN).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS We performed a cost-utility analysis of outpatients ≥ 18 years of age receiving chronic RAAS-I, with a history of hyperkalemia or chronic kidney disease, prescribed either sodium polystyrene sulfonate or a theoretical "drug X" binding resin for chronic hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	One-way sensitivity analysis showed sodium polystyrene sulfonate to be the cost-effective option for CN incidences ≤ 19.9%.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Limitations include incomplete information on outpatient outcomes and lack of data directly comparing sodium polystyrene sulfonate to potential alternatives.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Alternatives may not be cost-effective unless priced similarly to sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24656316_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This analysis may guide decisions regarding adoption of alternative agents for chronic hyperkalemia control, and suggests that sodium polystyrene sulfonate be employed as an active control in clinical trials of these agents.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7675864_20210111_0.5			Polysulfonate Resins in Hyperkalemia: A Systematic Review	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7675864_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	adverse events|hyperkalemia|polystyrene exchange resin|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7675864_20210111_0.5			Adult|Humans|Male|Aged, 80 and over|Hyperkalemia|Cation Exchange Resins|polystyrene sulfonic acid|Polystyrenes|Data Management|Potassium|Chelating Agents|Renal Insufficiency, Chronic|Intestines|Inpatients|Proportional Hazards Models	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7675864_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Polystyrene resins, including sodium polystyrene sulfonate (SPS) and calcium polystyrene sulfonate (CPS), have long been used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7675864_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate/calcium polystyrene sulfonate act by exchanging a cation for potassium within the intestinal lumen.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29960362_20201005_0.5			Conformation and dynamics of flexible polyelectrolytes in semidilute salt-free solutions.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29960362_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We present steady shear rheology data for sodium polystyrene sulfonate (NaPSS) in semidilute unentangled salt-free aqueous solution as a function of polymer concentration (c) and degree of polymerisation (N).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25808008_20201005_0.5			Subtherapeutic serum quetiapine concentrations after absorption inhibition by binding resins: a case report.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25808008_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	drug-drug interaction|quetiapine|sevelamer carbonate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25808008_20201005_0.5			Antipsychotic Agents|Cation Exchange Resins|Chelating Agents|Drug Administration Schedule|Drug Interactions|Female|Humans|Middle Aged|Polystyrenes|Quetiapine Fumarate|Sevelamer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5			Aged|Aged, 80 and over|Cation Exchange Resins|Crystallization|Duodenum|Endoscopy, Gastrointestinal|Esophagus|Female|Gastrointestinal Diseases|Humans|Hyperkalemia|Male|Middle Aged|Mucous Membrane|Polystyrenes|Sorbitol|Stomach|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11342776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Kayexalate (sodium polystyrene sulfonate) in sorbitol has been demonstrated to cause colonic necrosis in a subset of uremic patients who are administered the cation exchange resin for treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11581080_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Potassium repletion fails to interfere with reduction of serum lithium by sodium polystyrene sulfonate in mice.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11581080_20201005_0.5			Animals|Lithium|Male|Mice|Models, Animal|Neuroprotective Agents|Polystyrenes|Potassium|Prospective Studies|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11581080_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE Previous studies have shown that oral sodium polystyrene sulfonate (SPS) lowers serum lithium concentrations after acute and chronic toxic lithium exposures.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30384707_20201005_0.5			Molecular weight dependence of chain conformation of strong polyelectrolytes.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30384707_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Using sodium polystyrene sulfonate (NaPSS) and quarternized poly 4-vinylpyridine (QP4VP) as model systems, the chain conformation of polyelectrolytes under finite salt concentrations is investigated at a single molecular level.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17269822_20201005_0.5			Multilayered films fabricated from an oligoarginine-conjugated protein promote efficient surface-mediated protein transduction.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17269822_20201005_0.5			Adsorption|Animals|Arginine|COS Cells|Cations|Cattle|Chlorocebus aethiops|Electrolytes|Fluorescent Dyes|Models, Chemical|Polystyrenes|Proteins|Ribonuclease, Pancreatic|Surface Properties	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17269822_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We demonstrate that it is possible to fabricate multilayered assemblies 80 nm thick using sodium polystyrene sulfonate (SPS) and bovine pancreatic ribonuclease (RNase A) conjugated to the cationic protein transduction domain nonaarginine (R(9)) using an entirely aqueous layer-by-layer process.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2543544_20201005_0.5			Reversible hyporeninemic hypoaldosteronism in a patient with tetraplegia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2543544_20201005_0.5			Adrenocorticotropic Hormone|Aged|Aldosterone|Angiotensin II|Blood Pressure|Epinephrine|Fludrocortisone|Furosemide|Humans|Hypoaldosteronism|Male|Norepinephrine|Polystyrenes|Posture|Quadriplegia|Renin|Resins, Synthetic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2543544_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The patient was treated with sodium polystyrene sulfonate resin and/or 9-alpha-fluorohydrocortisone, and wheelchair rehabilitation.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6431938_20201005_0.5			Enhanced Water Vapor Transmission through Porous Membranes Based on Melt Blending of Polystyrene Sulfonate with Polyethylene Copolymers and Their CNT Nanocomposites	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6431938_20201005_0.5			breathable membranes|melt blending|polystyrene sulfonate|carbon nanotubes|water vapor transmission rate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6431938_20201005_0.5			Nanocomposites|polystyrene sulfonic acid|Polyethylene|Nanotubes, Carbon|Steam|Polystyrenes|Polymers|Porosity|Polyethylene Glycols|Water|Microscopy, Electron, Scanning|Membranes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6431938_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section A novel concept for the use of an immiscible and non-meltable polymer, such as sodium polystyrene sulfonate (PSSNa), in order to prepare polyethylene non-woven breathable membranes is described.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8431031_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate: a cation exchange resin used in treating hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8431031_20201005_0.5			Cation Exchange Resins|Humans|Hyperkalemia|Polystyrenes|Resins, Synthetic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8431031_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate is a cation exchange resin used in the treatment of nonlife-threatening hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8431031_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Proper administration, assessment of drug effectiveness, and detection and prevention of potential adverse side effects of sodium polystyrene sulfonate are the responsibility of the nephrology nurse.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9063542_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Enhancement of lithium elimination by multiple-dose sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9063542_20201005_0.5			Administration, Oral|Animals|Dose-Response Relationship, Drug|Injections, Intravenous|Lithium|Male|Mice|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9063542_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To determine whether multiple doses of sodium polystyrene sulfonate (SPS) enhance the elimination of IV-administered lithium (Li).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID698249_20201005_0.5			[2 types of soluble complexes of bovine serum albumin with polyelectrolytes].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID698249_20201005_0.5			Acrylic Resins|Chemical Phenomena|Chemistry|Polymethacrylic Acids|Polystyrenes|Serum Albumin, Bovine|Solubility|Sulfonic Acids|Ultracentrifugation	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID698249_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section It has been shown by high-velocity sedimentation that BSA forms soluble complexes with polyacrylic acid (PAA) and sodium polystyrene sulfonate (PSSNa) with neutral water solutions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5			Inflammatory Pseudotumor Containing Kayexalate Crystals: A Case Report and Review of the Literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5			Kayexalate|inflammatory pseudotumor|myofibroblastic|perihepatic pseudotumor|pseudotumor	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5			Cation Exchange Resins|Female|Granuloma, Plasma Cell|Humans|Hyperkalemia|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24178951_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Kayexalate (sodium polystyrene sulfonate), a cation exchange resin often used to treat hyperkalemia, is known to produce gastrointestinal complications in a minority of patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1594533_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Multiple-dose sodium polystyrene sulfonate in lithium intoxication: an animal model.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1594533_20201005_0.5			Animals|Cation Exchange Resins|Disease Models, Animal|Lithium|Male|Mice|Mice, Inbred Strains|Polystyrenes|Resins, Synthetic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1594533_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Previous work in our laboratory has demonstrated that sodium polystyrene sulfonate (SPS) significantly lowered serum lithium (Li) concentrations when administered in a single oral dose after an oral dose of lithium in a mouse model.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32667374_20201005_0.5			Screening lengths and osmotic compressibility of flexible polyelectrolytes in excess salt solutions.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32667374_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We report results of small angle neutron scattering measurements made on sodium polystyrene sulfonate in aqueous salt solutions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19904912_20201005_0.5			Total mass difference statistics algorithm: a new approach to identification of high-mass building blocks in electrospray ionization Fourier transform ion cyclotron mass spectrometry data of natural organic matter.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19904912_20201005_0.5			Algorithms|Benzopyrans|Models, Statistical|Polymethacrylic Acids|Polystyrenes|Software|Spectrometry, Mass, Electrospray Ionization	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19904912_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	To verify the approach, it was used for processing mass spectra of sodium polystyrene sulfonate (PSS, M(w) = 2200 Da) and polymethacrylate (PMA, M(w) = 3290 Da) which produce heavy multielement and multiply-charged ions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27908499_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A strategy to modulate the electrophoretic behavior in plastic microchips using sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27908499_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Biogenic amines|Cyclic olefin copolymer|Electroosmotic flow|Microchip electrophoresis|Sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27908499_20201005_0.5			Biogenic Amines|Calibration|Electrolytes|Electrophoresis, Microchip|Fish Products|Fluorescein-5-isothiocyanate|Hydrodynamics|Limit of Detection|Meat|Plastics|Polystyrenes|Reference Standards|Regression Analysis|Reproducibility of Results|Sodium Hydroxide	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27908499_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A cathodic EOF of ∼3.3×10-4cm2V-1s-1 was maintained using sodium polystyrene sulfonate (PSSNa) with a molecular weight of 5×105 as the BGE, which ensured fluorescein isothiocyanate labeled biogenic amines (BAs) appeared ahead of other components in the electropherograms obtained with microchips of cyclic olefin copolymer.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23820459_20201005_0.5			Apparent lisinopril overdose requiring hemodialysis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23820459_20201005_0.5			Acute Kidney Injury|Angiotensin-Converting Enzyme Inhibitors|Drug Overdose|Humans|Lisinopril|Male|Middle Aged|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23820459_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	two doses of sodium polystyrene sulfonate 30 g orally, three doses of insulin 10 units i.v.,	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19937490_20201005_0.5			Biofouling control using microparticles carrying a biocide.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19937490_20201005_0.5			Benzalkonium Compounds|Biofilms|Biofouling|Disinfectants|Microspheres|Plankton|Pseudomonas fluorescens	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19937490_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Oppositely charged molecules of polyethyleneimine (PEI), sodium polystyrene sulfonate (PSS), and BDMDAC were assembled on polystyrene (PS) cores.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32394928_20210411_0.5			Hyperkalemia mimicking brugada pattern in electrocardiogram: A rare case report from Nepal.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32394928_20210411_0.5			Action Potentials|Acute Kidney Injury|Arrhythmias, Cardiac|Brugada Syndrome|Diagnosis, Differential|Electrocardiography|Heart Conduction System|Heart Rate|Humans|Hyperkalemia|Male|Middle Aged|Nepal|Predictive Value of Tests|Rhabdomyolysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32394928_20210411_0.5	sodium polystyrene sulfonate	drug_umls_atom	Patient was treated with 10% calcium gluconate, insulin and dextrose, salbutamol nebulization, and sodium polystyrene sulfonate till hemodialysis was initiated.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26456884_20201005_0.5			Patiromer: a clinical review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26456884_20201005_0.5			Hyperkalemia|Patiromer|Patiromer FOS|RLY5016	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26456884_20201005_0.5			Aged|Clinical Trials as Topic|Female|Heart Failure|Humans|Hyperkalemia|Male|Polymers|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26456884_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 OBJECTIVE The primary objective of this review is to analyze the efficacy and safety of patiromer to treat hyperkalemia and compare its pharmacokinetics to currently available sodium polystyrene sulfonate (SPS) therapy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8688109_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8688109_20201005_0.5			Cation Exchange Resins|Cecum|Enema|Female|Humans|Hyperkalemia|Infant, Newborn|Infant, Premature, Diseases|Intestinal Perforation|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8688109_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We report a 650 g, 24 week hyperkalemic newborn who developed both cecal impaction and perforation after treatment with sodium polystyrene sulfonate enemas.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8688109_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pathological examination showed sodium polystyrene sulfonate crystals contained in the cecal abscess.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19306191_20201005_0.5			Management of yellow oleander poisoning.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19306191_20201005_0.5			Antibodies, Blocking|Antidotes|Antiemetics|Arrhythmias, Cardiac|Blood Pressure|Charcoal|Digoxin|Electrocardiography|Emetics|Fluid Therapy|Humans|Nerium|Ondansetron|Plant Poisoning|Potassium|Resuscitation|Therapeutic Irrigation|Water-Electrolyte Imbalance	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19306191_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Oral or rectal administration of sodium polystyrene sulfonate resin may result in hypokalemia when used together with digoxin-specific antibody fragments.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7449548_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Small bowel necrosis and perforation due to sodium polystyrene sulfonate in the setting of graft versus host disease and fulminant Clostridium difficile infection	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7449548_20201005_0.5			Female|Humans|Male|polystyrene sulfonic acid|Graft vs Host Disease|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Sorbitol|Gastrointestinal Diseases|Intestine, Small|Renal Insufficiency, Chronic|Necrosis|Clostridium Infections	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7449548_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Gastrointestinal injury is a common adverse event associated with use of sodium polystyrene sulfonate (SPS), tradename Kayexalate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1496969_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1496969_20201005_0.5			Administration, Oral|Adult|Aged|Cation Exchange Resins|Female|Humans|Incidence|Intestinal Diseases|Male|Middle Aged|Necrosis|Pharmaceutical Vehicles|Polystyrenes|Postoperative Care|Retrospective Studies|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1496969_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We estimated the incidence of intestinal necrosis in 752 hospitalized patients who had received sodium polystyrene sulfonate (SPS).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6128719_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate induced intestinal necrosis; a case report	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6128719_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate|Intestinal necrosis|Hyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6128719_20201005_0.5			Male|Humans|Adult|United States|Aged|polystyrene sulfonic acid|Cation Exchange Resins|Polystyrenes|Hyperkalemia|Sorbitol|Potassium|Colon|Cathartics|Necrosis|Intestinal Perforation|Colonic Diseases|Sodium|Gastrointestinal Diseases|Vascular Diseases	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6128719_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium Polystyrene sulfonate (SPS) is a cation-exchange resin that exchanges sodium for potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In vitro binding of lithium using the cation exchange resin sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5			Binding Sites|Charcoal|Humans|Hydrogen-Ion Concentration|Lithium|Poisoning|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate, a cation exchange resin, should be useful in the treatment of lithium overdosage.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This in vitro study was conducted to assess the ability of sodium polystyrene sulfonate to bind lithium, effects of pH on binding, binding efficacy in comparison to charcoal, and affinity for lithium versus potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Stock solutions of lithium were added to fixed amounts of sodium polystyrene sulfonate and charcoal.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Increasing concentrations of sodium polystyrene sulfonate bound more lithium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Lithium is bound to sodium polystyrene sulfonate more readily than to charcoal.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Potassium is preferentially bound to sodium polystyrene sulfonate over lithium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7755820_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate may provide a useful therapeutic modality in the treatment of lithium overdosage.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6629599_20201005_0.5			Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6629599_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Calcium polystyrene sulfonate|Patiromer|Potassium|Sodium polystyrene sulfonate|Sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6629599_20201005_0.5			Humans|Aged|Hyperkalemia|Renin-Angiotensin System|Potassium|polystyrene sulfonic acid|Polystyrenes|Renal Insufficiency, Chronic|Angiotensin-Converting Enzyme Inhibitors|ZS-9 compound|Silicates|patiromer|Polymers|Heart Failure|Asia|Republic of Korea	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6629599_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Whereas sodium polystyrene sulfonate (SPS) exchanges sodium for potassium, calcium polystyrene sulfonate (CPS) has the advantage of avoiding hypervolemia because it exchanges calcium for potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Thrombocytopenia associated with sodium polystyrene sulfonate].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5			Aged|Aged, 80 and over|Humans|Hyperkalemia|Male|Polystyrenes|Thrombocytopenia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9423342_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (Kayexalate) was administered orally for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33585335_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	A Case of Fatal Intestinal Infarct Preceded by Recurrent Ischaemic Colitis due to the Enterotoxic Effect of Sodium Polystyrene Sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33585335_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	Chronic renal failure|hyperkalaemia|iatrogenic ischaemic colitis|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33585335_20210311_0.5			Humans|Male|Middle Aged|polystyrene sulfonic acid|Colitis, Ischemic|Renal Dialysis|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Potassium|Kidney Failure, Chronic|Renal Insufficiency, Chronic|Chelating Agents|Ischemia|Sorbitol|Colon|Intestinal Mucosa|Vascular Diseases|Gastrointestinal Diseases|Infarction	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33585335_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	UNASSIGNED A 64-year-old patient with chronic renal failure and persistent hyperkalaemia not corrected by dialysis, was prescribed sodium polystyrene sulfonate (SPS) at a low dose (30 g/day for 2 days a week during the long interdialytic interval).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33585335_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	 UNASSIGNED Sodium polystyrene sulfonate can cause life-threatening colitis.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4784594_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pseudohypoaldosteronism Type 1 (arPHA1) Treated With Sodium Polystyrene Sulfonate Pretreated Milk	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4784594_20201005_0.5			Animals|Humans|polystyrene sulfonic acid|Pseudohypoaldosteronism|Milk|Polystyrenes|Cation Exchange Resins	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID5466528_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Treatment of hyperkalemia associated with renal insufficiency--clinical effects and side reactions of positive-ion-exchange resins, sodium polystyrene sulfonate (Kayexalate)].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID5466528_20201005_0.5			Adult|Humans|Hyperkalemia|Ion Exchange Resins|Kidney Diseases|Male|Polystyrenes|Sulfonic Acids	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6543963_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6543963_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	chronic kidney disease|end-stage renal disease|hyperkalemia|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6543963_20201005_0.5			Middle Aged|Aged|Male|Adult|Humans|Female|Hyperkalemia|polystyrene sulfonic acid|Retrospective Studies|Polystyrenes|Renal Insufficiency, Chronic|Kidney Failure, Chronic|Potassium|Cation Exchange Resins|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6543963_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Background The use of sodium polystyrene sulfonate (SPS) for the treatment of hyperkalemia lacks sufficient efficacy data in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD); however, use remains widespread.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5			Colonic necrosis in a young patient receiving oral kayexalate in sorbitol: case report and literature review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5			Administration, Oral|Adult|Colon|Colonoscopy|Crystallization|Humans|Male|Necrosis|Polystyrenes|Sorbitol|Staining and Labeling	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21463839_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Kayexalate (sodium polystyrene sulfonate) is a cation-exchange resin used to treat patients with hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9101004_20201005_0.5			Hypocalcemia and hypomagnesemia after ibuprofen overdose.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9101004_20201005_0.5			Acidosis|Anti-Inflammatory Agents, Non-Steroidal|Drug Overdose|Humans|Hypocalcemia|Ibuprofen|Infant|Magnesium|Male|Renal Insufficiency|Seizures	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9101004_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The mechanism is unclear, the situation was probably aggravated by the use of sodium polystyrene sulfonate and furosemide.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6392414_20201005_0.5			New frontiers for management of hyperkalaemia: the emergence of novel agents	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6392414_20201005_0.5			Kayexelate|Sodium Zirconium Cyclosilicate (SZC)|Patiromer|Hyperkalaemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6392414_20201005_0.5			Humans|Hyperkalemia|Renin-Angiotensin System|Potassium|Mineralocorticoid Receptor Antagonists|Renal Insufficiency, Chronic|Heart Failure|ZS-9 compound|Silicates|patiromer|Polymers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6392414_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The use of sodium polystyrene sulfonate (SPS/Kayexelate) for chronic hyperkalaemia has been low, due to poor tolerability, potential gastrointestinal safety concerns, and remaining uncertainty in regards to its efficacy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5			Kayexalate-induced colonic ulcer	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5			Kayexalate|medication|side effect|gastrointestinal bleed	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5			PRC|Male|polystyrene sulfonic acid|Ulcer|Polystyrenes|Colonic Diseases|Kidney Failure, Chronic|Sorbitol|Necrosis|Stomach|Colitis|Biopsy	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4124266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pertinent medications include pantoprazole and sodium polystyrene sulfonate in sorbitol (Kayexalate 30 g/d orally).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28460113_20201005_0.5			Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28460113_20201005_0.5			chronic haemodialysis|dialysis bath|hyperkalaemia|potassium binder|seasonality	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28460113_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Female|France|Humans|Hyperkalemia|Male|Middle Aged|Prevalence|Prospective Studies|Recurrence|Registries|Renal Dialysis|Surveys and Questionnaires|Young Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28460113_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A total of 61% of patients were prescribed a K-binding resin [essentially sodium polystyrene sulfonate (SPS)], while 2 mmol/L and 3 mmol/L K concentration baths were used relatively equally.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5			Aged|Aged, 80 and over|Cation Exchange Resins|Enterostomy|Female|Gastrointestinal Diseases|Hospitalization|Humans|Hyperkalemia|Intestinal Perforation|Male|Mesenteric Ischemia|Mesenteric Vascular Occlusion|Ontario|Polystyrenes|Proportional Hazards Models|Retrospective Studies|Severity of Illness Index|Thrombosis|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate is commonly prescribed for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Case reports of intestinal injury after administration of sodium polystyrene sulfonate with sorbitol resulted in a US Food and Drug Administration warning and discontinuation of combined 70% sorbitol-sodium polystyrene sulfonate formulations.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	There are ongoing concerns about the gastrointestinal (GI) safety of sodium polystyrene sulfonate use.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section To assess the risk of hospitalization for adverse GI events associated with sodium polystyrene sulfonate use in patients of advanced age.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section Population-based, retrospective matched cohort study of eligible adults of advanced age (≥66 years) dispensed sodium polystyrene sulfonate from April 1, 2003, to September 30, 2015, in Ontario, Canada, with maximum follow-up to March 31, 2016.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Cox proportional hazards regression models were used to examine the association of sodium polystyrene sulfonate use with a composite of GI adverse events compared with nonuse that was matched via a high-dimensional propensity score.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section Dispensed sodium polystyrene sulfonate in an outpatient setting.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section The primary outcome was a composite of adverse GI events (hospitalization or emergency department visit with intestinal ischemia/thrombosis, GI ulceration/perforation, or resection/ostomy) within 30 days of initial sodium polystyrene sulfonate prescription.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section From a total of 1 853 866 eligible adults, 27 704 individuals were dispensed sodium polystyrene sulfonate (mean [SD] age, 78.5 [7.7] years; 54.7% male), and 20 020 sodium polystyrene sulfonate users were matched to 20 020 nonusers.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate use compared with nonuse was associated with a higher risk of an adverse GI event over the following 30 days (37 events [0.2%]; incidence rate, 22.97 per 1000 person-years vs 18 events [0.1%]; incidence rate, 11.01 per 1000 person-years) (hazard ratio, 1.94; 95% CI, 1.10-3.41).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section The use of sodium polystyrene sulfonate is associated with a higher risk of hospitalization for serious adverse GI events.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31180477_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	These findings require confirmation and suggest caution with the ongoing use of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5			Colonic necrosis due to oral kayexalate in a critically-ill patient.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5			Cation Exchange Resins|Colon|Critical Illness|Female|Humans|Hyperkalemia|Middle Aged|Necrosis|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19365182_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Kayexalate (sodium polystyrene sulfonate in sorbitol) is commonly used for treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8914138_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Effects of sodium polystyrene sulfonate on gingival plaque: microbiological investigation and clinical follow-up.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8914138_20201005_0.5			Adult|Dental Plaque|Follow-Up Studies|Gingiva|Humans|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8914138_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The antiplaque agent, a 5% aqueous solution (p/v) of sodium polystyrene sulfonate, applied on the tooth surfaces by daily topical application for two weeks, caused a statistically significant 30% reduction of plaque index (PI), with corresponding reduction of total bacteria and qualitative modifications of plaque formation with reduction of Gram-negative bacteria.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26587776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26587776_20201005_0.5			Acute Disease|Aged|Cation Exchange Resins|Female|Humans|Hyperkalemia|Hypernatremia|Hypokalemia|Intestines|Male|Necrosis|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26587776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS), a cation exchange resin first approved by the FDA for the treatment of hyperkalemia in 1958, is frequently used alone or in conjunction with other medical therapies to lower serum potassium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7465118_20201005_0.5			New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7465118_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	chronic kidney disease|heart failure|hyperkalemia|patiromer|sodium polystyrene sulfonate|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7465118_20201005_0.5			Humans|Male|Female|Hyperkalemia|Renal Dialysis|Renal Insufficiency, Chronic|Potassium|polystyrene sulfonic acid|Polystyrenes|sodium zirconium cyclosilicate|Silicates|Cation Exchange Resins|Renin-Angiotensin System|patiromer|Polymers|Heart Failure	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7465118_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Until recently, the only therapeutic option for increasing fecal K excretion was represented by the cation-exchanging resin sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5			Cation Exchange Resins|Dose-Response Relationship, Drug|Enteral Nutrition|Food, Formulated|Humans|Polystyrenes|Potassium|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	BACKGROUND Sodium polystyrene sulfonate (Kayexalate) commonly is used in treating hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS Sodium polystyrene sulfonate and enteral formula were mixed into a slurry and allowed to settle, and then the supernatant was decanted off and tested as samples.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15080600_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS The treatment of an enteral formula with sodium polystyrene sulfonate significantly increases its sodium content, with a modest decrease in potassium content.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23600268_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Hypokalemic myopathy with severe constipation in a patient routinely administered sodium polystyrene sulfonate and the spherical carbon adsorbent].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23600268_20201005_0.5			Carbon|Constipation|Defecation|Humans|Hypokalemia|Kidney Failure, Chronic|Male|Middle Aged|Muscular Diseases|Oxides|Polystyrenes|Potassium|Severity of Illness Index|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23600268_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS) and the spherical carbon adsorbent AST-120 were routinely administered to him.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3614505_20201005_0.5			[Magnesium hydroxide treatment of hyperphosphatemia in chronic hemodialysis patients with an aluminum overload].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3614505_20201005_0.5			Adult|Aged|Aluminum Hydroxide|Female|Humans|Hypercalcemia|Magnesium|Magnesium Hydroxide|Male|Middle Aged|Phosphates|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3614505_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Metabolic alkalosis has been observed in association with the increase of ion exchange resin (sodium polystyrene sulfonate: Kayexalate) to treat progressive hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16088658_20201005_0.5			Management issues in toxicology.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16088658_20201005_0.5			Humans|Gastric Lavage|Charcoal|Therapeutic Irrigation|Pharmaceutical Preparations|Carbamazepine|Phenobarbital|Decontamination|Theophylline|Quinine	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16088658_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Although studies suggest that sodium polystyrene sulfonate may enhance elimination of lithium, no beneficial effects on clinical outcomes have been demonstrated and potential complications include hypokalemia and hypernatremia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	Lower Gastrointestinal Bleeding Associated With Sodium Polystyrene Sulfonate Use	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5			Humans|Male|Aged, 80 and over|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Gastrointestinal Hemorrhage|Ulcer|Colonic Diseases|Colonoscopy|Intestinal Perforation|Gastrointestinal Tract|Sorbitol|Acute Kidney Injury	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (kayexalate) is a cation-exchange resin widely used in the management of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	An 81-year-old man was admitted because of decompensation of cirrhosis with acute kidney injury and hyperkalemia, treated with sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8116012_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	Despite rare, the widespread use of sodium polystyrene sulfonate puts a large population at risk of serious complications related to its use.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6131120_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Risks and Benefits of Sodium Polystyrene Sulfonate for Hyperkalemia in Patients on Maintenance Hemodialysis	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6131120_20201005_0.5			Administration, Oral|Aged|Female|Humans|Hyperkalemia|Male|Polystyrenes|Renal Dialysis|Retrospective Studies|Risk Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6131120_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Background Concerns about sodium overload when using sodium polystyrene sulfonate (Na-resin) as an ion-exchange resin for the treatment of hyperkalemia led our institution to gradually shift to the use of calcium polystyrene sulfonate (Ca-resin).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28985189_20201005_0.5			Charge carrier transport in defective reduced graphene oxide as quantum dots and nanoplatelets in multilayer films.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28985189_20201005_0.5			Graphite|Quantum Dots|Oxides|Nanocomposites|Electrodes|Organic Chemicals	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28985189_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Here, we report a systematic study of the charge transport mechanisms of reduced graphene oxide chemically functionalized with sodium polystyrene sulfonate (PSS), named as GPSS.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27584929_20201005_0.5			New drugs to prevent and treat hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27584929_20201005_0.5			Cation Exchange Resins|Humans|Hyperkalemia|Polymers|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27584929_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section Without much evidence in the literature on its efficacy, sodium polystyrene sulfonate is being used frequently in the clinical setting to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5			Adsorption|Antidotes|Cation Exchange Resins|Charcoal|Ferrocyanides|Models, Chemical|Polystyrenes|Thallium|Thermodynamics	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Activated charcoal has been demonstrated to adsorb thallium in vitro, and the similarity between thallium and potassium has led some authors to consider the use of sodium polystyrene sulfonate as a potential adsorbent.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS A standard aqueous solution of thallium acetate buffered to pH 7.0 was agitated at 25 degrees C with activated charcoal, Prussian blue, or sodium polystyrene sulfonate at adsorbent:thallium ratios ranging from 1.5:1 to 100:1.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS The maximal adsorptive capacities defined as milligrams of thallium per gram of adsorbent (shown with linear regression p and r values) were as follows: activated charcoal, 59.7 mg/g (p = 0.005, r = 0.995); Prussian blue, 72.7 mg/g (p = 0.004, r = 0.996); and sodium polystyrene sulfonate, 713 mg/g (p = 0.049, r = 0.951).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	At a physiologic potassium concentration, the maximal adsorptive capacities for activated charcoal and Prussian blue were essentially unchanged (58.3 mg/g and 69.8 mg/g, respectively, p > 0.05 for each vs trials without potassium), while the maximal adsorptive capacity for sodium polystyrene sulfonate fell to 39.1 mg/g (p = 0.003, r = 0.997, p = 0.005 vs sodium polystyrene sulfonate without potassium).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10630266_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Although sodium polystyrene sulfonate demonstrates exceptional in vitro adsorption of thallium, its greater affinity for potassium probably renders it clinically ineffective.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27782532_20201005_0.5			Single chains of strong polyelectrolytes in aqueous solutions at extreme dilution: Conformation and counterion distribution.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27782532_20201005_0.5			Polyelectrolytes|Molecular Conformation|Water|polystyrene sulfonic acid|Polystyrenes|Electrolytes|Solutions|Polymers|Static Electricity|Sodium Chloride	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27782532_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The molecular conformation of two typical polyelectrolytes, sodium polystyrene sulfonate (NaPSS) and quarternized poly-4-vinylpyridine (QP4VP), was studied in aqueous solutions without salt addition at the single molecular level.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5			Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5			Aged|Cause of Death|Chelating Agents|Chelation Therapy|Chronic Disease|Humans|Hyperkalemia|Middle Aged|Polymers|Polystyrenes|Potassium|Quality of Life|Randomized Controlled Trials as Topic|Renal Insufficiency, Chronic|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and other adverse gastrointestinal (GI) symptoms, reducing their tolerability.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Potassium binders included calcium polystyrene sulfonate, sodium polystyrene sulfonate, patiromer, and sodium zirconium cyclosilicate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	We categorised treatments in newer agents (patiromer or sodium zirconium cyclosilicate) and older agents (calcium polystyrene sulfonate and sodium polystyrene sulfonate).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Calcium polystyrene sulfonate may make little or no difference to serum potassium levels at end of treatment, compared to sodium polystyrene sulfonate (2 studies, 117 participants: MD 0.38 mEq/L, 95% CI -0.03 to 0.79; I2 = 42%, low certainty evidence).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32588430_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	There was no evidence of a difference in systolic BP (one study), diastolic BP (one study), or constipation (one study) between calcium polystyrene sulfonate and sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9685938_20201005_0.5			Microparticle resins as a potential nasal drug delivery system for insulin.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9685938_20201005_0.5			Administration, Intranasal|Animals|Blood Glucose|Drug Delivery Systems|Humans|Insulin|Male|Rabbits|Resins, Plant	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9685938_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Intranasal administration of human insulin (28 U, 1 mg) mixed with fractionated sodium polystyrene sulfonate powder (an anionic resin with a particle size of 20-45 microns) caused a rapid increase of the plasma insulin level 413.0 +/- 71.7 microU/ml (mean +/- S.D.) after 15 min, while intranasal administration of insulin alone caused little increase.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27516079_20201005_0.5			Lithium Poisoning.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27516079_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	continuous renal replacement therapy|enhanced elimination|extracorporeal treatment|intermittent hemodialysis|neurotoxicity|sodium polystyrene sulfonate|syndrome of irreversible lithium effectuated neurotoxicity	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27516079_20201005_0.5			Acute Disease|Antimanic Agents|Bipolar Disorder|Chronic Disease|Drug Overdose|Humans|Lithium|Neurotoxicity Syndromes|Practice Guidelines as Topic|Renal Dialysis|Renal Insufficiency	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27194424_20201214_0.5			Potassium: friend or foe?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27194424_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hyperkalemia|Hypokalemia|Patiromer|Potassium homeostasis|Potassium intake|Sodium polystyrene sulfonate|ZS-9	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27194424_20201214_0.5			Aldosterone|Cation Exchange Resins|Cell Membrane|Child|Heart Failure|Homeostasis|Humans|Hyperkalemia|Hypertension|Hypokalemia|Kidney|Membrane Potentials|Polymers|Potassium|Potassium, Dietary|Protein-Serine-Threonine Kinases|Recommended Dietary Allowances|Renal Elimination|Renin-Angiotensin System|Respiratory Insufficiency|Risk Factors|Signal Transduction|Silicates|Sodium|Sodium Chloride Symporters|WNK Lysine-Deficient Protein Kinase 1	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10832954_20201005_0.5			Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10832954_20201005_0.5			Abdomen, Acute|Administration, Oral|Administration, Rectal|Cathartics|Cation Exchange Resins|Colectomy|Colon|Diagnosis, Differential|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Resins, Synthetic|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10832954_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Colonic necrosis is an unusual complication after treatment of hyperkalemia with sodium polystyrene sulfonate (SPS, Kayexalate) in sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32520437_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pelvic inflammatory mass associated with sodium polystyrene sulfonate crystals diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32520437_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	cytology|fine needle aspiration|peripheral notching|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32520437_20210211_0.5			Middle Aged|Humans|Female|Endoscopic Ultrasound-Guided Fine Needle Aspiration|polystyrene sulfonic acid|Polystyrenes|Cytological Techniques	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29248345_20201005_0.5			Aqueous size-exclusion chromatography of polyelectrolytes on reversed-phase and hydrophilic interaction chromatography columns.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29248345_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	NaPSS|Polyelectrolyte|Polymer|SEC|Size-exclusion chromatography|Sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29248345_20201005_0.5			Acetonitriles|Calibration|Chromatography, Gel|Chromatography, Reverse-Phase|Hydrophobic and Hydrophilic Interactions|Methanol|Polyelectrolytes|Polystyrenes|Reference Standards|Sodium|Solvents|Sulfonic Acids|Temperature|Uracil|Water	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29248345_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The size-exclusion separation of a water-soluble polyelectrolyte polymer, sodium polystyrene sulfonate (NaPSS), was demonstrated on common reversed-phase (C18, C4, phenyl, and cyano) and hydrophilic interaction chromatography (HILIC) columns.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Efficacy of the cation exchange resin, sodium polystyrene sulfonate, to decrease iron absorption.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5			Administration, Oral|Adolescent|Adult|Area Under Curve|Blood Cell Count|Blood Glucose|Cation Exchange Resins|Cross-Over Studies|Electrolytes|Female|Humans|Intestinal Absorption|Iron|Male|Middle Aged|Polystyrenes|Potassium|Prospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This study investigated the efficacy and safety of sodium polystyrene sulfonate to prevent absorption of iron in human volunteers.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Following an oral dose of elemental iron 10 mg/kg, each subject received sodium polystyrene sulfonate 30 g or water as control.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS A trend toward increased time to peak following sodium polystyrene sulfonate compared to the control arm (5.7 vs 3.6 hours) was observed but was not statistically significant (p = 0.517).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A trend toward smaller area-under-the-curve for the sodium polystyrene sulfonate was evident but was not statistically significant (p = 0.77).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10930055_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate is not an effective method of decontamination for iron overdose.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9241224_20201005_0.5			Effect of Nonadsorbing Polyelectrolytes on Colloidal Interactions in Aqueous Mixtures	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9241224_20201005_0.5			Polyelectrolytes|Water|Electrolytes|Ions|Particle Size|polystyrene sulfonic acid|Polystyrenes|Polymers|Flocculation|Latex	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9241224_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The effect of adding a nonadsorbing charged polymer, sodium polystyrene sulfonate (SPSS), on the interaction energy profile between a 15 &mgr;m diameter polystyrene particle and a glass plate was measured using the optical technique of total internal reflection microscopy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5815785_20201005_0.5			Ozone therapy induced sinus arrest in a hypertensive patient with chronic kidney disease	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5815785_20201005_0.5			chronic kidney disease|diabetes|hyperkalemia|hypertension|ozone therapy|treatment	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5815785_20201005_0.5			Electrocardiography|Female|Humans|Hyperkalemia|Hypertension|Middle Aged|Ozone|Renal Insufficiency, Chronic|Sick Sinus Syndrome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5815785_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Insulin, sodium bicarbonate, and sodium polystyrene sulfonate were administered to the patient.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29642732_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Evaluation of Appropriate Sodium Polystyrene Sulfonate Use With a Hyperkalemia Order Set: A Pilot Study.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29642732_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	cation-exchange resin|hyperkalemia|order set|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29642732_20201005_0.5			Aged|Chelating Agents|Cohort Studies|Female|Follow-Up Studies|Humans|Hyperkalemia|Male|Middle Aged|Pilot Projects|Polystyrenes|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29642732_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS) is a common treatment option for hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29627281_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colonic perforation associated with sodium polystyrene sulfonate (Kayexalate) use.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29627281_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Advent event|Colonic perforation|Computed tomography (CT)|Ogilvie syndrome|Sodium polystyrene sulfonate (Kayexalate)	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29627281_20201005_0.5			Cation Exchange Resins|Colonic Diseases|Humans|Intestinal Perforation|Male|Middle Aged|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33389507_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	Extra-intestinal sodium polystyrene sulfonate crystal-induced inflammatory pseudotumour in an asymptomatic haemodialysis patient.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33389507_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	Inflammatory pseudotumour|Kayexalate|Resonium|Sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33389507_20210611_0.5			Humans|polystyrene sulfonic acid|Granuloma, Plasma Cell|Polystyrenes|Cation Exchange Resins|Intestines|Renal Dialysis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7240434_20201005_0.5			Application of Spherical Polyelectrolyte Brushes Microparticle System in Flocculation and Retention	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7240434_20201005_0.5			anionic spherical polyelectrolyte brushes|flocculation|retention|mechanism	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7240434_20201005_0.5			Flocculation|Polyelectrolytes|polyacrylamide|Acrylic Resins|Waste Disposal, Fluid|Water Purification|Polymerization|Cations|Suspensions|polystyrene sulfonic acid|Polystyrenes|Microscopy, Electron, Scanning|Biological Assay|Cell-Derived Microparticles|Spectroscopy, Fourier Transform Infrared|Biological Phenomena	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7240434_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The ASPB, consisting of a carbon sphere (CS) core and a shell of sodium polystyrene sulfonate (PSSNa) brushes, was synthesized by surface-initiated polymerization.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5			Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5			Tumor lysis|Osteosarcoma|Case report|Uricemia|Kalemia|Rasburicase	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5			Abdominal Pain|Acute Kidney Injury|Aged|Antineoplastic Agents|Bone Neoplasms|Female|Gout Suppressants|Humans|Osteosarcoma|Peritoneal Neoplasms|Renal Dialysis|Treatment Outcome|Tumor Lysis Syndrome|Urate Oxidase	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5364542_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3782641_20201005_0.5			Mechanism of cardiac arrhythmias induced by epinephrine in dogs with hypokalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3782641_20201005_0.5			Animals|Arrhythmias, Cardiac|Biomechanical Phenomena|Calcium|Dogs|Electrolytes|Epinephrine|Female|Hypokalemia|Male|Mitochondria, Heart|Phospholipases|Potassium|Tachycardia|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3782641_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In the hypokalemia group, sodium polystyrene sulfonate (5 g/kg body weight) was infused into the colon.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6398969_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25715086_20201005_0.5			Carvedilol-induced hyperkalemia in a patient with chronic kidney disease.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25715086_20201005_0.5			adult|antihypertensive agents/adverse effects|carvedilol/adverse effects|humans|hyperkalemia/chemically induced|kidney failure	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25715086_20201005_0.5			Adrenergic beta-Antagonists|Aged|Atrial Fibrillation|Carbazoles|Carvedilol|Dose-Response Relationship, Drug|Humans|Hyperkalemia|Male|Potassium|Propanolamines|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25715086_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The patient's serum potassium then rose from 4.8 to 6.7 mEq/L, with no improvement following administration of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21643138_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Optical tweezers based active microrheology of sodium polystyrene sulfonate (NaPSS).	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21643138_20201005_0.5			Materials Testing|Optical Tweezers|Polystyrenes|Rheology|Shear Strength|Viscosity	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID21643138_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We used oscillatory optical tweezers to investigate the microrheological properties of Sodium polystyrene sulfonate (NaPSS; Mw = 70 kDa) polymer solutions with different concentrations from 0.001 mM to 10 mM in terms of elastic modulus G'(ω) and loss modulus G"(ω) as a function of angular frequency (ω) in the range of 6 rad/s to 6000 rad/s. The viscoelastic properties (including zero-shear-rate viscosity, crossing frequency and transition frequency) as a function of polymer concentration, deduced from our primary data, reveal the subtle structural changes in the polymer solutions as the polymer concentration increases from dilute to semi-dilute regimes, passing through the critical micelle formation concentration and the polymer overlapping concentration.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8500380_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colonic necrosis following sodium polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8500380_20201005_0.5			Colon|Enema|Humans|Hyperkalemia|Kidney Transplantation|Male|Middle Aged|Necrosis|Polystyrenes|Postoperative Complications	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24762462_20201005_0.5			Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24762462_20201005_0.5			Acute Disease|Biomarkers|Cardiovascular Diseases|Chronic Disease|Death, Sudden, Cardiac|Humans|Hyperkalemia|Kidney Diseases|Potassium|Prognosis|Risk Factors|Time Factors|Up-Regulation	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID24762462_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Traditional management steps have included reducing dietary potassium and discontinuing potassium supplements; withdrawal of exacerbating drugs; acute treatment with intravenous calcium gluconate, insulin, and glucose; nebulized albuterol; correction of acidosis with sodium bicarbonate for short-term shifts out of the plasma pool; and, finally, gastrointestinal ion exchange with oral sodium polystyrene sulfonate in sorbitol, which is mainly used in the hospital and is poorly tolerated due to gastrointestinal adverse effects.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26765867_20201005_0.5			Potassium-Binding Agents for the Clinical Management of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26765867_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	hyperkalemia|patiromer|sodium polystyrene sulfonate|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26765867_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Use of sodium polystyrene sulfonate (SPS) dominates the long-term treatment of hyperkalemia, but two new agents, sodium zirconium cyclosilicate and the recently FDA-approved patiromer, may offer potential advantages compared with SPS.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26377950_20201005_0.5			The Influence of Surface Modification on the Photoluminescence of CdTe Quantum Dots: Realization of Bio-Imaging via Cost-Effective Polymer.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26377950_20201005_0.5			bio-imaging|cytotoxicity|photoluminescence|polymers|quantum dots	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26377950_20201005_0.5			Cadmium Compounds|Cell Line, Tumor|HeLa Cells|Humans|Luminescence|Molecular Imaging|Molecular Structure|Particle Size|Photochemical Processes|Polymers|Quantum Dots|Surface Properties|Tellurium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26377950_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	To solve these problems, three kinds of conventional polymers, namely, polyvinyl alcohol (PVA, neutral), sodium polystyrene sulfonate (PSS, negative charged), and poly(diallyl dimethyl ammonium chloride) (PDDA, positive charged) were selected to modify the surface of QDs at low cost via a simple process in which the size of the QDs was kept small after modification.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18851071_20201005_0.5			Structural study of coacervation in protein-polyelectrolyte complexes.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18851071_20201005_0.5			Animals|Biophysics|Cattle|Computer Simulation|Electrolytes|Fractals|Hydrogen-Ion Concentration|Ions|Isoelectric Point|Neutrons|Polystyrenes|Protein Binding|Proteins|Scattering, Radiation|Serum Albumin, Bovine	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18851071_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Coacervation is a dense liquid-liquid phase separation and herein we report coacervation of protein bovine serum albumin (BSA) in the presence of polyelectrolyte sodium polystyrene sulfonate (NaPSS) under varying solution conditions.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9550776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Sodium polystyrene sulfonate (Resonium A) as possible cause of rectal blood loss].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9550776_20201005_0.5			Aged|Aortic Aneurysm, Abdominal|Cation Exchange Resins|Colitis, Ulcerative|Humans|Hyperkalemia|Male|Melena|Polystyrenes|Postoperative Complications|Resins, Synthetic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9550776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hyperkalaemia was temporarily treated with sodium polystyrene sulfonate (Resonium A) after which he lost blood per rectum.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9550776_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This complication is related to uraemia and the use of sodium polystyrene sulfonate with or without sorbitol.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID13129823_20201005_0.5			A physico-chemical approach of polyanion-polycation interactions aimed at better understanding the in vivo behaviour of polyelectrolyte-based drug delivery and gene transfection.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID13129823_20201005_0.5			Acrylic Resins|Anions|Body Fluids|Cations|Chemical Phenomena|Chemistry, Physical|Drug Carriers|Drug Incompatibility|Gene Transfer Techniques|Magnetic Resonance Spectroscopy|Methacrylates|Nephelometry and Turbidimetry|Nylons|Pharmaceutical Solutions|Polymethacrylic Acids|Polystyrenes|Spectrophotometry, Infrared|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID13129823_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Phase separation occurred regardless of ionic strength in the case of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10217624_20201005_0.5			Hyperkalemia risks in hemodialysed patients consuming fluoride-rich water.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10217624_20201005_0.5			Adult|Aged|Female|Fluorides|Humans|Hyperkalemia|Kidney Failure, Chronic|Male|Middle Aged|Renal Dialysis|Water Supply	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10217624_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	With respect to sodium polystyrene sulfonate consumption (n = 17), there was no significant difference between group C and NC (non-consumers group).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26698089_20201005_0.5			A novel sustained release drug-resin complex-based microbeads of ciprofloxacin HCl.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26698089_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	ciprofloxacin HCl|microbeads|pectin|sodium alginate|sodium polystyrene sulfonate USP resin	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26698089_20201005_0.5			Ciprofloxacin|Delayed-Action Preparations|Humans|Microspheres|Urinary Tract Infections	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26698089_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 Materials and methods An optimized complex (resinate) of CFN with sodium polystyrene sulfonate USP resin was prepared and entrapped within microbeads of sodium alginate and pectin.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Intestinal necrosis after co‐administration of sodium polystyrene sulfonate and activated charcoal	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5			activated charcoal|end‐stage renal disease|intentional drug overdose|kayexalate|kidney transplant	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7141745_20201005_0.5			Humans|polystyrene sulfonic acid|Charcoal|Polystyrenes|Intestinal Diseases|Cation Exchange Resins|Hyperkalemia|Vascular Diseases|Sorbitol|Necrosis	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5887418_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pretreatment of enteral nutrition with sodium polystyrene sulfonate: effective, but beware the high prevalence of electrolyte derangements in clinical practice	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5887418_20201005_0.5			chronic renal failure|CKD|hyperkalemia|nutrition|pediatrics	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5887418_20201005_0.5			Child|Male|Humans|Female|Infant|Adolescent|Child, Preschool|polystyrene sulfonic acid|Enteral Nutrition|Retrospective Studies|Prevalence|Hyperkalemia|Polystyrenes|Potassium|Sodium|Magnesium|Renal Insufficiency, Chronic|Electrolytes|Bicarbonates|Phosphorus|Chlorides|Philadelphia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5887418_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Background Current treatment options for chronic hyperkalemia in children with chronic kidney disease include dietary restrictions or enteral sodium polystyrene sulfonate (SPS); however, dietary restrictions may compromise adequate nutrition and enteral SPS may be limited by palatability, adverse effects and feeding tube obstruction.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15094686_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Colonic ulcer after prolongated administration of Kayexalate (sodium polystyrene sulfonate)].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15094686_20201214_0.5			Anti-Infective Agents|Colonic Diseases|Drug Administration Schedule|Humans|Kidney Failure, Chronic|Male|Middle Aged|Polystyrenes|Sepsis|Serratia Infections|Serratia marcescens|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7673871_20210111_0.5			Accuracy of Hemolyzed Potassium Levels in the Emergency Department	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7673871_20210111_0.5			Adolescent|Adult|Aged|Biomarkers|Emergency Service, Hospital|Female|Humans|Hyperkalemia|Male|Middle Aged|Potassium|Prospective Studies|Young Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7673871_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	Exclusion criteria were age > 65, glomerular filtration rate (GFR) < 60, creatine phosphokinase > 500, hematologic malignancy, taking potassium-sparing or angiotensin-acting agents, or treatment with potassium-lowering agents (albuterol, insulin, HCO3 , sodium polystyrene sulfonate, or potassium-excreting diuretic) prior to the repeat lab draw.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6365398_20201005_0.5			Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6365398_20201005_0.5			hemodialysis|hyperkalemia|patiromer	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6365398_20201005_0.5			Middle Aged|Male|Humans|Adult|Female|Hyperkalemia|patiromer|Renal Dialysis|Retrospective Studies|Polymers|Potassium|polystyrene sulfonic acid|Polystyrenes|Angiotensin-Converting Enzyme Inhibitors|Renal Insufficiency, Chronic|Chelating Agents|Heart Failure	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6365398_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 Methods In a retrospective cohort study, using electronic health record data from a large dialysis provider in the United States (study period: December 21, 2015, to December 20, 2016), HD patients were included who had a medication order for patiromer, sodium polystyrene sulfonate (SPS), or laboratory evidence of hyperkalemia (no K binder [NoKb] cohort).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31295160_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	Fractal Deposits of a Hemostatic Hydrophilic Polymer in Mohs Micrographic Surgery Frozen Sections: A Histologic Analysis and Comparison With Sodium Polystyrene Sulfonate (Kayexalate).	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31295160_20210211_0.5			Aged|Artifacts|Carcinoma, Basal Cell|Hemostatics|Humans|Iron Compounds|Male|Mohs Surgery|Polystyrenes|Potassium Compounds|Skin Neoplasms	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31295160_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	We noted HPPF in skin closely resembles sodium polystyrene sulfonate (SPS) seen in colonic necrosis; SPS is a potassium binder given orally or rectally in hyperkalemic patients with end-stage renal disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6019050_20201005_0.5			Let food be thy medicine and medicine be thy food?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6019050_20201005_0.5			Child|Humans|Child, Preschool|Retrospective Studies|Hyperkalemia|Potassium|Cation Exchange Resins|polystyrene sulfonic acid|Polystyrenes|Hypokalemia|Hypernatremia|Enteral Nutrition|Food|Incidence|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6019050_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pre-treatment of feeds, whether milk, formula or enteral nutrition, with sodium polystyrene sulfonate (SPS) is practiced in some paediatric centres internationally.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2334084_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Cleansing enemas after sodium polystyrene sulfonate enemas.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2334084_20201005_0.5			Colon|Enema|Humans|Necrosis|Polystyrenes|Product Labeling	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6764378_20201005_0.5			Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6764378_20201005_0.5			Paula J. Alvarez palvarez@relypsa.com	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6764378_20201005_0.5			Humans|Male|United States|Female|Middle Aged|Adult|Aged|Hyperkalemia|patiromer|Retrospective Studies|Polymers|Renin-Angiotensin System|Angiotensin-Converting Enzyme Inhibitors|Angiotensin Receptor Antagonists|polystyrene sulfonic acid|Polystyrenes|Potassium|Heart Failure|Renal Insufficiency, Chronic|Hypertension|Medicare Part C	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6764378_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Three HK cohorts were identified: (1) patiromer (PAT cohort) or (2) sodium polystyrene sulfonate (SPS cohort), or (3) HK diagnosis code without K+-binder prescription (NoKb cohort).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22057933_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22057933_20201005_0.5			Adult|Aged|Aged, 80 and over|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Female|Follow-Up Studies|Heart Diseases|Humans|Hyperkalemia|Male|Middle Aged|Polystyrenes|Renal Insufficiency, Chronic|Renin-Angiotensin System|Secondary Prevention|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID22057933_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS) is a potassium-binding resin used for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32892634_20210211_0.5			An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32892634_20210211_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hyperkalemia|SZC|ZS-9|patiromer|potassium|sodium polystyrene sulfonate (SPS)|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32892634_20210211_0.5			Chelating Agents|Heart Failure|Humans|Hyperkalemia|Mineralocorticoid Receptor Antagonists|Polymers|Potassium|Renal Insufficiency, Chronic|Renin-Angiotensin System|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Esophageal necrosis associated with sodium polystyrene sulfonate (Kayexalate) use.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Acute esophageal necrosis|Gurvits syndrome|Kayexalate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5			Humans|polystyrene sulfonic acid|Polystyrenes|African Americans|Alcoholism|Caustics|Colon|Color|Gastric Juice|Gastrointestinal Hemorrhage|Gastrointestinal Tract|Margins of Excision|Necrosis|Risk Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate use has been associated with severe gastrointestinal adverse events, including increased risk of small bowel and colonic necrosis and perforation.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33100548_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	In susceptible individuals, sodium polystyrene sulfonate can also induce esophageal ischemia and necrosis, as illustrated in this case.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1843183_20201005_0.5			Acute toxic effects of sustained-release verapamil in chronic renal failure.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1843183_20201005_0.5			Delayed-Action Preparations|Female|Humans|Hypertension|Kidney Failure, Chronic|Male|Middle Aged|Monitoring, Physiologic|Verapamil	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1843183_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Supportive treatment consisted of intravenous catecholamines, sodium polystyrene sulfonate, and dialysis, and all patients recovered completely without any residual hepatic or cardiac disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800078_20201005_0.5			Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800078_20201005_0.5			electrolyte abnormalities|hyperkalemia|serum potassium|treatment	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800078_20201005_0.5			Chelating Agents|Dose-Response Relationship, Drug|Humans|Hyperkalemia|Mineralocorticoid Receptor Antagonists|Polystyrenes|Potassium|Renin-Angiotensin System|Silicates|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31800078_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Strategies for the treatment of nonemergent hyperkalemia include the use of cation-exchange resins, polymers or other novel mechanisms of potassium trapping, including sodium polystyrene sulfonate, patiromer and sodium zirconium cyclosilicate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8909271_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In vitro binding of iron with the cation-exchange resin sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8909271_20201005_0.5			Cation Exchange Resins|Ferrous Compounds|Humans|In Vitro Techniques|Iron|Polystyrenes|Reactive Oxygen Species|Resins, Synthetic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8909271_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To investigate the ability of the cation exchange resin sodium polystyrene sulfonate to bind iron from ferrous sulfate solutions, along with the effects of pH on binding.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8909271_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS We performed a series of in vitro experiments in which various concentrations of iron and sodium polystyrene sulfonate were combined and free ferrous iron was measured with the use of a colorimetric assay.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8909271_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS Sodium polystyrene sulfonate bound iron from ferrous sulfate solutions at pH 2 and pH 7.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8909271_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Sodium polystyrene sulfonate may be a useful therapy in acute iron poisoning once safety and efficacy are determined with the use of in vivo models.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5243974_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Comparison of activated charcoal and sodium polystyrene sulfonate resin efficiency on reduction of amitriptyline oral absorption in rat as treatments for overdose and toxicities	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5243974_20201005_0.5			Activated charcoal|Amitriptyline|Poisoning|Sodium polstyrene – sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5243974_20201005_0.5			Rats|Animals|Male|Amitriptyline|Charcoal|polystyrene sulfonic acid|Rats, Sprague-Dawley|Drug Overdose|Polystyrenes|Antidepressive Agents, Tricyclic|Adsorption|Physical Phenomena|Administration, Oral|Resins, Plant|Stomach	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5243974_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Objective(s): Comparative in vivo studies were carried out to determine the adsorption characteristics of amitriptyline (AMT) on activated charcoal (AC) and sodium polystyrene sulfonate (SPS).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3428292_20201005_0.5			Complications following oral administration of exchange resins in extremely low-birth-weight infants.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3428292_20201005_0.5			Administration, Oral|Bezoars|Calcium Phosphates|Cation Exchange Resins|Female|Humans|Hyperkalemia|Infant, Low Birth Weight|Infant, Newborn|Ion Exchange Resins|Male|Polystyrenes|Stomach	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID3428292_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Complications of the oral use of sodium polystyrene sulfonate and calcium polystyrene sulfonate are reported in five extremely low-birth-weight infants in which exchange resins were used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31560022_20201005_0.5			Ion-selective binding as a new trigger for micellization of block copolyelectrolytes with two anionic blocks.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31560022_20201005_0.5			Micelles|Polymers|Scattering, Small Angle|Hydrophobic and Hydrophilic Interactions|carbopol 940|Acrylic Resins|Anions|Temperature|polystyrene sulfonic acid|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31560022_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section This work presents well-defined and switchable micelles of block copolymers consisting of the two anionic polyelectrolytes sodium polyacrylate (NaPA) and sodium polystyrene sulfonate (NaPSS).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2025533_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2025533_20201005_0.5			Humans|Infant|Infant Food|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID2025533_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (SPSS) is commonly administered for the acute and chronic treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4273971_20201005_0.5			Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4273971_20201005_0.5			Calcium|Humans|Hydrogen-Ion Concentration|Hyperkalemia|Ion Exchange|Ions|Porosity|Potassium|Silicates|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4273971_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Current methods of managing hyperkalemia, including organic polymer resins such as sodium polystyrene sulfonate (SPS), are poorly tolerated and/or not effective.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28934609_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Quantitative measurement of sodium polystyrene sulfonate adsorption onto CTAB capped gold nanoparticles reveals hard and soft coronas.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28934609_20201005_0.5			Gold nanoparticles|Layer by layer|Polyelectrolytes	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28934609_20201005_0.5			Gold|Adsorption|polystyrene sulfonic acid|Cetrimonium|Metal Nanoparticles|Polystyrenes|Polymers|Surface Properties|Hardness	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28934609_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In this work CTAB capped gold nanoparticles, synthesized in a flow reactor, are coated with sodium polystyrene sulfonate and purified through a series of equilibrium dialysis steps.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12847543_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Successful treatment of Sodium PolyStyrene Sulfonate bezoars with serial water-soluble contrast enemas.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12847543_20201005_0.5			Bezoars|Contrast Media|Enema|Follow-Up Studies|Humans|Hyperkalemia|Infant, Newborn|Infant, Premature|Infant, Very Low Birth Weight|Iohexol|Male|Polystyrenes|Risk Assessment|Solubility|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Kayexalate|hyperkalemia|sodium polystyrene sulfonate (SPS)	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5			Middle Aged|Aged|Male|Humans|Adult|Female|Hyperkalemia|polystyrene sulfonic acid|Retrospective Studies|Prospective Studies|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Chelating Agents	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26327703_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	BACKGROUND Sodium polystyrene sulfonate (SPS) is a potassium-binding resin that is commonly used to treat mild hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32678607_20201005_0.5			Local Confinement Controls Diffusive Nanoparticle Dynamics in Semidilute Polyelectrolyte Solutions.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32678607_20201005_0.5			Polyelectrolytes|Diffusion|Nanoparticles|Polymers|polystyrene sulfonic acid|Polystyrenes|Solutions|Viscosity|Osmolar Concentration|Molecular Conformation|Microscopy, Fluorescence	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32678607_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We investigate the mobility of polystyrene particles ranging from 100 to 790 nm in diameter in dilute and semidilute sodium polystyrene sulfonate (NaPSS) solutions using fluorescence microscopy.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29326277_20201005_0.5			▼Patiromer for the management of hyperkalaemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29326277_20201005_0.5			Contraindications, Drug|Drug Interactions|Humans|Hyperkalemia|Polymers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29326277_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Hyperkalaemia is a potentially life-threatening condition, in which there is an abnormally high concentration of potassium ions in the blood.1,2 Cation-exchange resins (e.g. calcium or sodium polystyrene sulfonate) that bind potassium in the gastrointestinal tract to increase faecal elimination have been used as part of the management of hyperkalaemia but they have some serious adverse effects, including potentially fatal gastrointestinal necrosis.3,4 Patiromer (▼Veltassa - Vifor Fresenius) is a cation-exchange polymer that is licensed for the treatment of hyperkalaemia in adults and, unlike other exchange resins, its licence is not restricted to people with anuria, severe oliguria or those requiring or undergoing dialysis.5,6 Here, we review the evidence for the efficacy and safety of patiromer and consider its place in the management of hyperkalaemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26371733_20201005_0.5			Potassium Disorders: Hypokalemia and Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26371733_20201005_0.5			Education, Medical, Continuing|Humans|Hyperkalemia|Hypokalemia|Practice Guidelines as Topic|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID26371733_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Insulin, usually with concomitant glucose, and albuterol are preferred to lower serum potassium levels in the acute setting; sodium polystyrene sulfonate is reserved for subacute treatment.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Treatment of pediatric hyperkalemia with sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5			Adverse events|Efficacy|Hyperkalemia|Kayexalate|Pediatric	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5			Administration, Oral|Administration, Rectal|Adolescent|Body Weight|Cation Exchange Resins|Child|Child, Preschool|Diarrhea|Female|Humans|Hyperkalemia|Infant|Male|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Retrospective Studies|Texas|Treatment Outcome|Vomiting	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27215929_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section To describe the safety and efficacy of sodium polystyrene sulfonate (SPS) in pediatric patients with acute hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28893921_20201005_0.5			Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28893921_20201005_0.5			Arm|Control Groups|Diet|Humans|Hyperkalemia|Neuroprotection|Nutritional Status|Polystyrenes|Potassium|Potassium, Dietary|Prospective Studies|Renal Insufficiency, Chronic|Single-Blind Method|Walking Speed|chronic kidney disease|clinical trial|electrolytes|electrophysiology|polystyrene sulfonic acid|quality of life|renal dialysis	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28893921_20201005_0.5			Administration, Oral|Aged|Chelating Agents|Female|Health Status|Humans|Hyperkalemia|Male|Middle Aged|New South Wales|Peripheral Nervous System Diseases|Polystyrenes|Potassium, Dietary|Prospective Studies|Quality of Life|Recovery of Function|Renal Insufficiency, Chronic|Single-Blind Method|Time Factors|Treatment Outcome|Walking Speed	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28893921_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The intervention arm (n=23) was prescribed a diet focusing on potassium restriction to meet a monthly serum potassium level of ≤4.5 mEq/L, with oral sodium polystyrene sulfonate provided if dietary advice failed to achieve the target.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23255245_20201005_0.5			Management of hyperkalemia in hospitalized patients.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23255245_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Albuterol|Calcium|Cation Exchange Resins|Dose-Response Relationship, Drug|Female|Humans|Hyperkalemia|Insulin|Kidney Diseases|Male|Middle Aged|Polystyrenes|Renal Dialysis|Sodium Bicarbonate|Young Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23255245_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS There were 154 hyperkalemic episodes, 32 with K ≥6.5 mEq/L and 122 with K<6.5 mEq/L. Overall, 97% received treatment for an average K of 5.9 mEq/L. Sodium polystyrene sulfonate (SPS) was included in 95% of the regimens.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5			SPS(Kayexalate)/CPS(K-Bind) crystals in the gastrointestinal tract-An experience from a tertiary center.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5			GI injury|SPS/CPS crystals|hyperkalemia	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5			Humans|Male|Female|Middle Aged|Adult|Aged|polystyrene sulfonic acid|Polystyrenes|Cation Exchange Resins|Hyperkalemia|Renal Insufficiency, Chronic|Gastrointestinal Tract|Sorbitol|Pharmaceutical Preparations|India	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33851618_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	UNASSIGNED Kayexalate (Sodium Polystyrene Sulfonate/SPS) and K-bind (Calcium Polystyrene Sulfonate/CPS) are cation exchange resins, commonly used for treatment of hyperkalaemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33608262_20210511_0.5			Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33608262_20210511_0.5			chronic kidney disease|clinical nephrology|electrolytes|epidemiology and outcomes|hyperkalemia|recurrence|renin|renin-angiotensin system	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33608262_20210511_0.5			Humans|Male|Middle Aged|Female|Aged|Hyperkalemia|Renin-Angiotensin System|Retrospective Studies|Neoplasm Recurrence, Local|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Potassium|Diuretics|Renal Insufficiency, Chronic|Heart Failure|polystyrene sulfonic acid|Polystyrenes|Cohort Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33608262_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS We performed a population-based, retrospective cohort study of older adults (n=49,571; mean age 79 years) who developed hyperkalemia (potassium ≥5.3 mEq/L) while on a RAASi and were grouped as follows: no intervention, RAASi discontinuation, RAASi dose decrease, new diuretic, diuretic dose increase, or sodium polystyrene sulfonate within 30 days.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33608262_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS Among patients who received a pharmacologic intervention (23% of the cohort), RAASi discontinuation was the most commonly prescribed strategy (74%), followed by RAASi decrease (15%), diuretic increase (7%), new diuretic (3%), and sodium polystyrene sulfonate (1%).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33608262_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	Compared with no intervention (35%, referent), the cumulative incidence of recurrent hyperkalemia was lower with RAASi discontinuation (29%; hazard ratio, 0.82; 95% confidence interval, 0.78 to 0.85), whereas there was no difference with RAASi dose decrease (36%; hazard ratio, 0.94; 95% confidence interval, 0.86 to 1.02), new diuretic (32%; hazard ratio, 0.95; 95% confidence interval, 0.78 to 1.17), or diuretic increase (38%; hazard ratio, 0.99; 95% confidence interval, 0.87 to 1.12) and a higher incidence with sodium polystyrene sulfonate (55%; hazard ratio, 1.30; 95% confidence interval, 1.04 to 1.63).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28008346_20201005_0.5			Polyelectrolyte multilayer electrostatic gating of graphene field-effect transistors.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28008346_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	dirac point|electrostatic gating|graphene|polyallylamine hydrochloride (PAH)|sodium polystyrene sulfonate (PSS)|transistor	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID28008346_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We apply polyelectrolyte multilayer films by consecutive alternate adsorption of positively charged polyallylamine hydrochloride and negatively charged sodium polystyrene sulfonate to the surface of graphene field effect transistors.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11134566_20201005_0.5			Potassium-adsorption filter for RBC transfusion: a phase III clinical trial.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11134566_20201005_0.5			Adenine|Adolescent|Adsorption|Adult|Aged|Aged, 80 and over|Blood Preservation|Child|Erythrocyte Transfusion|Female|Filtration|Humans|Male|Mannitol Phosphates|Middle Aged|Potassium|Solutions	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11134566_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	To prevent potassium (K(+)) overload by RBC transfusion at the bedside, a K(+)-adsorption filter made of sodium polystyrene sulfonate was developed.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4789397_20201005_0.5			Resin-Induced Colonic Pseudotumor: Rare Complication from Chronic Use of Potassium Binders in a Hemodialysis Patient	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4789397_20201005_0.5			PRC|Humans|Renal Dialysis|Resins, Plant|Kidney Failure, Chronic|Colonic Neoplasms|Hyperkalemia|Colectomy|Hospitalization|polystyrene sulfonic acid|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4789397_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	This report describes a case involving an end-stage renal disease patient on hemodialysis who developed a colonic mass after being on sodium polystyrene sulfonate chronically for persistent hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The Successful Treatment of Sodium Polystyrene Sulfonate-induced Enteritis Diagnosed by Small Bowel Endoscopy	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	sodium polystyrene sulfonate|chronic kidney disease|small bowel necrosis	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5			Aged|Cation Exchange Resins|Endoscopy, Gastrointestinal|Enteritis|Humans|Hyperkalemia|Intestine, Small|Laparoscopy|Male|Necrosis|Polystyrenes|Renal Insufficiency, Chronic|Tomography, X-Ray Computed	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6028675_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (SPS: Kayexalate ) is an ion-exchange resin used to treat hyperkalemia in patients with chronic kidney disease.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11105913_20201005_0.5			Evaluation of poly(styrene-4-sulfonate) as a preventive agent for conception and sexually transmitted diseases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11105913_20201005_0.5			Animals|Anti-Bacterial Agents|Anti-Infective Agents|Antiviral Agents|Chlamydia trachomatis|Female|HIV|Humans|Hyaluronoglucosaminidase|Insemination, Artificial|Male|Microbial Sensitivity Tests|Neisseria gonorrhoeae|Polystyrenes|Rabbits|Sexually Transmitted Diseases|Simplexvirus|Spermatocidal Agents|Spermatozoa	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11105913_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section A commercial preparation of a sodium polystyrene sulfonate (designated as N-PSS; its molecular weight is 500000 daltons) was tested as an inhibitor of sperm function and as a preventive agent for conception and the transmission of sexually transmitted diseases.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33571357_20210311_0.5			New Kids on the Block: A Review of the Latest Iatrogenic Foreign Materials Seen in Gastrointestinal Specimens.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33571357_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	 UNASSIGNED To discuss the histopathologic features, clinical scenarios and significance, and differential diagnosis of relatively recently described, yet quickly expanding, family of iatrogenic agents that can present as foreign materials in gastrointestinal specimens-pharmaceutical fillers (crospovidone and microcrystalline cellulose), submucosal lifting agents (Eleview and ORISE), lanthanum carbonate, hydrophilic polymers, OsmoPrep, yttrium 90 microspheres (SIR-Sphere and TheraSphere), and resins (sodium polystyrene sulfonate, sevelamer, and bile acid sequestrants).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5			Treatment of Severe Hyperkalemia: Confronting 4 Fallacies	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	colonic necrosis|Kayexalate|low potassium dialysate|severe hyperkalemia|sodium bicarbonate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5			Humans|Hyperkalemia|Potassium|Cation Exchange Resins|polystyrene sulfonic acid|Polystyrenes|Renal Insufficiency, Chronic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5762976_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	It is of concern then that, based on questions about effectiveness and safety, many physicians no longer use 3 key modalities in the treatment of severe hyperkalemia: sodium bicarbonate, sodium polystyrene sulfonate (Kayexalate [Concordia Pharmaceuticals Inc., Oakville, ON, Canada], SPS [CMP Pharma, Farmville, NC]), and hemodialysis with low potassium dialysate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32439127_20210411_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Case report of an infant hyperkalemia: Suggestion of a hospital procedure for the milk pretreatment with sodium polystyrene sulfonate resin].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32439127_20210411_0.5			Gestion de la pharmacotherapie|Hyperkaliemia|Hyperkaliemie|Medication therapy management|Pediatrics|Pediatrie	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32439127_20210411_0.5			Animals|Drug Compounding|Humans|Hyperkalemia|Infant, Newborn|Kidney Failure, Chronic|Male|Milk|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32439127_20210411_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (SPS) is used to reduce intestinal potassium absorption in hyperkalemia during conservative management of chronic renal failure in infants.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17097101_20201005_0.5			Characterization limits of a polymer adsorbed under a monolayer by GIXD measurements.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17097101_20201005_0.5			Polymers|Adsorption|X-Ray Diffraction|Thermodynamics|Surface Properties|Water|dimethyldioctadecylammonium|Quaternary Ammonium Compounds|Pressure	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID17097101_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The study of interactions between a polyelectrolyte (sodium polystyrene sulfonate, PSSt) or its water-soluble monomer (SSt) at different concentrations and a monolayer of dioctadecyldimethylammonium bromide (DODA) has been investigated.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33887938_20210511_0.5			Phase separation in mixed suspensions of bacteria and nonadsorbing polymers.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33887938_20210511_0.5			Polymers|Suspensions|Phase Transition|polystyrene sulfonic acid|Polystyrenes|Bacteria	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33887938_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	Here, it is shown that free volume theory (FVT) can semi-quantitatively describe the phase transitions observed when adding sodium polystyrene sulfonate polymers to E. coli bacteria [Schwarz-Linek et al.,	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Successful management of severe acute respiratory distress syndrome caused by sodium polystyrene sulfonate aspiration	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	acute respiratory distress syndrome|extracorporeal membrane oxygenation|Kayexalate|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5			Bronchoscopy|Extracorporeal Membrane Oxygenation|Humans|Male|Middle Aged|Polystyrenes|Respiration, Artificial|Respiratory Aspiration|Respiratory Distress Syndrome|Severity of Illness Index	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Rationale: Sodium polystyrene sulfonate is commonly administered to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	He aspirated sodium polystyrene sulfonate while consuming the drug.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6708910_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 Lessons: Aspiration of sodium polystyrene sulfonate is not common but can be lethal.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16740839_20201005_0.5			Reported medication use in the neonatal intensive care unit: data from a large national data set.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16740839_20201005_0.5			Drug Utilization|Female|Humans|Infant, Newborn|Intensive Care Units, Neonatal|Male|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16740839_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Medications used for patient populations with >20% mortality rates included amphotericin, clonazepam, dobutamine, epinephrine, ethacrynic acid, insulin, lidocaine, metolazone, milrinone, inhaled nitric oxide, nitroglycerin, octreotide, pancuronium, phenytoin, sodium nitroprusside, sodium polystyrene sulfonate (Kayexalate), tris-hydroxymethylaminomethane acetate buffer, and tolazoline.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6523181_20201005_0.5			Bioelectrochemical Properties of Enzyme-Containing Multilayer Polyelectrolyte Microcapsules Modified with Multiwalled Carbon Nanotubes	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6523181_20201005_0.5			multilayer membrane structures|polyelectrolyte microcapsules (PMCs)|glucose oxidase|modification with multiwalled carbon nanotubes|PMC impedance decrease	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6523181_20201005_0.5			Nanotubes, Carbon|Capsules|Polyelectrolytes|Glucose Oxidase|Biosensing Techniques|Electrodes|Glucose|Bioelectric Energy Sources|polystyrene sulfonic acid|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6523181_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	PMCs were made using sodium polystyrene sulfonate (polyanion) and poly(allylamine hydrochloride) (polycation).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID20073518_20201005_0.5			Small angle neutron scattering study of polyelectrolyte brushes grafted to well-defined gold nanoparticle interfaces.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID20073518_20201005_0.5			Electrolytes|Gold|Metal Nanoparticles|Neutron Diffraction|Polystyrenes|Scattering, Small Angle|Surface Properties	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID20073518_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The polyelectrolyte layer is prepared at a constant coverage by grafting thiol-functionalized polystyrene (M(w) = 53k) to gold nanoparticles of well-defined interfacial curvature (R(c) = 26.5 nm) followed by a soft-sulfonation of 38% of the segments to sodium polystyrene sulfonate (NaPSS).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Lithium absorption prevented by sodium polystyrene sulfonate in volunteers.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5			Absorption|Adult|Cation Exchange Resins|Female|Humans|Hypokalemia|Lithium Carbonate|Male|Polystyrenes|Prospective Studies|Resins, Synthetic	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To determine if sodium polystyrene sulfonate prevents absorption of lithium in human beings.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	One hour later, they ingested either 857 mg/kg sodium polystyrene sulfonate in 4 mL water/g sodium polystyrene sulfonate (experimental) or an equal volume of water without sodium polystyrene sulfonate (control).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The sodium polystyrene sulfonate group had a smaller mean area under the serum concentration curve (11.6 +/- 1.0 mEq/L.hr versus 13.6 +/- 1.5 mEq/L.hr, P < .001) and lower mean highest measured lithium level (0.85 +/- 0.11 mEq/L versus 1.05 +/- 0.10 mEq/L, P < .05) compared with the control group.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Sodium polystyrene sulfonate administration decreased absorption of lithium after a lithium carbonate overdose.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416323_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate may be useful clinically for gastric decontamination after lithium overdoses.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15274582_20201005_0.5			Synthesis and nanostructure of strong polyelectrolyte brushes in amphiphilic diblock copolymer monolayers on a water surface.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15274582_20201005_0.5			Water|Polyelectrolytes|Nanostructures|Polymers|Hydrophobic and Hydrophilic Interactions|polystyrene sulfonic acid|Polystyrenes|Membranes, Artificial|Surface Properties|Sodium Chloride|Anions	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15274582_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The monolayer of the diblock copolymer on a water surface had a smooth hydrophobic PIp-h2 layer on water and a "carpet"/polymer brush double layer in a hydrophilic sodium polystyrene sulfonate (PSSNa) layer under the water.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5			Patiromer for the treatment of hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5			Dialysis|heart failure|hyperkalemia|hypertension|kidney disease|patiromer|potassium	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5			Animals|Chelating Agents|Humans|Hyperkalemia|Polymers|Polystyrenes|Potassium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	Recently newer oral potassium-binding agents have been approved for clinical use, as an alternative to the decades long use of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID32511052_20210311_0.5	sodium polystyrene sulfonate	drug_umls_atom	 UNASSIGNED Pubmed was used to search from 1960 to 2020 on free subject terms: Hyperkalemia, Potassium, Patiromer, Veltassa, Kayexalate, Sodium polystyrene sulfonate, and Sodium Zirconium cyclosilicate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33136308_20210511_0.5			A pH-Responsive Polymer-CeO2 Hybrid to Catalytically Generate Oxidative Stress for Tumor Therapy.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33136308_20210511_0.5			CeO 2|nanoreactors|pH-responsive polymer-nanorod hybrids|reactive oxygen species|tumor therapy	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33136308_20210511_0.5			Cerium|Humans|Hydrogen-Ion Concentration|Neoplasms|Oxidative Stress|Polymers|Tumor Microenvironment	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID33136308_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	Herein, this therapy strategy is demonstrated by a pH-responsive hybrid of porous CeO2 nanorods and sodium polystyrene sulfonate that delivers high oxidative activity for O2 •- generation within acidic tumor microenvironments for chemodynamic therapy and only limited oxidative activity in neutral media to limit damage to healthy organs.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10649740_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Mineral content of infant formula after treatment with sodium polystyrene sulfonate or calcium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10649740_20201005_0.5			Calcium|Cation Exchange Resins|Chemical Precipitation|Humans|Hyperkalemia|Infant|Infant Food|Minerals|Polystyrenes|Potassium|Potassium, Dietary|Renal Insufficiency|Sodium|Zinc	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10649740_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Precipitation of potassium (K+) from infant formula with sodium polystyrene sulfonate (KX) prior to feeding has been reported.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Vancomycin-resistant Enterococcus faecium bacteraemia as a complication of Kayexalate (sodium polystyrene sulfonate, SPS) in sorbitol-induced ischaemic colitis.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5			contraindications and precautions|drugs: gastrointestinal system|endoscopy|gi bleeding|infectious diseases	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5			Aged, 80 and over|Bacteremia|Colitis, Ischemic|Female|Humans|Hypokalemia|Polystyrenes|Renal Insufficiency, Chronic|Sorbitol|Tomography, X-Ray Computed|Vancomycin-Resistant Enterococci	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29127125_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS, Kayexalate) in sorbitol suspension was given orally to treat her hyperkalaemia, which precipitated an episode of SPS in sorbitol-induced ischaemic colitis with the subsequent complication of vancomycin-resistant Enterococcus (VRE) bacteraemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416324_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Effect of sodium polystyrene sulfonate on lithium bioavailability.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416324_20201005_0.5			Absorption|Adult|Biological Availability|Cation Exchange Resins|Female|Humans|Lithium Carbonate|Male|Polystyrenes|Resins, Synthetic|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416324_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To examine the effect of a single dose of sodium polystyrene sulfonate and sorbitol on lithium absorption.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416324_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS Subjects ingested 600 mg lithium carbonate on two occasions, with and without 30 g concomitant sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416324_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 RESULTS Compared with control, sodium polystyrene sulfonate and sorbitol reduced the area under the lithium serum concentration-time curve by 11.33%, reduced the mean observed peak serum lithium concentration 0.07 +/- 0.08 mmol/L, and delayed the time to the mean observed peak serum lithium concentration by 2.04 +/- 2.40 hours.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1416324_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Sodium polystyrene sulfonate and sorbitol may be used in patients immediately or shortly after ingestion of a significant acute overdose of lithium in situations in which hemodialysis cannot be instituted promptly.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15875381_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Flocculation of microgel particles with sodium chloride and sodium polystyrene sulfonate as a function of temperature.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15875381_20201005_0.5			Temperature|polystyrene sulfonic acid|Flocculation|Sodium Chloride|Polystyrenes|poly-N-isopropylacrylamide|Acrylic Resins|Water|Surface Properties|Particle Size|Static Electricity	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1951347_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Use of sodium polystyrene sulfonate in sorbitol in the United States, 1985-1989.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID1951347_20201005_0.5			Cation Exchange Resins|Drug Utilization|Humans|Hyperkalemia|Polystyrenes|Sorbitol|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16343008_20201005_0.5			Role of nonadsorbing polymers in bacterial aggregation.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16343008_20201005_0.5			Adsorption|Bacterial Adhesion|Electrophoresis|Escherichia coli|Polymers	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID16343008_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Aggregation studies were carried out using 0.5 to 2.5 wt% E. coli AB1157 harvested in different growth phases with varying concentrations of a nonadsorbing polymer, sodium polystyrene sulfonate (SPS).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8865238_20201005_0.5			Severe pseudohypoaldosteronism in a pair of twins not associated with hydramnios.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8865238_20201005_0.5			Body Height|Female|Fludrocortisone|Humans|Infant|Male|Mineralocorticoids|Polyhydramnios|Pregnancy|Pseudohypoaldosteronism|Twins, Dizygotic|Weight Gain	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8865238_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Despite continuous treatment with sodium chloride and sodium bicarbonate (< or = 20 g/day) and cation exchange resin (Kayexalate, sodium polystyrene sulfonate, < or = 4 g/kg per day), the children had repeated episodes of dehydration, hyponatremia, and hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[Colonic ulcers associated with taking Kayexalate(®) (sodium polystyrene sulfonate): about two cases].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colon|Côlon|Kayexalate(®)|Polystyrène sulfonate de sodium|Sodium polystyrene sulfonate|Ulcers|Ulcérations	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25796574_20201005_0.5			Adult|Colonic Diseases|Female|Humans|Male|Middle Aged|Polystyrenes|Ulcer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27427666_20201214_0.5			Preparation of Chitosan/Polystyrene Sulfonate Multilayered Composite Metal Nanoparticles and Its Application.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27427666_20201214_0.5			Catalysis|Chitosan|Electrochemistry|Metal Nanoparticles|Nanocomposites|Polystyrenes|Surface Properties	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27427666_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	The formed composite was alternately deposited on the base with sodium polystyrene sulfonate (PSS) through a layer-by-layer self-assembling technique, followed by an in situ reduction by sodium borohydride to produce a polyelectrolyte nanocomposite thin film containing metal nanoparticles.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5			Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5			Administration, Intranasal|Animals|Antibodies, Viral|Cytokines|Female|Hemagglutinin Glycoproteins, Influenza Virus|Immunoglobulin A|Influenza Vaccines|Ion Exchange Resins|Mice|Nasal Cavity|Particle Size|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Female Balb/c mice were intranasally immunized with inactivated influenza HA vaccine with one of four kinds of resin microparticles: sodium polystyrene sulfonate, calcium polystyrene sulfonate, polystyrene benzyltrimetylammonium chloride, or polystyrene divinylbenzene.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The results demonstrated that intranasal administration of influenza HA vaccine in combination with the 20-45 microns sized particles of sodium polystyrene sulfonate resin induced the highest levels of mucosal IgA, and enhanced systemic haemagglutinin-inhibiting antibodies.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	While the Th2-type cytokine IL-4 was detected in the sera after intranasal immunization with HA vaccine and sodium polystyrene sulfonate, neither IFN-gamma nor IL-2 could be detected.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Furthermore, mice intranasally immunized with HA vaccine together with sodium polystyrene sulfonate resin showed higher protection against viral challenge than those that received HA vaccine alone.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID9562695_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Intranasal administration of influenza HA vaccine with sodium polystyrene sulfonate resin might be both a safe and an effective means of immunization.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5			Adult|Aged|Cation Exchange Resins|Child, Preschool|Cholestyramine Resin|Crystallization|Digestive System|Diuretics, Osmotic|Female|Humans|Hyperkalemia|Male|Middle Aged|Necrosis|Polystyrenes|Sorbitol|Uremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8990142_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Sodium polystyrene sulfonate (Kayexalate) in sorbitol given as an enema or orally to treat hyperkalemia has been reported to induce intestinal necrosis in uremic patients.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7509977_20201214_0.5			Prevalence and factors associated with false hyperkalaemia in Asians in primary care: a cross-sectional study (the Unlysed Hyperkalaemia- the Unseen Burden (UHUB) study)	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7509977_20201214_0.5			eGFR|false hyperkalemia|hyperkalaemia|primary care|serum potassium	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7509977_20201214_0.5			Aged|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Asian Continental Ancestry Group|Cross-Sectional Studies|Female|Humans|Hyperkalemia|Male|Middle Aged|Potassium|Prevalence|Primary Health Care|Singapore	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7509977_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Haemolysed specimens and patients on sodium polystyrene sulfonate (SPS) suspension were excluded.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25656422_20201005_0.5			Characterization of the cation-binding capacity of a potassium-adsorption filter used in red blood cell transfusion.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25656422_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Extracellular potassium|Resin filter|Sodium polystyrene sulfonate resin|Stored irradiated red blood cells	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25656422_20201005_0.5			Adsorption|Cation Exchange Resins|Cations|Erythrocyte Transfusion|Filtration|Humans|Polystyrenes|Potassium|Sodium	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25656422_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Artificial solutions containing various cations were continuously passed through the filter in 30 mL of sodium polystyrene sulfonate at 10 mL/min using an infusion pump at room temperature.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID25656422_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The filter may also be useful to gain a better understanding of the pharmacological properties of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6710635_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Interaction behavior of polyion-counterion for sodium polystyrene sulfonate	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6710635_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Specific conductance|Sodium polystyrene sulfonate|Methanol–water mixture|Scaling theory approach|Counterion dissociation	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6710635_20201005_0.5			polystyrene sulfonic acid|Ions|Polystyrenes|Electric Conductivity|Solvents|Water	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6710635_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The specific conductances are measured for sodium polystyrene sulfonate in water and methanol-water mixture.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC6710635_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The charge density of sodium polystyrene sulfonate was used for the research article [1] to see the variation of the critical aggregation concentration of cetyltrimethyl ammonium bromide in sodium polystyrene sulfonate against the charge density of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5			Kayexalate Intake (in Sorbitol) and Jejunal Diverticulitis, a Causative Role or an Innocent Bystander?	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5			Jejunal diverticulosis|Diverticulitis|Kayexalate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5			Male|Humans|polystyrene sulfonic acid|Sorbitol|Polystyrenes|Jejunum|Cation Exchange Resins|Hyperkalemia|Diverticulitis|Colon|Necrosis|Uremia|Mucous Membrane	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC3073802_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Kayexalate (sodium polystyrene sulfonate) in sorbitol has been associated with colonic necrosis and less frequently with upper gastrointestinal injuries in a subset of uremic patients treated for hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29200139_20210111_0.5			Hyperkalemia and Acute Kidney Injury in an Adolescent: Thinking Outside the Box.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29200139_20210111_0.5			Acute Kidney Injury|Addison Disease|Adolescent|Female|Humans|Hydrocortisone|Hyperkalemia|Hyponatremia	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29200139_20210111_0.5	sodium polystyrene sulfonate	drug_umls_atom	This case demonstrates key diagnostic clues in evaluation of an adolescent who presented with severe hyperkalemia and acute kidney injury that was resistant to insulin, glucose, and sodium polystyrene sulfonate and was found to have primary adrenal insufficiency.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18057793_20201005_0.5			[In-vitro study of the drug interactions between Miglitol, an alpha-glucosidase inhibitor, and adsorbents].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18057793_20201005_0.5			1-Deoxynojirimycin|Adsorption|Carbohydrates|Carbon|Cation Exchange Resins|Cholestyramine Resin|Drug Interactions|Enzyme Inhibitors|Epichlorohydrin|Glycoside Hydrolase Inhibitors|Hydrogen-Ion Concentration|Hypoglycemic Agents|Imidazoles|Imino Pyranoses|In Vitro Techniques|Polyamines|Polystyrenes|Resins, Synthetic|Sevelamer	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18057793_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The interactions between miglitol, an alpha-glucosidase inhibitor, and six adsorbents (carbon spheres, cholestyramine, colestimide, sevelamer hydrochloride, calcium polystyrene sulfonate, and sodium polystyrene sulfonate) were investigated in vitro.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID18057793_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Adsorption of miglitol to calcium polystyrene sulfonate was nearly the same, 15.0-21.9%, at both pH. The adsorption ratio of miglitol to sodium polystyrene sulfonate was 43.4% and 45.5%, respectively, in pH 1.2 solution without and with carbohydrates.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5			Cation Exchange Resins|Colonic Diseases|Drug Therapy, Combination|Female|Gastrointestinal Diseases|Gastrointestinal Tract|Humans|Male|Middle Aged|Necrosis|Polystyrenes|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	BACKGROUND Sodium polystyrene sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Although the addition of sorbitol to sodium polystyrene sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium polystyrene sulfonate itself may be toxic.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium polystyrene sulfonate use.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	 METHODS MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium polystyrene sulfonate use.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23321430_20201214_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS Sodium polystyrene sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7396044_20201005_0.5			Sevelamer Carbonate Crystal-Induced Colitis	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7396044_20201005_0.5			Humans|Male|Middle Aged|Sevelamer|Hyperphosphatemia|Kidney Failure, Chronic|Chelating Agents|Renal Dialysis|Colitis|Calcium Carbonate|Polyamines|Phosphates|calcium acetate|Acetates|Calcium Compounds|Heterocyclic Compounds|Hyperparathyroidism, Secondary|Inflammatory Bowel Diseases	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC7396044_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Clinicians providing care to end-stage renal patients taking either sevelamer and/or sodium polystyrene sulfonate should have increased awareness of the possible gastrointestinal side effects.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31124680_20201005_0.5			Viscosity of Semidilute and Concentrated Nonentangled Flexible Polyelectrolytes in Salt-Free Solution.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31124680_20201005_0.5			Viscosity|Polyelectrolytes|Solutions|Rheology|Diffusion|polystyrene sulfonic acid|Polystyrenes|Polymers|Water	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31124680_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We report viscosity data of nonentangled sodium polystyrene sulfonate (NaPSS) in salt-free aqueous solution as a function of polymer concentration ( c) and degree of polymerization ( N).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	[The presence of crystals of sodium polystyrene sulfonate in the colonic wall: innocent bystander or pathogenic factor?].	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5			Body Mass Index|Cation Exchange Resins|Diabetes Complications|Humans|Kidney Failure, Chronic|Male|Middle Aged|Polystyrenes|Renal Dialysis|Risk Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27067217_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS; Kayexalate) is a resin widely used for hyperkalemia treatment.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4643456_20201005_0.5			Cation Exchange Resins and colonic perforation. What surgeons need to know	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4643456_20201005_0.5			Cation Exchange Resin|Colonic necrosis|Calcium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4643456_20201005_0.5			Middle Aged|Male|Humans|Adult|Female|Cation Exchange Resins|Hyperkalemia|Intestinal Perforation|polystyrene sulfonic acid|Polystyrenes|Colonic Diseases|Sorbitol|Cathartics|Colon|Potassium|Necrosis|Intestines|Renal Insufficiency, Chronic|Surgeons	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC4643456_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Cation Exchange Resins have been the mainstream treatment for chronic hyperkalemia.. In 1987 the first case series of uremic patients with colonic perforations associated with the use of sodium polystyrene sulfonate was reported.. The pathologic damage of Cation Exchange Resin in gastrointestinal tract goes from mucosal edema, ulcers, pseudomembranes, and the most severe transmural necrosis.. Surgeons must avoid therapies with intestinal osmotic challenge implication in patients presenting gastrointestinal adverse reactions derived from Cation Exchange Resins.. Introduction Since 1961 the use of Cation Exchange Resins has been the mainstream treatment for chronic hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15846466_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID15846466_20201005_0.5			Animals|Anti-Infective Agents|Cell Line|Cervix Mucus|Chemistry, Pharmaceutical|Contraceptive Agents|Drug Delivery Systems|Excipients|HIV-1|Herpesvirus 2, Human|Humans|Hyaluronoglucosaminidase|Hydrogels|In Vitro Techniques|Plasticizers|Polystyrenes|Polyvinyl Alcohol|Sorbitol|Sperm Motility|Vaginal Creams, Foams, and Jellies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31997484_20210611_0.5			Intestinal necrosis related to administration of cation exchange resin without sorbitol: A retrospective analysis of 61 patients with end-stage renal diseases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31997484_20210611_0.5	sodium polystyrene sulfonate	drug_umls_atom	calcium polystyrene sulfonate (Kalimate)|cation exchange resin|end-stage renal disease|intestinal necrosis|sodium polystyrene sulfonate (Kayexalate)	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31997484_20210611_0.5			Adult|Aged|Aged, 80 and over|Cation Exchange Resins|Female|Humans|Intestines|Kidney Failure, Chronic|Male|Middle Aged|Necrosis|Retrospective Studies|Sorbitol	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31155546_20201005_0.5			Comparative Study of Electrochemical Sensors Based on Enzyme Immobilized into Polyelectrolyte Microcapsules and into Chitosan Gel.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31155546_20201005_0.5			Electrochemical biosensor|chitosan|glucose|glucose oxidase|polyelectrolyte microcapsules|screen-printed electrode	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31155546_20201005_0.5			Biosensing Techniques|Buffers|Calibration|Capsules|Chitosan|Electrochemistry|Electrodes|Enzymes, Immobilized|Ferrocyanides|Gels|Glucose|Glucose Oxidase|Polyamines|Polyelectrolytes|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31155546_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	PMC with the embedded enzyme were formed using sodium polystyrene sulfonate and poly(allylamine hydrochloride).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5			Small crystals with severe consequences	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5			Humans|Male|Young Adult|Adult|Cation Exchange Resins|polystyrene sulfonic acid|Polystyrenes|Hyperkalemia|Stomach|Gastrointestinal Tract|Ulcer|Sorbitol|Heterocyclic Compounds|Necrosis|Ischemia|Diagnostic Tests, Routine	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC8068420_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section We present the case of a 23-year-old patient who developed a severe gastric ischemia after the ingestion of a single dose of sodium polystyrene sulfonate (SPS) orally.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (kayexalate) aspiration: histologic appearance and infrared microspectrophotometric analysis of two cases.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5			Cation Exchange Resins|Child, Preschool|Fatal Outcome|Female|Humans|Hyperkalemia|Infant, Newborn|Lung|Pneumonia, Aspiration|Polystyrenes|Spectrophotometry, Infrared	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE Sodium polystyrene sulfonate (kayexalate) is a cation-exchange resin given enterally for the treatment of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In two cases, recognition of the characteristic morphology of the foreign material raised the question of sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Histories of the patients were reviewed for exposure to sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Both patients had received sodium polystyrene sulfonate previously for control of hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID12046610_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 CONCLUSIONS To our knowledge, we report the first two cases of sodium polystyrene sulfonate aspiration in children.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31682699_20210511_0.5	sodium polystyrene sulfonate	drug_umls_atom	An Alternative to Sodium Polystyrene Sulfonate and Patiromer for the Treatment of Hyperkalemia-Reply.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID31682699_20210511_0.5			Humans|Hyperkalemia|Polymers|Polystyrenes	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Kayexalate|dose-response|hyperkalemia|sodium polystyrene sulfonate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5			Administration, Oral|Administration, Rectal|Adult|Chelating Agents|Dose-Response Relationship, Drug|Female|Humans|Hyperkalemia|Hypokalemia|Inpatients|Male|Medical Records|Middle Aged|Polystyrenes|Potassium|Retrospective Studies	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27048188_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section Hyperkalemia occurs frequently in an inpatient setting, for which sodium polystyrene sulfonate (SPS) is a common treatment modality.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8630152_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	In-vivo binding of lithium using the cation exchange resin sodium polystyrene sulfonate.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8630152_20201005_0.5			Adult|Antidepressive Agents|Binding, Competitive|Cation Exchange Resins|Drug Monitoring|Humans|Intestinal Absorption|Lithium Carbonate|Male|Metabolic Clearance Rate|Pilot Projects|Poisoning|Polystyrenes|Resins, Synthetic|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8630152_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	No section The purpose of this study was to determine if the exchange resin sodium polystyrene sulfonate increases the clearance of lithium in a healthy volunteer.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8630152_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	A sodium polystyrene sulfonate dose of either 0, 20, or 40 grams was administered one half hour after each lithium dose to assess the effect on lithium clearance.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8630152_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate was found to increase the clearance of lithium in a single volunteer.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8630152_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate may be useful in the treatment of lithium intoxication by increasing the clearance of lithium.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10479415_20201005_0.5			Light Scattering Study of Magnetic Latex Particles and Their Interaction with Polyelectrolytes.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10479415_20201005_0.5			Microspheres|Polyelectrolytes|polystyrene sulfonic acid|Polystyrenes|Magnetics|Colloids|Scattering, Radiation|Diffusion|Anions|Light|Latex|Physical Phenomena	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID10479415_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The interaction of these negatively charged particles with a linear polyelectrolyte, negatively charged sodium polystyrene sulfonate, was studied by static and dynamic light scattering.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23807233_20201005_0.5			A paper-based microbial fuel cell: instant battery for disposable diagnostic devices.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23807233_20201005_0.5			Microbial fuel cell|Microfabrication|Paper-based battery|Series/parallel connection	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23807233_20201005_0.5			Bioelectric Energy Sources|Disposable Equipment|Electricity|Equipment Design|Paper|Polystyrenes|Shewanella	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23807233_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	The MFC features (1) a paper-based proton exchange membrane by infiltrating sulfonated sodium polystyrene sulfonate and (2) micro-fabricated paper chambers by patterning hydrophobic barriers of photoresist.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29368958_20201005_0.5			The prevalence of hyperkalemia in the United States.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29368958_20201005_0.5			Hyperkalemia|chronic kidney disease|heart failure|prevalence	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29368958_20201005_0.5			Adult|Aged|Diabetes Mellitus|Female|Heart Failure|Humans|Hyperkalemia|Hypertension|Male|Middle Aged|Polystyrenes|Potassium|Prevalence|Renal Insufficiency, Chronic|Retrospective Studies|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID29368958_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hyperkalemia was defined as ≥2 serum potassium measurements >5.0 mEq/L or one hyperkalemia diagnosis code (ICD-9-CM, 276.7) or one sodium polystyrene sulfonate fill.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30848186_20201005_0.5			Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30848186_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Hyperkalemia|MRAs|RAAS|patiromer|sodium polystyrene sulfonate|zirconium cyclosilicate 9.	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30848186_20201005_0.5			Humans|Hyperkalemia|Mineralocorticoid Receptor Antagonists|Polymers|Potassium|Silicates	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID30848186_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	 No section The management of chronic hyperkalemia seems to be challenging and includes a variety of traditional interventions, such as restriction in the intake of the dietary potassium, loop diuretics or sodium polystyrene sulfonate.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27609505_20201005_0.5			Managing Hyperkalemia: Stepping Into a New Frontier.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27609505_20201005_0.5			electrolytes|hyperkalemia|patiromer|potassium|sodium zirconium cyclosilicate	author_keywords
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27609505_20201005_0.5			Animals|Disease Management|Humans|Hyperkalemia|Polymers|Potassium|Randomized Controlled Trials as Topic|Silicates|Water-Electrolyte Balance	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID27609505_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS), diuretics, and hemodialysis are currently available methods for removing potassium from the body; however, these options have their limitations.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23707305_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23707305_20201005_0.5			Bicarbonates|Blood Urea Nitrogen|Calcium|Chlorides|Creatinine|Endpoint Determination|Humans|Hyperkalemia|Infant|Infant Formula|Magnesium|Milk, Human|Phosphorus|Polystyrenes|Potassium|Renal Insufficiency, Chronic|Retrospective Studies|Sodium|United States	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID23707305_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To evaluate the effect on serum potassium of treating infant formula or expressed breast milk (EBM) with sodium polystyrene sulfonate (SPS) before patient consumption.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7584745_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Effect of delayed treatment with sodium polystyrene sulfonate on serum lithium concentrations in mice.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7584745_20201005_0.5			Administration, Oral|Animals|Body Weight|Cation Exchange Resins|Dose-Response Relationship, Drug|Drug Evaluation|Drug Monitoring|Lithium|Male|Mice|Mice, Inbred Strains|Poisoning|Polystyrenes|Time Factors	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID7584745_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To determine the efficacy of sodium polystyrene sulfonate (SPS) in lowering serum lithium (Li) concentrations.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5478771_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Commentary: Comparison of activated charcoal and sodium polystyrene sulfonate resin efficiency on reduction of amitriptyline oral absorption in rat as treatments for overdose and toxicities	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMC5478771_20201005_0.5			Rats|Animals|Amitriptyline|Charcoal|polystyrene sulfonic acid|Drug Overdose|Polystyrenes|Resins, Plant|Physical Phenomena	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8881542_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate treatment for lithium toxicity: effects on serum potassium concentrations.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8881542_20201005_0.5			Analysis of Variance|Animals|Disease Models, Animal|Drug Overdose|Hypokalemia|Lithium|Male|Mice|Mice, Inbred Strains|Polystyrenes|Potassium|Treatment Outcome	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID8881542_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	OBJECTIVE To examine the effects of sodium polystyrene sulfonate (SPS) on serum potassium (K) concentrations in mice pretreated with parenteral lithium (Li).	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19826644_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Ileocolic perforation secondary to sodium polystyrene sulfonate in sorbitol use: a case report.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19826644_20201005_0.5			Cathartics|Cation Exchange Resins|Colonic Diseases|Female|Humans|Hyperkalemia|Ileal Diseases|Intestinal Perforation|Necrosis|Polystyrenes|Sorbitol|Young Adult	mesh_terms
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID19826644_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Sodium polystyrene sulfonate (SPS) in sorbitol is an ion-exchange resin that can be used to treat hyperkalemia.	abstract
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11900946_20201005_0.5	sodium polystyrene sulfonate	drug_umls_atom	Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate in a burn patient.	title
Polystyrenes	C0032604	kionex|resonium-a|kayexalate|kalexate		polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate	inn	PubMed	PMID11900946_20201005_0.5			Anti-Infective Agents|Burns|Colon|Diarrhea|Female|Humans|Hyperkalemia|Intestinal Perforation|Middle Aged|Necrosis|Polystyrenes|Self-Injurious Behavior	mesh_terms
rituximab-arrx	C5432357	riabni			inn	PubMed	PMID33976089_20210611_0.5			Drugs for multiple sclerosis.	title
rituximab-arrx	C5432357	riabni			inn	PubMed	PMID33976089_20210611_0.5	riabni	drug_synonym	Aubagio|Avonex|Betaseron|Copaxone|Extavia|Gilenya|Glatect|Glatopa|Kesimpta|Lemtrada|Mavenclad|Mayzent|Orevus|Plegridy|Rebif|Riabni|Rituxan|Riximyo|Ruxience|Tecfidera|Truxima|Tysabri|Vumerity|Zeposia|adverse effects|alemtuzumab|cladribine|dimethyl fumarate|diroximel|dosage|drug interactions|efficacy|fingolimod|glatiramer acetate|interferon beta|lactation|mitoxantrone|multiple sclerosis|natalizumab|ocrelizumab|ofatumumab|ozanimod|pregnancy|rituximab|safety|siponimod|teriflunomide	author_keywords
rituximab-arrx	C5432357	riabni			inn	PubMed	PMID33976089_20210611_0.5			Drug Administration Routes|Drug Interactions|Humans|Immunologic Factors|Immunosuppressive Agents|Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33098622_20210411_0.5			The respiratory impact of novel therapies for spinal muscular atrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33098622_20210411_0.5			SMA|respiratory outcomes|treatment	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33098622_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	No section The phenotype of spinal muscular atrophy (SMA) has been changing with the recent availability of three FDA-approved treatments: intrathecal nusinersen, intravenous onasemnogene abeparvovec-xioi, and enteral risdiplam.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC7819167_20210211_0.5			Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC7819167_20210211_0.5	onasemnogene abeparvovec-xioi	drug_name	Discrete choice experiment|Nusinersen|Onasemnogene abeparvovec-xioi|Patient preferences|Spinal muscular atrophy|Treatment attributes	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC7819167_20210211_0.5	onasemnogene abeparvovec-xioi	drug_name	Child|Humans|Male|Female|United States|Infant|Child, Preschool|Adolescent|Young Adult|Adult|Middle Aged|Aged|onasemnogene abeparvovec-xioi|Muscular Atrophy, Spinal|nusinersen|Oligonucleotides|Spine|Surveys and Questionnaires	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC7819167_20210211_0.5	onasemnogene abeparvovec-xioi	drug_name	Nusinersen and onasemnogene abeparvovec-xioi use were reported in 59 and 10 patients, respectively.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC8107939_20210611_0.5			Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC8107939_20210611_0.5			disability|functional scale|spinal muscular atrophy|treatment	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC8107939_20210611_0.5			Humans|Infant|Zolgensma|Disabled Persons|Motor Disorders|Muscular Atrophy, Spinal|nusinersen|Oligonucleotides|Oligonucleotides, Antisense|Motor Neurons|Genetic Therapy|Drug Approval|Central Nervous System Agents|Genes, Regulator	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC8107939_20210611_0.5	onasemnogene abeparvovec-xioi	drug_name	Recently, 3 disease-modifying therapies have been approved for SMA patients: nusinersen, an intrathecal antisense oligonucleotide enhancing SMN protein production by the SMN2 gene, risdiplam, also influencing the SMN2 gene to stimulate SMN production but administered orally, and onasemnogene abeparvovec-xioi, an SMN1 gene replacement therapy.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32843442_20210411_0.5			Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32843442_20210411_0.5			Adenoviruses, Human|Age Factors|Alanine Transaminase|Aspartate Aminotransferases|Biological Products|Genetic Therapy|Genetic Vectors|Glucocorticoids|Humans|Infant|Ohio|Outcome Assessment, Health Care|Prednisolone|Recombinant Fusion Proteins|Spinal Muscular Atrophies of Childhood|Survival of Motor Neuron 1 Protein|gamma-Glutamyltransferase	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32843442_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	SMA is caused by the absence of the SMN1 gene, and SMN1 gene replacement therapy, onasemnogene abeparvovec-xioi, was Food and Drug Administration approved in May 2019.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32843442_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	However, gene transfer with onasemnogene abeparvovec-xioi has been only studied in children age ≤8 months.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32843442_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	 No section In this population, with thorough screening and careful post-gene transfer management, replacement therapy with onasemnogene abeparvovec-xioi is safe and shows promise for early efficacy.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32204605_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32204605_20210411_0.5			AVXS-101|Zolgensma|onasemnogene|spinal muscular atrophy	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32204605_20210411_0.5			Biological Products|Child, Preschool|Drug Approval|Female|Genetic Therapy|Humans|Mutation|Recombinant Fusion Proteins|Spinal Muscular Atrophies of Childhood|Survival of Motor Neuron 1 Protein|United States|United States Food and Drug Administration	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32204605_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	No section To review the efficacy and safety of onasemnogene abeparvovec-xioi (Zolgensma) in the treatment of spinal muscular atrophy (SMA).	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31037425_20201005_0.5			Current Treatment Options in Neurology-SMA Therapeutics.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31037425_20201005_0.5			Antisense oligonucleotide|Gene therapy|Nusinersen|Spinal muscular atrophy	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31037425_20201005_0.5			Humans|Muscular Atrophy, Spinal|nusinersen|Oligonucleotides|Oligonucleotides, Antisense|Neurology	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31037425_20201005_0.5	onasemnogene abeparvovec-xioi	drug_name	We discuss the evidence leading to the approval of nusinersen and the evidence leading to the anticipated approval of onasemnogene abeparvovec-xioi.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33959970_20210611_0.5			Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33959970_20210611_0.5			SMA|gene replacement|preterm|spinal muscular atrophy|treatment	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33959970_20210611_0.5			Infant|United States|Humans|Infant, Newborn|Zolgensma|Infant, Premature|Muscular Atrophy, Spinal|Spinal Muscular Atrophies of Childhood|Genetic Therapy|United States Food and Drug Administration|Neonatal Screening|Musculoskeletal System|Motor Neurons|Muscles|Time	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33959970_20210611_0.5	onasemnogene abeparvovec-xioi	drug_name	The US Food and Drug Administration does not recommend using onasemnogene abeparvovec-xioi in preterm infants.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33938671_20210511_0.5			[Consensus statement of the Hungarian Clinical Neurogenic Society about the therapy of adult SMA patients].	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33938671_20210511_0.5	onasemnogene abeparvovec-xioi	drug_name	onasemnogene abeparvovec-xioi|risdiplam|spinal muscular atrophy|spinal muscular atrophy (SMA)|therapy	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33938671_20210511_0.5			Adult|Child|Consensus|Humans|Hungary|Muscular Atrophy, Spinal|Prospective Studies|Retrospective Studies	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32886442_20210411_0.5			Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32886442_20210411_0.5			antisense oligonucleotide|genetic therapy|neuromuscular diseases|review	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32886442_20210411_0.5			United States|Humans|Female|Muscular Dystrophy, Duchenne|Zolgensma|Muscular Atrophy, Spinal|Oligonucleotides, Antisense|Genetic Therapy|Morpholinos|Exons|RNA Splicing|Motor Neurons	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32886442_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	We review the transformative work from clinical trials to United States Food and Drug Administration approval of onasemnogene abeparvovec-xioi in SMA and its application in clinical practice and the early results of microdystrophin delivery in DMD.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC6822795_20201005_0.5			Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164–76. doi:10.1007/s12325-019-00923-8	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC6822795_20201005_0.5	onasemnogene abeparvovec-xioi	drug_name	AVXS-101|Onasemnogene abeparvovec-xioi|Spinal muscular atrophy|NNT|Nusinersen	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMC6822795_20201005_0.5			Humans|Infant|Muscular Atrophy, Spinal|Oligonucleotides	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33003005_20210511_0.5			Spinal Muscular Atrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33003005_20210511_0.5			Infant|Infant, Newborn|United States|Humans|Muscular Atrophy, Spinal|Spinal Muscular Atrophies of Childhood|Genetic Therapy|United States Food and Drug Administration|Oligonucleotides	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33003005_20210511_0.5	onasemnogene abeparvovec-xioi	drug_name	 No section Over the past decades, an understanding of the role of SMN protein in the development and maintenance of the motor unit and the intricate genetics underlying SMA has led to striking developments in therapeutics with three FDA-approved treatments for SMA, one targeting SMN1 gene replacement (onasemnogene abeparvovec-xioi) and two others enhancing SMN protein production from the SMN2 gene (nusinersen and risdiplam).	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32710634_20210411_0.5			Combination molecular therapies for type 1 spinal muscular atrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32710634_20210411_0.5			SMA|combine|gene therapy|nusinersen|onasemnogene	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32710634_20210411_0.5			Biological Products|Child, Preschool|Drug Therapy, Combination|Female|Humans|Infant|Male|Oligonucleotides|Recombinant Fusion Proteins|Retrospective Studies|Spinal Muscular Atrophies of Childhood|Treatment Outcome	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32710634_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	 No section Five children received nusinersen and onasemnogene abeparvovec-xioi (onasemnogene).	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32703464_20201214_0.5			Spinal Muscular Atrophy in the Treatment Era.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32703464_20201214_0.5	onasemnogene abeparvovec-xioi	drug_name	Multidisciplinary care|Newborn screen|Nusinersen|Onasemnogene abeparvovec-xioi|Spinal muscular atrophy	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID32703464_20201214_0.5			Activities of Daily Living|Adolescent|Adult|Female|Gene Transfer Techniques|Humans|Infant|Infant, Newborn|Male|Muscular Atrophy, Spinal|Neonatal Screening|Oligonucleotides	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31270752_20201005_0.5			Onasemnogene Abeparvovec: First Global Approval.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31270752_20201005_0.5			Dependovirus|Drug Approval|Genetic Therapy|Genetic Vectors|Humans|Infant|Infant, Newborn|Infusions, Intravenous|Motor Neurons|Muscular Atrophy, Spinal|Mutation|SMN Complex Proteins|United States|United States Food and Drug Administration	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31270752_20201005_0.5	onasemnogene abeparvovec-xioi	drug_name	No section Onasemnogene abeparvovec (onasemnogene abeparvovec-xioi; formerly AVXS-101; ZOLGENSMA®) is an adeno-associated viral vector-based gene therapy designed to deliver a functional copy of the human survival motor neuron (SMN) gene to the motor neuron cells of patients with spinal muscular atrophy (SMA).	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33130193_20210411_0.5			Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33130193_20210411_0.5			Autosomal-recessive disorder|Duchenne muscular dystrophy|Dystrophin protein|SMN1 gene|Spinal muscular atrophy	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33130193_20210411_0.5			Humans|Male|Middle Aged|Adult|viltolarsen|Muscular Dystrophy, Duchenne|golodirsen|Zolgensma|Muscular Atrophy, Spinal|Oligonucleotides|nusinersen|Spinal Muscular Atrophies of Childhood|eteplirsen|Morpholinos|Oligonucleotides, Antisense|Dystrophin|Genetic Therapy|Phenotype|Gene Deletion	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID33130193_20210411_0.5	onasemnogene abeparvovec-xioi	drug_name	Furthermore, drug therapies including injectables such as onasemnogene abeparvovec-xioi (ZOLGENSMA®), nusinersen (SPINRAZA®), and an oral-solution, risdiplam (EVRYSDITM), are medications that have been FDA-approved for the treatment of SMA.	abstract
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31870859_20201005_0.5	onasemnogene abeparvovec-xioi	drug_name	Siponimod, onasemnogene abeparvovec-xioi, and brexanolone.	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31286145_20201005_0.5			[Gene therapies for neuromuscular diseases].	title
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31286145_20201005_0.5			Duchenne muscular dystrophy|Gene therapy|Neuromuscular diseases|Spinal muscular atrophy	author_keywords
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31286145_20201005_0.5			Genetic Therapy|Humans|Neuromuscular Diseases	mesh_terms
onasemnogene abeparvovec-xioi	C5140521				trade_name	PubMed	PMID31286145_20201005_0.5	onasemnogene abeparvovec-xioi	drug_name	Initial preliminary results are promising and the first preparation onasemnogene abeparvovec-xioi (Zolgensma®) for the treatment of spinal muscular atrophy has recently been approved by the U.S. Food and Drug Administration (FDA).	abstract
ROTAVIRUS VACCINE, LIVE	C0795661				inn	PubMed	PMID19155881_20201005_0.5	rotavirus vaccine, live	drug_name	Drug approvals: '08 in review. Rotavirus vaccine, live, oral (Rotarix).	title
ROTAVIRUS VACCINE, LIVE	C0795661				inn	PubMed	PMID19155881_20201005_0.5			Humans|Rotavirus Vaccines|Vaccines, Attenuated	mesh_terms
ROTAVIRUS VACCINE, LIVE	C0795661				inn	PubMed	PMID22294581_20201005_0.5			Adventitious Agent Risk Assessment Case Study: Evaluation of RotaTeq(R) for the Presence of Porcine Circovirus.	title
ROTAVIRUS VACCINE, LIVE	C0795661				inn	PubMed	PMID22294581_20201005_0.5			Biological Products|Biomedical Research|Circovirus|Humans|Polymerase Chain Reaction|Risk Assessment	mesh_terms
ROTAVIRUS VACCINE, LIVE	C0795661				inn	PubMed	PMID22294581_20201005_0.5	rotavirus vaccine, live	drug_name	This testing did not detect any sequences of contaminating viruses in RotaTeq® (rotavirus vaccine, live, oral, pentavalent, RV5, Merck & Co., Inc., Whitehouse Station, NJ).	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4883197_20210511_0.5			Can a Compact Pre-Filled Auto-Disable Injection System (cPAD) Save Costs for DTP-HepB-Hib Vaccine as Compared with Single-Dose (SDV) and Multi-Dose Vials (MDV)? Evidence from Cambodia, Ghana, and Peru	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4883197_20210511_0.5	diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	drug_name	Child|Humans|Haemophilus influenzae type b|Cambodia|Ghana|Peru|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Vaccines, Combined|Vaccination|Immunization Programs|Hepatitis B Vaccines|Vaccines, Conjugate|Costs and Cost Analysis	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4751340_20201005_0.5			Oral Polio Vaccination and Hospital Admissions With Non-Polio Infections in Denmark: Nationwide Retrospective Cohort Study	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4751340_20201005_0.5			heterologous immunity|immunization|nonspecific effects|nontargeted effects|oral polio vaccination	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4751340_20201005_0.5	diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	drug_name	Child|Male|Infant|Humans|Female|Retrospective Studies|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine|Poliovirus Vaccine, Inactivated|Poliovirus Vaccine, Oral|Poliomyelitis|Measles-Mumps-Rubella Vaccine|Vaccines, Combined|Diphtheria-Tetanus-acellular Pertussis Vaccines|Hepatitis B Vaccines|Vaccines, Conjugate|Vaccines, Attenuated|Hospitalization|Vaccines, Inactivated|Vaccination|Denmark	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID20212950_20201005_0.5			Effect of reminder notices on the timeliness of early childhood immunizations.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID20212950_20201005_0.5			Childhood|Immunization|Reminder notice	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID20212950_20201005_0.5	diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	drug_name	Child, Preschool|Male|Humans|Female|Child|Prospective Studies|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Poliovirus Vaccine, Inactivated|Measles-Mumps-Rubella Vaccine|Immunization Schedule|Vaccination|Immunization, Secondary|Immunization Programs	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5			The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5			Non-specific vaccine effects|Measles|DTP|Nasopharyngeal bacterial carriage	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5	diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	drug_name	Child|Infant|Male|Humans|Female|Longitudinal Studies|Nasopharynx|Haemophilus influenzae type b polysaccharide vaccine|Haemophilus Vaccines|Pneumococcal Infections|Pneumococcal Vaccines|Streptococcus pneumoniae|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Vaccines, Conjugate|Haemophilus influenzae|Haemophilus Infections|Carrier State|Moraxella (Branhamella) catarrhalis|Prevalence|Staphylococcus aureus|Vaccination|Diphtheria-Tetanus-Pertussis Vaccine|Bacterial Capsules|Gambia	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC6406170_20201005_0.5			Clinical study of safety and immunogenicity of pentavalent DTP-HB-Hib vaccine administered by disposable-syringe jet injector in India	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC6406170_20201005_0.5			DTP-HB-Hib vaccine|Jet injector|DSJI|Vaccine adjuvant|Immunogenicity|Injection site reactions	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC6406170_20201005_0.5	diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	drug_name	United States|Child|Infant|Male|Humans|Adolescent|Female|Haemophilus influenzae type b|Syringes|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Tetanus|Diphtheria|Whooping Cough|Vaccination|Hepatitis B|India	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC3373025_20201005_0.5			Haemophilus influenzae Type b Reemergence after Combination Immunization	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC3373025_20201005_0.5			Haemophilus influenzae type b|haemophilus vaccines|antibody avidity|diphtheria-tetanus-acellular pertussis vaccines|antibodies|carrier state/epidemiology|research	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC3373025_20201005_0.5			Antibodies, Viral|Antibody Affinity|Bacterial Capsules|Child, Preschool|Diphtheria-Tetanus-acellular Pertussis Vaccines|Haemophilus Infections|Haemophilus Vaccines|Haemophilus influenzae type b|Humans|Immunization|Pharynx|Polysaccharides, Bacterial|Statistics, Nonparametric|United Kingdom|Vaccines, Conjugate	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC3373025_20201005_0.5	dtp-hib	drug_umls_atom	We measured anti-polyribosyl-ribitol phosphate antibody concentration and avidity before and after a Hib booster in 176 children 2-4 years of age who had received 3 doses of DTP-Hib (either DT whole cell pertussis-Hib or DTaP-Hib) combination vaccine in infancy.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7483772_20201005_0.5			Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7483772_20201005_0.5			Animals|Antibodies, Bacterial|Bacterial Capsules|Diphtheria-Tetanus-Pertussis Vaccine|Dose-Response Relationship, Drug|Female|Guinea Pigs|Haemophilus Vaccines|Immunization, Secondary|Polysaccharides, Bacterial|Tetanus Toxoid|Vaccines, Conjugate	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7483772_20201005_0.5	dtp-hib	drug_umls_atom	We propose that the guinea pig model may be useful to verify the immunogenicity of PRP conjugate vaccines and for pre-clinical evaluations of DTP-Hib combination vaccines containing PRP conjugates.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID17289221_20201005_0.5			Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID17289221_20201005_0.5			Antibodies, Bacterial|Dietary Supplements|Female|Heptavalent Pneumococcal Conjugate Vaccine|Humans|Immunization|Infant|Male|Meningococcal Vaccines|Pneumococcal Vaccines|Zinc	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID17289221_20201005_0.5	dtp-hib	drug_umls_atom	Titres were significantly higher for infants who had received PNC compared to infants who had only received DTP-Hib.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC5947506_20201005_0.5			Compliance with the vaccination schedule in children hospitalized with pneumonia and associated factors	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC5947506_20201005_0.5			Criança|Pacientes Internados|Pneumonia, epidemiologia|Cobertura Vacinal|Programas de Imunização	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC5947506_20201005_0.5			Adult|Brazil|Child, Preschool|Cross-Sectional Studies|Female|Hospitalization|Humans|Immunization Programs|Infant|Male|Pneumococcal Vaccines|Pneumonia|Prevalence|Risk Factors|Severity of Illness Index|Socioeconomic Factors|Vaccination|Young Adult	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC5947506_20201005_0.5	dtp-hib	drug_umls_atom	OBJECTIVE: To verify the adequacy and factors associated with compliance with the immunization schedule (BCG, DTP-Hib, MMR, PCV-10) in children hospitalized with pneumonia at a pediatric referral hospital in Northeast Brazil.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID19838618_20201005_0.5			Effect of probiotic supplementation on immunoglobulins, isoagglutinins and antibody response in children of low socio-economic status.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID19838618_20201005_0.5			Agglutinins|Antibody Formation|Child|Child, Preschool|Dietary Supplements|Double-Blind Method|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunoglobulins|Infant|Lactobacillus acidophilus|Lactobacillus casei|Male|Probiotics|Socioeconomic Factors|Streptococcus thermophilus	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID19838618_20201005_0.5	dtp-hib	drug_umls_atom	According to their age, children were vaccinated with DTP-Hib vaccine or a 23-valent anti-pneumococcal vaccine.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5			The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5			Non-specific vaccine effects|Measles|DTP|Nasopharyngeal bacterial carriage	author_keywords
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5			Child|Infant|Male|Humans|Female|Longitudinal Studies|Nasopharynx|Haemophilus influenzae type b polysaccharide vaccine|Haemophilus Vaccines|Pneumococcal Infections|Pneumococcal Vaccines|Streptococcus pneumoniae|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Vaccines, Conjugate|Haemophilus influenzae|Haemophilus Infections|Carrier State|Moraxella (Branhamella) catarrhalis|Prevalence|Staphylococcus aureus|Vaccination|Diphtheria-Tetanus-Pertussis Vaccine|Bacterial Capsules|Gambia	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5	dtp-hib	drug_umls_atom	The presence of bacteria in the nasopharynx (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus ) was compared before and after the administration of DTP-Hib-HepB and measles-yellow fever vaccines.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5	dtp-hib	drug_umls_atom	Carriage of H. influenzae (OR = 0.36; 95% CI: 0.13, 0.99) and S. pneumoniae (OR = 0.25; 95% CI: 0.07, 0.90) were significantly reduced after measles-yellow fever vaccination; while DTP-Hib-HepB had no effect on bacterial carriage.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4312604_20201005_0.5	dtp-hib	drug_umls_atom	 Conclusions Nasopharyngeal bacterial carriage is unaffected by DTP-Hib-HepB vaccination and reduced after measles-yellow fever vaccination.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID23313652_20201005_0.5			Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID23313652_20201005_0.5			Brazil|Child, Preschool|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Haemophilus influenzae|Humans|Immunization Programs|Immunization Schedule|Infant|Male|Membrane Glycoproteins|Rotavirus|Rotavirus Vaccines|Vaccination	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID23313652_20201005_0.5	dtp-hib	drug_umls_atom	 METHODS We analyzed data from Brazil's national immunization program on uptake of oral rotavirus vaccine by geographic region and compared administrative coverage estimates for first and second doses of oral rotavirus vaccine (Rota1 and Rota2) with first and second doses of diphtheria-tetanus-pertussis-Haemophilus influenzae type b vaccine (DTP-Hib1 and DTP-Hib2).	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID23313652_20201005_0.5	dtp-hib	drug_umls_atom	For 27 Brazilian cities, we compared differences between estimated rotavirus and DTP-Hib coverage in 2010 with delayed receipt of DTP-Hib vaccine among a cohort of children surveyed before rotavirus introduction.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID23313652_20201005_0.5	dtp-hib	drug_umls_atom	 RESULTS In 2010, infant vaccination coverage was 99.0% for DTP-Hib1 versus 95.2% for Rota1 (3.8% difference), and 98.4% for DTP-Hib2 versus 83.0% for Rota2 (15.4% difference), with substantial regional variation.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID23313652_20201005_0.5	dtp-hib	drug_umls_atom	Differences between DTP-Hib and rotavirus vaccination coverage in Brazilian cities correlated with delay in DTP-Hib vaccination among children surveyed.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7779362_20201005_0.5			Control testing of combined vaccines: a consideration of potential problems and approaches.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7779362_20201005_0.5			Bacterial Vaccines|Clinical Trials as Topic|Diphtheria Toxin|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Humans|Models, Molecular|Neisseria meningitidis|Protein Conformation|Vaccines, Combined	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7779362_20201005_0.5	dtp-hib	drug_umls_atom	No section Vaccines comprising combinations of diphtheria, tetanus and pertussis (DTP) components with Haemophilus influenzae b polysaccharide--protein conjugates (DTP-Hib) are now available.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7779362_20201005_0.5	dtp-hib	drug_umls_atom	Combinations of DTP-Hib with additional components such as inactivated poliomyelitis vaccine, hepatitis B vaccine, meningococcal and pneumococcal polysaccharide-protein conjugates are under development.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID7779362_20201005_0.5	dtp-hib	drug_umls_atom	Indications of this have already arisen with some DTP-Hib combinations but are likely to increase as additional components are added.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4489587_20201005_0.5			Vaccination Coverage and Compliance with Three Recommended Schedules of 10-Valent Pneumococcal Conjugate Vaccine during the First Year of Its Introduction in Brazil: A Cross-Sectional Study	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4489587_20201005_0.5			Brazil|Cross-Sectional Studies|Guideline Adherence|Humans|Immunization Schedule|Infant|Pneumococcal Vaccines	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4489587_20201005_0.5	dtp-hib	drug_umls_atom	Coverage of DTP-Hib was used for comparison purposes.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMC4489587_20201005_0.5	dtp-hib	drug_umls_atom	Overall, vaccination coverage was 54.6% (95% CI 52.1-57.7%), lower than DTP-Hib coverage (93.0%; 95% CI 91.5-94.3%).	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID11282204_20201005_0.5			Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID11282204_20201005_0.5			Antibodies, Bacterial|Female|Humans|Immunoglobulin G|Infant|Male|Meningococcal Vaccines|Neisseria meningitidis|Serotyping|Vaccines, Conjugate	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID11282204_20201005_0.5	dtp-hib	drug_umls_atom	Local reactions were less frequent at the MenC injection site than at the DTP-Hib site.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID15779786_20201005_0.5			General practitioners' concerns about childhood immunisation and suggestions for improving professional support and vaccine uptake.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID15779786_20201005_0.5			Attitude of Health Personnel|Attitude to Health|Family Practice|Female|Health Care Surveys|Humans|Immunization|Information Dissemination|Male|Measles-Mumps-Rubella Vaccine|Practice Patterns, Physicians'|Scotland	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID15779786_20201005_0.5	dtp-hib	drug_umls_atom	Of GPs 98% thought it was 'likely' that the benefits of the DTP-Hib, polio and men C vaccines outweighed the possible risks.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID15779786_20201005_0.5	dtp-hib	drug_umls_atom	Approximately three quarters of GPs described themselves 'very confident' in discussing the DTP-Hib vaccine with parents, compared with 57% for MMR.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID22230581_20201005_0.5			Measles control in Sub-Saharan Africa: South Africa as a case study.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID22230581_20201005_0.5			Humans|Immunization|Immunization Programs|Measles|Measles Vaccine|South Africa	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID22230581_20201005_0.5	dtp-hib	drug_umls_atom	The data included routine immunization for 1st and 2nd doses of measles vaccine (MCV1, MCV2), SIAs, 1st dose of Bacille Calmette-Guérin vaccine, 1st and 3rd doses of oral polio vaccine (OPV1, OPV3), 3rd dose of Diphtheria-Tetanus-Pertussis-Haemophilus-influenzae-B vaccine (DTP-Hib3), and the number of under-one-year-olds having completed a primary course of immunization (Imm1).	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID22230581_20201005_0.5	dtp-hib	drug_umls_atom	In any given year, occurrence of SIAs was associated with a decrease in routine immunization coverage of MCV1, MCV2, OPV1, OPV3, DTP-Hib3, and Imm1, at the district level.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16670121_20201005_0.5			Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16670121_20201005_0.5			Diphtheria-Tetanus-Pertussis Vaccine|Diphtheria-Tetanus-acellular Pertussis Vaccines|Dose-Response Relationship, Immunologic|Haemophilus Vaccines|Humans|Infant|Influenza Vaccines|Meningococcal Vaccines|Poliovirus Vaccine, Inactivated|Vaccines, Conjugate	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16670121_20201005_0.5	dtp-hib	drug_umls_atom	Coadministration of MCC vaccine can influence the Hib response, and the MCC response to a tetanus conjugate can be influenced by the nature of the coadministered DTP-Hib vaccine.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID12443662_20201005_0.5			Occurrence of adverse events following inadvertent administration of childhood vaccines.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID12443662_20201005_0.5			Adolescent|Adverse Drug Reaction Reporting Systems|Child|Child, Preschool|Female|Humans|Infant|Male|Medication Errors|Seizures|Vaccines	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID12443662_20201005_0.5	dtp-hib	drug_umls_atom	Five of these six cases involved a DTP-containing vaccine: one case where DTP was given instead of diphtheria and tetanus toxoid (DT) vaccine as a pre-school booster, one case where a fourth dose of DTP-Haemophilus influenzae type b conjugate vaccine (Hib) was given at 20 weeks of age and three cases where DTP was mixed with DTP-Hib.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16621858_20201005_0.5			The effect of zinc supplementation during pregnancy on immune response to Hib and BCG vaccines in Bangladesh.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16621858_20201005_0.5			Antibodies, Bacterial|BCG Vaccine|Bangladesh|Dietary Supplements|Female|Haemophilus Infections|Haemophilus Vaccines|Humans|Immunity|Infant, Newborn|Male|Pregnancy|Tuberculosis|Zinc	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16621858_20201005_0.5	dtp-hib	drug_umls_atom	A subcohort of 203 infants were in addition immunized at 1-month intervals with three doses of DTP-Hib vaccine starting at 9 weeks of age.	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID17316928_20201005_0.5			Rates of contraindications and use of alternative vaccines in routine immunisation of children: a population based study in the Czech Republic.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID17316928_20201005_0.5			Child|Child, Preschool|Contraindications|Czech Republic|Humans|Immunization|Immunization Programs|Medical Records|Parental Consent|Population Surveillance|Refusal to Participate|Vaccination	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID17316928_20201005_0.5	dtp-hib	drug_umls_atom	Contraindications were most commonly reported for the DTP-Hib vaccine (263 children, 5.2%), and the most frequent type were central nervous system disorders (171 cases).	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID9489191_20201005_0.5			Fragmentation of scheduled visits and missed doses among infants receiving multiple injected vaccines.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID9489191_20201005_0.5			Australia|Bacterial Capsules|Cohort Studies|Diphtheria-Tetanus-Pertussis Vaccine|Dose-Response Relationship, Drug|Female|Haemophilus Vaccines|Hepatitis B Vaccines|Humans|Immunization Schedule|Infant|Infant, Newborn|Injections, Intramuscular|Male|Office Visits|Patient Compliance|Patient Dropouts|Polysaccharides, Bacterial|Retrospective Studies|Surveys and Questionnaires|Vaccination	mesh_terms
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID9489191_20201005_0.5	dtp-hib	drug_umls_atom	Infants in the latter group received the first DTP-Hib dose on average one week later than did those not in the hepatitis B program (DTP, P = 0.016; Hib, P = 0.047).	abstract
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16303216_20201005_0.5	dtp-hib	drug_umls_atom	Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.	title
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine	C0215600			dtp-hib	inn	PubMed	PMID16303216_20201005_0.5			Antibodies, Bacterial|Diphtheria-Tetanus-Pertussis Vaccine|Double-Blind Method|Fever|Haemophilus Infections|Haemophilus Vaccines|Haemophilus influenzae type b|Humans|Immunization, Secondary|Indonesia|Infant|Pentosephosphates|Polysaccharides, Bacterial|Tetanus Toxoid|Vaccines, Conjugate	mesh_terms
e-z-hd	Z0000014038				trade_name	PubMed	PMID6467823_20201005_0.5			A comparison of two high-density barium sulphate preparations for double-contrast barium meals.	title
e-z-hd	Z0000014038				trade_name	PubMed	PMID6467823_20201005_0.5			Barium Sulfate|Contrast Media|Digestive System|Humans|Radiography	mesh_terms
e-z-hd	Z0000014038				trade_name	PubMed	PMID6467823_20201005_0.5	e-z-hd	drug_name	No section The mucosal coating properties, liability to bubble formation and palatability of a new barium sulphate suspension (Micropaque HD) were compared with those of the barium suspension shown by previous trials to produce the best results (E-Z-HD).	abstract
e-z-hd	Z0000014038				trade_name	PubMed	PMID6467823_20201005_0.5	e-z-hd	drug_name	The results show that E-Z-HD gave significantly better mucosal coating and was less liable to bubble formation.	abstract
e-z-hd	Z0000014038				trade_name	PubMed	PMID7067341_20201005_0.5	e-z-hd	drug_name	Double contrast barium meal examination: a comparison of two high density barium preparations, E-Z-HD and X-Opaque.	title
e-z-hd	Z0000014038				trade_name	PubMed	PMID7067341_20201005_0.5			Barium Sulfate|Gastric Mucosa|Humans|Radiography|Stomach	mesh_terms
e-z-hd	Z0000014038				trade_name	PubMed	PMID6725592_20201005_0.5			Varied light and scanning electron microscopic appearances of barium sulphate in smears and histological sections.	title
e-z-hd	Z0000014038				trade_name	PubMed	PMID6725592_20201005_0.5			Barium Sulfate|Birefringence|Digestive System|Electron Probe Microanalysis|Gastrointestinal Diseases|Humans|Microscopy, Electron, Scanning|Particle Size|Radiography	mesh_terms
e-z-hd	Z0000014038				trade_name	PubMed	PMID6725592_20201005_0.5	e-z-hd	drug_name	One type of barium sulphate (E-Z-HD) includes much larger, bright birefringent particles and has very different appearances from other widely used types.	abstract
e-z-hd	Z0000014038				trade_name	PubMed	PMC7879210_20210311_0.5			Hip Adductor Longus Tendon Origin Anatomy Is Consistent and May Inform Surgical Reattachment	title
e-z-hd	Z0000014038				trade_name	PubMed	PMC7879210_20210311_0.5			Humans|Female|Adult|Tomography, X-Ray Computed|Tendons|Thigh|Pubic Bone|Muscle, Skeletal|Pubic Symphysis|Cadaver	mesh_terms
e-z-hd	Z0000014038				trade_name	PubMed	PMC7879210_20210311_0.5	e-z-hd	drug_name	11150 Island Blue; Rust-Oleum Corp, Vernon Hills, IL) with 15g of E-Z-HD 98% w/w barium sulfate (Bracco Diagnostics Inc., Anjou Quebec, Canada) and applied to the marked footprint.	abstract
e-z-hd	Z0000014038				trade_name	PubMed	PMID3510043_20201005_0.5			The effect of barium suspension viscosity on the delineation of areae gastricae.	title
e-z-hd	Z0000014038				trade_name	PubMed	PMID3510043_20201005_0.5			Barium Sulfate|Clinical Trials as Topic|Double-Blind Method|Female|Gastric Mucosa|Gastritis|Humans|Male|Middle Aged|Peptic Ulcer|Radiography|Stomach Ulcer|Viscosity|Water	mesh_terms
e-z-hd	Z0000014038				trade_name	PubMed	PMID3510043_20201005_0.5	e-z-hd	drug_name	A double-blind trial involving 600 patients used E-Z-HD of the same batch number suspended with 65-70 ml water.	abstract
Denti Care	C1612479			denti-care	trade_name	PubMed	PMID21434729_20201005_0.5			The effect of laser-activated Acidulated Phosphate Fluoride on enamel submitted to erosive solution only: an in vitro preliminary evaluation.	title
Denti Care	C1612479			denti-care	trade_name	PubMed	PMID21434729_20201005_0.5			Acidulated Phosphate Fluoride|Cariostatic Agents|Combined Modality Therapy|Dental Enamel|Hardness|Humans|Laser Therapy|Lasers, Solid-State|Molar, Third|Statistics, Nonparametric|Tooth Demineralization|Tooth Erosion	mesh_terms
Denti Care	C1612479			denti-care	trade_name	PubMed	PMID21434729_20201005_0.5	denti-care	drug_umls_atom	Group 2, positive control group: only 1.23% APF gel (Denti-Care gel, Medicom) 1 minute application.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5	golytely	drug_synonym	Comparison of Golytely lavage with standard diet/cathartic preparation for double-contrast barium enema.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5			Adult|Barium Sulfate|Bisacodyl|Cathartics|Diet|Electrolytes|Enema|Female|Humans|Male|Middle Aged|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5	golytely	drug_synonym	In part 1, a standard 1-day diet/cathartic combination was compared with Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5	golytely	drug_synonym	In part 2, diet/cathartics was compared with Golytely plus Dulcolax (bisacodyl).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5	golytely	drug_synonym	Golytely alone was successful in only 21 (53%) of 40 patients, but Golytely followed by Dulcolax achieved good or excellent feces removal in 31 (82%) of 38.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5	golytely	drug_synonym	Degraded mucosal coating with Golytely alone, due to excessive fluid retention, was also corrected by the addition of Dulcolax.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6609598_20201005_0.5	golytely	drug_synonym	Golytely alone is not an adequate method of colon cleansing for double-contrast barium enema, but Golytely plus Dulcolax is as effective as the standard preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1977339_20201005_0.5			Whole-bowel irrigation as treatment for zinc sulfate overdose.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1977339_20201005_0.5			Administration, Rectal|Adolescent|Electrolytes|Gastric Lavage|Humans|Ipecac|Male|Poisoning|Polyethylene Glycols|Suicide, Attempted|Sulfates|Therapeutic Irrigation|Urography|Zinc|Zinc Sulfate	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1977339_20201005_0.5	golytely	drug_synonym	Whole-bowel irrigation was begun with a polyethylene glycol lavage solution (PEG; Golytely) that was administered through a nasogastric tube; within one hour, the patient began producing a rectal effluent that contained pills.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2214653_20201005_0.5			[The effect of various cleansing methods for total fiber optic colonoscopy].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2214653_20201005_0.5			Adult|Barium Sulfate|Colonic Neoplasms|Colonoscopy|Enema|Female|Fiber Optic Technology|Humans|Male|Optical Fibers|Rectal Neoplasms|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2214653_20201005_0.5	golytely	drug_synonym	In conclusion, we believe that the Golytely of the mechanical cleansing solution for fiber optic colonoscopy was the most effective, but others depended on the patient's condition and bowel habit.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2209499_20201005_0.5	golytely	drug_synonym	Golytely preparation for colonoscopy: 1.5 liters is enough for outpatients.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2209499_20201005_0.5			Adult|Aged|Colonoscopy|Electrolytes|Humans|Middle Aged|Outpatients|Patient Acceptance of Health Care|Polyethylene Glycols|Prospective Studies|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2209499_20201005_0.5	golytely	drug_synonym	No section In a prospective double-blind study of the effectiveness and patient acceptance of Golytely whole-gut preparation for colonoscopy, 50 consecutive patients were randomly allocated to drink either 1.5 l (Group I) or 3 l (Group II).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2209499_20201005_0.5	golytely	drug_synonym	After completion of the randomized study, oral cleansing with 1.5 l Golytely has been our daily routine.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8724255_20201214_0.5			Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8724255_20201214_0.5			Anti-Bacterial Agents|Child, Preschool|Chronic Disease|Clostridium difficile|Combined Modality Therapy|Electrolytes|Enterocolitis, Pseudomembranous|Female|Humans|Infant|Intestines|Male|Polyethylene Glycols|Recurrence|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8724255_20201214_0.5	golytely	drug_synonym	No section We report the successful treatment of two patients with chronic, intractable Clostridium difficile infection using whole-bowel irrigation with a polyethylene glycol solution (Golytely) as adjunctive therapy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5			A low-sodium solution for gastrointestinal lavage.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5			Colon|Electrolytes|Humans|Polyethylene Glycols|Solutions|Sulfates|Taste|Therapeutic Irrigation|Water-Electrolyte Balance	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	No section Golytely is a sodium sulfate-based solution used for lavage cleansing of the colon.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	Although most patients and physicians prefer Golytely lavage over other methods of bowel cleansing, its highly salty taste is a drawback.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	Golytely, reduced sodium sulfate Golytely (Golytely-RSS), and a balanced electrolyte solution were infused into the stomachs of normal subjects.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	Average fluid absorption rate was 791 ml/h with the balanced electrolyte solution, compared with only 63 and 45 ml/h with Golytely and Golytely-RSS, respectively.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	Golytely-RSS was studied at 3 infusion rates, from 0.9-1.8 L/h, and the time and volume of solution required for colon cleansing was determined; the lower infusion rate (0.9 L/h) took longer but required less solution to cleanse the colon.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	In conclusion, Golytely-RSS has the essential feature of Golytely; i.e., lavage is associated with negligible salt and water absorption.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2293568_20201005_0.5	golytely	drug_synonym	The less-salty taste of Golytely-RSS may make it less difficult to drink and thereby enhance patient compliance; the total volume of solution required for cleansing is less when the solution is ingested at 0.9 L/h than when the ingestion rate is 1.8 L/h.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5	golytely	drug_synonym	MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5			Adult|Aged|Aged, 80 and over|Colonoscopy|Electrolytes|Female|Humans|Male|Mass Screening|Middle Aged|Polyethylene Glycols|Preoperative Care|Prospective Studies|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5	golytely	drug_synonym	We compared split-dose (PEG) 3350 with electrolytes (GoLytely; Braintree Laboratories, Inc, Braintree, MA) with split-dose MiraLAX alone and in combination with pretreatment medications (bisacodyl or lubiprostone) to determine the efficacy and patient tolerability of MiraLAX as an agent for bowel preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5	golytely	drug_synonym	Patients (n=403) were randomly assigned to groups given GoLytely, MiraLAX, MiraLAX with bisacodyl (10 mg), or MiraLAX with lubiprostone (24 μg).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5	golytely	drug_synonym	 RESULTS GoLytely was more effective at bowel cleansing (average Ottawa score, 5.1) than MiraLAX alone (average Ottawa score, 6.9) or in combination with lubiprostone (average Ottawa score, 6.8), or bisacodyl (average Ottawa score, 6.3) (P<.001).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5	golytely	drug_synonym	Groups given MiraLAX rated the overall experience as more satisfactory than those given GoLytely (P<.001).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21115134_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS Split-dose MiraLAX in 64 oz of Gatorade is not as effective as 4 L split-dose GoLytely in bowel cleansing for screening colonoscopies.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2927514_20201005_0.5	golytely	drug_synonym	Patient acceptance and cleansing effectiveness of Golytely for colon surgery.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2927514_20201005_0.5			Adult|Aged|Cathartics|Colon|Electrolytes|Enema|Female|Humans|Male|Middle Aged|Patient Acceptance of Health Care|Polyethylene Glycols|Preoperative Care|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1397914_20201005_0.5			Serum electrolyte, mineral, and blood pH changes after phosphate enema, water enema, and electrolyte lavage solution enema for flexible sigmoidoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1397914_20201005_0.5			Calcium|Double-Blind Method|Electrolytes|Enema|Female|Humans|Hydrogen-Ion Concentration|Male|Middle Aged|Phosphates|Phosphorus|Polyethylene Glycols|Sigmoidoscopy|Solutions|Water	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1397914_20201005_0.5	golytely	drug_synonym	The purpose of this study was to compare the serum electrolytes, mineral, and blood pH changes before and after the administration of Fleet with water and polyethylene glycol electrolyte lavage solution (Golytely) as enemas in an adult population undergoing flexible sigmoidoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1397914_20201005_0.5	golytely	drug_synonym	Sixty-six patients were randomized in a double-blind fashion to receive two enemas of either Fleet (N = 22), water (N = 20), or Golytely (N = 24).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1397914_20201005_0.5	golytely	drug_synonym	The Fleet had significantly better optimal cleansing efficacy compared with water (p < 0.05) but not to Golytely (p > 0.05).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1397914_20201005_0.5	golytely	drug_synonym	There was a significant increase in the serum phosphorus in the Fleet group compared with water (p < 0.001) or Golytely (p < 0.001).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID17147088_20201005_0.5			The bowel cleansing for colonoscopy. A randomized trial comparing three methods.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID17147088_20201005_0.5			Aged|Anthraquinones|Bisacodyl|Cathartics|Chi-Square Distribution|Colonoscopy|Electrolytes|Female|Humans|Magnesium Sulfate|Male|Middle Aged|Patient Compliance|Phosphates|Polyethylene Glycols|Preoperative Care|Senna Extract|Sennosides|Solutions|Solvents	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID17147088_20201005_0.5	golytely	drug_synonym	Constipated patients had a significantly better cleansing with Sodium Phosphate preparation compared with senna plus Magnesium Sulphate (p = 0.017), but not significantly better compared with Golytely solution.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29913465_20201005_0.5			In brief: Auvi-Q epinephrine auto-injector for infants and toddlers.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29913465_20201005_0.5	golytely	drug_synonym	1547b|Auvi-Q|Bi-Peglyte|Colyte|EpiPen|Gatorade|GaviLyte|GoLYTELY|HalfLytely|MiraLax|MoviPrep|NuLYTELY|OsmoPrep|PEG|Peglyte|PicoSalax|Plenvu|Purg-Odan|Restoralax|Suprep|Symjepi|TriLyte|anaphylaxis|bisacodyl|bowel preparation|cancer screening|colonoscopy|colorectal cancer |dosage|efficacy|electrolyte solutions|epinephrine|safety|sodium phosphate|sodium picosulfate|sodium sulfate	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29913465_20201005_0.5			Age Factors|Anaphylaxis|Anti-Allergic Agents|Body Weight|Child, Preschool|Drug Delivery Systems|Epinephrine|Equipment Design|Humans|Infant|Injections, Intramuscular|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2587105_20201005_0.5	golytely	drug_synonym	Preop use of Golytely in pediatrics.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2587105_20201005_0.5			Anti-Bacterial Agents|Child|Electrolytes|Humans|Isotonic Solutions|Polyethylene Glycols|Premedication|Preoperative Care|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2587105_20201005_0.5	golytely	drug_synonym	This method relies on pediatric nurses safely administering a large volume of PEG-ELS, marketed as Golytely, to produce the flushing effect without significant absorption of the Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11558059_20201005_0.5	golytely	drug_synonym	[Preparation for colonoscopy: A comparison between 3 commercially available Golytely solutions].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11558059_20201005_0.5			Adult|Aged|Ambulatory Care|Colonoscopy|Electrolytes|Female|Humans|Male|Middle Aged|Patient Acceptance of Health Care|Polyethylene Glycols|Prospective Studies|Single-Blind Method|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11558059_20201005_0.5	golytely	drug_synonym	The effectiveness of 3 commercially available Golytely solutions for colonoscopy (Original-Golytely-salt, Oralav and Delcoprep) were compared in a randomized prospective study.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29913466_20201005_0.5			Clenpiq--a low-volume sodium picosulfate-based colonoscopy preparation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29913466_20201005_0.5	golytely	drug_synonym	Bi-Peglyte|Colyte|Gatorade|GaviLyte|GoLYTELY|HalfLytely|MiraLax|MoviPrep|NuLYTELY|OsmoPrep|PEG|Peglyte|PicoSalax|Plenvu|Purg-Odan|Restoralax|Suprep|TriLyte|adverse effects|bisacodyl|bowel preparation|cancer screening|colonoscopy|colorectal cancer |dosage|drug interactions|efficacy|electrolyte solutions|pregnancy|safety|sodium phosphate|sodium picosulfate|sodium sulfate	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29913466_20201005_0.5			Cathartics|Citrates|Citric Acid|Colonoscopy|Drug Combinations|Drug Interactions|Humans|Magnesium Oxide|Organometallic Compounds|Picolines|Therapeutic Irrigation|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15515578_20201005_0.5			Complications associated with 355 flexible colonoscopic procedures in dogs.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15515578_20201005_0.5			Animals|Colonoscopy|Dog Diseases|Dogs|Female|Gastrointestinal Hemorrhage|Intestinal Diseases|Intestinal Perforation|Intestine, Large|Male|Pneumonia, Aspiration	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15515578_20201005_0.5	golytely	drug_synonym	Major complications consisting of fatal aspiration of GoLYTELY, colonic perforation, and excessive hemorrhage after biopsy of an adenocarcinoma with rigid forceps occurred in 3 (0.85%) dogs.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15515578_20201005_0.5	golytely	drug_synonym	Vomiting of GoLYTELY occurred with the administration of 4.6% of doses in 6.5% of dogs.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15515578_20201005_0.5	golytely	drug_synonym	When administering GoLYTELY, clinicians should be prepared to rapidly remove the orogastric tube and mouth speculum if vomiting occurs to reduce the potential for aspiration.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8409317_20201005_0.5	golytely	drug_synonym	The use of GoLYTELY and Dulcolax in combination in outpatient colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8409317_20201005_0.5			Ambulatory Care|Bisacodyl|Colonoscopy|Double-Blind Method|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Premedication|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8409317_20201005_0.5	golytely	drug_synonym	No section One hundred and sixty patients were enrolled in a double-blind, placebo-controlled trial to evaluate the effectiveness of the combination of the polyethylene glycol electrolyte lavage solution GoLYTELY (Braintree Laboratories, Inc., Braintree, MA, U.S.A.) and the contact laxative bisacodyl (Dulcolax, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, U.S.A.) in improving outpatient preparation for colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8409317_20201005_0.5	golytely	drug_synonym	One hundred and fourteen patients completed the study; 59 received GoLYTELY followed by three Dulcolax capsules and 55 received GoLYTELY followed by three placebo capsules.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8409317_20201005_0.5	golytely	drug_synonym	These results suggest that an improved colonoscopy preparation can be obtained by combining a standard GoLYTELY preparation with three 5-mg Dulcolax tablets, without sacrificing patient safety or comfort.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC8019517_20210511_0.5	golytely	drug_synonym	Lethal Complication From Inappropriately Prepared Polyethylene Glycol (Golytely) in a Pediatric Patient	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC8019517_20210511_0.5			colonic interposition|esophageal atresia repair|polyethylene glycol|pediatric	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC8019517_20210511_0.5	golytely	drug_synonym	Adult|Humans|Child|Female|Golytely|Electrolytes|Polyethylene Glycols|Cathartics|Colonoscopy|Therapeutic Irrigation|Colon|Water-Electrolyte Imbalance|Acid-Base Imbalance	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC8019517_20210511_0.5	golytely	drug_synonym	No section Polyethylene glycol with electrolytes (PEG-ELS, Golytely) is a widely used osmotic solution for colonic preparation in adults who are undergoing colonoscopy or colon surgeries.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC8019517_20210511_0.5	golytely	drug_synonym	Golytely is known to cause minimal electrolyte disturbances with no major sequelae.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC8019517_20210511_0.5	golytely	drug_synonym	 No section In this report, we present a case of an inappropriate preparation of Golytely administered to a pediatric patient leading to severe electrolyte disturbances and death.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7949524_20201005_0.5	golytely	drug_synonym	Decreased cyclosporine absorption after treatment with GoLytely lavage solution in a kidney transplant patient.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7949524_20201005_0.5			Administration, Oral|Adult|Cyclosporine|Electrolytes|Humans|Injections, Intravenous|Intestinal Absorption|Kidney Transplantation|Male|Polyethylene Glycols|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC7255656_20201005_0.5			Management of polyethylene glycol solution aspiration using bronchoscopic lavage in a dog	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC7255656_20201005_0.5	golytely	drug_synonym	acute respiratory distress syndrome|bronchoscopy|colonoscopy|endoscopic complication|GoLytely|pulmonary edema	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC7255656_20201005_0.5			Animals|Bronchoalveolar Lavage|Dogs|Electrolytes|Endoscopy|Male|Polyethylene Glycols|Pulmonary Edema|Respiratory Aspiration|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4071165_20201005_0.5			Bowel cleansing with polyethylene glycol electrolyte lavage solution.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4071165_20201005_0.5			Colonic Diseases|Electrolytes|Evaluation Studies as Topic|Gases|Humans|Polyethylene Glycols|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4071165_20201005_0.5	golytely	drug_synonym	No section We reviewed our experience with an oral gut lavage solution (GoLYTELY), used as a rapid bowel cleansing preparation, and the prospective clinical trials reported in the literature to compare the overall experience with this type of preparation for colonoscopy and colon surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4071165_20201005_0.5	golytely	drug_synonym	Five studies (546 patients) compared GoLYTELY to standard preparations for colonoscopy, while three trials (177 patients) have studied surgical patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4071165_20201005_0.5	golytely	drug_synonym	After evaluating patient tolerance, quality of colonic cleansing, and changes in microflora and colonic gas, GoLYTELY was found to be safe, rapid, and effective.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5			Randomized clinical trial of two colonoscopy preparation methods for elderly patients.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5			Aged|Aged, 80 and over|Bisacodyl|Citrates|Citric Acid|Colonoscopy|Electrolytes|Enema|Female|Humans|Male|Patient Acceptance of Health Care|Polyethylene Glycols|Randomized Controlled Trials as Topic	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5	golytely	drug_synonym	No section Colonic lavage with enemas or with Golytely are standard preparation methods for colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5	golytely	drug_synonym	Previous studies have demonstrated that Golytely has a statistically significant advantage in both adequacy of preparation and patient tolerance.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5	golytely	drug_synonym	Sixty-three patients were randomized to receive Golytely; 17 were inpatients, 33 were outpatients, and colonoscopy was canceled in 13.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5	golytely	drug_synonym	For adequacy of the preparation, no differences were statistically significant, but the enema preparation was superior in outpatients while Golytely was superior in inpatients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2204651_20201005_0.5	golytely	drug_synonym	Contrary to previous reports of a significant advantage with Golytely, patients greater than or equal to 75 years old did not enjoy this advantage, but seemed to tolerate enemas better than Golytely with little difference in adequacy of the preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7886982_20201005_0.5	golytely	drug_synonym	[Improving the effect of orthograde colonic lavage with golytely solution by adding dimethicone].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7886982_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Colonoscopy|Double-Blind Method|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Prospective Studies|Simethicone|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7886982_20201005_0.5	golytely	drug_synonym	No section The effectiveness of an additional application of Simethicone during an orthograde lavage with Golytely solution in preparation for colonoscopy was tested in a prospective, randomized, placebo-controlled double blind study on 152 patients 78 Simethicone, 74 placebo).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7886982_20201005_0.5	golytely	drug_synonym	We conclude that the additional application of Simethicone during the orthograde colon lavage with Golytely solution results in an improvement in the preparation for the colonoscopy as well as visibility of the colon mucosa.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6343173_20201005_0.5	golytely	drug_synonym	Double-contrast examination of the colon after preparation with Golytely (a balanced lavage solution).	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6343173_20201005_0.5			Adult|Aged|Clinical Trials as Topic|Colon|Contrast Media|Electrolytes|Humans|Middle Aged|Polyethylene Glycols|Prospective Studies|Radiography|Random Allocation|Therapeutic Irrigation|Time Factors	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3721152_20201005_0.5	golytely	drug_synonym	A complication of Golytely preparation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3721152_20201005_0.5			Cecum|Electrolytes|Foreign Bodies|Humans|Phosphates|Polyethylene Glycols|Tablets	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5	golytely	drug_synonym	A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5			Colonoscopy|Electrolytes|Enema|Female|Humans|Male|Middle Aged|Patient Acceptance of Health Care|Phosphates|Polyethylene Glycols|Randomized Controlled Trials as Topic|Single-Blind Method|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5	golytely	drug_synonym	No section One hundred and two patients were randomized to receive either oral sodium phosphate or standard polyethylene glycol-based lavage solution (Golytely) prior to colonoscopy in order to establish whether the much smaller volume of the former agent enhanced patient tolerance while maintaining or improving effectiveness and safety.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5	golytely	drug_synonym	In 37 patients who had had a previous colonoscopy prepared with Golytely, 100% of those now receiving sodium phosphate found it easier to complete and over 90% felt it caused less discomfort, compared with their previous experience with Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5	golytely	drug_synonym	Colonoscopists, unaware of the type of lavage solution used, scored the degree of colonic cleansing significantly higher for sodium phosphate-prepared colons compared with colons prepared with Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5	golytely	drug_synonym	Sodium phosphate is significantly less expensive than Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2183591_20201005_0.5	golytely	drug_synonym	We conclude that, in the group of patients studied, sodium phosphate is a safe colonic cleansing agent that is better tolerated and more effective than Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10606310_20201005_0.5			A randomized, prospective study to evaluate the efficacy and acceptance of three bowel preparations for colonoscopy in children.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10606310_20201005_0.5			Adolescent|Adult|Anthraquinones|Bisacodyl|Cathartics|Child|Child, Preschool|Citric Acid|Colonoscopy|Electrolytes|Female|Humans|Male|Organometallic Compounds|Patient Acceptance of Health Care|Phosphates|Polyethylene Glycols|Prospective Studies|Therapeutic Irrigation|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10606310_20201005_0.5	golytely	drug_synonym	 METHODS Seventy patients (ages 3-20 yr, 38 males) were randomly assigned to one of the three study preparations: Magnesium citrate with X-prep and clear liquid diet for 2 days (group A); Dulcolax for 2 days and Fleet enema without dietary restriction (group B); and Golytely 20 ml/kg (up to 1 L) per hour for 4 h with clear liquid diet for 1 day (group C).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10606310_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS Although the least well tolerated, Golytely provided the best cleansing.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3168097_20201005_0.5	golytely	drug_synonym	[Biological effects of golytely in children].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3168097_20201005_0.5			Adolescent|Blood Proteins|Calcium|Child|Child, Preschool|Creatinine|Electrolytes|Evaluation Studies as Topic|Humans|Infant|Intestines|Polyethylene Glycols|Potassium|Preoperative Care|Sodium|Solutions|Urea	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3168097_20201005_0.5	golytely	drug_synonym	No section Golytely solution is now commonly used in preoperative bowel preparation or in colonoscopy and barium enema in adults.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3168097_20201005_0.5	golytely	drug_synonym	Our study aimed to confirm there was no electrolytic movement caused by golytely and that using it without reserve in children was possible, even in the very young ones.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3168097_20201005_0.5	golytely	drug_synonym	Children are generally very sensible to those movements and mainly as they have a general anaesthesia in the hours following the golytely administration for investigation or surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3168097_20201005_0.5	golytely	drug_synonym	These results confirm that golytely is safe and effective in preparing the bowel in children.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5			The location of the receptors involved in the human diuretic response to drinking an isotonic electrolyte solution.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5			Adult|Arginine Vasopressin|Diuresis|Drinking|Electrolytes|Female|Humans|Isotonic Solutions|Male|Oropharynx|Osmolar Concentration|Plasma Volume|Polyethylene Glycols|Receptors, Cell Surface	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	This study aimed to shed light on the receptors involved in the diuretic response to drinking isotonic fluids in man by employing a polyethylene glycol-based bowel lavage solution (Golytely) which is reported to cause no net movement of fluid across the gut.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	Drinking Golytely resulted in a transient hypotonic diuresis.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	Neither solution produced changes in plasma osmolality or electrolytes, but Golytely provoked a 6.8% contraction of plasma volume, whereas drinking Tyrode resulted in plasma expansion.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	Copious diarrhoea was experienced by all subjects who drank Golytely solution and by none on drinking Tyrode solution.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	The infusion of Golytely into the stomach resulted in a hypotonic diuresis similar in magnitude to that elicited by drinking.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	Plasma arginine vasopressin (AVP) levels did not fall following the drinking of Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	The findings show that signals from the oropharynx do not mediate the diuretic response to drinking Golytely in man and that a mechanism other than inhibition of AVP release appears to be involved.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1331420_20201005_0.5	golytely	drug_synonym	The receptors mediating this response may lie in the stomach and/or small bowel since Golytely is not absorbed, as evidenced by the contraction of plasma volume and diarrhoea.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7615227_20201005_0.5			The effects of cisapride on the quality and tolerance of colonic lavage: a double-blind randomized study.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7615227_20201005_0.5			Aged|Cisapride|Colonoscopy|Double-Blind Method|Electrolytes|Humans|Middle Aged|Piperidines|Polyethylene Glycols|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7615227_20201005_0.5	golytely	drug_synonym	Of 84 patients undergoing colonoscopy, 41 were randomized (double-blind) to Golytely plus cisapride (10 mg per OS three times during the day before the procedure and one 10-mg dose on the morning of the procedure) and 43 to Golytely plus a placebo of identical appearance.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11987095_20201005_0.5			New strategies in nonoperative management of meconium ileus.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11987095_20201005_0.5			Animals|Constipation|Diatrizoate Meglumine|Enema|Humans|In Vitro Techniques|Infant, Newborn|Intestinal Obstruction|Intestines|Male|Meconium|Mice|Viscosity	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11987095_20201005_0.5	golytely	drug_synonym	Each then received an enema solution (perflubron, surfactant, Tween-80, Gastrografin, Golytely, DNase, N-Acetylcysteine, Viokase, or normal saline).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6706069_20201005_0.5			Comparison of colon cleansing methods in preparation for colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6706069_20201005_0.5			Adult|Aged|Breath Tests|Cathartics|Colon|Colonoscopy|Diet|Enema|Female|Gases|Humans|Hydrogen|Male|Methane|Middle Aged|Patient Acceptance of Health Care|Random Allocation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6706069_20201005_0.5	golytely	drug_synonym	No section Colonoscopy cleansing regimens were evaluated in 197 patients randomized in two study phases to one of four methods: group 1 (64 patients), 3-day clear liquid diet; group 2 (40 patients), 3-day minimum-residue diet; group 3 (44 patients), 1-day minimum-residue diet; group 4 (49 patients), Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6706069_20201005_0.5	golytely	drug_synonym	It is concluded that Golytely is a safe, effective method of colon cleansing, well tolerated by patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11280539_20201005_0.5	golytely	drug_synonym	Decreased efficacy of polyethylene glycol lavage solution (golytely) in the preparation of diabetic patients for outpatient colonoscopy: a prospective and blinded study.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11280539_20201005_0.5			Adult|Aged|Aged, 80 and over|Colonoscopy|Diabetes Mellitus|Electrolytes|Female|Humans|Male|Middle Aged|Outpatients|Polyethylene Glycols|Prospective Studies|Reference Values|Single-Blind Method|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11280539_20201005_0.5	golytely	drug_synonym	OBJECTIVE The aim of the present study was to compare, in a prospective and blinded fashion, the efficacy of 6 L of polyethylene glycol-based lavage solution (Golytely) administered on an outpatient basis in diabetic versus nondiabetic patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11280539_20201005_0.5	golytely	drug_synonym	 METHODS A total of 54 consecutive nondiabetic and 45 consecutive diabetic patients requiring outpatient colonoscopy underwent colonic cleansing by drinking 6 L of Golytely the evening before the procedure.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11280539_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS We conclude that diabetic patients (irrespective of insulin use, diabetic control, or diabetic neuropathy) have a significantly poorer response to a 6-L Golytely preparation than do nondiabetic patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8899092_20201005_0.5			The palatability of five colonic lavage solutions.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8899092_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Data Collection|Electrolytes|Female|Flavoring Agents|Gastric Lavage|Humans|Male|Middle Aged|Patient Compliance|Polyethylene Glycols|Solutions|Taste	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8899092_20201005_0.5	golytely	drug_synonym	Colyte-Flavored, Cherry-NuLytely, NuLytely and GoLytely had similar median taste scores and a similar frequency of taste scores labelled as 'unacceptable' (8-11%); these four products ranked ahead of plain Colyte (which had a 25% frequency of taste scores labelled as 'unacceptable').	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8899092_20201005_0.5	golytely	drug_synonym	Twenty-two per cent of subjects rated an unflavoured lavage solution (generally NuLytely or GoLytely) as their first choice.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7597608_20201005_0.5	golytely	drug_synonym	A study of a new osmotic purgative for colonoscopy. Is Golytely worth its salt?	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7597608_20201005_0.5			Cathartics|Colonoscopy|Costs and Cost Analysis|Double-Blind Method|Electrolytes|Female|Humans|Male|Middle Aged|Patient Satisfaction|Polyethylene Glycols|Solutions|Sulfates	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7597608_20201005_0.5	golytely	drug_synonym	No section An osmotic laxative containing polyethylene glycol and sodium sulfate (Golytely Braintree Laboratories, Inc., Braintree, MA) is widely used to clean the colon for colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7597608_20201005_0.5	golytely	drug_synonym	We therefore tested the claim that a similar solution but without sodium sulfate (Golytely-RSS Braintree Laboratories, Inc., Braintree, MA) makes preparation of the colon more acceptable to patients in a double-blinded randomized controlled trial.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3739857_20201005_0.5	golytely	drug_synonym	Golytely: a new approach to faecal impaction in old age.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3739857_20201005_0.5			Aged|Electrolytes|Enema|Fecal Impaction|Female|Humans|Lactulose|Male|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3739857_20201005_0.5	golytely	drug_synonym	No section Forty-five elderly subjects with faecal impaction were entered into a study of the efficacy of golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3739857_20201005_0.5	golytely	drug_synonym	Twenty-three were treated with golytely 2 l/day for 2 days and then lactulose 30 ml b.d.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3739857_20201005_0.5	golytely	drug_synonym	A good response was achieved in 13 (56%) within 1 week and in 20 (87%) within 2 weeks when golytely was used, as compared to only 5 (23%) within 1 week and 9 (41%) within 2 weeks when it was not used.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5	golytely	drug_synonym	Possible GoLytely-Associated Cardiac Arrest: A Case Report and Literature Review.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5	golytely	drug_synonym	GoLytely|cardiac arrest|critical care|medication safety|polyethylene glycol	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5			Diabetes Mellitus, Type 2|Electrolytes|Heart Arrest|Humans|Male|Middle Aged|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5	golytely	drug_synonym	UNASSIGNED To report a case of sudden cardiac arrest possibly associated with the administration of GoLytely® (polyethylene glycol 3350 and electrolytes).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5	golytely	drug_synonym	The patient had received GoLytely as treatment to alleviate symptoms of constipation and abdominal pain.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5	golytely	drug_synonym	After ruling out other possible etiologies, GoLytely was suspected as a possible cause of cardiac arrest.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30727797_20210511_0.5	golytely	drug_synonym	 UNASSIGNED Although GoLytely appears to be a safe agent with fewer side effects, clinicians need to be mindful of potential life-threatening adverse events following GoLytely administration and monitor patients closely during and after administration.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11867987_20201005_0.5			Mercuric oxide poisoning treated with whole-bowel irrigation and chelation therapy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11867987_20201005_0.5			Adult|Charcoal|Chelating Agents|Dimercaprol|Electrolytes|Humans|Intestines|Male|Mercury Poisoning|Polyethylene Glycols|Succimer|Suicide, Attempted|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11867987_20201005_0.5	golytely	drug_synonym	Gastrointestinal decontamination was accomplished with activated charcoal and whole-bowel irrigation with polyethylene glycol solution (Golytely) for 24 hours until repeat abdominal radiographs no longer demonstrated the substance in the gastrointestinal tract.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5			Comparison of three colon cleansing methods: evaluation of a randomized clinical trial with 300 ambulatory patients.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Colon|Colonoscopy|Female|Humans|Male|Middle Aged|Preoperative Care|Prospective Studies|Randomized Controlled Trials as Topic|Surface-Active Agents|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5	golytely	drug_synonym	The patients were randomly assigned to one of the following three groups for colon preparation: Group 1 (n = 100) 4 liters of Golytely, group 2 (n = 102) 2 liters of Golytely combined with Cascara-Salax, and group 3 (n = 98) X-Prep (a Senna preparation) combined with an enema.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5	golytely	drug_synonym	X-Prep (group 3) caused significantly more abdominal cramps than 4 liters of Golytely (group 1) or 2 liters of Golytely with Cascara-Salax (group 2) (p less than 0.001).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5	golytely	drug_synonym	The patients therefore preferred X-Prep to 4 liters of Golytely (p less than 0.01).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5	golytely	drug_synonym	The cleanest colon was obtained with 4 liters of Golytely, while 2 liters of Golytely with Cascara-Salax was least efficacious.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2693078_20201005_0.5	golytely	drug_synonym	We thus conclude that while 4 liters of Golytely and X-Prep plus enema have equivalent cleansing efficacy for colonoscopy, patients judged X-Prep to be less unpleasant.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5	golytely	drug_synonym	Bowel preparation for the total colonoscopy by 2,000 ml of balanced lavage solution (Golytely) and sennoside.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Anthraquinones|Cathartics|Colonoscopy|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Senna Extract|Sennosides|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5	golytely	drug_synonym	No section One of disadvantages of the Golytely preparation is that examinees have to drink as much as 4,000 ml of Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5	golytely	drug_synonym	To overcome this disadvantage, we designed a modified preparation regimen in which examinees have to drink only 2,000 ml of Golytely by taking sennoside orally.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5	golytely	drug_synonym	On the day of the examination, the examinees drank a total of 2,000 ml of Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5	golytely	drug_synonym	Subjects who had also experienced bowel preparation by the modified method of Brown were asked to compare the two regimens, and only 1% preferred Brown's method while 73% preferred bowel preparation by our Golytely method.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1468604_20201005_0.5	golytely	drug_synonym	We conclude that bowel preparation for total colonoscopy using 2,000 ml of Golytely and sennoside is superior because it is highly acceptable to the examinees and provides excellent gut irrigation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10693671_20201005_0.5			Home bowel preparation for elective colonic procedures in children: cost savings with quality assurance and improvement.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10693671_20201005_0.5			Anus, Imperforate|Child|Child, Preschool|Colonic Diseases|Cost Savings|Elective Surgical Procedures|Electrolytes|Female|Hirschsprung Disease|Home Care Services|Humans|Indiana|Infant|Male|Polyethylene Glycols|Prospective Studies|Quality Assurance, Health Care|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10693671_20201005_0.5	golytely	drug_synonym	 METHODS For an elective colorectal procedure, pediatric patients underwent a home bowel preparation using GoLYTELY (100 mL/kg) via a nasogastric tube infused over 4 hours by a pediatric home health nurse trained in this technique.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID10693671_20201005_0.5	golytely	drug_synonym	There was one complication caused by incorrect mixing of GoLYTELY causing gastrointestinal cramping.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8196027_20201005_0.5	golytely	drug_synonym	Hypoglycaemia and Golytely in distal intestinal obstruction syndrome.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8196027_20201005_0.5			Child|Cystic Fibrosis|Electrolytes|Female|Humans|Hypoglycemia|Intestinal Obstruction|Liver Diseases|Polyethylene Glycols|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3486210_20201005_0.5	golytely	drug_synonym	Colonoscopy after Golytely preparation in acute rectal bleeding.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3486210_20201005_0.5			Adolescent|Adult|Aged|Child|Colonic Diseases|Colonoscopy|Electrocoagulation|Electrolytes|Female|Gastrointestinal Hemorrhage|Humans|Male|Middle Aged|Polyethylene Glycols|Rectum|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3486210_20201005_0.5	golytely	drug_synonym	No section Thirty-five consecutive patients with acute hematochezia, negative gastric aspirates, and negative sigmoidoscopy underwent urgent colonoscopy after Golytely purgation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3486210_20201005_0.5	golytely	drug_synonym	The data suggest that urgent colonoscopy following Golytely purgation is a safe, sensitive, and specific diagnostic procedure that provides an opportunity for early nonoperative treatment of acute colonic hemorrhage.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8286425_20201005_0.5			Colon cleanout preparations in children and adolescents.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8286425_20201005_0.5			Adolescent|Cathartics|Child|Child, Preschool|Colonoscopy|Enema|Evaluation Studies as Topic|Humans|Infant|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8286425_20201005_0.5	golytely	drug_synonym	The most effective preparations were X-Prep liquid+Adult Fleet enema, GoLYTELY, and GoLYTELY+Adult Fleet enema, all of which allowed a complete examination of the colon.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8286425_20201005_0.5	golytely	drug_synonym	The most effective cleanout preparation with the fewest side effects was GoLYTELY, used alone or in combination with enemas.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8286425_20201005_0.5	golytely	drug_synonym	These results suggest that many typical cleanout preparations yield inadequate results, wasting time or money, and argue in favor of the use of more effective preparations with fewer side effects, such as GoLYTELY.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID28957968_20201005_0.5			A Comparison of Bowel Preparations for Colonoscopy in Constipated Adults.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID28957968_20201005_0.5			Adult|Aged|Cathartics|Cohort Studies|Colonoscopy|Constipation|Female|Humans|Male|Middle Aged|Patient Safety|Polyethylene Glycols|Reference Values|Risk Assessment|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID28957968_20201005_0.5	golytely	drug_synonym	This study included 372 patients and compared the effectiveness of high-volume (4 L) polyethylene glycol solution (GoLYTELY) with low-volume (2 L) polyethylene glycol solution with ascorbate (MoviPrep) in constipated and nonconstipated adults.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID28957968_20201005_0.5	golytely	drug_synonym	There was no statistically significant difference in quality of bowel preparation between GoLYTELY and MoviPrep in chronically constipated adults (p = .27).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID28957968_20201005_0.5	golytely	drug_synonym	This study concluded that patients with constipation were more likely than nonconstipated patients to have poor bowel preparation, and there was no statistically significant difference between GoLYTELY and MoviPrep.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3770351_20201214_0.5	golytely	drug_synonym	A rapid colonic lavage solution (Golytely) vs standard preparation for barium enema and colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3770351_20201214_0.5			Administration, Oral|Barium Sulfate|Bisacodyl|Electrolytes|Enema|Humans|Polyethylene Glycols|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8700818_20201005_0.5			Bowel preparation before colonoscopy. Choosing the best lavage regimen.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8700818_20201005_0.5			Administration, Oral|Colonoscopy|Electrolytes|Humans|Intestines|Phosphates|Polyethylene Glycols|Prospective Studies|Randomized Controlled Trials as Topic|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8700818_20201005_0.5	golytely	drug_synonym	Balancing the importance of such factors as cleansing effectiveness, safety, ease of completion, side effects, patient tolerance, and cost, the authors recommend four methods: (1) PEG-electrolyte solution (eg, CoLyte, GoLYTELY, NuLytely) in combination with senna (eg, X-Prep), (2) PEG-electrolyte solution alone (either single dose or split dose), (3) oral sodium phosphate (Fleets Phosphosoda) given in split dose, and (4) oral magnesium citrate in combination with rectal pulsed irrigation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11044526_20201005_0.5			Whole gut washout ameliorates the progression of acute experimental pancreatitis.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11044526_20201005_0.5			Acute Disease|Alanine Transaminase|Amylases|Animals|Bicarbonates|Blood Glucose|Calcium|Disease Progression|Electrolytes|Female|Hematocrit|Hydrogen-Ion Concentration|L-Lactate Dehydrogenase|Lactic Acid|Leukocyte Count|Liver|Lymph Nodes|Oxygen|Pancreas|Pancreatitis|Partial Pressure|Polyethylene Glycols|Postoperative Complications|Rats|Rats, Sprague-Dawley|Solutions|Spleen|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11044526_20201005_0.5	golytely	drug_synonym	The first group of animals (n = 20) received high volume polyethylene glycol-3500 (GoLYTELY) for 6 hours through a silastic catheter introduced into the proximal part of the jejunum from a puncture gastrostomy during the initial laparotomy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID27871178_20201005_0.5			Use of polyethylene glycol in functional constipation and fecal impaction.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID27871178_20201005_0.5			Adult|Child|Constipation|Fecal Impaction|Humans|Laxatives|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID27871178_20201005_0.5	golytely	drug_synonym	 METHODS Search on MEDLINE, EMBASE and Cochrane databases until May 2016 of all publications adjusted to the following terms: constipation AND/OR fecal impaction AND (PEG OR polyethylene glycol OR macrogol OR movicol OR idralax OR miralax OR transipeg OR forlax OR golytely OR isocolan OR mulytely) NOT colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5	golytely	drug_synonym	Unintentional intravenous infusion of Golytely in a 4-year-old girl.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5			Child, Preschool|Electrolytes|Female|Humans|Infusions, Intravenous|Medication Errors|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5	golytely	drug_synonym	OBJECTIVE To report an accidental intravenous infusion of Golytely (polyethylene glycol and electrolyte solution; PEG-ELS) in a pediatric patient that did not result in systemic toxicity.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5	golytely	drug_synonym	Golytely administered through a nasogastric tube was ordered.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5	golytely	drug_synonym	Upon reevaluation, it was noted that the patient had received 391 mL of Golytely intravenously.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5	golytely	drug_synonym	Potential toxicity from Golytely is mainly related to the molecular weight of PEG in the formulation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15173559_20201005_0.5	golytely	drug_synonym	Fortunately, this patient did not have any toxicity from the intravenous infusion of Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2221304_20201005_0.5	golytely	drug_synonym	[Lung edema following intestinal irrigation with golytely solution].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2221304_20201005_0.5			Critical Care|Cystectomy|Electrolytes|Hemangiosarcoma|Humans|Intestines|Intraoperative Complications|Male|Middle Aged|Polyethylene Glycols|Preoperative Care|Prostatectomy|Prostatic Neoplasms|Pulmonary Edema|Therapeutic Irrigation|Urinary Bladder Neoplasms	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2221304_20201005_0.5	golytely	drug_synonym	No section A case of pulmonary edema following whole gut lavage with Golytely's solution is reported.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7054041_20201005_0.5	golytely	drug_synonym	Patient acceptance and effectiveness of a balanced lavage solution (Golytely) versus the standard preparation for colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7054041_20201005_0.5			Adult|Aged|Colonoscopy|Electrolytes|Humans|Middle Aged|Patient Compliance|Random Allocation|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7054041_20201005_0.5	golytely	drug_synonym	To determine the efficacy of this solution (Golytely) for colonoscopy, 20 consecutive patients were randomized to either a standard colonoscopy prep or Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7054041_20201005_0.5	golytely	drug_synonym	Although Golytely produced mild cramps (3 of 12) and transient fullness (6 of 12 vs. 0 of 8 with standard prep, p less than 0.02), 11 of 12 were willing to repeat Golytely vs. 3 of 8 with the standard prep (p less than 0.02).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7054041_20201005_0.5	golytely	drug_synonym	It is concluded that Golytely is an effective prep for colonoscopy and well tolerated by patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3694378_20201005_0.5			Removal of a colonic foreign body by enteral lavage.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3694378_20201005_0.5			Adolescent|Colon|Foreign Bodies|Humans|Male|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3694378_20201005_0.5	golytely	drug_synonym	It successfully passed after oral colonic lavage solution (Golytely), obviating endoscopic intervention.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8338088_20201005_0.5			A comparison of the effectiveness and patient tolerance of oral sodium phosphate, castor oil, and standard electrolyte lavage for colonoscopy or sigmoidoscopy preparation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8338088_20201005_0.5			Administration, Oral|Castor Oil|Colonoscopy|Costs and Cost Analysis|Electrolytes|Female|Humans|Male|Middle Aged|Patient Satisfaction|Phosphates|Polyethylene Glycols|Prospective Studies|Sigmoidoscopy|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8338088_20201005_0.5	golytely	drug_synonym	No section One hundred thirteen patients were randomized to receive either oral sodium phosphate (Fleet Phospho-Soda), lemon-flavored castor oil (Purge), or standard polyethylene glycol-based lavage solution (GoLYTELY) before elective colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18721951_20201214_0.5			Tap water irrigation and additives to optimize success with the Malone antegrade continence enema: the Indiana University algorithm.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18721951_20201214_0.5			Adolescent|Adult|Algorithms|Child|Child, Preschool|Chronic Disease|Clinical Protocols|Constipation|Digestive System Surgical Procedures|Enema|Fecal Incontinence|Female|Humans|Male|Retrospective Studies|Spinal Dysraphism|Water	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18721951_20201214_0.5	golytely	drug_synonym	Those in whom tap water irrigation failed underwent complete bowel cleanout with enemas and GoLYTELY via the Malone antegrade continence enema, followed by a gradual increase in irrigation volume.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29596128_20201005_0.5			A Retrospective Study Comparing Polyethylene Glycol-Electrolyte Solution With Magnesium Citrate for Treatment of Fecal Disimpaction.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29596128_20201005_0.5			Administration, Oral|Adolescent|Age Factors|Ambulatory Care|Child|Child, Preschool|Citric Acid|Cohort Studies|Electrolytes|Fecal Impaction|Female|Follow-Up Studies|Humans|Intubation, Gastrointestinal|Male|Organometallic Compounds|Polyethylene Glycols|Retrospective Studies|Risk Assessment|Sex Factors|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID29596128_20201005_0.5	golytely	drug_synonym	This study evaluated the efficiency of 2 disimpaction therapies: nasogastric GoLYTELY (polyethylene glycol-electrolyte solution) compared with oral magnesium citrate.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6341159_20201005_0.5	golytely	drug_synonym	A randomized blinded clinical trial of a rapid colonic lavage solution (Golytely) compared with standard preparation for colonoscopy and barium enema.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6341159_20201005_0.5			Adult|Aged|Barium Sulfate|Clinical Trials as Topic|Colon|Colonoscopy|Electrolytes|Enema|Humans|Middle Aged|Polyethylene Glycols|Random Allocation|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6341159_20201005_0.5	golytely	drug_synonym	No section The efficacy and safety of the new colonic lavage solution, Golytely (an electrolyte-polyethylene glycol solution), was compared with standard 2- and 3-day bowel preparations in a randomized blinded study of patients undergoing colonoscopy and barium enema examination.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6341159_20201005_0.5	golytely	drug_synonym	For colonoscopy, preparation with Golytely allowed better visualization of colonic mucosa (p less than 0.002) due to less retained stool (p less than 0.002), produced more optimal exams (p less than 0.002), and required less time to reach the cecum (p less than 0.05).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6341159_20201005_0.5	golytely	drug_synonym	We conclude that Golytely is effective for barium enema examination and is the preparation of choice for colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1557921_20201005_0.5	golytely	drug_synonym	Senna vs. bisacodyl in addition to Golytely lavage for colonoscopy preparation--a prospective randomized trial.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1557921_20201005_0.5			Adult|Aged|Bisacodyl|Cathartics|Colonoscopy|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Prospective Studies|Senna Extract|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1557921_20201005_0.5	golytely	drug_synonym	Immediately before examination all patients underwent whole gut irrigation with Golytely solution.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1567745_20201005_0.5			[Whole gut irrigation in pediatric patients: a comparative study].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1567745_20201005_0.5			Adolescent|Age Factors|Child|Child, Preschool|Colon|Colonoscopy|Double-Blind Method|Electrolytes|Erythromycin|Humans|Infant|Intestines|Neomycin|Polyethylene Glycols|Postoperative Complications|Preoperative Care|Prospective Studies|Sodium Chloride|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1567745_20201005_0.5	golytely	drug_synonym	To realize our aim, a prospective and double blinded study was designed on 124 patients irrigated with a saline solution (S-I), or with the Golytely solution (S-II).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3451520_20201214_0.5	golytely	drug_synonym	[Electrolyte solution (Golytely) versus laxatives and enema as a cleansing procedure prior to colonoscopy].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3451520_20201214_0.5			Administration, Oral|Adult|Aged|Cathartics|Colonoscopy|Electrolytes|Enema|Female|Humans|Male|Middle Aged|Patient Compliance|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID20453762_20201005_0.5			Inhibition of intraluminal pancreatic enzymes with nafamostat mesilate improves clinical outcomes after hemorrhagic shock in swine.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID20453762_20201005_0.5			Analysis of Variance|Animals|Disease Models, Animal|Drug Evaluation, Preclinical|Duodenostomy|Electrolytes|Enteral Nutrition|Guanidines|Leukocytes|Male|Multiple Organ Failure|Pancreas|Polyethylene Glycols|Resuscitation|Serine Proteinase Inhibitors|Shock, Hemorrhagic|Swine|Swine, Miniature|Systemic Inflammatory Response Syndrome|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID20453762_20201005_0.5	golytely	drug_synonym	Animals were allocated to three groups: (1) shock only (n = 15), (2) shock + enteroclysis with 100 mL/kg GoLYTELY (GL) as a carrier (n = 11), and (3) shock + enteroclysis with GL + 0.37 mmol/L NM (GL+NM, n = 7).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3112357_20201005_0.5			The safety and cost-effectiveness of polyethylene glycol electrolyte solution bowel preparation in infants and children.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3112357_20201005_0.5			Age Factors|Child|Child, Preschool|Cost-Benefit Analysis|Electrolytes|Female|Follow-Up Studies|Humans|Infant|Infant, Newborn|Intestines|Male|Polyethylene Glycols|Preoperative Care|Safety|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3112357_20201005_0.5	golytely	drug_synonym	No section Golytely, a polyethylene glycol electrolyte solution (Braintree Laboratories, Braintree, MA), was evaluated in the preoperative bowel preparation of 21 infants and children.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3112357_20201005_0.5	golytely	drug_synonym	All children were given 25 mL/kg/h of Golytely until rectal effluent was clear and free of particulate matter.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3112357_20201005_0.5	golytely	drug_synonym	Golytely is safe and effective in preparing the bowel prior to surgery in children.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3112357_20201005_0.5	golytely	drug_synonym	Using Golytely can eliminate the need for multiple-day hospitalizations for bowel preparation and thus decrease the cost of medical care.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7965513_20201005_0.5	golytely	drug_synonym	Effect of Golytely on serum electrolytes and hydration status of infants.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7965513_20201005_0.5			Child, Preschool|Electrolytes|Humans|Infant|Infant, Newborn|Polyethylene Glycols|Solutions|Therapeutic Irrigation|Water-Electrolyte Balance	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7965513_20201005_0.5	golytely	drug_synonym	No section Golytely (GLP) is a commonly used oral preparation for infants and children undergoing intestinal surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11730117_20201005_0.5			Laparoscopic intestinal injury: a review and case presentation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11730117_20201005_0.5			Adult|Female|Humans|Intestinal Perforation|Laparoscopy	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID11730117_20201005_0.5	golytely	drug_synonym	For this reason, mechanical bowel preparation with GoLYTELY was carried out.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30856159_20201005_0.5			Plenvu - a low-volume PEG-based colonoscopy preparation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30856159_20201005_0.5	golytely	drug_synonym	Bi-Peglyte|Clenpiq|Colyte|Gatorade|GaviLyte|GoLYTELY|MiraLax|MoviPrep|NuLYTELY|OsmoPrep|PEG|PicoSalax|Plenvu|Prepopik|Purg-Odan|Suprep|TriLyte|adverse effects|bisacodyl|bowel preparation|cancer screening|colonoscopy|colorectal cancer |dosage|drug interactions|efficacy|pregnancy|safety|sodium phosphate|sodium picosulfate|sodium sulfate	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30856159_20201005_0.5			Administration, Oral|Cathartics|Colonoscopy|Humans|Pharmaceutical Solutions|Polyethylene Glycols|Randomized Controlled Trials as Topic|Salix	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2764533_20210611_0.5			Suppression of colonic microflora by cefoperazone and evaluation of the drug as potential prophylaxis in bowel surgery.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2764533_20210611_0.5			Administration, Oral|Adult|Cefoperazone|Colon|Feces|Humans|Injections, Intravenous|Intestines|Male|Premedication|Surgical Wound Infection	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2764533_20210611_0.5	golytely	drug_synonym	A mechanical bowel preparation, Golytely, was also given to each of the subjects.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3780584_20201005_0.5	golytely	drug_synonym	Comparison of whole-gut irrigation with golytely (GOL) and with a balanced electrolyte solution (BES) as preparation for colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3780584_20201005_0.5			Adult|Aged|Colon|Colonoscopy|Double-Blind Method|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Random Allocation|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3780584_20201005_0.5	golytely	drug_synonym	No section The cleansing results of whole-gut irrigation with golytely (GOL) or with a balanced electrolyte solution (BES) were compared in otherwise unprepared patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	Randomised clinical trial: MiraLAX vs. Golytely - a controlled study of efficacy and patient tolerability in bowel preparation for colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5			Aged|Aged, 80 and over|Cathartics|Colonoscopy|Electrolytes|Female|Humans|Male|Middle Aged|Patient Satisfaction|Polyethylene Glycols|Randomized Controlled Trials as Topic|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	We hypothesize that MiraLAX/Gatorade is as efficacious for bowel cleansing as Golytely and is more tolerable for patients undergoing screening colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	 OBJECTIVE To compare bowel preparation scores of MiraLAX/Gatorade vs. Golytely and examine differences in patient tolerability.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	 METHODS Patients undergoing screening colonoscopy were randomized to 4 L Golytely or 238 g MiraLAX in 64 ounces Golytely and four bisacodyl tablets.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	6.3); 87 were randomized to MiraLAX, 103 to Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	Golytely's median total BBPS score was significantly higher than that of MiraLAX [9 (IQR 7-9) vs. 8 (IQR 6-9), P = 0.034].	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	Golytely had a higher rate of an excellent equivalent BBPS score of 8 or 9 than MiraLAX (70% vs. 55%, P = 0.036).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21083586_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS Golytely was more efficacious than MiraLAX/Gatorade in bowel cleansing; both preparations were equally tolerated by patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2954969_20201005_0.5	golytely	drug_synonym	A comparison of Golytely and standard preparation for barium enema.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2954969_20201005_0.5			Barium Sulfate|Clinical Trials as Topic|Colon|Contrast Media|Electrolytes|Enema|Humans|Polyethylene Glycols|Prospective Studies|Radiography|Random Allocation|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2954969_20201005_0.5	golytely	drug_synonym	No section A randomized prospective trial was performed comparing Golytely (with bisacodyl) with our standard two-day catharsis and bowel washout regimen as colon preparation for double-contrast barium enema examinations.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2954969_20201005_0.5	golytely	drug_synonym	Of the 107 patients who participated, 50 received the standard preparation and 57 Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2954969_20201005_0.5	golytely	drug_synonym	We conclude that routine use of Golytely is preferable to methods involving catharsis and standard tap water enemas for barium enema examination, on the grounds that it is equally effective, yet more convenient for patients and for the radiology department, and reduces total costs.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21656469_20201005_0.5			Bowel preparation and peri-operative management for radical cystectomy in Turkey: Turkish Urooncology Association multicenter survey.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21656469_20201005_0.5			Antibiotic Prophylaxis|Cystectomy|Data Collection|Enema|Humans|Intubation, Gastrointestinal|Laxatives|Perioperative Care|Turkey|Urinary Diversion|Venous Thrombosis	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21656469_20201005_0.5	golytely	drug_synonym	Bowel preparation methods included long conservative methods, short enema protocols, and Golytely, but there were significant differences in application of each method.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID32691384_20210611_0.5			Comparative Effectiveness of Commercial Bowel Preparations in Ambulatory Patients Presenting for Screening or Surveillance Colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID32691384_20210611_0.5			Adenoma detection rate|Bowel preparation quality|Commercial bowel preparation|Inadequate bowel preparation	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID32691384_20210611_0.5	golytely	drug_synonym	Humans|Male|Female|Middle Aged|Adult|Retrospective Studies|Colonoscopy|Colonic Polyps|Adenoma|Cathartics|Mass Screening|polyethylene glycol 3350|Polyethylene Glycols|Colonic Neoplasms|Colorectal Neoplasms|Golytely|Laxatives|Electrolytes|Time Factors|Logistic Models	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID32691384_20210611_0.5	golytely	drug_synonym	In adjusted analyses, compared to GoLYTELY, only NuLYTELY [OR 0.66 (95% CI 0.60, 0.72)] and SuPREP [OR 0.53 (95% CI 0.40, 0.69)] were associated with reduced IBP.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15128119_20201005_0.5			Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15128119_20201005_0.5			Animals|Blood Transfusion|Electrolytes|Enema|Guanidines|Intestinal Mucosa|Intestine, Small|Liver|Lung|Male|Neutrophil Activation|Peroxidase|Polyethylene Glycols|Protease Inhibitors|Shock, Hemorrhagic|Swine|Systemic Inflammatory Response Syndrome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15128119_20201005_0.5	golytely	drug_synonym	Treated animals received 100 mL/kg of 0.37 mmol/L nafamostat mesilate in GoLYTELY through the duodenal catheter at 1 L/h. Control animals received GoLYTELY only.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15128119_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS Nafamostat mesilate given by means of enteroclysis with GoLYTELY significantly reduces enteral protease levels, leukocyte activation, and transfusion requirements during resuscitation from hemorrhagic shock.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID20584228_20201005_0.5			Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID20584228_20201005_0.5			Adult|Constipation|Defecation|Electrolytes|Humans|Laxatives|Osmolar Concentration|Polyethylene Glycols|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID20584228_20201005_0.5	golytely	drug_synonym	Search terms were (constipation) AND (randomised OR randomized) AND (PEG OR polyethylene OR macrogol OR movicol OR idrolax OR miralax OR transipeg OR forlax OR colyte OR golytely OR isocolan OR nulytely) NOT colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2717290_20201005_0.5			Lavage treatment of distal intestinal obstruction syndrome in children with cystic fibrosis.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2717290_20201005_0.5			Adolescent|Adult|Cystic Fibrosis|Electrolytes|Female|Humans|Intestinal Obstruction|Male|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2717290_20201005_0.5	golytely	drug_synonym	No section The efficacy, adverse reactions, and long-term effects of intestinal lavage treatment with a balanced electrolyte solution (Golytely) was evaluated in patients with cystic fibrosis and distal intestinal obstruction syndrome.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2717290_20201005_0.5	golytely	drug_synonym	Twenty-two patients with cystic fibrosis (mean age 21.8 years, range 14 to 34 years, 15 boys or men) who sought medical attention because of abdominal pain and a mass in the right iliac fossa received Golytely, 5.6 +/- 1.9 L (mean +/- 1 SD), either orally (n = 14) or via nasogastric tube (n = 8) during 5.6 +/- 2.4 hours.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2717290_20201005_0.5	golytely	drug_synonym	During follow-up (mean 15.2 months, range 4 to 26 months), 11 patients required a total of 38 (range one to nine) additional doses of Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	MiraLAX vs. Golytely: is there a significant difference in the adenoma detection rate?	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5			Adenoma|Age Factors|Aged|Colonoscopy|Colorectal Neoplasms|Electrolytes|Female|Humans|Male|Mass Screening|Middle Aged|Multivariate Analysis|Polyethylene Glycols|Preoperative Care|Randomized Controlled Trials as Topic|Retrospective Studies|Solvents	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	BACKGROUND In recent clinical trials (RCT) of bowel preparation, Golytely was more efficacious than MiraLAX.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	We hypothesised that there is a difference in adenoma detection between Golytely and MiraLAX.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	 METHODS This was a post hoc analysis of an RCT that assessed efficacy and patient tolerability of Golytely vs. MiraLAX/Gatorade in average risk screening colonoscopy patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	 RESULTS One hundred and ninety patients were prospectively enrolled (87 MiraLAX, 103 Golytely).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	Golytely had a higher rate of a BBPS score ≥ 7 (82.5% vs. MiraLAX 67.8%, P=0.02).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	The ADR in the Golytely cohort was 26.2% (27/103), and was 16.1% (14/87) for MiraLAX (P = 0.091).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	On multivariate analyses, Golytely was 2.13 × more likely to be associated with a BBPS ≥ 7 (95% CI 1.05-4.32, P = 0.04) and 2.28 × more likely to be associated with adenoma detection (95% CI 1.05-4.98, P = 0.04) than MiraLAX.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS Golytely was more efficacious than MiraLAX in bowel cleansing, and was independently associated with both bowel prep quality (BBPS ≥ 7) and higher adenoma detection.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21848798_20201005_0.5	golytely	drug_synonym	Golytely should be used as first line for bowel prep for colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9012222_20201005_0.5			[Preparation for colonoscopy: a reliable and easily implemented regimen].	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9012222_20201005_0.5			Administration, Oral|Adult|Aged|Anthraquinones|Cathartics|Colon|Colonoscopy|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Prospective Studies|Single-Blind Method|Sulfates|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9012222_20201005_0.5	golytely	drug_synonym	The original Golytely-recepture with three litres of liquid was tested against Clean Prep which has to be dissolved in four litres of liquid.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9012222_20201005_0.5	golytely	drug_synonym	The preparation with the three bags containing three litres of Golytely solution according to the original recepture proved to be the least troublesome for the patients and was the most efficient method when it came to cleanliness and the formation of foam.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9246046_20201005_0.5	golytely	drug_synonym	Use of oral GoLytely solution in relief of refractory fecal impaction.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9246046_20201005_0.5			Administration, Oral|Aged|Aged, 80 and over|Electrolytes|Fecal Impaction|Female|Humans|Intubation, Gastrointestinal|Male|Middle Aged|Polyethylene Glycols|Solutions|Time Factors	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9246046_20201005_0.5	golytely	drug_synonym	We describe the use of GoLytely oral solution in 10 patients admitted to a community hospital and referred to a single gastroenterologist for fecal impaction refractory to conventional medical treatment.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9246046_20201005_0.5	golytely	drug_synonym	Seven women and three men received enemas, bisacodyl suppositories, and digital fragmentation either solely or in combination prior to the administration of GoLytely oral solution.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9246046_20201005_0.5	golytely	drug_synonym	GoLytely oral solution (Braintree Laboratories, Inc.) was administered at a rate of 100 ml/hr per orem to three patients, via nasogastric tube in six patients, and via gastrostomy tube in one patient.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9246046_20201005_0.5	golytely	drug_synonym	GoLytely oral solution effectively relieved fecal impaction in 10 patients refractory to conventional medical treatment.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3536524_20201005_0.5			Preoperative preparation of the bowel for urological surgery: a review.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3536524_20201005_0.5			Digestive System|Humans|Surgical Wound Infection|Urinary Tract	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3536524_20201005_0.5	golytely	drug_synonym	We prefer oral lavage with Golytely solution since it allows rapid preparation of the gut and is well tolerated.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3344724_20201214_0.5			Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis. A safe and effective therapeutic program.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3344724_20201214_0.5			Adolescent|Child|Child, Preschool|Colonoscopy|Electrolytes|Encopresis|Humans|Infant|Mineral Oil|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3344724_20201214_0.5	golytely	drug_synonym	A balanced electrolyte solution of the nonabsorbable polymer polyethylene glycol (GoLytely, Braintree [Mass] Laboratories Inc) offers a safe and efficient method for clearing the intestine.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23949576_20201005_0.5			Adding pineapple juice to a polyethylene glycol-based bowel cleansing regime improved the quality of colon cleaning.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23949576_20201005_0.5			Adult|Aged|Aged, 80 and over|Ananas|Beverages|Colon|Colonoscopy|Electrolytes|Female|Fruit|Humans|Male|Middle Aged|Polyethylene Glycols|Therapeutic Irrigation|Turkey|Young Adult	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23949576_20201005_0.5	golytely	drug_synonym	A total of 126 patients were randomized into 3 groups receiving 3 different PEG-EL (Golytely®) regimes, i.e. 4 liters of PEG-EL (group 1, n = 44), 2 liters of PEG-EL (group 2, n = 39) or 2 liters of PEG-EL with 1 liter of pineapple juice (Dimes® 100%; group 3, n = 43).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID12664385_20201005_0.5			A randomized, blinded, prospective trial to compare the safety and efficacy of three bowel-cleansing solutions for colonoscopy (HSG-01*).	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID12664385_20201005_0.5			Adolescent|Adult|Aged|Cathartics|Colonoscopy|Electrolytes|Female|Humans|Male|Middle Aged|Phosphates|Polyethylene Glycols|Prospective Studies|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID12664385_20201005_0.5	golytely	drug_synonym	This study was carried out to compare the efficacy, safety, and tolerability of three widely used bowel lavage solutions: the standard polyethylene glycol-electrolyte solution based on the GoLytely formulation (PEG-EL1; Klean-Prep); a sulphate-free PEG-EL solution based on the NuLytely formulation (PEG-EL2, Endofalk); and a sodium phosphate preparation (NaP, Fleet Phospho-Soda).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3965343_20201005_0.5	golytely	drug_synonym	Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3965343_20201005_0.5			Aged|Colonic Diseases|Colonoscopy|Contrast Media|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3965343_20201005_0.5	golytely	drug_synonym	Eighteen consecutive patients undergoing colonoscopy for polyps or mass lesions, properly age- and sex-matched, were randomized to receive Golytely lavage (3-4 L) or a standard preparation (48-h clear liquid diet, 240 ml of magnesium citrate and "X-Prep" senna derivative).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3965343_20201005_0.5	golytely	drug_synonym	Statistically significant differences were found for preservation of surface epithelial and goblet cells and less edema in favor of patients receiving Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2011703_20201005_0.5			Effectiveness and acceptability of three bowel cleansing regimens.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2011703_20201005_0.5			Adult|Aged|Aged, 80 and over|Colonoscopy|Electrolytes|Female|Humans|Isotonic Solutions|Male|Middle Aged|Patient Compliance|Polyethylene Glycols|Prospective Studies|Sodium Chloride|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2011703_20201005_0.5	golytely	drug_synonym	No section The effectiveness and acceptability of three colon cleansing regimens for colonoscopy were compared in a prospective study in 271 patients stratified as in- and out-patients and randomly assigned to either I) a diet and Senna laxative (X-prep), combined with a saline enema (n = 88); II) 41 of a polyethylene glycol electrolyte lavage solution (Golytely) (n = 90); or III) a combined regimen of Cascara-Salax laxative (PicoSalax) and 1.51 Golytely (n = 93).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID26084134_20201005_0.5			What is the main target: a clearer colon with a sennoside-based regime, or adequate bowel cleansing before colonoscopy with a PEG-EL-based regime?	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID26084134_20201005_0.5			Adult|Cathartics|Colonic Diseases|Colonoscopy|Electrolytes|Female|Humans|Male|Pharmaceutical Solutions|Polyethylene Glycols|Reproducibility of Results|Senna Extract|Sennosides|Therapeutic Irrigation|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID26084134_20201005_0.5	golytely	drug_synonym	The patients were divided into 2 groups; in Group 1, 91 patients were given sennoside a + b calcium 500 mg/250 mL (X-M solution, Yenişehir Laboratuarı, Ankara, Turkey), and in Group 2, 94 patients were given 4 L of PEG-EL (Golytely, Boston, MA, USA).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC4052121_20201005_0.5			Aspiration Pneumonitis Caused by Polyethylene Glycol-Electrolyte Solution Treated with Conservative Management	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC4052121_20201005_0.5	golytely	drug_synonym	Male|Humans|Child|Conservative Treatment|Golytely|Polyethylene Glycols|Electrolytes|Pneumonia, Aspiration|Colonoscopy|Therapeutic Irrigation|Bronchoalveolar Lavage|Lung|Intestines|Intubation, Gastrointestinal	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMC4052121_20201005_0.5	golytely	drug_synonym	No section Polyethylene glycol (PEG) electrolyte solution, Golytely, is an osmotic laxative commonly used in preoperative bowel cleansing.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7996392_20201005_0.5	golytely	drug_synonym	Decreased cyclosporin A absorption after treatment with GoLytely lavage solution in rats.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7996392_20201005_0.5			Analysis of Variance|Animals|Cyclosporine|Dose-Response Relationship, Drug|Drug Interactions|Electrolytes|Humans|Immunosuppression|Intestinal Absorption|Kidney Transplantation|Male|Models, Biological|Polyethylene Glycols|Rats|Rats, Wistar|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7996392_20201005_0.5	golytely	drug_synonym	No section Recently we observed a case in which the cyclosporin A absorption decreased after treatment with GoLytely lavage solution in a kidney transplant patient.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7996392_20201005_0.5	golytely	drug_synonym	In this study, we confirmed the decrease of the blood concentration of cyclosporin A after oral administration by GoLytely (Macrogol 3350) based on experiments with rats.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7996392_20201005_0.5	golytely	drug_synonym	The peak blood cyclosporin A concentration, and the area under the blood drug concentration-time curve from 0 to 24 h in the GoLytely-administered group were significantly lower than the control group.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID7996392_20201005_0.5	golytely	drug_synonym	In the case of gastrointestinal dysfunction such as diarrhoea, or in treatment with laxatives such as GoLytely lavage solution, whole blood cyclosporin levels must be carefully monitored, and intravenous cyclosporin A may be more suitable for providing adequate immunosuppression.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5			Comparison of cleansing methods in preparation for colonic surgery.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5			Adult|Aged|Colon|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Prospective Studies|Random Allocation|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5	golytely	drug_synonym	No section Golytely, an oral gut lavage solution, was compared with a standard bowel cleansing preparation in patients undergoing elective colonic surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5	golytely	drug_synonym	Sixty patients were randomly assigned to either a one-day preparation with Golytely and bisacodyl or a standard method using a three-day clear liquid diet, cathartics, and enemas.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5	golytely	drug_synonym	Colon cleansing was better with Golytely (100 percent optimal cleansing vs. 64 percent, P less than 0.05).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5	golytely	drug_synonym	Patients receiving Golytely had less weight loss and found this preparation more tolerable.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID4017808_20201005_0.5	golytely	drug_synonym	In this surgical bowel preparation study, Golytely and Bisacodyl were found to be safe, rapid, and effective.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9609437_20201005_0.5	golytely	drug_synonym	Life-threatening complications of nasogastric administration of polyethylene glycol-electrolyte solutions (Golytely) for bowel cleansing.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9609437_20201005_0.5			Administration, Oral|Aged|Aged, 80 and over|Colonoscopy|Electrolytes|Fatal Outcome|Female|Follow-Up Studies|Humans|Intubation, Gastrointestinal|Male|Middle Aged|Pneumonia, Aspiration|Polyethylene Glycols|Pulmonary Edema|Radiography|Respiratory Distress Syndrome, Adult|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21502828_20201005_0.5			Long-term follow-up of patients after antegrade continence enema procedure.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21502828_20201005_0.5			Adolescent|Anal Canal|Cerebral Palsy|Child|Constipation|Constriction, Pathologic|Defecation|Electrolytes|Enema|Fecal Incontinence|Female|Follow-Up Studies|Hematologic Diseases|Humans|Infections|Male|Ostomy|Pain|Patient Compliance|Polyethylene Glycols|Postoperative Complications|Rectum|Retrospective Studies|Sodium Chloride|Surgical Stomas|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID21502828_20201005_0.5	golytely	drug_synonym	Patients were started on normal saline, but were switched to GoLYTELY (PEG-3350 and electrolyte solution) if there was an inadequate response (61% at final encounter).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3976636_20201005_0.5	golytely	drug_synonym	Golytely lavage--is metoclopramide necessary?	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3976636_20201005_0.5			Adolescent|Adult|Aged|Colon|Colonoscopy|Consumer Behavior|Drug Evaluation|Electrolytes|Female|Humans|Male|Metoclopramide|Middle Aged|Polyethylene Glycols|Premedication|Random Allocation|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3976636_20201005_0.5	golytely	drug_synonym	No section During Golytely cleansing for colonoscopy, two dose forms of oral metoclopramide were evaluated in separate studies for patient tolerance and adequacy of preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3976636_20201005_0.5	golytely	drug_synonym	The percentage of patients preferring Golytely was similar in both studies (70-79%, p = NS) and 85% of all patients were willing to repeat Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3976636_20201005_0.5	golytely	drug_synonym	Neither 10 nor 20 mg oral metoclopramide improved adequacy of colon cleansing for colonoscopy or decreased symptoms associated with Golytely lavage.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30730859_20201005_0.5			Comparing the Real-World Effectiveness of Competing Colonoscopy Preparations: Results of a Prospective Trial.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30730859_20201005_0.5			Adolescent|Adult|Aged|Cathartics|Citric Acid|Colonoscopy|Electrolytes|Female|Humans|Isotonic Solutions|Male|Middle Aged|Organometallic Compounds|Polyethylene Glycols|Prospective Studies|Young Adult	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30730859_20201005_0.5	golytely	drug_synonym	Magnesium citrate, MiraLAX with Gatorade, MoviPrep, OsmoPrep, Prepopik/Clenpiq, and Suprep all had significantly higher prep tolerability compared with GoLYTELY (all P < 0.05).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID30730859_20201005_0.5	golytely	drug_synonym	For bowel cleansing, Suprep (7.28 ± 1.66; P < 0.001), MoviPrep (7.11 ± 1.62; P = 0.004), and MiraLAX with Gatorade (7.09 ± 1.64; P < 0.001) had higher total Boston Bowel Preparation Scale scores compared with GoLYTELY (6.67 ± 1.87); there were no significant differences among the remaining preps.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3902550_20201005_0.5	golytely	drug_synonym	Randomized single-blind clinical trial of a rapid colonic lavage solution (Golytely) vs. standard preparation for barium enema and colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3902550_20201005_0.5			Adult|Aged|Barium Sulfate|Clinical Trials as Topic|Colon|Colonoscopy|Electrolytes|Enema|Humans|Male|Middle Aged|Patient Acceptance of Health Care|Polyethylene Glycols|Radiography|Random Allocation|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3902550_20201005_0.5	golytely	drug_synonym	For colonoscopy, Golytely preparation resulted in slightly better results than standard preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3902550_20201005_0.5	golytely	drug_synonym	We conclude that Golytely can be used as an alternative to standard preparation for barium enema.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15194933_20201005_0.5			Reasons for poor colonic preparation with inpatients.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15194933_20201005_0.5			Attitude of Health Personnel|Bisacodyl|Cathartics|Colonoscopy|Diet|Electrolytes|Enema|Female|Humans|Male|Medical Staff, Hospital|Middle Aged|Polyethylene Glycols|Preoperative Care|Time Factors|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID15194933_20201005_0.5	golytely	drug_synonym	The optimal bowel preparation was a 6-liter Golytely preparation along with a secondary preparation (e.g., tap water enema, Fleets enema, Dulcolax tablets).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6737193_20201005_0.5	golytely	drug_synonym	Use of Golytely in children and adolescents.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6737193_20201005_0.5			Adolescent|Child|Colonoscopy|Drug Evaluation|Electrolytes|Female|Humans|Male|Polyethylene Glycols|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6737193_20201005_0.5	golytely	drug_synonym	The experience of 24 children and adolescents with Golytely, a new colonic lavage solution, is presented.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID6737193_20201005_0.5	golytely	drug_synonym	Oral Golytely was found to be less inconvenient for patients, safe, and more cost-effective because it decreased hospitalization time.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2371150_20201005_0.5			Polyethylene glycol-electrolyte solution for rectal sunflower seed bezoar.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2371150_20201005_0.5			Bezoars|Child|Electrolytes|Humans|Intubation, Gastrointestinal|Male|Polyethylene Glycols|Rectum|Seeds|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2371150_20201005_0.5	golytely	drug_synonym	No section We describe the successful use of polyethylene glycoelectrolyte solution (Golytely) in the management of a child who developed a rectal phytobezoar after ingestion of unshelled sunflower seeds.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2305174_20201005_0.5			Effect of bismuth subsalicylate on fecal microflora.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2305174_20201005_0.5			Adult|Bacteria|Bismuth|Colony Count, Microbial|Feces|Humans|Male|Middle Aged|Organometallic Compounds|Salicylates|Yeasts	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2305174_20201005_0.5	golytely	drug_synonym	In the second group, a standard oral intestinal lavage preparation (GoLYTELY) was used to clean the colon and then 8 ounces of BSS was given during a 4-hour period.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2305174_20201005_0.5	golytely	drug_synonym	On day 2 the yeast counts rose 2.4 log10 colony-forming units/g in the group taking 16 ounces of BSS but did not increase in the group taking 8 ounces of BSS plus GoLYTELY.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1992646_20201005_0.5	golytely	drug_synonym	Comment on oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) content.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1992646_20201005_0.5			Electrolytes|Humans|Phosphates|Polyethylene Glycols|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5			The efficacy of polyethylene glycol-electrolyte lavage solution versus traditional mechanical bowel preparation for elective colonic surgery: a randomized, prospective, blinded clinical trial.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5			Adult|Aged|Anti-Bacterial Agents|Bacteria|Clinical Trials as Topic|Colectomy|Colon|Colonic Neoplasms|Diverticulitis, Colonic|Double-Blind Method|Electrolytes|Female|Gastrointestinal Hemorrhage|Humans|Male|Middle Aged|Polyethylene Glycols|Premedication|Preoperative Care|Prospective Studies|Random Allocation|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5	golytely	drug_synonym	No section This study documents the efficacy, safety and patient tolerance of GoLYTELY (Braintree Laboratories, Inc., Braintree, Mass.) an orally administered, nonexplosive, polyethylene glycol-electrolyte lavage solution, in elective colonic surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5	golytely	drug_synonym	Fifty-three patients admitted for colonic surgery were randomized to either GoLYTELY or a traditional 3-day bowel preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5	golytely	drug_synonym	Mechanical preparation with GoLYTELY resulted in a greater feeling of fullness, while the traditional preparation produced more hunger and abdominal cramping.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5	golytely	drug_synonym	The use of GoLYTELY resulted in better scores of overall quality and bowel appearance, reflecting a greater efficiency with which it removed air, fluid, and feces from the bowel.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5	golytely	drug_synonym	GoLYTELY also resulted in significantly fewer total aerobic and anaerobic organisms in sigmoid aspirates.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3901374_20201005_0.5	golytely	drug_synonym	This study suggests that GoLYTELY is a safe, well-tolerated, and effective orthograde lavage solution that has significant advantages over other mechanical preparations and should be considered the preparation of choice for elective colonic surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5	golytely	drug_synonym	MiraLAX-Gatorade bowel prep versus GoLytely before screening colonoscopy: an endoscopic database study in a community hospital.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5			Aged|Bisacodyl|Cathartics|Colonoscopy|Confidence Intervals|Early Detection of Cancer|Electrolytes|Female|Hospitals, Community|Humans|Isotonic Solutions|Male|Middle Aged|Odds Ratio|Polyethylene Glycols|Retrospective Studies	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5	golytely	drug_synonym	 OBJECTIVE To compare the frequency of excellent/good/fair/poor bowel cleansing with PM-only dosing of MiraLAX-Gatorade-bisacodyl versus 4-liter GoLytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5	golytely	drug_synonym	Data were extracted for the last 4 months when 4-liter GoLytely was the preferred bowel purgative and the first 4 months when 238-g MiraLAX in 64-ounce Gatorade and four 5-mg bisacodyl tablets became the preferred purgative.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5	golytely	drug_synonym	 RESULTS A total of 778 subjects [GoLytely (n=395) vs. MiraLAX+Gatorade+bisacodyl (n=383)] were identified.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5	golytely	drug_synonym	Patients who took the MiraLAX bowel preparation were more likely to achieve an excellent/good bowel cleansing compared with patients taking the GoLytely preparation (93.3% vs. 89.3%, respectively; P=0.048).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID23060223_20201005_0.5	golytely	drug_synonym	 CONCLUSIONS The MiraLAX+Gatorade+bisacodyl combination produces similar rates of excellent/good bowel cleansing as compared with GoLytely in most average-risk individuals undergoing colonoscopy for colorectal screening in a community setting.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8761394_20201005_0.5	golytely	drug_synonym	A blinded clinical trial comparing conventional cleansing enema, Pico-salax and Golytely for barium enema bowel preparation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8761394_20201005_0.5			Adult|Barium Sulfate|Cathartics|Citrates|Citric Acid|Defecation|Electrolytes|Enema|Humans|Magnesium Oxide|Middle Aged|Organometallic Compounds|Picolines|Polyethylene Glycols|Prospective Studies|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8761394_20201005_0.5	golytely	drug_synonym	No section An evaluator-blinded randomized clinical trial was undertaken to assess the effectiveness and patient acceptance of three bowel cleansing regimens: conventional cleansing enema, Pico-salax and Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8761394_20201005_0.5	golytely	drug_synonym	 RESULTS The mean (standard deviation) of bowel opening frequency for the cleansing enema, Pico-Salax and Golytely were 3.6(4.4), 8.3(4.8) and 7.1(4.2), respectively, with less bowel opening in the cleansing enema.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8761394_20201005_0.5	golytely	drug_synonym	There was less nausea associated with the cleansing enema (P = 0.006), more vomiting with Golytely (P = 0.008), less abdominal fullness with Pico-salax (P = 0.0006), less anorectal irritation with Golytely (P = 0.025), and no difference in the abdominal pain amongst three groups.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8761394_20201005_0.5	golytely	drug_synonym	Patients found that Pico-salax tasted better than Golytely (P = 0.0094) and Golytely was less accepted in the amount of fluid intake (P = 0.0018 and P < 0.0002 comparing Golytely with the cleansing enema and Pico-salax).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1675852_20201005_0.5			Use of whole bowel irrigation in an infant following iron overdose.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1675852_20201005_0.5			Deferoxamine|Ferrous Compounds|Humans|Infant|Intestine, Large|Ipecac|Male|Poisoning|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1675852_20201005_0.5	golytely	drug_synonym	Whole bowel irrigation with polyethylene glycol electrolyte lavage solution (Golytely, Braintree Laboratories, Inc, Braintree, MA) was begun via nasogastric tube 14 hours after the ingestion.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID17055683_20201005_0.5			Bowel preparation for CT-colonography: comparison of two different cleansing protocols.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID17055683_20201005_0.5			Bisacodyl|Cathartics|Colonography, Computed Tomographic|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Prone Position|Retrospective Studies|Solutions|Statistics, Nonparametric|Supine Position|Surface-Active Agents	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID17055683_20201005_0.5	golytely	drug_synonym	Fifty-one patients received preparation 1 (BP1; based on a GoLytely formulation+bisacodyl), 52 preparation 2 (BP2; based on a NuLytely formulation+bisacodyl).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9145984_20201005_0.5			Management of neurogenic fecal incontinence in myelodysplastic children by a modified continent appendiceal stoma and antegrade colonic enema.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9145984_20201005_0.5			Adolescent|Adult|Appendix|Child|Colostomy|Enema|Fecal Incontinence|Female|Follow-Up Studies|Humans|Male|Proctocolectomy, Restorative|Spinal Dysraphism	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9145984_20201005_0.5	golytely	drug_synonym	 RESULTS All patients reached fecal continence for at least 38 hours (median 45.3) by using antegrade colonic enemas with 1.5% saline solution (n = 9) or GoLYTELY solution (n = 1), 0.5 to 1.5 L every 2 to 3 days.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9404202_20201005_0.5	golytely	drug_synonym	Comparison of two oral evacuants (Citromag and Golytely) for bowel preparation before barium enema.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9404202_20201005_0.5			Adolescent|Adult|Age Distribution|Aged|Attitude to Health|Barium Sulfate|Cathartics|Citric Acid|Electrolytes|Enema|Female|Humans|Intestine, Large|Male|Middle Aged|Observer Variation|Polyethylene Glycols|Prospective Studies|Radiography|Sex Distribution|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9404202_20201005_0.5	golytely	drug_synonym	We performed a prospective study comparing the side-effects and efficacy of two commonly used oral bowel evacuants (Citromag and Golytely) for bowel preparation before barium enema examination in 102 patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9404202_20201005_0.5	golytely	drug_synonym	There was no significant difference in the side-effects between the two agents although more patients taking Golytely (45.5%) deemed its taste unacceptable than those taking Citromag (25.9%).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9404202_20201005_0.5	golytely	drug_synonym	The amount of faecal residue was less in the Golytely group (p < 0.05).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID9404202_20201005_0.5	golytely	drug_synonym	The quality of mucosal coating by barium was also better in the Golytely group than the Citromag group (p < 0.05).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID25474093_20201005_0.5			Orbeez: the magic water absorbing bead--risk of pediatric bowel obstruction?	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID25474093_20201005_0.5			Absorption, Physicochemical|Animals|Child|Child, Preschool|Eating|Electrolytes|Ethanol|Foreign Bodies|Hazardous Substances|Humans|Infant|Intestinal Obstruction|Milk|Play and Playthings|Polyethylene Glycols|Polymers|Solutions|Water	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID25474093_20201005_0.5	golytely	drug_synonym	 METHODS Three Orbeez beads were added to 210 mL of the following liquid media: room temperature tap water, whole milk, simulated gastric fluid, GoLytely (polyethelyelene glycol, 3350 and electrolytes), and vodka (40% ethanol by volume).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8583438_20201005_0.5			Role of oral sodium phosphate and its effectiveness in large bowel preparation for out-patient colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8583438_20201005_0.5			Administration, Oral|Ambulatory Care|Colonoscopy|Drug Tolerance|Enema|Female|Humans|Male|Middle Aged|Phosphates	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID8583438_20201005_0.5	golytely	drug_synonym	Seventy-nine patients (35 male, 44 female) for elective out-patient colonoscopy were randomized to receive either PEG (GoLYTELY) solution or oral sodium phosphate (Fleet PhosphoSoda) before the procedure.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5			Improvement of oral colonic lavage with supplemental simethicone.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5			Administration, Oral|Adult|Aged|Aged, 80 and over|Colon|Colonoscopy|Double-Blind Method|Electrolytes|Feces|Humans|Male|Middle Aged|Polyethylene Glycols|Random Allocation|Silicones|Simethicone|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5	golytely	drug_synonym	No section We have noted that colons of patients prepared for colonoscopy with Golytely, a nonabsorbable electrolyte lavage solution, frequently contain foam which may obscure small mucosal lesions.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5	golytely	drug_synonym	Therefore, a randomized, blinded controlled trial was performed to determine the prevalence of Golytely-induced foam and the effect of supplemental simethicone in decreasing the prevalence of foam.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5	golytely	drug_synonym	Foam was present in 32% of colons prepared with Golytely alone but in none of the colons prepared with Golytely supplemented with simethicone.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5	golytely	drug_synonym	In addition, only 5% of colons prepared with supplemental simethicone had residual stool noted at the time of colonoscopy, a significant improvement over the 39% prevalence of residual stool in colons prepared with Golytely alone.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID3338367_20201214_0.5	golytely	drug_synonym	Addition of simethicone to Golytely lavage decreases the prevalence of colonic foam and residual stool.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5	golytely	drug_synonym	Evaluation of rapid colon preparation with Golytely.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5			Colon|Colorectal Neoplasms|Electrolytes|Female|Humans|Male|Middle Aged|Polyethylene Glycols|Preoperative Care|Solutions|Therapeutic Irrigation	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5	golytely	drug_synonym	Though Golytely, an oral lavage solution, has been developed since 1980 as an alternative for cleansing the colon and much literature has favored it, it has not been widely used in Taiwan.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5	golytely	drug_synonym	In this study, we used Golytely without enema for rapid colon cleansing in a consecutive series of 48 patients.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5	golytely	drug_synonym	The average amount of Golytely used in this preparation was 3.16 liters, and the average time was 8 hours and 43 minutes.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5	golytely	drug_synonym	About 87% of patients receiving Golytely achieved a good to excellent preparation.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID2819568_20201005_0.5	golytely	drug_synonym	The patient's acceptance of Golytely was better than that of castor oil.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1623022_20201005_0.5			NuLYTELY (PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution).	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1623022_20201005_0.5			Colonoscopy|Electrolytes|Humans|Polyethylene Glycols|Premedication|Solutions	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1623022_20201005_0.5	golytely	drug_synonym	No section NuLYTELY (PEG 3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution), a product from Braintree Laboratories, Inc. is a modification of GoLYTELY (PEG 3350 and Electrolytes for Oral Solution) that has been found to have the same therapeutic advantages in terms of safety, efficacy, speed and patient acceptance.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID1623022_20201005_0.5	golytely	drug_synonym	This product was developed to improve upon the taste of GoLYTELY.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID33755652_20210511_0.5			Sodium sulfate-based tablets (Sutab) for colonoscopy preparation.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID33755652_20210511_0.5	golytely	drug_synonym	Clenpiq|Colyte|Gatorade|GaviLyte|GoLYTELY|Miralax|MoviPrep|NuLYTELY|OsmoPrep|PEG|Pico-Salax|Plenvu|Suprep|Sutab|TriLyte|adverse effects|bowel preparation|cancer screening|colonoscopy|colorectal cancer|dosage|drug interactions|efficacy|electrolyte solutions|lactation|pregnancy|safety|sodium phosphate|sodium picosulfate|sodium sulfate	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID33755652_20210511_0.5			Cathartics|Colonoscopy|Drug Interactions|Humans|Randomized Controlled Trials as Topic|Sulfates|Tablets	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5			Split-dosed MiraLAX/Gatorade is an effective, safe, and tolerable option for bowel preparation in low-risk patients: a randomized controlled study.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5			Analysis of Variance|Cathartics|Colonoscopy|Electrolytes|Female|Humans|Isotonic Solutions|Male|Middle Aged|Polyethylene Glycols|Risk Assessment|Single-Blind Method|Surface-Active Agents|Treatment Outcome	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5	golytely	drug_synonym	OBJECTIVE MiraLAX with Gatorade is a low-volume bowel preparation regimen that has been used widely in community practice and is anecdotally better tolerated than Golytely.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5	golytely	drug_synonym	The primary aim of this study was to compare the efficacy, safety, and tolerability of single-dosed and split-dosed regimens of MiraLAX/Gatorade with Golytely for bowel preparation before colonoscopy.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5	golytely	drug_synonym	Subjects were randomized into four groups: 4 l Golytely single-dosed (Go-Si), 4 l Golytely split-dosed (Go-Sp), 238 g MiraLAX in 64 oz of Gatorade single-dosed (Mlax-Si), and MiraLAX/Gatorade split-dosed (Mlax-Sp) groups.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5	golytely	drug_synonym	Subjects rated the taste and overall experience of Mlax/Gatorade preparation better than Golytely (P<0.01).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5	golytely	drug_synonym	In all, 96.8% of Mlax/Gatorade subjects were willing to repeat the same preparation vs. 75% for Golytely subjects (P<0.01).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID22565162_20201005_0.5	golytely	drug_synonym	MiraLAX/Gatorade appears to be more tolerable than Golytely as a bowel cleansing regimen and was the preferred agent by the patients in this study.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID31298628_20210611_0.5			A Digital Preprocedure Instruction Program for Outpatient Colonoscopy.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID31298628_20210611_0.5			e-health|education|technology|telehealth|telemedicine	author_keywords
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID31298628_20210611_0.5			Appointments and Schedules|Colonoscopy|Early Detection of Cancer|Humans|Outpatients|Text Messaging	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID31298628_20210611_0.5	golytely	drug_synonym	Eligible patients included English speakers on GoLYTELY Our controlled study demonstrated the effectiveness of digital instructions to reduce no-show and same-day cancellation rates for outpatient colonoscopy from 10.40% to 6.08% (p < 0.001).	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18197928_20201005_0.5	golytely	drug_synonym	Aspiration pneumonia due to polyethylene glycol-electrolyte solution (Golytely) treated by bronchoalveolar lavage.	title
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18197928_20201005_0.5			Administration, Oral|Aged|Bronchoalveolar Lavage|Electrolytes|Humans|Male|Pneumonia, Aspiration|Polyethylene Glycols	mesh_terms
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18197928_20201005_0.5	golytely	drug_synonym	No section Polyethylene glycol (PEG)-electrolyte solution (Golytely), is most commonly used for bowel preparation before colonoscopy, as well as for barium enema and colon surgery.	abstract
polyethyleneglycol	Z0000068882	golytely			inn	PubMed	PMID18197928_20201005_0.5	golytely	drug_synonym	In this case, a 70-year-old man developed ARDS following the administration of Golytely by mouth before a scheduled colonoscopy.	abstract
dipridamole	Z0000093938				inn	PubMed	PMID6156327_20201005_0.5			Effect of dipyridamole on ischemia-induced changes in cardiac performance and metabolism.	title
dipridamole	Z0000093938				inn	PubMed	PMID6156327_20201005_0.5			Animals|Coronary Circulation|Coronary Disease|Dipyridamole|Dogs|Heart|Myocardial Contraction|Myocardium|Nifedipine	mesh_terms
dipridamole	Z0000093938				inn	PubMed	PMID6156327_20201005_0.5	dipridamole	drug_name	Dipridamole administered at the end of the ischemic period and prior to reperfusion also prevented the ischemia-induced fall in dp/dt but not the decrease in compliance.	abstract
dipridamole	Z0000093938				inn	PubMed	PMID17943063_20201005_0.5			The endothelium, platelets, and brain ischemia.	title
dipridamole	Z0000093938				inn	PubMed	PMID17943063_20201005_0.5			Animals|Blood Coagulation|Blood Platelets|Brain Ischemia|Cell Adhesion|Cerebral Arteries|Endothelial Cells|Fibrinogen|Fibrinolytic Agents|Humans|Intracranial Thrombosis	mesh_terms
dipridamole	Z0000093938				inn	PubMed	PMID17943063_20201005_0.5	dipridamole	drug_name	There are now 4 general strategies for reducing the formtion of white platelet-fibrin clots:1) administration of agents that affect platelets and the endothelium (dipridamole, cilostazol); 3)administration of agents that affect the attachment of platelets to fibrinogen (abciximab and other glycoprotein IIIb/IIIa inhibitors); and 4) reducing fibrinogen levels and activity.	abstract
dipridamole	Z0000093938				inn	PubMed	PMID845612_20201005_0.5			Transient ischaemic attacks and increased platelet aggregability associated with oral contraceptives. Treatment with dipyridamole and aspirin.	title
dipridamole	Z0000093938				inn	PubMed	PMID845612_20201005_0.5			Adult|Aspirin|Contraceptives, Oral|Dipyridamole|Female|Humans|Ischemic Attack, Transient|Platelet Aggregation	mesh_terms
dipridamole	Z0000093938				inn	PubMed	PMID845612_20201005_0.5	dipridamole	drug_name	A significant increase in spontaneous platelet aggregation was found, and combined treatment with dipridamole and aspirin was started.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	oral treprostinil|prostacyclin analogue|pulmonary arterial hypertension|6-minute walk distance|dose–response	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	Humans|Male|Adult|Middle Aged|Female|treprostinil|Pulmonary Arterial Hypertension|Prospective Studies|Epoprostenol|Familial Primary Pulmonary Hypertension|Walking|Hypertension, Pulmonary|Antihypertensive Agents|Exercise Tolerance|Treatment Outcome|Administration, Oral|Prostaglandins I	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	No section Oral treprostinil may be an option for low- and intermediate-risk patients with pulmonary arterial hypertension, a rare lung vascular disease.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	This open-label extension study collected data on participants who completed previously reported, placebo-controlled oral treprostinil studies.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	Eligible participants had completed the prospective parent studies and took increasing doses of oral treprostinil twice daily; some later transitioned to three times daily dosing.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	Oral treprostinil is associated with modest but durable, dose-responsive effects on exercise tolerance for those who remained on therapy at one year in this prospective, uncontrolled study.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7731723_20210111_0.5	treprostinil	drug_name	The recently completed Freedom-EV study will provide further insights into the utility of oral treprostinil ( ).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20660124_20201005_0.5			Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20660124_20201005_0.5			Acetamides|Animals|Dinoprostone|Dose-Response Relationship, Drug|Epoprostenol|Gastric Emptying|Gastrointestinal Transit|Humans|Iloprost|Male|Muscle Contraction|Pulmonary Artery|Pyrazines|RNA, Messenger|Rats|Receptors, Epoprostenol|Reverse Transcriptase Polymerase Chain Reaction|Stomach	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20660124_20201005_0.5	treprostinil	drug_name	Contraction to treprostinil was observed at high concentration (10(-4) M).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29886070_20201005_0.5			Inhalation of repurposed drugs to treat pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29886070_20201005_0.5	treprostinil	drug_name	Aerosol therapy|Inhalation|Inhaled iloprost|Inhaled treprostinil|Prostacyclin analogues|Pulmonary arterial hypertension|Pulmonary selectivity|Repurposed drugs|Vascular remodeling	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29886070_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Drug Repositioning|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29886070_20201005_0.5	treprostinil	drug_name	Among these, the stable prostacyclin analogues iloprost and treprostinil have been repurposed for inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32657835_20210511_0.5			Evolving spectrum of treatment for CTEPH.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32657835_20210511_0.5			Angioplasty, Balloon|Anticoagulants|Antihypertensive Agents|Chronic Disease|Endarterectomy|Endothelin Receptor Antagonists|Enzyme Activators|Epoprostenol|Humans|Hypertension, Pulmonary|Pulmonary Embolism|Pyrazoles|Pyrimidines|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32657835_20210511_0.5	treprostinil	drug_name	Recently published data suggest that endothelin receptor blockers and treprostinil may also have a role in medical management of this patient population.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21029834_20201214_0.5			Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21029834_20201214_0.5			Antihypertensive Agents|Bosentan|Child|Connective Tissue Diseases|Disease Progression|Female|Heart Defects, Congenital|Humans|Hypertension, Pulmonary|Male|Retrospective Studies|Sulfonamides|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21029834_20201214_0.5	treprostinil	drug_name	Eighty-six children (37 male, 49 female) 11 ± 5 years of age with idiopathic/heritable PAH (n = 36), PAH associated with congenital heart disease (n = 48), or PAH associated with connective tissue disease (n = 2) received bosentan as monotherapy (n = 42) or as an add-on to pre-existing continuous intravenous epoprostenol or subcutaneous treprostinil (n = 44).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18355483_20201005_0.5	treprostinil	drug_name	Treatment of a nonhealing saphenous vein harvest graft with treprostinil sodium.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18355483_20201005_0.5			Aged|Arterial Occlusive Diseases|Coronary Artery Bypass|Coronary Disease|Epoprostenol|Humans|Infusions, Intravenous|Injections, Subcutaneous|Male|Peripheral Vascular Diseases|Postoperative Complications|Risk Assessment|Saphenous Vein|Tissue and Organ Harvesting|Treatment Outcome|Wound Healing|Wounds and Injuries	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18355483_20201005_0.5	treprostinil	drug_name	We report the use of a continuous subcutaneous infusion of treprostinil sodium, an analog of prostacyclin, to treat a limb-threatening, nonhealing saphenous vein harvest incision site after myocardial revascularization.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6659193_20201005_0.5	treprostinil	drug_name	Oral treprostinil use in children: a multicenter, observational experience	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6659193_20201005_0.5			pediatric pulmonary hypertension|pulmonary hypertension|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6659193_20201005_0.5	treprostinil	drug_name	Adult|Child|Humans|Male|Adolescent|Child, Preschool|treprostinil|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Administration, Oral|Prostaglandins|Administration, Inhalation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6659193_20201005_0.5	treprostinil	drug_name	Therapeutic options for children are limited and infrequently described, including newer agents such as treprostinil, an oral prostanoid.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6659193_20201005_0.5	treprostinil	drug_name	This descriptive, observational study describes the various methods of initiation of oral treprostinil in both prostanoid-naïve patients and those transitioning from parenteral or inhaled prostanoids.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3040815_20201005_0.5	treprostinil	drug_name	Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3040815_20201005_0.5	treprostinil	drug_name	Pulmonary hypertension|Congenital heart disease|Vasodilator treatment|Treprostinil|EPC	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3040815_20201005_0.5			Animals|Antihypertensive Agents|Cell Count|Cell Separation|Child|Colony-Forming Units Assay|Endothelial Cells|Epoprostenol|Familial Primary Pulmonary Hypertension|Hematopoietic Stem Cells|Humans|Hypertension, Pulmonary|Mice|Neovascularization, Physiologic|Stem Cells	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3040815_20201005_0.5	treprostinil	drug_name	ECFC grown ex vivo were tested for their angiogenic capacities before and after prostacyclin analog therapy (subcutaneous treprostinil).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3040815_20201005_0.5	treprostinil	drug_name	 Results ECFC counts were significantly enhanced in the 8 children treated with treprostinil, while no change was observed in children receiving oral therapy with endothelin antagonists and/or PDE5 inhibitors.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3040815_20201005_0.5	treprostinil	drug_name	ECFC from patients treated with treprostinil had a hyperproliferative phenotype and showed enhanced angiogenic potential in a nude mouse preclinical model of limb ischemia.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5			Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5			Animals|Arteries|Cyclic AMP|Epoprostenol|GTP-Binding Protein alpha Subunits, Gi-Go|In Vitro Techniques|Male|Phosphatidylinositol 3-Kinases|Rats|Rats, Sprague-Dawley|Receptors, Epoprostenol|Receptors, Prostaglandin|Receptors, Prostaglandin E, EP3 Subtype|Tail|Vasodilation|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5	treprostinil	drug_name	We investigated the role of these receptors in modulating relaxation to PGI(2) analogues cicaprost, iloprost and treprostinil in pre-contracted segments of rat tail artery.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5	treprostinil	drug_name	All analogues caused relaxation which was significantly (P<0.01) inhibited by RO1138452; with maximum response to cicaprost, iloprost and treprostinil reduced by 51%, 66% and 37%, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5	treprostinil	drug_name	GW627368X had no effect when used alone, but in combination with RO1138452, caused a rightward shift of the curves for cicaprost and iloprost but not treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5	treprostinil	drug_name	Basal cAMP levels were higher in PTX-treated tissues and DDA- and Rp-2'-O-MB-cAMPs--sensitive responses increased to analogue concentrations <0.1μM. In conclusion, prostanoid EP(3) receptors via G(i/o) negatively modulate prostanoid IP receptor-mediated relaxation to cicaprost, iloprost and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21185823_20201005_0.5	treprostinil	drug_name	However, other pathways contribute to analogue-induced vasorelaxation, the nature of which remains unclear for treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5			Adolescent|Antihypertensive Agents|Child|Child, Preschool|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Retrospective Studies|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	Recently, intravenous treprostinil has been studied, primarily in adults with PAH, and found to provide effective therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	The effects of continuous intravenous treprostinil were retrospectively evaluated in 13 children with stable PAH who had been treated with epoprostenol for >1 year.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	The children were a mean age of 11 years (range 3 to 17) and were transitioned to treprostinil from August 2004 to August 2005.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	Patients were treated with treprostinil for 1.1 +/- 0.5 years.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	Despite a higher dose of treprostinil, the side effects were subjectively diminished.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17317374_20201005_0.5	treprostinil	drug_name	In conclusion, treprostinil provides an alternative therapy in children with PAH, with fewer side effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation	title
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5			Animals|Bone Marrow|Bone Marrow Transplantation|Cell Cycle|Cell Differentiation|Cell Survival|Chemokine CXCL12|Cholera Toxin|Colforsin|Cyclic AMP|Drug Repositioning|Epoprostenol|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cells|Humans|Mice, Inbred BALB C|Receptors, CXCR4|Receptors, Epoprostenol|Survival Analysis|Whole-Body Irradiation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	We tested the hypothesis that treprostinil, a prostacyclin analog approved for the treatment of pulmonary hypertension, can be repurposed to improve hematopoietic stem cell transplantation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	Among several prostanoid agonists tested in combination with forskolin, treprostinil was most efficacious in raising intracellular cAMP levels in murine and human HPSCs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	Injection of murine and human HSPCs, which had been pretreated with treprostinil and forskolin, enhanced survival of lethally irradiated recipient mice.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	Survival was further improved if recipient mice were subcutaneously administered treprostinil (0.15 mg kg 8 h ) for 10 days.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	Enhanced survival of recipient mice was causally related to treprostinil-enhanced CXCR4-dependent migration of HSPCs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4885501_20201005_0.5	treprostinil	drug_name	Treprostinil stimulates the engraftment of human and murine hematopoietic stem cells without impairing their capacity for self-renewal.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	pediatric pulmonary arterial hypertension|prostacyclin therapy|treprostinil|implantable pump|bridge to lung transplantation	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	Humans|Female|Child|treprostinil|Epoprostenol|Hypertension, Pulmonary|Infusion Pumps, Implantable|Antihypertensive Agents|Familial Primary Pulmonary Hypertension|Administration, Intravenous|Bosentan|Sildenafil Citrate|Exercise Tolerance|Dyspnea|Infusion Pumps|Iloprost|Infusions, Intravenous|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	We describe the first long-term use of an implanted pump for intravenous treprostinil delivery in a pediatric patient with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	Parenteral prostacyclin-based therapy was discussed and the patient rejected options involving external pumps; she finally chose intravenous treprostinil delivery via an implanted pump (LENUS Pro®; fixed flow rate; 20 ml reservoir).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	During follow-up, the pump showed an unexpected, progressive increase in flow rate that allowed a treprostinil dose of 170 ng/kg/min to be achieved, but at the cost of shortened intervals between refills.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	The patient is currently receiving treprostinil 170 ng/kg/min with percutaneous refills every 12-13 days.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6295941_20201005_0.5	treprostinil	drug_name	Thus, implantable pumps might be a valuable alternative to external pumps for treprostinil infusion in pediatric PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18473715_20201005_0.5	treprostinil	drug_name	Treprostinil for the treatment of pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18473715_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Clinical Trials as Topic|Drug Stability|Epoprostenol|Humans|Hypertension, Pulmonary|Injections, Intravenous|Injections, Subcutaneous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18473715_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treprostinil sodium is a stable prostacyclin analogue, sharing pharmacologic actions similar to epoprostenol with comparable haemodynamic effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18473715_20201005_0.5	treprostinil	drug_name	Treprostinil is chemically stable at room temperature and has a long half-life (2 - 4 h), making this drug suitable for subcutaneous administration, with practical benefits in avoiding the risk of line infection and thrombosis, and cardiovascular reactions due to abrupt drug discontinuation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32391733_20210611_0.5	treprostinil	drug_name	Treprostinil in the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32391733_20210611_0.5	treprostinil	drug_name	implanted|inhaled|pulmonary arterial hypertension|pulmonary hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32391733_20210611_0.5	treprostinil	drug_name	In 2009, inhaled treprostinil was approved followed by oral treprostinil in 2013 providing patients with more convenient routes of administration compared with the parenteral alternatives.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32391733_20210611_0.5	treprostinil	drug_name	We are on the cusp of having the first fully implantable infusion pump for continuous intravenous treprostinil delivery.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32391733_20210611_0.5	treprostinil	drug_name	In 2019, generic treprostinil was approved, making the medication much more affordable for patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32391733_20210611_0.5	treprostinil	drug_name	In this review, we discuss in detail the recent developments surrounding both traditional and novel treprostinil products.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3004515_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil and pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3004515_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|bosentan|prostacyclin|treprostinil|6MWD	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3004515_20201005_0.5			Administration, Inhalation|Administration, Oral|Antihypertensive Agents|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3004515_20201005_0.5	treprostinil	drug_name	Treprostinil is a prostacyclin analog that has been demonstrated to be effective when administered by continuous subcutaneous or intravenous infusion, and more recently by nebulization.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5			Administration, Inhalation|Blood Pressure|Cross-Over Studies|Dose-Response Relationship, Drug|Drug Administration Schedule|Epoprostenol|Humans|Hypertension, Pulmonary|Nebulizers and Vaporizers|Pilot Projects|Pulmonary Artery|Pulmonary Circulation|Severity of Illness Index|Single-Blind Method|Ultrasonics|Vascular Resistance|Vasodilation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	OBJECTIVE This study sought to investigate the effects of inhaled treprostinil on pulmonary hemodynamics and gas exchange in severe pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	Treprostinil has a longer plasma half-life and might provide favorable properties when applied by inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	In study 1, both treprostinil and iloprost at an inhaled dose of 7.5 mug displayed a comparable PVR decrease, with a significantly different time course (p < 0.001), treprostinil showing a more sustained effect on PVR (p < 0.0001) and fewer systemic side effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	In study 2, effects of inhalation were observed for 3 h. A near-maximal acute PVR decrease was observed at 30 mug treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	In study 3, treprostinil was inhaled at increasing concentrations with a pulsed ultrasonic nebulizer, mimicking a metered dose inhaler.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	A dose of 15 mug treprostinil was inhaled with 18, 9, 3, 2 pulses, or 1 pulse, each mode achieving comparable, sustained pulmonary vasodilation without significant side effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17045906_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Inhaled treprostinil exerts sustained pulmonary vasodilation with excellent tolerability at relatively low doses and may be inhaled in a few breaths.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7641841_20210111_0.5	treprostinil	drug_name	Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7641841_20210111_0.5	treprostinil	drug_name	PAH|Postoperative effect|Treprostinil|Valvular disease	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7641841_20210111_0.5			Antihypertensive Agents|Aortic Valve|Arterial Pressure|Epoprostenol|Female|Heart Valve Diseases|Heart Valve Prosthesis Implantation|Humans|Infusions, Subcutaneous|Male|Middle Aged|Mitral Valve|Pulmonary Arterial Hypertension|Pulmonary Artery|Retrospective Studies|Severity of Illness Index|Time Factors|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7641841_20210111_0.5	treprostinil	drug_name	Background To investigate the midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension (PAH) using subcutaneous injection of treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7641841_20210111_0.5	treprostinil	drug_name	The patients were divided into the treprostinil group and the conventional treatment group according to whether they received treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7641841_20210111_0.5	treprostinil	drug_name	 Conclusions Continuous subcutaneous infusion of treprostinil was not capable of decreasing pulmonary pressures in patients with severe left heart valvular disease combined with moderate or severe PAH during 1 year follow-up, although which some of our data suggest that might improve the symptoms and quality of life of these patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7074510_20201005_0.5	treprostinil	drug_name	Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7074510_20201005_0.5			implantable infusion pump|pulmonary hypertension|treatment|prostanoid	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7074510_20201005_0.5	treprostinil	drug_name	Humans|treprostinil|Infusion Pumps, Implantable|Pulmonary Arterial Hypertension|Retrospective Studies|Epoprostenol|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Antihypertensive Agents|Administration, Intravenous|Infusions, Intravenous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7074510_20201005_0.5	treprostinil	drug_name	No section Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3194296_20201005_0.5	treprostinil	drug_name	Treprostinil stimulates the engraftment of haematopoetic stem cells	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3194296_20201005_0.5	treprostinil	drug_name	Humans|treprostinil|Epoprostenol|Central Nervous System Stimulants|Hematopoiesis|Stem Cells	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|pediatric|prostacyclin|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Adult|Child|Humans|Adolescent|Male|Female|Child, Preschool|treprostinil|Quality of Life|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Administration, Inhalation|Exercise Tolerance|Prostaglandins|Administration, Oral|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	No section Treprostinil, a prostacyclin analogue, is approved for the treatment of pulmonary arterial hypertension (PAH) in adults.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Transition from parenteral to oral treprostinil has been successfully accomplished in adults with PAH but not in children.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	In this multicenter study, pediatric patients treated with parenteral (Cohort 1) or inhaled (Cohort 2) treprostinil were transitioned to oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Prostacyclin-naïve individuals on background oral PAH therapy received oral treprostinil as add-on therapy (Cohort 3).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Successful transition was oral treprostinil dose maintenance through week 24.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Overall, patients (96.9%) maintained transition to oral treprostinil; one patient (Cohort 1) transitioned to oral treprostinil, then back to parenteral after experiencing syncope and WHO FC change from II to III.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Cohorts 1, 2, and 3 received a final mean oral treprostinil dose of 5.6, 3.3, and 4.5 mg t.i.d.,	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6628532_20201005_0.5	treprostinil	drug_name	Pediatric patients maintained transition to oral treprostinil with preservation of exercise capacity and WHO FC.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17138674_20201005_0.5	treprostinil	drug_name	Long-term treprostinil in pulmonary arterial hypertension: Is the glass half full or half empty?	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17138674_20201005_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Survival Rate|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	Treprostinil Attains Clinically Therapeutic Concentrations in Neonates with Pulmonary Hypertension on Extracorporeal Membrane Oxygenation Support.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	extracorporeal membrane oxygenation|newborn|pulmonary hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	Infant, Newborn|Child|Humans|Male|Adult|Female|Extracorporeal Membrane Oxygenation|treprostinil|Hypertension, Pulmonary|Retrospective Studies|Epoprostenol|Antihypertensive Agents|Ventricular Function, Right|Echocardiography, Doppler|Ductus Arteriosus, Patent	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	No section TREPROSTINIL IS A PROSTACYCLIN ANALOG USED FOR TREATMENT OF PULMONARY HYPERTENSION (PH) IN ADULTS AND CHILDREN, CURRENTLY AWAITING CLINICAL ASSESSMENT FOR USE IN NEONATES.:	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	 OBJECTIVES WE AIMED TO INVESTIGATE THE USE OF TREPROSTINIL IN NEONATES WITH PH ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) SUPPORT AND MEASURE PLASMA CONCENTRATIONS OF THE DRUG.:	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	TREPROSTINIL DOSES OF 20-58 NG/KG/MIN REACHED CONCENTRATIONS OF 0.99-4.39 NG/ML AND INDUCED CLINICAL IMPROVEMENT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	INFUSION OF TREPROSTINIL WAS ASSOCIATED WITH IMPROVED RIGHT VENTRICULAR FUNCTION, REVERSED RIGHT-TO-LEFT SHUNTING THROUGH THE DUCTUS ARTERIOSUS, AND STABLE OR DECREASING NEED FOR VASOPRESSOR SUPPORT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32866289_20210111_0.5	treprostinil	drug_name	 CONCLUSIONS THIS IS THE FIRST STUDY TO REPORT CLINICALLY THERAPEUTIC TREPROSTINIL CONCENTRATIONS IN CIRCULATING PLASMA AFTER TREPROSTINIL ADMINISTRATION IN NEONATES ON ECMO, WITH ASSOCIATED CLINICAL IMPROVEMENT OF PH AND NO SIGNS OF HEMODYNAMIC INSTABILITY.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5	treprostinil	drug_name	Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5			prostacyclin therapy|pulmonary hypertension|right heart failure	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5			Administration, Inhalation|Administration, Oral|Aged, 80 and over|Antihypertensive Agents|Dose-Response Relationship, Drug|Epoprostenol|Female|Follow-Up Studies|Home Care Services|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Middle Aged|Retrospective Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5	treprostinil	drug_name	Treprostinil is a prostacyclin analogue that has proven clinical efficacy in patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5	treprostinil	drug_name	Difficulties in the administration of inhaled and parenteral prostacyclins led to the development of extended-release treprostinil diolamine for oral use.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5	treprostinil	drug_name	Limited data exist on the transition to oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28464760_20201005_0.5	treprostinil	drug_name	The purpose of this case series is to describe the transition from subcutaneous or inhaled treprostinil to oral treprostinil in the outpatient setting.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	Effect of Treprostinil on the Early Postoperative Prognosis of Patients with Severe Left Heart Valvular Disease Combined with Severe Pulmonary Hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	postoperative effect|pulmonary arterial hypertension|treprostinil|valvular disease	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5			Adult|Antihypertensive Agents|Arterial Pressure|Epoprostenol|Female|Heart Valve Diseases|Heart Valve Prosthesis Implantation|Humans|Hypertension, Pulmonary|Male|Middle Aged|Pulmonary Artery|Recovery of Function|Retrospective Studies|Severity of Illness Index|Time Factors|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	No section Objective: To investigate the effect of treprostinil on the early postoperative prognosis of patients with severe left heart valvular disease combined with severe pulmonary hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	Patients were divided into two groups (treprostinil group and control group), and the clinical data of patients in the two groups were compared and analyzed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	Compared with the control group, the treprostinil group had a significantly lower mPAP.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	Moreover, the postoperative mechanical ventilation time, intensive care unit (ICU) stay, and hospital stay of the treprostinil group were significantly shorter than those of the control group.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8043024_20210511_0.5	treprostinil	drug_name	 No section Conclusions: Treprostinil can improve the early postoperative prognosis of patients with severe left heart valvular disease combined with severe PAH undergoing prosthetic valve replacement.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17492235_20201005_0.5			[Pulmonary arterial hypertension--experience of Centro Hospitalar de Vila Nova de Gaia].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17492235_20201005_0.5			Adolescent|Adult|Aged|Algorithms|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Retrospective Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17492235_20201005_0.5	treprostinil	drug_name	At the time of diagnosis most patients were in NYHA/ /WHO Functional Class III/IV, mean systolic pulmonary artery pressure was 98+/-32 mm Hg and mean distance walked in the 6-minute walk test was 401 m. Initial treatment: Three patients had inhaled iloprost, two subcutaneous treprostinil, three oral bosentan, one oral sildenafil and two patients under- went surgery.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3412595_20201005_0.5	treprostinil	drug_name	Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3412595_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|treprostinil|epoprostenol|prostanoids|six minute walk distance|New York Heart Association functional class|hemodynamics	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3412595_20201005_0.5	treprostinil	drug_name	Humans|United States|treprostinil|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Prostaglandins|Connective Tissue Diseases|Exercise Tolerance|Hemodynamics|Treatment Outcome|United States Food and Drug Administration	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3412595_20201005_0.5	treprostinil	drug_name	This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31167237_20201005_0.5	treprostinil	drug_name	Neonates Effects and Tolerability of Treprostinil in Hypertension with Persistent Pulmonary.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31167237_20201005_0.5	treprostinil	drug_name	Infant, Newborn|Male|Humans|Female|Middle Aged|Adult|Adolescent|treprostinil|Epoprostenol|Hypertension, Pulmonary|Hypertension|Lung|Milrinone|Antihypertensive Agents|Hernias, Diaphragmatic, Congenital|Nitric Oxide|Administration, Inhalation|Ductus Arteriosus, Patent|Echocardiography|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31167237_20201005_0.5	treprostinil	drug_name	No section The aim of this study was to establish the effects of treprostinil in congenital diaphragmatic hernia (CDH) patients with persistent pulmonary hypertension (PHT) after 1 week of treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31167237_20201005_0.5	treprostinil	drug_name	Clinical data were compared before and after treprostinil treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31167237_20201005_0.5	treprostinil	drug_name	 No section Treprostinil was well tolerated with satisfactory clinical response.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Blood Pressure|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Pulmonary Artery|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5	treprostinil	drug_name	No section Treprostinil is a prostacyclin derivative approved for the treatment of pulmonary arterial hypertension by intravenous, subcutaneous and inhalational administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5	treprostinil	drug_name	Unlike its precursor epoprostenol, treprostinil is chemically stable at room temperature and neutral pH, and its plasma half-life is longer.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5	treprostinil	drug_name	In addition to promoting smooth muscle relaxation in the pulmonary vasculature, treprostinil has suppressive effects on platelet aggregation, smooth muscle proliferation and inflammation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5	treprostinil	drug_name	A Phase III study, investigating the addition of inhaled treprostinil to oral bosentan or sildenafil, confirmed significant improvements in exercise capacity and quality of life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22788940_20201005_0.5	treprostinil	drug_name	This review examines the pharmacodynamics, pharmacokinetics, clinical efficacy and safety of inhaled treprostinil for use in pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18517170_20201005_0.5	treprostinil	drug_name	Patient safety challenges in treprostinil therapy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18517170_20201005_0.5			Academic Medical Centers|Antihypertensive Agents|Drug Monitoring|Epoprostenol|Equipment Design|Equipment Failure|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Intravenous|Nursing Assessment|Nursing Records|Patient Care Planning|Patient Care Team|Patient Education as Topic|Safety Management|Severity of Illness Index|Southwestern United States|Total Quality Management	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18517170_20201005_0.5	treprostinil	drug_name	No section Treprostinil (Remodulin) is a new therapy for pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5			Adult|Antihypertensive Agents|Epoprostenol|Exercise Tolerance|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Male|Middle Aged|Prospective Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	BACKGROUND Pulmonary arterial hypertension (PAH) is a life-threatening disease for which both continuous IV epoprostenol and continuous subcutaneous treprostinil have proven effective.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	With continuous IV treprostinil having potential advantages over both of the above therapies, we investigated the safety and efficacy of this regimen in patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	 METHODS We conducted a 12-week, prospective, open-label, uncontrolled, multicenter study of continuous IV treprostinil in 16 patients with PAH that was idiopathic (n = 8), related to connective tissue disease (n = 6), or related to congenital heart disease (n = 2).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	 RESULTS Continuous IV treprostinil increased 6MW distance (mean +/- SE) by 82 m from baseline (319 +/- 22 m) to week 12 (400 +/- 26 m) [n = 14; p = 0.001].	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	One death, unrelated to study drug, occurred during the 12-week study in a patient who received 3 days of treprostinil and died 2 weeks later.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16537868_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Long-term IV infusion of treprostinil is safe and appears to be effective for the treatment of patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5841903_20201005_0.5			Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5841903_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|pathobiology|leptin|adiponectin|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5841903_20201005_0.5			Middle Aged|Adult|Aged|Male|Humans|Female|ADIPOQ protein, human|Adiponectin|Leptin|Prognosis|Double-Blind Method|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|pro-brain natriuretic peptide (1-76)|Natriuretic Peptide, Brain|Epoprostenol|Antihypertensive Agents|Peptide Fragments|Exercise Tolerance|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16635673_20201005_0.5	treprostinil	drug_name	A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16635673_20201005_0.5			Adult|Epoprostenol|Female|Fingers|Humans|Injections, Subcutaneous|Male|Middle Aged|Scleroderma, Systemic|Skin Ulcer|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16635673_20201005_0.5	treprostinil	drug_name	No section We performed a pilot trial of subcutaneous treprostinil for the treatment of digital ulcers in scleroderma.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33979500_20210611_0.5	treprostinil	drug_name	Inhaled Treprostinil in Group 3 Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33979500_20210611_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Lung Diseases, Interstitial	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18041894_20201005_0.5			Nebulized milrinone use in a pulmonary hypertensive crisis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18041894_20201005_0.5			Acute Disease|Administration, Inhalation|Adult|Antihypertensive Agents|Blood Pressure|Bronchodilator Agents|Drug Therapy, Combination|Epoprostenol|Female|Heart Rate|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Milrinone|Nebulizers and Vaporizers|Nitric Oxide|Phosphodiesterase Inhibitors|Salvage Therapy	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18041894_20201005_0.5	treprostinil	drug_name	She was acutely treated with intravenous treprostinil 2 ng/kg/minute and inhaled nitric oxide 20 ppm.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18041894_20201005_0.5	treprostinil	drug_name	However, increasing the treprostinil infusion rate or adding other therapies such as intravenous milrinone for acute symptomatic relief was limited by her hemodynamic instability, which required treatment with dobutamine, vasopressin, and epinephrine.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18041894_20201005_0.5	treprostinil	drug_name	Nebulized milrinone in addition to inhaled nitric oxide and low-dose intravenous treprostinil may have played a major role in the acute management of her PAH crisis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	Inpatient Initiation of Oral Treprostinil in an Academic Medical System.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	Prostacyclins|Pulmonary arterial hypertension|Pulmonary hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5			Academic Medical Centers|Administration, Oral|Adult|Aged|Antihypertensive Agents|Arterial Pressure|Drug Substitution|Epoprostenol|Female|Humans|Inpatients|Male|Middle Aged|Ohio|Pulmonary Arterial Hypertension|Pulmonary Artery|Retrospective Studies|Treatment Outcome|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	No section Clinicians may transition patients on parenteral or inhaled prostacyclins to oral treprostinil for ease of use or to avoid adverse effects related to parenteral therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	The purpose of this analysis is to describe the inpatient initiation of oral treprostinil at an academic medical system.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	 No section This is a retrospective cohort analysis of patients newly initiated on oral treprostinil at Cleveland Clinic Heath System from 2015 to 2017.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	Outcomes evaluated included doses of oral treprostinil utilized, adverse effects related to therapy, and measures of clinical and functional status before and after the initiation of oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	 No section Overall, 29 patients were prescribed oral treprostinil, of which 15 patients were included in the analysis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	Common reasons for initiation of oral treprostinil included disease progression (6, 40%) and patient desire (4, 25%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	The median duration of transition/initiation of oral treprostinil was 4 days (range, 3-11 days).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	Median daily dose of oral treprostinil on day 1 of initiation was 2 mg (0.25-4 mg).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	No patients required discontinuation of oral treprostinil due to adverse effects within 90 days of initiation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	 No section Inpatient initiation/transition to oral treprostinil was relatively well tolerated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32424651_20201214_0.5	treprostinil	drug_name	Future studies should evaluate clinical outcomes surrounding the transitioning to oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	mortality|prostacyclin|pulmonary arterial hypertension|pulmonary hypertension|risk assessment|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5			Administration, Intravenous|Adult|Antihypertensive Agents|Drug Therapy, Combination|Epoprostenol|Female|Humans|Male|Middle Aged|Pulmonary Arterial Hypertension|Retrospective Studies|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	 No section This retrospective multicenter study evaluated patients with pulmonary arterial hypertension who received intravenous treprostinil as an add-on therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	The risk at baseline and follow-up (6-12 months after the initiation of treprostinil) was classified as low, intermediate, or high according to current recommendations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	The outcome was measured as transplant-free survival after the initiation of treprostinil therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	Before the initiation of intravenous treprostinil, 2 (2%) patients had a low-risk profile; 100 (79%), an intermediate-risk profile; and 24 (19%), a high-risk profile.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31128966_20210111_0.5	treprostinil	drug_name	 No section Risk assessment at 6-12 months after the initiation of add-on intravenous treprostinil in patients with an insufficient response to nonparenteral treatments allows the prediction of transplant-free survival over the ensuing years.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5704856_20201005_0.5			Pulmonary hypertension as a manifestation of mitochondrial disease	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5704856_20201005_0.5			combination therapies|literature review|mitochondrial disease|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5704856_20201005_0.5			Adolescent|Humans|Hypertension, Pulmonary|Male|Mitochondrial Diseases	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5704856_20201005_0.5	treprostinil	drug_name	 Diagnoses and Outcomes: The initial diagnosis was idiopathic pulmonary arterial hypertension and an injection of vasodilator (Treprostinil) was given.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22135338_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22135338_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Medical Illustration|Randomized Controlled Trials as Topic|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22135338_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil (Tyvaso) is a prostacyclin analog indicated for the treatment of pulmonary arterial hypertension to increase walk distance in patients with symptoms classified as New York Heart Association functional class III.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22135338_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was approved by the Food and Drug Administration in July 2009.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22135338_20201005_0.5	treprostinil	drug_name	This article provides a brief overview of the pathophysiology of pulmonary arterial hypertension and reviews the mechanism of action, key clinical data, and the practical management of inhaled treprostinil in patients with pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19285625_20201005_0.5	treprostinil	drug_name	A pediatric case study of treprostinil overdose.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19285625_20201005_0.5			Antihypertensive Agents|Child|Drug Overdose|Epoprostenol|Female|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19285625_20201005_0.5	treprostinil	drug_name	No section This case study reports the effects of a treprostinil accidental overdose in a patient with pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19285625_20201005_0.5	treprostinil	drug_name	Treprostinil is labeled for treatment of pulmonary hypertension with New York Heart Association (NYHA) Class II, III and IV symptoms.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16636723_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16636723_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16636723_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs: 131I-labetuzumab; Abacavir sulfate, abatacept, adalimumab, ademetionine, adjuvanted influenza vaccine, alefacept, alemtuzumab, amlodipine, amphotericin B, anakinra, aripiprazole, aspirin, axitinib; Betamethasone dipropionate, bevacizumab, biphasic insulin aspart, bortezomib, bosentan, botulinum toxin type B, BQ-123; Calcium folinate, canertinib dihydrochloride, carboplatin, carmustine, cetirizine hydrochloride, cetuximab, cholecalciferol, ciclesonide, ciclosporin, cinacalcet hydrochloride, cisplatin, clarithromycin, clofazimine, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, darifenacin hydrobromide, DB-289, desloratadine, Dexamet, dicycloverine hydrochloride, dimethyl fumarate, docetaxel, dolastatin 10, drospirenone, drospirenone/estradiol, duloxetine hydrochloride; Ecogramostim, edotecarin, efaproxiral sodium, enalapril maleate, epoetin beta, epoprostenol sodium, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, estradiol, etanercept; Fluconazole, fludarabine phosphate, fluorouracil; Gefitinib, gemcitabine, Ghrelin (human), glibenclamide, glimepiride, GTI-2040; Haloperidol, human insulin, hydrocortisone probutate; Imatinib mesylate, indisulam, influenza vaccine, inhaled insulin, insulin aspart, insulin glulisine, insulin lispro, irinotecan, ispronicline; Lamivudine, lamivudine/zidovudine/abacavir sulfate, lapatinib, letrozole, levocetirizine, lomustine, lonafarnib, lumiracoxib;Magnesium sulfate, MD-1100, melphalan, metformin hydrochloride, methotrexate, metoclopramide hydrochloride, mitiglinide calcium hydrate, monophosphoryl lipid A, montelukast sodium, motexafin gadolinium, mycophenolate mofetil, mycophenolic acid sodium salt; Nitisinone; Omalizumab, omapatrilat, ONYX-015, oxaliplatin; Paclitaxel, paclitaxel nanoparticles, panitumumab, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pertuzumab, phosphatidylcholine-rich phospholipid mixture, pimecrolimus, pioglitazone hydrochloride, pramlintide acetate, prasterone; QR-333; Ranelic acid distrontium salt, ranolazine, rasagiline mesilate, RFB4(dsFv)-PE38, ribavirin, rifabutin, risperidone, rituximab, rofecoxib, rosiglitazone maleate, rosiglitazone maleate/metformin hydrochloride, rotavirus vaccine; S-236, salmeterol xinafoate, sarizotan hydrochloride, sildenafil, sildenafil citrate, sunitinib malate; Tadalafil, tegaserod maleate, temozolomide, tenofovir disoproxil fumarate, teriparatide, tiotropium bromide, tipifarnib, trabectedin, treprostinil sodium; Vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, vinflunine, virosome influenza vaccine, voriconazole; Zidovudine.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29275453_20201005_0.5	treprostinil	drug_name	Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29275453_20201005_0.5	treprostinil	drug_name	Exercise capacity|Lung disease|Pulmonary hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29275453_20201005_0.5			Administration, Inhalation|Aged|Antihypertensive Agents|Arterial Pressure|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Lung Diseases|Male|Middle Aged|Pulmonary Artery|Recovery of Function|Retrospective Studies|Time Factors|Treatment Outcome|Vascular Remodeling|Vascular Resistance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29275453_20201005_0.5	treprostinil	drug_name	In the present retrospective study, data from 22 patients with PH associated with lung disease treated with inhaled treprostinil (iTre) and followed up clinically for at least 3 months are presented.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5	treprostinil	drug_name	Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5			Administration, Cutaneous|Adolescent|Aged|Antihypertensive Agents|Dose-Response Relationship, Drug|Double-Blind Method|Epoprostenol|Feasibility Studies|Female|Fingers|Humans|Iontophoresis|Male|Middle Aged|Regional Blood Flow|Scleroderma, Systemic|Skin|Skin Ulcer|Tissue Distribution|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5	treprostinil	drug_name	Our objective was to evaluate the effect of iontophoresis (a noninvasive drug delivery method) of treprostinil in SSc patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5	treprostinil	drug_name	Three studies were conducted: a pharmacokinetic study in 12 healthy volunteers showed that peak dermal concentration was reached at 2 hours, whereas plasma treprostinil was undetected.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5	treprostinil	drug_name	Then, a placebo-controlled, double-blind incremental dose study assessed the effect of treprostinil on digital skin blood flow in 22 healthy subjects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5	treprostinil	drug_name	Treprostinil significantly increased skin blood flow in healthy subjects (P = 0.006) and in SSc patients (P = 0.023).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24458011_20201005_0.5	treprostinil	drug_name	In conclusion, digital iontophoresis of treprostinil is feasible, is well tolerated, and increases digital skin perfusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	Cutaneous iontophoresis of treprostinil, a prostacyclin analog, increases microvascular blood flux in diabetic malleolus area.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	Diabetic foot ulcers|Iontophoresis|Laser speckle contrast imaging|Microcirculation|Prostacyclin|Sodium chloride (PubChem CID: 5234)|Treprostinil|Treprostinil (PubChem CID: 6918140)	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5			Administration, Cutaneous|Adult|Ankle|Diabetes Mellitus, Type 2|Double-Blind Method|Epoprostenol|Female|Humans|Iontophoresis|Male|Microcirculation|Middle Aged|Skin|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	The main objective of the present study was to determine whether iontophoresis of treprostinil, a prostacyclin analog, increases skin microvascular blood flux in the malleolus area of healthy subjects and diabetic patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	Cathodal iontophoresis (40mC/cm2) of treprostinil 250μM and NaCl 0.9% was performed in the malleolus area.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	In healthy controls and diabetic patients, treprostinil 250μM induced a significant increase in CVC compared with NaCl (for diabetic patients, AUC0-6h was 19970±8697; versus 2893±5481%BL.min, respectively; P=0.002).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	In both groups, the peak flux was obtained between 30min and 1h after the end of treprostinil iontophoresis and flux remained higher than baseline up to 6h after ending of iontophoresis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	Cutaneous iontophoresis of 250μM treprostinil increases microvascular blood flux in the malleolus area in healthy volunteers and diabetic patients, without inducing systemic or local side-effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25843412_20201005_0.5	treprostinil	drug_name	Treprostinil cathodal iontophoresis should be further investigated as a new local therapy for diabetic ulcers.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19715380_20201005_0.5			Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19715380_20201005_0.5			Antihypertensive Agents|Cost-Benefit Analysis|Decision Support Techniques|Drug Costs|Drug Therapy, Combination|Humans|Hypertension, Pulmonary|Markov Chains|Medicaid|Medicare|Quality of Life|Quality-Adjusted Life Years|United States|United States Food and Drug Administration	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19715380_20201005_0.5	treprostinil	drug_name	 METHODS We created a Markov-type model to evaluate 1-year treatment with bosentan, treprostinil, epoprostenol, inhaled iloprost, sildenafil, sitaxentan and ambrisentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29525197_20201005_0.5			Perioperative Management of Pregnant Women With Idiopathic Pulmonary Arterial Hypertension: An Observational Case Series Study From China.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29525197_20201005_0.5			idiopathic pulmonary arterial hypertension|outcome|pregnancy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29525197_20201005_0.5			Abortion, Therapeutic|Adult|Antihypertensive Agents|Cesarean Section|China|Disease Management|Familial Primary Pulmonary Hypertension|Female|Humans|Maternal Mortality|Perioperative Care|Pregnancy|Pregnancy Complications, Cardiovascular|Pulmonary Wedge Pressure|Treatment Outcome|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29525197_20201005_0.5	treprostinil	drug_name	Fifteen patients (88.2%) received PAH-specific therapy before delivery, including sildenafil, iloprost, and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	Treprostinil for pulmonary hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	pulmonary hypertension|prostacyclin|epoprostenol|treprostinil|congenital heart disease|connective tissue disease|portal hypertension|HIV infection|anorexigens	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5			Administration, Cutaneous|Antihypertensive Agents|Chronic Disease|Epoprostenol|Exercise Test|Exercise Tolerance|Humans|Hypertension, Pulmonary|Thromboembolism	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	No section Treprostinil is a stable, long-acting prostacyclin analogue which can be administered as a continuous subcutaneous infusion using a portable miniature delivery system.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil has been shown in a large multicenter randomized controlled trial to improve exercise capacity, clinical state, functional class, pulmonary hemodynamics, and quality of life in patients with pulmonary arterial hypertension, an uncommon disease of poor prognosis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	Long-term survival in pulmonary arterial hypertension patients treated with subcutaneous treprostinil is similar to that reported with intravenous epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	There are uncontrolled data suggesting efficacy of subcutaneous treprostinil in chronic thromboembolic pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	Treprostinil can also be administered intravenously, although increased doses, up to 2-3 times those given subcutaneously, appear to be needed to obtain the same efficacy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	Preliminary results of a randomized controlled trial of inhaled treprostinil on top of bosentan and sildenafil therapies have shown significance on the primary endpoint, which was exercise capacity as assessed by the distance walked in 6 minutes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2515411_20201005_0.5	treprostinil	drug_name	Trials of oral formulations of treprostinil have been initiated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5	treprostinil	drug_name	Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5			Adult|Antihypertensive Agents|Dyspnea|Epoprostenol|Equipment Design|Exercise Tolerance|Feasibility Studies|Female|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Intravenous|Male|Middle Aged|Severity of Illness Index|Time Factors|Treatment Outcome|United States|Walking	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5	treprostinil	drug_name	OBJECTIVE Treprostinil is approved for the treatment of pulmonary arterial hypertension (PAH) via continuous intravenous (IV) infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5	treprostinil	drug_name	Treprostinil's anti-platelet aggregation characteristics and stability at room temperature may allow for low infusion rates (0.1-0.2 mL/hr) using a miniaturized infusion pump.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5	treprostinil	drug_name	 METHODS A 12-week, multi-center, open-label study in 12 adult PAH patients, evaluated the feasibility and safety of low-flow IV treprostinil administration via the 407C miniaturized pump.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5	treprostinil	drug_name	Patients receiving IV treprostinil at a stable dose were transitioned from their current CADD-Legacy pump to the 407C and were assessed for adverse events including catheter occlusions, pump alarms, and efficacy (six minute walk distance (6MWD), Borg Dyspnea Score (BDS), NYHA functional class, and PAH signs/symptoms).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17019662_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS This study demonstrates that treprostinil can be administered intravenously at infusion rates as low as 0.1 mL/hr for 12 weeks without catheter occlusions.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33775048_20210411_0.5			[Ruptured chordae tendineae of tricuspid valve in neonate with intractable persistent pulmonary hypertension: a case report and literature review].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33775048_20210411_0.5			Cesarean Section|Child|Chordae Tendineae|Female|Humans|Hypertension, Pulmonary|Infant|Infant, Newborn|Male|Pregnancy|Retrospective Studies|Tricuspid Valve	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33775048_20210411_0.5	treprostinil	drug_name	Addition of prostacyclin analog (treprostinil) on day 3 led to significant improvement of pulmonary blood flow, oxygenation, and stabilization, so that the extracorporeal membrane oxygenation therapy was avoided.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5991194_20201005_0.5			Is hyponatremia associated with mortality in pulmonary arterial hypertension?	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5991194_20201005_0.5			pulmonary hypertension|pulmonary arterial hypertension|hyponatremia|prognosis|mortality	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5991194_20201005_0.5	treprostinil	drug_name	Middle Aged|Male|Humans|Aged|Female|Hyponatremia|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Heart Failure|treprostinil|Epoprostenol|Prognosis|Kaplan-Meier Estimate|Sodium|Registries|Middle Aged|Male|Humans|Aged|Female|Hyponatremia|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Heart Failure|treprostinil|Epoprostenol|Prognosis|Kaplan-Meier Estimate|Sodium|Registries	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5991194_20201005_0.5	treprostinil	drug_name	This study is a secondary analysis evaluating the association between hyponatremia and one-year mortality in patients treated with subcutaneous treprostinil (cohort 1).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	Effect of continuous vs pulsed iontophoresis of treprostinil on skin blood flow.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5			Continuous current|Iontophoresis|Microcirculation|Periodic current|Prostacyclin	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5			Animals|Antihypertensive Agents|Epoprostenol|Iontophoresis|Male|Rats, Wistar|Regional Blood Flow|Skin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	Iontophoresis of treprostinil could be a promising local therapeutic alternative for SSc-related digital ulcers.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	The objective of the present work is to compare the effect of continuous vs pulsed iontophoresis of treprostinil in rats.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	 METHODS Treprostinil (0.64 mM and 0.064 mM) and NaCl were delivered by cathodal iontophoresis onto the hindquarters of anaesthetized rats.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	At the lower concentration (0.064 mM treprostinil) the pulsed 10/50 sequence significantly enhanced cutaneous blood flow (Table 1; Fig.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS In conclusion, pulsed iontophoresis of treprostinil with a 10 s/50 s (On/Off) protocol at 600 μA increases the efficacy of iontophoresis at 0.064 mM but not at a tenfold higher concentration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25712367_20201005_0.5	treprostinil	drug_name	Pulsed iontophoresis could be used to optimize treprostinil iontophoresis, to provide similar efficacy with decreased costs, and should now be tested on humans.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	oral treprostinil|pulmonary arterial hypertension|pulmonary delphi studies|drug side effects	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	Humans|treprostinil|Pulmonary Circulation|Consensus|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Administration, Oral|Exercise Tolerance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	No section Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	Following a methodology commonly used in business and social sciences (the 'Delphi Process'), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5448528_20201005_0.5	treprostinil	drug_name	The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17128524_20201005_0.5	treprostinil	drug_name	Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17128524_20201005_0.5			Antihypertensive Agents|Epoprostenol|Europe|Humans|Hypertension, Pulmonary|Treatment Outcome|United States|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17128524_20201005_0.5	treprostinil	drug_name	2) Following the approval of inhaled iloprost, another prostacycline analogue, treprostinil, has been approved for use as a continuous subcutaneous infusion. (	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17128524_20201005_0.5	treprostinil	drug_name	5) The adverse effect profile of treprostinil is the same as that of epoprostenol, and is mainly due to its vasodilatory properties (diarrhoea, ankle swelling).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17128524_20201005_0.5	treprostinil	drug_name	6) Treprostinil must be administered as a continuous subcutaneous infusion; this is not convenient, but it is easier to set up than central intravenous epoprostenol infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5	treprostinil	drug_name	Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5			Aged|Antihypertensive Agents|Cardiac Output|Case-Control Studies|Chronic Disease|Epoprostenol|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Infusion Pumps|Kaplan-Meier Estimate|Male|Middle Aged|Natriuretic Peptide, Brain|Odds Ratio|Pain|Pain Measurement|Platelet Aggregation Inhibitors|Proportional Hazards Models|Prospective Studies|Pulmonary Embolism|Risk Assessment|Severity of Illness Index|Thromboembolism|Time Factors|Treatment Outcome|Vascular Resistance|Vasodilator Agents|Walking	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5	treprostinil	drug_name	 OBJECTIVE In an open-label uncontrolled study, we investigated the prostacyclin analog treprostinil given s.c.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5	treprostinil	drug_name	Treprostinil plasma concentrations were determined after at least six months of treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5	treprostinil	drug_name	 RESULTS Treprostinil-treated patients demonstrated significant improvements in 6-MWD (P = 0.01), WHO functional class (P = 0.001), B-type brain natriuretic peptide plasma levels (P = 0.02), cardiac outputs (P = 0.007) and pulmonary vascular resistances (P = 0.01) after 19 +/- 6.3 months.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5	treprostinil	drug_name	Treprostinil plasma concentrations correlated with drug dose (P < 0.001), indicating stable absorption over time.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17319903_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treprostinil improves exercise capacity, hemodynamics and survival in patients with severe inoperable CTEPH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26336595_20201005_0.5			Medical treatment update on pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26336595_20201005_0.5	treprostinil	drug_name	macitentan|oral treprostinil|pulmonary arterial hypertension|riociguat	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26336595_20201005_0.5	treprostinil	drug_name	Humans|United States|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Endothelin Receptor Antagonists|macitentan|Pyrimidines|treprostinil|Epoprostenol|riociguat|Pyrazoles|Sulfonamides|Antihypertensive Agents|Guanylate Cyclase|Phosphodiesterase 5 Inhibitors|Prostaglandins|Chronic Disease	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26336595_20201005_0.5	treprostinil	drug_name	Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5			Adult|Antihypertensive Agents|Arterial Pressure|Epoprostenol|Female|Hospital Mortality|Humans|Infusions, Intravenous|Parturition|Postpartum Period|Pregnancy|Pulmonary Arterial Hypertension|Pulmonary Artery|Retrospective Studies|Severity of Illness Index|Time Factors|Treatment Outcome|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	The relatively long-acting, specific pulmonary vasodilator treprostinil has been used to improve survival in these parturients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	 No section We retrospectively reviewed 17 pregnant patients with severe pulmonary arterial hypertension who were treated with intravenous treprostinil in our institution between 2014 and 2016.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	 No section Rapid titration of intravenous treprostinil was initiated at 1.25 ng/kg/min and increased to effective dose of 10 ng/kg/min by 1.25-2.5 ng/kg/min every 3 hours.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	Treprostinil was weaned off by 0.50-1.25 ng/kg/min every 3 hours in 94.3 ± 42.4 hours.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	No treprostinil infusion-related postpartum complication was observed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31743181_20201005_0.5	treprostinil	drug_name	 No section Our experience suggested that rapid uptitration of intravenous treprostinil combined with oral sildenafil in the postpartum period may be a safe and effective approach for these very sick parturients with severe pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27919660_20201005_0.5			A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27919660_20201005_0.5			Human|MRE-269|NS-304|Prostacyclin receptor|Pulmonary arterial hypertension|Selexipag	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27919660_20201005_0.5			Acetamides|Acetates|Animals|Cyclic AMP|Endothelium, Vascular|Humans|Male|Nitric Oxide|Pulmonary Artery|Pyrazines|Rats|Receptors, Epoprostenol|Swine|Vasodilation|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27919660_20201005_0.5	treprostinil	drug_name	cAMP formation in human pulmonary artery smooth muscle cells was induced by all test compounds (MRE-269, epoprostenol, iloprost, treprostinil and beraprost sodium) and suppressed by IP receptor antagonists (CAY10441 and 2-[4-(1H-indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27919660_20201005_0.5	treprostinil	drug_name	In contrast, endothelial denudation or the addition of a nitric oxide synthase inhibitor markedly attenuated the vasodilation of EPA induced by epoprostenol, treprostinil and beraprost sodium but not iloprost.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5	treprostinil	drug_name	Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5			Administration, Oral|Adult|Aged|Antihypertensive Agents|Area Under Curve|Epoprostenol|Female|Fingers|Half-Life|Humans|Ischemia|Male|Middle Aged|Scleroderma, Systemic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5	treprostinil	drug_name	Introduction Treprostinil diethanolamine is an innovative salt form of the prostacyclin analogue, treprostinil sodium, developed as an oral sustained release (SR) osmotic tablet.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5	treprostinil	drug_name	We evaluated pharmacokinetics and perfusion in scleroderma patients with digital ischemia following escalating twice-daily doses of treprostinil diethanolamine SR.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5	treprostinil	drug_name	 Results Nineteen scleroderma patients (84% female, 53% limited scleroderma) received treprostinil diethanolamine SR with dose titration up to 4 mg twice daily as tolerated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5	treprostinil	drug_name	 Conclusions Oral treprostinil diethanolamine was effectively absorbed in patients with scleroderma.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5011881_20210311_0.5	treprostinil	drug_name	Treprostinil diethanolamine may provide a new therapeutic option for Raynaud's phenomenon and the peripheral vascular disease of scleroderma.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5	treprostinil	drug_name	Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5			Pulmonary hypertension|Medical therapy|Combination therapy|Prostanoid	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5			Acetamides|Adult|Antihypertensive Agents|Drug Therapy, Combination|Epoprostenol|Exercise Tolerance|Familial Primary Pulmonary Hypertension|Female|Hemodynamics|Humans|Prospective Studies|Pyrazines|Pyrimidines|Sulfonamides	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5	treprostinil	drug_name	Background In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise tolerance.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5	treprostinil	drug_name	 Case presentation A 38-year-old female with idiopathic PAH (IPAH) had received initial triple combination therapy (macitentan PO, tadalafil PO, and treprostinil SC) and achieved excellent improvement in hemodynamics.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5	treprostinil	drug_name	Afterwards, due to the development of side effects from subcutaneous administration, we replaced treprostinil therapy with oral selexipag, resulting in stable hemodynamic parameters and exercise capacities.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5659015_20201005_0.5	treprostinil	drug_name	 Conclusions We report the first case of successful replacement of treprostinil (20.1 ng/kg/min) with selexipag (1600 μg BID) as a component of triple combination therapy, which provides incentive to perform a larger, prospective exchange study.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21362657_20201005_0.5			Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21362657_20201005_0.5			Adult|Bronchial Arteries|Embolization, Therapeutic|Familial Primary Pulmonary Hypertension|Fatal Outcome|Female|Hemoptysis|Humans|Hypertension, Pulmonary|Recurrence	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21362657_20201005_0.5	treprostinil	drug_name	We present the case of a 27-year-old woman with IPAH, who suffered from recurrent hemoptysis and who was treated with sitaxsentan and treprostinil and remained stable in World Health Organization functional class II.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16894408_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16894408_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16894408_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, BMS-188797, bortezomib, bosentan, brivudine; Calcipotriol/betamethasone dipropionate, cannabidiol, caspofungin acetate, catumaxomab, CERE-120, cetuximab, ciclesonide, cilomilast, cizolirtine citrate, Cypher, cystemustine; Dalbavancin, darifenacin hydrobromide, dasatinib, deferasirox, denosumab, desmoteplase, dihydrexidine, dimethyl fumarate, dutasteride, DW-166HC; Eculizumab, enfuvirtide, entecavir, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, eszopiclone, etoricoxib, everolimus; Fallypride, febuxostat, fenretinide, fesoterodine, fingolimod hydrochloride; Gabapentin enacarbil, gefitinib; hMaxi-K, human papillomavirus vaccine, HYAL-CT1101; Imatinib mesylate, indiplon, inolimomab, ISAtx-247; J591; Lacosamide, landiolol, lasofoxifene tartrate, lestaurtinib, lidocaine/prilocaine, linezolid, lixivaptan, lonafarnib, lopinavir, lopinavir/ritonavir, lumiracoxib; Natalizumab, nesiritide; OC-108, omalizumab, onercept, OSC; Palifermin, palonosetron hydrochloride, parathyroid hormone (human recombinant), parecoxib sodium, PD-MAGE-3 vaccine, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegsunercept, pelitinib, pitavastatin calcium, plerixafor hydrochloride, posaconazole, prasterone sulfate, pregabalin; Ramelteon, ranelic acid distrontium salt, rasburicase, rosuvastatin calcium, rotigotine, RSD-1235, rufinamide, rupatadine fumarate; Sarizotan hydrochloride, SHL-749, sirolimus-eluting stent, solifenacin succinate, sunitinib malate; Tadalafil, talampanel, tasidotin hydrochloride, Taxus, tegaserod maleate, telavancin hydrochloride, tenofovir disoproxil fumarate, tiotropium bromide, tocilizumab, tositumomab, treprostinil sodium, tridolgosir hydrochloride, TTS-CD3; Ularitide; Valdecoxib, Val-Tyr sardine peptidase, vardenafil hydrochloride hydrate, voriconazole; Yttrium (90Y) edotreotide, Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zucapsaicin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5			inhaled prostacyclin|pharmacokinetics|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	Humans|Male|Adult|Middle Aged|Female|Powders|treprostinil|Double-Blind Method|Epoprostenol|Hypertension, Pulmonary|Antihypertensive Agents|Administration, Inhalation|Familial Primary Pulmonary Hypertension|Pulmonary Arterial Hypertension|Administration, Oral|Dry Powder Inhalers	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	No section A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hypertension via nebulized Tyvaso® inhalation solution.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	Six sequential, escalating doses (25, 50, 75, 100, 125, and 150 mcg) were studied to investigate treprostinil exposure from LIQ861 inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	Following single-dose administration, treprostinil exposure from LIQ861 increased proportionally across the dose range studied, and the pharmacokinetics profile of treprostinil administered as LIQ861 was similar to prior reports of inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7682229_20210111_0.5	treprostinil	drug_name	We conclude that the pharmacokinetics profile of treprostinil using a dry-powder inhaled formulation increased in proportion to dose as anticipated and was similar to earlier reports of inhaled, nebulized treprostinil (Tyvaso®).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4589584_20201005_0.5	treprostinil	drug_name	The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC4589584_20201005_0.5	treprostinil	drug_name	Male|Humans|Adult|treprostinil|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Administration, Intravenous|Prostaglandins|Infusions, Intravenous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC4589584_20201005_0.5	treprostinil	drug_name	If there are complicating factors or relative contraindications to intravenous and subcutaneous prostanoids, oral treprostinil provides another pathway to prostanoid therapy, but this usually requires a prolonged titration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4589584_20201005_0.5	treprostinil	drug_name	Intravenous treprostinil was initiated, titrated to high dose, and then rapidly transitioned to oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4589584_20201005_0.5	treprostinil	drug_name	A rapid initiation, titration, and transition from intravenous to oral treprostinil can be safely performed under watchful supervision in order to achieve higher and more efficacious doses of oral treprostinil in a timely manner.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068830_20201005_0.5	treprostinil	drug_name	An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7068830_20201005_0.5			Double-Blind Method|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Pulmonary Arterial Hypertension	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15846646_20201005_0.5			Prostacyclin for pulmonary hypertension in adults.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15846646_20201005_0.5			Adult|Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Randomized Controlled Trials as Topic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15846646_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil versus placebo (two studies, 8-12 weeks):One large study reported a significant median improvement in exercise capacity of around 16 metres.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15846646_20201005_0.5	treprostinil	drug_name	Cardiopulmonary haemodynamics and symptom scores favoured treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15846646_20201005_0.5	treprostinil	drug_name	Infusion site pain and withdrawals due to adverse events were more frequent with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27670656_20201005_0.5			Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27670656_20201005_0.5			Implantable pump|Intravenous prostanoid|Pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27670656_20201005_0.5			Adult|Antihypertensive Agents|Epoprostenol|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Infusion Pumps, Implantable|Male|Middle Aged|Prospective Studies|Prostaglandins|Pulmonary Wedge Pressure|Retrospective Studies|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27670656_20201005_0.5	treprostinil	drug_name	Recently, a fully implantable pump for continuous application of intravenous treprostinil was approved in Germany.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27670656_20201005_0.5	treprostinil	drug_name	 METHODS All patients with pulmonary hypertension undergoing pump implantation for the continuous application of intravenous treprostinil were included from two German centers.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5137257_20201005_0.5			Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5137257_20201005_0.5			Ca|pulmonary hypertension|pulmonary artery|smooth muscle|calcilytics	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5137257_20201005_0.5			Animals|Calcium|Cell Proliferation|Disease Models, Animal|Drug Design|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Mice|Molecular Targeted Therapy|Muscle, Smooth, Vascular|Naphthalenes|Pulmonary Artery|Receptors, Calcium-Sensing|Up-Regulation|Vasoconstriction	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5137257_20201005_0.5	treprostinil	drug_name	In addition to Ca channel blockers (nifedipine, diltiazem), three categories of drug have been developed for the treatment of PAH based on the pathological mechanisms: prostacyclin and its analogues (epoprostenol, treprostinil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan), and phosphodiesterase type 5 inhibitors (sildenafil, tadalafil).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	Treprostinil inhibits the adhesion and differentiation of fibrocytes via the cyclic adenosine monophosphate-dependent and Ras-proximate protein-dependent inactivation of extracellular regulated kinase.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5			Cell Adhesion|Cell Differentiation|Cells, Cultured|Cyclic AMP|Cyclic AMP Response Element-Binding Protein|Cyclic AMP-Dependent Protein Kinases|Epoprostenol|Extracellular Matrix|Extracellular Signal-Regulated MAP Kinases|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Integrin alpha5|Integrin beta1|Leukocytes, Mononuclear|Mutation|Phosphorylation|Protein Kinase Inhibitors|Proto-Oncogene Proteins c-raf|Receptors, Prostaglandin|Signal Transduction|Time Factors|Transfection|rap1 GTP-Binding Proteins|ras Proteins	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	We recently showed that the stable prostacyclin analogue treprostinil, a clinically approved drug for pulmonary arterial hypertension (PAH), significantly reduced the recruitment of fibrocytes to sites of vascular remodeling in experimental hypoxic pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	Here we report on the molecular mechanism underlying the inhibitory action of treprostinil on the adhesion and differentiation of human fibrocytes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	The generation of intracellular cyclic adenosine monophosphate (cAMP) by treprostinil reduced the expression of the integrins CD49 and CD29 when freshly isolated human peripheral blood mononuclear cells were treated with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	Cell-matrix adhesion was significantly impaired by treatment with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	We present evidence for a treprostinil/cAMP-induced downstream suppression of extracellular regulated kinase (ERK) that is transmitted via a protein kinase A-independent pathway through Rap proteins, which sequester Ras.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21278326_20201005_0.5	treprostinil	drug_name	Thus our data suggest that treprostinil inhibits the adhesion and differentiation of fibrocytes by limiting the activity of ERK via the cAMP-Rap axis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5			Adult|Aged|Aged, 80 and over|Anticoagulants|Antihypertensive Agents|Calcium Channel Blockers|Chromatography, Liquid|Digoxin|Diuretics|Dose-Response Relationship, Drug|Drug Therapy, Combination|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Injections, Subcutaneous|Male|Mass Spectrometry|Middle Aged|Oxygen|Phosphodiesterase 5 Inhibitors|Regression Analysis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	No section This study assessed the relationship between dose and plasma concentration following administration of treprostinil sodium infusion therapy in pulmonary arterial hypertension patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	This was a multicenter, open-label, multiple-cohort, steady-state, pharmacokinetic study in subjects with pulmonary arterial hypertension receiving treprostinil by continuous intravenous or subcutaneous infusion at doses between 10 and 125 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	Forty-nine subjects receiving treprostinil were enrolled.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	Treprostinil doses ranged from 12.1 to 125 ng/kg/min; treprostinil plasma concentrations ranged from 14.9 to 18 248 pg/mL. Linear regression analysis revealed a correlation between treprostinil dose and treprostinil plasma concentration with an R2 value of 0.561.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	Subset linear regression analysis, which excluded 2 subjects with anomalous treprostinil plasma concentrations, increased the R2 value to 0.796.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18094217_20201005_0.5	treprostinil	drug_name	This study supports previous findings of linearity at lower doses up to 15 ng/kg/min and demonstrates linearity at treprostinil doses up to 125 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28904003_20201005_0.5	treprostinil	drug_name	Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28904003_20201005_0.5			Administration, Inhalation|Animals|Antihypertensive Agents|Dogs|Dose-Response Relationship, Drug|Drug Compounding|Drug Delivery Systems|Drug Evaluation, Preclinical|Epoprostenol|Excipients|Female|Guinea Pigs|Humans|Hypertension, Pulmonary|Lung|Male|Nanoparticles|Phosphatidylethanolamines|Platelet Aggregation|Polyethylene Glycols|Prodrugs|Rats, Sprague-Dawley|Squalene|Vasodilation|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28904003_20201005_0.5	treprostinil	drug_name	No section This article describes the preclinical pharmacology and pharmacokinetics (PK) of hexadecyl-treprostinil (C16TR), a prodrug of treprostinil (TRE), formulated in a lipid nanoparticle (LNP) for inhalation as a pulmonary vasodilator.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5	treprostinil	drug_name	Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Antihypertensive Agents|Child|Drug Administration Schedule|Epoprostenol|Exercise Test|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Infusions, Parenteral|Male|Middle Aged|Recovery of Function|Retrospective Studies|Survival Rate|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5	treprostinil	drug_name	OBJECTIVE The aim of this long-term multicenter analysis was to investigate whether subcutaneously infused treprostinil could provide sustained improvements of exercise capacity and survival benefits in patients with pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5	treprostinil	drug_name	Subcutaneous administration of the prostacyclin analog treprostinil is an effective treatment for PAH that, unlike epoprostenol, does not require the insertion of a permanent central venous catheter.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5	treprostinil	drug_name	These changes were observed under a mean dose of subcutaneously infused treprostinil at 40 +/- 2.6 ng/kg/min (range, 16 to 84 ng/kg/min).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5	treprostinil	drug_name	Subcutaneously infused treprostinil was well tolerated, and local pain at the subcutaneous site accounted for treatment interruption in only 5% of the cases.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16778286_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Long-term subcutaneous therapy with treprostinil appears to continuously improve exercise tolerance and symptoms in patients with PAH and inoperable CTEPH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16483811_20201005_0.5			Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16483811_20201005_0.5			Adult|Bosentan|Cardiac Catheterization|Cohort Studies|Digoxin|Drug Administration Routes|Epoprostenol|Female|Follow-Up Studies|Hemodynamics|Humans|Hypertension, Pulmonary|Lung Transplantation|Male|Pulmonary Circulation|Retrospective Studies|Serotonin Uptake Inhibitors|Sulfonamides|Survival Analysis|Treatment Outcome|Vasodilation|Warfarin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16483811_20201005_0.5	treprostinil	drug_name	Seventy-nine (94%) patients were treated with warfarin; 38 (45%) received continuous intravenous epoprostenol; 12 (14%) received continuous subcutaneous treprostinil, and 23 (27%) were treated with oral bosentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25542069_20201005_0.5	treprostinil	drug_name	Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25542069_20201005_0.5	treprostinil	drug_name	Naxaprostene|Prostanoid DP receptor|Prostanoid EP receptor|Prostanoid IP receptor|Smooth muscle relaxation|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25542069_20201005_0.5			Animals|Epoprostenol|Hydantoins|Indoles|Male|Mice|Mice, Inbred C57BL|Molecular Structure|Muscle Contraction|Muscle, Smooth|Rabbits|Rats|Rats, Sprague-Dawley|Receptors, Prostaglandin|Structure-Activity Relationship	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25542069_20201005_0.5	treprostinil	drug_name	No section In this study, the inhibitory profiles of the prostacyclin analogues treprostinil and naxaprostene on several isolated smooth muscle preparations have been investigated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25542069_20201005_0.5	treprostinil	drug_name	Treprostinil was an agonist for prostanoid DP1, EP2 and IP receptors, but not EP4 receptors; its DP1 potency was only 3-4 times less than PGD2 itself.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25542069_20201005_0.5	treprostinil	drug_name	Treprostinil is a 13,14-dihydro analogue and the role of conformation around C12-15 in controlling agonist specificity is debated; the synthesis of new analogues is proposed and possible clinical usage discussed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5			DPP4/CD26-inhibitor|Drug combination therapy|Engraftment|Hematopoietic cell transplantation/HCT|Homing|Migration|Prostanoid receptor agonist	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5			Animals|Antihypertensive Agents|Cells, Cultured|Dipeptidyl Peptidase 4|Dipeptidyl-Peptidase IV Inhibitors|Drug Antagonism|Drug Synergism|Epoprostenol|Fetal Blood|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cells|Humans|Mice|Vildagliptin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	Here we explored the synergism between treprostinil, a stable prostaglandin agonist, and the DPP4/CD26-inhibitor vildagliptin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	The combination of treprostinil and forskolin caused a modest but statistically significant increase in the surface levels of DPP4/CD26 on hematopoietic stem and progenitor cells (HSPCs) derived from murine bone and human cord blood.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	Their migration towards stromal cell-derived factor-1 (SDF-1/CXCL12) was enhanced, if they were pretreated with treprostinil and forskolin, and further augmented by vildagliptin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	Administration of vildagliptin rescued 25% of lethally irradiated recipient mice injected with a limiting number of untreated HSPCs, but 90 to 100% of recipients injected with HSPCs preincubated with treprostinil and forskolin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	The efficacy of vildagliptin surpassed that of treprostinil (60% rescue).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	Surprisingly, concomitant administration of vildagliptin and treprostinil resulted in poor survival of recipients indicating mutual antagonism, which was recapitulated when homing of and colony formation by HSPCs were assessed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	These observations of regimen-dependent synergism and antagonism of treprostinil and vildagliptin are of translational relevance for the design of clinical trials.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7007891_20210311_0.5	treprostinil	drug_name	 Key messages Pretreatment with treprostinil increases surface levels of DPP4/CD26 in HSPCs.. Vildagliptin enhances in vitro migration of pretreated HSPCs.. Vildagliptin enhances in vivo homing and engraftment of pretreated HSPCs.. Unexpected mutual antagonism in vivo by concomitant administration of vildagliptin and treprostinil.. Electronic supplementary material The online version of this article (10.1007/s00109-019-01869-8) contains supplementary material, which is available to authorized users.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15029402_20201005_0.5			Current medical treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15029402_20201005_0.5			Algorithms|Antihypertensive Agents|Bosentan|Calcium Channel Blockers|Drug Therapy, Combination|Epoprostenol|Humans|Hypertension, Pulmonary|Platelet Aggregation Inhibitors|Sulfonamides	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15029402_20201005_0.5	treprostinil	drug_name	Agents currently approved for the specific treatment of pulmonary arterial hypertension are continuous intravenous epoprostenol, subcutaneous treprostinil and oral bosentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32999581_20201005_0.5			Microfluidic device using a gold pillar array and integrated electrodes for on-chip endothelial cell immobilization, direct RBC contact, and amperometric detection of nitric oxide.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32999581_20201005_0.5			Humans|Nitric Oxide|Endothelial Cells|Lab-On-A-Chip Devices|Gold|Electrodes|Erythrocytes|Microfluidic Analytical Techniques|Polystyrenes	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32999581_20201005_0.5	treprostinil	drug_name	RBCs were pharmacologically treated with treprostinil in the absence and presence of glybenclamide, and ATP release was determined as was the resultant NO release from endothelial cells.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32999581_20201005_0.5	treprostinil	drug_name	Treprostinil treatment of RBCs resulted in ATP release that stimulated endothelial cells to release on average 1.8 ± 0.2 nM NO per endothelial cell (average ± SEM, n = 8).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32999581_20201005_0.5	treprostinil	drug_name	Pretreatment of RBCs with glybenclamide inhibited treprostinil-induced ATP release and, therefore, less NO was produced by the endothelial cells (0.92 ± 0.1 nM NO per endothelial cell, n = 7).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17618103_20201005_0.5			Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17618103_20201005_0.5			Adult|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Lupus Vulgaris|Middle Aged|Retrospective Studies|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17618103_20201005_0.5	treprostinil	drug_name	Eight patients were started on epoprostenol and 2 each on bosentan or treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17618103_20201005_0.5	treprostinil	drug_name	After a mean follow-up of 41+/-25 months, 5 patients were on combination therapy (3 epoprostenol plus bosentan, 1 treprostinil plus bosentan, 1 bosentan plus sildenafil) and 7 were on monotherapy (2 epoprostenol, 4 bosentan, 1 sildenafil); 6MWD increased by 139 m (95% CI, 36 to 259, p=0.007), 8 patients were functional class I or II and 4 were class III; right ventricular systolic pressure (RVSP) decreased by 22 mmHg (95% CI, 6 to 36; p=0.012), mPAP decreased by 18 mmHg (95% CI, 8 to 29; p=0.014), and cardiac index increased by 1.44 L/min/m(2) (95% CI, 0.76 to 2.08; p=0.016).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5			Congenital diaphragmatic hernia|Infant|Newborn|Prostacyclin|Pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5			Antihypertensive Agents|Echocardiography|Epoprostenol|Female|Follow-Up Studies|Gestational Age|Hernias, Diaphragmatic, Congenital|Humans|Hypertension, Pulmonary|Infant|Infant, Newborn|Male|Pulmonary Artery	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	 OBJECTIVE To report the effects and tolerability of subcutaneous treprostinil in newborns with severe CDH and late life-threatening PH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	 METHODS We recorded clinical and echocardiography data before and after starting subcutaneous treprostinil, on patients with severe CDH and late PH, refractory to inhaled nitric oxide and oral sildenafil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	 RESULTS 14 patients were treated with treprostinil (gestational age: 39.1±2.0weeks; birth weight: 3200±600g).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	Treprostinil was initiated at a median age of 12days [5-157].	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	After starting treprostinil, ΔSpO2 decreased to 3% at day 7 (p<0.05), and the mean blood flow velocities in the right pulmonary arteries increased by 110% (p<0.05).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28389079_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The subcutaneous treprostinil improves pulmonary hemodynamics and outcomes in infants with CDH and life-threatening PH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5			Administration, Inhalation|Administration, Oral|Antihypertensive Agents|Dose-Response Relationship, Drug|Epoprostenol|Familial Primary Pulmonary Hypertension|Half-Life|Humans|Hypertension, Pulmonary|Injections, Intravenous|Injections, Subcutaneous|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	No section Treprostinil is a synthetic prostacyclin analogue with antiplatelet and vasodilatory properties.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil has been shown in short- and long-term studies to improve exercise capacity, functional class, haemodynamics and survival in patients with pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Pain at the infusion site has been a major drawback of subcutaneous treprostinil, hampering dose titration, and ultimately leading to increased discontinuation rates.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	The additional clinical interest in treprostinil as an alternative intravenous prostacyclin has developed due to its favourable properties, including longer half-life, chemical stability, the possibility of intravenous infusion without the need for ice packs, and easy drug preparation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Intravenous treprostinil improves exercise capacity, functional class and haemodynamics in patients with PAH, over the period of 12 weeks.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	If patients are switched to intravenous treprostinil, they usually need to double the dose to attain the same efficacy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Whether the effect of intravenous treprostinil remains clinically relevant beyond 12 weeks is not known, and a longer follow-up would be required to investigate this.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil is an efficacious treatment in PAH patients who are moderately symptomatic on background oral therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23231023_20201005_0.5	treprostinil	drug_name	Oral treprostinil on top of background therapy did not lead to an improvement in 6-minute walking distance after 16 weeks of treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20508873_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20508873_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20508873_20201005_0.5	treprostinil	drug_name	No section O(6)-Benzylguanine; (-)-Gossypol; Abatacept, AC-2592, Adalimumab, AIDSVAX gp120 B/E, Alemtuzumab, Aliskiren fumarate, ALVAC E120TMG, Ambrisentan, Amlodipine, Anakinra, Aripiprazole, Armodafinil, Atomoxetine hydrochloride, Avotermin; Bevacizumab, BIBW-2992, Bortezomib, Bosentan, Botulinum toxin type B; Canakinumab, CAT-354, Ciclesonide, CMV gB vaccine, Corifollitropin alfa, Daptomycin, Darbepoetin alfa, Dasatinib, Denosumab; EndoTAG-1, Eplerenone, Esomeprazole sodium, Eszopiclone, Etoricoxib, Everolimus, Exenatide, Ezetimibe, Ezetimibe/simvastatin; F-50040, Fesoterodine fumavate, Fondaparinux sodium, Fulvestrant; Gabapentin enacarbil, Golimumab; Imatinib mesylate, Inhalable human insulin, Insulin glargine, Ivabradine hydrochloride; Lercanidipine hydrochloride/enalapril maleate, Levosimendan, Liposomal vincristine sulfate, Liraglutide; MDV-3100, Mometasone furoate/formoterol fumavate, Multiepitope CTL peptide vaccine, Mycophenolic acid sodium salt, Nabiximols, Natalizumab, Nesiritide; Obeticholic acid, Olmesartan medoxomil, Omalizumab, Omecamtiv mecarbil; Paclitaxel-eluting stent, Paliperidone, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ ribavirin, Pemetrexed disodium, Polymyxin B nonapeptide, PORxin-302, Prasugrel, Pregabalin, Pridopidine; Ranelic acid distrontium salt, Rasagiline mesilate, rDEN4delta30-4995, Recombinant human relaxin H2, rhFSH, Rilonacept, Rolofylline, Rosiglitazone maleate/metformin hydrochloride, Rosuvastatin calcium, Rotigotine; Salcaprozic acid sodium salt, Sirolimus-eluting stent, Sitagliptin phosphate monohydrate, Sitaxentan sodium, Sorafenib, Sunitinib malate; Tadalafil, Tapentadol hydrochloride, Temsirolimus, Tenofovir, Tenofovir disoproxil fumarate, Teriparatide, Tiotropium bromide, Tocilizumab, Tolvaptan, Tozasertib, Treprostinil sodium; Ustekinumab; Vardenafil hydrochloride hydrate, Varenicline tartrate, Vatalanib succinate, Voriconazole, Vorinostat; Zotarolimus-eluting stent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18518827_20201005_0.5			Inhaled prostanoids in the therapy of pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18518827_20201005_0.5			Administration, Inhalation|Aerosols|Controlled Clinical Trials as Topic|Humans|Hypertension, Pulmonary|Prostaglandins|Prostaglandins, Synthetic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18518827_20201005_0.5	treprostinil	drug_name	Strategies for further improvement of inhaled prostanoid therapy include use of prostacyclin analogues with longer half-life (e.g., treprostinil), combinations with oral drugs (e.g., phosphodiesterase inhibitors or endothelin receptor antagonists) and development of aerosolized controlled release formulations such as liposomes and nanoparticles.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15834459_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15834459_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15834459_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs:[188Re]-HDD; A-179578, adalimumab, AK-602, albumin interferon alfa, alfimeprase, amelubant, anakinra, anti-CD2 MAb, APD-356, aripiprazole, atvogen; Bimatoprost, bimosiamose, BLP-25, brivaracetam; Caspofungin acetate, cilansetron, CMV vaccine (bivalent), conivaptan hydrochloride, Cypher; Darbepoetin alfa, darifenacin hydrobromide, D-D4FC, decitabine, dnaJP1, doranidazole, dronedarone hydrochloride; Efalizumab, efaproxiral sodium, emtricitabine, Endeavor, entecavir, erlotinib hydrochloride, escitalopram oxalate, etoricoxib, etravirine, ezetimibe; Fampridine, fenretinide, ferumoxtran-10, forodesine hydrochloride; Gantacurium chloride, gemi-floxacin mesilate, Glyminox, GW-501516; HBV-ISS, hepavir B, human insulin, HuMax-CD20, hyaluronic acid, HyCAMP; Icatibant, IDEA-070, IGN-311, imatinib mesylate, insulin detemir, insulin glargine, insulin glulisine; Lapatinib, lasofoxifene tartrate, LB-80380, liarozole fumarate, liposome encapsulated doxorubicin, lumiracoxib, LY-570310; MC-1, melatonin, merimepodib, metanicotine, midostaurin; Natalizumab, nicotine conjugate vaccine, NYVAC-HIV C; Patupilone, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pelitinib, Peru-15, pexelizumab, PHP, pimecrolimus, prednisolone sodium metasulfobenzoate; Recombinant alfa1-antitrypsin (AAT), retigabine, rHA influenza vaccine, rifalazil, rofecoxib, rosiglitazone maleate/Metformin hydrochloride, rostaporfin, rosuvastatin calcium, rubitecan; Selenite sodium, semilente insulin, SMP-797, sorafenib; Talampanel, tenofovir disoproxil fumarate, TER-199, tiotropium bromide, torcetrapib, treprostinil sodium, TTA; ValboroPro, valdecoxib, val-mCyd, valtorcitabine dihydrochloride: XP-828L.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16574908_20201005_0.5			Impact of TASK-1 in human pulmonary artery smooth muscle cells.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16574908_20201005_0.5			Cells, Cultured|DNA Primers|Gene Expression Regulation|Humans|Muscle, Smooth, Vascular|Nerve Tissue Proteins|Patch-Clamp Techniques|Potassium|Potassium Channels|Potassium Channels, Tandem Pore Domain|Pulmonary Artery|RNA, Messenger	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16574908_20201005_0.5	treprostinil	drug_name	Moreover, we showed that TASK-1 is blocked by moderate hypoxia and activated by treprostinil at clinically relevant concentrations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16574908_20201005_0.5	treprostinil	drug_name	Treatment of human PASMC with TASK-1 siRNA resulted in loss of sensitivity to anandamide, acidosis, alkalosis, hypoxia, and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16574908_20201005_0.5	treprostinil	drug_name	These results suggest that (1) TASK-1 is expressed in human PASMC; (2) TASK-1 is hypoxia-sensitive and controls the resting membrane potential, thus implicating an important role for TASK-1 K+ channels in the regulation of pulmonary vascular tone; and (3) treprostinil activates TASK-1 at clinically relevant concentrations via PKA, which might represent an important mechanism underlying the vasorelaxing properties of prostanoids and their beneficial effect in vivo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30947510_20201005_0.5	treprostinil	drug_name	Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22814427_20201005_0.5			Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22814427_20201005_0.5			Adaptive Immunity|Adult|Aged|Aged, 80 and over|Antihypertensive Agents|Cell Proliferation|Cells, Cultured|Cyclic AMP-Dependent Protein Kinases|Epoprostenol|Female|Humans|Iloprost|Interferon-gamma|Interleukin-17|Interleukin-23 Subunit p19|Interleukins|Male|Middle Aged|Monocytes|Platelet Aggregation Inhibitors|Scleroderma, Systemic|Th1 Cells|Th17 Cells|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22814427_20201005_0.5	treprostinil	drug_name	PGI(2) analogues (iloprost, treprostinil and beraprost) significantly increased IL-17A and IL-22 in vitro while decreasing IFNγ production both in SSc and HD PBMC.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5			Adult|Antihypertensive Agents|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Intravenous|Injections, Subcutaneous|Male|Middle Aged	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	Treprostinil is a longer-acting prostacyclin analog, chemically stable, and suitable for continuous subcutaneous administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	We report successful transitioning to subcutaneous treprostinil of patients who presented with life-threatening complications of i.v.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	 METHODS Transition to subcutaneous treprostinil following an empiric protocol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	 RESULTS Transition to treprostinil was achieved successfully in 21 to 96 h, with no major adverse side effects, and no change in the improved clinical status achieved with i.v.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	Doses of treprostinil at completion of the transition ranged from 3 to 65 ng/kg/min (mean, 22 ng/kg/min).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12006444_20201005_0.5	treprostinil	drug_name	epoprostenol to subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4734815_20201005_0.5	treprostinil	drug_name	Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC4734815_20201005_0.5	treprostinil	drug_name	oral treprostinil|pulmonary arterial hypertension|selexipag	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC4734815_20201005_0.5	treprostinil	drug_name	PRC|Humans|United States|treprostinil|Hypertension, Pulmonary|Antihypertensive Agents|Epoprostenol|Familial Primary Pulmonary Hypertension|Infusions, Intravenous|Injections, Intravenous|United States Food and Drug Administration|Administration, Inhalation|Injections, Subcutaneous|Drug-Related Side Effects and Adverse Reactions|Biomimetics|Drama|Educational Personnel	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC4734815_20201005_0.5	treprostinil	drug_name	Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4734815_20201005_0.5	treprostinil	drug_name	Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4734815_20201005_0.5	treprostinil	drug_name	While oral treprostinil's current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16082422_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16082422_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16082422_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs: Abiraterone acetate, acyline, adalimumab, adenosine triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4 MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171; Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan; Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher, cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide, DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium, fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, VRX-496, VX-385; Warfarin sodium; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zidovudine.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32204626_20210611_0.5			Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32204626_20210611_0.5			PAH|Pulmonary hypertension|inhaled nitric oxide|prostacyclin analogues|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32204626_20210611_0.5			Administration, Inhalation|Adult|Aged|Antihypertensive Agents|Child|Child, Preschool|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infant|Male|Middle Aged|Nitric Oxide|Randomized Controlled Trials as Topic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32204626_20210611_0.5	treprostinil	drug_name	Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20216163_20201005_0.5			Prostacyclin in the intensive care setting.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20216163_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Child|Critical Care|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20216163_20201005_0.5	treprostinil	drug_name	Three prostanoids have been developed to treat PAH: epoprostenol, treprostinil, and iloprost.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19907722_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19907722_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19907722_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline mesilate, Recombinant human relaxin H2, rhGAD65, Rivaroxaban, Rosuvastatin calcium, Rotigotine; Saxagliptin, SCH-530348, Sirolimus-eluting stent, SLIT-amikacin, Sorafenib, Sotrastaurin, SR-16234, Sulforaphane; Tadalafil, Tanespimycin, Tapentadol hydrochloride, Teriparatide, Tesofensine, Tiotropium bromide, Tipifarnib, Tirapazamine, TMC-207, Tocilizumab, Tolvaptan, Tosedostat, Treprostinil sodium; Ustekinumab; Varespladib methyl, Vicriviroc, Vildagliptin, Vildagliptin/metformin hydrochloride, Volociximab, Voriconazole; Ziconotide, Ziprasidone hydrochloride.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33346142_20210611_0.5	treprostinil	drug_name	Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33346142_20210611_0.5	treprostinil	drug_name	Inhaled|Pulmonary vasodilation|Tachyphylaxis|Treprostinil palmitil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33346142_20210611_0.5	treprostinil	drug_name	Male|Rats|Animals|treprostinil|Vasodilator Agents|Tachyphylaxis|Rats, Sprague-Dawley|Epoprostenol|Antihypertensive Agents|Lung|Hypertension, Pulmonary|Vasodilation|Administration, Inhalation|Prodrugs|Nebulizers and Vaporizers|Nanoparticles	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33346142_20210611_0.5	treprostinil	drug_name	No section Treprostinil palmitil (TP) is an inhaled long-acting pulmonary vasodilator prodrug of treprostinil (TRE) that has been formulated for delivery as a suspension (treprostinil palmitil inhalation suspension; TPIS) and as a dry powder (treprostinil palmitil inhalation powder; TPIP).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25409915_20201005_0.5	treprostinil	drug_name	Oral treprostinil diethanolamine for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25409915_20201005_0.5	treprostinil	drug_name	PAH treatment|oral treprostinil|orenitram|prostanoid • orenitram dosing|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25409915_20201005_0.5			Administration, Oral|Antihypertensive Agents|Clinical Trials, Phase III as Topic|Epoprostenol|Ethanolamines|Humans|Hypertension, Pulmonary|Pulmonary Artery|Randomized Controlled Trials as Topic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25409915_20201005_0.5	treprostinil	drug_name	No section The approval of oral treprostinil is a landmark event in the treatment of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25409915_20201005_0.5	treprostinil	drug_name	Although the current data in prostanoid naïve patients are unimpressive, emerging data suggest that in carefully selected patients oral treprostinil may be able to replace continuously infused treprostinil; however, many hurdles exist for this new medication including overcoming a complex side effect profile, astronomical cost and perhaps other entrants into the oral prostanoid space.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26220250_20201005_0.5			In Vitro and In Vivo Performance of a Pre-Filled, Electrochemically-Actuated Infusion System.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26220250_20201005_0.5	treprostinil	drug_name	parenteral|pharmacokinetic|pump|treprostinil|wearable	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26220250_20201005_0.5			Adult|Antihypertensive Agents|Biosensing Techniques|Chemistry, Pharmaceutical|Electrochemical Techniques|Epoprostenol|Equipment Design|Erythema|Healthy Volunteers|Humans|Infusion Pumps|Male|Reproducibility of Results|Sodium Chloride	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26220250_20201005_0.5	treprostinil	drug_name	A second clinical study examined the PK of delivering treprostinil at an average dose of 2.3 ng/kg/min to 5 healthy volunteers for 18 h. RESULTS Relative to a design target of 0.042 mL/hr, the average flow rate of 23 PatchPumps operating for 48 continuous hours was 0.043 ± 0.007 mL/hr as tested in vitro.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26220250_20201005_0.5	treprostinil	drug_name	PK results with an infusion rate of 0.045 mL/hr of treprostinil resulted in mean Css of 297 pg/mL and T1/2 of 4.44 h, comparable to prior studies using conventional infusion pumps.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32356433_20201005_0.5	treprostinil	drug_name	Long-term experience with implantable treprostinil pumps in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32356433_20201005_0.5			LenusPro quality of life.|implantable pump|pulmonary arterial hypertension|treptostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32356433_20201005_0.5			Antihypertensive Agents|Epoprostenol|Humans|Pulmonary Arterial Hypertension|Quality of Life	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12804447_20201005_0.5			Prostacyclin for pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12804447_20201005_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Randomized Controlled Trials as Topic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12804447_20201005_0.5	treprostinil	drug_name	One RCT compared oral prostacyclin with placebo, another compared subcutaneous infusion of treprostinil with placebo and a further RCT studied the effects of inhaled iloprost.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28289495_20201005_0.5			Treatment of Chronic Thromboembolic Pulmonary Hypertension: The Role of Medical Therapy and Balloon Pulmonary Angioplasty.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28289495_20201005_0.5			balloon pulmonary angioplasty|chronic thromboemboli|pulmonary hypertension|pulmonary hypertension targeted medical therapy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28289495_20201005_0.5			Angioplasty, Balloon|Antihypertensive Agents|Arterial Pressure|Chronic Disease|Exercise Tolerance|Humans|Hypertension, Pulmonary|Pulmonary Artery|Pulmonary Embolism|Recovery of Function|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28289495_20201005_0.5	treprostinil	drug_name	Previous unblinded cohort trials have assessed PH-targeted medical therapy in various subpopulations of CTEPH patients using epoprostenol, treprostinil, sildenafil, bosentan, and iloprost, each demonstrating measurable pulmonary hemodynamic effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16218473_20201005_0.5			Pulmonary arterial hypertension associated to connective tissue diseases.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16218473_20201005_0.5			Algorithms|Connective Tissue Diseases|Evidence-Based Medicine|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16218473_20201005_0.5	treprostinil	drug_name	Also, the endothelin receptor antagonists bosentan and sitaxentan, the phosphodyesterase-type-5 sildenafil and subcutaneous treprostinil have shown favourable results.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5			Administration, Oral|Antihypertensive Agents|Canada|Cost Control|Cost Savings|Cost-Benefit Analysis|Economics, Pharmaceutical|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Male|Monte Carlo Method|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	In the present study, an economic evaluation of patients with PAH treated with either treprostinil or epoprostenol was performed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	 METHODS A cost-minimization analysis (a cost-effectiveness subtype) was performed under the assumption that treprostinil and epoprostenol were clinically equivalent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	Two cohorts of 60 patients, treated with treprostinil or epoprostenol, were evaluated over three years by using a dynamic spreadsheet model.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	 RESULTS In the base-case analysis (over three years), treatment with treprostinil resulted in an expected savings of 2,610,642 US dollars and 2,781,438 US dollars from the ministries of health and societal perspectives, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	On a per-patient level, treatment with treprostinil resulted in an average annual savings of 14,504 US dollars and 15,452 US dollars, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	The greatest savings with treprostinil came from reduced hospitalizations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16331313_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS By initiating and continuing treprostinil treatment over a three-year period, the economic burden associated with PAH may be reduced compared with epoprostenol treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30559025_20201005_0.5			Reply.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30559025_20201005_0.5	treprostinil	drug_name	congenital diaphragmatic hernia|pulmonary hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID30559025_20201005_0.5			Epoprostenol|Hernias, Diaphragmatic, Congenital|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	Treprostinil for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5			Administration, Inhalation|Administration, Oral|Antihypertensive Agents|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Infusions, Parenteral	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23259441_20201005_0.5	treprostinil	drug_name	This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4630896_20201005_0.5			Laparoscopy shows superiority over endoscopy for early detection of malignant atrophic papulosis gastrointestinal complications: a case report and review of literature	title
treprostinil|water	Z0000025801				inn	PubMed	PMC4630896_20201005_0.5	treprostinil	drug_name	MAP|Malignant|Atrophic papulosis|Treprostinil|Eculizumab|Laparoscopy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC4630896_20201005_0.5			Adolescent|Early Diagnosis|Endoscopy, Gastrointestinal|Gastrointestinal Diseases|Humans|Laparoscopy|Male|Malignant Atrophic Papulosis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31044326_20201005_0.5			Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31044326_20201005_0.5			Bridging therapy|Chronic thromboembolic pulmonary hypertension|Combination therapy|Pulmonary arterial hypertension-targeted therapy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31044326_20201005_0.5			Adult|Aged|Angioplasty, Balloon|Antihypertensive Agents|Chronic Disease|Drug Therapy, Combination|Endarterectomy|Endothelin Receptor Antagonists|Epoprostenol|Female|Heart Failure|Hemodynamics|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Male|Molecular Targeted Therapy|Phosphodiesterase 5 Inhibitors|Prostaglandins I|Pulmonary Artery|Pulmonary Embolism|Pyrazoles|Pyrimidines|Randomized Controlled Trials as Topic|Sulfonamides|Treatment Outcome|Walk Test	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31044326_20201005_0.5	treprostinil	drug_name	To date, riociguat, macitentan, and subcutaneous treprostinil are the only drugs proven by randomized control trials to be capable of improving the exercise capacity (6-min walking distance) of CTEPH patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11936539_20201005_0.5			Pulmonary hypertension in collagen vascular disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID11936539_20201005_0.5			Collagen Diseases|Comorbidity|Female|Humans|Hypertension, Pulmonary|Male|Prognosis|Risk Assessment|Vascular Diseases	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID11936539_20201005_0.5	treprostinil	drug_name	Continuous intravenous prostacyclin remains the standard treatment of associated pulmonary hypertension but less invasive alternatives such as subcutaneous treprostinil, oral beraprost or aerosolized iloprost, as well as, novel substances such as endothelin receptor antagonists may be appropriate for selected patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27162621_20201005_0.5	treprostinil	drug_name	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27162621_20201005_0.5	treprostinil	drug_name	oral treprostinil|prostacyclin|pulmonary hypertension|switch|transition	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27162621_20201005_0.5	treprostinil	drug_name	Middle Aged|Adult|Humans|Female|treprostinil|Epoprostenol|Prostaglandins I|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Vasodilator Agents|Clinical Protocols|Administration, Inhalation|Treatment Outcome|Administration, Oral|Administration, Intravenous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27162621_20201005_0.5	treprostinil	drug_name	No section Oral treprostinil (TRE) is a prostacylin approved for the management of pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	Middle Aged|Adult|Male|Humans|Female|treprostinil|Prospective Studies|Epoprostenol|Hypertension, Pulmonary|Antihypertensive Agents|Analgesics|Familial Primary Pulmonary Hypertension|Prostaglandins|Injections, Subcutaneous|Pain|Subcutaneous Tissue	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	Infusion site pain has discouraged some physicians from considering subcutaneous (SQ) treprostinil therapy even though it has safety and convenience advantages over intravenous epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	We conducted a 1-year prospective study of patients utilizing SQ treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	Contrary to published guidelines, infusion site pain was independent of treprostinil dose in a rigorous analysis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	No subject discontinued SQ treprostinil because of site discomfort.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	A strategy emphasizing infrequent site changes and early analgesia can facilitate use of SQ treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24618545_20201005_0.5	treprostinil	drug_name	These data may allow physicians to consider treprostinil earlier in the treatment algorithm for this fatal disease.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	oral treprostinil|prostacyclin|pulmonary hypertension|switch|transition	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5			Administration, Inhalation|Administration, Oral|Adult|Antihypertensive Agents|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Parenteral|Middle Aged	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	No section Treprostinil diolamine is the first oral dosage preparation of a prostacyclin analogue for use in treatment naive pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	This case series and review of the available literature describes the experience of patients with PAH receiving treprostinil by intravenous (IV), subcutaneous (SQ), or inhalation route who were transitioned to treprostinil diolamine.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	At our institution, 3 patients were transitioned to treprostinil diolamine who received treprostinil administered by each of the alternative routes: IV, SQ, and inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	In the literature, 5 additional reports representing 48 patients were transitioned to treprostinil diolamine from an alternate route of administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	The most common dosing frequency utilized for treprostinil diolamine was 3 times per day.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29558853_20201005_0.5	treprostinil	drug_name	In patients with stable PAH receiving parenteral or inhaled treprostinil, a transition to treprostinil diolamine was a safe approach in a highly select population meeting clinical end points.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26511384_20201005_0.5			Use of Pulmonary Hypertension Medications in Patients with Tetralogy of Fallot with Pulmonary Atresia and Multiple Aortopulmonary Collaterals.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26511384_20201005_0.5			Aortopulmonary collaterals|Pulmonary atresia|Pulmonary hypertension|Tetralogy of Fallot	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26511384_20201005_0.5			Abnormalities, Multiple|Adolescent|Antihypertensive Agents|Bosentan|Catheterization|Child|Child, Preschool|District of Columbia|Echocardiography|Female|Hemodynamics|Hospitals, Pediatric|Humans|Hypertension, Pulmonary|Infant|Infant, Newborn|Lung|Male|Phenylpropionates|Pulmonary Artery|Pulmonary Atresia|Pyridazines|Retrospective Studies|Sildenafil Citrate|Sulfonamides|Tertiary Care Centers|Tetralogy of Fallot|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26511384_20201005_0.5	treprostinil	drug_name	PH medications included sildenafil, bosentan, ambrisentan, inhaled treprostinil and prostacyclin infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20627625_20201005_0.5			Epoprostenol-associated pneumonitis: diagnostic use of a T-cell proliferation assay.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20627625_20201005_0.5			Adult|Amiodarone|Anti-Arrhythmia Agents|Antihypertensive Agents|Drug Interactions|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Lung Diseases|Lymphocyte Activation|Pneumonia|Prednisone|T-Lymphocytes|Ultrasonography	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20627625_20201005_0.5	treprostinil	drug_name	There was a trend towards an increased T-cell response to treprostinil but this was statistically insignificant.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15320842_20201005_0.5			Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15320842_20201005_0.5			Antihypertensive Agents|Clinical Trials as Topic|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Pulmonary Circulation|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15320842_20201005_0.5	treprostinil	drug_name	Recent clinical studies with more stable prostacyclin analogs such as subcutaneously delivered treprostinil, orally active beraprost and aerosolized iloprost have demonstrated beneficial effects of each of these prostanoids, especially in NYHA Class II and III patients and, therefore, these agents should be considered first for prostanoid therapy in the early stages of PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22853986_20201005_0.5	treprostinil	drug_name	Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22853986_20201005_0.5			Administration, Inhalation|Adult|Aged|Antihypertensive Agents|Dose-Response Relationship, Drug|Epoprostenol|Exercise Tolerance|Familial Primary Pulmonary Hypertension|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Injections, Intravenous|Injections, Subcutaneous|Male|Middle Aged|Prostaglandins|Pulmonary Wedge Pressure|Retrospective Studies|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22853986_20201005_0.5	treprostinil	drug_name	In this retrospective cohort study we collected clinical, hemodynamic, and functional data from 18 clinically stable patients with World Health Organization group I PAH seen in 6 large national PAH centers before and after transitioning to inhaled treprostinil from IV/SQ prostanoids.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22853986_20201005_0.5	treprostinil	drug_name	Before transition 15 patients had been receiving IV or SQ treprostinil (mean dose 73 ng/kg/min) and 3 patients had been on IV epoprostenol (mean dose 10 ng/kg/min) for an average duration of 113 ± 80 months.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22853986_20201005_0.5	treprostinil	drug_name	Although most patients who transitioned to inhaled treprostinil demonstrated no statistically significant worsening of hemodynamics or 6-minute walk distance, a minority demonstrated worsening of New York Heart Association functional class over a 7-month period.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22853986_20201005_0.5	treprostinil	drug_name	In conclusion, although transition of patients from IV/SQ prostanoids to inhaled treprostinil appears to be well tolerated in clinically stable patients, they should remain closely monitored for signs of clinical decompensation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20855220_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20855220_20201005_0.5			Antihypertensive Agents|Biological Availability|Dose-Response Relationship, Drug|Epoprostenol|Humans|Hypertension, Pulmonary|Infusions, Subcutaneous|Pain	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20855220_20201005_0.5	treprostinil	drug_name	No section Treprostinil, which is available for subcutaneous (SC) and intravenous (IV) administration, has demonstrated efficacy in increasing exercise capacity, reducing signs and symptoms of pulmonary arterial hypertension (PAH), and improving cardiopulmonary hemodynamics in patients with PAH; however, the infusion site pain commonly experienced with SC treprostinil has limited its use.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20855220_20201005_0.5	treprostinil	drug_name	Prospective and observational clinical studies have shown that the dose of SC treprostinil can be escalated at a higher rate than described in early clinical trials to achieve symptom relief, in part because of favorable tolerability of treatment and the apparent dose independence of site pain.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20855220_20201005_0.5	treprostinil	drug_name	Dosing to achieve rapid onset of efficacy and proactively managing infusion site pain enhance the likelihood for a patient with PAH to maintain and derive benefit from SC treprostinil therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5	treprostinil	drug_name	Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5			Congenital heart disease|Pediatric treatment|Prostacyclin|Pulmonary hypertension|Subcutaneous prostanoid	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5			Adolescent|Analgesics|Antihypertensive Agents|Cardiac Catheterization|Child|Child, Preschool|Cohort Studies|Echocardiography|Epoprostenol|Female|France|Humans|Hypertension, Pulmonary|Infant|Infusions, Subcutaneous|Male|Natriuretic Peptide, Brain|Pain, Procedural|Peptide Fragments|Retrospective Studies|Severity of Illness Index|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5	treprostinil	drug_name	We sought to evaluate the safety, efficacy and management of subcutaneous (SC) treprostinil in children with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5	treprostinil	drug_name	 No section Fifty-six children (median age 65, range 1-200 months) were treated with SC treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5	treprostinil	drug_name	Right heart catheterization was performed in 54 patients before starting SC treprostinil infusion and was repeated at 6 months in 31 patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29650343_20201005_0.5	treprostinil	drug_name	 No section Subcutaneous treprostinil infusion is an effective therapy without serious side effects in children with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5			Adult|Antihypertensive Agents|Drug Administration Schedule|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Injections, Subcutaneous|Male|Middle Aged|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	BACKGROUND We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	 METHODS This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	Placebo or SC treprostinil doses were titrated in response to symptoms.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	Seven of 8 patients (88%) [corrected] withdrawn to placebo had clinical deterioration, while only 1 of 14 patients (7%) [corrected] withdrawn to SC treprostinil had clinical deterioration (p = 0.00023 based on a treatment comparison of time to deterioration).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	Analyses of exercise capacity and symptoms strongly supported the efficacy of SC treprostinil in epoprostenol-treated patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17400684_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS SC treprostinil is effective in pulmonary arterial hypertension and prevents clinical deterioration and maintains functional status in patients transitioned from epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5			Administration, Inhalation|Adolescent|Antihypertensive Agents|Child|Child, Preschool|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Male|Nitric Oxide|Oxygen|Prospective Studies|Statistics, Nonparametric	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	This study aimed to report the initial experience with inhaled treprostinil used for AVT in children with PAH and to evaluate the hemodynamic change after inhaled treprostinil compared with inhaled nitric oxide.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	This prospective cohort study was designed for 13 children who underwent AVT with inhaled treprostinil or oxygen plus inhaled nitric oxide (iNO) during catheterization.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was delivered during cardiac catheterization by adapting the Optineb ultrasonic nebulizer via either a flow-inflating bag or the manual mode of the anesthesia system.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	All the patients tolerated inhaled treprostinil without marked clinical worsening and received six or nine breaths (36 or 54 μg) of treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	The median of the total treprostinil doses was 1.53 μg/kg (range 0.71-2.89 μg/kg).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was administrated via an endotracheal tube (n = 8), anesthesia mask (n = 3), or laryngeal mask airway (n = 2).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	Inhaled nitric oxide (iNO) and inhaled treprostinil significantly decreased the mean pulmonary artery pressure and the pulmonary vascular resistance index compared with baseline.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	Three adverse events were reported after inhaled treprostinil, including cough and mild to moderate hypotension with higher doses.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	This study report is the first to describe the use of inhaled treprostinil for AVT in children with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23184020_20201005_0.5	treprostinil	drug_name	In this small pediatric cohort, inhaled treprostinil was effectively delivered and well tolerated and may be useful for AVT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29679599_20201005_0.5			Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29679599_20201005_0.5			biomarkers|catheterizations|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29679599_20201005_0.5			Adolescent|Adult|Aged|Antihypertensive Agents|Biomarkers|Child|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Prognosis|Retrospective Studies|Survival Analysis|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29679599_20201005_0.5	treprostinil	drug_name	 No section In this retrospective cohort study, patients initiating IV epoprostenol or IV or subcutaneous (SC) treprostinil therapy for PAH from 2007 to 2016 at UT Southwestern and The Ohio State University were included.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29679599_20201005_0.5	treprostinil	drug_name	 No section Patients with group 1 PAH receiving IV epoprostenol (n = 132), IV treprostinil (n = 25), or SC treprostinil (n = 38) were included.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17338932_20201005_0.5			Prostanoid therapy for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17338932_20201005_0.5			Antihypertensive Agents|Chronic Disease|Epoprostenol|Heart Defects, Congenital|Humans|Hypertension, Portal|Hypertension, Pulmonary|Iloprost|Prostaglandins|Randomized Controlled Trials as Topic|Respiratory Distress Syndrome, Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17338932_20201005_0.5	treprostinil	drug_name	No section Epoprostenol and the structurally related compounds treprostinil, iloprost, and beraprost are collectively referred to as prostanoids.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil: a therapeutic review	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|prostacyclin|treprostinil|inhaled|nebulizer	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Clinical Trials as Topic|Drug Approval|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|United States|United States Food and Drug Administration	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	The prostacyclin analog treprostinil has proven efficacious when delivered by subcutaneous or intravenous infusion, and most recently by inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil has been shown to be 64%-72% bioavailable in healthy volunteers.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	Likewise, chronically administered inhaled treprostinil resulted in clinical and hemodynamic improvement.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	The pivotal Phase III trial, TRIUMPH-I, demonstrated the efficacy and safety of inhaled treprostinil (target dose of 54 μg four times daily) in PAH patients added to background therapies of bosentan or sildenafil, as assessed by improvements in the primary endpoint, peak six-minute walk distance (median placebo-corrected treatment effect of 20 m), as well as select secondary endpoints.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3267519_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil is approved by the US Food and Drug Administration for patients with World Health Organization Group I PAH to improve exercise ability.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15965810_20201005_0.5			[Treatment algorithm for pulmonary arterial hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15965810_20201005_0.5			Algorithms|Decision Support Systems, Clinical|Humans|Hypertension, Pulmonary|Patient Selection	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15965810_20201005_0.5	treprostinil	drug_name	Novel prostanoids including subcutaneous treprostinil and inhaled iloprost also have beneficial effects in many patients, although their long-term efficacy is less well known.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16725066_20201005_0.5			Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16725066_20201005_0.5			Adult|Antihypertensive Agents|Bosentan|Eisenmenger Complex|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Male|Pulmonary Wedge Pressure|Retrospective Studies|Sulfonamides|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16725066_20201005_0.5	treprostinil	drug_name	Of the patients, 17 had never received specific treatment for pulmonary arterial hypertension, five were transitioned from treprostinil, and one from beraprost to bosentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5130072_20201005_0.5			Recent advances in the management of pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5130072_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|riociguat|macitentan|treprostinil|selexipag	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5130072_20201005_0.5			Humans|Hypertension, Pulmonary|Endothelin Receptor Antagonists|riociguat|Pyrimidines|Pyrazoles|Epoprostenol|Antihypertensive Agents|Familial Primary Pulmonary Hypertension|Sulfonamides|Guanylate Cyclase|Disease Progression	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5130072_20201005_0.5	treprostinil	drug_name	Recently, the field has seen the introduction of riociguat, a soluble guanylate cyclase stimulator, a new endothelin receptor antagonist (macitentan), and oral prostanoids (treprostinil and selexipag).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5	treprostinil	drug_name	Oral treprostinil in the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5	treprostinil	drug_name	Pulmonary hypertension|prostanoid|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5			Acetamides|Administration, Oral|Antihypertensive Agents|Clinical Trials as Topic|Drug Approval|Epoprostenol|Humans|Hypertension, Pulmonary|Phosphodiesterase 5 Inhibitors|Pyrazines|Receptors, Prostaglandin|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5	treprostinil	drug_name	Infused medications present unique challenges, and the search for an efficacious oral prostanoid culminated in the FDA approval of oral treprostinil - a first in class oral prostanoid medication approved to treat pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5	treprostinil	drug_name	Areas covered: In this discussion, we review the pharmacologic properties of oral treprostinil, and discuss three original major registration studies that resulted in the approval and widespread use of the drug.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5	treprostinil	drug_name	Competition from oral prostaglandin receptor agonist selexipag challenges the commercial success of oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28922964_20201005_0.5	treprostinil	drug_name	The long-term viability of oral treprostinil rests largely on the outcome of the long-term event-driven study of the molecule added to background approved ERA or PDE5 inhibitor monotherapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5	treprostinil	drug_name	Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5			Adult|Antihypertensive Agents|Area Under Curve|Case-Control Studies|Delayed-Action Preparations|Epoprostenol|Female|Half-Life|Humans|Kidney Failure, Chronic|Male|Middle Aged|Renal Dialysis|Time Factors	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5	treprostinil	drug_name	No section Treprostinil diolamine sustained release (UT-15C SR) is being evaluated as an oral therapy for pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5	treprostinil	drug_name	This study evaluated the pharmacokinetics (PKs) of treprostinil following administration of UT-15C SR in subjects with end-stage renal disease (ESRD) compared with healthy subjects with normal renal function (NRF) and the effect of hemodialysis on the PK parameters of treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5	treprostinil	drug_name	The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5	treprostinil	drug_name	There was no substantial difference in treprostinil PKs between ESRD and NRF subjects following administration of UT-15C SR tablets.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23188123_20201005_0.5	treprostinil	drug_name	Hemodialysis did not have clinically important effect on treprostinil PK in ESRD subjects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430649_20201005_0.5			Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20430649_20201005_0.5			Antihypertensive Agents|Data Collection|Epoprostenol|Humans|Hypertension, Pulmonary|Incidence|Inpatients|Interviews as Topic|Medication Errors|Policy|United States	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20430649_20201005_0.5	treprostinil	drug_name	BACKGROUND Epoprostenol and treprostinil are intravenous prostacyclin medications used to treat pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430649_20201005_0.5	treprostinil	drug_name	 RESULTS The electronic survey respondents reported wide variability in prostacyclin infusion policies, including variability in the use of home vs hospital infusion pumps, and variability in the use and storage of back-up epoprostenol and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26081027_20201005_0.5			A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26081027_20201005_0.5	treprostinil	drug_name	Interferon|Pulmonary arterial hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26081027_20201005_0.5			Antihypertensive Agents|Arterial Pressure|Drug Therapy, Combination|Epoprostenol|Humans|Hypertension, Pulmonary|Immunologic Factors|Interferon-alpha|Liver Transplantation|Living Donors|Male|Middle Aged|Pulmonary Artery|Tadalafil|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26081027_20201005_0.5	treprostinil	drug_name	In our case, we achieved good outcome by the withdrawal of IFN and administration of combination therapy using tadalafil, beraprost, and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33979499_20210611_0.5	treprostinil	drug_name	Inhaled Treprostinil in Group 3 Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33979499_20210611_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Lung Diseases, Interstitial	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5			Administration, Inhalation|Administration, Oral|Adult|Aged|Antihypertensive Agents|Blood Pressure|Bosentan|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Lung|Male|Middle Aged|Severity of Illness Index|Sulfonamides|Treatment Outcome|Vascular Resistance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	OBJECTIVE This study evaluated the safety and efficacy of inhaled treprostinil as add-on therapy to oral bosentan in patients with pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	 METHODS Twelve patients with symptomatic PAH despite bosentan received either 30 microg of inhaled treprostinil 4 times daily (n = 6) or 45 microg 4 times daily (n = 6), via an ultrasonic nebulizer.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	In the remaining 11 patients, inhaled treprostinil was safe and well tolerated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was associated with an increase in 6MWD at 12 weeks (baseline 339 +/- 86, 12 week, 1 h post-inhalation 406 +/- 121 m, 67-m change, p = 0.01).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	An improvement in 6MWD of 49 m from baseline was noted during the trough period, just before inhalation of treprostinil (p = 0.009).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17010807_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS This trial suggests that inhaled treprostinil is safe, well tolerated, and associated with significant improvements in exercise capacity, functional class, and pulmonary hemodynamics in symptomatic patients with PAH on bosentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17130975_20201005_0.5			[Update in the diagnosis and therapy for pulmonary arterial hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17130975_20201005_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Phosphodiesterase Inhibitors|Piperazines|Platelet Aggregation Inhibitors|Prognosis|Purines|Sildenafil Citrate|Sulfones	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17130975_20201005_0.5	treprostinil	drug_name	Intravenous, subcutaneous or inhaled prostanoids such as Epoprostenol, Treprostinil or Iloprost respectively have been approved for Pulmonary Arterial Hypertension treatment as well as oral endothelial receptor blockers.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18042471_20201005_0.5			Evidence-based pharmacologic management of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18042471_20201005_0.5			Calcium Channel Blockers|Drug Therapy, Combination|Endothelin Receptor Antagonists|Evidence-Based Medicine|Humans|Hypertension, Pulmonary|Phosphodiesterase Inhibitors|Prostaglandins	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18042471_20201005_0.5	treprostinil	drug_name	In a 12-week, randomized, doubleblind, placebo-controlled trial in 470 patients with moderate to severe PAH, subcutaneous treprostinil plus conventional therapy was associated with a significant improvement on the 6-MWT compared with conventional therapy alone (+10 vs 0 m, respectively; P = 0.006).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18042471_20201005_0.5	treprostinil	drug_name	Infusions of the prostacyclin analogues epoprostenol and treprostinil appear to be the treatment of choice for moderate to severe PAH, and agents with alternate routes of delivery such as inhaled iloprost may be advantageous in adjunctive roles.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16548288_20201005_0.5			[Clinical implications and prognostic significance of the study on the circadian variation of heart rate variability in patients with severe pulmonary hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16548288_20201005_0.5			Circadian Rhythm|Electrocardiography, Ambulatory|Epoprostenol|Female|Heart Rate|Humans|Hypertension, Pulmonary|Male|Prognosis|Severity of Illness Index|Sympathetic Nervous System|Vagus Nerve	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16548288_20201005_0.5	treprostinil	drug_name	After detection of sympatho-vagal balance 15 patients were randomized, Treprostinil (prostaglandin) was administered to 6 patients and subcutaneous placebo to 9.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16548288_20201005_0.5	treprostinil	drug_name	p < .05), after administering treprostinil a recovery of sympathovagal balance was observed CONCLUSIONS Autonomic cardiac disturbance is clearly present in PPH and ES.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22231731_20201005_0.5			Effect of prostaglandin I2 analogs on cytokine expression in human myeloid dendritic cells via epigenetic regulation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22231731_20201005_0.5			Activating Transcription Factor 2|Calcium|Cells, Cultured|Cyclic AMP|Cytokines|Dendritic Cells|Epigenesis, Genetic|Epoprostenol|Histones|Humans|Iloprost|Methylation|Mitogen-Activated Protein Kinases|PPAR alpha|PPAR gamma|Receptors, Epoprostenol|Receptors, Prostaglandin|Receptors, Prostaglandin E|T-Lymphocytes	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22231731_20201005_0.5	treprostinil	drug_name	The effects of PGI(2) analogs iloprost and treprostinil on cytokine production, maturation and T-cell stimulatory function of human mDCs were investigated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22231731_20201005_0.5	treprostinil	drug_name	We found that iloprost and treprostinil induced IL-10, but suppressed TNF-α production in polyinosinic-polycytidylic acid (poly I:C)-stimulated mDCs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22231731_20201005_0.5	treprostinil	drug_name	Iloprost and treprostinil increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, and iloprost also increased intracellular Ca(2+).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19950085_20201005_0.5			Therapeutic methods used in patients with Eisenmenger syndrome.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19950085_20201005_0.5			Anemia, Iron-Deficiency|Antihypertensive Agents|Arrhythmias, Cardiac|Blood Coagulation Disorders|Blood Viscosity|Cyanosis|Eisenmenger Complex|Endothelin Receptor Antagonists|Female|Heart Defects, Congenital|Humans|Hypertension, Pulmonary|Male|Nitric Oxide|Phosphodiesterase Inhibitors|Polycythemia|Pregnancy|Pregnancy Complications, Cardiovascular|Prostaglandins I|Risk Reduction Behavior|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19950085_20201005_0.5	treprostinil	drug_name	Recent decades have seen developments in pulmonary hypertension pathophysiology which have led to the introduction of new groups of drugs: prostacycline analogs (Epoprostenol, Treprostinil, Beraprost, Illoprost), phosphodiesterase inhibitors (Sildenafil, Tadalafil), endothelin receptor antagonists (Bosentan, Sitaxantan, Ambrisentan) and nitric oxide.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5	treprostinil	drug_name	Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil – early experience	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5	treprostinil	drug_name	MAP|Treprostinil|Malignant atrophic papulosis	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5			Adolescent|Adult|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Lupus Erythematosus, Systemic|Male|Malignant Atrophic Papulosis|Scleroderma, Systemic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5	treprostinil	drug_name	 Methods We describe the clinical and pathologic findings in two patients, one with MAP and the other with MAP like lesions, who received treatment with subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5	treprostinil	drug_name	 Results Patient one was placed on therapy with treprostinil for her pulmonary hypertension, but in the months subsequent to initiation of treatment, dramatic and complete resolution of cutaneous MAP like lesions and disabling digital pain occurred.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5	treprostinil	drug_name	In patient two, therapy with treprostinil was temporally associated with clearing of hematuria, resolution of CNS symptoms and improvement in MRI findings.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3636001_20201005_0.5	treprostinil	drug_name	 Conclusions Treprostinil may offer a second effective treatment approach to individuals with MAP or “rescue therapy” to those in whom eculizumab treatment has failed to maintain suppression of disease activity.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	epoprostenol|prostacyclin|pulmonary arterial hypertension|transition|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5			Administration, Inhalation|Adult|Antihypertensive Agents|Cohort Studies|Drug Administration Schedule|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Injections, Subcutaneous|Middle Aged|Retrospective Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	OBJECTIVE Inhaled treprostinil represents an attractive alternative to the other available prostacyclin formulations by obviating the use of continuous infusions and its associated risks.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	Published evidence describing the process of transition from infusion prostacyclin therapy to inhaled treprostinil is limited.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	The purpose of this report is to describe an inpatient protocol for transitioning patients with pulmonary arterial hypertension (PAH) from intravenous (IV) or subcutaneous (SQ) prostacyclin therapy to inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	 METHODS A retrospective case cohort study was performed evaluating medical records of three patients undergoing transition from IV/SQ continuous infusion prostacyclin therapy to inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	No patients discontinued inhaled treprostinil following transition.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	The transition to inhaled treprostinil from IV/SQ infusion prostacyclin therapy appears to be safe in carefully selected patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24806480_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Our report describes a standard method used to transition patients from IV/SQ infusion prostacyclin to inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5			Adolescent|Adult|Aged|Antihypertensive Agents|Blood Pressure|Bosentan|Drug Therapy, Combination|Dyspnea|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Longitudinal Studies|Male|Middle Aged|Retrospective Studies|Severity of Illness Index|Sulfonamides	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	BACKGROUND Treprostinil, a long-acting prostacyclin analog, diminished the symptoms of pulmonary arterial hypertension (PAH) in controlled 12-week clinical efficacy studies.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	This retrospective, single-center, open-label study was designed to assess the efficacy of long-term, subcutaneously administered, treprostinil-based therapy alone or in combination with bosentan for the treatment of moderate-to-severe PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	 METHODS Thirty-eight patients with pulmonary hypertension treated with subcutaneous treprostinil were followed up for a mean (+/-SD) duration of 984+/-468 days (range, 165 to 1,847 days).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	Oral bosentan was added to the treprostinil regimen if patients remained in New York Heart Association (NYHA) functional class III or II with intolerable prostacyclin side effects that limited therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	At the final observation, the mean dose of treprostinil was 37.8 ng/kg/min (range, 7.5 to 115 ng/kg/min).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Long-term treatment with subcutaneous treprostinil-based therapy improved functional parameters and hemodynamics in patients with moderate-to-severe PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18403673_20201005_0.5	treprostinil	drug_name	In patients requiring combination therapy, the addition of oral bosentan to treprostinil-based therapy was safe, well-tolerated, and associated with further clinical improvements.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20045181_20201005_0.5			Targeting of the prostacyclin specific IP1 receptor in lungs with molecular conjugates comprising prostaglandin I2 analogues.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20045181_20201005_0.5			Animals|Blotting, Western|Cattle|Cell Line|Epithelial Cells|Epoprostenol|Female|Fluorescein|Genetic Vectors|Humans|Iloprost|Ligands|Lung|Mice|Mice, Inbred BALB C|Organ Specificity|Polyethyleneimine|Receptors, Epoprostenol|Reproducibility of Results|Serum Albumin, Bovine|Transfection	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20045181_20201005_0.5	treprostinil	drug_name	Iloprost (ILO) and treprostinil (TRP), two prostaglandin I2 analogues, were conjugated to fluorescein-labeled BSA (FLUO-BSA) and compared for IP1 receptor binding/uptake in different lung cell lines.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5			Adrenergic beta-Agonists|Animals|Antihypertensive Agents|Catecholamines|Cell Size|Dose-Response Relationship, Drug|Epoprostenol|In Vitro Techniques|Isoproterenol|Male|Myocardial Contraction|Myocytes, Cardiac|Rats|Rats, Wistar	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	We investigated whether treprostinil exerts direct contractile effects on cardiomyocytes that may explain partly the beneficial effects of these drugs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	 RESULTS Treprostinil (0.15 - 15 ng ml(-1)) slightly increased contractile dynamics of cardiomyocytes at clinically relevant concentrations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	Treprostinil exerted this effect at all beating frequencies under investigation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	Treprostinil mimicked this potentiating effect in a Langendorff preparation as well.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	The potentiating effect of treprostinil on isoprenaline-dependent cell shortening was no longer seen after phosphodiesterase inhibition.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	Long-term cultivation of cardiomyocytes with treprostinil did not modify load free cell shortening of these cells, but reduces the duration of contraction.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17533419_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS We conclude that the clinically used prostanoid treprostinil potentiates the positive inotropic effects of catecholamines in adult ventricular cardiomyocytes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25154882_20201005_0.5			Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25154882_20201005_0.5			Cell Line|Chemokine CCL2|Enzyme-Linked Immunosorbent Assay|Epoprostenol|Humans|Monocytes	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25154882_20201005_0.5	treprostinil	drug_name	We investigated the effects of three conventional (iloprost, beraprost and treprostinil) and one new (ONO-1301) PGI2 analogs, on the expression of MCP-1 expression in human monocytes and macrophages.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5	treprostinil	drug_name	Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5			Administration, Cutaneous|Animals|Antihypertensive Agents|Electrodes|Epoprostenol|Hemodynamics|Humans|Iloprost|Iontophoresis|Male|Nitroprusside|Rats|Rats, Wistar|Skin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5	treprostinil	drug_name	The objective of this study was to test whether treprostinil, iloprost and epoprostenol can induce sustained vasodilatation in rats when delivered locally using cutaneous iontophoresis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5	treprostinil	drug_name	 METHODS Treprostinil, iloprost and epoprostenol were delivered by cathodal and anodal iontophoresis onto the hindquarters of anaesthesized rats (n= 8 for each group).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5	treprostinil	drug_name	 RESULTS Cathodal but not anodal iontophoresis of treprostinil (6.4 mM), iloprost (0.2 mM) and epoprostenol (1.4 mM) induced a significant and sustained increase in cutaneous blood flow.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5	treprostinil	drug_name	The effects of treprostinil and iloprost were significantly different from those of treprostinil vehicle.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20860718_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Cathodal iontophoresis of treprostinil and iloprost increases cutaneous blood flow with a good local tolerance.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26828324_20201005_0.5	treprostinil	drug_name	Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26828324_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Cohort Studies|Dose-Response Relationship, Drug|Epoprostenol|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Male|Middle Aged|Retrospective Studies|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26828324_20201005_0.5	treprostinil	drug_name	We aimed to determine the safety and tolerability of inhaled treprostinil (iTRE) titrated to target maintenance dose higher than the labeled dose for PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21852894_20201005_0.5			Non-congenital heart disease associated pediatric pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21852894_20201005_0.5			Child|Adult|Humans|Female|Hypertension, Pulmonary|Endothelin Receptor Antagonists|Familial Primary Pulmonary Hypertension|Epoprostenol|Vasodilator Agents|Antihypertensive Agents|Phosphodiesterase Inhibitors|Prostaglandins|Heart Defects, Congenital|Drug Therapy, Combination	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21852894_20201005_0.5	treprostinil	drug_name	Three classes of drugs have been extensively studied for the treatment of IPAH in adults: prostanoids (epoprostenol, treprostinil, iloprost, beraprost), endothelin receptor antagonists (bosentan, sitaxsentan, ambrisentan), and phosphodiesterase inhibitors (Sildenafil, tadalafil).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31672620_20201214_0.5			Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31672620_20201214_0.5			Endothelin receptor antagonist|Human pulmonary artery|PGI(2)ET-1|Pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31672620_20201214_0.5			Aged|Endothelin-1|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Muscle, Smooth, Vascular|Pulmonary Artery|Pulmonary Veins|Receptor, Endothelin A|Receptor, Endothelin B|Signal Transduction	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31672620_20201214_0.5	treprostinil	drug_name	Prostacyclin (PGI2) analogues (iloprost, treprostinil) and endothelin-1 (ET-1) receptor antagonists (ERA) (used alone or in combination) are therapies used for treating PH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31672620_20201214_0.5	treprostinil	drug_name	The mechanisms underlying the positive/negative effects of combination treatment are not well documented, and in this study, we tested the hypothesis that the combination of a PGI2 analogue (iloprost, treprostinil) and an ERA may be more effective than either drug alone to treat vasculopathies observed in PH Group-III patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31672620_20201214_0.5	treprostinil	drug_name	Of note, while the ETB receptor antagonist (BQ788) increases ET-1 production from PH Group-III patients' preparations (HPA, parenchyma), even under these more proliferative conditions, iloprost and treprostinil are still effective to inhibit hPASMCs proliferation (-22/-24%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5			Adolescent|Adult|Circadian Rhythm|Dose-Response Relationship, Drug|Drug Administration Schedule|Epoprostenol|Female|Half-Life|Humans|Infusion Pumps|Injections, Subcutaneous|Isotonic Solutions|Male|Metabolic Clearance Rate|Middle Aged|Spectrometry, Mass, Electrospray Ionization|Time Factors	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	No section The objective of this study was to assess the pharmacokinetics and safety of treprostinil sodium administered as a 28-day continuous subcutaneous infusion at escalating infusion rates of 2.5 to 15 ng/kg/min in normal subjects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	Fourteen healthy adult volunteers received a 28-day continuous sub-cutaneous infusion of treprostinil at escalating infusion rates of 2.5, 5, 10, and 15 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	Plasma treprostinil concentration was measured by a validated liquid chromatography atmospheric pressure ionization tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 25 pg/mL. Distinct steady states were achieved for each of the four treprostinil doses.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	Linear regression analysis of mean steady-state treprostinil concentration versus targeted dose yielded a fitted line with an r(2) of 0.92.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	Consistent diurnal cycles of two peak and two trough treprostinil concentrations were observed over a 24-hour steady-state interval for each dose with peak levels 20% to 30% higher than trough levels.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	The terminal half-life of treprostinil was 2.93 hours.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15102871_20201005_0.5	treprostinil	drug_name	At clinically relevant doses, the pharmacokinetics of treprostinil were linear and dose independent with modest, consistent diurnal cycles consisting of two daily peaks and two daily troughs observed for all four doses.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5			Transitioning From Intravenous to Subcutaneous Prostacyclin Therapy in Neonates With Severe Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	congenital diaphragmatic hernia|epoprostenol|neonatal intensive care unit|prostacyclin|pulmonary hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	Infant|Infant, Newborn|Humans|Male|treprostinil|Epoprostenol|Retrospective Studies|Hypertension, Pulmonary|Antihypertensive Agents|Infusions, Intravenous|Administration, Intravenous|Administration, Inhalation|Injections, Subcutaneous|Infusions, Parenteral|Subcutaneous Tissue	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	No section This article aims to present our neonatal intensive care unit experience transitioning from intravenous epoprostenol to IV and subcutaneous treprostinil in patients with persistent pulmonary hypertension of the neonate.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	Once the dose was stable for a few days epoprostenol was transitioned to IV treprostinil using double the last epoprostenol dose.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	A few days later infants were switched to SQ treprostinil using the same dose by stopping the IV infusion and starting the SQ infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	All patients survived to hospital discharge and were sent home on SQ treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33041721_20201214_0.5	treprostinil	drug_name	Additionally, rapid high-dose transition from IV epoprostenol to IV treprostinil and then to SQ treprostinil is well tolerated in neonates, with minimal adverse effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16301977_20201005_0.5			[Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16301977_20201005_0.5			Antihypertensive Agents|Diagnosis-Related Groups|France|Humans|Hypertension, Pulmonary|National Health Programs|Reimbursement Mechanisms|Societies, Medical	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16301977_20201005_0.5	treprostinil	drug_name	Four drugs used for treatment of pulmonary arterial hypertension are eligible for this additional reimbursement: 3 prostacyclin derivatives (intravenous epoprostenol, inhaled iloprost, and subcutaneous treprostinil), and oral bosentan, an endothelin receptor antagonist.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5			Adolescent|Adult|Aged|Analysis of Variance|Child|Epoprostenol|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Male|Middle Aged|Statistics, Nonparametric	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	In the first trial, intravenous epoprostenol and intravenous treprostinil were compared.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	In the second trial, intravenous treprostinil and subcutaneous treprostinil were compared.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	In the third trial, subcutaneous treprostinil was compared with placebo infusion during an 8-week period.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	Intravenous epoprostenol and intravenous treprostinil resulted in a similar reduction in pulmonary vascular resistance acutely (22% and 20%, respectively).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	Intravenous treprostinil and subcutaneous treprostinil also demonstrated comparable short-term decrease in pulmonary vascular resistance (23% and 28%, respectively).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	The placebo-controlled 8-week trial demonstrated a mean improvement of 37 +/- 17 m as measured by the 6-minute walk distance in patients receiving treprostinil compared with a 6 +/- 28 m reduction in those receiving placebo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	There were trends toward an improvement in cardiac index and pulmonary vascular resistance index in the treprostinil group.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12548091_20201005_0.5	treprostinil	drug_name	Treprostinil can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23329255_20201214_0.5	treprostinil	drug_name	Chryseomonas luteola bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23329255_20201214_0.5			Adolescent|Anti-Bacterial Agents|Antihypertensive Agents|Bacteremia|Blood|Epoprostenol|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Male|Pseudomonas|Pseudomonas Infections|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23329255_20201214_0.5	treprostinil	drug_name	No section Treprostinil is a prostacyclin analogue approved for the treatment of pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23329255_20201214_0.5	treprostinil	drug_name	Treprostinil is associated with the incidence of Gram-negative bacterial bloodstream infections (BSI), a susceptibility that has been associated with a diluent used for treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23329255_20201214_0.5	treprostinil	drug_name	We report the case of a 14-year-old boy with idiopathic PAH on continuous intravenous treprostinil therapy who presented with fever and fatigue.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23329255_20201214_0.5	treprostinil	drug_name	This is the only documented case of a C. luteola BSI in a PAH patient receiving continuous intravenous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3487309_20201005_0.5			Takotsubo cardiomyopathy after treatment of pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3487309_20201005_0.5	treprostinil	drug_name	pulmonary hypertension|takotsubo cardiomyopathy|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3487309_20201005_0.5			Male|Humans|Female|Takotsubo Cardiomyopathy|Electrocardiography|Ventricular Function, Left|Stress, Psychological|Hypertension, Pulmonary|Syndrome|Familial Primary Pulmonary Hypertension|Stress, Physiological	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3487309_20201005_0.5	treprostinil	drug_name	This case report describes a patient with pulmonary arterial hypertension who developed Takotsubo cardiomyopathy after treatment initiation with intravenous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5			Administration, Inhalation|Administration, Oral|Adult|Aged|Antihypertensive Agents|Bosentan|Drug Therapy, Combination|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Natriuretic Peptide, Brain|Peptide Fragments|Piperazines|Purines|Quality of Life|Sildenafil Citrate|Sulfonamides|Sulfones|Treatment Outcome|Vasodilator Agents|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	OBJECTIVE This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	The addition of inhaled treprostinil, a long-acting prostacyclin analog, might be a safe and effective treatment addition to other PAH-specific oral therapies.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	 METHODS Two hundred thirty-five PAH patients with New York Heart Association (NYHA) functional class III (98%) or IV symptoms and a 6-min walk distance (6MWD) of 200 to 450 m while treated with bosentan (70%) or sildenafil were randomized to inhaled treprostinil (up to 54 mug) or inhaled placebo 4 times daily.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	 RESULTS Twenty-three patients withdrew from the study prematurely (13 treprostinil, 10 placebo).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was safe and well-tolerated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS This trial demonstrates that, among PAH patients who remain symptomatic on bosentan or sildenafil, inhaled treprostinil improves exercise capacity and quality of life and is safe and well-tolerated. (	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20430262_20201005_0.5	treprostinil	drug_name	TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension; NCT00147199).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22883740_20201005_0.5			Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22883740_20201005_0.5			Adolescent|Adult|Aged|Antihypertensive Agents|Bacteremia|Chi-Square Distribution|Child|Cross Infection|Epoprostenol|Female|Gram-Negative Bacterial Infections|Gram-Positive Bacterial Infections|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Middle Aged|Prostaglandins|Registries|Risk Factors|Survival Rate|United States	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22883740_20201005_0.5	treprostinil	drug_name	Bloodstream infections rates were significantly increased in patients receiving IV treprostinil vs IV epoprostenol (0.36 vs 0.12 per 1000 treatment days; P<.001), primarily due to gram-negative organisms (0.20 vs 0.03 per 1000 treatment days; P<.001).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22883740_20201005_0.5	treprostinil	drug_name	Multivariate analysis adjusting for age, causes of PAH, and year of BSI found that treatment with IV treprostinil was associated with a 3.08-fold increase (95% confidence interval, 2.05-4.62; P<.001) in BSIs of any type and a 6.86-fold increase (95% confidence interval, 3.60-13.07; P<.001) in gram-negative BSIs compared with treatment with IV epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22883740_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Compared with IV epoprostenol therapy, treatment with IV treprostinil is associated with a significantly higher rate of gram-negative BSIs; observed differences in BSI rate did not seem to be due to any other analyzed factors.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17003851_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17003851_20201005_0.5			Clinical Trials as Topic|Combined Modality Therapy|Drug Therapy|Humans|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17003851_20201005_0.5	treprostinil	drug_name	The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000, Pseudostat; R24, rasburicase, RHAMM R3 peptide, rilonacept, rosuvastatin calcium, rotavirus vaccine, rufinamide; Sabarubicin hydrochloride, SHL-749, sirolimus-eluting stent, SLx-2101, sodium butyrate, sorafenib, SU-6668; TachoSil, tadalafil, taxus, tegaserod maleate, telbivudine, tenofovir disoproxil fumarate, teriparatide, tetramethylpyrazine, teverelix, tiotropium bromide, tipifarnib, tirapazamine, tolvaptan, TransvaxTM hepatitis C vaccine, treprostinil sodium; Valganciclovir hydrochloride, valsartan/amlodipine, vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, veglin, voriconazole; Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zotarolimus, zotarolimus-eluting stent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5914427_20201005_0.5	treprostinil	drug_name	8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5914427_20201005_0.5			Aged|Antihypertensive Agents|Capsaicin|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Subcutaneous|Male|Middle Aged|Pain|Pain Management|Sensory System Agents|Severity of Illness Index|Transdermal Patch	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID30261985_20201005_0.5			Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30261985_20201005_0.5			Dose titration|Endothelin receptor antagonist|Nitric oxide|Prostacyclin|Pulmonary arterial hypertension|Specialty pharmacy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID30261985_20201005_0.5			Drug Administration Schedule|Endothelin Receptor Antagonists|Endothelin-1|Epoprostenol|Evidence-Based Medicine|Female|Humans|Hypertension, Pulmonary|Middle Aged|Nitric Oxide	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID30261985_20201005_0.5	treprostinil	drug_name	Here, based on our clinical experience, we provide our recommendations for dose titration schemes for PAH medications that require individualized dosing in adult patients, including agents acting on the endothelin-1 pathway (bosentan and ambrisentan), the prostacyclin pathway (epoprostenol, treprostinil, and selexipag), and the nitric oxide pathway (tadalafil and the soluble guanylate cyclase stimulator riociguat).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29126699_20201214_0.5	treprostinil	drug_name	Subcutaneous treprostinil in pediatric patients with failing single-ventricle physiology.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16395422_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16395422_20201005_0.5			Clinical Trials as Topic|Humans|Oligopeptides|Somatostatin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16395422_20201005_0.5	treprostinil	drug_name	gamma-globulin; Levetiracetam, levocetirizine, lintuzumab, liposomal nystatin, lumiracoxib, lurtotecan; Manitimus, mapatumumab, melatonin, micafungin sodium, mycophenolic acid sodium salt; Oblimersen sodium, OGX-011, olmesartan medoxomil, omalizumab, omapatrilat, oral insulin; Parathyroid hormone (human recombinant), pasireotide, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, phVEGF-A165, pimecrolimus, pitavastatin calcium, plerixafor hydrochloride, posaconazole, pramlintide acetate, prasterone, pregabalin, PT-141; Quercetin; Ranolazine, rosuvastatin calcium, rubitecan, rupatadine fumarate; Sardomozide, sunitinib malate; Tadalafil, talactoferrin alfa, tegaserod maleate, telithromycin, testosterone transdermal patch, TH-9507, tigecycline, tiotropium bromide, tipifarnib, tocilizumab, treprostinil sodium; Valdecoxib, vandetanib, vardenafil hydrochloride hydrate, voriconazole.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5			Cost effectiveness of prostacyclins in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5			Antihypertensive Agents|Computer Simulation|Cost-Benefit Analysis|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Markov Chains|Models, Economic|Prostaglandins I|Quality-Adjusted Life Years|Spain|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	 OBJECTIVE This study provides a cost-effectiveness and cost-utility comparison of initiating prostacyclin therapy with three different treatment alternatives (inhaled iloprost [ILO], intravenous epoprostenol [EPO] and subcutaneous treprostinil [TRE]) for patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	 RESULTS At the end of the 3 years, in the base case of the deterministic analysis, initiating prostacyclin therapy with iloprost was the less costly strategy (€132,840), followed by treprostinil (€359,869) and epoprostenol (€429,775).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	Epoprostenol has shown the best efficacy results with 2.73 LYG and 1.78 QALY, followed by iloprost (2.69 LYG and 1.74 QALY) and treprostinil (2.69 LYG and 1.73 QALY).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	Incremental cost-effectiveness ratios (ICER) and cost-utility ratios (ICUR) of epoprostenol versus iloprost and treprostinil were much above the €30,000 per LYG or QALY threshold commonly used in Spain.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	Iloprost was dominant compared with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	When compared with treprostinil, epoprostenol was dominant in 43% of the simulations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22452448_20201214_0.5	treprostinil	drug_name	Iloprost was dominant compared with treprostinil in 45% of the cases and it was a cost-effective alternative in 39% of the simulations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16253609_20201005_0.5	treprostinil	drug_name	Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16253609_20201005_0.5			3',5'-Cyclic-GMP Phosphodiesterases|Adult|Drug Therapy, Combination|Epoprostenol|Exercise Test|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Male|Pilot Projects|Piperazines|Pulmonary Wedge Pressure|Purines|Retrospective Studies|Sildenafil Citrate|Sulfones|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16253609_20201005_0.5	treprostinil	drug_name	To test for a therapeutic benefit of the combination of a prostacyclin analogue, subcutaneous treprostinil, and sildenafil, a proof-of-concept, open-label investigational trial was initiated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16253609_20201005_0.5	treprostinil	drug_name	Subjects with PAH in World Health Organization (WHO) functional classes II to IV receiving subcutaneous treprostinil for > or =6 months were evaluated with an exercise treadmill test using the Naughton-Balke protocol at baseline and after 12 weeks.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16253609_20201005_0.5	treprostinil	drug_name	Sildenafil 50 mg 3 times daily was added to the treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16253609_20201005_0.5	treprostinil	drug_name	In conclusion, this pilot study of subcutaneous treprostinil with sildenafil for PAH suggests additive beneficial effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29791923_20201005_0.5	treprostinil	drug_name	Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29791923_20201005_0.5			Administration, Inhalation|Animals|Antihypertensive Agents|Delayed-Action Preparations|Disease Models, Animal|Dogs|Drug Compounding|Drug Evaluation, Preclinical|Epoprostenol|Half-Life|Humans|Hypertension, Pulmonary|Lipids|Lung|Macaca fascicularis|Male|Nanoparticles|Prodrugs|Rats|Rats, Sprague-Dawley|Vasodilation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29791923_20201005_0.5	treprostinil	drug_name	No section Treprostinil (TRE), a prostanoid analogue approved in the USA for the treatment of pulmonary arterial hypertension, requires continuous infusion or multiple dosing sessions per day for inhaled and oral routes of administration due to its short half-life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29791923_20201005_0.5	treprostinil	drug_name	Together, this sustained presentation of TRE to the lungs and plasma is consistent with a once- or twice-daily dosing schedule in the absence of high Cmax-associated adverse events which could provide patients with an improved treprostinil therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33465538_20210311_0.5			Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33465538_20210311_0.5			Balloon pulmonary angioplasty|CTEPH|Endarterectomy|Hypertension|Pulmonary|Riociguat	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33465538_20210311_0.5	treprostinil	drug_name	Humans|Middle Aged|Female|Hypertension, Pulmonary|Prospective Studies|Endarterectomy|Pulmonary Embolism|Angioplasty, Balloon|Pulmonary Artery|riociguat|Pyrimidines|treprostinil|Epoprostenol|macitentan|Pyrazoles|Sulfonamides|Heart Failure|Chronic Disease	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33465538_20210311_0.5	treprostinil	drug_name	Studies of macitentan in patients with inoperable CTEPH and treprostinil in patients with inoperable or persistent/recurrent CTEPH showed positive results.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15319815_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15319815_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15319815_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol; Valganciclovir hydrochloride, val-mCyd, vardenafil hydrochloride hydrate, vinflunine, voriconazole; Ximelagatran, XTL-002; Yttrium 90 (90Y) ibritumomab tiuxetan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5			Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5			Animals|Cell Proliferation|Cells, Cultured|Epoprostenol|Fibroblasts|Ligands|Lung|Mice|Mice, Mutant Strains|PPAR gamma|PPAR-beta|Receptors, Epoprostenol|Receptors, Prostaglandin|Thiazoles	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5	treprostinil	drug_name	Using the newly approved (for pulmonary hypertension) prostacyclin mimetic treprostinil sodium, reporter gene assays for PPARbeta activation and measurement of lung fibroblast proliferation were analyzed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5	treprostinil	drug_name	Treprostinil sodium was found to activate PPARbeta in reporter gene assays and to inhibit proliferation of human lung fibroblasts at concentrations consistent with an effect on PPARs but not on IP receptors.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5	treprostinil	drug_name	The effects of treprostinil sodium on human lung cell proliferation are mimicked by those of the highly selective PPARbeta ligand GW0742.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5	treprostinil	drug_name	There are no receptor antagonists for PPARbeta or for IP receptors, but by using lung fibroblasts cultured from mice lacking PPARbeta (PPARbeta-/-) or IP (IP-/-), we demonstrate that the antiproliferative effects of treprostinil sodium are mediated by PPARbeta and not IP in lung fibroblasts.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16239641_20201005_0.5	treprostinil	drug_name	These observations suggest that some of the local, longer-term benefits of treprostinil sodium on reducing the remodeling associated with pulmonary hypertension may be mediated by PPARbeta.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27470680_20201005_0.5			Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27470680_20201005_0.5			Inhaled|Parenteral|Prostacyclin|Pulmonary arterial hypertension|Pulmonary hypertension|Transition	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27470680_20201005_0.5			Administration, Inhalation|Administration, Intravenous|Adult|Aged|Antihypertensive Agents|Epoprostenol|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Intensive Care Units|Length of Stay|Male|Middle Aged|Patient Preference|Quality of Life|Retrospective Studies|Time Factors	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27470680_20201005_0.5	treprostinil	drug_name	 No section We describe a retrospective observational analysis of adults with PAH who were transitioned from a parenteral prostacyclin to inhaled treprostinil at our institution.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27470680_20201005_0.5	treprostinil	drug_name	Seven patients receiving intravenous prostacyclin therapy were transitioned in an ICU setting, while one patient was transitioned from subcutaneous treprostinil as an outpatient.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27470680_20201005_0.5	treprostinil	drug_name	One adverse event was observed while initiating inhaled treprostinil that only required slowing of the transition process.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4881725_20201005_0.5			Inhaled therapy for the management of perioperative pulmonary hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC4881725_20201005_0.5			Nitric oxide-donating drugs|Phosphodiesterase inhibitors|Prostanoids|Prototypical inhaled pulmonary-specific vasodilator	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC4881725_20201005_0.5			Administration, Inhalation|Antihypertensive Agents|Humans|Hypertension, Pulmonary|Intraoperative Complications|Perioperative Care|Postoperative Complications|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC4881725_20201005_0.5	treprostinil	drug_name	Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7026823_20210311_0.5			Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7026823_20210311_0.5			cardiac catheterization|pulmonary hypertension|selexipag	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7026823_20210311_0.5	treprostinil	drug_name	Adult|Humans|Male|Child|selexipag|Hypertension, Pulmonary|Acetamides|Pyrazines|treprostinil|Epoprostenol|Pulmonary Arterial Hypertension|Hemodynamics|Antihypertensive Agents|Familial Primary Pulmonary Hypertension|Administration, Oral|Echocardiography	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7026823_20210311_0.5	treprostinil	drug_name	One patient was transitioned from subcutaneous treprostinil to selexipag, and in three patients, selexipag was added as a third agent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7026823_20210311_0.5	treprostinil	drug_name	One patient transitioned successfully from subcutaneous treprostinil to selexipag.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16098438_20201005_0.5			Effects of long-term bosentan in children with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16098438_20201005_0.5			Adolescent|Antihypertensive Agents|Bosentan|Child|Child, Preschool|Drug Therapy, Combination|Endothelin A Receptor Antagonists|Endothelin B Receptor Antagonists|Female|Humans|Hypertension, Pulmonary|Male|Prostaglandins|Retrospective Studies|Risk Assessment|Risk Factors|Safety|Sulfonamides|Survival Analysis|Time|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16098438_20201005_0.5	treprostinil	drug_name	 METHODS In this retrospective study, 86 children with PAH (idiopathic, associated with congenital heart or connective tissue disease) started bosentan with or without concomitant intravenous epoprostenol or subcutaneous treprostinil therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8116805_20210611_0.5			Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus	title
treprostinil|water	Z0000025801				inn	PubMed	PMC8116805_20210611_0.5			G protein-coupled receptor|cAMP|extracellular signal-regulated kinase|localised signalling|prostacyclin receptor	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC8116805_20210611_0.5			Humans|Receptors, Epoprostenol|Fibroblasts|Lung|Signal Transduction|MAP Kinase Signaling System|Cell Nucleus|Idiopathic Pulmonary Fibrosis|Cyclic AMP|Elementary Particles|Fibrosis|Cell Proliferation|Cells, Cultured|Proto-Oncogene Proteins c-sis|Cell Division|8-chloro-cyclic adenosine monophosphate|8-Bromo Cyclic Adenosine Monophosphate	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC8116805_20210611_0.5	treprostinil	drug_name	MRE-269 and treprostinil caused sustained cAMP signalling in the nucleus and complete inhibition of PDGF-induced nuclear ERK and fibroblast proliferation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5			Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5			pulmonary hypertension|pediatric|cost|prostacyclin	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Child|Male|Humans|Female|United States|treprostinil|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Prostaglandins I|Antihypertensive Agents|Administration, Oral|Health Resources	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Patients with PAH initiated on parenteral epoprostenol and treprostinil (2004-2014) were identified using a nationwide administrative database.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Demographics, clinical characteristics, and resource utilization were compared between epoprostenol and treprostinil groups.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Among 1448 children admitted with a primary or secondary diagnosis of PAH, 280 (19%) were initiated on parenteral prostacyclins (epoprostenol n = 195 and treprostinil n = 85).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Epoprostenol predominated early (97% of initiations in 2005); however, treprostinil predominated recently (52-67% of initiations/year).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Children initiated on treprostinil had shorter ICU stays (1 [IQR = 0-4] vs. 4 [0-10] days, P  < 0.001), shorter total lengths of stay (4 [2-9] vs. 8 [4-18] days, P  = 0.001), and lower in-hospital mortality (1 vs. 12%, P  = 0.001) with no difference in 30-day (13 vs. 19%, P  = 0.19) or one-year readmission rates (56 vs. 61%, P  = 0.41).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Inpatient costs were lower for treprostinil initiation ($23,779 [11,830-39,535] vs. $32,976 [11,904-94,082], P  = 0.03), with a greater difference in the recent era (2009-2013).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5824913_20201005_0.5	treprostinil	drug_name	Treprostinil initiation has been increasing and is associated with less resource utilization and lower cost compared to epoprostenol initiation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33710843_20210611_0.5			The evolving treatment landscape of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33710843_20210611_0.5	treprostinil	drug_name	Humans|Pulmonary Arterial Hypertension|treprostinil|Epoprostenol|Prostaglandins I|selexipag|Acetamides|Hypertension, Pulmonary|Antihypertensive Agents|Pyrazines|Familial Primary Pulmonary Hypertension|Vasodilation|Prognosis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33710843_20210611_0.5	treprostinil	drug_name	Finally, trial data will be evaluated for the recently developed agent selexipag and improved treprostinil delivery formulations that may provide enhanced convenience.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5			hemodynamics|prostacyclin|pulmonary arterial hypertension|survival|treatment	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Middle Aged|Adult|Aged|Male|Humans|Female|treprostinil|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Blood Pressure|Exercise Tolerance|Vascular Resistance|Treatment Outcome|Longitudinal Studies|Administration, Oral|Sulfonamides|Administration, Inhalation|Drug Therapy, Combination|Hemodynamics	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	No section Sustained-release oral treprostinil, an oral prostacyclin, led to significant improvement in 6-minute walk distance (6MWD) versus placebo in treatment-naive patients with pulmonary arterial hypertension (PAH) but failed to lead to significant improvement in two 16-week trials in patients receiving background PAH therapies (FREEDOM studies).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Our objective was to evaluate 6MWD, functional class, hemodynamics, and other long-term outcomes during oral treprostinil administration in PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Patients receiving oral treprostinil through the FREEDOM studies at our institution were included and were followed for up to 7 years.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Thirty-seven patients received oral treprostinil for a median of 948 days, with 81%, 61%, and 47% continuing therapy at 1, 2, and 3 years, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Mean treprostinil dose at 3, 12, and 24 months was 4.3 ± 2.3, 8.6 ± 3.2, and 11.7 ± 5.8 mg/24 h, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	Oral treprostinil dose was inversely associated with change in PVR (r = -0.42, P < 0.05), and change in PVR was numerically better among patients in the highest dosing quartile.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26401252_20201005_0.5	treprostinil	drug_name	No significant improvement in 6MWD, functional class, or hemodynamics versus pretreatment values was seen with long-term oral treprostinil therapy, potentially because of inability to achieve a clinically effective dose.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25917921_20201005_0.5			The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25917921_20201005_0.5	treprostinil	drug_name	Beraprost|Cell proliferation|Cyclic AMP|Iloprost|Peroxisome proliferator-activator receptor|Prostacyclin analogues|Prostanoid receptors|Pulmonary arterial hypertension|Treprostinil|Vascular remodelling	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25917921_20201005_0.5			Animals|Cell Membrane|Drug Stability|Epoprostenol|Humans|Hypertension, Pulmonary|Receptors, Cytoplasmic and Nuclear|Vascular Remodeling	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25917921_20201005_0.5	treprostinil	drug_name	This review discusses evidence that the pharmacology of each prostacyclin (IP) receptor agonist so far developed is distinct, with non-IP receptor targets clearly contributing to the therapeutic and side effect profile of PGI2 (EP3), iloprost (EP1), treprostinil (EP2, DP1) along with a family of nuclear receptors known as peroxisome proliferator-activated receptors (PPARs), to which PGI2 and some analogues directly bind.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26501411_20201005_0.5			Hemodynamic Thresholds for Precapillary Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26501411_20201005_0.5			heart failure|hemodynamics|pulmonary circulation|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26501411_20201005_0.5			Adult|Aged|Antihypertensive Agents|Cardiac Catheterization|Cohort Studies|Databases, Factual|Diagnosis, Differential|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Male|Middle Aged|Proportional Hazards Models|Pulmonary Circulation|Pulmonary Wedge Pressure|ROC Curve|Retrospective Studies|Vascular Resistance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26501411_20201005_0.5	treprostinil	drug_name	In a second step, we performed a patient-level pooled analysis of four randomized, placebo-controlled trials including 541 patients with PAH who received treprostinil or placebo, to validate hemodynamic cutoffs with regard to treatment response.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33979498_20210611_0.5	treprostinil	drug_name	Inhaled Treprostinil in Group 3 Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33979498_20210611_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Lung Diseases, Interstitial	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19716051_20201005_0.5	treprostinil	drug_name	Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19716051_20201005_0.5			Aged|Antihypertensive Agents|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Idiopathic Pulmonary Fibrosis|Lung Transplantation|Piperazines|Purines|Sildenafil Citrate|Spirometry|Sulfones|Tomography, X-Ray Computed|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19716051_20201005_0.5	treprostinil	drug_name	We describe a case where intravenous treprostinil was used to bridge an elderly patient with idiopathic pulmonary fibrosis with severe pulmonary hypertension to successful single-lung transplantation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review	title
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	treprostinil|prostacyclin|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	PRC|Humans|treprostinil|Hypertension, Pulmonary|Antihypertensive Agents|Epoprostenol|Familial Primary Pulmonary Hypertension|Half-Life|Endothelin Receptor Antagonists|Phosphodiesterase 5 Inhibitors|Administration, Oral|Administration, Inhalation|Organizations	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	Its management strategy consists of the endothelin receptor antagonists (ambrisentan, bosentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil), and prostacyclin analogs (epoprostenol, treprostinil, iloprost).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	Treprostinil, a stable prostacyclin analog, displays vasodilatory effects in the pulmonary vasculature, as well as antiplatelet aggregation properties.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	However, treprostinil may be an alternative option in these severe PAH patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	The longer half-life and stability at room temperature with treprostinil may be associated with lower risk of pulmonary hemodynamic worsening as a result of abrupt infusion discontinuation and less frequent drug preparation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	These characteristics make treprostinil an attractive alternative to continuous infusion of epoprostenol, due to convenience and patient safety.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC4073912_20201005_0.5	treprostinil	drug_name	The purpose of this review is to evaluate the safety and efficacy of continuous infusion of treprostinil as well as the inhaled and oral routes of administration in PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5			Stem cells|endothelial progenitor cells|prostacyclin analogues|vascular remodelling|vasculogenesis	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5			Adolescent|Adult|Angiogenesis Inducing Agents|Animals|Antibodies|Antihypertensive Agents|Biomarkers|Cell Differentiation|Cell Lineage|Cell Proliferation|Cell Survival|Cells, Cultured|Child|Child, Preschool|Dose-Response Relationship, Drug|Endothelial Progenitor Cells|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infant|Male|Mesenchymal Stem Cells|Mice, Nude|Neovascularization, Physiologic|Paracrine Communication|RNA Interference|Signal Transduction|Transfection|Up-Regulation|Vascular Endothelial Growth Factor A|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	Endothelial dysfunction is a key feature of PH, and we previously reported that treprostinil therapy increases number and proliferative potential of endothelial colony forming cells (ECFC) isolated from PH patients' blood.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	In the present study, the objective was to determine how treprostinil contributes to the proangiogenic functions of ECFC.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	We examined the effect of treprostinil on ECFC obtained from cord blood in terms of colony numbers, proliferative and clonogenic properties in vitro, as well as in vivo vasculogenic properties.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	Surprisingly, treprostinil inhibited viability of cultured ECFC but did not modify their clonogenic properties or the endothelial differentiation potential from cord blood stem cells.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	Treprostinil treatment significantly increased the vessel-forming ability of ECFC combined with mesenchymal stem cells (MSC) in Matrigel implanted in nude mice.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	In vitro, ECFC proliferation was stimulated by conditioned media from treprostinil-pretreated MSC, and this effect was inhibited either by the use of VEGF-A blocking antibodies or siRNA VEGF-A in MSC.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	Silencing VEGF-A gene in MSC also blocked the pro-angiogenic effect of treprostinil in vivo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	In conclusion, increased VEGF-A produced by MSC can account for the increased vessel formation observed during treprostinil treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	The clinical relevance of these data was confirmed by the high level of VEGF-A detected in plasma from patients with paediatric PH who had been treated with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26062754_20201005_0.5	treprostinil	drug_name	Moreover, our results suggest that VEGF-A level in patients could be a surrogate biomarker of treprostinil efficacy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Dynamic exercise changes in venous pressure and liver stiffness in Fontan patients: effects of Treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Fontan|Treprostinil|exercise capacity|liver stiffness|pulmonary vasodilation|ultrasound shear wave elastography	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Humans|Male|Adult|Middle Aged|Female|treprostinil|Double-Blind Method|Prospective Studies|Epoprostenol|Hypertension, Pulmonary|Antihypertensive Agents|Vasodilator Agents|Fontan Procedure|Administration, Inhalation|Exercise Tolerance|Hemodynamics|Venous Pressure|Liver	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	The aim of this study was to assess the acute effects of exercise on liver stiffness and venous pressures and to assess the impact of inhaled Treprostinil on this response.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	 METHODS In this prospective, double-blind, placebo-controlled, crossover trial, 14 patients with a Fontan circulation were randomised to inhalation of placebo and Treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Incremental and constant work rate exercise tests were performed to assess the effect of Treprostinil on exercise tolerance.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Overall, Treprostinil failed to attenuate exercise-induced increases in liver stiffness.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Compared with placebo, Treprostinil did not significantly impact venous pressure responses, VO2peak, nor exercise endurance times.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	 CONCLUSIONS Peripheral venous pressure increased acutely during exercise by an average of 88% above baseline and was not altered by administration of inhaled Treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33504408_20210211_0.5	treprostinil	drug_name	Liver stiffness measured immediately post-exercise increased acutely by an average of 30%, with no attenuation following Treprostinil inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29408757_20201005_0.5	treprostinil	drug_name	Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29408757_20201005_0.5	treprostinil	drug_name	Fibroblasts|Hexadecyl-treprostinil|INS1009|Inhalation treatment|Pulmonary fibrosis|Rats	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29408757_20201005_0.5			Administration, Inhalation|Animals|Antihypertensive Agents|Bleomycin|Cells, Cultured|Disease Models, Animal|Dose-Response Relationship, Drug|Epoprostenol|Fibroblasts|Humans|Hydroxyproline|Idiopathic Pulmonary Fibrosis|Lipids|Male|Nanoparticles|Prodrugs|Pyridones|Rats|Rats, Inbred F344|Real-Time Polymerase Chain Reaction	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29408757_20201005_0.5	treprostinil	drug_name	Recently, prostacyclin analogs such as iloprost and treprostinil (TRE) have been shown to exert some protection against bleomycin-induced pulmonary fibrosis in mice when administered in a prophylactic regimen.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29408757_20201005_0.5	treprostinil	drug_name	In this study, we evaluated the effect of the inhaled treprostinil prodrug hexadecyl-treprostinil (C16TR) formulated in a lipid nanoparticle (INS1009) administered therapeutically in a fibrotic rat model.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23558027_20201005_0.5			When to initiate intravenous therapy and/or refer.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23558027_20201005_0.5			Disease Management|Drug Therapy, Combination|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Piperazines|Platelet Aggregation Inhibitors|Purines|Referral and Consultation|Sildenafil Citrate|Sulfones|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23558027_20201005_0.5	treprostinil	drug_name	No section Intravenous (IV) prostacyclin (epoprostanol) and its analogs (iloprost and treprostinil) are effective in treating pulmonary artery hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC1997304_20201005_0.5			IP receptor-dependent activation of PPARγ by stable prostacyclin analogues	title
treprostinil|water	Z0000025801				inn	PubMed	PMC1997304_20201005_0.5			Prostacyclin (IP) receptor|Peroxisome proliferator-activated receptors|Luciferase reporter gene assay|Prostacyclin analogues|Cell proliferation	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC1997304_20201005_0.5			Cell Line|Cell Proliferation|Cyclic AMP|Epoprostenol|Humans|PPAR gamma|Prostaglandins I|Receptors, Prostaglandin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC1997304_20201005_0.5	treprostinil	drug_name	Likewise, the anti-proliferative effects of treprostinil observed in IP receptor expressing cells, were partially inhibited by the PPARγ antagonist, GW9662.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7464771_20201005_0.5			Targeted Therapy for Pulmonary Hypertension in Premature Infants	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7464771_20201005_0.5			bronchopulmonary dysplasia|prematurity|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7464771_20201005_0.5	treprostinil	drug_name	Infant, Newborn|Infant|Humans|Male|Female|Infant, Premature|Infant, Premature, Diseases|Hypertension, Pulmonary|Bronchopulmonary Dysplasia|Sildenafil Citrate|treprostinil|Epoprostenol|Bosentan|Iloprost|Endothelin Receptor Antagonists	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7464771_20201005_0.5	treprostinil	drug_name	Of these, 99 (98.0%) patients were treated with sildenafil, 13 (12.9%) with bosentan, 35 (34.7%) with inhaled iloprost, 12 (11.9%) with intravenous epoprostenol, and nine (8.9%) with subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23575261_20201005_0.5	treprostinil	drug_name	Understanding the pharmacokinetics of oral treprostinil in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23575261_20201005_0.5			Antihypertensive Agents|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Male	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15349141_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15349141_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15349141_20201005_0.5	treprostinil	drug_name	TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide, testosterone gel, tezosentan disodium, tipifarnib, tolvaptan, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Vardenafil hydrochloride hydrate; Xcellerated T cells, XR-5944; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziconotide.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28476928_20201005_0.5			Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28476928_20201005_0.5			Acetamides|Acetates|Animals|CHO Cells|Cell Proliferation|Contractile Proteins|Cricetinae|Cricetulus|Cyclic AMP|Epoprostenol|Extracellular Matrix|Humans|Hypertension, Pulmonary|Iloprost|Male|Muscle Contraction|Muscle Relaxation|Pyrazines|Rats|Rats, Inbred SHR|Rats, Wistar|Receptors, Epoprostenol|beta-Arrestins	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28476928_20201005_0.5	treprostinil	drug_name	In contrast, ACT-333679 displayed partial agonism in receptor-proximal-or upstream-cAMP accumulation assays (Emax 56%) when compared with iloprost and the PGI2 analogs beraprost and treprostinil (Emax ∼100%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28476928_20201005_0.5	treprostinil	drug_name	In line with these in vitro findings, selexipag, but not treprostinil, displayed sustained efficacy in rat models of pulmonary and systemic hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30303062_20201005_0.5			Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30303062_20201005_0.5			Ortner syndrome|Pulmonary arterial hypertension|hereditary haemorrhagic telangiectasia type 2|veno-arterial extracorporeal membrane oxygenation	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID30303062_20201005_0.5			Activin Receptors, Type II|Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Infant|Male|Mutation|Vocal Cord Paralysis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID30303062_20201005_0.5	treprostinil	drug_name	The patient had a partial response to intravenous treprostinil in addition to inhaled nitric oxide, bosentan, and sildenafil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7686618_20210111_0.5			Severe thrombocytopenia in patients with idiopathic pulmonary arterial hypertension provided several strategies for lung transplantation	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7686618_20210111_0.5	treprostinil	drug_name	drug-induced thrombocytopenia|epoprostenol|idiopathic thrombocytopenic purpura|microangiopathic thrombocytopenia|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7686618_20210111_0.5	treprostinil	drug_name	Humans|Female|Young Adult|Adult|Familial Primary Pulmonary Hypertension|Lung Transplantation|treprostinil|Epoprostenol|Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic|Hypertension, Pulmonary|Platelet Count|Anemia|Lung	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7686618_20210111_0.5	treprostinil	drug_name	Her medication was switched from epoprostenol to treprostinil, suspecting possible drug-induced thrombocytopenia.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5	treprostinil	drug_name	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5	treprostinil	drug_name	central venous catheters|drugs|health-related quality of life|pulmonary arterial hypertension|pulmonary hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5			Adult|Antihypertensive Agents|Catheter Obstruction|Catheter-Related Infections|Drug Monitoring|Drug-Related Side Effects and Adverse Reactions|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusion Pumps, Implantable|Male|Middle Aged|Outcome and Process Assessment, Health Care|Prospective Studies|United States	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5	treprostinil	drug_name	We therefore investigated a fully implantable intravascular delivery system for treprostinil infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5	treprostinil	drug_name	 RESULTS Patients (n = 60) with severe PAH (World Health Organization group 1) receiving a stable dose of IV treprostinil for at least 4 weeks received an implant device and were followed up for 12.1 ± 4.4 months.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5	treprostinil	drug_name	Plasma treprostinil levels at 1 week postimplantation were highly correlated with baseline levels (r = 0.91; P < .0001).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27396777_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The implantable intravascular delivery system delivered treprostinil to patients with PAH with a low rate of catheter-related complications and a high rate of patient satisfaction.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23418342_20201005_0.5			Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23418342_20201005_0.5			Animals|Bone Morphogenetic Protein Receptors, Type II|Cell Proliferation|Codon, Nonsense|Epoprostenol|Familial Primary Pulmonary Hypertension|HEK293 Cells|Humans|Hypertension, Pulmonary|Lung|MAP Kinase Signaling System|Male|Mice|Monocrotaline|Myocytes, Smooth Muscle|Phosphorylation|Protein-Serine-Threonine Kinases|Rats|Rats, Sprague-Dawley|Receptor, Transforming Growth Factor-beta Type II|Receptors, Transforming Growth Factor beta|Smad3 Protein|Transforming Growth Factor beta1	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23418342_20201005_0.5	treprostinil	drug_name	Finally, in a monocrotaline-induced rat model of PAH, which is associated with increased TGF-β signaling, this study confirms that treprostinil, a stable prostacyclin analog, inhibits the TGF-β pathway by reducing SMAD3 phosphorylation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33979501_20210611_0.5	treprostinil	drug_name	Inhaled Treprostinil in Group 3 Pulmonary Hypertension. Reply.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33979501_20210611_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5			Bloodstream infections in patients given treatment with intravenous prostanoids.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5			Adolescent|Adult|Antihypertensive Agents|Bacteremia|Catheters, Indwelling|Centers for Disease Control and Prevention, U.S.|Cohort Studies|Cross Infection|Epoprostenol|Female|Gram-Negative Bacteria|Gram-Negative Bacterial Infections|Home Infusion Therapy|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Proportional Hazards Models|Prostaglandins|Retrospective Studies|Risk Factors|Surveys and Questionnaires|United States	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5	treprostinil	drug_name	OBJECTIVE In September 2006, the Centers for Disease Control and Prevention was notified of cases of gram-negative bloodstream infection (BSI) occurring among outpatients who received an intravenous formulation of the prostanoid treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5	treprostinil	drug_name	 METHODS We performed a retrospective cohort study of patients who had received intravenous formulations of at least 1 of the 2 approved prostanoids (epoprostenol and treprostinil) from January 1, 2004, through late 2006.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5	treprostinil	drug_name	BSI rates were higher for patients who received intravenous treprostinil than for patients who received intravenous epoprostenol (1.13 vs. 0.42 BSIs per 1,000 treatment-days; P < .001), as were rates of BSI due to gram-negative organisms (0.81 vs. 0.04 BSIs per 1,000 treatment-days; P < .001).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5	treprostinil	drug_name	Adjusted hazard ratios for all BSIs and for BSIs due to gram-negative organisms were higher among patients given treatment with intravenous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18462147_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS At 2 centers, BSI due to gram-negative pathogens was more common than previously reported and was more frequent among patients given treatment with intravenous treprostinil than among patients given treatment with intravenous epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5			Adult|Antihypertensive Agents|Double-Blind Method|Epoprostenol|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Infusion Pumps|Injections, Subcutaneous|Linear Models|Male|Patient Selection|Physical Endurance|Statistics, Nonparametric	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	Treprostinil, a stable prostacyclin analogue, can be administered by a continuous subcutaneous infusion, avoiding these risks.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	Exercise capacity improved with treprostinil and was unchanged with placebo; the between treatment group difference in median six-minute walking distance was 16 m (p = 0.006).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	Concomitantly, treprostinil significantly improved indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	The most common side effect attributed to treprostinil was infusion site pain (85%) leading to premature discontinuation from the study in 8% of patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	Three patients in the treprostinil treatment group presented with an episode of gastrointestinal hemorrhage.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID11897647_20201005_0.5	treprostinil	drug_name	We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25882070_20201005_0.5			What's new in the treatment of portopulmonary hypertension?	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25882070_20201005_0.5	treprostinil	drug_name	macitentan|portopulmonary hypertension|pulmonary arterial hypertension|riociguat|treatment|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25882070_20201005_0.5			Heart Failure|Humans|Hypertension, Portal|Hypertension, Pulmonary|Liver Transplantation|Prognosis|Pulmonary Artery|Vascular Remodeling|Vasoconstriction	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5			Adolescent|Adult|Aged|Child|Connective Tissue Diseases|Double-Blind Method|Epoprostenol|Exercise Tolerance|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Injections, Subcutaneous|Lupus Erythematosus, Systemic|Male|Middle Aged|Mixed Connective Tissue Disease|Prospective Studies|Scleroderma, Limited|Scleroderma, Systemic|Treatment Outcome|Walking	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	OBJECTIVE To assess the efficacy and safety of continuous subcutaneous infusion of treprostinil, a stable prostacyclin analogue, for treating pulmonary arterial hypertension (PAH) in patients with connective tissue disease (CTD).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	 METHODS Two multicenter, randomized, double-blind, placebo-controlled, prospective trials of treprostinil vs placebo in 470 patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	 METHODS Patients received either treprostinil (initiated at 1.25 ng/kg/min, and titrated upward) or placebo via continuous subcutaneous infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	The maximum dose of treprostinil allowed was 22.5 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	The mean dose of treprostinil at week 12 was 8.4 ng/kg/min (range, 1.25 to 17.5 ng/kg/min).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	After 12 weeks, the change in cardiac index from baseline was + 0.2 +/- 0.08 L/min/m(2) in the treprostinil group and - 0.07 +/- 0.07 L/min/m(2) in the placebo group (p = 0.007).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	The pulmonary vascular resistance index decreased by 4 +/- 2 U x m(2) in the treprostinil group and increased by 1 +/- 1 U x m(2) in the placebo group (p = 0.006).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	The placebo-corrected median improvement from baseline in 6MW distance was 25 m in treprostinil-treated patients (p = 0.055); this improvement appeared to be dose related.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	Dyspnea fatigue scores also improved in the treprostinil group compared with the placebo group (p = 0.014).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15302727_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Continuous subcutaneous infusion of treprostinil in patients with PAH associated with CTD improved exercise capacity, symptoms of PAH, and hemodynamics.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	prostacyclin analogs|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5			Administration, Oral|Antihypertensive Agents|Drug Approval|Epoprostenol|Humans|Hypertension, Pulmonary|Randomized Controlled Trials as Topic|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	BACKGROUND This review summarizes current information on the first oral prostanoid approved for treatment of pulmonary arterial hypertension, treprostinil diolamine , which, similar to other prostacyclin analogs, vasodilates, impacts remodeling (antiproliferative), reduces endothelial cell dysfunction, inhibits platelet aggregation (antithrombotic) and increases right heart inotropy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	This review discusses three randomized trials of oral treprostinil that have been completed (FREEDOM-M, FREEDOM-C, FREEDOM-C2).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	FREEDOM-C and -C2 evaluated oral treprostinil in patients on stable background therapy; FREEDOM-M evaluated oral treprostinil as monotherapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	Thus, another clinical trial (FREEDOM-EV) is underway: oral treprostinil in patients on background therapy evaluating co-primary end points: i) change in 6MWD; and ii) occurrence of predetermined events.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	In the interim, oral treprostinil was approved in December 2013.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25204984_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The use and future of oral treprostinil is not clear.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5			Impact of Pulmonary Capillary Wedge Pressure on Long-Term Mortality in Patients With Pulmonary Arterial Hypertension Treated With Parenteral Trepostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5			Pulmonary arterial hypertension|Pulmonary capillary wedge pressure|Trepostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5			Adult|Antihypertensive Agents|Cause of Death|Dose-Response Relationship, Drug|Double-Blind Method|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Follow-Up Studies|Humans|Infusions, Intravenous|Male|Middle Aged|Prognosis|Pulmonary Wedge Pressure|Survival Rate|Time Factors|United States|Vascular Resistance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5	treprostinil	drug_name	BACKGROUND The clinical impact of pulmonary capillary wedge pressure (PCWP) on long-term mortality among patients with pulmonary arterial hypertension (PAH) has been incompletely reported, particularly in relation to concomitant treprostinil administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5	treprostinil	drug_name	The goal of this study was to assess the impact of PCWP on long-term mortality in PAH patients treated with parenteral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5	treprostinil	drug_name	 METHODS We studied a cohort of 743 patients with PAH treated with parenteral treprostinil therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28400191_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS In this study of patients with PAH receiving parenteral treprostinil, PCWP was not associated with long-term all-cause mortality.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12196062_20201005_0.5			Current and emerging therapy for primary pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12196062_20201005_0.5			Anti-Inflammatory Agents|Anticoagulants|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Iloprost|Male|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12196062_20201005_0.5	treprostinil	drug_name	Iloprost, treprostinil, and beraprost are investigational agents in Phase III studies.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5826011_20201005_0.5			Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5826011_20201005_0.5			Pulmonary Hypertension|central line|central line infection|pediatric|intravenous prostanoid	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5826011_20201005_0.5	treprostinil	drug_name	Child|Male|Humans|Adolescent|Female|Child, Preschool|Retrospective Studies|Hypertension, Pulmonary|treprostinil|Epoprostenol|Central Venous Catheters|Prostaglandins|Catheter-Related Infections|Antihypertensive Agents|Bacteremia|Familial Primary Pulmonary Hypertension|Catheters, Indwelling|Infusions, Intravenous|Administration, Intravenous|Eicosanoids	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5826011_20201005_0.5	treprostinil	drug_name	This study is a retrospective review of all pediatric PH patients receiving intravenous epoprostenol (EPO) or treprostinil (TRE) at one academic tertiary care center between 2000 and 2014.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5			Adolescent|Adult|Antihypertensive Agents|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Prospective Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	The chemically stable prostacyclin analogue treprostinil has a longer half-life, and improves hemodynamics and signs/symptoms of PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	This study investigated the feasibility of transitioning patients with PAH from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	Patients were switched from intravenous epoprostenol to intravenous treprostinil (1:1 ng/kg/min) by a direct switch of the medication reservoir from epoprostenol to treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	The dose of treprostinil was adjusted throughout the study to achieve a 2-fold increase of treprostinil compared with the baseline epoprostenol dose.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	Rapid transition to treprostinil was achieved without serious adverse events and, baseline clinical status was maintained over 12 weeks.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	At week 12, the mean treprostinil dose was 62 +/- 30 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	All patients reported less prostacyclin-related side effects with treprostinil and remained on treprostinil after study completion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17261956_20201005_0.5	treprostinil	drug_name	Selected patients with PAH can be safely transitioned from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12716139_20201005_0.5			Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12716139_20201005_0.5			Antihypertensive Agents|Calcium Channel Blockers|Controlled Clinical Trials as Topic|Drug Therapy, Combination|Endothelin Receptor Antagonists|Epoprostenol|Humans|Hypertension, Pulmonary|Platelet Aggregation Inhibitors|Quality of Life|Risk Factors|Vasodilator Agents|Vasomotor System|Ventricular Dysfunction, Right	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12716139_20201005_0.5	treprostinil	drug_name	Three drugs-the prostacyclin analogues epoprostenol and treprostinil and the endothelin receptor antagonist bosentan-are currently approved for the primary treatment of PAH and have been clinically shown to improve outcomes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Antihypertensive Agents|Child|Child, Preschool|Dose-Response Relationship, Drug|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Male|Middle Aged|Multivariate Analysis|Prognosis|Retrospective Studies|Survival Rate|Treatment Outcome|Vascular Resistance|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	BACKGROUND Because of the challenges associated with conducting large survival studies of patients with pulmonary arterial hypertension (PAH), we analyzed the surrogate markers predictive of long-term survival in a large cohort of patients treated with subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	 METHODS A retrospective review was conducted using data from a total of 811 patients with New York Heart Association Functional Class (NYHA FC) II to IV PAH, who were treated with subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	The 6-minute walk distance (6MWD) of ≤295 m after 12 weeks of treprostinil treatment was associated with reduced survival at 3 years (58%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	Treprostinil dose of ≥40 ng/kg/min (p < 0.001) and every 10-ng/kg/min dose increase (p = 0.009) resulted in improved long-term survival.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	In a multivariate analysis, only SVO(2), 6MWD and treprostinil dose were significant on-treatment predictors (p < 0.02) of survival.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21531577_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Disease etiology, baseline factors (NYHA FC, PVRI and SVO(2)) and on-treatment factors (6MWD, SVO(2) and treprostinil dose) were predictors of survival in this study and may be used to aid in treatment optimization.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5			Treatment of pulmonary arterial hypertension: a preliminary decision analysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5			Antihypertensive Agents|Bosentan|Decision Support Techniques|Epoprostenol|Fees, Pharmaceutical|Humans|Hypertension, Pulmonary|Markov Chains|Quality-Adjusted Life Years|Sulfonamides	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5	treprostinil	drug_name	 METHODS We compare key outcomes related to survival, costs, and QOL using a Markov-type decision model to estimate the expected outcomes and costs for PAH patients treated for 1 year with bosentan and treprostinil compared to patients treated with epoprostenol, as well as patients treated with bosentan compared to those treated with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5	treprostinil	drug_name	Treatment effect was estimated using 6-min walk data for treprostinil and epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5	treprostinil	drug_name	 RESULTS Treatment with bosentan compared to treatment with either epoprostenol or treprostinil was less costly and resulted in a greater gain in quality-adjusted life years (QALYs).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5	treprostinil	drug_name	Conversely, treprostinil was significantly more expensive than epoprostenol, without an appreciable gain in QALYs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14665484_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treatment with bosentan is more cost-effective than treatment with either treprostinil or epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	Continuous low volume delivery of intravenous treprostinil via a central venous catheter with a miniature pump in a conscious dog model.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	Humans|Male|Animals|Dogs|treprostinil|Central Venous Catheters|Pilot Projects|Epoprostenol|Antihypertensive Agents|Hypertension, Pulmonary|Infusion Pumps|Administration, Intravenous|Infusions, Intravenous|Longitudinal Studies|Injections, Subcutaneous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	OBJECTIVE Two animal studies were conducted to determine the feasibility of infusing treprostinil via a central venous catheter at an infusion rate of 0.1 mL/hour.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	Currently treprostinil is administered intravenously at infusion rates of approximately 1.0 to 2.0 mL/hour to patients with pulmonary arterial hypertension, which reflects standard clinical practice to ensure line patency with continuous intravenous administration via a central venous catheter.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	 METHODS In a pilot study three male beagle dogs were administered 50 ng/kg/min of treprostinil continuously at an infusion rate of 0.1 mL/hr via the MiniMed 407C infusion pump for 21 days.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	In a definitive study, six male beagle dogs were administered 50 ng/kg/min of treprostinil continuously at an infusion rate of 0.1 mL/hr via the MiniMed 407C infusion pump for 60 days.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	In both studies, pharmacokinetic data were similar to that observed in previous animal studies evaluating treprostinil administration at the same dose and at higher infusion rates.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16552698_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS These animal data support the evaluation of administering treprostinil at a low infusion rate via the MiniMed 407C infusion pump in patients with pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5			Administration, Inhalation|Adult|Aged|Aged, 80 and over|Antihypertensive Agents|Double-Blind Method|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Least-Squares Analysis|Lung Diseases, Interstitial|Male|Middle Aged|Quality of Life|Walk Test	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	The safety and efficacy of inhaled treprostinil for patients with this condition are unclear.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	Patients were assigned in a 1:1 ratio to receive inhaled treprostinil, administered by means of an ultrasonic, pulsed-delivery nebulizer in up to 12 breaths (total, 72 μg) four times daily, or placebo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	 No section A total of 326 patients underwent randomization, with 163 assigned to inhaled treprostinil and 163 to placebo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	At week 16, the least-squares mean difference between the treprostinil group and the placebo group in the change from baseline in the 6-minute walk distance was 31.12 m (95% confidence interval [CI], 16.85 to 45.39; P<0.001).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	There was a reduction of 15% in NT-proBNP levels from baseline with inhaled treprostinil as compared with an increase of 46% with placebo (treatment ratio, 0.58; 95% CI, 0.47 to 0.72; P<0.001).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	Clinical worsening occurred in 37 patients (22.7%) in the treprostinil group as compared with 54 patients (33.1%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.40 to 0.92; P = 0.04 by the log-rank test).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33440084_20210611_0.5	treprostinil	drug_name	 No section In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, assessed with the use of a 6-minute walk test, as compared with placebo. (	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18429760_20201005_0.5			[Pulmonary hypertension and right ventricular failure. Part XIV. Differentiated therapy of primary (idiopathic) and associated forms of pulmonary arterial hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18429760_20201005_0.5			Calcium Channel Blockers|Cardiotonic Agents|Eicosanoids|Heart Failure|Humans|Hypertension, Pulmonary|Incidence|Phosphodiesterase Inhibitors|Pulmonary Wedge Pressure|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18429760_20201005_0.5	treprostinil	drug_name	Is this tiple combination is not effective iloprost inhalations can be replaced by subcutaneous treprostinil or continuous intravenous infusion of epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18429760_20201005_0.5	treprostinil	drug_name	In patients with IV FC PAH therapy is started with subcutaneous administration of treprostinil or infusion of epoprostenol, while bosentan or/and sildenafil is added when necessary.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31632754_20201005_0.5			Pharmacotherapy for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31632754_20201005_0.5	treprostinil	drug_name	Pulmonary arterial hypertension (PAH)|ambrisentan|bosentan|endothelin|epoprostenol|macitentan|nitric oxide|prostacyclin|riociguat|selexipag|sildenafil|tadalafil|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31632754_20201005_0.5			Humans|Female|Pulmonary Arterial Hypertension|Endothelin Receptor Antagonists|Familial Primary Pulmonary Hypertension|Epoprostenol|Hypertension, Pulmonary|Drug Therapy, Combination	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3610124_20201005_0.5	treprostinil	drug_name	Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3610124_20201005_0.5	treprostinil	drug_name	Pulmonary arterial hypertension|Treatment satisfaction|Quality of life|Inhaled prostacyclin|Iloprost|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3610124_20201005_0.5			Administration, Inhalation|Adolescent|Adult|Aged|Antihypertensive Agents|Drug Administration Schedule|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Nebulizers and Vaporizers|Patient Satisfaction|Prospective Studies|Quality of Life|Surveys and Questionnaires|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3610124_20201005_0.5	treprostinil	drug_name	In this study, we sought to evaluate the psychometric properties of a patient-reported treatment satisfaction measure and its relationship to quality of life (QoL) among patients transitioning from inhaled iloprost (iILO) to inhaled treprostinil (iTRE).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5467943_20201005_0.5			A systematic review of transition studies of pulmonary arterial hypertension specific medications	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5467943_20201005_0.5			pulmonary hypertension|transition|pulmonary arterial hypertension|pulmonary vascular disease|pharmacotherapy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5467943_20201005_0.5	treprostinil	drug_name	Adult|Humans|United States|Hypertension, Pulmonary|treprostinil|Epoprostenol|Familial Primary Pulmonary Hypertension|Sildenafil Citrate|Antihypertensive Agents|bosentan|Sulfonamides|Sulfones|ambrisentan|Phenylpropionates|sitaxsentan|Thiophenes|Pyridazines|Piperazines|Isoxazoles|Administration, Inhalation|Administration, Oral	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5467943_20201005_0.5	treprostinil	drug_name	Transitioning from parenteral epoprostenol to parenteral treprostinil appears to be safe and efficacious in patients who have less severe disease and more favorable hemodynamics.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12966661_20201005_0.5			[What is new in the treatment of pulmonary artery hypertension?].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12966661_20201005_0.5			Bosentan|Endothelin Receptor Antagonists|Epoprostenol|Forecasting|Humans|Hypertension, Pulmonary|Sulfonamides	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12966661_20201005_0.5	treprostinil	drug_name	Recently, the Food and Drug Administration has approved two new compounds, Bosentan (an oral, non-selective endothelin receptor blocker) and Treprostinil (a subcutaneous prostacyclin analog).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15163595_20201005_0.5			Prostacyclin and its analogues in the treatment of pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15163595_20201005_0.5			Epoprostenol|Humans|Hypertension, Pulmonary|Models, Biological|Molecular Structure|Prostaglandins	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15163595_20201005_0.5	treprostinil	drug_name	infusion of treprostinil, p.o.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15163595_20201005_0.5	treprostinil	drug_name	While the principal pharmacological properties of all prostanoids are very similar due to a main action on IP receptors, there are considerable differences in pharmacokinetics and metabolism, with half-lives of 2 min for prostacyclin and about 34 min for treprostinil for i.v.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15163595_20201005_0.5	treprostinil	drug_name	infused treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5			Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5			Dose-Response Relationship, Drug|Humans|Hypertension, Pulmonary|Injections, Intravenous|Prostaglandins|Pulmonary Wedge Pressure|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5	treprostinil	drug_name	 RESULTS Clinical studies have demonstrated that the 2 prostanoids available for IV administration in the United States, epoprostenol and treprostinil, improve exercise capacity, dyspnea, and cardiopulmonary hemodynamics in patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5	treprostinil	drug_name	The safety profiles of epoprostenol and IV treprostinil during short-term therapy appear comparable.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5	treprostinil	drug_name	Whereas long-term data with subcutaneous treprostinil have been published, such data for IV treprostinil are not currently available.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5	treprostinil	drug_name	The physician survey revealed differences in the common maintenance doses used for both drugs, with IV treprostinil dosing approximately twice that of epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19332188_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The unique properties of epoprostenol and treprostinil translate into clinical differences, which can influence the amount of drug used to achieve satisfactory patient improvement in the acute and long-term settings.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16273137_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16273137_20201005_0.5			Clinical Trials as Topic|Drug Therapy|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16273137_20201005_0.5	treprostinil	drug_name	gamma-globulin, ivabradine hydrochloride, ixabepilone; Lanthanum carbonate, L-arginine hydrochloride, liposomal doxorubicin, LY-450139; Magnesium sulfate, melatonin, motexafin gadolinium, mycophenolic acid sodium salt; Natalizumab, nesiritide, niacin/lovastatin; OGX-011, olmesartan medoxomil, omalizumab, ospemifene; PACAP38, panitumumab, parathyroid hormone (human recombinant), parecoxib sodium, patupilone, pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, pimecrolimus, pirfenidone, posaconazole, prasterone, pregabalin; R-112, ramelteon, ranolazine, rasagiline mesilate, rebimastat, roflumilast, rosuvastatin calcium, rotigotine hydrochloride, rupatadine fumarate; S-3013, S-3304, semustine, sitaxsentan sodium, St. John's Wort extract; Tadalafil, tamoxifen, Taxus, Tc-99m-EDDA-HYNIC-TOC, TH-9507, tiotropium bromide, tipifarnib, tocilizumab, tolvaptan, torcetrapib, TR-14035, tramadol hydrochloride/acetaminophen, treprostinil diethanolamine, troglitazone, troxacitabine; Valdecoxib, valganciclovir hydrochloride, vandetanib, vardenafil hydrochloride hydrate, VAS-991, veglin, vinflunine, voriconazole; White sweet potato extract; Ximelagatran.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5142319_20201005_0.5			Atrial septostomy and disease targeting therapy in pulmonary hypertension secondary to neurofibromatosis	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5142319_20201005_0.5			Neurofibromatosis|Pulmonary hypertension|Septostomy|Case report	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5142319_20201005_0.5			Antihypertensive Agents|Cardiac Surgical Procedures|Echocardiography|Epoprostenol|Female|Heart Atria|Hemodynamics|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Middle Aged|Neurofibromatosis 1|Prognosis|Ventricular Remodeling	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5142319_20201005_0.5	treprostinil	drug_name	The patient was treated with initial atrial septostomy followed by administration of high-dose subcutaneous treprostinil with a favorable medium-term clinical and hemodynamic response.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12616965_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12616965_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12616965_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs: Abacavir sulfate, adalimumab, AERx morphine sulphate, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, almotriptan, amprenavir, aripiprazole, atenolol, atorvastatin calcium; BSYX-A110; Cantuzumab mertansine, capravirine, CDP-571, CDP-870, celecoxib; Delavirdine mesilate, docetaxel, dofetilide, donepezil hydrochloride, duloxetine hydrochloride, dutasteride, dydrogesterone; Efavirenz, emtricitabine, enjuvia, enteryx, epristeride, erlotinib hydrochloride, escitalopram oxalate, etanercept, etonogestrel, etoricoxib; Fesoterodine, finasteride, flt3ligand; Galantamine hydrobromide, gemtuzumab ozogamicin, genistein, gepirone hydrochloride; Indinavir sulfate, infliximab; Lamivudine, lamivudine/zidovudine/abacavir sulfate, leteprinim potassium, levetiracetam, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, losartan potassium; MCC-465, MRA; Nebivolol, nesiritide, nevirapine; Olanzapine, OROS(R)-Methylphenidate hydrochloride; Peginterferon alfa-2a, peginterferon alfa-2b, Pimecrolimus, polyethylene glycol 3350, pramlintide acetate, pregabalin, PRO-2000; Risedronate sodium, risperidone, ritonavir, rituximab, rivastigmine tartrate, rofecoxib, rosuvastatin calcium; Saquinavir mesilate, Stavudine; Tacrolimus, tadalafil, tamsulosin hydrochloride, telmisartan, tomoxetine hydrochloride, treprostinil sodium, trimegestone, trimetrexate; Valdecoxib, venlafaxine hydrochloride; Zoledronic acid monohydrate.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID24402297_20201005_0.5			Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1α in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID24402297_20201005_0.5			Cell Line|Cells, Cultured|Chemokine CCL3|Cyclic AMP|Epoprostenol|Humans|Iloprost|Monocytes|Pyridines|Receptors, Epoprostenol|Receptors, Prostaglandin|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID24402297_20201005_0.5	treprostinil	drug_name	 METHODS We investigated the effects of 3 conventional (iloprost, beraprost, and treprostinil) and 1 new (ONO-1301) PGI2 analogs, on the expression of MIP-1α expression in human monocytes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	Catastrophic circulatory collapse after inadvertent subcutaneous injection of treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	overdose|pulmonary hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5			Adult|Antihypertensive Agents|Drug Overdose|Epoprostenol|Female|Fluid Therapy|Humans|Hypertension, Pulmonary|Infusion Pumps|Injections, Subcutaneous|Medical Errors|Resuscitation|Vasoconstrictor Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	OBJECTIVE A case of life-threatening cardiovascular collapse after inadvertent subcutaneous injection of undiluted treprostinil is reported.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS A 29-year-old, 76-kg woman with group 1 pulmonary arterial hypertension managed with subcutaneous treprostinil infusion arrived at the emergency department (ED) with headache, nausea, vomiting, and a syncopal episode.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	Admission orders were placed, and the appropriate 3-mL syringe containing 7.5 mg of treprostinil intended for use with the patient's home microinfusion pump was sent from inpatient pharmacy to the ED.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	The order in the electronic medical record stated to administer treprostinil as a subcutaneous injection rather than an infusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	The patient's nurse transferred the 7.5 mg (3 mL) of undiluted treprostinil to a standard syringe and administered it as a single subcutaneous injection.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil was restarted at a reduced dose 12 hours after the overdose event and was adjusted to the patient's home dose 24 hours after the initial event.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29674328_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS A patient who received an inadvertent overdose of subcutaneous treprostinil experienced cardiovascular collapse requiring aggressive resuscitation measures.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5			Acute Disease|Administration, Inhalation|Aerosols|Animals|Antihypertensive Agents|Blood Pressure|Disease Models, Animal|Epoprostenol|Female|Hypertension, Pulmonary|Injections, Intravenous|Male|Pulmonary Circulation|Recovery of Function|Sheep|Treatment Outcome|Vasodilation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	We compared the effects of intravenous vs. aerosolized treprostinil on pulmonary and systemic hemodynamics in an unanesthetized sheep model of sustained acute pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	The sheep were then administered identical doses of treprostinil either intravenously or by aerosol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	Both intravenous and aerosol delivery of treprostinil reduced pulmonary vascular resistance and pulmonary arterial pressure, but the effect was significantly greater with aerosol delivery (P < 0.05).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	Aerosol delivery of treprostinil had minimal effects on systemic hemodynamics, whereas intravenous delivery increased heart rate and cardiac output and decreased left atrial pressure and systemic blood pressure.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	Aerosol delivery of the prostacyclin analog treprostinil has a greater vasodilatory effect in the lung with minimal alterations in systemic hemodynamics compared with intravenous delivery of the drug.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16141385_20201005_0.5	treprostinil	drug_name	We speculate that this may result from treprostinil stimulated production of vasodilatory mediators from pulmonary epithelium.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5	treprostinil	drug_name	An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5	treprostinil	drug_name	Pulmonary arterial hypertension|Treprostinil|Implantable pump|Quality of life|SF-36 form	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5			Administration, Intravenous|Adult|Aged|Antihypertensive Agents|Catheters, Indwelling|Epoprostenol|Equipment Failure|Female|Hematoma|Humans|Hypertension, Pulmonary|Infusion Pumps, Implantable|Male|Middle Aged|Natriuretic Peptide, Brain|Peptide Fragments|Quality of Life|Retrospective Studies|Walk Test	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5	treprostinil	drug_name	Background Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5	treprostinil	drug_name	The aim of this paper was to assess the feasibility of treatment with intravenous treprostinil administered by means of the Lenus Pro® implantable pump.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5	treprostinil	drug_name	 Methods This was a retrospective, multi-center study involving 12 patients (8 females) with PAH treated with a subcutaneous infusion of treprostinil with intolerable pain at the infusion site.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5712081_20201005_0.5	treprostinil	drug_name	 Conclusions In patients with PAH who do not tolerate subcutaneous infusion of treprostinil, the use of the Lenus Pro® implantable pump results in significant subjective improvement of vitality and physical aspect of the HRQoL with acceptable safety profile.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5	treprostinil	drug_name	Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5			Adult|Area Under Curve|Biological Availability|Epoprostenol|Female|Half-Life|Humans|Infusions, Intravenous|Injections, Subcutaneous|Male|Mass Spectrometry|Middle Aged	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5	treprostinil	drug_name	No section The objective of this study was to evaluate the absolute bioavailability and acute pharmacokinetics of treprostinil sodium administered by continuous, short-term subcutaneous infusion in normal subjects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5	treprostinil	drug_name	Fifteen healthy volunteers received treprostinil via an intravenous infusion at 15 ng/kg/min over 150 minutes, followed by a 5- to 7-day washout and a subcutaneous infusion at the same rate administered over 150 minutes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5	treprostinil	drug_name	Serial plasma samples were collected predosing, during dosing, and postdosing, and plasma treprostinil concentration levels were measured by a validated liquid chromatography atmospheric pressure ionization tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 25 pg/mL. Acute administration of treprostinil administered by subcutaneous infusion at a rate of 15 ng/kg/min for 150 minutes achieved a mean Cmax of 1.47 ng/mL. Mean AUC infinity values for intravenous and subcutaneous dosing were 3.52 and 3.97 ng.h/mL, respectively, resulting in a mean apparent absolute bioavailability of 113% for subcutaneous administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5	treprostinil	drug_name	The mean apparent elimination half-life of treprostinil following subcutaneous administration was 1.38 hours, compared to 0.87 hours following intravenous administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14681345_20201005_0.5	treprostinil	drug_name	It was concluded that treprostinil administered by subcutaneous administration is completely absorbed, with a slightly longer half-life compared to intravenously administered treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29071454_20201005_0.5			What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29071454_20201005_0.5	treprostinil	drug_name	Beraprost|Oral prostacyclin|Prostacyclin|Selexipag|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29071454_20201005_0.5			Acetamides|Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Pyrazines	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29071454_20201005_0.5	treprostinil	drug_name	We review the development of the oral prostacyclin agents beraprost, treprostinil, and selexipag and including current indications and limitations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29071454_20201005_0.5	treprostinil	drug_name	 RESULTS Two oral prostacyclin pathway medications, oral treprostinil and selexipag, were FDA approved in December 2013 and 2015, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29071454_20201005_0.5	treprostinil	drug_name	Current guidelines recommend use of selexipag in WHO-FC II and III (class 1, level B recommendation) and oral treprostinil in WHO-FC III (class 2b, level B recommendation).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5			A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5			HPA|HPV|Human pulmonary artery|Human pulmonary vein|PAH|PCH|PVOD|Prostacyclin mimetic|Prostanoid receptors|Pulmonary hypertension|Vasorelaxation|human pulmonary artery|human pulmonary vein|pulmonary arterial hypertension|pulmonary capillary hemangiomatosis|pulmonary veno-occlusive disease	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5			Acetates|Aged|Drug Evaluation, Preclinical|Epoprostenol|Female|Humans|Iloprost|In Vitro Techniques|Inhibitory Concentration 50|Male|Middle Aged|Molecular Mimicry|Pulmonary Artery|Pulmonary Veins|Pyrazines|Receptors, Epoprostenol|Receptors, Immunologic|Receptors, Prostaglandin|Receptors, Prostaglandin E, EP4 Subtype|Vasodilation|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5	treprostinil	drug_name	No section Prostacyclin (PGI2) and its mimetics (iloprost, treprostinil, beraprost and MRE-269) are potent vasodilators (via IP-receptor activation) and a major therapeutic intervention for pulmonary hypertension (PH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5	treprostinil	drug_name	Iloprost and treprostinil were the more potent relaxant agonists when both vessels were analyzed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5	treprostinil	drug_name	HPA were significantly more sensitive to iloprost than to treprostinil, pEC50 values: 7.94±0.06 (n=23) and 6.73±0.08 (n=33), respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5	treprostinil	drug_name	The relaxations induced by treprostinil were completely or partially inhibited by IP-antagonists in HPA or HPV, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5	treprostinil	drug_name	Finally, DP-antagonists inhibited the relaxations induced by treprostinil in HPV, suggesting that the DP-receptor plays a role in treprostinil-induced relaxation in the HPV.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23850788_20201005_0.5	treprostinil	drug_name	These data suggest that iloprost and treprostinil should be the most effective clinically available agonists to decrease pulmonary vascular resistance and to prevent oedema formation (by similar decrease in HPA and HPV resistance) in PH patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5			Antihypertensive Agents|Bacteremia|Catheter-Related Infections|Catheterization, Peripheral|Catheters|Dose-Response Relationship, Drug|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Follow-Up Studies|Gram-Negative Bacterial Infections|Humans|Hydrogen-Ion Concentration|Hypertension, Pulmonary|Illinois|Incidence|Injections, Intravenous|Male|Middle Aged|Prognosis|Prospective Studies|Risk Factors	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	BACKGROUND Recent studies have reported an increase in catheter-related bloodstream infections (BSIs) and gram-negative BSIs among patients with pulmonary arterial hypertension treated with IV treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	One possible explanation is the neutral pH of the treprostinil diluent compared with the basic pH of epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	We hypothesized that administering IV treprostinil with epoprostenol diluent will lower the rate of gram-negative BSI.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	 METHODS We prospectively enrolled patients treated with IV treprostinil and changed the diluent from native diluent to epoprostenol diluent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	We compared the incidence of BSI and gram-negative BSI between those receiving IV treprostinil with epoprostenol diluent (n = 25) and those actively receiving IV epoprostenol (n = 61), as well as with a cohort of patients who received IV treprostinil in native diluent (n = 34).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	 RESULTS There were similar rates of BSI in those treated with treprostinil with epoprostenol diluent and those treated with epoprostenol (0.32 of 1,000 vs 0.40 of 1,000; P = .79).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	BSI rates were not statistically different between those treated with treprostinil with epoprostenol diluent and those treated with treprostinil (0.32 of 1,000 vs 0.90 of 1,000; P = .06).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	However, gram-negative BSIs were significantly lower in patients treated with treprostinil with epoprostenol diluent than in those treated with treprostinil (0.08 of 1,000 vs 0.71 of 1,000, respectively; P = .01).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Patients treated with treprostinil with epoprostenol diluent have a lower incidence of gram-negative BSI than do those treated with treprostinil and a similar rate to those treated with epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21659437_20201005_0.5	treprostinil	drug_name	Changing the diluent of treprostinil to epoprostenol diluent, in combination with the use of water-tight seals throughout the delivery system, appears to be an effective safety measure.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23997048_20201005_0.5			Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23997048_20201005_0.5			Animals|Antihypertensive Agents|Arterial Pressure|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Pulmonary Artery|Signal Transduction|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23997048_20201005_0.5	treprostinil	drug_name	Prostanoids, such as epoprostenol or treprostinil have a vasodilator, antiproliferative and immunomodulatory effect and, despite the administration inconveniences, represent established therapies for severe cases of PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23924675_20201005_0.5	treprostinil	drug_name	Physical and Chemical Stability of Treprostinil Sodium Injection Packaged in Plastic Syringe pump Reservoirs.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23924675_20201005_0.5	treprostinil	drug_name	No section The objective of this study was to evaluate the physical and chemical stability of treprostinil (as sodium) injections in concentrations of 1, 2.5, 5 and 10 mg/mL packaged in MiniMed plastic syringe pump reservoirs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23924675_20201005_0.5	treprostinil	drug_name	Test samples of treprostinil (as sodium) injections having concentrations of 1, 2.5, 5, and 10 mg/mL were packaged as 3 mL of drug solution in 3-mL MiniMed plastic syringe pump reservoirs, sealed with plastic tip caps and stored at -20 deg C, 4 deg C, 23 deg C and 37 deg C for 60 days.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23924675_20201005_0.5	treprostinil	drug_name	All samples of treprostinil (as sodium) injection remained free of visible precipitation throughout the study.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23924675_20201005_0.5	treprostinil	drug_name	Changes in treprostinil concentration were found to be small; treprostinil sodium concentrations were found to be 95% or greater over 60 days at all temperatures studied.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23924675_20201005_0.5	treprostinil	drug_name	Treprostinil (as sodium) injections at concentrations ranging from 1 to 10 mg/mL can be packaged in MiniMed plastic syringe reservoirs, stored and shipped with little or no loss of drug stability.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18552072_20201005_0.5			[Systemic sclerosis].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18552072_20201005_0.5			Evidence-Based Medicine|Fibrosis|Gastroesophageal Reflux|Humans|Immunosuppressive Agents|Kidney Diseases|Raynaud Disease|Scleroderma, Systemic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18552072_20201005_0.5	treprostinil	drug_name	The therapeutic options for treatment of pulmonary hypertension associated with SSc include bosentan, sildenafil and various prostacyclin analogs (eg, epoprostenol, treprostinil, iloprost).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5			Biomarkers|Cell Proliferation|Cells, Cultured|Cyclic AMP|Epoprostenol|Extracellular Matrix|Fibroblasts|Humans|Idiopathic Pulmonary Fibrosis|Transforming Growth Factor beta1	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Thus, the effect of Treprostinil on TGF-ß1 and PDGF-induced fibroblast proliferation and ECM deposition was investigated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Cells were pre-incubated (30 min) with either Treprostinil, forskolin, di-deoxyadenosine (DDA), or vehicle.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Treprostinil time dependently activated cAMP thereby preventing PDGF-BB induced proliferation and TGF-β1 secretion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Myo-fibroblast indicating α-SMA expression was significantly reduced and its formation was altered by Treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Collagen type-I and fibronectin deposition were also reduced by Treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	The effect of Treprostinil on collagen type-I deposition was cAMP sensitive as it was counteracted by DDA, while the effect on fibronectin was not cAMP mediated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	Treprostinil antagonized the pro-fibrotic effects of both PDGF-BB and TGF-β1 in primary human lung fibroblasts.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5773699_20201005_0.5	treprostinil	drug_name	The data presented propose a therapeutic relevant anti-fibrotic effect of Treprostinil in IPF.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17237412_20201005_0.5			Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17237412_20201005_0.5			Animals|Bacteria|Cells, Cultured|Cytokines|Epoprostenol|Iloprost|Immunity|Macrophages|Macrophages, Alveolar|Macrophages, Peritoneal|Phagocytosis|Protein Binding|Rats|Receptors, Prostaglandin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17237412_20201005_0.5	treprostinil	drug_name	The effects of iloprost, carbaprostacyclin, and treprostinil on the regulation of phagocytosis, bacterial killing, and inflammatory mediator production were determined in both macrophage populations from rats.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17237412_20201005_0.5	treprostinil	drug_name	Treprostinil inhibited phagocytosis, bacterial killing, and cytokine generation in AMs to a much greater degree than the other PGI(2) analogs and more closely resembled the effects of PGE(2).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17237412_20201005_0.5	treprostinil	drug_name	Studies with the E prostanoid (EP) 2 receptor antagonist AH-6809 and EP2-null macrophages indicated that this was due in part to the previously unknown ability of treprostinil to stimulate the EP2 receptor.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17110807_20201005_0.5	treprostinil	drug_name	Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17110807_20201005_0.5			Animals|Blood Pressure|Disease Models, Animal|Epoprostenol|Hypertension, Pulmonary|Pulmonary Circulation|Rats|Rats, Wistar|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17110807_20201005_0.5	treprostinil	drug_name	BACKGROUND Beneficial effects of treprostinil, a stable prostacyclin analogue, were demonstrated in patients with pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17110807_20201005_0.5	treprostinil	drug_name	Subsequently, rats were treated with subcutaneous treprostinil (50 ng/kg/min, treated; n = 8) or saline (untreated; n = 9).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17110807_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treprostinil treatment improved clinical course and ameliorated symptoms of heart failure in a model of advanced PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5	treprostinil	drug_name	Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5	treprostinil	drug_name	pulmonary hypertension|selexipag|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5			Acetamides|Administration, Intravenous|Administration, Oral|Adult|Antihypertensive Agents|Drug Substitution|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Male|Middle Aged|Pyrazines	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5	treprostinil	drug_name	OBJECTIVE Safe transition of patients with pulmonary arterial hypertension (PAH) from parenteral treprostinil to oral selexipag therapy in both inpatient and outpatient settings is described.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS There is a paucity of published data on how to safely transition patients to oral therapy in the event of complications and problems during parenteral administration of prostacyclins, which can include bloodstream infections, injection-site pain (with use of subcutaneous treprostinil), infusion pump malfunction, and dosing errors due to incorrect dose preparation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5	treprostinil	drug_name	n = 3) and subcutaneous (n = 1) treprostinil infusion therapy to oral selexipag use.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30301721_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Four patients with WHO group I PAH who were not candidates for continued parenteral treprostinil therapy were safely transitioned to oral selexipag in both inpatient and outpatient settings.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	glucose intolerance|metabolic syndrome|metformin|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5			AMP-Activated Protein Kinases|Animals|Antihypertensive Agents|Diet, High-Fat|Epoprostenol|Heart|Heart Failure|Hyperglycemia|Hypertension, Pulmonary|Hypoglycemic Agents|Insulin Resistance|Male|Metabolic Syndrome|Metformin|Mice|Mice, Inbred C57BL|Obesity|Rats|Receptors, Leptin|Stroke Volume	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	The stable prostacyclin analog, treprostinil, is an effective and widely used Food and Drug Administration-approved drug for the treatment of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	While the effect of treprostinil on metabolic syndrome is unknown, a recent study suggests that the prostacyclin analog beraprost can improve glucose intolerance and insulin sensitivity.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	We sought to evaluate the effectiveness of treprostinil in the treatment of metabolic syndrome-associated PH-HFpEF.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	Approach and Results Treprostinil treatment was given to mice with mild metabolic syndrome-associated PH-HFpEF induced by high-fat diet and to SU5416/obese ZSF1 rats, a model created by the treatment of rats with a more profound metabolic syndrome due to double leptin receptor defect (obese ZSF1) with a vascular endothelial growth factor receptor blocker SU5416.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	In high-fat diet-exposed mice, chronic treatment with treprostinil reduced hyperglycemia and pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	In SU5416/Obese ZSF1 rats, treprostinil improved hyperglycemia with similar efficacy to that of metformin (a first-line drug for type 2 diabetes mellitus); the glucose-lowering effect of treprostinil was further potentiated by the combined treatment with metformin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	Early treatment with treprostinil in SU5416/Obese ZSF1 rats lowered pulmonary pressures, and a late treatment with treprostinil together with metformin improved pulmonary artery acceleration time to ejection time ratio and tricuspid annular plane systolic excursion with AMPK (AMP-activated protein kinase) activation in skeletal muscle and the right ventricle.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32268788_20210611_0.5	treprostinil	drug_name	 No section Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15494704_20201005_0.5			Pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15494704_20201005_0.5			Cardiotonic Agents|Diagnostic Techniques, Cardiovascular|Diagnostic Techniques, Respiratory System|Digoxin|Diuretics|Humans|Hypertension, Portal|Life Style|Lung|Oxygen Inhalation Therapy	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15494704_20201005_0.5	treprostinil	drug_name	In addition to continuous intravenous epoprostenol, subcutaneous treprostinil and oral bosentan are now FDA approved for the treatment of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18698881_20201005_0.5	treprostinil	drug_name	A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18698881_20201005_0.5			Adult|Aged|Antihypertensive Agents|Blood Pressure|Dose-Response Relationship, Drug|Drug Administration Schedule|Epoprostenol|Exercise Tolerance|Female|Follow-Up Studies|Heart Rate|Humans|Hypertension, Pulmonary|Infusions, Subcutaneous|Male|Middle Aged|Respiration|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18698881_20201005_0.5	treprostinil	drug_name	OBJECTIVE Subcutaneous treprostinil is an effective treatment for pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18698881_20201005_0.5	treprostinil	drug_name	We hypothesized that a rapid-escalation treprostinil dosing regimen would be as safe and effective as a slow-escalation dosing regimen.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18698881_20201005_0.5	treprostinil	drug_name	 METHODS Twenty-three patients received treprostinil to treat PH of various aetiologies and were randomized into two groups.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18698881_20201005_0.5	treprostinil	drug_name	At follow-up, the treprostinil dose reached 12.9 +/- 2.7 ng/kg/min in group 1 and 20.3 +/- 5.8 ng/kg/min in group 2 (p < 0.01).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5			[Long-term experience with trerpostinil infusion treatment in patients with pulmonary arterial hypertension in the Czech Republic].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5			Adult|Aged|Antihypertensive Agents|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Intravenous|Male|Middle Aged|Pulmonary Circulation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5	treprostinil	drug_name	Treprostinil is a stable analogue of prostacyclin, which can be administered subcutaneously, intravenously or by inhalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5	treprostinil	drug_name	 RESULTS The patients for whom treprostinil treatment was indicated had an average pressure in the right atrium of 11.9 +/- 4.2 mm Hg, average pressure in the pulmonary artery of 56.8 +/- 10.7 mm Hg, a cardiac index of 1.78 +/- 0.25 l/min/m2 and a total pulmonary resistance of 16.26 +/- 4.48 WU.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5	treprostinil	drug_name	The average distance achieved in a 6-minute walk test before the start of treatment was 326 +/- 83 m. When treated with gradually increasing doses of treprostinil the distance achieved in the 6-minute walk test improved.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5	treprostinil	drug_name	In total 5 patients were unable to tolerate the subcutaneous infusion, of whom 3 were placed on intravenous treprostinil and 2 on oral bosentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17578162_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treprostinil improves symptoms and hemodynamics for PAH patients and reduces mortality.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14533998_20201005_0.5			[Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID14533998_20201005_0.5			Abdominal Pain|Adult|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Lupus Erythematosus, Systemic|Piperazines|Purines|Sildenafil Citrate|Sulfones|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID14533998_20201005_0.5	treprostinil	drug_name	No section Subcutaneous prostacyclin (treprostinil) is an effective short-term treatment for pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14533998_20201005_0.5	treprostinil	drug_name	We describe the use of sildenafil as a substitute for treprostinil in a patient with pulmonary hypertension associated with lupus erythematosus.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14533998_20201005_0.5	treprostinil	drug_name	Treatment with treprostinil was discontinued due to uncontrollable abdominal pain.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18814092_20201005_0.5			[Specific drugs for the treatment of pulmonary arterial hypertension - current status].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18814092_20201005_0.5			Antihypertensive Agents|Bosentan|Endothelin Receptor Antagonists|Humans|Hypertension, Pulmonary|Isoxazoles|Phenylpropionates|Phosphodiesterase 5 Inhibitors|Phosphodiesterase Inhibitors|Piperazines|Prostaglandins|Purines|Pyridazines|Sildenafil Citrate|Sulfonamides|Sulfones|Survival Rate|Thiophenes|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18814092_20201005_0.5	treprostinil	drug_name	To-date all relevant studies have consistently shown improvement in the 6-minute walking test (Iloprost, Treprostinil, Bosentan, Sitaxentan, Ambrisentan, Sildenafil).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25006402_20201005_0.5	treprostinil	drug_name	Safety of epoprostenol and treprostinil in children less than 12 months of age.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25006402_20201005_0.5			infant|prostacyclin|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25006402_20201005_0.5	treprostinil	drug_name	Child|Male|Humans|Female|Child, Preschool|treprostinil|Epoprostenol|Retrospective Studies|Hypertension, Pulmonary|Antihypertensive Agents|Injections, Intravenous|Hemodynamics|Infusions, Intravenous|Administration, Intravenous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25006402_20201005_0.5	treprostinil	drug_name	Subject medical records, bedside flow sheets, and progress notes were reviewed to identify use of intravenous epoprostenol or treprostinil within the first year of life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25006402_20201005_0.5	treprostinil	drug_name	Outcomes included 21 deaths unrelated to prostacyclin, 1 lung transplant, 6 PH resolutions, 8 transitions to oral PH medications, and 1 continuation of treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5			Different efficacy of inhaled and oral medications in pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	Bioavailability|Pulmonary arterial hypertension|Route of delivery|Selexipag|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5			Acetamides|Administration, Inhalation|Administration, Oral|Antihypertensive Agents|Blood Pressure|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Pyrazines	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	Treprostinil is a prostacyclin analogue and selexipag is a selective IP receptor agonist.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	Treprostinil can be delivered by a variety of routes including oral, inhaled, subcutaneous and intravenous.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	The impact of the route of delivery and the optimal dosing for transitioning inhaled treprostinil to oral treprostinil or selexipag is unknown.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	More importantly, given the different selectivity for prostacyclin receptors, it is uncertain whether treprostinil and selexipag can be substituted.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	We present two patients with PAH who received medications targeting the prostacyclin pathway and were transitioned from inhaled treprostinil to either oral treprostinil or selexipag.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28527831_20201005_0.5	treprostinil	drug_name	These cases highlight that the route of delivery (inhaled versus oral) and/or the specific PH medication (treprostinil versus selexipag) matter; therefore close monitoring during transitions is imperative.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18638170_20201005_0.5			Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18638170_20201005_0.5			Antihypertensive Agents|Bacteremia|Catheters, Indwelling|Cross Infection|Equipment Contamination|Home Infusion Therapy|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Prostaglandins	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18638170_20201005_0.5	treprostinil	drug_name	Currently, two prostanoids are approved by the US Food and Drug administration for parenteral administration: epoprostenol (Flolan) and treprostinil (Remodulin).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17202330_20201005_0.5			Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17202330_20201005_0.5			Animals|B7-2 Antigen|Bone Marrow|CD40 Antigens|Cell Differentiation|Cell Proliferation|Cells, Cultured|Cyclic AMP|Cytokines|Dendritic Cells|Epoprostenol|Histocompatibility Antigens Class II|Inflammation Mediators|Lymphocyte Activation|Mice|NF-kappa B|T-Lymphocytes	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17202330_20201005_0.5	treprostinil	drug_name	We report that PGI(2) analogs (iloprost, cicaprost, treprostinil) differentially modulate the response of murine bone marrow-derived DC (BMDC) to LPS in an IP-dependent manner.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	French noninvasive|Registry to Evaluate Early and Long-term PAH disease management (REVEAL)|TRIUMPH|pulmonary arterial hypertension|risk stratification|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	Humans|treprostinil|Epoprostenol|Antihypertensive Agents|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Pulmonary Arterial Hypertension|Administration, Inhalation|Cohort Studies|Administration, Oral|Treatment Outcome|Lung|Risk Assessment|New York	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	Our objectives were: (1) to investigate the impact of inhaled treprostinil on risk stratification using the French noninvasive approach and REVEAL 2.0, and (2) to analyze the prognostic utility of both risk stratification methods in the predominantly New York Heart Association/World Health Organization functional class III/IV cohorts of TRIUMPH and BEAT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	A post hoc analysis was performed to assess risk at baseline and follow-up at Week 12 in the TRIUMPH cohort (n  = 148) and at Week 16, 21, and 30 in the inhaled treprostinil naïve placebo BEAT cohort (n  = 73).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	Overall survival, clinical worsening-free survival, and pulmonary arterial hypertension-related hospitalization-free survival were all assessed in the pooled TRIUMPH and inhaled treprostinil naïve placebo BEAT cohorts based on risk group/strata at Week 12/16 follow-up.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	Inhaled treprostinil improved REVEAL 2.0 risk stratum (OR: 2.38, 95% CI: 1.09-5.19, p  = 0.0298) and REVEAL 2.0 score (p  = 0.0008) compared to placebo in the TRIUMPH cohort at Week 12.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	REVEAL 2.0 risk stratum and the number of low-risk criteria by the French approach improved at Weeks 16, 21, and 30 in the inhaled treprostinil naïve placebo BEAT cohort.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7739096_20210111_0.5	treprostinil	drug_name	These post-hoc pooled analyses suggest inhaled treprostinil improves risk status and indicates that the REVEAL 2.0 calculator may be more suitable than the French noninvasive method for evaluating short-term clinical change in the New York Heart Association/World Health Organization functional class III/IV population.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with chronic kidney disease on hemodialysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5	treprostinil	drug_name	Chronic kidney disease|Hemodialysis|Infection|Pulmonary hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5			Antihypertensive Agents|Dose-Response Relationship, Drug|Drug Tolerance|Epoprostenol|Hemodynamics|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Male|Middle Aged|Renal Dialysis|Renal Insufficiency, Chronic|Severity of Illness Index	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5	treprostinil	drug_name	 OBJECTIVE To determine whether subcutaneous infusion of treprostinil was effective and tolerable CKD-PH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5	treprostinil	drug_name	We added subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5	treprostinil	drug_name	Surprisingly, 9-month treprostinil (50 ng/kg/min) normalized hemodynamics (PAP: 25/4/13 mmHg and PVR: 1.9 w.u.).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28189266_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS This is the first report that subcutaneous treprostinil was very effective and tolerable in a PH patient with CKD-HD.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5			Administration, Inhalation|Aged|Antihypertensive Agents|Area Under Curve|Dose-Response Relationship, Drug|Epoprostenol|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Male|Metered Dose Inhalers|Middle Aged|Nitric Oxide|Vasodilation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	BACKGROUND The stable prostanoid analogue treprostinil is approved as continuous infusion for treatment of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	 RESULTS Randomised open label investigation of acute haemodynamic effects, safety and tolerability of inhaled treprostinil delivered in seconds by a metered dose inhaler (MDI-TRE).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	Haemodynamics and blood gases were measured for 2h following treprostinil application.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	MDI-TRE induced effects were comparable to a historical control group that inhaled treprostinil from an ultrasonic nebuliser.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	No impact on ventilation/perfusion matching by treprostinil was demonstrated in 5 patients with pre-existing gas exchange limitations by use of the multiple inert gas elimination technique.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19071225_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The application of inhaled treprostinil with a metered dose inhaler is feasible and well tolerated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5			Adolescent|Adult|Aged|Antihypertensive Agents|Biomarkers|Double-Blind Method|Epoprostenol|Exercise|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Middle Aged|Physical Endurance|Severity of Illness Index|Treatment Outcome|Walking	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	 METHODS We conducted a placebo-controlled trial of intravenous treprostinil, a prostacyclin analog, in treatment-naive PAH patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	During 12 weeks of treatment with treprostinil or placebo, we quantified 6-minute walk distance (6MW), clinical symptoms and 11 cytokines/growth factors.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	Treprostinil increased 6MW by a placebo-corrected median of 83 meters (p = 0.008; mean increase 93 +/- 42 meters), reduced Borg score by a median 2.0 units (p = 0.02), and improved NYHA class by a median of 1.0 (p = 0.02).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	There was a trend toward improved survival with treprostinil (p = 0.051).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	Treatment with treprostinil was associated with decreased Ang-2 levels.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20022264_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS We conclude that treprostinil treatment significantly improved exercise capacity, dyspnea and functional class.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15148531_20201005_0.5	treprostinil	drug_name	Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15148531_20201005_0.5			Antihypertensive Agents|Endothelium, Vascular|Epoprostenol|Humans|Hypertension, Pulmonary|Lung|Randomized Controlled Trials as Topic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15148531_20201005_0.5	treprostinil	drug_name	These alternative therapies include iloprost (inhaled delivery) and treprostinil (subcutaneous delivery).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15148531_20201005_0.5	treprostinil	drug_name	As a result, the Food and Drug Administration (FDA) recently approved treprostinil for the treatment of pulmonary arterial hypertension in patients with NYHA classes II-IV.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15148531_20201005_0.5	treprostinil	drug_name	This review will offer a discussion of the basic pharmacology of treprostinil, its similarities to and differences from epoprostenol, the animal studies as well as the initial investigational studies leading to its FDA approval, and clinical uses of the drug alone or in combination with newer therapies directed at pulmonary arterial hypertension developed over the last decade.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31845591_20210111_0.5			Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31845591_20210111_0.5			comparative effectiveness research|endothelin receptor antagonists|epoprostenol|mortality|network meta-analysis|phosphodiesterase-5 inhibitors|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31845591_20210111_0.5			Antihypertensive Agents|Bayes Theorem|Comparative Effectiveness Research|Drug Combinations|Drug Therapy, Combination|Epoprostenol|Humans|Male|Network Meta-Analysis|Phenylpropionates|Pulmonary Arterial Hypertension|Pyridazines|Randomized Controlled Trials as Topic|Tadalafil|Treatment Outcome|Walk Test	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31845591_20210111_0.5	treprostinil	drug_name	Combination of ambrisentan and tadalafil showed the greatest impact on 6MWD, followed by epoprostenol and intravenous treprostinil (high dose).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15170869_20201005_0.5			Pulmonary arterial hypertension in children.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15170869_20201005_0.5			Anticoagulants|Calcium Channel Blockers|Cardiac Catheterization|Cardiac Surgical Procedures|Cause of Death|Child|Child, Preschool|Drug Therapy, Combination|Epoprostenol|Female|Genetic Therapy|Humans|Hypertension, Pulmonary|Infant|Male|Nitric Oxide|Physical Examination|Prognosis|Risk Assessment|Severity of Illness Index|Survival Analysis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15170869_20201005_0.5	treprostinil	drug_name	Therapeutic modalities such as new drugs, e.g., epoprostenol, treprostinil, and bosentan, and surgical/interventional options, e.g., transplantation and atrial septostomy, which were unavailable several decades ago, have had a significant impact on prognosis and outcome.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5			Adolescent|Adult|Antihypertensive Agents|Area Under Curve|Bosentan|Chromatography, High Pressure Liquid|Cross-Over Studies|Drug Interactions|Epoprostenol|Female|Half-Life|Humans|Male|Middle Aged|Sulfonamides|Tandem Mass Spectrometry|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	No section Treprostinil diethanolamine is an oral prostacyclin analog currently being evaluated for the treatment of pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	Treprostinil is metabolized primarily by cytochrome P450 (CYP) 2C8 with minor contribution from CYP2C9.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	It is expected that oral treprostinil will be administered with bosentan, approved for the treatment of PAH and known to induce CYP2C9 and 3A4.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	This study evaluated whether a drug interaction exists between oral treprostinil, bosentan, and its active metabolite Ro 48-5033 during co-administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	Twenty-four participants were randomized in a 3-way crossover study to oral treprostinil 1 mg twice daily, bosentan 125 mg twice daily, and oral treprostinil 1 mg twice daily and bosentan 125 mg twice daily.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	Treprostinil geometric mean ratios (GMRs) (90% confidence interval [CIs]) for steady-state AUC(0-12) and C(max) (combination/treprostinil) were 0.92 (0.83, 1.03) and 0.96 (0.83, 1.11), respectively, whereas bosentan GMRs (combination/bosentan) were 1.02 (0.95, 1.10) and 1.04 (0.94, 1.15), respectively, and Ro 48-5033 GMRs were 0.99 (0.93, 1.06) and 1.03 (0.94, 1.13).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20133511_20201005_0.5	treprostinil	drug_name	In conclusion, because the GMR and 90% CI are within the equivalence interval of 0.8 to 1.25, co-administration of oral treprostinil and bosentan did not result in a pharmacokinetic interaction for either agent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5889558_20201005_0.5			The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5889558_20201005_0.5			cAMP|Idiopathic pulmonary fibrosis|Human lung fibroblasts|G protein-coupled receptors|Drug discovery	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5889558_20201005_0.5			Adenosine A2 Receptor Agonists|Cell Differentiation|Cell Proliferation|Cells, Cultured|Cyclic AMP|Dose-Response Relationship, Drug|Fibroblasts|Forecasting|GTP-Binding Protein alpha Subunits, Gs|Humans|Lung	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5889558_20201005_0.5	treprostinil	drug_name	Measuring cAMP accumulation in the presence of selected Gs -coupled receptor ligands as well as an adenylyl cyclase activator and inhibitors of phosphodiesterase showed formoterol, PGE2 , treprostinil and forskolin elicited maximal cAMP responses.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25364518_20201005_0.5	treprostinil	drug_name	Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25364518_20201005_0.5			Pulmonary hypertension (PH)|aerosol|bonsetan|interstitial lung fibrosis|pirfenidone	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25364518_20201005_0.5	treprostinil	drug_name	Humans|pirfenidone|treprostinil|Aerosols|Pyridones|Epoprostenol	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25364518_20201005_0.5	treprostinil	drug_name	Bonsetan, treprostinil, sidenafil and pirfenidone were modified in order to be produced as aerosol in an effort to identify parameters which influence the droplet size production size.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5790717_20201005_0.5			Successful Pulmonary Artery Embolization for the Management of Hemoptysis in a Patient with Eisenmenger Syndrome Caused by Patent Ductus Arteriosus	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5790717_20201005_0.5			hemoptysis|lung hemorrhage|pulmonary arterial hypertension|Eisenmenger syndrome|embolization|epoprostenol	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5790717_20201005_0.5			Angiography|Antihypertensive Agents|Ductus Arteriosus, Patent|Eisenmenger Complex|Embolization, Therapeutic|Epoprostenol|Female|Hemoptysis|Humans|Pulmonary Artery|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5790717_20201005_0.5	treprostinil	drug_name	treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6276424_20201005_0.5			Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6276424_20201005_0.5			Antihypertensive Agents|Bosentan|Cost-Benefit Analysis|Endothelin Receptor Antagonists|Epoprostenol|Humans|Hypertension, Pulmonary|Phenylpropionates|Pyridazines|Sildenafil Citrate|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6276424_20201005_0.5	treprostinil	drug_name	Among them were two studies comparing bosentan with epoprostenol and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6276424_20201005_0.5	treprostinil	drug_name	Both results indicated that bosentan was more cost-effective than epoprostenol, while the results of bosentan and treprostinil were not consistent.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5	treprostinil	drug_name	Cathodal iontophoresis of treprostinil induces a sustained increase in cutaneous blood flux in healthy volunteers.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5			Adult|Antihypertensive Agents|Electrodes|Epoprostenol|Female|Forearm|Humans|Iloprost|Iontophoresis|Male|Regional Blood Flow|Skin|Vasodilation|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5	treprostinil	drug_name	The authors tested whether the prostacyclin analogues treprostinil and iloprost, delivered by cutaneous iontophoresis, induce sustained vasodilatation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5	treprostinil	drug_name	 METHODS Twenty healthy volunteers received treprostinil by cathodal iontophoresis on the forearm.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5	treprostinil	drug_name	 RESULTS Treprostinil 250 μM induced an increase in cutaneous vascular conductance AUC(80) (min) (31 897 ± 24 390 %BL·min) compared with NaCl 0.9% (P < .005), treprostinil 2.5 μM (P < .005), and treprostinil 25 μM (P < .005).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5	treprostinil	drug_name	Systemic and skin tolerance of treprostinil were good.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23400744_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treprostinil cathodal iontophoresis induces a sustained increase in cutaneous blood flow with good local tolerance.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32468125_20210211_0.5	treprostinil	drug_name	The Effect of Perioperative Administration of Treprostinil in Infants with Non-restrictive Ventricular Septal Defect and Severe Pulmonary Arterial Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32468125_20210211_0.5	treprostinil	drug_name	Infant|Perioperative administration|Pulmonary arterial hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32468125_20210211_0.5			Administration, Intravenous|Antihypertensive Agents|Epoprostenol|Female|Heart Septal Defects, Ventricular|Heart Ventricles|Humans|Infant|Length of Stay|Male|Perioperative Period|Pulmonary Arterial Hypertension|Retrospective Studies|Time Factors|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32468125_20210211_0.5	treprostinil	drug_name	No section This study investigated the efficacy and safety of intravenous treprostinil during the perioperative period in infants with non-restrictive ventricular septal defect (VSD) and severe pulmonary arterial hypertension (PAH) undergoing surgical VSD repair.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32468125_20210211_0.5	treprostinil	drug_name	The patients were divided into the treprostinil group and control group according to whether intravenous treprostinil was used during the perioperative period.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32468125_20210211_0.5	treprostinil	drug_name	Although the pulmonary artery pressure in both groups was significantly lower postoperatively than preoperatively, the postoperative pulmonary artery systolic pressure was significantly lower in group T than in group C. The postoperative mechanical ventilation time, ICU stay, and hospital stay in group T were shorter than those in group C. Treprostinil can be used effectively and safely to reduce the perioperative pulmonary artery pressure in infants with non-restrictive VSD and severe PAH undergoing surgical VSD repair.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12570125_20201005_0.5			Pulmonary arterial hypertension in children.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12570125_20201005_0.5			Cardiac Catheterization|Child|Endothelin Receptor Antagonists|Enzyme Inhibitors|Epoprostenol|Genetic Therapy|Heart Septum|Heart Transplantation|Heart-Lung Transplantation|Humans|Hypertension, Pulmonary|Infant|Lung Transplantation|Nitric Oxide|Oxygen Inhalation Therapy|Physical Examination|Prognosis|Receptor, Endothelin A|Risk Factors|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12570125_20201005_0.5	treprostinil	drug_name	Therapeutic modalities such as new drugs, e.g. epoprostenol, treprostinil and bosentan, and surgical interventions, e.g. transplantation and blade septostomy, which were unavailable several decades ago, have had a significant impact on prognosis and outcome.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5			Adenosine Triphosphate|Animals|Cold Ischemia|Epoprostenol|Interferon-gamma|Liver Circulation|Liver Transplantation|Male|Neutrophil Infiltration|Rats|Rats, Inbred Lew|Reperfusion Injury|Tumor Necrosis Factor-alpha	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	Treprostinil, a prostacyclin (PGI(2) ) analog, has a higher potency and longer elimination half-life than other commercially available PGI(2) analogs.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	We examined the efficacy of treprostinil to prevent IRI during OLT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	IRI significantly increased serum ALT and AST levels, neutrophil infiltration, hepatic necrosis and mRNA levels of proinflammatory cytokines post-OLT, while treatment with treprostinil decreased all the parameters.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	Cold storage of liver grafts significantly reduced ATP levels and treprostinil restored energy levels in liver grafts early postreperfusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	In addition, treprostinil preserved the sinusoidal endothelial cell lining and reduced platelet deposition early post-transplantation compared to placebo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	Hepatic tissue blood flow was significantly compromised in the placebo group, whereas treprostinil maintained blood-flow similar to normal levels.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	Treprostinil protected the liver graft against IRI during OLT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21668631_20201005_0.5	treprostinil	drug_name	Treprostinil has the potential to serve as a therapeutic option to protect the liver graft against I/R injury in patients undergoing OLT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33011365_20210511_0.5	treprostinil	drug_name	Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33011365_20210511_0.5	treprostinil	drug_name	Lung fibroblasts|Prostanoid receptors|Pulmonary arteries|Pulmonary hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33011365_20210511_0.5	treprostinil	drug_name	Humans|Rats|Male|Animals|treprostinil|Vasodilation|Pulmonary Artery|Epoprostenol|Receptors, Prostaglandin|Receptors, Epoprostenol|Iloprost|Vasodilator Agents|Lung|Muscle, Smooth, Vascular|Endothelium, Vascular|Fibroblasts|Collagen|Gene Expression	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33011365_20210511_0.5	treprostinil	drug_name	No section Treprostinil (TRE) is a potent pulmonary vasodilator with effects on other pathological aspects of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5			Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5			Adult|Aged|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Injections, Intravenous|Male|Middle Aged	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	BACKGROUND Treprostinil is an intravenous prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	Few studies have compared the pharmacodynamics and effectiveness of treprostinil and epoprostenol in patients with high-risk PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	 METHODS Case series of patients with PAH admitted to a Medical Intensive Care Unit for transition from epoprostenol to intravenous treprostinil for refractory class III-IV functional symptoms or right heart failure.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	 RESULTS Five of fourteen patients treated with intravenous treprostinil during the study period underwent transition to epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	Pulmonary arterial pressures (PAP) and pulmonary vascular resistance significantly increased within 1 h after discontinuation of treprostinil in all subjects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	Mean PAPs immediately prior to discontinuation of treprostinil (53.4 ± 7.5 mmHg) were significantly lower than the values 1 h after discontinuation (63.6 ± 9.6 mmHg, p = 0.026), but were significantly higher than the values following transition to epoprostenol (45.4 ± 5.5, p = 0.0493); 4/5 subjects had short-term clinical follow-up data available; all improved in functional class.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS High-risk PAH patients with an inadequate response to treprostinil may have significant clinical and hemodynamic response to epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21251994_20201005_0.5	treprostinil	drug_name	Following discontinuation of treprostinil in these patients, the hemodynamic effects of discontinuation were seen in substantially shorter time than what is known to be the pharmacokinetic terminal half-life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18276980_20201005_0.5			Prostacyclin among prostanoids.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18276980_20201005_0.5			Animals|Cardiovascular Agents|Endothelium, Vascular|History, 20th Century|Humans|Prostaglandin H2|Prostaglandin-Endoperoxide Synthases|Prostaglandins|Prostaglandins G|Prostaglandins I|Signal Transduction|Thromboxane A2	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18276980_20201005_0.5	treprostinil	drug_name	Prostacyclin sodium salt and its synthetic stable analogues (iloprost, beraprost, treprostinil, epoprostenol, cicaprost) are useful drugs for the treatment of the advanced critical limb ischemia, e.g. in the course of Buerger's disease, and also for the treatment of pulmonary artery hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	Treprostinil improves hemodynamics and symptoms in children with mild pulmonary hypertension awaiting heart transplantation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5			heart failure|prostacyclin|prostanoids|pulmonary hypertension|transplantation	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	Humans|Child|Adolescent|Male|Child, Preschool|Female|Infant|treprostinil|Retrospective Studies|Epoprostenol|Hypertension, Pulmonary|Hemodynamics|Antihypertensive Agents|Familial Primary Pulmonary Hypertension|Exercise Tolerance|Heart|Treatment Outcome|Heart Transplantation	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	No section Treprostinil, a prostacyclin analog, is a safe and effective therapy for children with PAH; however, the use of this agent in children with mild PVR elevations related to HF, including those with SV congenital heart disease awaiting HT, is understudied.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	We describe the hemodynamic and symptomatic changes in pediatric patients awaiting HT treated with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	 No section Single-center retrospective review of all patients was listed for HT who received treprostinil during the listing period.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	Treprostinil significantly decreased PVR (3.8 vs 3.1 WU, P = .03), while mLA or mPCW pressure did not change (11 vs 13 mm Hg, P = .9).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32428328_20201005_0.5	treprostinil	drug_name	 No section Treprostinil may be used safely in patients with mild PAH awaiting HT, including those with SV disease.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	personalized medicine|pharmacogenomics|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	Humans|Male|Female|Adult|Middle Aged|Pilot Projects|treprostinil|Pulmonary Arterial Hypertension|Retrospective Studies|Pharmacogenetics|Epoprostenol|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Antihypertensive Agents|Administration, Oral|Treatment Outcome|Cohort Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	Background and aims: Treprostinil is a prostacyclin analog used to treat pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	Pharmacogenomic variants that may affect treprostinil metabolism and transport have not been well-characterized.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	A cohort of patients who received oral treprostinil were screened for participation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	 Results: A total of 15 patients received oral treprostinil and were consented.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	 Conclusion: Genetic variants responsible for the metabolism and transport of oral treprostinil were common.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	However, dosing was not associated with genetic variants in metabolizing enzymes for treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8111525_20210611_0.5	treprostinil	drug_name	Our findings suggest significant variability in treatment persistence to oral treprostinil, with pharmacogenomics being a potentially important contributor.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25621159_20201005_0.5	treprostinil	drug_name	Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25621159_20201005_0.5			goal-oriented therapy|multicenter study|prostacyclin analogues	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25621159_20201005_0.5	treprostinil	drug_name	We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25621159_20201005_0.5	treprostinil	drug_name	We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25621159_20201005_0.5	treprostinil	drug_name	Twenty-six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25621159_20201005_0.5	treprostinil	drug_name	In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5	treprostinil	drug_name	Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5			Administration, Inhalation|Adult|Aerosols|Antihypertensive Agents|Child|Child, Preschool|Combined Modality Therapy|Drug Delivery Systems|Epoprostenol|Feasibility Studies|Humans|Hypertension, Pulmonary|Infant, Newborn|Models, Anatomic|Nebulizers and Vaporizers|Particle Size|Respiration, Artificial|Vibration	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5	treprostinil	drug_name	OBJECTIVE To determine the feasibility of delivering inhaled treprostinil during mechanical ventilation and spontaneous unassisted ventilation using the Tyvaso Inhalation System and the vibrating mesh nebulizer.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5	treprostinil	drug_name	We sought to compare differences in fine particle fraction, and absolute inhaled treprostinil mass delivered to neonatal, pediatric, and adult models affixed with a face mask, conventional, and high-frequency ventilation between Tyvaso Inhalation System and with different nebulizer locations between Tyvaso Inhalation System and vibrating mesh nebulizer.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was then nebulized with both the Tyvaso Inhalation System and vibrating mesh nebulizer, and the filter was analyzed via high-performance liquid chromatography.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5	treprostinil	drug_name	The vibrating mesh nebulizer delivered the same or greater inhaled treprostinil than the Tyvaso Inhalation System in every simulated model and condition.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28441181_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The vibrating mesh nebulizer is a suitable alternative to the Tyvaso Inhalation System for inhaled treprostinil delivery.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6831973_20201005_0.5			Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6831973_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|treprostinil|prostacyclin|internal device	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6831973_20201005_0.5	treprostinil	drug_name	Middle Aged|Male|Adult|Humans|Female|Pulmonary Arterial Hypertension|Prospective Studies|treprostinil|Epoprostenol|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Antihypertensive Agents|Infusion Pumps, Implantable|Administration, Intravenous|Infusions, Intravenous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6831973_20201005_0.5	treprostinil	drug_name	Background The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system consisting of a pump and a catheter for intravenous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6831973_20201005_0.5	treprostinil	drug_name	Two participants had adverse events of abdominal pain, rash, due to subcutaneous treprostinil “leaks” after one catheter puncture and one catheter laceration during pump refill and replacement, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6831973_20201005_0.5	treprostinil	drug_name	 Conclusion Delivery of treprostinil with an intravascular delivery system is a safe alternative to an external delivery system, while providing enhanced life experiences.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	oral treprostinil|prostacyclins|pulmonary arterial hypertension|pulmonary hypertension|treprostinil diolamine	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5			Administration, Oral|Animals|Antihypertensive Agents|Arterial Pressure|Delayed-Action Preparations|Drug Administration Schedule|Drug Compounding|Epoprostenol|Humans|Hypertension, Pulmonary|Pulmonary Artery|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	No section Treprostinil diolamine is the first oral prostacyclin approved for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	Oral treprostinil is recommended to be administered three times daily in order to facilitate more rapid titration, higher doses achieved, and improved tolerability.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	Oral treprostinil has also been studied in carefully selected, stable patients that transitioned from parenteral or inhaled therapy with close monitoring for late deterioration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	Ongoing clinical trials will determine the long-term effects of higher doses of oral treprostinil on clinical outcomes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5941659_20201005_0.5	treprostinil	drug_name	This review describes the clinical evidence and practical experience with the use of oral treprostinil for PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12892628_20201214_0.5			[Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12892628_20201214_0.5			Adult|Antihypertensive Agents|Bacterial Infections|Catheterization, Central Venous|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Injections, Subcutaneous|Middle Aged	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12892628_20201214_0.5	treprostinil	drug_name	Treprostinil is a prostacyclin analogue suitable for continuous subcutaneous administration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12892628_20201214_0.5	treprostinil	drug_name	We report the successful transition from intravenous epoprostenol to subcutaneuos treprostinil in four patients with severe pulmonary hypertension who suffered from serious complications associated with the epoprostenol infusion system.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16807265_20201005_0.5			Sildenafil treatment for portopulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16807265_20201005_0.5			Administration, Oral|Adult|Aged|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Piperazines|Purines|Sildenafil Citrate|Sulfones|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16807265_20201005_0.5	treprostinil	drug_name	Eight patients were newly started on pulmonary vasoactive treatment, while six patients were already on treatment with inhaled prostanoids (iloprost, n = 5; treprostinil, n = 1).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5	treprostinil	drug_name	Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5			hemodynamics|pharmacokinetics|pharmacology|prostaglandins|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5			Administration, Oral|Adult|Aged|Aged, 80 and over|Cohort Studies|Dose-Response Relationship, Drug|Drug Administration Schedule|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Infusions, Parenteral|Infusions, Subcutaneous|Male|Middle Aged|Patient Selection|Prostaglandins|Quality of Life|Retrospective Studies|Risk Assessment|Severity of Illness Index|Time Factors|Treatment Outcome|Vascular Resistance|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5	treprostinil	drug_name	 METHODS Subjects with a favorable risk profile transitioned from parenteral to oral treprostinil using a protocol-driven titration during 5 days of inpatient observation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5	treprostinil	drug_name	Thirty-three subjects (76% female, mean age 50 years) enrolled; 85% were using subcutaneous treprostinil with a median dose of 57 (range 25 to 111) ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5	treprostinil	drug_name	All 33 subjects transitioned to oral treprostinil therapy within 4 weeks, but 2 transitioned back to parenteral drug before Week 24.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27469018_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Lower risk patients managed on parenteral treprostinil may be candidates for transition to a more convenient, oral form of the drug.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7711148_20210111_0.5	treprostinil	drug_name	Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7711148_20210111_0.5			prostacyclin|pulmonary hypertension|pump implantation	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7711148_20210111_0.5	treprostinil	drug_name	Humans|Male|Adult|Middle Aged|Female|treprostinil|Infusion Pumps, Implantable|Retrospective Studies|Epoprostenol|Pulmonary Artery|Hypertension, Pulmonary|Administration, Intravenous|Antihypertensive Agents|Prostaglandins|Infusions, Intravenous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7711148_20210111_0.5	treprostinil	drug_name	No section Implantable pumps for intravenous treprostinil provide a promising option to overcome drawbacks of parenteral prostanoid administration with external pumps in pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23414683_20201005_0.5			Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23414683_20201005_0.5			Emergency Treatment|Humans|Hypertension, Pulmonary|Prostaglandins I|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23414683_20201005_0.5	treprostinil	drug_name	The currently approved prostacyclins for the treatment of PAH include epoprostenol, iloprost, and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31917615_20210611_0.5			Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31917615_20210611_0.5			DP1 receptor|hypertrophy and proliferation|mTOR signaling|pulmonary arterial hypertension|pulmonary artery smooth muscle cell	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31917615_20210611_0.5			Animals|Antihypertensive Agents|Cell Proliferation|Cyclic AMP-Dependent Protein Kinases|Down-Regulation|Epoprostenol|Humans|Hypertrophy|Hypoxia|Immunosuppressive Agents|Mechanistic Target of Rapamycin Complex 1|Mice|Mice, Knockout|Muscle, Smooth, Vascular|Myocytes, Smooth Muscle|Pulmonary Arterial Hypertension|Pulmonary Artery|RNA, Messenger|Rats|Receptors, Immunologic|Receptors, Prostaglandin|Sirolimus|Vascular Remodeling	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31917615_20210611_0.5	treprostinil	drug_name	Prostaglandin I2 analogs (beraprost, iloprost, and treprostinil) are effective in the treatment of PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31917615_20210611_0.5	treprostinil	drug_name	Of note, the clinically favorable effects of treprostinil in severe PAH may be attributable to concomitant activation of DP1 (D prostanoid receptor subtype 1).Objectives: To study the role of DP1 in the progression of PAH and its underlying mechanism.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31917615_20210611_0.5	treprostinil	drug_name	Moreover, treprostinil treatment blocked the progression of hypoxia-induced PAH in mice in part by targeting the DP1 receptor.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32654737_20210611_0.5			A 50-Year-Old Woman With Limited Scleroderma Presenting With Shortness of Breath.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32654737_20210611_0.5			Antihypertensive Agents|Dyspnea|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Lung Diseases, Interstitial|Middle Aged|Scleroderma, Limited	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32654737_20210611_0.5	treprostinil	drug_name	She was started on IV treprostinil that had been up-titrated over the course of 6 months before presentation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29610176_20201005_0.5			Pediatric Malignant Atrophic Papulosis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29610176_20201005_0.5			Antibodies, Monoclonal, Humanized|Anticoagulants|Cerebral Cortex|Cerebral Hemorrhage|Child, Preschool|Enoxaparin|Fatal Outcome|Female|Humans|Malignant Atrophic Papulosis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29610176_20201005_0.5	treprostinil	drug_name	Nonetheless, because the C5b-9 complex is detected in MAP, some researchers have suggested combined treatment with eculizumab (a humanized monoclonal antibody against C5) and treprostinil (a prostacyclin analog).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7805187_20210211_0.5			PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7805187_20210211_0.5			Diabetic nephropathy|Microarray|Molecular biology|Type 2 diabetes mellitus|microRNAs	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7805187_20210211_0.5			Humans|Male|Diabetic Nephropathies|Matrix Metalloproteinase 2|MIRN1237 microRNA, human|MicroRNAs|Data Management|Gene Expression Profiling|RNA, Long Noncoding|Gene Regulatory Networks|Gene Expression Regulation, Neoplastic|RNA, Messenger|Up-Regulation|Computational Biology|Down-Regulation|Signal Transduction|Diabetes Mellitus|PTGER3 protein, human|Receptors, Prostaglandin E, EP3 Subtype	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7805187_20210211_0.5	treprostinil	drug_name	PTGER3 and MMP -2 were targeted by drugs including iloprost, treprostinil, or captopril, and the deregulation of the two genes was confirmed in the plasma samples from patients with DN as compared with controls.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28702718_20201214_0.5			Single-Center Experience Using Selexipag in a Pediatric Population.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28702718_20201214_0.5	treprostinil	drug_name	Pediatrics|Pulmonary hypertension|Remodulin(R)|Selexipag|Treprostinil|Uptravi(R)	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28702718_20201214_0.5			Acetamides|Adolescent|Antihypertensive Agents|Child|Epoprostenol|Female|Heart Defects, Congenital|Humans|Hypertension, Pulmonary|Male|Pyrazines|Treatment Outcome|Walk Test|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20622039_20201005_0.5			Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20622039_20201005_0.5			Animals|Antihypertensive Agents|Blotting, Western|Cell Proliferation|Down-Regulation|Epoprostenol|HEK293 Cells|Humans|Hypertension, Pulmonary|Iloprost|Immunohistochemistry|Mice|Muscle, Smooth, Vascular|PPAR gamma|Prostaglandins, Synthetic|Receptors, Epoprostenol|Rosiglitazone|Thiazolidinediones|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20622039_20201005_0.5	treprostinil	drug_name	IP receptor protein levels were lower in PASMCs from patients with IPAH, but treprostinil reduced replication and treprostinil-induced cAMP elevation appeared normal.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5			Adult|Antihypertensive Agents|Bacteremia|Cohort Studies|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Gram-Negative Bacteria|Humans|Hypertension, Pulmonary|Incidence|Infusions, Intravenous|Male|Middle Aged|Retrospective Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	BACKGROUND An excessive risk for bacteremia has recently been reported in patients with pulmonary arterial hypertension (PAH) treated with intravenous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	 METHODS We performed a retrospective cohort study that included 55 patients diagnosed with PAH who received a continuous intravenous infusion of a prostanoid (epoprostenol or treprostinil) for ≥1month at our center between January 1991 and December 2011.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	The incidence of bacteremia was 0.118 episodes per 1,000 treatment days in patients receiving epoprostenol versus 0.938 episodes per 1,000 treatment-days in patients receiving treprostinil (P=.0037).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	All episodes of bacteremia due to Gram-negative bacilli were diagnosed in patients on treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	In the univariate analysis the treatment with intravenous treprostinil was associated with the incidence of bacteremia (hazard ratio: 4.09; 95% confidence interval: 1.24-14.53), although the low number of events prevented us from performing a multivariate analysis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22858303_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Therapy with intravenous treprostinil is associated with a higher risk for bacteremia, especially due to non-fermenting Gram-negative bacilli.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6696021_20201005_0.5			Combined Ensemble Docking and Machine Learning in Identification of Therapeutic Agents with Potential Inhibitory Effect on Human CES1	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6696021_20201005_0.5			carboxylesterase 1|docking|ensemble docking|machine learning|CES1 inhibitors|adverse drug reactions|metabolism	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6696021_20201005_0.5			Carboxylic Ester Hydrolases|Drug Discovery|Enzyme Activation|Humans|Machine Learning|Molecular Docking Simulation|Molecular Dynamics Simulation|Protease Inhibitors|Quantitative Structure-Activity Relationship|ROC Curve|Reproducibility of Results|Small Molecule Libraries	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6696021_20201005_0.5	treprostinil	drug_name	Three others drugs (benztropine, iloprost and treprostinil), exhibited a weak CES1 inhibitory effects with IC50 values of 298.2 μM, 366.8 μM and 391.6 μM respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5	treprostinil	drug_name	Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5	treprostinil	drug_name	hemodialysis|intradialytic hypotension|midodrine|treprostinil-induced hypotension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5			Antihypertensive Agents|Dose-Response Relationship, Drug|Epoprostenol|Humans|Hypotension|Kidney Failure, Chronic|Male|Middle Aged|Midodrine|Pulmonary Arterial Hypertension|Renal Dialysis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5	treprostinil	drug_name	OBJECTIVE Use of the vasodilator midodrine for the treatment of treprostinil-induced hypotension is reported.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil infusions were initiated for PAH, subsequently causing hypotension, with predialysis blood pressure values as low as 60/50 mm Hg.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5	treprostinil	drug_name	Counteraction of treprostinil effects was achieved by increasing the total daily midodrine dose from 30 mg to 90 mg over 6 months, with no remarkable adverse effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31381098_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS A 49-year-old patient tolerated 60-mg daily doses of midodrine along with 30-mg intradialytic doses for the management of treprostinil-induced hypotension and prevention of HD interruption, without adverse effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19018187_20201005_0.5			Advances in prostanoid infusion therapy for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19018187_20201005_0.5			Adult|Child|Epoprostenol|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Intravenous|Monitoring, Physiologic	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19018187_20201005_0.5	treprostinil	drug_name	Though complex, intravenous epoprostenol and treprostinil may improve long-term survival, exercise capacity, hemodynamics, and other clinical symptoms of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19018187_20201005_0.5	treprostinil	drug_name	Recent advances in infusion pump technology offer ambulatory pump sizes as small as a pager and continuous infusion flow rates as low as 0.1 mL/h, which may provide quality-of-life advantages for patients treated with treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID19018187_20201005_0.5	treprostinil	drug_name	Transition methods from epoprostenol to treprostinil vary and require close patient monitoring for up to several months.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20819749_20201005_0.5			[Prostanoids in the treatment of pulmonary arterial hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20819749_20201005_0.5			Hemodynamics|Humans|Hypertension, Pulmonary|Prostaglandins|Prostaglandins, Synthetic|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20819749_20201005_0.5	treprostinil	drug_name	In the last decade other prostanoids (treprostinil, iloprost) has been approved for the treatment of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7662390_20210111_0.5	treprostinil	drug_name	Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7662390_20210111_0.5	treprostinil	drug_name	implantable pump|internal device|prostacyclin analogs|pulmonary arterial hypertension|treprostinil delivery	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7662390_20210111_0.5	treprostinil	drug_name	Humans|Female|treprostinil|Pulmonary Arterial Hypertension|Prospective Studies|Epoprostenol|Familial Primary Pulmonary Hypertension|Infusion Pumps, Implantable|Hypertension, Pulmonary|Antihypertensive Agents|Infusions, Intravenous|Administration, Intravenous|Acceleration|Patients	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7662390_20210111_0.5	treprostinil	drug_name	No section Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary arterial hypertension (PAH) treatment and is the subject of recent publications.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7662390_20210111_0.5	treprostinil	drug_name	We analyzed the treprostinil flow rate administered by the Lenus Pro® implantable pump in 2 patients suffering from PAH during follow-up times of respectively 4.2 and 3 years.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7662390_20210111_0.5	treprostinil	drug_name	This correlated with the in-vivo measurement, which suggests a continuous flow increase even after pump removal and without treprostinil use.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21329286_20201005_0.5			Survival of geriatric idiopathic pulmonary arterial hypertension patients.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21329286_20201005_0.5			Aged|Antihypertensive Agents|Blood Pressure|Cardiac Output|Cohort Studies|Connecticut|Drug Therapy, Combination|Familial Primary Pulmonary Hypertension|Female|Follow-Up Studies|Geriatric Assessment|Health Status|Humans|Hypertension, Pulmonary|Male|Retrospective Studies|Survival Analysis|Treatment Outcome|Vascular Resistance|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21329286_20201005_0.5	treprostinil	drug_name	Six subjects received PAH combination therapy with bosentan, sildenafil, iloprost, or treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12525997_20201214_0.5			Emerging medical therapies for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12525997_20201214_0.5			Arginine|Bosentan|Controlled Clinical Trials as Topic|Drug Therapy, Combination|Endothelin-1|Endothelium, Vascular|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Nitric Oxide|Piperazines|Platelet Aggregation Inhibitors|Purines|Pyridines|Signal Transduction|Sildenafil Citrate|Sulfonamides|Sulfones|Thromboxane A2|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12525997_20201214_0.5	treprostinil	drug_name	Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogues treprostinil, beraprost, and iloprost, and the endothelin receptor antagonist bosentan have been tested in clinical trials in more than 1,100 patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28524738_20201005_0.5			Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28524738_20201005_0.5			Pulmonary arterial hypertension|Selexipag|pharmacology|prostacyclin receptor agonists	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28524738_20201005_0.5			Acetamides|Acetates|Administration, Oral|Animals|Antihypertensive Agents|Drug Design|Humans|Hypertension, Pulmonary|Pyrazines|Receptors, Epoprostenol	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28524738_20201005_0.5	treprostinil	drug_name	Areas covered: The review covers receptor selectivity, pharmacokinetics, pharmacodynamics and adverse effects (AEs) of intravenous (IV) epoprostenol (synthetic prostacyclin); the prostacyclin analogs iloprost, beraprost, and treprostinil administered by IV, subcutaneous, inhaled or oral routes; and the oral selective prostacyclin receptor agonist selexipag.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	case study|prostacyclin|prostanoid|pulmonary arterial hypertension|transition|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	Aged|Male|Humans|Female|treprostinil|Quality of Life|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Administration, Inhalation|Exercise Tolerance|Administration, Intravenous|Drug-Related Side Effects and Adverse Reactions	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	No section Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	Availability of an inhaled formulation of treprostinil has provided clinicians with an alternative to continuous SC or IV treprostinil in appropriate patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	Stable PAH patients whose quality of life has been dramatically impacted by side effects of parenteral therapy or those who have had recurrent, life-threatening bloodstream infections but are otherwise responding well to treatment may be the candidates for continuing prostacyclin therapy with inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3641714_20201005_0.5	treprostinil	drug_name	However, there is little clinical experience with transitioning patients from parenteral to inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30378654_20201005_0.5			Lung transplantation as a viable option of treatment for pulmonary veno-occlusive disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30378654_20201005_0.5			idiopathic pulmonary arterial hypertension|lung transplantation|pulmonary veno-occlusive disease	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID30378654_20201005_0.5			Adult|Humans|Lung|Lung Transplantation|Male|Pulmonary Veno-Occlusive Disease|Respiratory Function Tests|Tomography, X-Ray Computed|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID30378654_20201005_0.5	treprostinil	drug_name	Patient was administered with prostacycline (PGI2) mimetic (Treprostinil), what made qualification process and lung transplantation possible.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31379316_20201005_0.5	treprostinil	drug_name	Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31379316_20201005_0.5			Selexipag|infant|paediatric|prostacyclin|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31379316_20201005_0.5			Acetamides|Administration, Intravenous|Administration, Oral|Antihypertensive Agents|Echocardiography|Enteral Nutrition|Epoprostenol|Humans|Infant, Newborn|Infusions, Intravenous|Male|Pulmonary Arterial Hypertension|Pulmonary Wedge Pressure|Pyrazines|Receptors, Prostaglandin	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31379316_20201005_0.5	treprostinil	drug_name	We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32362477_20210211_0.5			Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32362477_20210211_0.5			IP receptor agonist|heart failure|prostacyclin|pulmonary hypertension|pulmonary vascular disease|right ventricle	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32362477_20210211_0.5	treprostinil	drug_name	Adult|Humans|Male|Female|Child|selexipag|Prospective Studies|Pulmonary Arterial Hypertension|Acetamides|Pyrazines|treprostinil|Epoprostenol|Hypertension, Pulmonary|Antihypertensive Agents|Familial Primary Pulmonary Hypertension|Arterial Pressure|pro-brain natriuretic peptide (1-76)|Natriuretic Peptide, Brain|Lung|Administration, Oral|Peptide Fragments|Pharmaceutical Preparations|Cohort Studies	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32362477_20210211_0.5	treprostinil	drug_name	One patient with heritable PAH died on intravenous treprostinil (off selexipag).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5	treprostinil	drug_name	Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5			Adult|Epoprostenol|Female|Headache|Hot Flashes|Humans|Hypertension, Pulmonary|Pulmonary Artery	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5	treprostinil	drug_name	OBJECTIVE To describe a successful transition process from subcutaneous treprostinil to intravenous epoprostenol after the failure of treprostinil in a patient with idiopathic pulmonary arterial hypertension and present an algorithm to achieve the conversion without significant adverse reactions.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5	treprostinil	drug_name	 METHODS A 25-year-old white female receiving subcutaneous treprostinil 97 ng/kg/min was admitted to the intensive care unit for transition from subcutaneous treprostinil to a target intravenous epoprostenol dose of 72 ng/kg/min via a staggered interval dose adjustment approach.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS This case demonstrates a suboptimal therapeutic response to treprostinil for the treatment of idiopathic pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5	treprostinil	drug_name	The transition of treprostinil to epoprostenol is rare; however, in the event therapy change is needed, dosing information is minimal.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15755791_20201005_0.5	treprostinil	drug_name	A staggered transition dosing regimen that accounts for the pharmacokinetic differences between epoprostenol and treprostinil was successfully used in this case.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5			Administration, Inhalation|Adolescent|Antihypertensive Agents|Child|Child, Preschool|Dose-Response Relationship, Drug|Epoprostenol|Exercise Tolerance|Familial Primary Pulmonary Hypertension|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Male|Nebulizers and Vaporizers|Pulmonary Wedge Pressure|Retrospective Studies|Treatment Outcome|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil has been shown to be safe and efficacious in adults.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	This study describes the safety and efficacy of inhaled treprostinil in children with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	A retrospective analysis of 29 children treated with inhaled treprostinil for ≥6 weeks was performed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	Effects of inhaled treprostinil on exercise capacity, functional class, and echocardiographic and hemodynamic data were evaluated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	Patients received 3 to 9 breaths (6 μg/breath) of inhaled treprostinil 4 times/day.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was discontinued in 4 patients because of symptoms including cough and bronchospasm (n = 3) and progression of PAH (n = 1).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	In conclusion, inhaled treprostinil was associated with improvement in exercise capacity and World Health Organization functional class when added to background targeted PAH therapy in children and had an acceptable safety profile.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22917554_20201005_0.5	treprostinil	drug_name	Based on these early data, further study of inhaled treprostinil appears warranted in pediatric patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5	treprostinil	drug_name	Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5			Right ventricular dysfunction|prostacyclin|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5			Animals|Antihypertensive Agents|Disease Models, Animal|Dose-Response Relationship, Drug|Epoprostenol|Heart Failure|Hypertrophy, Right Ventricular|Infusions, Subcutaneous|Male|Rats|Rats, Wistar|Ventricular Function, Right	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5	treprostinil	drug_name	We investigated whether treatment with the prostacyclin analogue treprostinil could prevent pressure overload-induced right ventricular hypertrophy and failure.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5	treprostinil	drug_name	The banded rats were randomised to 6 weeks of treatment with a moderate dose of treprostinil (300 ng/kg/minute), a high dose of treprostinil (900 ng/kg/minute), or vehicle.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5	treprostinil	drug_name	Treatment with treprostinil neither reduced right ventricular hypertrophy nor improved right ventricular function.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27087410_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS In the pulmonary trunk banding model of pressure overload-induced right ventricular hypertrophy and failure, moderate- and high-dose treatment with treprostinil did not improve right ventricular function neither in compensated nor in decompensated right heart failure.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5	treprostinil	drug_name	One-year experience with intravenous treprostinil for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5	treprostinil	drug_name	prostacyclin|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5			Administration, Intravenous|Adolescent|Adult|Aged|Antihypertensive Agents|Blood Pressure|Child|Endpoint Determination|Epoprostenol|Exercise Tolerance|Familial Primary Pulmonary Hypertension|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Longitudinal Studies|Male|Middle Aged|Outcome Assessment, Health Care|Prospective Studies|Treatment Outcome|Walking|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5	treprostinil	drug_name	Continuous IV treprostinil has several potential advantages over IV epoprostenol; however, there has been a lack of published long-term efficacy and safety data on IV treprostinil in PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5	treprostinil	drug_name	 METHODS We conducted a 48-week, multicenter, prospective, open-label, uncontrolled, study of continuous IV treprostinil in 16 patients on no prior PAH specific therapy at baseline (de novo), or 31 patients transitioned at baseline from IV epoprostenol (transition).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5	treprostinil	drug_name	 RESULTS In de novo patients, IV treprostinil increased the mean ± standard error 6MWD by 125 m from 332 ± 21 m at baseline to 457 ± 26 m at Week 48.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23953817_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS In this open-label trial, continuous IV treprostinil for 1 year appears to be safe and effective in de novo PAH patients and those transitioned from IV epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32845776_20201005_0.5	treprostinil	drug_name	Letter by Wang et al Regarding Article, 'Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction'.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32845776_20201005_0.5			Epoprostenol|Heart Failure|Humans|Hyperglycemia|Hypertension, Pulmonary|Metformin|Stroke Volume	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25590376_20201005_0.5			Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25590376_20201005_0.5	treprostinil	drug_name	chronic thromboembolic pulmonary hypertension|macitentan|oral treprostinil|riociguat	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25590376_20201005_0.5			Administration, Oral|Antihypertensive Agents|Chronic Disease|Drug Approval|Endothelin Receptor Antagonists|Epoprostenol|Humans|Hypertension, Pulmonary|Pulmonary Embolism|Pyrazoles|Pyrimidines|Sulfonamides|Treatment Outcome|United States|United States Food and Drug Administration	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25590376_20201005_0.5	treprostinil	drug_name	No section In the past 18 months, the U.S. Food and Drug Administration approved macitentan, riociguat, and treprostinil as oral agents for the treatment of pulmonary arterial hypertension (PAH); riociguat also became the first agent approved for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25590376_20201005_0.5	treprostinil	drug_name	Oral treprostinil, approved to improve exercise capacity in PAH, is associated with gastrointestinal side effects and headaches that are often dose limiting.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5731519_20201005_0.5			Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG)	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5731519_20201005_0.5			pulmonary hypertension|preliminary survey data of Turkey	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5731519_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Outcome Assessment, Health Care|Patient Acceptance of Health Care|Registries|Surveys and Questionnaires|Turkey|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5731519_20201005_0.5	treprostinil	drug_name	Bosentan and ambrisentan, as monotreatment or combination treatment (CT), were noted in 845 and 28 patients, respectively, and inhaled iloprost, subcutaneous treprostinil, and intravenous epoprostenol were noted in 283, 30, and four patients, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23446048_20201005_0.5	treprostinil	drug_name	Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23446048_20201005_0.5			Adult|Angiography|Antihypertensive Agents|Combined Modality Therapy|Epoprostenol|Familial Primary Pulmonary Hypertension|Gastrointestinal Hemorrhage|Gastroscopy|Humans|Hypertension, Pulmonary|Male|Sigmoidoscopy|Tomography, X-Ray Computed	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23446048_20201005_0.5	treprostinil	drug_name	Prostacyclins were introduced in the early 90s, and treprostinil is one of the most frequently used drugs of this class today, owing to its long half-life and to the possibility to administer the molecule through several routes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23446048_20201005_0.5	treprostinil	drug_name	Treprostinil is considered a safe drug and is associated with a significant improvement of exercise capacity, especially in patients with idiopathic PAH (iPAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23446048_20201005_0.5	treprostinil	drug_name	Despite these considerations, safety data on treprostinil are still limited and mainly derived from randomised controlled trials and retrospective studies with relatively small and heterogeneous cohorts of patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23446048_20201005_0.5	treprostinil	drug_name	We report the occurrence of a severe intra-abdominal bleeding during treprostinil infusion in a patient with sc-PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	Adverse events|Prostacyclin|Pulmonary arterial hypertension|Therapy adherence|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	Humans|treprostinil|Consensus|Patient Selection|Epoprostenol|Antihypertensive Agents|Hypertension, Pulmonary|Pulmonary Arterial Hypertension|Administration, Inhalation|Administration, Oral	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	No section Treprostinil, a prostacyclin analogue used in the treatment of pulmonary arterial hypertension (PAH), is available for administration by parenteral, oral, or inhaled routes.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	Transitioning between routes may be beneficial for appropriate patients; however, there is little published data on transitions between oral and inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	Key consensus recommendations included (1) accurately defining successful transition, as stable or improved PAH with good tolerability and adherence, and (2) patients with stable, low-risk PAH showing insufficient response or tolerability to their existing treprostinil therapy (and due to restrictions in up titration of dosing), as appropriate candidates for transitions between treprostinil formulations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	Consensus was also achieved on recommendations for adverse event management, including reassurance, administration of oral treprostinil 3 times daily with food, and dosing inhaled treprostinil at intervals ≥3 hours apart.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	The Delphi process aided in developing expert consensus recommendations that may provide clinically useful guidance for transitioning between treprostinil formulations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33259923_20210611_0.5	treprostinil	drug_name	However, additional data from centers with high volumes of PAH patients undergoing treprostinil transitions would be optimal for defining more complete and robust strategies to facilitate successful transition.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	clinical trials|prostacyclin analogue|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	Male|Humans|Female|treprostinil|Epoprostenol|Pulmonary Arterial Hypertension|Quality of Life|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Antihypertensive Agents|selexipag|Acetamides|Pyrazines|Administration, Inhalation|Administration, Oral|Iloprost	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	Treprostinil, a stable prostacyclin analogue, was FDA-approved in 2002 to improve exercise capacity in PAH patients and is available in intravenous, subcutaneous, inhaled and oral form.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	The four different possible ways of administration, a long half-life and its stability at room temperature give treprostinil an advantage over epoprostenol, iloprost and selexipag, the three other FDA-approved drugs targeting the prostacyclin pathway.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	In clinical trials, treprostinil improved exercise capacity, quality of life (QOL), functional class and clinical status.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	While the different forms of treprostinil lead to specific complications, its general adverse effects are dizziness, nausea, pain in the jaw and extremities, diarrhoea, flushing and headache.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	This MiniReview will assess the benefits and drawbacks of treprostinil in the treatment of PAH by examining its specific mechanism of action and pharmacological properties, such as pharmacokinetics, pharmacodynamics, adverse effects and interactions.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31403254_20201005_0.5	treprostinil	drug_name	In addition, we will analyse and discuss results from different clinical trials, comparing treprostinil's four different forms to each other as well as to other drugs targeting the prostacyclin pathway.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26370630_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil via the Tyvaso Inhalation System through a tracheostomy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26370630_20201005_0.5			Administration, Inhalation|Administration, Oral|Adult|Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Male|Respiratory Insufficiency|Tracheostomy|Tracheotomy|Vocal Cord Paralysis|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23578069_20201005_0.5			Combination therapy in the management of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23578069_20201005_0.5			Antihypertensive Agents|Disease Management|Disease Progression|Drug Monitoring|Drug Therapy, Combination|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|Treatment Outcome|Ventricular Dysfunction, Right	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23578069_20201005_0.5	treprostinil	drug_name	Searches were limited to English, human and clinical trial using the terms sildenafil, tadalafil, vardenafil, phosphodiesterase inhibitor, prostacyclin, prostaglandin, epoprostenol, treprostinil, iloprost, beraprost, endothelin receptor antagonist, bosentan, ambrisentan, sitaxsentan and pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID29874936_20201005_0.5			Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29874936_20201005_0.5			Accelerated Approval Designation|Breakthrough Therapy Designation|FDA|Fast Track Designation|Priority Review Designation|expedited program designations|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29874936_20201005_0.5			Drug Approval|Drug Repositioning|Humans|Hypertension, Pulmonary|Orphan Drug Production|Rare Diseases|United States|United States Food and Drug Administration	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29874936_20201005_0.5	treprostinil	drug_name	 No section This investigation finds that (1) only ambrisentan received the Fast Track Designation; (2) no Breakthrough Designations were elucidated; (3) bosentan and treprostinil received Accelerated Approval Designations, and (4) ambrisentan, sildenafil, riociguat, epoprostenol, iloprost, and treprostinil received Priority Review Designations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5			Adult|Antihypertensive Agents|Cross-Over Studies|Drug Interactions|Drug Therapy, Combination|Epoprostenol|Female|Humans|Male|Middle Aged|Piperazines|Purines|Sildenafil Citrate|Sulfones|Vasodilator Agents|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	No section Treprostinil, a stable prostacyclin analogue used in the treatment of pulmonary arterial hypertension, is in development as a sustained release oral tablet, treprostinil diolamine (United Therapeutics Corp, Research Triangle Park, NC).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	As combination therapy yields additional benefit in pulmonary arterial hypertension, treprostinil diolamine may be used with sildenafil, a phosphodiesterase-5 inhibitor.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	This study was designed to evaluate the presence of a pharmacokinetic drug interaction between treprostinil diolamine and sildenafil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	Treprostinil is primarily metabolized by cytochrome (CYP) P450 2C8 with minor contribution from CYP2C9.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	Eighteen healthy volunteers were randomized to receive 4.5 days each of (1) treprostinil diolamine alone, (2) sildenafil alone, and (3) combination treprostinil diolamine and sildenafil in an open-label, 3-period, 3-sequence crossover study.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	The geometric mean ratio (90% confidence intervals) for combination/agent alone of steady state area under the concentration-time curve and peak concentration (Cmax) were 0.972 (0.824-1.145) and 1.030 (0.900, 1.1-9), respectively, for treprostinil diolamine and were 0.881 (0.804-0.966) and 0.910 (0.876-0.946), respectively, for sildenafil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23429588_20201005_0.5	treprostinil	drug_name	The results suggest lack of a metabolic interaction between treprostinil diolamine and sildenafil, as geometric mean ratio 90% confidence intervals were within 0.8-1.25.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33343879_20210111_0.5			Prostanoids in pediatric pulmonary hypertension: clinical response, time-to-effect, and dose-response.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33343879_20210111_0.5			cardiac output|prognosis|prostacyclin	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33343879_20210111_0.5	treprostinil	drug_name	Humans|Male|Child|Female|Hypertension, Pulmonary|Prostaglandins|Retrospective Studies|treprostinil|Epoprostenol|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Pulmonary Arterial Hypertension|Hemodynamics|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33343879_20210111_0.5	treprostinil	drug_name	3) Lower mPAP was seldom seen with doses of epoprostenol >60 ng/kg/min (100 ng/kg/min for treprostinil).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33343879_20210111_0.5	treprostinil	drug_name	Cardiac index was positively correlated with the dose of epoprostenol but not treprostinil; cardiac index >4 l/min/m2 was seen at modest as well as high doses.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21280186_20201005_0.5			Portopulmonary hypertension as an indication for combined heart, lung, and liver or lung and liver transplantation: literature review and case presentation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21280186_20201005_0.5			Antihypertensive Agents|Drug Resistance|End Stage Liver Disease|Heart-Lung Transplantation|Humans|Hypertension, Portal|Hypertension, Pulmonary|Immunosuppressive Agents|Liver Transplantation|Lung Transplantation|Male|Middle Aged|Patient Selection|Risk Assessment|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21280186_20201005_0.5	treprostinil	drug_name	A 52-year-old man had end-stage liver disease due to hepatitis C and PPHTN; the latter showed a suboptimal response to pulmonary vasodilator therapy with continuous intravenous treprostinil sodium and oral sildenafil citrate and was considered a contraindication to isolated LT.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	Treprostinil, a prostacyclin analog, ameliorates renal ischemia-reperfusion injury: preclinical studies in a rat model of acute kidney injury.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5			acute kidney injury|apoptosis|ischemia-reperfusion injury|oxidative stress|prostacyclin	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5			Acute Kidney Injury|Animals|Antihypertensive Agents|Biomarkers|Blood Urea Nitrogen|Caspase 3|Creatinine|Disease Models, Animal|Epoprostenol|Interleukin-1beta|Kidney Function Tests|Lipocalin-2|Male|Rats|Rats, Sprague-Dawley|Reperfusion Injury	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	Here we investigate the protective effects of treprostinil, a prostacyclin analog, against renal IRI in vivo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	 No section Male Sprague Dawley rats were subjected to bilateral renal ischemia (45 min) followed by reperfusion for 1-168 h. Treprostinil (100 ng/kg/min) or placebo was administered subcutaneously for 18-24 h before ischemia.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	 No section Treatment with treprostinil both significantly reduced peak elevation and accelerated the return to baseline levels for serum creatinine and blood urea nitrogen versus I/R-placebo animals following IRI.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	I/R-treprostinil animals exhibited reduced histopathological features of tubular epithelial injury versus I/R-placebo animals.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	Upregulation of expression of all these genes was significantly suppressed by treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	Treprostinil significantly suppressed the elevation in renal lipid peroxidation found in the I/R-placebo group at 1-h post-reperfusion.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	In addition, renal protein expression of cleaved poly(ADP-ribose) polymerase 1 and caspase-3, -8 and -9 in I/R-placebo animals was significantly inhibited by treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	 No section This study demonstrates the efficacy of treprostinil in ameliorating I/R-induced AKI in rats by significantly improving renal function early post-reperfusion and by inhibiting renal inflammation and tubular epithelial apoptosis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33156922_20210511_0.5	treprostinil	drug_name	Importantly, these data suggest that treprostinil has the potential to serve as a therapeutic agent to protect the kidney against IRI in vivo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7306662_20201005_0.5			Remodulin® Pump Failure: An Emergency Medicine Simulation Scenario	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7306662_20201005_0.5	treprostinil	drug_name	remodulin|pulmonary hypertension|simulation|critical care|pulmonary critical care|simulation in medical education|emergency medicine|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7306662_20201005_0.5	treprostinil	drug_name	Humans|treprostinil|Activities of Daily Living|Epoprostenol|Emergency Medicine|Hypertension, Pulmonary|Patient Simulation|Hemodynamics|Maintenance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7306662_20201005_0.5	treprostinil	drug_name	One common delivery method for this targeted therapy is through a Remodulin® (treprostinil) pump.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21080575_20201005_0.5	treprostinil	drug_name	Add-on treprostinil therapy and PAH.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5			Administration, Inhalation|Administration, Oral|Antihypertensive Agents|Area Under Curve|Blood Pressure|Cough|Drug Synergism|Drug Therapy, Combination|Epoprostenol|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Male|Middle Aged|Phosphodiesterase 5 Inhibitors|Phosphodiesterase Inhibitors|Piperazines|Pulmonary Fibrosis|Pulmonary Gas Exchange|Purines|Sildenafil Citrate|Sulfones|Treatment Outcome|Vascular Resistance	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	BACKGROUND Inhaled treprostinil was recently developed for the treatment of pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	We investigated the safety and acute haemodynamic effects of the combination oral sildenafil and inhaled treprostinil in an open label study in patients with precapillary pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	 METHODS Inhaled nitric oxide (20ppm; n=50), sildenafil (50mg; n=50) and inhaled treprostinil (15microg; n=25 or 30microg; n=25) were applied in subsequent order during right heart catheter investigation to consecutive patients with pulmonary arterial hypertension (PAH; n=28), non-operable chronic thromboembolic pulmonary hypertension (CTEPH; n=17) and pulmonary fibrosis associated pulmonary hypertension (n=5).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	Treprostinil, inhaled 1h after sildenafil, reduced PVR to 66.3+/-3.8%, mPAP to 77.8+/-3.3%, and increased CO to 107.1+/-3.3% (mean+/-95% confidence interval).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	Ventilation/perfusion distribution measurement in six patients with pre-existing gas exchange limitations was not changed by sildenafil and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18657627_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS The combination of sildenafil and inhaled treprostinil was well tolerated and induced additive, pulmonary selective vasodilatation in pulmonary hypertension patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5731720_20201005_0.5			Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5731720_20201005_0.5			compliance|medicines|concordance|Morisky|MMAS-8	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5731720_20201005_0.5			Middle Aged|Aged|Male|Adult|Female|Humans|Medication Adherence|Psychometrics|Surveys and Questionnaires|Reproducibility of Results|Hypertension|Self Report|Hypertension, Pulmonary|Middle Aged|Aged|Male|Adult|Female|Humans|Medication Adherence|Psychometrics|Surveys and Questionnaires|Reproducibility of Results|Hypertension|Self Report|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5731720_20201005_0.5	treprostinil	drug_name	Patients taking at least one specialist medicine (sildenafil, tadalafil, bosentan, ambrisentan, iloprost, epoprostenol, treprostinil) completed a Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31651921_20201005_0.5	treprostinil	drug_name	Synthesis of treprostinil: key Claisen rearrangement and catalytic Pauson-Khand reactions in continuous flow.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31651921_20201005_0.5	treprostinil	drug_name	No section A new synthesis of treprostinil is described using a plug flow reactor in two of the key steps.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31651921_20201005_0.5	treprostinil	drug_name	Scaling up of this reaction safely ensures a good yield of an advanced intermediate which is transformed into treprostinil in three steps.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5	treprostinil	drug_name	Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5			drug delivery|pulmonary arterial hypertension|right ventricle function and dysfunction	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5	treprostinil	drug_name	Middle Aged|Male|Humans|Female|treprostinil|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Vascular Resistance|Heart Ventricles|Exercise Tolerance|Parenteral Nutrition|Administration, Oral|Hemodynamics|Infusions, Intravenous|Injections, Subcutaneous	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5	treprostinil	drug_name	No section Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5	treprostinil	drug_name	We investigated both the effectiveness of parenteral to oral treprostinil transition and the characteristics associated with transition failure over a duration of two years.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5	treprostinil	drug_name	Both U Transition and S Transition had similar hemodynamics at diagnosis and treprostinil dose before and after transition.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6122247_20201005_0.5	treprostinil	drug_name	While a subset of PAH patients on combination therapy may be safely transitioned from parenteral to oral treprostinil, caution should be exercised in patients with elevated baseline PVR to avoid irreversible destabilization.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28848883_20201005_0.5			The COPD Pipeline XXXI.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28848883_20201005_0.5	treprostinil	drug_name	BI1026706|GLPG1837|GSK2269557|PT003|batefenterol|moracin M|nicotine delivery devices|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5	treprostinil	drug_name	Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5			cGMP|cyclic guanylate monophosphate|CTEPH|chronic thromboembolic pulmonary hypertension|FDA|Federal Drug Administration|NO|nitric oxide|PAH|pulmonary arterial hypertension|PDE5|phosphodiesterase 5|PEA|pulmonary endarterectomy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5	treprostinil	drug_name	PRC|Female|Humans|treprostinil|Epoprostenol|Hypertension, Pulmonary|riociguat|Pyrazoles|Combined Modality Therapy|Endarterectomy|Hypertrophy, Right Ventricular|Sildenafil Citrate|Pulmonary Artery|Pulmonary Embolism|Warfarin|Cardiac Output|Cyclic GMP|Echocardiography	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5	treprostinil	drug_name	We describe the favorable recovery of a patient with inoperable CTEPH treated with combination riociguat and inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil was added to sildenafil and warfarin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5	treprostinil	drug_name	 No section We describe significant recovery in a patient with inoperable, progressive CTEPH treated with riociguat and inhaled treprostinil after failing sequential addition of sildenafil and inhaled treprostinil to warfarin.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5133662_20201005_0.5	treprostinil	drug_name	There may also be a unique interaction between riocguat and treprostinil that enhanced treatment outcome.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5	treprostinil	drug_name	Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5			Antihypertensive Agents|Binding, Competitive|Calcium|Cell Culture Techniques|Cyclic AMP|Epoprostenol|HEK293 Cells|Humans|Hypertension, Pulmonary|Iloprost|Radioligand Assay|Receptors, Epoprostenol|Receptors, Prostaglandin|Receptors, Prostaglandin E, EP2 Subtype|Transfection	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5	treprostinil	drug_name	No section The prostacyclin analogues, iloprost and treprostinil are extensively used in treating pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5	treprostinil	drug_name	By contrast, treprostinil had high affinity for the DP1, EP2 and IP receptors (Ki 4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5	treprostinil	drug_name	As with binding studies, treprostinil elevated cyclic AMP with a similar high potency in cells expressing DP1, IP and EP2 receptors (EC50 0.6, 1.9 and 6.2 nM, respectively), but had low activity at the other receptors.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5	treprostinil	drug_name	Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22480736_20201005_0.5	treprostinil	drug_name	Treprostinil may therefore differ from iloprost in its overall beneficial pulmonary vasorelaxant profile and other pharmacological actions, especially in diseases where the IP receptor is down-regulated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5			adverse events|prostacyclin|tolerability	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	Middle Aged|Male|Aged|Humans|Female|United States|treprostinil|Prospective Studies|Epoprostenol|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Administration, Inhalation|Antihypertensive Agents|Exercise Tolerance|Administration, Oral|Cough	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	No section Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	The objectives of this study were to characterize respiratory-related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory-related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)-approved PAH therapies.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	The number of PAH patients enrolled was 1,333, 666 treated with inhaled treprostinil and 667 controls (treated with an FDA-approved PAH therapy other than inhaled treprostinil), for a total of 958 and 1,094 patient-years of exposure, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	In the inhaled-treprostinil group, 1,281 respiratory-related AEs were reported in 403 patients (61%), and in the control group, 1,295 respiratory-related AEs were reported in 388 patients (58%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	Cough, throat irritation, nasal discomfort, and hemoptysis were the most common respiratory-related AEs (occurring in ≥2% of patients in either treatment group) that demonstrated a higher number of events per patient-year of exposure in the inhaled-treprostinil group than in the control group (risk ratio [95% confidence interval]: 1.487 [1.172-1.887], 3.777 [2.050-6.956], 2.039 [1.072-3.879], and 1.957 [1.024-3.741], respectively).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27683610_20201005_0.5	treprostinil	drug_name	Overall, inhaled treprostinil was well tolerated by PAH patients in routine clinical care, with respiratory-related AEs consistent with the known safety profile (trial registration: clinicaltrials.gov identifier: NCT01266265).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID21085923_20201005_0.5			Effects of PGI2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID21085923_20201005_0.5			Adjuvants, Immunologic|Anti-Asthmatic Agents|Cell Line|Cells, Cultured|Chemokines|Cyclic AMP|Epigenomics|Epoprostenol|Gene Expression Regulation|Humans|Iloprost|Lipopolysaccharides|Mitogen-Activated Protein Kinases|Monocytes|NF-kappa B|Th1 Cells|Th2 Cells	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID21085923_20201005_0.5	treprostinil	drug_name	The human monocytes were pretreated with iloprost and treprostinil before lipopolysaccharide (LPS) stimulation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12412701_20201005_0.5			The new clinical trials on pharmacological treatment in pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12412701_20201005_0.5			Dose-Response Relationship, Drug|Drug Administration Schedule|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Iloprost|Male|Prognosis|Pyridines|Randomized Controlled Trials as Topic|Severity of Illness Index|Survival Rate|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12412701_20201005_0.5	treprostinil	drug_name	Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogues treprostinil, beraprost and iloprost, and the endothelin receptor antagonist bosentan have been tested in clinical trials in >1,100 patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5			Administration, Oral|Adolescent|Adult|Aged|Antihypertensive Agents|Child|Dyspnea|Epoprostenol|Exercise Tolerance|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Incidence|International Cooperation|Longitudinal Studies|Male|Middle Aged|Treatment Outcome|Walking|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	This study was designed to evaluate the safety and efficacy of the oral prostacyclin analogue treprostinil diolamine as initial treatment for de novo PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	 RESULTS Three hundred forty-nine patients (intent-to-treat population) not receiving endothelin receptor antagonist or phosphodiesterase type-5 inhibitor background therapy were randomized (treprostinil, n=233; placebo, n=116).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	The primary analysis population (modified intent-to-treat) included 228 patients (treprostinil, n=151; placebo, n=77) with access to 0.25-mg treprostinil tablets at randomization.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	Oral treprostinil therapy was generally well tolerated; the most common adverse events (intent-to-treat) were headache (69%), nausea (39%), diarrhea (37%), and pain in jaw (25%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Oral treprostinil improves exercise capacity in PAH patients not receiving other treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23307827_20201005_0.5	treprostinil	drug_name	Oral treprostinil could provide a convenient, first-line prostacyclin treatment option for PAH patients not requiring more intensive therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5			Adolescent|Adult|Aged|Antihypertensive Agents|Child|Cross-Over Studies|Epoprostenol|Exercise Tolerance|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Middle Aged|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	The prostacyclin analog treprostinil is also efficacious by subcutaneous infusion, is easier to administer, and has a longer half-life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	With the demonstration of bioequivalence between subcutaneous and intravenous treprostinil, intravenous treprostinil may have an overall better risk-benefit profile than intravenous epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	 OBJECTIVE To evaluate the safety and efficacy of transitioning patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	 METHODS Patients enrolled in a 12-wk prospective open label study were switched from intravenous epoprostenol to intravenous treprostinil over 24 to 48 h. The intravenous treprostinil dose was adjusted to minimize symptoms/side effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	Six-minute walk distance (n = 27; baseline, 438 +/- 16 m; Week 12, 439 +/- 16 m), Naughton-Balke treadmill test time (n = 26; baseline, 582 +/- 50 s; Week 12, 622 +/- 48 s), functional class, and Borg score were maintained with intravenous treprostinil at Week 12 versus intravenous epoprostenol before transition.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	No serious adverse events were attributed to treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16151039_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS These data suggest that transition from intravenous epoprostenol to intravenous treprostinil is safe and effective; whether the hemodynamic differences associated with intravenous treprostinil are clinically important requires longer follow-up.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5			secondary pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5			Adult|Antihypertensive Agents|Cohort Studies|Epoprostenol|Female|Heart Defects, Congenital|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Subcutaneous|Male|Natriuretic Peptide, Brain|Oxygen|Vascular Resistance|Walk Test	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5	treprostinil	drug_name	Objective To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5	treprostinil	drug_name	 Methods Consecutive adult patients with CHD-PAH received subcutaneous treprostinil to maximum tolerated doses in an observational study.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5	treprostinil	drug_name	 Results Advanced CHD-PAH patients with WHO class III or IV disease (n=32, age 40±10 years, 20 females) received treprostinil for suboptimal response to bosentan (n=12), WHO functional class IV disease (FC, n=7) or prior to bosentan approval (n=13).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5	treprostinil	drug_name	In those 14 patients who had haemodynamic data before and after initiation of treprostinil, pulmonary vascular resistance decreased significantly (from 18.4±11.1 to 12.6±7.9 Wood units, P=0.003).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6047165_20201005_0.5	treprostinil	drug_name	 Conclusions Subcutaneous treprostinil therapy is generally safe and effective for at least 12 months and may be used in CHD-related PAH class III and IV.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17927481_20201005_0.5			Expert opinion on available options treating pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17927481_20201005_0.5			Antihypertensive Agents|Calcium Channel Blockers|Drug Therapy, Combination|Enzyme Inhibitors|Humans|Hypertension, Pulmonary|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17927481_20201005_0.5	treprostinil	drug_name	Similar benefits were subsequently reported and extended to all PAH categories, and confirmed with more stable prostacyclin analogues administered subcutaneously (treprostinil), by inhalation (iloprost), or even orally (beraprost).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26064468_20201005_0.5			Selective pulmonary vasodilation improves ventriculovascular coupling and gas exchange in a patient with unrepaired single-ventricle physiology.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26064468_20201005_0.5			congenital heart disease|pulmonary hypertension|treatment effect|ventricular/vascular coupling hemodynamics	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26064468_20201005_0.5	treprostinil	drug_name	Humans|Female|Middle Aged|Vasodilation|Heart Ventricles|Hypertension, Pulmonary|Pulmonary Circulation|Hemodynamics|Lung|Ventricular Dysfunction, Right|treprostinil|Epoprostenol|Vasodilator Agents|Hypoxia|Nitric Oxide|Pulmonary Artery|Tricuspid Atresia|Vascular Diseases	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26064468_20201005_0.5	treprostinil	drug_name	Hemodynamic and coupling data were obtained before and after pulmonary vasoactive treatment, first inhaled nitric oxide and later inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26064468_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil significantly increased 6-minute walk distance and improved hypoxia.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16121316_20201005_0.5			Prostacyclin therapy for pulmonary arterial hypertension: new directions.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16121316_20201005_0.5			Antihypertensive Agents|Clinical Trials as Topic|Drug Therapy, Combination|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16121316_20201005_0.5	treprostinil	drug_name	Current therapies based on evidence-based medicine include epoprostenol, treprostinil, iloprost, and beraprost, each with limitations based on the drugs' inherent properties and administration route.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7306336_20201005_0.5			Pregnancy outcomes in patients with pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7306336_20201005_0.5			China|pregnancy outcomes|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7306336_20201005_0.5			Abortion, Induced|Adult|Anesthesia|Antihypertensive Agents|Cesarean Section|Critical Care|Female|Fetal Death|Gestational Age|Humans|Pregnancy|Pregnancy Complications, Cardiovascular|Pregnancy Outcome|Pulmonary Arterial Hypertension|Retrospective Studies|Severity of Illness Index|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7306336_20201005_0.5	treprostinil	drug_name	Fifty-seven patients received PAH-specific therapy during pregnancy, including sildenafil, iloprost, and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28387950_20201005_0.5	treprostinil	drug_name	Vascular Effects of Treprostinil Cutaneous Iontophoresis on the Leg, Finger, and Foot.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28387950_20201005_0.5	treprostinil	drug_name	iontophoresis|laser speckle contrast imaging|microcirculation|prostacyclin|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28387950_20201005_0.5			Administration, Cutaneous|Adult|Epoprostenol|Female|Fingers|Foot|Humans|Iontophoresis|Leg|Male|Skin|Skin Physiological Phenomena|Vasodilator Agents|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32301422_20201005_0.5	treprostinil	drug_name	Combination of treprostinil with sympathectomy and vascular reconstruction to treat recurrent digital ulcer disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32301422_20201005_0.5			Epoprostenol|Humans|Skin Ulcer|Sympathectomy|Ulcer	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27304246_20201005_0.5	treprostinil	drug_name	Reply: Oral Treprostinil Combination Trials Post Hoc Secondary Analyses: A Step toward Verifying Its Efficacy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27304246_20201005_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Randomized, Placebo-controlled Trial of Inhaled Treprostinil for Patients at Risk for Acute Respiratory Distress Syndrome.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	ARDS|hypoxemia|pneumonia|prevention|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Humans|Male|Adult|Middle Aged|Female|Respiratory Distress Syndrome|treprostinil|Double-Blind Method|Epoprostenol|Respiratory Insufficiency|Respiration, Artificial|COVID-19|Administration, Inhalation|Lung|SARS-CoV-2|Hypoxia|Oximetry	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Rationale Inhaled treprostinil may improve oxygenation and have additional antiinflammatory effects in early acute hypoxemic respiratory failure, potentially preventing or reducing the severity of acute respiratory distress syndrome (ARDS).Objectives: To determine whether administration of inhaled treprostinil to patients at risk for ARDS is feasible, safe, and efficacious.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Trends in daily baseline and 30-minute postdose SpO:FiO ratio for all treatment points were not significantly different between placebo and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Four patients required positive pressure ventilation in the treprostinil group versus one in the placebo group.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Conclusions: Inhaled treprostinil administration is feasible in patients at risk for ARDS but was not associated with improvement in the SpO:FiO ratio relative to placebo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33095030_20210411_0.5	treprostinil	drug_name	Drug-associated adverse events were not severe nor unexpected based on the known adverse effect profile of inhaled treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18378784_20201005_0.5			Prostacyclin therapies for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18378784_20201005_0.5			Biosynthetic Pathways|Clinical Trials as Topic|Hemodynamics|Humans|Hypertension, Pulmonary|Prostaglandins, Synthetic|Pulmonary Alveoli|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18378784_20201005_0.5	treprostinil	drug_name	Epoprostenol, a synthetic analogue of prostacyclin, and the chemically stable analogues iloprost, beraprost and treprostinil were tested in randomised controlled trials.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18378784_20201005_0.5	treprostinil	drug_name	In the USA and some European countries, intravenous infusion of epoprostenol and treprostinil, as well as subcutaneous infusion of treprostinil and inhalation of iloprost, have been approved for therapy of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18378784_20201005_0.5	treprostinil	drug_name	Ongoing clinical studies investigate oral treprostinil, inhaled treprostinil and the combination of inhaled iloprost and sildenafil in pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33979496_20210611_0.5	treprostinil	drug_name	Inhaled Treprostinil in Group 3 Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33979496_20210611_0.5			Antihypertensive Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Lung Diseases, Interstitial	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15703889_20201005_0.5			[Therapy of pulmonary arterial hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15703889_20201005_0.5			Antihypertensive Agents|Calcium Channel Blockers|Drug Administration Routes|Drug Interactions|Drug Therapy, Combination|Endothelin Receptor Antagonists|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Phosphodiesterase Inhibitors|Prostaglandins|Randomized Controlled Trials as Topic|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15703889_20201005_0.5	treprostinil	drug_name	Alternatively, subcutaneous treprostinil can be applied.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33766958_20210611_0.5	treprostinil	drug_name	Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33766958_20210611_0.5			pulmonary embolism|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33766958_20210611_0.5			Chronic Disease|Endarterectomy|Epoprostenol|Humans|Hypertension, Pulmonary|Pulmonary Embolism	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33766958_20210611_0.5	treprostinil	drug_name	Here, we present a case report of severe CTEPH related to ventriculoatrial shunt in which intravenous treprostinil was used as a bridge to PTE.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18729002_20201214_0.5			Pulmonary arterial hypertension: on the way to a manageable disease.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18729002_20201214_0.5			Animals|Antihypertensive Agents|Clinical Trials as Topic|Genetic Therapy|Humans|Hypertension, Pulmonary|Nitric Oxide Synthase Type III	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18729002_20201214_0.5	treprostinil	drug_name	Drug candidates undergoing phase III clinical trials for PAH include inhalable and oral treprostinil, aviptadil (an inhalable vasoactive intestinal peptide), and the PDE5 inhibitor tadalafil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC8141819_20210611_0.5			Onset of rupioid psoriasis after vasodilatory regimen initiation in a patient with pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC8141819_20210611_0.5	treprostinil	drug_name	ETA, endothelin A|ETB, endothelin B|PAH, pulmonary arterial hypertension|RupP, rupioid psoriasis|cAMP, cyclic adenosine monophosphate|cGMP, cyclic guanosine monophosphate|drug-induced psoriasis|macitentan|pulmonary arterial hypertension|rupioid psoriasis|tadalafil|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC8141819_20210611_0.5			Humans|Male|Adult|Pulmonary Arterial Hypertension|Familial Primary Pulmonary Hypertension|Vasodilation|Psoriasis|Exanthema	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27717619_20201005_0.5			Diffuse atrophic papules and plaques, intermittent abdominal pain, paresthesias, and cardiac abnormalities in a 55-year-old woman.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27717619_20201005_0.5	treprostinil	drug_name	Degos disease|complement|eculizumab|interferon|malignant atrophic papulosis|treprostinil|vasculopathy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27717619_20201005_0.5			Abdominal Pain|Anti-Arrhythmia Agents|Antibodies, Monoclonal, Humanized|Atrial Fibrillation|Factor Xa Inhibitors|Female|Humans|Malignant Atrophic Papulosis|Metoprolol|Middle Aged|Paresthesia|Pyrazoles|Pyridones|Tricuspid Valve Insufficiency	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29310475_20201005_0.5			Human factors and usability engineering in the development of SMT-101 for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID29310475_20201005_0.5	treprostinil	drug_name	Human factors|SMT-101|parenteral|pulmonary arterial hypertension|treprostinil|wearable infusion pump	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID29310475_20201005_0.5			Adult|Aged|Antihypertensive Agents|Biomedical Engineering|Epoprostenol|Equipment Design|Ergonomics|Female|Humans|Hypertension, Pulmonary|Infusion Pumps|Male|Middle Aged|Surveys and Questionnaires	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID29310475_20201005_0.5	treprostinil	drug_name	No section SMT-101, a novel, proprietary, water-resistant wearable infusion pump prefilled with a preset dosage of treprostinil, was designed to address many of the administration-related shortcomings of existing parenteral therapy for pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31476020_20210411_0.5			Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31476020_20210411_0.5			Adult|Aged|Aged, 80 and over|Antihypertensive Agents|Bronchi|Bronchodilator Agents|Dinoprostone|Dose-Response Relationship, Drug|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Iloprost|Male|Middle Aged|Organ Culture Techniques|Pyrrolidinones|Receptors, Prostaglandin E, EP4 Subtype|Tetrazoles|Vasodilator Agents|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31476020_20210411_0.5	treprostinil	drug_name	However, maximal relaxations produced by PGI2 -mimetics (iloprost, treprostinil, and beraprost) were similar for both groups of patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2841582_20201005_0.5			Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?	title
treprostinil|water	Z0000025801				inn	PubMed	PMC2841582_20201005_0.5			Adult|Aged|Antihypertensive Agents|Bosentan|Cohort Studies|Epoprostenol|Female|Hemodynamics|Humans|Hypertension, Pulmonary|Isoxazoles|Male|Middle Aged|Piperazines|Purines|Randomized Controlled Trials as Topic|Sildenafil Citrate|Sulfonamides|Sulfones|Thiophenes|Time Factors|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC2841582_20201005_0.5	treprostinil	drug_name	Suitable hemodynamic data were identified for bosentan, sitaxentan, sildenafil, epoprostenol, beraprost and treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC2841582_20201005_0.5	treprostinil	drug_name	The estimated 1-year survival was 78.4%, 77.8%, 76.1%, 75.8%, 75.2%, and 74.1% for epoprostenol, bosentan, treprostinil, sitaxentan, sildenafil, and beraprost, respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7144673_20201005_0.5	treprostinil	drug_name	Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7144673_20201005_0.5			pulmonary arterial hypertension|echocardiography|hemodynamics|angiography|prostaglandins	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7144673_20201005_0.5	treprostinil	drug_name	Middle Aged|Male|Humans|treprostinil|selexipag|Pulmonary Arterial Hypertension|Epoprostenol|Acetamides|Pyrazines|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Antihypertensive Agents|Prostaglandins I|Administration, Oral|Hemodynamics|Echocardiography	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7144673_20201005_0.5	treprostinil	drug_name	This case highlights the transition from selexipag to oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7144673_20201005_0.5	treprostinil	drug_name	A possible explanation is that selexipag has a maximal dose, whereas there is no recommended maximum dose of oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7144673_20201005_0.5	treprostinil	drug_name	Another theory is oral treprostinil has higher affinity to the IP receptor, though selexipag has a higher specificity.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID27418235_20201005_0.5			Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID27418235_20201005_0.5			TC-E 500|benign prostatic hyperplasia (BPH)|lower urinary tract symptoms (LUTS)|phosphodiesterase 10 (PDE10)|phosphodiesterase inhibitors|prostate smooth muscle contraction	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID27418235_20201005_0.5			Heterocyclic Compounds, 3-Ring|Humans|In Vitro Techniques|Male|Muscle Contraction|Muscle, Smooth|Phosphodiesterase Inhibitors|Phosphoric Diester Hydrolases|Prostate|Prostatectomy|Prostatic Neoplasms	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID27418235_20201005_0.5	treprostinil	drug_name	The prostacyclin analog treprostinil and the nitric oxide donor DEA NONOate induced relaxations of precontracted prostate strips, which were significantly amplified by TCE 5005.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3677895_20201005_0.5			Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening	title
treprostinil|water	Z0000025801				inn	PubMed	PMC3677895_20201005_0.5			Administration, Oral|Adolescent|Adult|Antihypertensive Agents|Case-Control Studies|Child|Child, Preschool|Drug Resistance|Endothelial Cells|Endothelin Receptor Antagonists|Endothelium, Vascular|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Follow-Up Studies|Heart Defects, Congenital|Humans|Hypertension, Pulmonary|Immunomagnetic Separation|Infant|Male|Middle Aged|Phosphodiesterase 5 Inhibitors|Prospective Studies|Severity of Illness Index|Vascular Resistance|Vasodilator Agents|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC3677895_20201005_0.5	treprostinil	drug_name	In 10 children with refractory PAH despite oral combination therapy, subcutaneous (SC) treprostinil was added and we observed a significant decrease in CEC counts during the first month of such treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC3677895_20201005_0.5	treprostinil	drug_name	CECs were quantified during a 6 to 36 month-follow-up after initiation of SC treprostinil and we found that CEC counts changed over time, with rising counts always preceding clinical deterioration.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5			Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	hospitalization|oral treprostinil|pulmonary hypertension|retrospective database analysis|selexipag	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	Humans|Male|United States|Middle Aged|Adult|Female|Hypertension, Pulmonary|Retrospective Studies|Data Management|treprostinil|Epoprostenol|selexipag|Acetamides|Antihypertensive Agents|Pyrazines|Hospitalization|Pulmonary Arterial Hypertension|Administration, Oral|Pharmaceutical Preparations	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	No section Two oral medications targeting the prostacyclin pathway are available to treat pulmonary arterial hypertension in the United States: oral treprostinil and selexipag.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	Cohort inclusion required age ≥ 18 years, first oral treprostinil or selexipag prescription between 1 January 2015 and 30 September 2017 (index date), and continuous enrollment in the prior ≥6 months.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	Multivariable Cox proportional hazard and Poisson regression were used to compare risk and rate, respectively, of hospitalization associated with oral treprostinil vs. selexipag, adjusting for potential confounders.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	The study cohort included 99 patients receiving oral treprostinil and 123 receiving selexipag.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	Compared with oral treprostinil, selexipag was associated with a 46% lower risk of all-cause hospitalization (hazard ratio 0.54, 95% confidence interval 0.31, 0.92; P  = 0.02), a 47% lower risk of pulmonary hypertension-related hospitalization (hazard ratio 0.53, 95% confidence interval 0.31, 0.93; P  = 0.03), a 42% lower all-cause hospitalization rate (rate ratio 0.58, 95% confidence interval 0.39, 0.87; P  = 0.01), and a 46% lower pulmonary hypertension-related hospitalization rate (rate ratio 0.54, 95% confidence interval 0.35, 0.82; P  = 0.004).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7675886_20210111_0.5	treprostinil	drug_name	This study suggests that selexipag is associated with lower hospitalization risk and rate than oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6805312_20201005_0.5			Management of acutely decompensated chronic thromboembolic pulmonary hypertension in late pregnancy: a case report	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6805312_20201005_0.5			Maternal morbidity|Late pregnancy|Pulmonary hypertension|Chronic thromboembolic pulmonary hypertension|Right heart failure	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6805312_20201005_0.5			Adult|Antihypertensive Agents|Cesarean Section|Chronic Disease|Computed Tomography Angiography|Dose-Response Relationship, Drug|Drug Therapy, Combination|Echocardiography|Endarterectomy|Epoprostenol|Female|Heparin, Low-Molecular-Weight|Humans|Hypertension, Pulmonary|Pregnancy|Pregnancy Complications, Cardiovascular|Prenatal Diagnosis|Pulmonary Artery|Pulmonary Embolism|Pulmonary Wedge Pressure	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6805312_20201005_0.5	treprostinil	drug_name	Epoprostenol treatment was successfully converted to subcutaneous treprostinil therapy and the patient was discharged home to care for her healthy baby girl.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15890512_20201005_0.5			Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15890512_20201005_0.5			Administration, Inhalation|Analysis of Variance|Cardiac Output|Drug Administration Schedule|Drug Therapy, Combination|Epoprostenol|Exercise Test|Female|Humans|Hypertension, Pulmonary|Lung|Male|Middle Aged|Nitric Oxide|Piperazines|Prospective Studies|Pulmonary Artery|Purines|Sildenafil Citrate|Sulfones|Time Factors|Treatment Outcome|Vascular Resistance|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15890512_20201005_0.5	treprostinil	drug_name	We also provided sildenafil to patients who were ineligible for, or had clinical deterioration on epoprostenol, treprostinil, or bosentan.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial	title
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	pulmonary arterial hypertension|oral treprostinil|clinical study|combination therapy|sequential therapy	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5			Administration, Oral|Adolescent|Adult|Aged|Antihypertensive Agents|Double-Blind Method|Epoprostenol|Female|Humans|Male|Middle Aged|Placebos|Pulmonary Arterial Hypertension|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	No section Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	 No section Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	 No section Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	 No section Measurements and Main Results: Clinical worsening occurred in 26% of the oral treprostinil group compared with 36% of placebo participants (hazard ratio, 0.74; 95% confidence interval, 0.56-0.97; P  = 0.028).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	Key measures of disease status, including functional class, Borg dyspnea score, and N-terminal pro-brain natriuretic peptide, all favored oral treprostinil treatment at Week 24 and beyond.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	A noninvasive risk stratification analysis demonstrated that oral treprostinil-assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from Study Weeks 12-60.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	The most common adverse events in the oral treprostinil group were headache, diarrhea, flushing, nausea, and vomiting.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC7068822_20201005_0.5	treprostinil	drug_name	 No section Conclusions: In participants with PAH, addition of oral treprostinil to approved oral monotherapy reduced the risk of clinical worsening.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30293617_20201005_0.5	treprostinil	drug_name	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30293617_20201005_0.5	treprostinil	drug_name	mortality|pulmonary hypertension|pump|survival|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID30293617_20201005_0.5			Adult|Cause of Death|Chronic Disease|Epoprostenol|Equipment Failure|Female|Follow-Up Studies|Humans|Hypertension, Pulmonary|Infusion Pumps, Implantable|Lung Transplantation|Male|Middle Aged|Risk Factors|Survival Rate|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID30293617_20201005_0.5	treprostinil	drug_name	No section We examined safety and long-term outcomes of intravenous treprostinil administered via the implantable LENUS Pro pump in patients with severe pulmonary hypertension (PH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30293617_20201005_0.5	treprostinil	drug_name	 No section Our data suggest that intravenous treprostinil via the LENUS Pro pump in advanced PH is associated with a very low risk of bloodstream infections, but other serious adverse events may occur.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5	treprostinil	drug_name	Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5	treprostinil	drug_name	pulmonary hypertension|selexipag|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5			Acetamides|Administration, Oral|Adult|Antihypertensive Agents|Chronic Disease|Epoprostenol|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Male|Paraplegia|Pyrazines|Severity of Illness Index|Ventricular Dysfunction, Right	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5	treprostinil	drug_name	In order to facilitate goals of care (hospital discharge to a skilled nursing facility where parenteral prostanoids could not be administered), he underwent rapid transition from intravenous treprostinil to oral selexipag in the form of a cross-taper over 6 days.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5	treprostinil	drug_name	The patient required readmission due to worsening symptoms and was transitioned back to intravenous treprostinil; he tolerated conversion to oral treprostinil for approximately 4 months, but it was subsequently discontinued due to nausea and modified goals of care.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5	treprostinil	drug_name	To our knowledge, this is the first report to describe transition from intravenous treprostinil to selexipag as well as conversion from parenteral treprostinil to oral treprostinil in a patient with CTEPH and illustrates the approaches to and potential issues with prostanoid transitions.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28513869_20201005_0.5	treprostinil	drug_name	Additional observations are necessary to better understand the relative roles of selexipag and oral treprostinil regarding comparative efficacy and tolerability.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5467940_20201005_0.5			Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5467940_20201005_0.5	treprostinil	drug_name	cluster analysis|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5467940_20201005_0.5	treprostinil	drug_name	Middle Aged|Adult|Aged|Male|Humans|Hypertension, Pulmonary|treprostinil|Epoprostenol|Familial Primary Pulmonary Hypertension|Antihypertensive Agents|Exercise Tolerance|Administration, Oral|Treatment Outcome|Dyspnea|Walking|Cluster Analysis	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC5467940_20201005_0.5	treprostinil	drug_name	An unbiased cluster analysis was performed on 17 baseline clinical variables of PAH patients from the FREEDOM-M, FREEDOM-C, and FREEDOM-C2 randomized trials of oral treprostinil versus placebo.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5467940_20201005_0.5	treprostinil	drug_name	Mean treatment effect of oral treprostinil differed across Clusters 1-4 increased in a monotonic fashion (Cluster 1: 10.9 m; Cluster 2: 13.0 m; Cluster 3: 25.0 m; Cluster 4: 50.9 m; interaction P value = 0.048).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5467940_20201005_0.5	treprostinil	drug_name	Patients who were older, diagnosed with PAH for a shorter period, and had worse baseline symptoms and exercise capacity had the greatest response to oral treprostinil treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17389412_20201005_0.5	treprostinil	drug_name	Practical aspects of continuous intravenous treprostinil therapy.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17389412_20201005_0.5			Activities of Daily Living|Antihypertensive Agents|Critical Care|Drug Monitoring|Epoprostenol|Exercise Test|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Nurse's Role|Nursing Assessment|Patient Education as Topic|Practice Guidelines as Topic|Safety|Severity of Illness Index	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16899485_20201005_0.5	treprostinil	drug_name	Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16899485_20201005_0.5			Adolescent|Adult|Aged|Aged, 80 and over|Antihypertensive Agents|Bosentan|Child|Cohort Studies|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Iloprost|Injections, Subcutaneous|Male|Middle Aged|Placebos|Sulfonamides|Survival Rate|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16899485_20201005_0.5	treprostinil	drug_name	To evaluate the effects of subcutaneous (SC) treprostinil, a longer-acting prostacyclin analogue, followed by the addition of other PAH therapies if needed, 860 PAH patients treated with SC treprostinil for up to 4 yrs were followed.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16899485_20201005_0.5	treprostinil	drug_name	In total, 97 patients (11%) switched from SC treprostinil to an alternative prostacyclin analogue; bosentan was added in 105 patients (12%) and sildenafil in 25 (3%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16899485_20201005_0.5	treprostinil	drug_name	In conclusion, survival was 87-68% over 1-4 yrs for all 860 patients and 88-70% over 1-4 yrs with subcutaneous treprostinil monotherapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16899485_20201005_0.5	treprostinil	drug_name	The safety profile for long-term subcutaneous treprostinil was consistent with previous short-term trials with no unexpected adverse events.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	pulmonary arterial hypertension|selexipag|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5			Acetamides|Administration, Intravenous|Administration, Oral|Aged|Antihypertensive Agents|Blood Pressure|Drug Substitution|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Injections, Subcutaneous|Pyrazines|Time Factors	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	There is a paucity of data regarding how to safely transition from oral selexipag to parenteral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	We describe rapid transition from oral selexipag to parenteral treprostinil in this case report.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	 No section A 65-year-old female with mixed-etiology PAH as result of pulmonary fibrosis related to polymyositis was admitted to the intensive care unit to be transitioned from selexipag to treprostinil due to dyspnea at rest despite therapy with selexipag 1,600 mg twice daily and macitentan 10 mg daily for 3 years.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	treprostinil at a dose of 2 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	The treprostinil dose was increased by 2 ng/kg/min every 3 hours until a target dose of 22 ng/kg/min was achieved, at which point the patient had experienced dyspnea improvement.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	She experienced a mild headache and flushing during rapid treprostinil dose escalation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	treprostinil infusion, the patient was transitioned to subcutaneous treprostinil therapy and discharged.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32620953_20210511_0.5	treprostinil	drug_name	and then subcutaneous treprostinil therapy over a 30-hour period, with minimal adverse effects.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26152021_20201005_0.5	treprostinil	drug_name	Pregnancy in a woman with pulmonary hypertension: favorable outcome with intravenous treprostinil.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26152021_20201005_0.5			Adult|Anticoagulants|Antihypertensive Agents|Cesarean Section|Enoxaparin|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusions, Intravenous|Oxygen Inhalation Therapy|Pregnancy|Pregnancy Complications, Cardiovascular|Pregnancy Trimester, Second	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26152021_20201005_0.5	treprostinil	drug_name	The intravenous administration of treprostinil has demonstrated effectiveness for the treatment of PH, though documentations of its use during pregnancy are few.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26152021_20201005_0.5	treprostinil	drug_name	Treatment comprised of oxygen therapy, enoxaparin, and intravenous treprostinil from gestational week 25, following a successful elective cesarean section at 33 weeks gestation with favorable outcome.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26152021_20201005_0.5	treprostinil	drug_name	This report demonstrates the effectiveness of an intensive therapeutic protocol, including intravenous treprostinil, for the treatment of PH in pregnancy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15920997_20201005_0.5	treprostinil	drug_name	Treprostinil for the treatment of severe digital necrosis in systemic sclerosis.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15920997_20201005_0.5			Adult|Epoprostenol|Female|Fingers|Humans|Infusions, Parenteral|Raynaud Disease|Scleroderma, Systemic|Skin Ulcer|Wound Healing	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15920997_20201005_0.5	treprostinil	drug_name	No section We report a case of severe digital ulcerations associated with systemic sclerosis, successfully treated with treprostinil (Remodulin).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15920997_20201005_0.5	treprostinil	drug_name	Treprostinil is a prostacyclin analogue that can be delivered by subcutaneous infusion and is approved in the USA only for treatment of primary pulmonary hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15920997_20201005_0.5	treprostinil	drug_name	This report provides an impressive example of an alternative, complementary indication for the use of treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID30477764_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?	title
treprostinil|water	Z0000025801				inn	PubMed	PMID30477764_20201005_0.5			Double-Blind Method|Epoprostenol|Humans|Hypertension, Pulmonary	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5	treprostinil	drug_name	Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5			Inhaled prostanoids|Prostacyclins|Prostanoids|Pulmonary arterial hypertension|Transition	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5			Administration, Inhalation|Adult|Ambulatory Care|Antihypertensive Agents|Cardiac Catheterization|Drug Substitution|Echocardiography|Epoprostenol|Exercise Test|Female|Humans|Infusions, Intravenous|Infusions, Subcutaneous|Male|Middle Aged|Natriuretic Peptide, Brain|Peptide Fragments|Pulmonary Arterial Hypertension|Walk Test	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5	treprostinil	drug_name	Combination therapy including inhaled treprostinil is an attractive alternative in clinically stable patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5	treprostinil	drug_name	 No section Sixteen stable patients with pulmonary arterial hypertension and favorable risk profile were transitioned from parenteral prostanoid to combination therapy including inhaled treprostinil in the home setting.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5	treprostinil	drug_name	Nine patients were using intravenous treprostinil, two patients were using subcutaneous treprostinil, and five patients were using intravenous epoprostenol at a median dose of 80 (interquartile range, IQR 72-90), 76.5 (68 and 85), and 28 (IQR 26-30) ng/kg/min respectively.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5	treprostinil	drug_name	 No section Patients tolerated the transition to inhaled treprostinil well without significant change in functional class (81.25% FC I/II before transition vs. 87.5% after), 6-min walk distance [349 m (IQR 226-461 m) to 364 m (IQR 238-565 m), p = 0.09] or NT-proBNP [149 pg/ml (IQR 71.5-383 pg/ml) to 186.5 pg/ml (IQR 83.5-444 pg/ml), p = 0.38].	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID31912412_20210611_0.5	treprostinil	drug_name	 No section For select patients, transition from a parenteral prostanoid-based therapy to a combination regimen including inhaled treprostinil in the home setting appears safe and well tolerated.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16258596_20201005_0.5			Gateways to clinical trials.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16258596_20201005_0.5			Clinical Trials as Topic|Humans	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID16258596_20201005_0.5	treprostinil	drug_name	This issue focuses on the following selection of drugs: AAV-NGFbeta, aprepitant, aripiprazole, atomoxetine hydrochloride; beta-Methyl-6-chloromelatonin, BMS-214662, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, CEA-TRICOM, cetuximab, ciclesonide, clofarabine, Cypher; Dalbavancin, darbepoetin alfa, darifenacin hydrobromide, desloratadine, Dexamet, drospirenone, drospirenone/ethinylestradiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, ertapenem sodium, escitalopram oxalate, eszopiclone; Fenretinide; Gefitinib, gestodene, ghrelin (human); hMaxi-K, human papillomavirus vaccine; Imatinib mesylate, indiplon, iodine (i131) tositumomab, irofulven, ISS-1018; Lasofoxifene tartrate, levodopa/carbidopa/entacapone, liposomal doxorubicin; Nemifitide ditriflutate, nesiritide; Omalizumab; Pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, phVEGF-A165, pimecrolimus, pramlintide acetate; Rasburicase, rimonabant hydrochloride; Satraplatin, St. John's Wort extract, sunitinib malate; Tadalafil, tanaproget, Taxus, tiotropium bromide, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate; Ximelagatran; Zileuton.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5	treprostinil	drug_name	Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5			Antihypertensive Agents|Catheters, Indwelling|Drug Contamination|Epoprostenol|Humans|Hypertension, Pulmonary|Infection Control|Infusions, Intravenous|Sepsis|United States	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5	treprostinil	drug_name	Two prostanoids are approved for intravenous (IV) use in the United States: epoprostenol (epoprostenol sodium [brand name Flolan], Gilead, Foster City, California) and treprostinil (treprostinil sodium [brand name Remodulin], United Therapeutics, Silver Spring, Maryland).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5	treprostinil	drug_name	In September 2006, CDC received a report from a PAH specialist of a suspected increase in the number of gram-negative bloodstream infections (BSIs) among PAH patients treated with IV treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5	treprostinil	drug_name	CDC conducted a retrospective investigation with the assistance of several state health departments and the cooperation of seven PAH treatment centers to determine the relative rates of BSI in a sample of patients treated with IV treprostinil and IV epoprostenol during 2003--2006.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5	treprostinil	drug_name	This report describes the results of that investigation, which indicated that, based on combined data from seven separate PAH treatment centers, pooled mean rates of BSI (primarily gram-negative BSI) were significantly higher for patients on treprostinil than for those on epoprostenol.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID17332729_20201005_0.5	treprostinil	drug_name	The results do not suggest intrinsic contamination of IV treprostinil as a cause of the infections; the difference in rates might have been caused by differences in preparation and storage of the two agents, differences in catheter care practices, or differences in the anti-inflammatory activity of the agents.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID25363827_20201005_0.5	treprostinil	drug_name	Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID25363827_20201005_0.5	treprostinil	drug_name	UT-15C|prostanoid treatment|pulmonary arterial hypertension|treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID25363827_20201005_0.5			Animals|Antihypertensive Agents|Drug Therapy, Combination|Epoprostenol|Humans|Hypertension, Pulmonary|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID25363827_20201005_0.5	treprostinil	drug_name	FREEDOM-M in treatment-naïve PAH patients resulted in significant improvements of 6-min walk distance supporting the use of oral treprostinil as initial monotherapy in PAH patients with class II or III symptoms.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID33647836_20210511_0.5			Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID33647836_20210511_0.5	treprostinil	drug_name	Epoprostenol|Iloprost|Implantable drug pump|Prostacyclin|Pulmonary arterial hypertension|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID33647836_20210511_0.5	treprostinil	drug_name	Humans|Female|treprostinil|Epoprostenol|Pulmonary Arterial Hypertension|Prostaglandins I|Hypertension, Pulmonary|Iloprost|Antihypertensive Agents|Familial Primary Pulmonary Hypertension|Infusion Pumps, Implantable	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID33647836_20210511_0.5	treprostinil	drug_name	Epoprostenol, iloprost and treprostinil have all been used intravenously in PAH, but titration, dosing and dose escalation in long-term therapy are not standardized.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5	treprostinil	drug_name	Experiences with treprostinil in the treatment of pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5			Antihypertensive Agents|Drug Approval|Drug Delivery Systems|Drug Stability|Drug Storage|Epoprostenol|Europe|Familial Primary Pulmonary Hypertension|Humans|Hypertension, Pulmonary|United States	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5	treprostinil	drug_name	Treprostinil is a newer prostacyclin analog similar to epoprostenol in its mechanism of action and relative efficacy with the advantage of a longer half life in human serum and room temperature stability.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5	treprostinil	drug_name	Additionally, oral treprostinil is currently under investigation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5	treprostinil	drug_name	Both subcutaneous and intravenous forms of treprostinil have demonstrated efficacy in short-term clinical trials and are currently approved for use in subjects with PAH and New York Heart Association functional class (NYHA FC) II-IV symptoms in the USA and for subjects with NYHA FC III and IV in Europe.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5	treprostinil	drug_name	Inhaled treprostinil has also demonstrated efficacy in short-term clinical trials primarily as add-on therapy and is currently approved for use in subjects with PAH and NYHA FC III-IV symptoms in the USA and Europe.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22868690_20201005_0.5	treprostinil	drug_name	The different formulations of treprostinil have significantly increased the treatment options and opportunities for treatment of patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23358265_20201005_0.5	treprostinil	drug_name	Hypertension: Treprostinil therapy for PAH.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5			What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5			Epidemiology|Pulmonary hypertension|Side effects	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5			Adult|Antihypertensive Agents|Cohort Studies|Drug-Related Side Effects and Adverse Reactions|Epoprostenol|Female|Gastrointestinal Diseases|Humans|Hypertension, Pulmonary|Male|Middle Aged|Retrospective Studies|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5	treprostinil	drug_name	The objective of this study was to determine whether common ADEs after initiating subcutaneous treprostinil were associated with prognosis in PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5	treprostinil	drug_name	 METHODS We assembled a retrospective cohort of participants from four clinical trials of treprostinil for PAH, including 908 participants who received subcutaneous treprostinil and 243 who received placebo at the time ADEs were ascertained.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5	treprostinil	drug_name	In participants who received treprostinil, infusion reactions, headaches, and jaw pain were not associated with mortality.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5	treprostinil	drug_name	Gastrointestinal side effects occurring during the first eight weeks following treprostinil infusion were associated with a 57% increase in the hazard of mortality (95% CI: 14-118%).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Gastrointestinal ADEs after starting subcutaneous treprostinil were associated with an increased risk for mortality.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID28412029_20201005_0.5	treprostinil	drug_name	Increased mortality was not observed with other early ADEs or with gastrointestinal symptoms in participants who were not receiving treprostinil at the time.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5			Administration, Oral|Adolescent|Adult|Aged|Antihypertensive Agents|Bosentan|Dose-Response Relationship, Drug|Double-Blind Method|Drug Therapy, Combination|Endothelin Receptor Antagonists|Epoprostenol|Exercise Tolerance|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Phosphodiesterase 5 Inhibitors|Piperazines|Purines|Sildenafil Citrate|Sulfonamides|Sulfones|Treatment Outcome|Walking|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	BACKGROUND Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	This study assessed the efficacy and safety of bid oral sustained-release treprostinil in the treatment of PAH with a concomitant endothelin receptor antagonist (ERA) and/or phosphodiesterase type 5 inhibitor.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	 METHODS A 16-week, multicenter, double-blind, placebo-controlled study was conducted in 350 patients with PAH randomized to placebo or oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	 RESULTS Thirty-nine patients (22%) receiving oral treprostinil and 24 patients (14%) receiving placebo discontinued the study.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	Improvements in dyspnea fatigue index score (P = .01) and combined 6MWD and Borg dyspnea score (P = .01) were observed with oral treprostinil vs placebo treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	Patients who achieved a week-16 bid oral treprostinil dose of 1.25 to 3.25 mg and 3.5 to 16 mg experienced a greater change in 6MWD (18 m and 34 m, respectively) than patients who achieved a bid dose of &lt; 1 mg or discontinued because of adverse events (4 m).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID22628490_20201005_0.5	treprostinil	drug_name	This study enhanced understanding of oral treprostinil titration and dosing, which has set the stage for additional studies.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID16248867_20201005_0.5	treprostinil	drug_name	Combining treprostinil and sildenafil in the treatment of pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID16248867_20201005_0.5			Adult|Antihypertensive Agents|Drug Combinations|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Piperazines|Purines|Sildenafil Citrate|Sulfones|Treatment Outcome|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID14720012_20201005_0.5			Prostanoids for pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID14720012_20201005_0.5			Adult|Age Distribution|Aged|Cause of Death|Dose-Response Relationship, Drug|Drug Administration Schedule|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Prognosis|Prostaglandins|Randomized Controlled Trials as Topic|Risk Assessment|Severity of Illness Index|Sex Distribution|Survival Analysis|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID14720012_20201005_0.5	treprostinil	drug_name	For these reasons, alternatives to intravenous epoprostenol have been sought and this has led to the development of analogs that can be administered subcutaneously (treprostinil), orally (beraprost sodium) or by inhalation (iloprost).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID14720012_20201005_0.5	treprostinil	drug_name	Subcutaneous treprostinil improved symptoms, exercise, hemodynamics and clinical events in the largest clinical trial ever performed in PAH, but local infusion site reactions limited efficacy in a proportion of patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5	treprostinil	drug_name	Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5			Administration, Oral|Adolescent|Adult|Aged|Antihypertensive Agents|Area Under Curve|Biological Availability|Dose-Response Relationship, Drug|Double-Blind Method|Epoprostenol|Familial Primary Pulmonary Hypertension|Female|Humans|Hypertension, Pulmonary|Male|Middle Aged|Tablets|Treatment Outcome|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5	treprostinil	drug_name	Treprostinil diolamine is an oral prostacyclin analogue; sustained release tablets of oral treprostinil are currently being evaluated for efficacy and safety as a potential therapy in patients with PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5	treprostinil	drug_name	Previous attempts at developing an oral prostanoid have been limited by rapid absorption and short plasma half-life; thus, the aim of this study was to characterize the pharmacokinetic profile of treprostinil diolamine in PAH patients after chronic dosing.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5	treprostinil	drug_name	The study enrolled 74 PAH patients who had been taking treprostinil diolamine for a minimum of 4 weeks (range: 0.5-16 mg).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5	treprostinil	drug_name	After chronic twice-daily oral dosing of treprostinil diolamine, mean area under the curve (AUC0-12) of treprostinil increased from 5244 to 20,4086 pg·hr-·mL- and mean maximum observed plasma concentration (Cmax) increased from 1383 to 33588 pg/mL. The apparent clearance (CL/F) was similar across all doses, indicating a linear dose-exposure relationship after twice-daily dosing.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23328389_20201214_0.5	treprostinil	drug_name	We conclude that twice-daily oral treprostinil provides sustained and proportional treprostinil concentrations over a wide range of doses during chronic administration to PAH patients.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	UT-15C|food effect|oral treprostinil|treprostinil diolamine	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5			Adolescent|Adult|Analysis of Variance|Antihypertensive Agents|Area Under Curve|Biological Availability|Chromatography, High Pressure Liquid|Cross-Over Studies|Dietary Fats|Energy Intake|Epoprostenol|Female|Food|Food-Drug Interactions|Half-Life|Healthy Volunteers|Humans|Male|Middle Aged|Nutritive Value|Tandem Mass Spectrometry|Young Adult	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	BACKGROUND Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue currently being evaluated for the treatment of pulmonary arterial hypertension as a sustained-release (SR) oral tablet.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	Previous data have demonstrated that the oral bioavailability of treprostinil was improved when taken with a meal containing at least 500 calories.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	 OBJECTIVE As twice-daily intake of a high-fat, high-calorie meal may be undesirable or not feasible for some patients, this open-label, randomized, crossover study evaluated the effect of different meal compositions [a 500-calorie well-balanced meal (WB500), a 250-calorie well-balanced meal (WB250), a 250-calorie high-fat meal (HF250) and a 250-calorie well-balanced liquid meal (Ensure®)] on the relative bioavailability of oral treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	 METHODS Thirty-two healthy volunteers were administered a single 1-mg SR tablet of oral treprostinil immediately following each study meal.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	Each dose of oral treprostinil was separated by a 7-day washout period.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Treprostinil plasma exposure (Cmax and AUC0-inf) decreased only slightly, 5-15% with decreasing caloric and increasing fat content.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Overall, there were no clinically significant differences in the relative bioavailability of oral treprostinil when administered immediately after meals containing 250-500 calories and 30-50% fat.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23927483_20201005_0.5	treprostinil	drug_name	These data support the administration of oral treprostinil with a meal containing as few as 250 calories and 30-50% fat, which is significant for ensuring patient convenience and compliance, particularly as consistency with regard to meals may impact oral treprostinil pharmacokinetics.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	Implantable LENUS pro pump for treprostinil infusion in three pediatric patients.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5			implantable pump|pediatrics|prostanoid treatment|pulmonary arterial hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5			Adolescent|Antihypertensive Agents|Child|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infusion Pumps, Implantable|Lung Transplantation|Male|Quality of Life	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	Subcutaneous administration of treprostinil has side effects, which limits their use and acceptance.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	An implantable pump for continuous intravenous treprostinil infusion has been recently approved.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	 No section The LENUS pro pump was implanted in three adolescents with severe PAH, who were treated with tadalafil, ambrisentan, and subcutaneous treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	The indication of the Lenus pro pump implantation was the local side effects of subcutaneous treprostinil (pain, inflammation, and local infection) that were not well tolerated and that severely decreased their quality of life.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	One patient, in functional class IV, suffered postoperative hemodynamic instability and small pneumothorax, requiring an increase in treprostinil dose up to 85 ng/kg/min and a decrease 9 days after the pump implantation.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID32149476_20201214_0.5	treprostinil	drug_name	The second patient who was discharged 4 days after surgery with treprostinil at 60 ng/kg/min reported improvement in his quality of life, but the dose requirement increased up to 92 ng/kg/min.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC6249551_20201005_0.5			A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension	title
treprostinil|water	Z0000025801				inn	PubMed	PMC6249551_20201005_0.5			Pulmonary arterial hypertension|6 minutes walking distance|functional class|randomized controlled trial|network meta-analysis	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC6249551_20201005_0.5			Bayes Theorem|Drug Combinations|Drug Delivery Systems|Endpoint Determination|Exercise Tolerance|Hemodynamics|Humans|Hypertension, Pulmonary|Randomized Controlled Trials as Topic|Treatment Outcome|Vasodilator Agents|Walking	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMC6249551_20201005_0.5	treprostinil	drug_name	Vardenafil and treprostinil were better for BDS.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID18260882_20201005_0.5			[Pulmonary hypertension and right ventricular failure. Part X. Prostanoids in the treatment of primary pulmonary arterial hypertension].	title
treprostinil|water	Z0000025801				inn	PubMed	PMID18260882_20201005_0.5			Global Health|Heart Failure|Humans|Hypertension, Pulmonary|Incidence|Prevalence|Prostaglandins|Survival Rate|Treatment Outcome|Ventricular Dysfunction, Right	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID18260882_20201005_0.5	treprostinil	drug_name	Subcutaneous administration of treprostinil and especially inhaled iloprost substantially widen possibilities of prolonged use of prostanoids in patients with various forms of PAH.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5			Anti-Infective Agents|Antihypertensive Agents|Bacteria|Bacterial Infections|Catheterization, Central Venous|Drug Stability|Epoprostenol|Equipment Contamination|Fungi|Humans|Infusions, Intravenous|Mycoses|Sodium Chloride|Time Factors|Water	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	BACKGROUND Long-term intravenous infusion of epoprostenol and treprostinil for treatment of pulmonary arterial hypertension (PAH) via a central venous catheter is associated with the risk of bloodstream infection (BSI).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	While several potential explanations exist for possible differences in BSI incidence among intravenous prostanoids, one hypothesis suggests that the alkaline pH of epoprostenol in Sterile Diluent for Flolan (SDF) has greater antimicrobial activity compared with the neutral pH of other common diluents such as sterile saline or water, which have been used for treprostinil.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	 METHODS The chemical stability and antimicrobial activity of 4 microg/ml and 130 microg/ml treprostinil in SDF were assessed according to United States and European Pharmacopeia.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	 RESULTS At both concentrations, treprostinil in SDF remained stable after incubation at 40 degrees C and ambient relative humidity for up to 52 h. Solution pH also remained stable (range 10.4-10.6), and the solutions were essentially free of particulate at all time points examined.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	The antimicrobial activity of both concentrations of treprostinil met United States Pharmacopeia requirements.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	Further, the antimicrobial activity of treprostinil in SDF against gram-negative bacteria (> 4 log(10) reductions) exceeded that previously described for treprostinil in sterile saline.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID20584221_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS These results suggest that dilution of treprostinil with the alkaline solution SDF may reduce the risk of infection from inadvertent patient contamination compared with dilution of treprostinil in sterile saline.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15151467_20201005_0.5	treprostinil	drug_name	Treprostinil for pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID15151467_20201005_0.5			Antihypertensive Agents|Clinical Trials as Topic|Epoprostenol|Humans|Hypertension, Pulmonary|Infusion Pumps|Infusions, Intravenous|Injections, Subcutaneous|Pilot Projects|Treatment Outcome	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID15151467_20201005_0.5	treprostinil	drug_name	No section Treprostinil (Remodulin, United Therapeutics) is a stable, long-acting prostacyclin analog, which has been shown to improve clinical state, functional class, exercise capacity and quality of life in patients with pulmonary arterial hypertension, an uncommon disease with poor prognosis.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15151467_20201005_0.5	treprostinil	drug_name	Otherwise, treprostinil has an excellent safety profile and compares favorably with reference continuous intravenous epoprostenol (Flolan, GlaxoSmithKline) therapy.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID15151467_20201005_0.5	treprostinil	drug_name	Treprostinil has a place in currently proposed treatment algorithms of pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5			Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	Endothelin|Iloprost|Norepinephrine|Pulmonary artery|Thromboxane|Treprostinil	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5			Adrenergic alpha-Agonists|Animals|Epoprostenol|Female|Humans|Iloprost|Male|Pulmonary Artery|Rats|Rats, Sprague-Dawley|Vasodilation|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	No section Prostacyclin (PGI2) mimetics (iloprost, treprostinil) are potent vasodilators (primarily via IP-receptor activation) and major therapeutic interventions for pulmonary hypertension (PH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	In this study, we aimed to compare relaxant effects of iloprost and treprostinil on human (HPA) and rat pulmonary arteries precontracted with either ET-1, thromboxane (U46619) or an α-adrenergic receptor agonist (Norepinephrine, NE or phenylephrine, PE).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	Treprostinil and iloprost induced vasorelaxation of HPA precontracted with NE, ET-1 or U46619.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	We obtained greater relaxation response and sensitivity to treprostinil when ET-1 or U46619 were used to induce the precontraction in comparison to NE.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	In the rat, treprostinil and iloprost induced vasorelaxation of pulmonary arteries precontracted with PE and U46619 but minimally with ET-1.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	Finally we suggest that in PH patients with high plasma concentration of TxA2, treprostinil (not iloprost) would be a preferential treatment.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26362969_20201005_0.5	treprostinil	drug_name	On the other hand, if the ET-1 plasmatic level is high, either treprostinil or iloprost will be effective.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23668545_20201005_0.5	treprostinil	drug_name	In vitro delivery of aerosolized treprostinil via modern mechanical ventilation.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23668545_20201005_0.5			Administration, Inhalation|Aerosols|Algorithms|Antihypertensive Agents|Drug Delivery Systems|Drug Dosage Calculations|Epoprostenol|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Inhalation|Models, Anatomic|Nebulizers and Vaporizers|Positive-Pressure Respiration|Respiration, Artificial|Time Factors|Ventilators, Mechanical	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID23668545_20201005_0.5	treprostinil	drug_name	BACKGROUND The Tyvaso Inhalation System is a hand-held nebulizer system used to administer treprostinil, an approved therapy for pulmonary arterial hypertension.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23668545_20201005_0.5	treprostinil	drug_name	Our goal was to establish an in vitro method for delivering a standard dose of treprostinil through a ventilator circuit and artificial airway.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23668545_20201005_0.5	treprostinil	drug_name	 CONCLUSIONS Using the algorithm, it was possible to deliver aerosolized treprostinil, at controlled doses, via mechanical ventilation over a wide range of controlled breathing patterns.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID26070575_20201005_0.5			Inhaled Therapies for Pulmonary Hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID26070575_20201005_0.5			aerosol therapies|inhaled nitric oxide|inhaled route|pulmonary arterial hypertension|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID26070575_20201005_0.5			Administration, Inhalation|Adult|Antihypertensive Agents|Bronchodilator Agents|Epoprostenol|Humans|Hypertension, Pulmonary|Iloprost|Infant, Newborn|Nitric Oxide|Off-Label Use|Prostaglandins I|Vasodilator Agents	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID26070575_20201005_0.5	treprostinil	drug_name	Aerosolized iloprost and treprostinil are both prostacyclins that have been cleared by the FDA to treat pulmonary arterial hypertension (PAH).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMC5613235_20201005_0.5			Liposomal-delivery of phosphodiesterase 5 inhibitors augments UT-15C-stimulated ATP release from human erythrocytes☆	title
treprostinil|water	Z0000025801				inn	PubMed	PMC5613235_20201005_0.5	treprostinil	drug_name	Tadalafil|Zaprinast|Treprostinil|Red blood cell|Liposomes|UT-15C	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMC5613235_20201005_0.5	treprostinil	drug_name	Male|Humans|Female|Phosphodiesterase 5 Inhibitors|treprostinil|Epoprostenol|Erythrocytes|Iloprost|Vasodilator Agents|Adenosine Triphosphate|Cyclic Nucleotide Phosphodiesterases, Type 5|Cyclic AMP|Hypertension, Pulmonary|Signal Transduction|Liposomes	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19006024_20201005_0.5			Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID19006024_20201005_0.5			Adult|Aged|Aged, 80 and over|Cause of Death|Chronic Disease|Comorbidity|Female|Hospital Mortality|Humans|Hypertension, Pulmonary|Male|Middle Aged|Poland|Prognosis|Pulmonary Embolism|Retrospective Studies|Risk Factors|Severity of Illness Index|Socioeconomic Factors|Survival Analysis|Ventricular Dysfunction, Right	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID19006024_20201005_0.5	treprostinil	drug_name	In contrast 'rescue therapy' with iloprost or treprostinil decreased mortality (RR 0.09, 95% CI 0.01-0.99, p=0.04).	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID23569707_20201005_0.5			Hip fracture in a patient with severe pulmonary hypertension.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID23569707_20201005_0.5			comanagement|comorbidity|palliative care|pulmonary hypertension	author_keywords
treprostinil|water	Z0000025801				inn	PubMed	PMID23569707_20201005_0.5	treprostinil	drug_name	No section This case presents a discussion of an 80-year-old woman with severe pulmonary hypertension (PH) on chronic intravenous treprostinil infusion and oxygen therapy who presents with a subcapital hip fracture.	abstract
treprostinil|water	Z0000025801				inn	PubMed	PMID12082102_20210211_0.5	treprostinil	drug_name	The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages.	title
treprostinil|water	Z0000025801				inn	PubMed	PMID12082102_20210211_0.5			Active Transport, Cell Nucleus|Adolescent|Adult|Antihypertensive Agents|Cell Adhesion|Cell Nucleus|Cytokines|Dose-Response Relationship, Drug|Down-Regulation|Epoprostenol|Humans|Inflammation|Interleukin-6|Interleukins|Lung|Macrophages|Middle Aged|NF-kappa B|Protein Binding|Protein Transport|Time Factors|Transcription Factor RelA	mesh_terms
treprostinil|water	Z0000025801				inn	PubMed	PMID12082102_20210211_0.5	treprostinil	drug_name	Treprostinil (TRE), a prostacyclin analogue with extended half-life and chemical stability, has shown promise in the treatment of PPH.	abstract
